-DOCSTART- X X O

[0001] JJ O
OLIGOMERIC NNP B-NP
AMIDOAMINES NNP I-NP
OR JJ O
AMIDOQUATS NNS B-NP
FOR IN O
FABRIC NNP O
OR NNP O
HAIR NNP O

TREATMENT NNP O
COMPOSITIONS NNS O

CROSS NNP O
REFERENCE NNP O
TO TO O
RELATED VBN O
APPLICATIONS NNS O

[0001] JJ O
This DT O
application NN O
claims VBZ O
priority NN O
to TO O
U.S. NNP O
Provisional NNP O
Patent NNP O
Application NNP O
No. NN O
60/694,966 CD O
, , O
filed VBN O
on IN O
29 CD O
June NNP O
2005 CD O
, , O
which WDT O
is VBZ O
incorporated JJ O
herein RB O
by IN O
reference NN O
. . O

BACKGROUND NN O
OF IN O
THE DT O
INVENTION NN O

[0002 CD O
] NNS O
Biodegradable JJ O
softeners NNS O
are VBP O
described VBN O
in IN O
the DT O
prior JJ O
art NN O
. . O

Compositions NNS O
containing VBG O
quaternary JJ B-NP
ammonium NN I-NP
salts NNS I-NP
having VBG O
at IN O
least JJS O
one CD O
long JJ O
chain NN O
hydrocarbyl NN B-NP
group NN O
are VBP O
commonly RB O
used VBN O
to TO O
provide VB O
fabric NN O
softening NN O
benefits NNS O
when WRB O
used VBN O
in IN O
a DT O
laundry NN O
rinse NN O
operation NN O
. . O

[0003] JJ O
Oligomeric NNP B-NP
esteramines NNS I-NP
and CC O
oligomeric JJ B-NP
esterquats NNS I-NP
are VBP O
compounds NNS O
commonly RB O
described VBN O
in IN O
the DT O
prior JJ O
art NN O
to TO O
effect NN O
fabric NN O
softening NN O
. . O

These DT O
compounds NNS O
are VBP O
sensitive JJ O
to TO O
hydrolysis NN O
and CC O
can MD O
degrade VB O
over IN O
time NN O
. . O

Consequently RB O
, , O
softening VBG O
compositions NNS O
in IN O
which WDT O
these DT O
ingredients NNS O
are VBP O
present JJ O
lose VBP O
some DT O
of IN O
their PRP$ O
ability NN O
to TO O
soften VB O
fabric NN O
over IN O
time NN O
. . O

Correspondingly NNP O
, , O
clear JJ O
softening NN O
compositions NNS O
obtained VBD O
with IN O
oligomeric JJ B-NP
esterquats NNS I-NP
become VBP O
turbid NN O
or CC O
cloudy NN O
due JJ O
to TO O
the DT O
increased JJ O
content NN O
of IN O
fatty JJ B-NP
acid NN I-NP
generated VBD O
by IN O
hydrolysis NN O
. . O

[0004 CD O
] NN O
Accordingly RB O
, , O
there EX O
is VBZ O
a DT O
need NN O
in IN O
the DT O
art NN O
for IN O
improving VBG O
the DT O
stability NN O
of IN O
oligomeric-type JJ B-NP
amines NNS I-NP
and CC O
quats NNS B-NP
while IN O
retaining VBG O
their PRP$ O
softening NN O
efficacy NN O
and CC O
ability NN O
to TO O
provide VB O
clear JJ O
or CC O
transparent JJ O
or CC O
translucent JJ O
compositions NNS O
. . O

SUMMARY NN O
OF IN O
THE DT O
INVENTION NN O

[0005 CD O
] NN O
In IN O
one CD O
aspect NN O
of IN O
the DT O
invention NN O
, , O
provided VBN O
is VBZ O
an DT O
oligomeric JJ B-NP
amidoamine NN I-NP
comprising VBG O
a DT O
reaction NN O
product NN O
of IN O
( -LRB- O
A DT O
) -RRB- O
, , O
( -LRB- O
B) NNP O
, , O
and CC O
( -LRB- O
C NN O
) -RRB- O
wherein WRB O
: : O

( -LRB- O
A DT O
) -RRB- O
represents VBZ O
an DT O
alkylene NN B-NP
polyamine NN I-NP
having VBG O
the DT O
formula NN O
: : O

R<1> JJ B-NP
N NNP I-NP
R<2> NN I-NP

R<3> JJ O
wherein IN O
R<1> NNP O
, , O
R<2> NNP O
, , O
R<3> NNP O
are VBP O
independently RB O
H NNP B-NP
or CC O
-R<5>-N-( JJ B-NP
R<4>)2 NN I-NP
, , O
wherein WRB O
not RB O
all DT O
of IN O
R<1> NNP O
, , O
R<2> NNP O
, , O
and CC O
R<3> NNP O
are VBP O
H NNP O
; : O

R<4>is NNP O
H NNP B-NP
or CC O
-R<5>-N-( JJ B-NP
R<8>)2 NN I-NP
; : O

R<8> NNP O
is VBZ O
independently RB O
H NNP O
or CC O
R<5> NNP O
; : O
and CC O
R<5> NNP O
is VBZ O
( -LRB- O
i NN O
) -RRB- O
a DT O
C1-C23 JJ B-NP
alkylene NN I-NP
or CC O
alkenyl NN B-NP
group NN I-NP
optionally RB O
substituted VBN O
or CC O
branched VBN O
; : O
or CC O
( -LRB- O
ii NNS O
) -RRB- O
an DT O
aryl NN B-NP
group NN O
; : O

( -LRB- O
B NN O
) -RRB- O
represents VBZ O
a DT O
dicarboxylic JJ B-NP
acid NN I-NP
or CC O
a DT O
reactive JJ O
derivative NN O
of IN O
such JJ O
acid NN O
having VBG O
the DT O
formula NN O
: : O

HOOC-R<5>-COOH NNP B-NP
wherein WRB O
R5 PRP O
is VBZ O
defined VBN O
as IN O
above JJ O
; : O
and CC O
( -LRB- O
C NN O
) -RRB- O
represents VBZ O

( -LRB- O
i NN O
) -RRB- O
a DT O
fatty NN B-NP
acid NN I-NP
having VBG O
the DT O
formula NN O
: : O

R<6>-COOH NNP B-NP
wherein WRB O
R<6> NNP O
is VBZ O
a DT O
linear NN O
or CC O
branched VBD O
C6-C23 DT B-NP
alkyl NN I-NP
or CC O
alkenyl NN B-NP
group NN I-NP
; : O
and/or CC O
( -LRB- O
ii NNS O
) -RRB- O
an DT O
alkyl NN B-NP
ester NN I-NP
or CC O
glyceride NN B-NP
of IN I-NP
the DT I-NP
fatty JJ I-NP
acid NN I-NP
( -LRB- O
i FW O
) -RRB- O
. . O

DETAILED VBN O
DESCRIPTION NN O
OF IN O
THE DT O
INVENTION NN O

[0006 CD O
] NN O
As IN O
used VBN O
throughout IN O
, , O
ranges NNS O
are VBP O
used VBN O
as IN O
a DT O
shorthand NN O
for IN O
describing VBG O
each DT O
and CC O
every DT O
value NN O
that WDT O
is VBZ O
within IN O
the DT O
range NN O
. . O

Any DT O
value NN O
within IN O
the DT O
range NN O
can MD O
be VB O
selected VBN O
as IN O
the DT O
terminus NN O
of IN O
the DT O
range NN O
. . O

[0007] JJ O
In IN O
one CD O
embodiment NN O
, , O
the DT O
invention NN O
relates VBZ O
to TO O
oligomeiic JJ B-NP
amidoamines NNS I-NP
, , O
amidoamine IN B-NP
salts NNS I-NP
, , O
and CC O
oligomeric JJ O
amidoquaternary JJ B-NP
ammonium NN I-NP
compounds NNS I-NP
(amidoquats NNS O
) -RRB- O
. . O

More RBR O
particularly RB O
, , O
the DT O
invention NN O
relates VBZ O
to TO O
such JJ O
oligomeric JJ B-NP
amidoamines NNS I-NP
, , O
oligomeric JJ B-NP
amidoamine IN I-NP
salts NNS I-NP
, , O
and CC O
amidoquats IN B-NP
which WDT O
are VBP O
obtained VBN O
by IN O
the DT O
amidation NN O
reaction NN O
of IN O
an DT O
alkylene NN B-NP
polyamine NN I-NP
with IN O
a DT O
fatty JJ B-NP
acid NN I-NP
in IN O
the DT O
presence NN O
of IN O
a DT O
dicarboxylic JJ B-NP
acid NN I-NP
or CC O
diester NN B-NP
. . O

The DT O
oligomeric JJ B-NP
amidoamine NN I-NP
may MD O
then RB O
be VB O
esterified VBN O
with IN O
fatty JJ B-NP
alcohol NN I-NP
or CC O
quaternized VBD O
to TO O
form VB O
the DT O
amidoamine JJ B-NP
salt NN I-NP
or CC O
the DT O
amidoquat JJ B-NP
, , O
respectively RB O
. . O

[0008 CD O
] NN O
In IN O
one CD O
embodiment NN O
, , O
oligomeric JJ O
refers VBZ O
to TO O
structures NNS O
having VBG O
2 CD O
to TO O
10 CD O
repeating VBG O
units NNS O
. . O

In IN O
another DT O
embodiment NN O
, , O
oligomeric NNP O
refers VBZ O
to TO O
structures NNS O
having VBG O
2 CD O
to TO O
5 CD O
, , O
2 CD O
to TO O
4 CD O
, , O
or CC O
2 CD O
to TO O
3 CD O
repeating VBG O
units NNS O
. . O

[0009 CD O
] NNS O
The DT O
softening NN O
compositions NNS O
of IN O
the DT O
invention NN O
comprising VBG O
an DT O
oligomeric JJ B-NP
amidoamine JJ I-NP
compound NN O
are VBP O
generally RB O
aqueous JJ O
compositions NNS O
which WDT O
may MD O
be VB O
milky JJ O
, , O
opaque JJ O
, , O
clear JJ O
, , O
transparent JJ O
or CC O
translucent JJ O
. . O

The DT O
compositions NNS O
may MD O
also RB O
be VB O
liquid JJ O
or CC O
solid JJ O
. . O

[0010] JJ O
In IN O
one CD O
embodiment NN O
, , O
the DT O
invention NN O
provides VBZ O
hair NN O
treatment NN O
compositions NNS O
comprising VBG O
an DT O
oligomeric JJ B-NP
amidoamine JJ I-NP
compound NN O
, , O
an DT O
oligomeric JJ B-NP
amdioamine NN I-NP
salt NN I-NP
, , O
and/or CC O
an DT O
amidoquat JJ B-NP
compound NN O
that WDT O
may MD O
be VB O
used VBN O
in IN O
a DT O
conventional JJ O
manner NN O
to TO O
condition NN O
hair NN O
. . O

[0011] JJ O
In IN O
one CD O
embodiment NN O
, , O
the DT O
invention NN O
provides VBZ O
fabric NN O
softening NN O
compositions NNS O
comprising VBG O
an DT O
oligomeric JJ B-NP
amidoamine JJ I-NP
compound NN O
, , O
an DT O
oligomeric JJ B-NP
amdioamine NN I-NP
salt NN I-NP
, , O
and/or CC O
an DT O
amidoquat JJ B-NP
compound NN O
that WDT O
may MD O
be VB O
used VBN O
in IN O
a DT O
conventional JJ O
manner NN O
in IN O
the DT O
rinse NN O
cycle NN O
of IN O
a DT O
washing NN O
machine NN O
in IN O
the DT O
form NN O
of IN O
an DT O
aqueous JJ O
dispersion NN O
, , O
but CC O
also RB O
in IN O
the DT O
form NN O
of IN O
a DT O
liquid NN O
, , O
powder NN O
, , O
or CC O
solid JJ O
product NN O
that WDT O
can MD O
be VB O
used VBN O
during IN O
the DT O
washing NN O
or CC O
drying VBG O
steps NNS O
of IN O
the DT O
fabric NN O
treatment NN O
process NN O
. . O

[0012] NN O
In IN O
a DT O
dryer NN O
, , O
for IN O
example NN O
, , O
the DT O
product NN O
may MD O
be VB O
in IN O
the DT O
form NN O
of IN O
a DT O
substrate NN O
, , O
such JJ O
as IN O
a DT O
sheet NN O
or CC O
sponge-type JJ O
material NN O
, , O
impregnated VBN O
with IN O
the DT O
oligomeric JJ B-NP
amidoamine JJ I-NP
derivative NN O
. . O

[0013] JJ O
The DT O
amidation IN O
reaction NN O
to TO O
provide VB O
the DT O
oligomeric JJ B-NP
amidoamine NN I-NP
or CC O
amidoamine IN B-NP
salt NN I-NP
or CC O
amidoquat IN B-NP
of IN O
the DT O
invention NN O
is VBZ O
obtained VBN O
by IN O
the DT O
reaction NN O
of IN O
an DT O
alkylene NN B-NP
polyamine NN I-NP
as IN O
defined VBN O
herein RB O
with IN O
a DT O
dicarboxylic JJ B-NP
acid NN I-NP
or CC O
a DT O
reactive NN O
derivative JJ O
as RB O
set VBN O
forth RB O
above IN O
. . O

[0014] JJ O
The DT O
polyalkylene NN B-NP
polyamine NN I-NP
includes VBZ O
, , O
but CC O
is VBZ O
not RB O
limited VBN O
to TO O
, , O
diethylene NN B-NP
triamine NN I-NP
, , O
dipropylene NN B-NP
triamine NN I-NP
, , O
hexamethylene NN B-NP
diamine NN I-NP
, , O
bis( JJ B-NP
hexamethylene NN I-NP
) -RRB- I-NP
triamine NN I-NP
, , O
Methylene NNP B-NP
tetraamine NN I-NP
, , O
and CC O
tris(2-aminoethyl NN B-NP
) -RRB- I-NP
amine VBP I-NP
. . O

[0015 CD O
] NNS O
The DT O
dicarboxylic NN B-NP
acid NN I-NP
includes VBZ O
, , O
but CC O
is VBZ O
not RB O
limited VBN O
to TO O
, , O
succinic JJ B-NP
acid NN I-NP
, , O
malic JJ B-NP
acid NN I-NP
, , O
glutaric JJ B-NP
acid NN I-NP
, , O
adipic JJ B-NP
acid NN I-NP
, , O
and CC O
maleic JJ B-NP
acid NN I-NP
. . O

The DT O
short JJ B-NP
esters NNS I-NP
, , O
anhydrides NNS B-NP
or CC O
chloride NN O
derivatives NNS O
of IN O
these DT O
acids NNS B-NP
may MD O
be VB O
used VBN O
as IN O
methyl NN O
of IN O
ethyl NN B-NP
esters NNS I-NP
. . O

In IN O
one CD O
embodiment NN O
, , O
the DT O
dicarboxylic NN B-NP
acid NN I-NP
is VBZ O
adipic JJ B-NP
acid NN I-NP
. . O

[0016] JJ O
The DT O
fatty JJ B-NP
acid NN I-NP
reactant NN O
may MD O
be VB O
derived VBN O
from IN O
vegetable NN O
and/or CC O
animal NN O
oils NNS O
and/or CC O
fats NNS O
, , O
such JJ O
as IN O
, , O
coconut NN O
, , O
tallow JJ O
, , O
and CC O
palm NN O
, , O
and CC O
may MD O
be VB O
partially RB O
or CC O
fully RB O
hydrogenated JJ O
. . O

The DT O
fatty JJ B-NP
acids NNS I-NP
may MD O
optionally RB O
be VB O
synthetic JJ O
acids NNS O
such JJ O
as IN O
, , O
lauric NN B-NP
, , O
palmetic JJ B-NP
, , O
and CC O
oleic JJ B-NP
. . O

[0017] JJ O
The DT O
molar JJ O
ratio NN O
of IN O
dicarboxylic JJ B-NP
acid NN I-NP
( -LRB- O
B NN O
) -RRB- O
to TO O
alkylene NN B-NP
polyamine NN I-NP
( -LRB- O
A DT O
) -RRB- O
is VBZ O
generally RB O
about IN O

0.2 CD O
to TO O
about IN O
1.2 CD O
, , O
preferably RB O
about IN O
0.5 CD O
to TO O
about RB O
0.8. CD O

[0018] JJ O
The DT O
molar JJ O
ratio NN O
of IN O
fatty JJ B-NP
acid NN I-NP
( -LRB- O
C NNP O
) -RRB- O
to TO O
polyamine VB O
( -LRB- O
A DT O
) -RRB- O
is VBZ O
about IN O
0.2 CD O
to TO O
about IN O
2.0, CD O
preferably RB O
about IN O
0.5 CD O
to TO O
about RB O
1.5 CD O
. . O

[0019] IN O
A DT O
fatty JJ B-NP
alcohol NN I-NP
or CC O
polyalkoxylated VBN B-NP
fatty JJ I-NP
alcohol NN I-NP
of IN O
the DT O
general JJ O
formula NN O

R<6>-O-(CR<7>HCH2O)n-H NNP B-NP
where WRB O
n=0 CD O
to TO O
10 CD O
and CC O
R<6> NNP O
is VBZ O
as IN O
defined VBN O
above IN O
, , O
and CC O
R<7> NNP O
is VBZ O
H NNP B-NP
or CC O
R<5> NNP O
. . O

[0020] JJ O
The DT O
oligomeric JJ B-NP
amidoamine NN I-NP
may MD O
be VB O
used VBN O
as IN O
an DT O
amine JJ B-NP
salt NN O
by IN O
neutralizing VBG O
the DT O
amine NN B-NP
with IN O
mineral NN O
or CC O
organic JJ O
acids NNS O
such JJ O
as IN O
hydrochloric JJ B-NP
, , O
sulfuric JJ B-NP
, , O
phosphoric JJ B-NP
, , O
citric JJ B-NP
or CC O
lactic JJ B-NP
acids NNS B-NP
. . O

Alternatively RB O
, , O
it PRP O
may MD O
be VB O
used VBN O
as IN O
a DT O
quaternary JJ B-NP
ammonium NN I-NP
compound NN I-NP
when WRB O
quaternized VBN O
with IN O
conventional JJ O
alkylation NN O
agents NNS O
such JJ O
as IN O
methyl NN B-NP
chloride NN I-NP
or CC O
dimethyl NN B-NP
sulfate NN I-NP
. . O

The DT O
oligomeric JJ B-NP
amidoamine NN I-NP
or CC O
derivative NN O
may MD O
be VB O
obtained VBN O
by IN O
controlled JJ O
alkoxylation NN O
of IN O
the DT O
oligomeric JJ B-NP
amidoamine NN I-NP
. . O

[0021] JJ O
Clear NNP O
or CC O
translucent JJ O
compositions NNS O
may MD O
be VB O
obtained VBN O
by IN O
selecting VBG O
a DT O
molar JJ O
ratio NN O
as IN O
herein RB O
described VBN O
and/or IN O
using VBG O
unsaturated JJ O
fatty JJ B-NP
acids NNS I-NP
or CC O
alcohols NNS B-NP
. . O

[0022] JJ O
The DT O
oligomeric JJ B-NP
amidoamine NN I-NP
is VBZ O
used VBN O
as IN O
the DT O
main JJ O
active JJ O
ingredient NN O
in IN O
fabric NN O
softening NN O
compositions NNS O
or CC O
hair NN O
conditioners NNS O
that WDT O
may MD O
also RB O
contain VB O
nonionic JJ O
fabric NN O
conditioning NN O
surfactants NNS O
, , O
cationic JJ O
softeners NNS O
, , O
co-softening JJ O
ingredients NNS O
such JJ O
as IN O
silicones NNS B-NP
, , O
anionic JJ O
surfactants NNS O
, , O
and CC O
amphoteric JJ O
surfactants NNS O
; : O
stabilizers NNS O
such JJ O
as IN O
non-ionic JJ O
surfactants NNS O
(ethoxylated VBD O
fatty JJ B-NP
alcohols NNS I-NP
, , O
amines NNS B-NP
or CC O
acids NNS B-NP
) -RRB- O
; : O
inorganic JJ O
salts NNS O
or CC O
thickening VBG O
agents NNS O
to TO O
stabilize VB O
the DT O
fabric NN O
softening NN O
composition NN O
viscosity NN O
; : O
pH : O
adjusting VBG O
compounds NNS O
such JJ O
as IN O
inorganic JJ O
or CC O
organic JJ O
acids NNS O
or CC O
bases NNS O
; : O
and CC O
added VBN O
benefit NN O
ingredients NNS O
such JJ O
as IN O
soil NN O
release NN O
polymers NNS O
and CC O
antibacterial JJ O
compounds NNS O
. . O

[0023] JJ O
Preferably RB O
cationic JJ O
softeners NNS O
are VBP O
also RB O
present JJ O
, , O
and CC O
especially RB O
preferred VBN O
are VBP O
softeners NNS O
such JJ O
as IN O
esterquats NNS B-NP
, , O
imidazolinium NN B-NP
quats NNS I-NP
, , O
difatty JJ B-NP
diamido NN I-NP
ammonium NN I-NP
methyl NN I-NP
sulfate NN I-NP
, , O
and CC O
ditallow JJ B-NP
dimethyl NN I-NP
ammonium NN I-NP
chloride NN I-NP
. . O

Suitable JJ O
cationic JJ O
softeners NNS O
are VBP O
described VBN O
in IN O
US NNP O

5,939,377 CD O
; : O
US PRP O
6,020,304 CD O
; : O
US PRP O
4,830,771 CD O
; : O
and CC O
US PRP O
5,501,806 CD O
; : O
the DT O
disclosures NNS O
of IN O
which WDT O
are VBP O
incorporated JJ O
herein RB O
by IN O
reference NN O
. . O

[0024] JJ O
A DT O
preferred JJ O
cationic JJ O
softener NN O
for IN O
the DT O
invention NN O
is VBZ O
produced VBN O
by IN O
reacting VBG O
two CD O
moles NNS O
of IN O
fatty JJ B-NP
acid NN I-NP
methyl NN I-NP
ester NN I-NP
with IN O
one CD O
mole NN O
of IN O
triethanolamine NN B-NP
followed VBN O
by IN O
quaternization NN O
with IN O
dimethyl NN B-NP
sulfate NN I-NP
( -LRB- O
further JJ O
details NNS O
on IN O
this DT O
preparation NN O
method NN O
are VBP O
disclosed VBN O
in IN O
US NNP O
3,915,867 CD O
, , O
which WDT O
is VBZ O
incorporated JJ O
herein RB O
by IN O
reference NN O
) -RRB- O
. . O

The DT O
reaction NN O
products NNS O
are VBP O
50 CD O
% NN O
diesterquat JJ B-NP
, , O
20 CD O
% NN O
monoester NN B-NP
form NN O
, , O
and CC O
30 CD O
% NN O
triester NN B-NP
form NN O
. . O

In IN O
the DT O
present JJ O
specification NN O
, , O
the DT O
above JJ O
reaction NN O
product NN O
mixture NN O
of IN O
triethanolamine NN B-NP
esterquat NN B-NP
is VBZ O
often RB O
referred VBN O
to TO O
simply RB O
as IN O
esterquat NN B-NP
. . O

It PRP O
is VBZ O
commercially RB O
available JJ O
from IN O
Kao NNP O
Corp. NNP O
as IN O
Tetranyl NNP O
AT1-75(TM) . O

[0025 CD O
] NN O
Another DT O
preferred JJ O
softener NN O
comprises VBZ O
a DT O
fatty NN B-NP
ester NN I-NP
quaternary JJ I-NP
ammonium NN I-NP
compound NN I-NP
represented VBN O
by IN O
the DT O
formula NN O
: : O

+ NN O

R1 CD O
- : O
Q NN O
- : O
( -LRB- O
CH2)S FW O
( -LRB- O
CH2)q JJ O
- : O
R2 CC O

N NNP O
X NNP O
_a VBD O
a DT O

/ NN O
\ NNS O

H NNP O
- : O
( -LRB- O
CH2 NN O
)r NN O
( -LRB- O
CH2X FW O
- : O
R2 CC O

wherein WRB O
Q NNP O
represents VBZ O
a DT O
carboxyl NN O
group NN O
having VBG O
the DT O
structure NN O
-OCO NNP B-NP
- : I-NP
and/or CC O
-COO-; JJ B-NP
R1 NN O
represents VBZ O
an DT O
aliphatic JJ B-NP
hydrocarbon NN I-NP
group NN I-NP
having VBG O
8 CD O
to TO O
22 CD O
carbon NN O
atoms NNS O
; : O
R2 DT O
represents VBZ O
-Q-R1 JJ O
and/or CC O
-OH JJ B-NP
; : O
q RB O
, , O
r NN O
, , O
s PRP O
and CC O
t NN O
, , O
each DT O
independently RB O
represent VBP O
a DT O
number NN O
of IN O
1 CD O
to TO O
3 CD O
; : O
and CC O
X NNP O
is VBZ O
an DT O
anion NN B-NP
of IN O
valence NN O
a DT O
; : O
and CC O
wherein WRB O
the DT O
fatty NN B-NP
ester NN I-NP
quaternary JJ I-NP
ammonium NN I-NP
compound NN I-NP
is VBZ O
comprised VBN O
of IN O
a DT O
distribution NN O
of IN O
monoester NN B-NP
, , O
diester NN B-NP
and CC O
triester NN B-NP
compounds NNS O
, , O
the DT O
monoester NN B-NP
compound NN O
being VBG O
formed VBN O
when WRB O
each DT O
R2 NN O
is VBZ O
-OH NNP B-NP
; : O
the DT O
diester NN B-NP
compound NN O
being VBG O
formed VBN O
when WRB O
one CD O
R2 NN O
is VBZ O
-OH NNP B-NP
and CC O
the DT O
other JJ O
R2 NN O
is VBZ O
-Q-R1 JJ O
; : O
and CC O
the DT O
triester NN B-NP
compound NN O
being VBG O
formed VBN O
when WRB O
each DT O
R2 NN O
is VBZ O
-Q-R1 JJ O
; : O
and CC O
wherein WRB O
the DT O
normalized JJ O
percentage NN O
of IN O
monoester NN B-NP
compound NN O
in IN O
the DT O
fatty JJ B-NP
ester NN I-NP
quaternary JJ I-NP
ammonium NN I-NP
compound NN I-NP
is VBZ O
about IN O
31 CD O
% NN O
to TO O
about IN O
37 CD O
% NN O
; : O
the DT O
normalized JJ O
percentage NN O
of IN O
diester NN B-NP
compound NN O
is VBZ O
about IN O
53 CD O
% NN O
to TO O
about IN O
59 CD O
% NN O
and CC O
the DT O
normalized JJ O
percentage NN O
of IN O
triester NN B-NP
compound NN O
is VBZ O
about IN O
8 CD O
% NN O
to TO O
about IN O
12 CD O
% NN O
; : O
all DT O
percentages NNS O
being VBG O
by IN O
weight NN O
. . O

EXAMPLES NNS O

[0026] JJ O
The DT O
following JJ O
prophetic JJ O
examples NNS O
are VBP O
illustrative JJ O
only RB O
and CC O
do VB O
not RB O
limit VB O
the DT O
invention NN O
. . O

[0027] JJ O
In IN O
Examples NNS O
1-4 JJ O
in IN O
the DT O
table NN O
below IN O
, , O
the DT O
materials NNS O
can MD O
be VB O
reacted VBN O
together RB O
at IN O
a DT O
combination NN O
of IN O
temperature NN O
and CC O
pressure NN O
for IN O
amidation NN O
of IN O
the DT O
amine NN B-NP
. . O

[0049] . O

EMI6.2 NN O

[0028 PRP O
] SYM O
The DT O
resulting VBG O
oligomeric JJ B-NP
amidoamines NNS I-NP
may MD O
be VB O
dissolved VBN O
in IN O
low JJ O
molecular JJ O
weight NN O
alcohol NN O
(ethanol NN O
and/or CC O
isopropanol NN B-NP
) -RRB- O
to TO O
make VB O
handling VBG O
easier JJR O
. . O

[0029 PRP O
] SYM O
The DT O
oligomeric JJ B-NP
amidoamines NNS I-NP
may MD O
be VB O
quaternized VBN O
by IN O
mixing VBG O
with IN O
8 CD O
% NN O
by IN O
weight NN O
isopropyl NN B-NP
alcohol NN I-NP
and CC O
a DT O
stoichiometric JJ O
amount NN O
of IN O
dimethyl NN B-NP
sulfate NN I-NP
or CC O
methyl NN B-NP
chloride NN I-NP
to TO O
quaternize VB O
the DT O
amine JJ B-NP
sites NNS O
. . O

[0030] JJ O
An DT O
oligomeric JJ B-NP
amidoamine NN I-NP
of IN O
Example NNP O
1 CD O
can MD O
have VB O
the DT O
following JJ O
structure NN O
: : O

[0053] . O

EMI6.1 . O

wherein WRB O
R NN O
is VBZ O
H NNP O
, , O
a DT O
1-22 JJ O
carbon NN O
atom NN O
alkyl NN B-NP
group NN I-NP
, , O
a DT O
1-22 JJ O
carbon NN O
atom NN O
alkenyl NN B-NP
group NN I-NP
, , O
and/or CC O

EMI7.1 . O

[0031] JJ O
As IN O
alternatives NNS O
to TO O
Examples NNS O
2 CD O
and CC O
4 CD O
, , O
0.6 CD O
moles NNS O
of IN O
H-Tallow JJ O
alcohol NN B-NP
can MD O
be VB O
used VBN O
. . O

[0032 CD O
] NN O
An DT O
oligomeric JJ B-NP
amidoaniine NN I-NP
of IN O
Example NNP O
3 CD O
can MD O
have VB O
the DT O
following JJ O
structure NN O
: : O

[0056] . O

EMI7.2 NN O

wherein WRB O
R NN O
is VBZ O
H NNP O
, , O
a DT O
1-22 JJ O
carbon NN O
atom NN O
alkyl NN B-NP
group NN I-NP
, , O
a DT O
1-22 JJ O
carbon NN O
atom NN O
alkenyl NN B-NP
group NN I-NP
, , O

[0058] . O

EMI7.3 . O

wherein WRB O
R<10> NNP O
is VBZ O
a DT O
1-22 JJ O
carbon NN O
atom NN O
alkyl NN B-NP
group NN I-NP
and/or IN O
a DT O
1-22 JJ O
carbon NN O
atom NN O
alkenyl NN B-NP
group NN I-NP
. . O

[0033] JJ O
Aqueous JJ O
fabric NN O
softeners NNS O
can MD O
be VB O
prepared VBN O
using VBG O
the DT O
quaternized JJ B-NP
amidoamine NN I-NP
of IN O
Example NNP O
2 CD O
with IN O
the DT O
dimethyl NN B-NP
sulfate NN I-NP
( -LRB- O
Examples NNS O
5 CD O
and CC O
6 CD O
) -RRB- O
and CC O
the DT O
quaternized JJ B-NP
amidoamine NN I-NP
of IN O
Example NNP O
4 CD O
with IN O
the DT O
dimethyl NN B-NP
sulfate NN I-NP
( -LRB- O
Examples NNS O
7 CD O
and CC O
8 CD O
) -RRB- O
. . O

Amounts NNS O
are VBP O
weight NN O
percent NN O
based VBN O
on IN O
the DT O
total JJ O
weight NN O
of IN O
the DT O
composition NN O
. . O

The DT O
compositions NNS O
can MD O
be VB O
prepared VBN O
by IN O
mixing NN O
of IN O
the DT O
ingredients NNS O
. . O

[0059] . O

EMI7.4 . O

EMI8.1 . O

[0034] NNP O
Other JJ O
amidoamines NNS B-NP
can MD O
be VB O
prepared VBN O
from IN O
the DT O
formulations NNS O
in IN O
the DT O
table NN O
below IN O
(amounts NNS O
are VBP O
molar JJ O
amounts NNS O
) -RRB- O
: : O

[0061] . O

EMI8.2 NN O

What WP O
is VBZ O
claimed VBN O
is VBZ O
: : O

1 CD O
. . O

An DT O
oligomeric JJ B-NP
amidoamine NN I-NP
comprising VBG O
a DT O
reaction NN O
product NN O
of IN O
( -LRB- O
A DT O
) -RRB- O
, , O
( -LRB- O
B) NNP O
, , O
and CC O
( -LRB- O
C NN O
) -RRB- O
wherein WRB O
: : O

( -LRB- O
A DT O
) -RRB- O
represents VBZ O
an DT O
alkylene NN B-NP
polyamine NN I-NP
having VBG O
the DT O
formula NN O
: : O

R1 NNP O
N NNP O
R<2> NN O

R<3> JJ O
wherein IN O
R<1> NNP O
, , O
R<2> NNP O
, , O
R<3> NNP O
are VBP O
independently RB O
H NNP B-NP
or CC O
-R<5>-N-( JJ B-NP
R<4>)2 NN I-NP
, , O
wherein WRB O
not RB O
all DT O
of IN O
R<1> NNP O
, , O
R<2> NNP O
, , O
and CC O
R<3> NNP O
are VBP O
H NNP O
; : O
R<4>is NNP O
H NNP B-NP
or CC O
-R<5>-N-( JJ B-NP
R<8>)2 NN I-NP
; : O

R<8> NNP O
is VBZ O
independently RB O
H NNP B-NP
or CC O
R<5> NNP O
; : O
and CC O
R<5> NNP O
is VBZ O
( -LRB- O
i NN O
) -RRB- O
a DT O
C1-C23 JJ B-NP
alkylene NN I-NP
or CC O
alkenyl NN B-NP
group NN I-NP
optionally RB O
substituted VBN O
or CC O
branched VBN O
; : O
or CC O
( -LRB- O
ii NNS O
) -RRB- O
an DT O
aryl NN B-NP
group NN O
; : O

( -LRB- O
B NN O
) -RRB- O
represents VBZ O
a DT O
dicarboxylic JJ B-NP
acid NN I-NP
or CC O
a DT O
reactive JJ O
derivative NN O
of IN O
such JJ O
acid NN O
having VBG O
the DT O
formula NN O
: : O

HOOC-R<5>-COOH NNP B-NP
wherein WRB O
R5 PRP O
is VBZ O
defined VBN O
as IN O
above JJ O
; : O
and CC O

( -LRB- O
C NNP O
) -RRB- O
represents VBZ O

( -LRB- O
i NN O
) -RRB- O
a DT O
fatty NN B-NP
acid NN I-NP
having VBG O
the DT O
formula NN O
: : O

R<6>-COOH NNP B-NP
wherein WRB O
R<6> NNP O
is VBZ O
a DT O
linear NN O
or CC O
branched VBD O
C6-C23 DT B-NP
alkyl NN I-NP
or CC O
alkenyl NN B-NP
group NN I-NP
; : O
and/or CC O
( -LRB- O
ii NNS O
) -RRB- O
an DT O
alkyl NN B-NP
ester NN I-NP
or CC O
glyceride NN B-NP
of IN O
the DT O
fatty JJ B-NP
acid NN I-NP
( -LRB- O
i FW O
) -RRB- O
. . O

2. . O
An DT O
oligomeric JJ B-NP
amidoamine NN I-NP
salt NN I-NP
formed VBN O
by IN O
neutralizing VBG O
the DT O
oligomeric JJ B-NP
amidoamine NN I-NP
of IN O
claim NN O
1 CD O
with IN O
a DT O
mineral NN O
acid NN O
and/or IN O
an DT O
organic JJ O
acid NN O
. . O

3. `` O
An DT O
oligomeric JJ B-NP
amidoquaternary JJ I-NP
ammonium NN I-NP
compound NN O
formed VBN O
by IN O
quaternizing VBG O
the DT O
oligomeric JJ B-NP
amidoamine NN I-NP
of IN O
claim NN O
1 CD O
with IN O
an DT O
alkylating JJ O
agent NN O
. . O

4 LS O
. . O
The DT O
oligomeric JJ B-NP
amidoamine NN I-NP
of IN O
claim NN O
1 CD O
, , O
wherein WRB O
the DT O
molar JJ O
ratio NN O
of IN O
dicarboxylic JJ B-NP
acid NN I-NP
( -LRB- O
B NN O
) -RRB- O
to TO O
polyamine VB O
( -LRB- O
A DT O
) -RRB- O
is VBZ O
about RB O
0.5 CD O
to TO O
about RB O
0.8. CD O

5 CD O
. . O
The DT O
oligomeric JJ B-NP
amidoamine JJ I-NP
claim NN O
1 CD O
, , O
wherein WRB O
the DT O
molar JJ O
ratio NN O
of IN O
the DT O
fatty JJ B-NP
acid NN I-NP
( -LRB- O
C NNP O
) -RRB- O
to TO O
the DT O
polyamine NN O
( -LRB- O
A DT O
) -RRB- O
is VBZ O
about RB O
0.5 CD O
to TO O
about RB O
1.5 CD O
. . O

6 CD O
. . O

The DT O
oligomeric JJ B-NP
amidoamine NN I-NP
of IN O
claim NN O
1 CD O
, , O
wherein WRB O
R5 PRP O
is VBZ O
a DT O
C1 JJ B-NP
- : I-NP
C6 IN I-NP
alkylene NN I-NP
or CC O
alkenyl NN B-NP
group NN I-NP
optionally RB O
substituted VBN O
or CC O
branched VBN O
. . O

7. CD O
A DT O
fabric NN O
softening NN O
composition NN O
comprising VBG O
an DT O
effective JJ O
amount NN O
of IN O
the DT O
oligomeric JJ B-NP
amidoamine NN I-NP
of IN O
claim NN O
1 CD O
, , O
an DT O
oligomeric JJ B-NP
amidoamine JJ I-NP
salt NN I-NP
of IN O
the DT O
oligomeric JJ B-NP
amdioamine NN I-NP
, , O
and/or CC O
an DT O
oligomeric JJ O
amidoquat IN B-NP
of IN O
the DT O
oligomeric JJ B-NP
amidoamine NN I-NP
. . O

8. DT O
The DT O
fabric NN O
softening NN O
composition NN O
of IN O
claim NN O
7 CD O
further JJ O
comprising NN O
water NN B-NP
. . O

9 CD O
. . O
The DT O
fabric NN O
softening NN O
composition NN O
of IN O
claim NN O
7 CD O
further JJ O
comprising VBG O
a DT O
second JJ O
softening VBG O
compound NN O
comprising VBG O
a DT O
cationic JJ O
softener NN O
and/or CC O
a DT O
nonionic JJ O
softener NN O
. . O

10 CD O
. . O

The DT O
fabric NN O
softening NN O
composition NN O
of IN O
claim NN O
9 CD O
, , O
wherein WRB O
the DT O
second JJ O
softening VBG O
compound NN O
comprises VBZ O
a DT O
compound NN O
represented VBN O
by IN O
the DT O
formula NN O
: : O

+ NN O

R1 CD O
- : O
Q NN O
- : O
( -LRB- O
CH2 NN O
) -RRB- O
, , O
, , O
( -LRB- O
CH2)q NNP O
- : O
R2 CC O

N NNP O
[chi]_a NN O

/ NN O
\ NNS O

H NNP O
- : O
( -LRB- O
CH2 NN O
) -RRB- O
, , O
( -LRB- O
CH2X NNP O
- : O
R2 CC O

wherein WRB O
Q NNP O
represents VBZ O
a DT O
carboxyl NN B-NP
group NN O
having VBG O
the DT O
structure NN O
-OCO NNP B-NP
- : I-NP
and/or CC O
-COO-; JJ B-NP
R1 NN O
represents VBZ O
an DT O
aliphatic JJ B-NP
hydrocarbon NN I-NP
group NN I-NP
having VBG O
8 CD O
to TO O
22 CD O
carbon NN O
atoms NNS O
; : O
R2 DT O
represents VBZ O
-Q-R1 JJ O
and/or CC O
-OH JJ B-NP
; : O
q RB O
, , O
r NN O
, , O
s PRP O
and CC O
t NN O
, , O
each DT O
independently RB O
represent VBP O
a DT O
number NN O
of IN O
1 CD O
to TO O
3 CD O
; : O
and CC O
X NNP O
is VBZ O
an DT O
anion NN B-NP
of IN O
valence NN O
a DT O
; : O
and CC O
wherein WRB O
the DT O
fatty NN B-NP
ester NN I-NP
quaternary JJ I-NP
ammonium NN I-NP
compound NN I-NP
is VBZ O
comprised VBN O
of IN O
a DT O
distribution NN O
of IN O
monoester NN B-NP
, , O
diester NN B-NP
and CC O
triester NN B-NP
compounds NNS O
, , O
the DT O
monoester NN B-NP
compound NN O
being VBG O
formed VBN O
when WRB O
each DT O
R2 NN O
is VBZ O
-OH NNP B-NP
; : O
the DT O
diester NN B-NP
compound NN O
being VBG O
formed VBN O
when WRB O
one CD O
R2 NN O
is VBZ O
-OH NNP B-NP
and CC O
the DT O
other JJ O
R2 NN O
is VBZ O
-Q-Rl JJ O
; : O
and CC O
the DT O
triester NN B-NP
compound NN O
being VBG O
formed VBN O
when WRB O
each DT O
R2 NN O
is VBZ O
-Q-Rl JJ O
; : O
and CC O
wherein WRB O
the DT O
normalized JJ O
percentage NN O
of IN O
monoester NN B-NP
compound NN O
in IN O
the DT O
fatty JJ B-NP
ester NN I-NP
quaternary JJ I-NP
ammonium NN I-NP
compound NN I-NP
is VBZ O
about IN O
31 CD O
% NN O
to TO O
about IN O
37 CD O
% NN O
; : O
the DT O
normalized JJ O
percentage NN O
of IN O
diester NN B-NP
compound NN O
is VBZ O
about IN O
53 CD O
% NN O
to TO O
about IN O
59 CD O
% NN O
and CC O
the DT O
normalized JJ O
percentage NN O
of IN O
triester NN B-NP
compound NN O
is VBZ O
about IN O
8 CD O
% NN O
to TO O
about IN O
12 CD O
% NN O
; : O
all DT O
percentages NNS O
being VBG O
by IN O
weight NN O
. . O

11 CD O
. . O

A DT O
hair NN O
conditioning NN O
composition NN O
comprising VBG O
an DT O
effective JJ O
amount NN O
of IN O
the DT O
oligomeric JJ B-NP
amidoamine NN I-NP
of IN O
claim NN O
1 CD O
, , O
an DT O
oligomeric JJ B-NP
amidoamine JJ I-NP
salt NN I-NP
of IN O
the DT O
oligomeric JJ B-NP
amidoamine NN I-NP
, , O
and/or CC O
an DT O
oligomeric JJ B-NP
amidoquat IN I-NP
of IN O
the DT O
oligomeric JJ B-NP
amidoamine NN I-NP
. . O

12 CD O
. . O
The DT O
hair NN O
conditioning NN O
composition NN O
of IN O
claim NN O
11 CD O
further RB O
comprising VBG O
a DT O
conditioning NN O
agent NN O
comprising VBG O
a DT O
cationic JJ O
or CC O
nonionic JJ O
hair NN O
conditioner NN O
. . O

13 CD O
. . O

The DT O
oligomeric JJ B-NP
amidoamine NN I-NP
of IN O
claim NN O
1 CD O
, , O
wherein WRB O
the DT O
amidoamine NN B-NP
comprises VBZ O
: : O

EMI11.1 . O

wherein WRB O
R NN O
is VBZ O
H NNP O
, , O
a DT O
1-22 JJ O
carbon NN O
atom NN O
alkyl NN B-NP
group NN I-NP
, , O
a DT O
1-22 JJ O
carbon NN O
atom NN O
alkenyl NN B-NP
group NN I-NP
, , O
and/or CC O

EMI11.2 NN O

14 CD O
. . O

The DT O
oligomeric JJ B-NP
amidoamine NN I-NP
of IN O
claim NN O
1 CD O
, , O
wherein WRB O
the DT O
amidoamine NN B-NP
comprises VBZ O

EMI11.3 . O

wherein WRB O
R NN O
is VBZ O
H NNP O
, , O
a DT O
1-22 JJ O
carbon NN O
atom NN O
alkyl NN B-NP
group NN I-NP
, , O
a DT O
1-22 JJ O
carbon NN O
atom NN O
alkenyl NN B-NP
group NN I-NP
, , O

EMI12.1 . O

wherein WRB O
R NN O
i VBZ O
lO NN O
is VBZ O
a DT O
1-22 JJ O
carbon NN O
atom NN O
alkyl NN B-NP
group NN I-NP
and/or IN O
a DT O
1-22 JJ O
carbon NN O
atom NN O
alkenyl NN B-NP
group NN I-NP
. . O

15 CD O
. . O

A DT O
method NN O
of IN O
softening VBG O
fabrics NNS O
comprising VBG O
a DT O
step NN O
of IN O
contacting VBG O
the DT O
fabrics NNS O
to TO O
be VB O
softened VBN O
with IN O
an DT O
effective JJ O
amount NN O
of IN O
the DT O
fabric NN O
softening NN O
composition NN O
of IN O
Claim NNP O
7. . O

16 CD O
. . O

A DT O
method NN O
of IN O
conditioning NN O
hair NN O
comprising VBG O
a DT O
step NN O
of IN O
contacting VBG O
the DT O
hair NN O
to TO O
be VB O
conditioned VBN O
with IN O
an DT O
effective JJ O
amount NN O
of IN O
the DT O
hair NN O
conditioning NN O
composition NN O
of IN O
claim NN O
11 CD O
. . O

17 CD O
. . O

A DT O
fabric NN O
softening NN O
composition NN O
comprising VBG O
an DT O
effective JJ O
amount NN O
of IN O
an DT O
oligomeric JJ B-NP
amidoamine NN I-NP
, , O
an DT O
oligomeric JJ B-NP
amidoamine JJ I-NP
salt NN I-NP
, , O
and/or CC O
an DT O
oligomeric JJ B-NP
amidoquat JJ I-NP
. . O

18 CD O
. . O

A DT O
hair NN O
treatment NN O
composition NN O
comprising VBG O
an DT O
effective JJ O
amount NN O
of IN O
an DT O
oligomeric JJ B-NP
amidoamine NN I-NP
, , O
an DT O
oligomeric JJ B-NP
amidoamine JJ I-NP
salt NN I-NP
, , O
and/or CC O
an DT O
oligomeric JJ O
amidoquat JJ B-NP
. . O

-DOCSTART- X X O

[0001] JJ O
Process NNP O
for IN O
the DT O
preparation NN O
of IN O
peroxy NN B-NP
acids NNS I-NP

Field NNP O
of IN O
the DT O
invention NN O

The DT O
invention NN O
relates VBZ O
to TO O
the DT O
preparation NN O
of IN O
relatively RB O
concentrated JJ O
, , O
storable JJ O
peroxy JJ B-NP
acid NN I-NP
solutions NNS O
containing VBG O
performic JJ B-NP
acid NN I-NP
. . O

The DT O
invention NN O
also RB O
relates VBZ O
to TO O
relatively RB O
concentrated JJ O
, , O
storable JJ O
peroxy JJ B-NP
acid NN I-NP
solutions NNS O
and CC O
to TO O
the DT O
use NN O
of IN O
such JJ O
solutions NNS O
. . O

Background NN O
of IN O
the DT O
invention NN O

Hydrogen JJ B-NP
peroxide NN I-NP
is VBZ O
known VBN O
as IN O
a DT O
moderately RB O
effective JJ O
disinfecting VBG O
agent NN O
with IN O
some DT O
bacteriostatic JJ O
properties NNS O
. . O

It PRP O
is VBZ O
applied VBN O
in IN O
the DT O
disinfection NN O
of IN O
sewage NN O
waters NNS O
etc NN O
. . O

The DT O
utilization NN O
of IN O
the DT O
reactivity NN O
of IN O
hydrogen NN B-NP
peroxide NN I-NP
with IN O
metal NN B-NP
ions NNS I-NP
( -LRB- O
Fenton JJ O
reaction NN O
) -RRB- O
is VBZ O
the DT O
most RBS O
powerful JJ O
use NN O
of IN O
hydrogen NN B-NP
peroxide NN I-NP
in IN O
disinfection NN O
. . O

UV NN O
irradiation NN O
is VBZ O
another DT O
applicable JJ O
way NN O
to TO O
activate VB O
hydrogen NN B-NP
peroxide NN I-NP
in IN O
disinfection NN O
. . O

Both DT O
Fenton NNP O
reaction NN O
and CC O
UV NN O
irradiation NN O
produce VBP O
hydroxyl NN B-NP
radicals NNS O
to TO O
the DT O
reaction NN O
media NNS O
. . O

However RB O
, , O
the DT O
disinfection NN O
power NN O
of IN O
hydrogen NN B-NP
peroxide NN I-NP
is VBZ O
not RB O
sufficient JJ O
for IN O
most JJS O
of IN O
the DT O
microbes NNS O
. . O

Peracetic JJ B-NP
acid NN I-NP
( -LRB- O
PAA NNP B-NP
) -RRB- O
is VBZ O
known VBN O
as IN O
an DT O
effective JJ O
disinfecting NN O
agent NN O
providing VBG O
a DT O
rapid JJ O
reduction NN O
of IN O
bacteria NNS O
growth NN O
for IN O
most JJS O
of IN O
the DT O
common JJ O
bacteria NNS O
. . O

It PRP O
is VBZ O
applied VBN O
in IN O
the DT O
sterilization NN O
of IN O
the DT O
equipment NN O
in IN O
dairy NN O
industry NN O
. . O

Moreover RB O
, , O
PAA NNP B-NP
is VBZ O
applied VBN O
in IN O
pulp NN O
and CC O
paper NN O
industry NN O
for IN O
the DT O
control NN O
of IN O
the DT O
microbial JJ O
growth NN O
in IN O
process NN O
waters NNS O
. . O

In IN O
addition NN O
, , O
peracetic JJ B-NP
acid NN I-NP
is VBZ O
applied VBN O
in IN O
the DT O
post-bleaching NN O
of IN O
kraft NN O
pulps NNS O
after IN O
delignification NN O
and CC O
peroxide NN B-NP
bleaching NN O
steps NNS O
. . O

Peracetic JJ B-NP
acid NN I-NP
is VBZ O
traditionally RB O
prepared VBN O
via IN O
an DT O
equilibrium NN O
reaction NN O
between IN O
acetic JJ B-NP
acid NN I-NP
and CC O
hydrogen NN B-NP
peroxide NN I-NP
resulting VBG O
in IN O
an DT O
equilibrium NN O
solution NN O
: : O

acetic JJ B-NP
acid NN I-NP
+ VBD O
hydrogen NN B-NP
peroxide NN I-NP
< IN O
> JJ O
peracetic JJ B-NP
acid NN I-NP
+ VBD O
water NN B-NP

This DT O
reaction NN O
occurs VBZ O
only RB O
when WRB O
catalyzed VBN O
by IN O
a DT O
strong JJ O
mineral NN O
acid NN O
, , O
e.g NN O
. . O

sulfuric JJ B-NP
acid NN I-NP
. . O

The DT O
equilibrium NN O
solution NN O
of IN O
peracetic JJ B-NP
acid NN I-NP
is VBZ O
used VBN O
as IN O
a DT O
disinfecting VBG O
agent NN O
for IN O
example NN O
in IN O
process NN O
water NN B-NP
applications NNS O
, , O
greenhouses NNS O
, , O
dairy NN O
industry NN O
etc NN O
. . O

Similar JJ O
equilibria NNS O
occur VBP O
with IN O
formic JJ B-NP
acid NN I-NP
and CC O
hydrogen NN B-NP
peroxide NN I-NP
, , O
resulting VBG O
in IN O
solutions NNS O
containing VBG O
performic JJ B-NP
acid NN I-NP
( -LRB- O
PFA NN B-NP
) -RRB- O
. . O

PFA NNS B-NP
solutions NNS O
are VBP O
proven VBN O
to TO O
be VB O
more RBR O
effective JJ O
disinfecting VBG O
agents NNS O
than IN O
peracetic JJ B-NP
acid JJ I-NP
solutions NNS O
. . O

Due JJ O
to TO O
instability NN O
and CC O
high JJ O
reactivity NN O
of IN O
PFA NNP B-NP
the DT O
solutions NNS O
of IN O
PFA NN B-NP
are VBP O
not RB O
stable JJ O
. . O

Thus RB O
, , O
PFA NNP B-NP
solutions NNS O
have VBP O
to TO O
be VB O
prepared VBN O
in IN O
situ FW O
. . O

A DT O
stable JJ O
disinfecting VBG O
agent NN O
comparable JJ O
with IN O
PFA NNP B-NP
should MD O
be VB O
desirable JJ O
for IN O
applications NNS O
in IN O
greenhouses NNS O
, , O
industrial JJ O
and CC O
institutional JJ O
( -LRB- O
I&I NN O
) -RRB- O
cleaning NN O
and CC O
control NN O
of IN O
microbial JJ O
growth NN O
in IN O
process NN O
waters NNS O
e.g VBP O
. . O
in IN O
pulp NN O
and CC O
paper NN O
( -LRB- O
P NNP O
&P NNP O
) -RRB- O
industry NN O
. . O

In IN O
WO NN O
94/20424 CD O
performic JJ B-NP
acid NN I-NP
is VBZ O
successfully RB O
applied VBN O
in IN O
the DT O
control NN O
of IN O
microbial JJ O
growth NN O
in IN O
the DT O
horticulture NN O
. . O

A DT O
dilute JJ O
performic JJ B-NP
acid NN I-NP
solution NN O
fed VBN O
into IN O
the DT O
nutrient JJ O
solution NN O
or CC O
drain NN O
water NN B-NP
prevents VBZ O
the DT O
growth NN O
of IN O
algae NNS O
in IN O
the DT O
pipelines NNS O
going VBG O
to TO O
the DT O
plants NNS O
preventing VBG O
them PRP O
from IN O
plugging VBG O
. . O

Extensive JJ O
studies NNS O
of IN O
the DT O
applicant NN O
have VBP O
shown VBN O
that IN O
the DT O
equilibrium NN O
mixtures NNS O
of IN O
PAA NNP B-NP
are VBP O
not RB O
applicable JJ O
in IN O
such JJ O
applications NNS O
due JJ O
to TO O
their PRP$ O
lower JJR O
reactivity NN O
towards IN O
microbes NNS O
. . O

Furthermore RB O
, , O
the DT O
disinfection NN O
power NN O
of IN O
formic JJ B-NP
acid NN I-NP
in IN O
the DT O
absence NN O
of IN O
hydrogen NN B-NP
peroxide NN I-NP
is VBZ O
proven VBN O
to TO O
be VB O
negligible JJ O
compared VBN O
to TO O
peroxy JJ B-NP
acids NNS I-NP
. . O

The DT O
stability NN O
of IN O
peroxy JJ B-NP
acids NNS I-NP
is VBZ O
known VBN O
to TO O
increase VB O
with IN O
increasing VBG O
molecular JJ O
weight NN O
. . O

On IN O
the DT O
other JJ O
hand NN O
, , O
together RB O
with IN O
the DT O
reactivity NN O
, , O
the DT O
disinfection NN O
power NN O
of IN O
peroxy JJ B-NP
acids NNS I-NP
increases NNS O
with IN O
the DT O
decrease NN O
of IN O
the DT O
molecular JJ O
weight NN O
. . O

Performic JJ B-NP
acid NN I-NP
( -LRB- O
PFA NN B-NP
) -RRB- O
is VBZ O
known VBN O
as IN O
the DT O
most RBS O
powerful JJ O
disinfection NN O
agent NN O
among IN O
the DT O
peroxy JJ B-NP
acids NNS I-NP
. . O

Several JJ O
studies NNS O
have VBP O
shown VBN O
the DT O
effect NN O
of IN O
performic JJ B-NP
acid NN I-NP
in IN O
the DT O
control NN O
of IN O
microbial JJ O
growth NN O
. . O

One CD O
of IN O
the DT O
earlier JJR O
references NNS O
is VBZ O
J. NNP O
Hyg NNP O
. . O

Epidem NNP O
. . O

Microbiol NNP O
. . O

Immunol NNP O
. . O

( -LRB- O
1968 CD O
) -RRB- O
12 CD O
, , O
115 CD O
. . O

WO NN O
94/20424 CD O
describes VBZ O
the DT O
preparation NN O
of IN O
performic JJ B-NP
acid JJ I-NP
solutions NNS O
in IN O
situ NN O
by IN O
reacting VBG O
formic JJ B-NP
acid NN I-NP
and CC O
hydrogen NN B-NP
peroxide NN I-NP
in IN O
a DT O
molar JJ O
ratio NN O
of IN O
from IN O
1:10 CD O
to TO O
10:1 CD O
, , O
preferably RB O
from IN O
1:1 CD O
to TO O
1:5 CD O
. . O

The DT O
PFA NNP B-NP
solution NN O
can MD O
be VB O
employed VBN O
for IN O
preventing VBG O
and CC O
combating VBG O
harmful JJ O
microorganisms NNS O
. . O

Typically RB O
PFA NNP B-NP
is VBZ O
used VBN O
in IN O
an DT O
amount NN O
of IN O
1 CD O
-1000 CD O
ppm NN O
. . O

EP NNP O
231632 CD O
A DT O
discloses VBG O
the DT O
industrial JJ O
use NN O
of IN O
performic JJ B-NP
acid NN I-NP
as IN O
a DT O
sanitizer NN O
. . O

The DT O
performic JJ B-NP
acid NN I-NP
solution NN O
is VBZ O
prepared VBN O
in IN O
situ FW O
from IN O
an DT O
aqueous JJ O
solution NN O
containing VBG O
from IN O
10 CD O
to TO O
50 CD O
% NN O
by IN O
weight NN O
hydrogen NN B-NP
peroxide NN I-NP
and CC O
a DT O
solution NN O
containing VBG O
from IN O
5 CD O
to TO O
100 CD O
% NN O
by IN O
weight NN O
formic JJ B-NP
acid NN I-NP
by IN O
reacting VBG O
the DT O
same JJ O
in IN O
the DT O
presence NN O
of IN O
a DT O
catalyst NN O
, , O
the DT O
weight NN O
ratio NN O
of IN O
hydrogen NN B-NP
peroxide NN I-NP
to TO O
formic JJ B-NP
acid NN I-NP
being VBG O
in IN O
the DT O
range NN O
of IN O
from IN O
1:6 CD O
to TO O
1:1.5 CD O
. . O

For IN O
greenhouse NN O
disinfection NN O
purposes NNS O
, , O
the DT O
solution NN O
of IN O
PFA NNP B-NP
is VBZ O
prepared VBN O
by IN O
mixing VBG O
for IN O
example NN O
, , O
35 CD O
% NN O
hydrogen NN B-NP
peroxide NN I-NP
with IN O
15 CD O
% NN O
formic JJ B-NP
acid NN I-NP
solution NN O
. . O

The DT O
resulting VBG O
solution NN O
is VBZ O
then RB O
diluted VBN O
with IN O
the DT O
nutrient JJ O
solution NN O
and CC O
fed VBN O
to TO O
the DT O
plants NNS O
. . O

Due JJ O
to TO O
the DT O
fact NN O
that IN O
performic JJ B-NP
acid NN I-NP
solutions NNS O
are VBP O
explosive JJ O
in IN O
higher JJR O
concentrations NNS O
, , O
only RB O
low JJ O
concentrations NNS O
of IN O
performic JJ B-NP
acid NN I-NP
solutions NNS O
can MD O
be VB O
handled VBN O
safely RB O
. . O

Mixtures NNS O
of IN O
dilute JJ O
solutions NNS O
of IN O
performic JJ B-NP
acid NN I-NP
and CC O
peracetic JJ B-NP
acid NN I-NP
are VBP O
known VBN O
from IN O
the DT O
recent JJ O
patent NN O
literature NN O
. . O

US PRP O
6 CD O
211 CD O
237 CD O
Bl NNP O
discloses NNS O
a DT O
dilute JJ O
disinfecting VBG O
agent NN O
comprising VBG O
small JJ O
amounts NNS O
of IN O
performic JJ B-NP
acid NN I-NP
and CC O
peracetic JJ B-NP
acid NN I-NP
, , O
the DT O
total JJ O
amount NN O
of IN O
these DT O
peracids NNS B-NP
typically RB O
being VBG O
less RBR O
than IN O
4 CD O
% NN O
by IN O
weight NN O
. . O

The DT O
main JJ O
component NN O
of IN O
the DT O
agent NN O
is VBZ O
hydrogen NN B-NP
peroxide NN I-NP
, , O
the DT O
amount NN O
thereof , O
typically RB O
being VBG O
about IN O
50 CD O
% NN O
by IN O
weight NN O
. . O

The DT O
agent NN O
may MD O
be VB O
used VBN O
for IN O
example NN O
for IN O
disinfecting VBG O
swimming VBG O
pool NN O
waters NNS O
. . O

The DT O
dilute JJ O
solutions NNS O
of IN O
PFA NNP B-NP
and CC O
PAA NNP B-NP
with IN O
hydrogen NN B-NP
peroxide NN I-NP
are VBP O
prepared VBN O
in IN O
situ FW O
. . O

It PRP O
is VBZ O
also RB O
known VBN O
for IN O
the DT O
man NN O
skilled JJ O
in IN O
the DT O
art NN O
that IN O
peroxy JJ B-NP
acid NN I-NP
solutions NNS O
, , O
even RB O
the DT O
equilibrium NN O
solutions NNS O
of IN O
performic JJ B-NP
acid NN I-NP
, , O
are VBP O
relatively RB O
stable JJ O
at IN O
low JJ O
concentrations NNS O
, , O
up IN O
to TO O
2 CD O
% NN O
by IN O
weight NN O
, , O
for IN O
several JJ O
days NNS O
. . O

US PRP O
2004/0035537 CD O
describes VBZ O
a DT O
method NN O
for IN O
bleaching VBG O
pulp NN O
with IN O
a DT O
solution NN O
containing VBG O
peracetic JJ B-NP
acid NN I-NP
and CC O
performic JJ B-NP
acid NN I-NP
. . O

Also RB O
in IN O
this DT O
application NN O
, , O
dilute JJ O
peroxy JJ B-NP
acid NN I-NP
solutions NNS O
are VBP O
prepared VBN O
in IN O
situ NN O
by IN O
bringing VBG O
acetic JJ B-NP
acid NN I-NP
and CC O
formic JJ B-NP
acid NN I-NP
into IN O
contact NN O
with IN O
hydrogen NN B-NP
peroxide NN I-NP
at IN O
a DT O
concentration NN O
greater JJR O
than IN O
50 CD O
% NN O
by IN O
weight NN O
. . O

The DT O
ratio NN O
of IN O
acetic JJ B-NP
acid NN I-NP
+ VBD O
peracetic JJ B-NP
acid NN I-NP
to TO O
formic JJ B-NP
acid NN I-NP
+ VBD O
performic JJ B-NP
acid NN I-NP
is VBZ O
preferably RB O
9 CD O
to TO O
1 CD O
by IN O
volume NN O
. . O

The DT O
amount NN O
of IN O
peracids NNS B-NP
in IN O
the DT O
obtained VBN O
solution NN O
is VBZ O
very RB O
low JJ O
, , O
typically RB O
less JJR O
than IN O
2 CD O
% NN O
by IN O
weight NN O
. . O

US PRP O
6 CD O
284 CD O
793 CD O
Bl NNP O
discloses NNS O
a DT O
biocidal JJ O
agent NN O
for IN O
treating VBG O
ballast NN O
sea NN O
water NN B-NP
. . O

The DT O
biocidal JJ O
agent NN O
is VBZ O
in IN O
the DT O
form NN O
of IN O
a DT O
solution NN O
containing VBG O
peracetic JJ B-NP
acid NN I-NP
, , O
performic JJ B-NP
acid NN I-NP
, , O
acetic JJ B-NP
acid NN I-NP
, , O
formic JJ B-NP
acid NN I-NP
, , O
hydrogen NN B-NP
peroxide NN I-NP
and CC O
water NN B-NP
and CC O
optionally RB O
a DT O
mineral NN O
acid NN O
catalyst NN O
and CC O
active JJ O
oxygen NN O
stabilizers NNS O
. . O

Such JJ O
a DT O
solution NN O
may MD O
be VB O
obtained VBN O
by IN O
adding VBG O
formic JJ B-NP
acid NN I-NP
to TO O
an DT O
equilibrium NN O
peracetic JJ B-NP
acid NN I-NP
solution NN O
, , O
typically RB O
containing VBG O
1 CD O
to TO O
15 CD O
% NN O
by IN O
weight NN O
peracetic JJ B-NP
acid NN I-NP
. . O

According VBG O
to TO O
this DT O
document NN O
performic JJ B-NP
acid NN I-NP
is VBZ O
more RBR O
effective JJ O
compared VBN O
with IN O
peracetic JJ B-NP
acid NN I-NP
, , O
but CC O
also RB O
more RBR O
susceptible JJ O
to TO O
decomposition NN O
and CC O
therefore RB O
formic JJ B-NP
acid NN I-NP
is VBZ O
added VBN O
to TO O
the DT O
solution NN O
containing VBG O
peracetic JJ B-NP
acid NN I-NP
only RB O
just RB O
prior RB O
to TO O
use VB O
. . O

When WRB O
the DT O
equilibrium NN O
peracetic JJ B-NP
acid NN I-NP
and CC O
formic JJ B-NP
acid NN I-NP
are VBP O
used VBN O
in IN O
combination NN O
, , O
the DT O
formic JJ B-NP
acid NN I-NP
being VBG O
added VBN O
directly RB O
to TO O
the DT O
peracetic JJ B-NP
acid NN I-NP
or CC O
simultaneously RB O
to TO O
the DT O
ballast NN O
water NN B-NP
, , O
the DT O
formic JJ B-NP
acid NN I-NP
is VBZ O
used VBN O
in IN O
a DT O
quantity NN O
of IN O
10 CD O
to TO O
1000 CD O
% NN O
by IN O
weight NN O
, , O
based VBN O
on IN O
the DT O
sum NN O
of IN O
peracetic JJ B-NP
acid NN I-NP
and CC O
acetic JJ B-NP
acid NN I-NP
. . O

In IN O
the DT O
working VBG O
examples NNS O
the DT O
formic JJ B-NP
acid NN I-NP
is VBZ O
added VBN O
to TO O
equilibrium NN O
peracetic JJ B-NP
acid NN I-NP
in IN O
an DT O
amount NN O
of IN O
about IN O
800 CD O
% NN O
by IN O
weight NN O
, , O
based VBN O
on IN O
the DT O
sum NN O
of IN O
peracetic JJ B-NP
acid NN I-NP
and CC O
acetic JJ B-NP
acid NN I-NP
. . O

Peroxy JJ B-NP
acid NN I-NP
solutions NNS O
are VBP O
most RBS O
commonly RB O
prepared VBN O
via IN O
an DT O
equilibrium NN O
reaction NN O
of IN O
hydrogen NN B-NP
peroxide NN I-NP
with IN O
the DT O
appropriate JJ O
carboxylic NN B-NP
acid NN I-NP
. . O

In IN O
the DT O
case NN O
of IN O
peracetic JJ B-NP
acid NN I-NP
and CC O
carboxylic NN B-NP
acids NNS I-NP
having VBG O
higher JJR O
molecular JJ O
weight NN O
, , O
an DT O
acid NN O
catalysis NN O
is VBZ O
required VBN O
in IN O
order NN O
to TO O
reach VB O
the DT O
equilibrium NN O
in IN O
an DT O
appropriate JJ O
period NN O
of IN O
time NN O
. . O

Mineral NNP O
acids NNS O
, , O
for IN O
example NN O
sulphuric JJ B-NP
acid NN I-NP
, , O
hydrochloric JJ B-NP
acid NN I-NP
etc NN O
. . O
are VBP O
commonly RB O
applied VBN O
as IN O
acid NN O
catalysts NNS O
in IN O
such JJ O
reactions NNS O
. . O

In IN O
the DT O
case NN O
of IN O
formic JJ B-NP
acid NN I-NP
, , O
an DT O
additional JJ O
acid NN O
catalyst NN O
is VBZ O
not RB O
necessary JJ O
according VBG O
to TO O
the DT O
literature NN O
( -LRB- O
Jones NNP O
, , O
C. NNP O
W. NNP O
, , O
" `` O
Applications NNS O
of IN O
hydrogen NN B-NP
peroxide NN I-NP
and CC O
derivatives VBZ O
" `` O
, , O
Royal NNP O
Society NNP O
of IN O
Chemistry NNP O
; : O
Clean NNP O
Technology NNP O
Monographs NNP O
, , O
1999 CD O
, , O
pp RB O
. . O

61- JJ O
77 CD O
) -RRB- O
. . O

Description NN O
of IN O
the DT O
invention NN O

According VBG O
to TO O
the DT O
invention NN O
it PRP O
was VBD O
surprisingly RB O
found VBN O
that IN O
in IN O
equilibrium NN O
solutions NNS O
prepared VBN O
by IN O
mixing VBG O
acetic JJ B-NP
acid NN I-NP
and CC O
hydrogen NN B-NP
peroxide NN I-NP
in IN O
molar JJ O
ratios NNS O
in IN O
the DT O
range NN O
from IN O
0.5 CD O
: : O
1 CD O
to TO O
8 CD O
: : O
1 CD O

( -LRB- O
mol NN O
acetic JJ B-NP
acid NN I-NP
/ VBD O
mol NN O
hydrogen NN B-NP
peroxide NN I-NP
) -RRB- O
, , O
acetic JJ B-NP
acid NN I-NP
can MD O
be VB O
replaced VBN O
by IN O
formic JJ B-NP
acid NN I-NP
in IN O
an DT O
amount NN O
of IN O
up RB O
to TO O
20 CD O
% NN O
by IN O
weight NN O
, , O
and CC O
yet RB O
provide VB O
a DT O
storable JJ O
solution NN O
. . O

In IN O
the DT O
presence NN O
of IN O
common JJ O
peroxide NN O
stabilizers NNS O
, , O
such JJ O
concentrated JJ O
peroxy JJ B-NP
acid NN I-NP
solutions NNS O
are VBP O
stable JJ O
enough RB O
for IN O
the DT O
storage NN O
for IN O
several JJ O
weeks NNS O
. . O

According VBG O
to TO O
the DT O
invention NN O
it PRP O
was VBD O
found VBN O
that IN O
substantial JJ O
amounts NNS O
of IN O
formic JJ B-NP
acid NN I-NP
can MD O
be VB O
introduced VBN O
without IN O
loosing VBG O
the DT O
stability NN O
of IN O
the DT O
resulting VBG O
peroxy JJ B-NP
acid NN I-NP
solution NN O
. . O

Thus RB O
, , O
in IN O
one CD O
aspect NN O
of IN O
the DT O
invention NN O
there EX O
is VBZ O
provided VBN O
a DT O
process NN O
for IN O
the DT O
preparation NN O
of IN O
a DT O
solution NN O
comprising VBG O
a DT O
first JJ O
peroxy JJ B-NP
acid NN I-NP
comprising NN O
performic JJ B-NP
acid NN I-NP
and CC O
a DT O
second JJ O
peroxy JJ B-NP
acid NN I-NP
, , O
said VBD O
process NN O
comprising NN O
forming VBG O
a DT O
carboxylic JJ B-NP
acid NN I-NP
solution NN O
comprising VBG O
a DT O
first JJ O
carboxylic NN B-NP
acid NN I-NP
comprising VBG O
formic JJ B-NP
acid NN I-NP
, , O
a DT O
second JJ O
carboxylic NN B-NP
acid NN I-NP
and CC O
hydrogen NN B-NP
peroxide NN I-NP
, , O
wherein WRB O
the DT O
amount NN O
of IN O
formic JJ B-NP
acid NN I-NP
is VBZ O
from IN O
0.5 CD O
to TO O
20 CD O
% NN O
by IN O
weight NN O
of IN O
the DT O
amount NN O
of IN O
the DT O
second JJ O
carboxylic NN B-NP
acid NN I-NP
, , O
and CC O
allowing VBG O
the DT O
components NNS O
to TO O
react VB O
to TO O
form VB O
a DT O
solution NN O
comprising NN O
performic JJ B-NP
acid NN I-NP
and CC O
said VBD O
second JJ O
peroxy JJ B-NP
acid NN I-NP
, , O
the DT O
amount NN O
of IN O
peroxy NN B-NP
acids NNS I-NP
being VBG O
at IN O
least JJS O
5 CD O
% NN O
by IN O
weight NN O
. . O

The DT O
peroxy JJ B-NP
acid NN I-NP
solution NN O
can MD O
be VB O
prepared VBN O
by IN O
pre-mixing VBG O
the DT O
first JJ O
and CC O
second JJ O
carboxylic NN B-NP
acids NNS I-NP
followed VBN O
by IN O
the DT O
addition NN O
of IN O
a DT O
hydrogen NN B-NP
peroxide NN I-NP
solution NN O
. . O

Alternatively RB O
, , O
the DT O
peroxy JJ B-NP
acid NN I-NP
solution NN O
can MD O
be VB O
prepared VBN O
by IN O
mixing VBG O
an DT O
aqueous JJ O
solution NN O
of IN O
the DT O
second JJ O
carboxylic NN B-NP
acid NN I-NP
, , O
e.g NN O
. . O

acetic JJ B-NP
acid NN I-NP
solution NN O
, , O
and CC O
hydrogen NN B-NP
peroxide NN I-NP
solution NN O
followed VBN O
by IN O
the DT O
addition NN O
of IN O
the DT O
first JJ O
carboxylic NN B-NP
acid NN I-NP
, , O
i IN O
.e NN O
. . O
formic JJ B-NP
acid NN I-NP
to TO O
the DT O
equilibrium NN O
mixture NN O
. . O

The DT O
reaction NN O
equilibria NN O
are VBP O
set VBN O
in IN O
1-2 JJ O
hour NN O
or CC O
in IN O
a DT O
longer JJR O
period NN O
of IN O
time NN O
, , O
largely RB O
depending VBG O
on IN O
the DT O
temperature NN O
of IN O
the DT O
reaction NN O
mixture NN O
. . O

The DT O
reaction NN O
temperature NN O
can MD O
be VB O
in IN O
the DT O
limits NNS O
of IN O
0 CD O
<0>C NNS O
to TO O
80 CD O
[deg.]C. . O

Preferably RB O
, , O
the DT O
reaction NN O
temperature NN O
should MD O
be VB O
between IN O
0 CD O
[deg.]C NNS O

and CC O
50 CD O
<0>C. . O

Most JJS O
preferably RB O
, , O
the DT O
reaction NN O
temperature NN O
should MD O
be VB O
between IN O
0[deg. DT O
] NN O
and CC O
25 CD O
[deg.]C NNS O
in IN O
order NN O
to TO O
obtain VB O
the DT O
best JJS O
stability NN O
of IN O
the DT O
peroxy JJ B-NP
acid NN I-NP
solution NN O
. . O

The DT O
concentrations NNS O
of IN O
the DT O
carboxylic JJ B-NP
acid NN I-NP
solutions NNS O
applied VBD O
in IN O
the DT O
formation NN O
of IN O
the DT O
peroxy JJ B-NP
acid NN I-NP
solution NN O
can MD O
vary VB O
from IN O
30 CD O
% NN O
to TO O
100 CD O
% NN O
by IN O
weight NN O
. . O

Generally RB O
, , O
higher JJR O
concentrations NNS O
are VBP O
favorable JJ O
in IN O
order NN O
to TO O
reach VB O
higher JJR O
final JJ O
concentrations NNS O
of IN O
the DT O
peroxy JJ B-NP
acids NNS I-NP
. . O

The DT O
concentration NN O
of IN O
hydrogen NN B-NP
peroxide NN I-NP
solution NN O
used VBN O
for IN O
the DT O
formation NN O
of IN O
peroxy JJ B-NP
acid NN I-NP
solution NN O
can MD O
be VB O
between IN O
10 CD O
% NN O
and CC O
80 CD O
% NN O
by IN O
weight NN O
. . O

The DT O
hydrogen NN B-NP
peroxide NN I-NP
is VBZ O
introduced VBN O
into IN O
the DT O
solution NN O
as IN O
an DT O
aqueous JJ O
hydrogen NN B-NP
peroxide NN I-NP
solution NN O
, , O
preferably RB O
having VBG O
a DT O
concentration NN O
of IN O
10 CD O
% NN O
to TO O
55 CD O
% NN O
, , O
more JJR O
preferably RB O
30 CD O
% NN O
to TO O
55 CD O
% NN O
by IN O
weight NN O
. . O

Generally RB O
, , O
higher JJR O
concentrations NNS O
of IN O
hydrogen NN B-NP
peroxide NN I-NP
are VBP O
favorable JJ O
in IN O
order NN O
to TO O
reach VB O
higher JJR O
final JJ O
concentrations NNS O
of IN O
the DT O
peroxy JJ B-NP
acids NNS I-NP
. . O

However RB O
, , O
safety NN O
aspects NNS O
must MD O
be VB O
taken VBN O
into IN O
consideration NN O
in IN O
the DT O
preparation NN O
of IN O
concentrated JJ O
peroxy JJ B-NP
acid NN I-NP
solutions NNS O
. . O

The DT O
principles NNS O
of IN O
the DT O
safety NN O
aspects NNS O
concerning VBG O
the DT O
preparation NN O
of IN O
mixtures NNS O
of IN O
hydrogen NN B-NP
peroxide NN I-NP
and CC O
organic JJ O
matter NN O
is VBZ O
described VBN O
for IN O
example NN O
in IN O
" `` O
Concentrated NNP O
Hydrogen NNP B-NP
Peroxide NNP I-NP
: : O
Summary NNP O
of IN O
Research NNP O
Data NNP O
and CC O
Safety NNP O
Limitations NNP O
" '' O
( -LRB- O
Shell NNP O
Chemical NNP O
Corp. NNP O
, , O
Bull NNP O
. . O

SC NNP O
59-44 CD O
) -RRB- O
. . O

The DT O
reaction NN O
time NN O
is VBZ O
largely RB O
depending VBG O
on IN O
the DT O
carboxylic NN B-NP
acids NNS I-NP
used VBN O
. . O

The DT O
kinetics NNS O
of IN O
the DT O
formation NN O
of IN O
peroxyformic JJ O
acid NN O
is VBZ O
described VBN O
by IN O
Mosovsky NNP O
et NNP O
.al NNP O
. . O
in IN O
Collect NNP O
Czech NNP O
. . O

Chem NNP O
. . O

Commun NNP O
. . O

vol NN O
61 CD O
, , O
1996 CD O
, , O
pp RP O
. . O

1457-1463 CD O
and CC O
by IN O
O.D. NNP O
Shapilov NNP O
and CC O
Ua NNP O
. . O

L. NNP O
Kostyukovskii NNP O
in IN O
Kinetika NNP O
Kataliz NNP O
vol NN O
. . O

15 CD O
, , O
n RB O
:o VB O
4 CD O
, , O
1974 CD O
p NN O
. . O
1065 CD O
. . O

The DT O
kinetics NNS O
of IN O
the DT O
formation NN O
of IN O
peracetic JJ B-NP
acid NN I-NP
is VBZ O
also RB O
well RB O
known VBN O
in IN O
the DT O
literature NN O
. . O

However RB O
, , O
the DT O
kinetics NNS O
of IN O
the DT O
formation NN O
of IN O
the DT O
mixtures NNS O
of IN O
the DT O
peroxy NN B-NP
acids NNS I-NP
may MD O
be VB O
different JJ O
when WRB O
mixtures NNS O
of IN O
carboxylic NN B-NP
acids NNS I-NP
are VBP O
applied VBN O
. . O

The DT O
amount NN O
of IN O
peroxy NN B-NP
acids NNS I-NP
in IN O
the DT O
obtained VBN O
solution NN O
is VBZ O
preferably RB O
from IN O
5 CD O
to TO O
20 CD O
% NN O
by IN O
weight NN O
, , O
more JJR O
preferably RB O
from IN O
10 CD O
to TO O
20 CD O
% NN O
by IN O
weight NN O
. . O

The DT O
amount NN O
of IN O
formic JJ B-NP
acid NN I-NP
is VBZ O
preferably RB O
from IN O
2 CD O
to TO O
15 CD O
% NN O
by IN O
weight NN O
of IN O
the DT O
amount NN O
of IN O
the DT O
second JJ O
carboxylic NN B-NP
acid NN I-NP
. . O

The DT O
molar JJ O
ratio NN O
of IN O
the DT O
carboxylic NN B-NP
acids NNS I-NP
to TO O
hydrogen NN B-NP
peroxide NN I-NP
in IN O
the DT O
carboxylic JJ B-NP
acid NN I-NP
solution NN O
is VBZ O
preferably RB O
in IN O
the DT O
range NN O
from IN O
0.5:1 CD O
to TO O
8:1 CD O
, , O
more RBR O
preferably RB O
from IN O
0.7 CD O
:1 CD O
to TO O
2:1. MD O

Said VBD O
molar JJ O
ratio NN O
may MD O
also RB O
be VB O
in IN O
the DT O
range NN O
from IN O
2:1 CD O
to TO O
8:1. CD O

The DT O
obtained VBN O
solution NN O
is VBZ O
preferably RB O
an DT O
equilibrium NN O
solution NN O
additionally RB O
comprising VBG O
formic JJ B-NP
acid NN I-NP
, , O
the DT O
second JJ O
carboxylic NN B-NP
acid NN I-NP
and CC O
hydrogen NN B-NP
peroxide NN I-NP
. . O

The DT O
amount NN O
of IN O
formic JJ B-NP
acid NN I-NP
and CC O
performic JJ B-NP
acid NN I-NP
in IN O
the DT O
equilibrium NN O
solution NN O
is VBZ O
preferably RB O
from IN O
2 CD O
to TO O
20 CD O
% NN O
by IN O
weight NN O
. . O

Said NNP O
second JJ O
carboxylic NN B-NP
acid NN I-NP
is VBZ O
preferably RB O
an DT O
aliphatic JJ O
C2-C18 CC B-NP
carboxylic JJ I-NP
acid NN I-NP
including VBG O
acetic JJ B-NP
acid NN I-NP
, , O
propionic JJ B-NP
acid NN I-NP
, , O
phtalic JJ B-NP
acid NN I-NP
, , O
oxalic JJ B-NP
acid NN I-NP
, , O
malic JJ B-NP
acid NN I-NP
, , O
maleic JJ B-NP
acid NN I-NP
and CC O
fumaric JJ B-NP
acid NN I-NP
and CC O
mixtures NNS O
thereof RB O
, , O
and CC O
said VBD O
second JJ O
peroxy JJ B-NP
acid NN I-NP
is VBZ O
preferably RB O
an DT O
aliphatic JJ B-NP
C2-C18 CC I-NP
peroxy JJ I-NP
carboxylic NN I-NP
acid NN I-NP
including VBG O
peracetic JJ B-NP
acid NN I-NP
, , O
perpropionic JJ B-NP
acid NN I-NP
, , O
peroxy JJ B-NP
phtalic JJ I-NP
acid NN I-NP
, , O
peroxy JJ B-NP
oxalic JJ I-NP
acid NN I-NP
, , O
peroxy JJ B-NP
malic JJ I-NP
acid NN I-NP
, , O
peroxy JJ B-NP
maleic JJ I-NP
acid NN I-NP
and CC O
peroxy NN B-NP
fumaric JJ I-NP
acid NN I-NP
and CC O
mixtures NNS O
thereof RB O
. . O

Especially RB O
preferred JJ O
are VBP O
acetic JJ B-NP
acid NN I-NP
and CC O
peracetic JJ B-NP
acid NN I-NP
. . O

The DT O
formation NN O
of IN O
the DT O
equilibrium NN O
mixtures NNS O
of IN O
peroxy JJ B-NP
acids NNS I-NP
can MD O
be VB O
catalyzed VBN O
by IN O
the DT O
addition NN O
of IN O
strong JJ O
acids NNS O
. . O

The DT O
strong JJ O
acids NNS O
can MD O
be VB O
organic JJ O
acids NNS O
. . O

Preferably RB O
, , O
low JJ O
molecular JJ O
weight NN O
carboxylic NN B-NP
acids NNS I-NP
can MD O
be VB O
used VBN O
as IN O
reaction NN O
catalysts NNS O
. . O

Most JJS O
preferably RB O
, , O
formic JJ B-NP
acid NN I-NP
can MD O
be VB O
used VBN O
as IN O
a DT O
catalyst NN O
. . O

Alternatively RB O
, , O
the DT O
formation NN O
of IN O
the DT O
equilibrium NN O
mixtures NNS O
of IN O
peroxy JJ B-NP
acids NNS I-NP
can MD O
be VB O
catalyzed VBN O
by IN O
mineral NN O
acids NNS O
. . O

The DT O
mineral NN O
acids NNS O
applicable JJ O
for IN O
catalyzing VBG O
the DT O
formation NN O
of IN O
peroxy JJ B-NP
acids NNS I-NP
include VBP O
sulphuric JJ B-NP
acid NN I-NP
, , O
phosphoric JJ B-NP
acid NN I-NP
, , O
hydrochloric JJ B-NP
acid NN I-NP
, , O
pyrophosphoric JJ B-NP
acid NN I-NP
and CC O
polyphosphoric JJ B-NP
acid NN I-NP
and CC O
mixtures NNS O
thereof RB O
. . O

One CD O
advantage NN O
of IN O
for IN O
example NN O
a DT O
sulphuric JJ O
acid NN O
catalyst NN O
is VBZ O
that IN O
it PRP O
also RB O
forms VBZ O
a DT O
peroxy JJ B-NP
acid NN I-NP
( -LRB- O
Caron NNP O
acid NN O
) -RRB- O
to TO O
some DT O
extend VBP O
. . O

The DT O
amount NN O
of IN O
the DT O
acid NN O
catalyst NN O
can MD O
be VB O
from IN O
0.1 CD O
to TO O
20 CD O
% NN O
of IN O
the DT O
weight NN O
of IN O
the DT O
solution NN O
, , O
more JJR O
preferably RB O
from IN O
1 CD O
to TO O
10 CD O
% NN O
of IN O
the DT O
weight NN O
of IN O
the DT O
solution NN O
, , O
most JJS O
preferably RB O
from IN O
1 CD O
to TO O
5 CD O
% NN O
of IN O
the DT O
weight NN O
of IN O
the DT O
solution NN O
. . O

In IN O
addition NN O
, , O
ion NN O
exchange NN O
resins NNS O
in IN O
their PRP$ O
acidic JJ O
forms NNS O
can MD O
be VB O
used VBN O
as IN O
a DT O
catalyst NN O
of IN O
said VBD O
reaction NN O
. . O

Additionally RB O
, , O
conventional JJ O
additives NNS O
may MD O
be VB O
introduced VBN O
into IN O
the DT O
solution NN O
. . O

The DT O
additives NNS O
include VBP O
stabilizers NNS O
such JJ O
as IN O
phosphonates NNS B-NP
, , O
e.g NN O
. . O

1-hydroxy JJ B-NP
ethylene-l,l-diphosphonic JJ I-NP
acid NN I-NP
( -LRB- O
HEDPA NNP B-NP
) -RRB- O
, , O
and CC O
pyridinecarboxylic JJ B-NP
acids NNS I-NP
, , O
e.g NN O
. . O

dipicolinic JJ B-NP
acid NN I-NP
, , O
chelating VBG O
agents NNS O
and CC O
radical JJ O
scavengers NNS O
. . O

Also RB O
mixtures NNS O
of IN O
stabilizers NNS O
maybe RB O
employed VBN O
. . O

The DT O
amount NN O
of IN O
stabilizer( NN O
s VBZ O
) -RRB- O
may MD O
be VB O
from IN O
0.01 CD O
to TO O
1 CD O
% NN O
by IN O
weight NN O
, , O
preferably RB O
from IN O
0.05 CD O
to TO O
0.5 CD O
% NN O
by IN O
weight NN O
. . O

In IN O
a DT O
second JJ O
aspect NN O
of IN O
the DT O
invention NN O
there EX O
is VBZ O
provided VBN O
a DT O
storable JJ O
solution NN O
comprising VBG O
a DT O
first JJ O
peroxy JJ B-NP
acid NN I-NP
comprising NN O
performic JJ B-NP
acid NN I-NP
, , O
a DT O
second JJ O
peroxy JJ B-NP
acid NN I-NP
, , O
a DT O
first JJ O
carboxylic NN B-NP
acid NN I-NP
comprising VBG O
formic JJ B-NP
acid NN I-NP
, , O
a DT O
second JJ O
carboxylic NN B-NP
acid NN I-NP
and CC O
hydrogen NN B-NP
peroxide NN I-NP
, , O
the DT O
amount NN O
of IN O
formic JJ B-NP
acid NN I-NP
and CC O
performic JJ B-NP
acid NN I-NP
being VBG O
from IN O
0.5 CD O
to TO O
20 CD O
% NN O
by IN O
weight NN O
of IN O
the DT O
total JJ O
amount NN O
of IN O
the DT O
second JJ O
carboxylic NN B-NP
acid NN I-NP
and CC O
the DT O
second JJ O
peroxy JJ B-NP
acid NN I-NP
, , O
and CC O
the DT O
amount NN O
of IN O
peroxy NN B-NP
acids NNS I-NP
being VBG O
at IN O
least JJS O
5 CD O
% NN O
by IN O
weight NN O
. . O

In IN O
this DT O
specification NN O
the DT O
term NN O
" `` O
storable JJ O
" '' O
means NNS O
that IN O
the DT O
decrease NN O
of IN O
active JJ B-NP
oxygen NN I-NP
( -LRB- O
peroxy JJ B-NP
acids NNS I-NP
+ IN O
hydrogen NN B-NP
peroxide NN I-NP
) -RRB- O
in IN O
the DT O
peroxy JJ B-NP
acid NN I-NP
solution NN O
is VBZ O
less JJR O
than IN O
20 CD O
% NN O
by IN O
mol NN O
after IN O
7 CD O
days NNS O
' POS O
storage NN O
at IN O
room NN O
temperature NN O
. . O

The DT O
decrease NN O
is VBZ O
preferably RB O
less JJR O
than IN O
15 CD O
% NN O
by IN O
mol NN O
, , O
and CC O
more RBR O
preferably RB O
less JJR O
than IN O
10 CD O
% NN O
by IN O
mol NN O
. . O

The DT O
amount NN O
of IN O
peroxy NN B-NP
acids NNS I-NP
in IN O
the DT O
solution NN O
is VBZ O
preferably RB O
from IN O
5 CD O
to TO O
20 CD O
% NN O
by IN O
weight NN O
, , O
more JJR O
preferably RB O
from IN O
10 CD O
to TO O
20 CD O
% NN O
by IN O
weight NN O
. . O

The DT O
molar JJ O
ratio NN O
of IN O
the DT O
peroxy NN B-NP
acids NNS I-NP
and CC O
carboxylic NN B-NP
acids NNS I-NP
to TO O
hydrogen NN B-NP
peroxide NN I-NP
in IN O
the DT O
solution NN O
is VBZ O
preferably RB O
in IN O
the DT O
range NN O
from IN O
0.5:1 CD O
to TO O
8:1 CD O
, , O
more RBR O
preferably RB O
from IN O
0.7 CD O
:1 CD O
to TO O
2:1. MD O

Said VBD O
molar JJ O
ratio NN O
may MD O
also RB O
be VB O
in IN O
the DT O
range NN O
from IN O
2 CD O
: : O
1 CD O
to TO O
8 CD O
: : O
1 CD O
. . O

The DT O
solution NN O
is VBZ O
preferably RB O
an DT O
equilibrium NN O
solution NN O
. . O

The DT O
amount NN O
of IN O
formic JJ B-NP
acid NN I-NP
and CC O
performic JJ B-NP
acid NN I-NP
in IN O
the DT O
solution NN O
is VBZ O
preferably RB O
from IN O
2 CD O
to TO O
20 CD O
% NN O
by IN O
weight NN O
. . O

Said NNP O
second JJ O
carboxylic NN B-NP
acid NN I-NP
and CC O
said VBD O
second JJ O
peroxy JJ B-NP
acid NN I-NP
are VBP O
as IN O
defined VBN O
above IN O
. . O

Preferably RB O
the DT O
solution NN O
additionally RB O
comprises VBZ O
a DT O
stabilizer NN O
as IN O
defined VBN O
above IN O
. . O

The DT O
invention NN O
also RB O
relates VBZ O
to TO O
the DT O
use NN O
of IN O
the DT O
solution NN O
as IN O
defined VBN O
above IN O
as IN O
a DT O
disinfecting VBG O
agent NN O
for IN O
controlling VBG O
micro-organisms NNS O
. . O

The DT O
solution NN O
of IN O
the DT O
invention NN O
may MD O
be VB O
used VBN O
as IN O
a DT O
disinfecting VBG O
agent NN O
for IN O
example NN O
in IN O
process NN O
water NN B-NP
applications NNS O
, , O
greenhouses NNS O
, , O
dairy NN O
industry NN O
, , O
I& IN O
I PRP O
cleaning VBG O
, , O
P&P NNP O
industry NN O
, , O
for IN O
example NN O
for IN O
controlling VBG O
microbial JJ O
growth NN O
on IN O
paper NN O
machines NNS O
etc FW O
. . O

The DT O
peroxy JJ B-NP
acid NN I-NP
solution NN O
may MD O
also RB O
be VB O
used VBN O
as IN O
bleaching VBG O
agent NN O
in IN O
pulp NN O
bleaching NN O
wherein WRB O
it PRP O
can MD O
be VB O
used VBN O
e.g RB O
. . O
as IN O
a DT O
post- NNS O
bleaching VBG O
agent NN O
of IN O
residual JJ O
lignin NN B-NP
. . O

Additionally RB O
, , O
the DT O
peroxy JJ B-NP
acid NN I-NP
solution NN O
is VBZ O
an DT O
effective JJ O
impregnating JJ O
agent NN O
of IN O
wood NN O
chips NNS O
before IN O
the DT O
preparation NN O
of IN O
mechanical JJ O
pulp NN O
. . O

Concentrated JJ O
solutions NNS O
of IN O
performic JJ B-NP
acid NN I-NP
and CC O
peracetic JJ B-NP
acid NN I-NP
according VBG O
to TO O
the DT O
invention NN O
have VBP O
superior JJ O
effectiveness NN O
in IN O
the DT O
control NN O
of IN O
microbial JJ O
growth NN O
in IN O
process NN O
waters NNS O
, , O
greenhouse NN O
nutrient JJ O
solutions NNS O
, , O
disinfection NN O
of IN O
sewage NN O
waters NNS O
etc FW O
. . O
compared VBN O
to TO O
pure JJ O
peracetic JJ B-NP
acid JJ I-NP
solutions NNS O
. . O

Moreover RB O
, , O
these DT O
PFA/PAA NNS B-NP
solutions NNS O
can MD O
be VB O
prepared VBN O
and CC O
stored VBN O
for IN O
several JJ O
weeks NNS O
without IN O
remarkable JJ O
decomposition NN O
. . O

As IN O
the DT O
anti- NNS O
microbial JJ O
features NNS O
of IN O
the DT O
said VBN O
solutions NNS O
are VBP O
equal JJ O
to TO O
performic JJ B-NP
acid NN I-NP
solutions NNS O
, , O
the DT O
use NN O
of IN O
PFA/PAA NNP B-NP
solutions NNS O
provides VBZ O
a DT O
safe JJ O
alternative NN O
for IN O
the DT O
use NN O
of IN O
performic JJ B-NP
acid JJ I-NP
solutions NNS O
. . O

This DT O
is VBZ O
a DT O
remarkable JJ O
advantage NN O
, , O
since IN O
performic JJ B-NP
acid NN I-NP
solutions NNS O
are VBP O
not RB O
storable JJ O
and CC O
thus RB O
, , O
they PRP O
have VBP O
to TO O
be VB O
prepared VBN O
in IN O
situ NN O
prior RB O
to TO O
use VB O
. . O

Another DT O
advantage NN O
compared VBN O
to TO O
performic JJ B-NP
acid NN I-NP
solutions NNS O
is VBZ O
the DT O
improved JJ O
safety NN O
factor NN O
. . O

PFA/PAA NNS B-NP
solutions NNS O
are VBP O
comparable JJ O
to TO O
pure JJ O
PAA NNP B-NP
solution NN O
in IN O
terms NNS O
of IN O
safety NN O
aspects NNS O
. . O

The DT O
good JJ O
stability NN O
of IN O
the DT O
PFA/PAA NNP B-NP
solutions NNS O
of IN O
the DT O
present JJ O
invention NN O
was VBD O
surprising JJ O
, , O
since IN O
performic JJ B-NP
acid NN I-NP
solutions NNS O
at IN O
higher JJR O
concentrations NNS O
are VBP O
regarded VBN O
to TO O
be VB O
unstable JJ O
. . O

Compared VBN O
to TO O
the DT O
use NN O
of IN O
performic JJ B-NP
acid NN I-NP
, , O
these DT O
solutions NNS O
of IN O
PAA NNP B-NP
and CC O
PFA NNP B-NP
provide VBP O
a DT O
good JJ O
alternative NN O
also RB O
in IN O
terms NNS O
of IN O
corrosivity NN O
. . O

By IN O
applying VBG O
a DT O
mixture NN O
of IN O
PAA NNP B-NP
and CC O
PFA NNP B-NP
having VBG O
the DT O
similar JJ O
anti-microbial JJ O
features NNS O
as IN O
performic JJ B-NP
acid NN I-NP
, , O
the DT O
risk NN O
of IN O
the DT O
corrosion NN O
of IN O
the DT O
equipment NN O
is VBZ O
remarkably RB O
lower JJR O
. . O

As IN O
explained VBN O
above IN O
up RB O
to TO O
20 CD O
% NN O
by IN O
weight NN O
, , O
preferably RB O
up IN O
to TO O
15 CD O
% NN O
by IN O
weight NN O
of IN O
peracetic JJ B-NP
acid NN I-NP
or CC O
another DT O
peroxy JJ B-NP
acid NN I-NP
can MD O
be VB O
replaced VBN O
by IN O
performic JJ B-NP
acid NN I-NP
, , O
still RB O
providing VBG O
storable JJ O
solutions NNS O
. . O

Following VBG O
advantages NNS O
can MD O
be VB O
obtained VBN O
by IN O
the DT O
present JJ O
invention NN O
: : O

Firstly RB O
, , O
a DT O
substantial JJ O
amount NN O
of IN O
performic JJ B-NP
acid NN I-NP
is VBZ O
formed VBN O
into IN O
the DT O
solution NN O
and CC O
this DT O
should MD O
increase VB O
the DT O
disinfecting JJ O
power NN O
of IN O
the DT O
peroxy JJ B-NP
acid NN I-NP
solution NN O
. . O

Secondly RB O
, , O
peroxy JJ B-NP
acid NN I-NP
solutions NNS O
, , O
suitable JJ O
for IN O
greenhouse NN O
applications NNS O
etc NN O
can MD O
be VB O
prepared VBN O
and CC O
stored VBN O
, , O
whereas IN O
nowadays RB O
PFA JJ B-NP
solutions NNS O
must MD O
be VB O
prepared VBN O
in IN O
situ NN O
from IN O
the DT O
solutions NNS O
of IN O
formic JJ B-NP
acid NN I-NP
and CC O
hydrogen NN B-NP
peroxide NN I-NP
. . O

Thirdly RB O
, , O
the DT O
resulting VBG O
peroxy JJ B-NP
acid NN I-NP
solution NN O
could MD O
be VB O
used VBN O
as IN O
bleaching VBG O
agent NN O
in IN O
pulp NN O
bleaching NN O
wherein WRB O
it PRP O
can MD O
be VB O
used VBN O
e.g RB O
. . O
as IN O
a DT O
post- NNS O
bleaching VBG O
agent NN O
of IN O
residual JJ O
lignin NN B-NP
. . O

Additionally RB O
, , O
the DT O
peroxy NN B-NP
acid NN I-NP
mixture NN O
is VBZ O
an DT O
effective JJ O
impregnating JJ O
agent NN O
of IN O
wood NN O
chips NNS O
before IN O
the DT O
preparation NN O
of IN O
mechanical JJ O
pulp NN O
. . O

hi PRP O
this DT O
specification NN O
percentages NNS O
refer VBP O
to TO O
% NN O
by IN O
weight NN O
unless IN O
otherwise RB O
specified VBN O
. . O

The DT O
invention NN O
is VBZ O
explained VBN O
in IN O
more JJR O
detail NN O
in IN O
the DT O
following VBG O
examples NNS O
. . O

Example NNP O
1 CD O

0.6 CD O
% NN O
, , O
3.04 CD O
% NN O
, , O
4.99 CD O
% NN O
, , O
10.04 CD O
% NN O
and CC O
15.01 CD O
% NN O
solutions NNS O
of IN O
formic JJ B-NP
acid NN I-NP
( -LRB- O
FA NNP B-NP
) -RRB- O
in IN O
acetic JJ B-NP
acid NN I-NP
( -LRB- O
AA NNP B-NP
) -RRB- O
were VBD O
prepared VBN O
. . O

The DT O
solutions NNS O
were VBD O
mixed VBN O
in IN O
molar JJ O
ratio NN O
2 CD O
: : O
1 CD O
( -LRB- O
AA NN B-NP
/H2O2 NN O
) -RRB- O
with IN O
50.5 CD O
% NN O
H2O2 NN B-NP
. . O

As IN O
stabilizers NNS O
, , O
phosphonate JJ B-NP
( -LRB- O
HEDPA NNP B-NP
, , O
500 CD O
mg/1 NNS O
) -RRB- O
and CC O
dipicolinic JJ B-NP
acid NN I-NP
( -LRB- O
DPA NNP O
, , O
300 CD O
mg/1 NN O
) -RRB- O
were VBD O
added VBN O
into IN O
each DT O
solution NN O
. . O

The DT O
resulting JJ O
solutions NNS O
were VBD O
stirred VBN O
overnight RB O
at IN O
room NN O
temperature NN O
. . O

The DT O
solutions NNS O
were VBD O
stored VBN O
in IN O
dark JJ O
, , O
at IN O
RT NNP O
for IN O
7 CD O
days NNS O
and CC O
the DT O
concentrations NNS O
of IN O
peroxy JJ B-NP
acid NN I-NP
( -LRB- O
here RB O
calculated VBN O
as IN O
peracetic JJ B-NP
acid NN I-NP
) -RRB- O
and CC O
hydrogen NN B-NP
peroxide NN I-NP
were VBD O
determined VBN O
by IN O
titrations NNS O
. . O

After IN O
3 CD O
d JJ O
storage NN O
, , O
0.48 CD O
% NN O
of IN O
sulfuric JJ B-NP
acid NN I-NP
was VBD O
added VBN O
to TO O
further RBR O
catalyze VB O
the DT O
reaction NN O
. . O

The DT O
total JJ O
active JJ B-NP
oxygen NN I-NP
content NN O
( -LRB- O
peracid JJ B-NP
+ NN O
peroxide NN B-NP
) -RRB- O
was VBD O
determined VBN O
for IN O
each DT O
sample NN O
. . O

The DT O
test NN O
results NNS O
are VBP O
shown VBN O
in IN O
following VBG O
Tables NNS O
1 CD O
to TO O
3. CD O
The DT O
stability NN O
% NN O
describes VBZ O
the DT O
ratio NN O
between IN O
the DT O
analyzed VBN O
amount NN O
of IN O
peracid NN B-NP
( -LRB- O
mol/kg NN O
) -RRB- O
+ NN O
H2O2 IN B-NP
( -LRB- O
mol/kg NN O
) -RRB- O
and CC O
the DT O
originally RB O
added VBN O
H2O2 IN B-NP
( -LRB- O
mol/kg NN O
) -RRB- O
. . O

Table NN O
1 CD O
( -LRB- O
results NNS O
after IN O
1 CD O
day NN O
) -RRB- O

% NN O
of IN O
FA NNP B-NP
H2O2 NNP B-NP
H2O2 NNP B-NP
peracid NN B-NP
peracid NN B-NP
act NN O
( -LRB- O
O UH O
) -RRB- O
stability NN O
in IN O
AA NNP B-NP
g/kg NNP O
mol/kg NN O
g/kg NN O
mol/kg NN O
mol/kg NN O
% NN O

0.60 CD O
141.18 CD O
4.15 CD O
87.34 CD O
1.12 CD O
5.27 CD O
100.59 CD O
% NN O

3.04 CD O
129.06 CD O
3.80 CD O
101.29 CD O
1.30 CD O
5.09 CD O
97.33 CD O
% NN O

4.99 CD O
129.74 CD O
3.82 CD O
103.64 CD O
1.33 CD O
5.14 CD O
97.61 CD O
% NN O

10.04 CD O
117.09 CD O
3.44 CD O
113.88 CD O
1.46 CD O
4.90 CD O
93.32 CD O
% NN O

15.01 CD O
110.41 CD O
3.25 CD O
117.73 CD O
1.51 CD O
4.76 CD O
90.65 CD O
% NN O

Table NN O
2 CD O
( -LRB- O
results NNS O
after IN O
3 CD O
days NNS O
) -RRB- O

% NN O
of IN O
FA NNP B-NP
H2O2 NNP B-NP
H2O2 NNP B-NP
peracid NN B-NP
peracid NN B-NP
act NN O
( -LRB- O
O UH O
) -RRB- O
stability NN O
in IN O
AA NNP B-NP
g/kg NNP O
mol/kg NN O
g/kg NN O
mol/kg NN O
mol/kg NN O
% NN O

0.60 CD O
122.27 CD O
3.60 CD O
123.16 CD O
1.58 CD O
5.18 CD O
99.36 CD O
% NN O

3.04 CD O
112.31 CD O
3.30 CD O
135.52 CD O
1.74 CD O
5.04 CD O
96.16 CD O
% NN O

4.99 CD O
111.32 CD O
3.27 CD O
131.05 CD O
1.68 CD O
4.95 CD O
94.64 CD O
% NN O

10.04 CD O
99.34 CD O
2.92 CD O
137.37 CD O
1.76 CD O
4.68 CD O
89.46 CD O
% NN O

15.01 CD O
89.29 CD O
2.63 CD O
136.67 CD O
1.75 CD O
4.38 CD O
84.67 CD O
% NN O

Table NN O
3 CD O
( -LRB- O
results NNS O
after IN O
7 CD O
days NNS O
) -RRB- O

% NN O
of IN O
FA NNP B-NP
H2O2 NNP B-NP
H2O2 NNP B-NP
peracid NN B-NP
peracid NN O
act NN O
( -LRB- O
O UH O
) -RRB- O
stability NN O
in IN O
AA NNP B-NP
g/kg NNP O
mol/kg NN O
g/kg NN O
mol/kg NN O
mol/kg NN O
% NN O
0.60 CD O
68.18 CD O
2.01 CD O
241.53 CD O
3.10 CD O
5.10 CD O
98.06 CD O
% NN O

3. DT O
04 CD O
68.66 CD O
2.02 CD O
233.59 CD O
2.99 CD O
5.01 CD O
94.89 CD O
% NN O

4 CD O
. . O
99 CD O
67.66 CD O
1.99 CD O
224.47 CD O
2.88 CD O
4.87 CD O
92.90 CD O
% NN O

10 CD O
.04 CD O

64.33 CD O
1.89 CD O
204.29 CD O
2.62 CD O
4.51 CD O
86.64 CD O
% NN O

15 CD O
.01 CD O

62.55 CD O
1.84 CD O
191.27 CD O
2.45 CD O
4.29 CD O
82.01 CD O
% NN O

From IN O
the DT O
tables NNS O
1 CD O
to TO O
3 CD O
can MD O
be VB O
seen VBN O
the DT O
amounts NNS O
and CC O
formation NN O
rates NNS O
of IN O
peracids NNS B-NP
when WRB O
different JJ O
amounts NNS O
of IN O
acetic JJ B-NP
acid NN I-NP
are VBP O
replaced VBN O
by IN O
formic JJ B-NP
acid NN I-NP
. . O

The DT O
decrease NN O
of IN O
active JJ B-NP
oxygen NN I-NP
( -LRB- O
peracid JJ B-NP
+ NN O
peroxide NN B-NP
) -RRB- O
indicates VBZ O
the DT O
decomposition NN O
of IN O
total JJ O
peroxy NN B-NP
acids NNS I-NP
when WRB O
the DT O
amount NN O
of IN O
formic JJ B-NP
acid NN I-NP
is VBZ O
increased VBN O
in IN O
the DT O
starting VBG O
solution NN O
. . O

However RB O
, , O
even RB O
when WRB O
15 CD O
% NN O
of IN O
acetic JJ B-NP
acid NN I-NP
was VBD O
substituted VBN O
by IN O
formic JJ B-NP
acid NN I-NP
, , O
over IN O
80 CD O
% NN O
of IN O
the DT O
active JJ B-NP
oxygen NN I-NP
was VBD O
preserved VBN O
after IN O
7 CD O
days NNS O
' POS O
storage NN O
. . O

Example NN O
2 CD O

Efficacy NN O
of IN O
PFA-PAA NNP B-NP
mixtures NNS O
towards IN O
pre-grown JJ O
biofilm NN O
on IN O
stainless JJ O
steel NN O
surface NN O

Kemira NNP O
has VBZ O
developed VBN O
a DT O
new JJ O
test NN O
intended VBD O
for IN O
rapid JJ O
efficacy NN O
testing NN O
of IN O
anti-biof[iota]lm JJ O
agents NNS O
. . O

The DT O
test NN O
is VBZ O
disclosed VBN O
in IN O
patent NN O
application NN O
WO NN O
2005/045132 CD O
. . O

m NN O
this DT O
assay NN O
different JJ O
products NNS O
are VBP O
compared VBN O
for IN O
their PRP$ O
relative JJ O
efficacy NN O
in IN O
inactivation/removal NN O
of IN O
pre-grown JJ O
biofilms NNS O
. . O

The DT O
real JJ O
situation NN O
in IN O
paper NN O
machines NNS O
is VBZ O
often RB O
that IN O
it PRP O
is VBZ O
not RB O
enough RB O
to TO O
prevent VB O
formation NN O
of IN O
new JJ O
biofilms NNS O
, , O
but CC O
the DT O
anti-biofilm JJ O
agents NNS O
should MD O
also RB O
perform VB O
on IN O
pre JJ O
- : O
contaminated JJ O
surfaces NNS O
. . O

In IN O
the DT O
new JJ O
test NN O
pre-grown JJ O
biofilms NNS O
are VBP O
exposed VBN O
for IN O
a DT O
short JJ O
time NN O
, , O
and CC O
after IN O
that IN O
the DT O
viability NN O
of IN O
remaining VBG O
biofilms NNS O
is VBZ O
quantified VBN O
. . O

Biofilms NNS O
were VBD O
produced VBN O
on IN O
the DT O
surfaces NNS O
of IN O
stainless JJ O
steel NN O
protrusions NNS O
. . O

This DT O
was VBD O
achieved VBN O
by IN O
immersing VBG O
the DT O
steel NN O
plate NN O
with IN O
protrusions NNS O
to TO O
a DT O
mixture NN O
of IN O
true JJ O
primary-biofilrn JJ O
formers NNS O
of IN O
paper NN O
industry NN O
( -LRB- O
Deinococcus NNP O
geothermalis NNP O
, , O
Pseudoxanthomonas NNP O
taiwanensis NN O
and CC O
Meiothermus JJ O
silvanus NN O
) -RRB- O
mixed JJ O
with IN O
clear JJ O
filtrate NN O
from IN O
a DT O
neutral JJ O
board NN O
machine NN O
and CC O
cultivating VBG O
in IN O
continuous JJ O
shaking NN O
( -LRB- O
2 CD O
d NN O
, , O
45 CD O
[deg.]C NNS O
) -RRB- O
. . O

Grown-up JJ O
biofilms NNS O
on IN O
the DT O
protrusions NNS O
were VBD O
exposed VBN O
to TO O
different JJ O
biocides NNS O
for IN O
1.5 CD O
hour NN O
at IN O
room NN O
temperature NN O
. . O

The DT O
viability NN O
of IN O
remaining VBG O
biofilms NNS O
was VBD O
measured VBN O
by IN O
transferring VBG O
the DT O
stainless JJ O
steel NN O
plates NNS O
to TO O
sterile JJ O
R2 NN O
broth NN O
and CC O
incubating VBG O
at IN O
45 CD O
[deg.]C NN O
for IN O
21 CD O
h NN O
. . O

The DT O
amount NN O
of IN O
new JJ O
biofilm NN O
formed VBD O
indicated VBN O
the DT O
survival NN O
rate NN O
of IN O
the DT O
original JJ O
, , O
treated VBN O
biofilms NNS O
. . O

The DT O
tested VBN O
biocides NNS O
were VBD O
: : O
PFA-PAA NNP B-NP
: : O
a DT O
mixture NN O
of IN O
performic JJ B-NP
acid NN I-NP
and CC O
peracetic JJ B-NP
acid NN I-NP
was VBD O
prepared VBN O
by IN O
mixing VBG O
5.9 CD O
g JJ O
formic JJ B-NP
acid NN I-NP
solution NN O
( -LRB- O
concentration NN O
75 CD O
weight NN O
% NN O
) -RRB- O
to TO O
44.6 CD O
g NN O
acetic JJ B-NP
acid NN I-NP
solution NN O
( -LRB- O
concentration NN O
99 CD O
weight NN O
% NN O
) -RRB- O
and CC O
100 CD O
g VBG O
hydrogen NN B-NP
peroxide NN I-NP
solution NN O
( -LRB- O
concentration NN O
50 CD O
weight NN O
% NN O
) -RRB- O
was VBD O
added VBN O
to TO O
the DT O
carboxylic NN B-NP
acid NN I-NP
mixture NN O
by IN O
cooling VBG O
. . O

Additionally RB O
2.0 CD O
g NN O
stabilizer NN O
and CC O
7.5 CD O
g NN O
concentrated VBD O
sulphuric JJ B-NP
acid NN I-NP
was VBD O
added VBN O
. . O

The DT O
peroxy JJ B-NP
acid NN I-NP
content NN O
was VBD O
9.3 CD O
weight NN O
% NN O
and CC O
H2O2 JJ B-NP
content JJ O
28 CD O
weight NN O
% NN O
. . O

ePAA NN O
: : O
an DT O
equilibrium NN O
peracetic JJ B-NP
acid NN I-NP
solution NN O
trade NN O
name NN O
Kemirox NNP O
WT NNP O
, , O
containing VBG O
15 CD O
weight NN O
% NN O
of IN O
pure JJ O
peracetic JJ B-NP
acid NN I-NP
, , O
15 CD O
weight NN O
% NN O
hydrogen NN B-NP
peroxide NN I-NP
and CC O
24 CD O
weight NN O
% NN O
acetic JJ B-NP
acid NN I-NP
. . O

The DT O
dosing NN O
of IN O
the DT O
mixture NN O
was VBD O
based VBN O
on IN O
the DT O
sum NN O
of IN O
peracids NNS B-NP
. . O

Following VBG O
doses NNS O
were VBD O
used VBN O
0, IN O
2 CD O
, , O
3 CD O
, , O
4 CD O
, , O
5 CD O
, , O
6 CD O
, , O
7<1>Z2 CD O
, , O
10 CD O
and CC O
15 CD O
ppm NN O
of IN O
PAA NNP B-NP
or CC O
a DT O
mixture NN O
of IN O
PAA NNP B-NP
and CC O
PFA NNP B-NP
, , O
respectively RB O
. . O

AU IN O
biocides NNS O
were VBD O
treated VBN O
as IN O
active JJ O
ingredient NN O
and CC O
weighted JJ O
in IN O
deionized JJ O
water NN B-NP
and CC O
diluted VBN O
in IN O
tap NN O
water NN B-NP
. . O

The DT O
test NN O
results NNS O
show VBP O
that IN O
the DT O
PFA-PAA NNP B-NP
mixture NN O
was VBD O
a DT O
clearly RB O
better RBR O
biocide JJ O
than IN O
ePAA NNS O
. . O

A DT O
clear JJ O
effect NN O
was VBD O
observed VBN O
with IN O
3 CD O
ppm NN O
and CC O
a DT O
complete JJ O
inactivation NN O
with IN O
5 CD O
ppm NN O
. . O

When WRB O
an DT O
ordinary JJ O
ePAA NN O
solution NN O
was VBD O
applied VBN O
a DT O
clear JJ O
effect NN O
was VBD O
not RB O
seen VBN O
until IN O
10 CD O
ppm JJ O
concentration NN O
of IN O
PAA NNP B-NP
was VBD O
applied VBN O
. . O

Even RB O
15 CD O
ppm JJ O
concentration NN O
of IN O
ePAA NN O
did VBD O
not RB O
result VB O
in IN O
complete JJ O
inactivation NN O
of IN O
the DT O
microbes NNS O
. . O

Based VBN O
on IN O
the DT O
active JJ O
PAA NNP B-NP
content NN O
, , O
PFA-PAA NNP B-NP
mixture NN O
was VBD O
3 CD O
to TO O
4 CD O
times NNS O
more RBR O
efficient JJ O
than IN O
ePAA NNS O
. . O

As IN O
product NN O
, , O
PFA-PAA NNP B-NP
was VBD O
roughly RB O
two CD O
times NNS O
more RBR O
efficient JJ O
than IN O
ePAA NNS O
in IN O
biofilm NN O
inactivation NN O
. . O

Claims NNS O

1 LS O
. . O
Process NNP O
for IN O
the DT O
preparation NN O
of IN O
a DT O
solution NN O
comprising VBG O
a DT O
first JJ O
peroxy JJ B-NP
acid NN I-NP
comprising NN O
performic JJ B-NP
acid NN I-NP
and CC O
a DT O
second JJ O
peroxy JJ B-NP
acid NN I-NP
, , O
said VBD O
process NN O
comprising NN O
forming VBG O
a DT O
carboxylic JJ B-NP
acid NN I-NP
solution NN O
comprising VBG O
a DT O
first JJ O
carboxylic NN B-NP
acid NN I-NP
comprising VBG O
formic JJ B-NP
acid NN I-NP
, , O
a DT O
second JJ O
carboxylic NN B-NP
acid NN I-NP
and CC O
hydrogen NN B-NP
peroxide NN I-NP
, , O
wherein WRB O
the DT O
amount NN O
of IN O
formic JJ B-NP
acid NN I-NP
is VBZ O
from IN O
0.5 CD O
to TO O
20 CD O
% NN O
by IN O
weight NN O
of IN O
the DT O
amount NN O
of IN O
the DT O
second JJ O
carboxylic NN B-NP
acid NN I-NP
, , O
and CC O
allowing VBG O
the DT O
components NNS O
to TO O
react VB O
to TO O
form VB O
a DT O
solution NN O
comprising NN O
performic JJ B-NP
acid NN I-NP
and CC O
said VBD O
second JJ O
peroxy JJ B-NP
acid NN I-NP
, , O
the DT O
amount NN O
of IN O
peroxy NN B-NP
acids NNS I-NP
being VBG O
at IN O
least JJS O
5 CD O
% NN O
by IN O
weight NN O
. . O

2. DT O
The DT O
process NN O
according VBG O
to TO O
claim NN O
1 CD O
wherein WRB O
the DT O
amount NN O
of IN O
peroxy NN B-NP
acids NNS I-NP
in IN O
the DT O
obtained VBN O
solution NN O
is VBZ O
from IN O
5 CD O
to TO O
20 CD O
% NN O
by IN O
weight NN O
. . O

3. DT O
The DT O
process NN O
according VBG O
to TO O
claim NN O
1 CD O
or CC O
2 CD O
wherein WRB O
the DT O
molar JJ O
ratio NN O
of IN O
the DT O
carboxylic NN B-NP
acids NNS I-NP
to TO O
hydrogen NN B-NP
peroxide NN I-NP
in IN O
the DT O
carboxylic JJ B-NP
acid NN I-NP
solution NN O
is VBZ O
in IN O
the DT O
range NN O
from IN O
0.5:1 CD O
to TO O
8:1 CD O
, , O
preferably RB O
from IN O
0.7 CD O
:1 CD O
to TO O
2:1. MD O

4 LS O
. . O
The DT O
process NN O
according VBG O
to TO O
any DT O
of IN O
claims NNS O
1 CD O
to TO O
3 CD O
wherein WRB O
the DT O
obtained VBN O
solution NN O
is VBZ O
an DT O
equilibrium NN O
solution NN O
additionally RB O
comprising VBG O
formic JJ B-NP
acid NN I-NP
, , O
the DT O
second JJ O
carboxylic NN B-NP
acid NN I-NP
and CC O
hydrogen NN B-NP
peroxide NN I-NP
. . O

5 CD O
. . O
The DT O
process NN O
according VBG O
to TO O
claim VB O
4 CD O
wherein WRB O
the DT O
amount NN O
of IN O
formic JJ B-NP
acid NN I-NP
and CC O
performic JJ B-NP
acid NN I-NP
in IN O
the DT O
equilibrium NN O
solution NN O
is VBZ O
from IN O
2 CD O
to TO O
20 CD O
% NN O
by IN O
weight NN O
. . O

6 CD O
. . O

The DT O
process NN O
according VBG O
to TO O
any DT O
of IN O
claims NNS O
1 CD O
to TO O
5 CD O
wherein WRB O
said VBD O
second JJ O
carboxylic NN B-NP
acid NN I-NP
comprises VBZ O
acetic JJ B-NP
acid NN I-NP
, , O
propionic JJ B-NP
acid NN I-NP
, , O
phtalic JJ B-NP
acid NN I-NP
, , O
oxalic JJ B-NP
acid NN I-NP
, , O
malic JJ B-NP
acid NN I-NP
, , O
maleic JJ B-NP
acid NN I-NP
or CC O
fumaric JJ B-NP
acid NN I-NP
or CC O
a DT O
mixture NN O
thereof RB O
, , O
and CC O
said VBD O
second JJ O
peroxy JJ B-NP
acid NN I-NP
comprises VBZ O
peracetic JJ B-NP
acid NN I-NP
, , O
perpropionic JJ B-NP
acid NN I-NP
, , O
peroxy JJ B-NP
phtalic JJ I-NP
acid NN I-NP
, , O
peroxy JJ B-NP
oxalic JJ I-NP
acid NN I-NP
, , O
peroxy JJ B-NP
malic JJ I-NP
acid NN I-NP
, , O
peroxy JJ B-NP
maleic JJ I-NP
acid NN I-NP
or CC O
peroxy NN B-NP
fumaric JJ I-NP
acid NN I-NP
or CC O
a DT O
mixture NN O
thereof RB O
. . O

7. DT O
The DT O
process NN O
according VBG O
to TO O
any DT O
of IN O
claims NNS O
1 CD O
to TO O
6 CD O
wherein WRB O
a DT O
catalyst NN O
is VBZ O
introduced VBN O
into IN O
the DT O
solution NN O
. . O

8. DT O
The DT O
process NN O
according VBG O
to TO O
claim NN O
7 CD O
wherein WRB O
the DT O
catalyst NN O
comprises VBZ O
a DT O
mineral NN O
acid NN O
, , O
preferably RB O
sulphuric JJ B-NP
acid NN I-NP
or CC O
hydrochloric JJ B-NP
acid NN I-NP
or CC O
a DT O
mixture NN O
thereof RB O
. . O

9 CD O
. . O
The DT O
process NN O
according VBG O
to TO O
claim NN O
7 CD O
wherein WRB O
the DT O
catalyst NN O
comprises VBZ O
an DT O
organic JJ O
acid NN O
, , O
preferably RB O
formic JJ B-NP
acid NN I-NP
. . O

10 CD O
. . O

The DT O
process NN O
according VBG O
to TO O
any DT O
of IN O
claims NNS O
1 CD O
to TO O
9 CD O
wherein WRB O
a DT O
stabilizer NN O
is VBZ O
introduced VBN O
into IN O
the DT O
solution NN O
. . O

11 CD O
. . O

The DT O
process NN O
according VBG O
to TO O
claim NN O
10 CD O
wherein WRB O
the DT O
stabilizer NN O
comprises VBZ O
a DT O
phosphonate NN B-NP
, , O
such JJ O
as IN O
1 CD B-NP
-hydroxy JJ I-NP
ethylene NN I-NP
- : I-NP
1,1-diphosphonic JJ I-NP
acid NN I-NP
, , O
or CC O
a DT O
pyridinecarboxylic JJ B-NP
acid NN I-NP
, , O
such JJ O
as IN O
dipicolinic JJ B-NP
acid NN I-NP
or CC O
a DT O
mixture NN O
thereof RB O
. . O

12 CD O
. . O
A DT O
storable JJ O
solution NN O
comprising VBG O
a DT O
first JJ O
peroxy JJ B-NP
acid NN I-NP
comprising NN O
performic JJ B-NP
acid NN I-NP
, , O
a DT O
second JJ O
peroxy JJ B-NP
acid NN I-NP
, , O
a DT O
first JJ O
carboxylic NN B-NP
acid NN I-NP
comprising VBG O
formic JJ B-NP
acid NN I-NP
, , O
a DT O
second JJ O
carboxylic NN B-NP
acid NN I-NP
and CC O
hydrogen NN B-NP
peroxide NN I-NP
, , O
the DT O
amount NN O
of IN O
formic JJ B-NP
acid NN I-NP
and CC O
performic JJ B-NP
acid NN I-NP
being VBG O
from IN O
0.5 CD O
to TO O
20 CD O
% NN O
by IN O
weight NN O
of IN O
the DT O
total JJ O
amount NN O
of IN O
the DT O
second JJ O
carboxylic NN B-NP
acid NN I-NP
and CC O
the DT O
second JJ O
peroxy JJ B-NP
acid NN I-NP
, , O
and CC O
the DT O
amount NN O
of IN O
peroxy NN B-NP
acids NNS I-NP
being VBG O
at IN O
least JJS O
5 CD O
% NN O
by IN O
weight NN O
. . O

13 CD O
. . O

The DT O
solution NN O
according VBG O
to TO O
claim VB O
12 CD O
wherein WRB O
the DT O
amount NN O
of IN O
peroxy NN B-NP
acids NNS I-NP
in IN O
the DT O
solution NN O
is VBZ O
from IN O
5 CD O
to TO O
20 CD O
% NN O
by IN O
weight NN O
. . O

14 CD O
. . O

The DT O
solution NN O
according VBG O
to TO O
claim VB O
12 CD O
or CC O
13 CD O
wherein WRB O
the DT O
molar JJ O
ratio NN O
of IN O
the DT O
peroxy NN B-NP
acids NNS I-NP
and CC O
carboxylic NN B-NP
acids NNS I-NP
to TO O
hydrogen NN B-NP
peroxide NN I-NP
is VBZ O
in IN O
the DT O
range NN O
from IN O
0.5:1 CD O
to TO O
8:1 CD O
, , O
preferably RB O
from IN O
0.7 CD O
:1 CD O
to TO O
2:1. MD O

15 CD O
. . O

The DT O
solution NN O
according VBG O
to TO O
any DT O
of IN O
claims NNS O
12 CD O
to TO O
14 CD O
wherein WRB O
the DT O
solution NN O
is VBZ O
an DT O
equilibrium NN O
solution NN O
. . O

16 CD O
. . O

The DT O
solution NN O
according VBG O
to TO O
any DT O
of IN O
claims NNS O
12 CD O
to TO O
15 CD O
wherein WRB O
the DT O
amount NN O
of IN O
formic JJ B-NP
acid NN I-NP
and CC O
performic JJ B-NP
acid NN I-NP
in IN O
the DT O
solution NN O
is VBZ O
from IN O
2 CD O
to TO O
20 CD O
% NN O
by IN O
weight NN O
. . O

17 CD O
. . O

The DT O
solution NN O
according VBG O
to TO O
any DT O
of IN O
claims NNS O
12 CD O
to TO O
16 CD O
wherein WRB O
said VBD O
second JJ O
carboxylic NN B-NP
acid NN I-NP
comprises VBZ O
acetic JJ B-NP
acid NN I-NP
, , O
propionic JJ B-NP
acid NN I-NP
, , O
phtalic JJ B-NP
acid NN I-NP
, , O
oxalic JJ B-NP
acid NN I-NP
, , O
malic JJ B-NP
acid NN I-NP
, , O
maleic JJ B-NP
acid NN I-NP
or CC O
fumaric JJ B-NP
acid NN I-NP
or CC O
a DT O
mixture NN O
thereof RB O
, , O
and CC O
said VBD O
second JJ O
peroxy JJ B-NP
acid NN I-NP
comprises VBZ O
peracetic JJ B-NP
acid NN I-NP
, , O
perpropionic JJ B-NP
acid NN I-NP
, , O
peroxy JJ B-NP
phtalic JJ I-NP
acid NN I-NP
, , O
peroxy JJ B-NP
oxalic JJ I-NP
acid NN I-NP
, , O
peroxy JJ B-NP
malic JJ I-NP
acid NN I-NP
, , O
peroxy JJ B-NP
maleic JJ I-NP
acid NN I-NP
or CC O
peroxy NN B-NP
fumaric JJ I-NP
acid NN I-NP
or CC O
a DT O
mixture NN O
thereof RB O
. . O

18 CD O
. . O

The DT O
solution NN O
according VBG O
to TO O
any DT O
of IN O
claims NNS O
12 CD O
to TO O
17 CD O
additionally NN O
comprising VBG O
a DT O
stabilizer NN O
. . O

19 CD O
. . O

The DT O
solution NN O
according VBG O
to TO O
claim NN O
18 CD O
wherein WRB O
the DT O
stabilizer NN O
comprises VBZ O
a DT O
phosphonate NN B-NP
, , O
such JJ O
as IN O
1 CD B-NP
-hydroxy JJ I-NP
ethylene NN I-NP
- : I-NP
1,1-diphosphonic JJ I-NP
acid NN I-NP
, , O
or CC O
a DT O
pyridinecarboxylic JJ B-NP
acid NN I-NP
, , O
such JJ O
as IN O
dipicolinic JJ B-NP
acid NN I-NP
or CC O
a DT O
mixture NN O
thereof RB O
. . O

20 CD O
. . O
Use NNP O
of IN O
the DT O
solution NN O
of IN O
any DT O
of IN O
claims NNS O
12 CD O
to TO O
19 CD O
as IN O
a DT O
disinfecting VBG O
agent NN O
for IN O
controlling VBG O
micro-organisms NNS O
. . O

21 CD O
. . O

The DT O
use NN O
according VBG O
to TO O
claim NN O
20 CD O
for IN O
greenhouse NN O
disinfection NN O
or CC O
sewage NN O
water NN B-NP
disinfection NN O
or CC O
for IN O
controlling VBG O
microbial JJ O
growth NN O
on IN O
paper NN O
machines NNS O
. . O

-DOCSTART- X X O

[0001] JJ O
STABILIZED NNP O
PROTEASE NNP O
COMPOSITION NN O

Field NNP O
of IN O
the DT O
invention NN O

The DT O
present JJ O
invention NN O
relates NNS O
to TO O
an DT O
enzyme NN O
composition NN O
in IN O
which WDT O
the DT O
enzyme NN O
is VBZ O
stabilized VBN O
by IN O
certain JJ O
additives NNS O
in IN O
an DT O
inventive JJ O
combination NN O
. . O

More RBR O
particularly RB O
, , O
the DT O
invention NN O
concerns VBZ O
a DT O
serine NN O
protease NN O
composition NN O
comprising VBG O
a DT O
reversible JJ B-NP
inhibitor NN I-NP
to TO I-NP
the DT I-NP
serine NN I-NP
protease NN I-NP
and CC O
an DT O
additional JJ O
stabilizing VBG O
agent NN O
M NNP O
as IN O
defined VBN O
below IN O
. . O

Background CC O
Serine NN O
proteases NNS O
are VBP O
a DT O
group NN O
of IN O
proteolytic JJ O
enzymes NNS O
characterized VBN O
by IN O
having VBG O
a DT O
serine NN O
and CC O
a DT O
histidine NN B-NP
residue NN I-NP
in IN O
their PRP$ O
active JJ O
site NN O
. . O

Many JJ O
well RB O
known VBN O
enzymes NNS O
belong VBP O
to TO O
this DT O
group NN O
, , O
for IN O
example NN O
trypsin NNS O
, , O
kallikrein NN O
, , O
thrombin NN O
and CC O
plasmin NN O
. . O

Several JJ O
of IN O
them PRP O
have VBP O
found VBN O
practical JJ O
use NN O
. . O

Trypsin NN O
is VBZ O
used VBN O
in IN O
the DT O
leather NN O
industry NN O
. . O

Thrombin NNP O
is VBZ O
used VBN O
as IN O
a DT O
haemostatic JJ O
agent NN O
to TO O
stop VB O
bleeding VBG O
from IN O
wounds NNS O
. . O

Urokinase NNP O
and CC O
tissue NN O
plasminogen NN O
activator NN O
, , O
two CD O
other JJ O
serine NN O
proteases NNS O
, , O
are VBP O
used VBN O
clinically RB O
as IN O
thrombolytic JJ O
agents NNS O
in IN O
the DT O
treatment NN O
of IN O
acute JJ O
myocardial JJ O
infarction NN O
. . O

A DT O
number NN O
of IN O
these DT O
enzymes NNS O
have VBP O
been VBN O
used VBN O
extensively RB O
as IN O
research NN O
tools NNS O
, , O
for IN O
instance NN O
in IN O
protein NN O
structure NN O
determination NN O
. . O

Furthermore RB O
, , O
the DT O
enzymes NNS O
are VBP O
used VBN O
in IN O
various JJ O
diagnostic JJ O
kits NNS O
. . O

Common JJ O
to TO O
most JJS O
of IN O
the DT O
serine NN O
proteases NNS O
are VBP O
their PRP$ O
limited JJ O
stability NN O
in IN O
solution NN O
. . O

This DT O
is VBZ O
mainly RB O
caused VBN O
by IN O
autodegradation NN O
when WRB O
left VBN O
in IN O
solution NN O
, , O
caused VBN O
by IN O
their PRP$ O
property NN O
as IN O
proteases NNS O
. . O

This DT O
limited JJ O
stability NN O
is VBZ O
a DT O
problem NN O
when WRB O
the DT O
material NN O
has VBZ O
to TO O
be VB O
stored VBN O
in IN O
solution NN O
. . O

Commercial JJ O
serine NN O
protease NN O
preparations NNS O
available JJ O
today NN O
are VBP O
essentially RB O
always RB O
in IN O
the DT O
form NN O
of IN O
frozen JJ O
solutions NNS O
orlyophilized VBN O
powders NNS O
, , O
with IN O
obvious JJ O
drawbacks NNS O
. . O

The DT O
extra JJ O
time NN O
needed VBN O
for IN O
dissolution NN O
of IN O
the DT O
powder NN O
or CC O
thawing NN O
of IN O
the DT O
frozen JJ O
solution NN O
to TO O
the DT O
correct JJ O
temperature NN O
is VBZ O
the DT O
most RBS O
important JJ O
issue NN O
. . O

There EX O
are VBP O
, , O
however RB O
, , O
other JJ O
problems NNS O
with IN O
these DT O
preparations NNS O
. . O

For IN O
frozen JJ O
solutions NNS O
, , O
there EX O
is VBZ O
a DT O
need NN O
for IN O
controlled JJ O
temperatures NNS O
(-20 JJ O
<0>C NN O
) -RRB- O
in IN O
all DT O
steps NNS O
from IN O
manufacture NN O
and CC O
transportation NN O
to TO O
storage NN O
. . O

For IN O
lyophilized VBN O
powders NNS O
, , O
there EX O
is VBZ O
a DT O
need NN O
for IN O
a DT O
reconstitution NN O
solution NN O
with IN O
an DT O
acceptable JJ O
grade NN O
of IN O
purity NN O
and CC O
stability NN O
. . O

Als NNP O
.o NNP O
, , O
the DT O
material NN O
frequently RB O
needs VBZ O
to TO O
be VB O
prepared JJ O
aseptically RB O
( -LRB- O
by IN O
mixing NN O
of IN O
the DT O
two CD O
parts NNS O
) -RRB- O
in IN O
an DT O
environment NN O
which WDT O
may MD O
be VB O
non-controlled JJ O
( -LRB- O
such JJ O
as IN O
inclement IN O
weather NN O
or CC O
lack NN O
of IN O
a DT O
clean JJ O
water NN B-NP
supply NN O
) -RRB- O
, , O
and CC O
there EX O
is VBZ O
a DT O
need NN O
to TO O
verify VB O
that IN O
the DT O
powders NNS O
have VBP O
been VBN O
properly RB O
mixed VBN O
. . O

These DT O
are VBP O
all DT O
major JJ O
drawbacks NNS O
of IN O
the DT O
products NNS O
available JJ O
today NN O
, , O
adding VBG O
to TO O
their PRP$ O
complexity NN O
, , O
of IN O
use NN O
as RB O
well RB O
as IN O
their PRP$ O
cost NN O
. . O

For IN O
thrombin NN O
, , O
which WDT O
preferably RB O
has VBZ O
to TO O
be VB O
immediately RB O
available JJ O
for IN O
use NN O
in IN O
arresting VBG O
bleeding NN O
, , O
the DT O
stability NN O
problems NNS O
have VBP O
forced VBN O
manufacturers NNS O
to TO O
use VB O
lyophilized VBN O
thrombin IN O
or CC O
deep JJ O
frozen JJ O
solutions NNS O
. . O

These DT O
then RB O
require VBP O
a DT O
certain JJ O
amount NN O
of IN O
time NN O
to TO O
prepare VB O
for IN O
use NN O
. . O

The DT O
two CD O
thrombolytic JJ O
agents NNS O
urokinase JJ O
and CC O
tissue NN O
plasminogen NN O
activator NN O
are VBP O
sold VBN O
in IN O
the DT O
form NN O
of IN O
lyophilized JJ O
preparations NNS O
that WDT O
have VBP O
to TO O
be VB O
dissolved VBN O
before IN O
use NN O
. . O

Since IN O
thrombolytic DT O
treatment NN O
of IN O
acute JJ O
myocardial JJ O
infarction NN O
has VBZ O
to TO O
be VB O
started VBN O
as RB O
early RB O
as IN O
possible JJ O
after IN O
onset NN O
of IN O
the DT O
infarction NN O
, , O
any DT O
time NN O
delay NN O
caused VBN O
by IN O
such JJ O
preparation NN O
is VBZ O
a DT O
problem NN O
. . O

Many JJ O
efforts NNS O
have VBP O
been VBN O
made VBN O
to TO O
find VB O
ways NNS O
to TO O
stabilize VB O
the DT O
various JJ O
serine NN O
proteases NNS O
. . O

For IN O
trypsin NN O
, , O
which WDT O
degrades VBZ O
itself PRP O
fairly RB O
rapidly RB O
, , O
a DT O
simple JJ O
and CC O
efficient JJ O
stabilizing VBG O
agent NN O
is VBZ O
the DT O
calcium NN B-NP
ion NN I-NP
( -LRB- O
Sipos NNP O
T NNP O
and CC O
Merkel NNP O
J NNP O
, , O
Biochemistry NNP O
9:2766 CD O
( -LRB- O
1970 CD O
) -RRB- O
) -RRB- O
. . O

Decreasing VBG O
the DT O
pH NNS O
to TO O
below IN O
4 CD O
is VBZ O
also RB O
a DT O
method NN O
that WDT O
works VBZ O
with IN O
some DT O
of IN O
the DT O
enzymes NNS O
, , O
like IN O
trypsin NN O
and CC O
plasmin NN O
, , O
but CC O
is VBZ O
not RB O
feasible JJ O
with IN O
thrombin NN O
, , O
since IN O
it PRP O
is VBZ O
irreversibly RB O
inactivated VBN O
by IN O
a DT O
pH NN O
below IN O
5 CD O
. . O
Reversible NNP O
protease NN O
inhibitors NNS O
can MD O
be VB O
used VBN O
, , O
but CC O
are VBP O
less JJR O
popular JJ O
, , O
since IN O
they PRP O
interfere VBP O
in IN O
a DT O
detrimental JJ O
fashion NN O
with IN O
the DT O
action NN O
of IN O
the DT O
enzyme NN O
when WRB O
they PRP O
are VBP O
used VBN O
by IN O
themselves PRP O
( -LRB- O
see VB O
below IN O
) -RRB- O
. . O

For IN O
stabilization NN O
of IN O
tissue NN O
plasminogen NN O
activator NN O
(tPA NN O
) -RRB- O
, , O
addition NN O
of IN O
the DT O
amino JJ B-NP
acid NN I-NP
arginine NN B-NP
is VBZ O
conventionally RB O
used VBN O
. . O

The DT O
tPA NN O
material NN O
in IN O
clinical JJ O
use NN O
today NN O
contains VBZ O
arginine RB B-NP
as IN O
stabilizer NN O
. . O

Also RB O
, , O
a DT O
lot NN O
of IN O
effort NN O
has VBZ O
been VBN O
devoted VBN O
to TO O
find VB O
ways NNS O
to TO O
stabilize VB O
thrombin IN O
solutions NNS O
. . O

As IN O
examples NNS O
of IN O
stabilizing VBG O
additives NNS O
, , O
the DT O
following VBG O
proposals NNS O
may MD O
be VB O
mentioned VBN O
: : O
carboxylic JJ B-NP
acids NNS I-NP
in IN O
high JJ O
concentrations NNS O
, , O
EDTA NNP B-NP
, , O
various JJ O
amino IN B-NP
acids NNS I-NP
, , O
albumin NN B-NP
, , O
polymers NNS O
such JJ O
as IN O
polyethylene NN B-NP
glycol NN I-NP
, , O
polyvinyl NN B-NP
pyrrolidone NN I-NP
and CC O
polyvinyl NN B-NP
alcohol NN I-NP
, , O
glycerol NN B-NP
, , O
various JJ O
inorganic JJ O
salts NNS O
, , O
carbohydrates NNS B-NP
, , O
gelatin NN B-NP
, , O
collagen NN O
. . O

Japanese JJ O
patent NN O
application NN O
JP2004191367 CD O
describes VBZ O
a DT O
stabilized VBN O
thrombin IN O
containing VBG O
test NN O
reagent NN O
for IN O
testing VBG O
blood NN O
coagulation NN O
ability NN O
. . O

The DT O
test NN O
reagent NN O
contains VBZ O
thrombin NN O
and CC O
a DT O
thrombin NN O
inhibitor NN O
, , O
and CC O
may MD O
also RB O
comprise VB O
one CD O
or CC O
more JJR O
thrombin IN O
stabilizing VBG O
compounds NNS O
selected VBN O
from IN O
calcium NN B-NP
ion NN I-NP
, , O
an DT O
organic JJ O
acid NN O
, , O
a DT O
surfactant NN O
and CC O
a DT O
protein NN O
. . O

WO NN O
02/100830 CD O
, , O
WO NN O
02/22575 CD O
, , O
WO NN O
00/20394 CD O
, , O
WO NN O
99/11658 CD O
, , O
WO NN O
02/37937 CD O
and CC O
US PRP O
5,409,927 VBD O
all DT O
describe VBP O
different JJ O
serine NN O
protease NN O
inhibiting VBG O
compounds NNS O
and CC O
their PRP$ O
use NN O
in IN O
pharmaceutical JJ O
compositions NNS O
for IN O
treatment NN O
of IN O
various JJ O
disease NN O
conditions NNS O
, , O
such JJ O
as IN O
thrombosis NN O
, , O
wherein WRB O
inhibition NN O
of IN O
the DT O
corresponding JJ O
serine NN O
proteases NNS O
is VBZ O
indicated VBN O
. . O

Nakamura NNP O
et NNP O
al NN O
. . O

{J. NNP O
Chrom NNP O
. . O

Ar NNP O
1009 CD O
, , O
( -LRB- O
2003 CD O
) -RRB- O
, , O
133-139 CD O
) -RRB- O
describe VBP O
the DT O
use NN O
of IN O
an DT O
immobilized JJ O
protease NN O
inhibitor NN O
for IN O
affinity NN O
chromatography NN O
of IN O
trypsin-like JJ O
proteases NNS O
. . O

Turner NNP O
et NNP O
al NN O
. . O

{Biochemistry NN O
, , O
25 CD O
, , O
( -LRB- O
1986 CD O
) -RRB- O
, , O
4929-4935 CD O
) -RRB- O
describe VBP O
three CD O
p-amidinophenyl JJ B-NP
esters NNS I-NP
that IN O
irreversibly RB O
inhibit VB O
human JJ O
factor NN O
IXa NNP O
. . O

Tsung NNP O
Fu NNP O
Yang NNP O
et NNP O
al NN O
. . O

{Biomacromolecules NNS O
, , O
25 CD O
, , O
( -LRB- O
2004 CD O
) -RRB- O
, , O
1926-1932 CD O
) -RRB- O
describe VBP O
the DT O
synthesis NN O
of IN O
a DT O
cationic JJ O
polymer NN O
, , O
N,N-diethylethylenediamin NNP O
polyurethane NN B-NP
, , O
for IN O
use NN O
in IN O
gene NN O
delivery NN O
. . O

US PRP O
patent NN O
application NN O
2001/0033837 CD O
( -LRB- O
corresponding JJ O
to TO O
EP NNP O
1 CD O
136 CD O
084 JJ O
Al NNP O
) -RRB- O
describes VBZ O
a DT O
thrombin NN O
preparation NN O
containing VBG O
a DT O
non-covalently RB O
bound VBN O
inhibitor NN O
as IN O
stabilizer NN O
. . O

Furthermore RB O
, , O
the DT O
inhibitor NN O
is VBZ O
combined VBN O
with IN O
other JJ O
stabilizing VBG O
additives NNS O
, , O
like IN O
sugars NNS B-NP
or CC O
carboxylic NN B-NP
acids NNS I-NP
, , O
which WDT O
have VBP O
been VBN O
previously RB O
described VBN O
in IN O
patents NNS O
or CC O
other JJ O
publications NNS O
. . O

JP NNP O
2000300250 CD O
describes VBZ O
the DT O
stabilization NN O
of IN O
thrombin DT O
solutions NNS O
by IN O
addition NN O
of IN O
polyvinyl NN B-NP
alcohol NN I-NP
, , O
gelatin NN B-NP
or CC O
polyvinyl NN B-NP
pyrrolidone NN I-NP
in IN O
different JJ O
buffer NN O
solutions NNS O
. . O

In IN O
GB NNP O
1354761 CD O
, , O
proteases NNS O
and CC O
amylases NNS O
are VBP O
stabilized VBN O
to TO O
various JJ O
extents NNS O
by IN O
a DT O
number NN O
of IN O
substances NNS O
, , O
such JJ O
as IN O
aliphatic JJ O
alcohols NNS O
, , O
carboxylic NN B-NP
acids NNS I-NP
, , O
heterocyclic NN B-NP
compounds NNS I-NP
containing VBG O
hydroxyl JJ B-NP
groups NNS O
, , O
and CC O
aliphatic JJ O
or CC O
alicyclic JJ O
amines NNS B-NP
. . O

Thus RB O
, , O
stabilization NN O
of IN O
a DT O
serine NN O
protease NN O
using VBG O
inhibitors NNS O
has VBZ O
been VBN O
described VBN O
( -LRB- O
for IN O
example NN O
US PRP O
2001/0033837 CD O
and CC O
JP NNP O
2004191367 CD O
, , O
supra NN O
) -RRB- O
. . O

The DT O
problem NN O
with IN O
this DT O
approach NN O
is VBZ O
that IN O
the DT O
inhibitor NN O
strongly RB O
diminishes VBZ O
the DT O
effect NN O
of IN O
the DT O
enzyme NN O
, , O
if IN O
it PRP O
is VBZ O
not RB O
removed VBN O
prior RB O
to TO O
use VB O
of IN O
the DT O
preparation NN O
. . O

If IN O
a DT O
potent JJ O
inhibitor NN O
is VBZ O
used VBN O
, , O
most JJS O
of IN O
the DT O
enzymatic JJ O
activity NN O
is VBZ O
lost VBN O
. . O

A DT O
better JJR O
approach NN O
is VBZ O
to TO O
use VB O
a DT O
reversible JJ O
inhibitor NN O
of IN O
intermediate JJ O
strength NN O
. . O

However RB O
, , O
even RB O
in IN O
this DT O
case NN O
, , O
a DT O
considerable JJ O
part NN O
of IN O
the DT O
initial JJ O
enzymatic JJ O
activity NN O
will MD O
be VB O
lost VBN O
as IN O
concentration NN O
of IN O
the DT O
inhibitor NN O
is VBZ O
increased VBN O
in IN O
order NN O
to TO O
get VB O
a DT O
good JJ O
stabilization NN O
effect NN O
. . O

Disclosure NN O
of IN O
the DT O
invention NN O

It PRP O
is VBZ O
therefore RB O
an DT O
object NN O
of IN O
the DT O
present JJ O
invention NN O
to TO O
accomplish VB O
a DT O
serine NN O
protease NN O
composition NN O
, , O
which WDT O
is VBZ O
stable JJ O
in IN O
solution NN O
and CC O
retains VBZ O
a DT O
degree NN O
of IN O
enzymatic JJ O
activity NN O
which WDT O
is VBZ O
sufficient JJ O
for IN O
practical JJ O
use NN O
of IN O
the DT O
composition NN O
. . O

It PRP O
is VBZ O
another DT O
object NN O
of IN O
the DT O
present JJ O
invention NN O
to TO O
provide VB O
a DT O
serine NN O
protease NN O
composition NN O
, , O
which WDT O
is VBZ O
amenable JJ O
to TO O
direct JJ O
use NN O
without IN O
prior JJ O
steps NNS O
of IN O
preparation NN O
from IN O
deep JJ O
frozen JJ O
or CC O
lyophilized VBN O
material NN O
. . O

It PRP O
is VBZ O
a DT O
further JJ O
object NN O
of IN O
the DT O
present JJ O
invention NN O
to TO O
enable VB O
practical JJ O
use NN O
of IN O
reversible JJ O
inhibitors NNS O
of IN O
serine NN O
proteases NNS O
for IN O
stabilization NN O
purposes NNS O
, , O
through IN O
the DT O
provision NN O
of IN O
an DT O
additional JJ O
stabilizing VBG O
component NN O
. . O

These DT O
, , O
and CC O
other JJ O
objects NNS O
apparent JJ O
from IN O
the DT O
present JJ O
text NN O
, , O
are VBP O
attained VBN O
by IN O
the DT O
different JJ O
aspects NNS O
of IN O
the DT O
present JJ O
invention NN O
as IN O
claimed VBN O
. . O

Thus RB O
, , O
one CD O
aspect NN O
of IN O
the DT O
invention NN O
provides VBZ O
a DT O
stabilized VBN O
serine NN O
protease NN O
composition NN O
comprising NN O
a DT O
) -RRB- O
a DT O
serine NN O
protease NN O
; : O
b NN O
) -RRB- O
a DT O
reversible JJ O
inhibitor NN O
of IN O
said VBD O
serine NN O
protease NN O
; : O
and CC O
c NNS O
) -RRB- O
a DT O
stabilizing VBG O
agent NN O
M NNP O
having VBG O
the DT O
formula NN O
I PRP O
: : O

[0019] . O

EMI6.1 . O

wherein WRB O
n NN O
is VBZ O
0, CD O
1 CD O
or CC O
2 CD O
; : O

X NNP O
is VBZ O
O UH B-NP
, , O
N NNP B-NP
or CC O
CH2 NNP B-NP
; : O

R<1->-R<4> JJ O
are VBP O
the DT O
same JJ O
or CC O
different JJ O
, , O
and CC O
selected VBN O
from IN O
H NNP B-NP
, , O
-CH2-R<6> JJ B-NP
, , O
-CH2-O-R<6> JJ B-NP
, , O
-CH2-S-R<6> JJ B-NP
, , O
-CH2-NH-R<6> JJ B-NP
, , O
-CO-O-R<6> JJ B-NP
, , O
-CO-NH-R<6> JJ B-NP
, , O
-CH2-NH-CO-R<6> JJ B-NP
, , O
-CH2-O-CO-R<6> JJ B-NP
, , O
-CH2-NH-CO-NHR<6> JJ B-NP
, , O
-CH2-NH-CO-OR<6> JJ B-NP
, , O
-CH2-NH-CS-NHR<6> JJ B-NP
and CC O
-CH2-O-CO-NHR<6> JJ B-NP
; : O

R<5> NN O
is VBZ O
as IN O
R<3^>-R<4> JJ O
or CC O
P-Q JJ O
; : O

P NNP O
is VBZ O
selected VBN O
from IN O
-(CH2 JJ O
)* NN O
- : O
and CC O
- : B-NP
( -LRB- I-NP
CH2)m-Y- FW I-NP
( -LRB- I-NP
CH2)m-, JJ I-NP
wherein WRB O
m NN O
is VBZ O
1-6 JJ O
and CC O
Y PRP O
is VBZ O
0, JJ B-NP
NH NNP B-NP
or CC O
S NNP B-NP
; : O

Q NN O
is VBZ O
selected VBN O
from IN O
H NNP B-NP
, , O
-SO3 JJ B-NP
, , O
-COOH NNP B-NP
, , O
-NH2 NNP B-NP
, , O
-OH NNP B-NP
and CC O
-CONH2 NNP B-NP
; : O
each DT O
R<6> JJ O
individually RB O
being VBG O
selected VBN O
from IN O
H NNP B-NP
, , O
substituted VBN B-NP
or CC I-NP
non-substituted JJ I-NP
lower JJR I-NP
alkyl NN I-NP
, , O
substituted VBN B-NP
or CC I-NP
non-substituted JJ I-NP
cycloalkyl NN I-NP
, , O
substituted VBN B-NP
or CC I-NP
non FW I-NP
- : I-NP
substituted VBN I-NP
benzyl NN I-NP
, , O
substituted VBN B-NP
or CC I-NP
non-substituted JJ I-NP
aryl NN I-NP
or CC O
mono-, JJ B-NP
bi-, JJ I-NP
or CC I-NP
tricyclic JJ I-NP
unsubstituted JJ I-NP
or CC I-NP
substituted VBN I-NP
heteroaromatic JJ I-NP
ring( NN I-NP
s VBZ O
) -RRB- O
with IN O
one CD O
or CC O
more JJR O
heteroatoms NNS B-NP
and CC I-NP
non-aromatic JJ I-NP
heterocycles NNS I-NP
, , O
the DT O
substituents NNS O
of IN O
the DT O
substituted VBN O
groups NNS O
being VBG O
selected VBN O
from IN O
lower JJR B-NP
alkyl NN I-NP
, , O
halogens NNS B-NP
, , O
substituted VBN B-NP
or CC I-NP
non-substituted JJ I-NP
aryl NN I-NP
, , O
substituted VBN B-NP
or CC I-NP
non-substituted JJ I-NP
hetero-aromatic JJ I-NP
compounds NNS I-NP
, , O
non-aromatic JJ B-NP
heterocycles NNS I-NP
, , O
alkyloxy RB B-NP
, , O
alkylamino RB B-NP
; : O
or CC O
a DT O
pharmaceutically RB O
acceptable JJ O
salt NN O
thereof '' O
. . O

The DT O
present JJ O
invention NN O
derives NNS O
from IN O
initial JJ O
results NNS O
from IN O
a DT O
study NN O
on IN O
the DT O
stability NN O
of IN O
thrombin NN O
, , O
in IN O
which WDT O
it PRP O
was VBD O
surprisingly RB O
found VBN O
that IN O
the DT O
inventive JJ O
combination NN O
of IN O
a DT O
reversible JJ O
inhibitor NN O
of IN O
the DT O
enzyme NN O
and CC O
a DT O
stabilizing VBG O
agent NN O
M NNP O
as IN O
defined VBN O
above IN O
had VBD O
a DT O
strong JJ O
stabilizing VBG O
effect NN O
on IN O
the DT O
enzyme NN O
in IN O
solution NN O
. . O

Both DT O
the DT O
thrombin NN O
inhibitor NN O
and CC O
the DT O
stabilizing VBG O
agent NN O
M NNP O
alone RB O
had VBD O
stabilization NN O
effects NNS O
on IN O
thrombin NN O
, , O
but CC O
the DT O
combination NN O
was VBD O
several JJ O
fold NN O
better RBR O
than IN O
any DT O
of IN O
them PRP O
( -LRB- O
see VB O
Example JJ O
1 CD O
) -RRB- O
. . O

Thus RB O
, , O
when WRB O
a DT O
low JJ O
concentration NN O
of IN O
enzyme JJ O
inhibitor NN O
was VBD O
combined VBN O
with IN O
morpholine NN B-NP
, , O
MOPS NNP B-NP
or CC O
related VBN O
compounds NNS O
, , O
a DT O
very RB O
strong JJ O
stabilizing VBG O
effect NN O
on IN O
the DT O
enzyme NN O
was VBD O
obtained VBN O
. . O

Some DT O
tested VBN O
compositions NNS O
were VBD O
stable JJ O
, , O
as IN O
indicated VBN O
by IN O
less JJR O
than IN O
30 CD O
% NN O
decrease NN O
in IN O
activity NN O
, , O
for IN O
more JJR O
than IN O
2 CD O
months NNS O
at IN O
37 CD O
<0>C. . O

This DT O
would MD O
, , O
according VBG O
to TO O
data NNS O
in IN O
prior JJ O
publications NNS O
and CC O
confirmed VBN O
by IN O
the DT O
present JJ O
inventors NNS O
, , O
correspond NN O
to TO O
6 CD O
months NNS O
at IN O
room NN O
temperature NN O
or CC O
2.5 CD O
years NNS O
at IN O
refrigerator NN O
temperature NN O
. . O

The DT O
results NNS O
from IN O
the DT O
initial JJ O
study NN O
were VBD O
expanded VBN O
to TO O
include VB O
experiments NNS O
on IN O
other JJ O
serine NN O
proteases NNS O
, , O
and CC O
in IN O
these DT O
experiments NNS O
the DT O
surprising JJ O
stabilizing VBG O
effect NN O
was VBD O
also RB O
observed VBN O
. . O

As IN O
exemplified VBN O
below IN O
, , O
the DT O
composition NN O
according VBG O
to TO O
the DT O
invention NN O
exhibits VBZ O
a DT O
substantially RB O
improved VBN O
stability NN O
as IN O
compared VBN O
to TO O
enzyme VB O
compositions NNS O
without IN O
the DT O
inventive JJ O
combination NN O
of IN O
ingredients NNS O
b NN O
) -RRB- O
and CC O
c NN O
) -RRB- O
. . O

With IN O
the DT O
inventive JJ O
approach NN O
, , O
a DT O
low JJ O
concentration NN O
of IN O
serine NN O
protease NN O
inhibitor NN O
may MD O
be VB O
used VBN O
, , O
and CC O
a DT O
satisfactory JJ O
degree NN O
of IN O
stabilization NN O
still RB O
obtained VBD O
. . O

For IN O
example NN O
, , O
the DT O
concentration NN O
of IN O
the DT O
inhibitor NN O
may MD O
be VB O
lower JJR O
than IN O
what WP O
has VBZ O
been VBN O
suggested VBN O
previously RB O
, , O
e NN O
g NN O
in IN O
US NNP O
2001/0033837 CD O
. . O

With IN O
such PDT O
a DT O
low JJ O
concentration NN O
of IN O
inhibitor NN O
, , O
much RB O
more JJR O
of IN O
the DT O
enzymatic JJ O
activity NN O
is VBZ O
retained VBN O
in IN O
the DT O
stabilized VBN O
enzyme NN O
solution NN O
. . O

It PRP O
should MD O
be VB O
noted VBN O
that IN O
the DT O
increase NN O
in IN O
stabilization NN O
due JJ O
to TO O
the DT O
combination NN O
of IN O
the DT O
reversible JJ O
serine NN O
protease NN O
inhibitor NN O
and CC O
stabilizing VBG O
agent NN O
M NNP O
is VBZ O
not RB O
regarded VBN O
as IN O
an DT O
additional JJ O
inhibitory JJ O
effect NN O
provided VBN O
by IN O
M. NNP O
In IN O
fact NN O
M NNP O
, , O
as IN O
described VBN O
in IN O
Illustrative NNP O
Example NNP O
A NNP O
, , O
may MD O
lack VB O
any DT O
serine NN O
protease NN O
inhibiting VBG O
capacity NN O
. . O

Without IN O
wishing NN O
to TO O
be VB O
bound VBN O
by IN O
theory NN O
, , O
the DT O
present JJ O
inventors NNS O
believe VBP O
that IN O
the DT O
surprisingly RB O
increased VBN O
stabilizing VBG O
effect NN O
observed VBN O
is VBZ O
achieved VBN O
through IN O
a DT O
beneficial JJ O
synergy NN O
between IN O
reversible JJ O
serine NN O
protease NN O
inhibitors NNS O
and CC O
stabilizing VBG O
agents NNS O
M NNP O
of IN O
the DT O
inventive JJ O
composition NN O
. . O

The DT O
present JJ O
invention NN O
provides VBZ O
such JJ O
a DT O
combination NN O
of IN O
a DT O
reversible JJ O
serine NN O
protease NN O
inhibitor NN O
and CC O
stabilizing VBG O
agent NN O
M NNP O
in IN O
a DT O
stabilized VBN O
serine NN O
protease NN O
composition NN O
and CC O
use NN O
of IN O
such PDT O
a DT O
combination NN O
for IN O
stabilizing VBG O
a DT O
serine NN O
protease NN O
composition NN O
. . O

In IN O
an DT O
embodiment NN O
of IN O
the DT O
invention NN O
, , O
the DT O
serine NN O
protease NN O
in IN O
the DT O
composition NN O
is VBZ O
selected VBN O
from IN O
the DT O
group NN O
consisting VBG O
of IN O
trypsin NN O
, , O
kallikrein NN O
, , O
thrombin NN O
, , O
plasmin NN O
, , O
urokinase JJ O
, , O
tissue NN O
plasminogen NN O
activator NN O
, , O
active JJ O
form NN O
of IN O
factor NN O
IX NNP O
, , O
active JJ O
form NN O
of IN O
factor NN O
X NNP O
and CC O
active JJ O
form NN O
of IN O
factor NN O
XI. . O

In IN O
a DT O
more RBR O
specific JJ O
' '' O
embodiment NN O
, , O
the DT O
serine NN O
protease NN O
is VBZ O
thrombin RB O
. . O

In IN O
another DT O
specific JJ O
embodiment NN O
, , O
the DT O
serine NN O
protease NN O
is VBZ O
plasmin NN O
. . O

In IN O
yet RB O
another DT O
specific JJ O
embodiment NN O
, , O
the DT O
serine NN O
protease NN O
is VBZ O
trypsin RB O
. . O

Reversible JJ O
inhibitors NNS O
to TO O
serine NN O
proteases NNS O
are VBP O
known VBN O
to TO O
persons NNS O
of IN O
skill NN O
in IN O
the DT O
art NN O
, , O
and CC O
which WDT O
one CD O
is VBZ O
the DT O
optimal JJ O
to TO O
use VB O
will MD O
vary VB O
depending VBG O
on IN O
what WP O
specific JJ O
serine NN O
protease NN O
is VBZ O
used VBN O
. . O

In IN O
general JJ O
, , O
it PRP O
is VBZ O
of IN O
importance NN O
for IN O
the DT O
intended JJ O
effect NN O
that IN O
the DT O
inhibitor NN O
is VBZ O
not RB O
of IN O
great JJ O
strength NN O
. . O

In IN O
other JJ O
words NNS O
, , O
the DT O
inhibitory JJ O
effect NN O
has VBZ O
to TO O
be VB O
moderate JJ O
enough RB O
that IN O
the DT O
enzymatic JJ O
activity NN O
remains VBZ O
usefully RB O
high JJ O
. . O

As IN O
a DT O
guideline NN O
, , O
it PRP O
has VBZ O
been VBN O
found VBN O
that IN O
inhibitors NNS O
having VBG O
a DT O
Ki NNP O
of IN O
between IN O
0.01 CD O
mM NNS O
and CC O
2 CD O
mM NNS O
are VBP O
suitable JJ O
for IN O
use NN O
in IN O
the DT O
composition NN O
according VBG O
to TO O
the DT O
invention NN O
, , O
with IN O
from IN O
0.04 CD O
mM NN O
to TO O
0.5 CD O
mM NN O
as IN O
a DT O
preferred JJ O
range NN O
. . O

In IN O
one CD O
embodiment NN O
, , O
in IN O
which WDT O
the DT O
serine NN O
protease NN O
is VBZ O
thrombin RB O
, , O
the DT O
reversible JJ O
inhibitor NN O
may MD O
be VB O
selected VBN O
from IN O
N- NNP B-NP
( -LRB- I-NP
2' JJ I-NP
-phenoxy NN I-NP
) -RRB- I-NP
-4-aminopyridin : I-NP
and CC O
derivatives NNS O
thereof RB O
, , O
benzamidine NN B-NP
, , O
N NNP B-NP
, , I-NP
N-diethylethylenediamine NNP I-NP
, , O
aminobenzamidine JJ B-NP
, , O
amidinopyridin IN B-NP
and CC O
tert-butylamidin NN B-NP
. . O

In IN O
another DT O
embodiment NN O
, , O
in IN O
which WDT O
the DT O
serine NN O
protease NN O
is VBZ O
thrombin RB O
, , O
the DT O
reversible JJ O
inhibitor NN O
is VBZ O
selected VBN O
from IN O
N- NNP B-NP
( -LRB- I-NP
2' JJ I-NP
-phenoxy NN I-NP
) -RRB- I-NP
-4-aminopyridin : I-NP
and CC O
derivatives NNS O
thereof RB O
, , O
N NNP B-NP
, , I-NP
N- NNP I-NP
diethylethylenediamine NN I-NP
, , O
amidinopyridin IN B-NP
and CC O
tert- DT B-NP
butylamidin NN I-NP
. . O

In IN O
a DT O
more RBR O
specific JJ O
embodiment NN O
, , O
in IN O
which WDT O
the DT O
serine NN O
protease NN O
is VBZ O
thrombin RB O
, , O
the DT O
reversible JJ O
inhibitor NN O
is VBZ O
N- NNP B-NP
( -LRB- I-NP
2' JJ I-NP
-phenoxy NN I-NP
) -RRB- I-NP
-4-aminopyridin NN I-NP
or CC O
a DT O
derivative JJ O
thereof NN O
. . O

In IN O
another DT O
embodiment NN O
, , O
in IN O
which WDT O
the DT O
serine NN O
protease NN O
is VBZ O
plasmin NN O
, , O
the DT O
reversible JJ O
inhibitor NN O
is VBZ O
selected VBN O
from IN O
N NNP B-NP
, , I-NP
N- NNP I-NP
diethylethylenediamine NN I-NP
, , O
aminobenzamidine JJ B-NP
and CC O
benzamidine JJ B-NP
. . O

In IN O
another DT O
embodiment NN O
, , O
in IN O
which WDT O
the DT O
serine NN O
protease NN O
is VBZ O
trypsin RB O
, , O
the DT O
reversible JJ O
inhibitor NN O
is VBZ O
selected VBN O
from IN O
aminobenzamidine JJ B-NP
and CC O
benzamidine JJ B-NP
. . O

These DT O
combinations NNS O
of IN O
enzymes NNS O
and CC O
inhibitors NNS O
are VBP O
illustrative JJ O
examples NNS O
, , O
and CC O
are VBP O
not RB O
to TO O
be VB O
interpreted VBN O
as IN O
limiting VBG O
. . O

In IN O
one CD O
embodiment NN O
of IN O
the DT O
invention NN O
, , O
the DT O
value NN O
of IN O
n NN O
in IN O
formula NN O
I PRP O
is VBZ O
1 CD O
or CC O
2. CD O
In IN O
a DT O
more RBR O
specific JJ O
embodiment NN O
, , O
n RB O
in IN O
formula NN O
I PRP O
is VBZ O
1 CD O
. . O

The DT O
composition NN O
according VBG O
to TO O
the DT O
invention NN O
comprises VBZ O
a DT O
stabilizing VBG O
agent NN O
M NNP O
with IN O
the DT O
general JJ O
formula NN O
I PRP O
given VBN O
above IN O
. . O

In IN O
embodiments NNS O
of IN O
the DT O
invention NN O
, , O
stabilizing VBG O
agent NN O
M NNP O
is VBZ O
a DT O
compound NN O
of IN O
formula NN O
II NNP O
: : O

[0031] . O

EMI9.1 . O

wherein WRB O
R<3->-R<4> NNP O
are VBP O
the DT O
same JJ O
or CC O
different JJ O
, , O
and CC O
selected VBN O
from IN O
H NNP B-NP
, , O
-CH2-R<6> JJ B-NP
; : O

R<5> NN O
is VBZ O
as IN O
R<3->-R<4> JJ O
or CC O
P-Q JJ O
; : O
P NNP O
is VBZ O
selected VBN O
from IN O
- : B-NP
( -LRB- I-NP
CH2 NN I-NP
) -RRB- I-NP
m NN I-NP
- : I-NP
and CC O
- : B-NP
( -LRB- I-NP
CH2 NN I-NP
) -RRB- I-NP
m-Y- FW I-NP
( -LRB- I-NP
CH2 NN I-NP
) -RRB- I-NP
m-, , I-NP
wherein WRB O
m NN O
is VBZ O
1-6 JJ O
and CC O
Y PRP O
is VBZ O
0, JJ O
NH NNP B-NP
or CC O
S NNP B-NP
; : O

Q NN O
is VBZ O
selected VBN O
from IN O
H NNP B-NP
, , O
-SO3 JJ B-NP
, , O
-COOH NNP B-NP
, , O
-NH2 NNP B-NP
, , O
-OH NNP B-NP
and CC O
-CONH2 NNP B-NP
; : O
each DT O
R<6> JJ O
individually RB O
being VBG O
selected VBN O
from IN O
H NNP B-NP
, , O
substituted VBN B-NP
or CC I-NP
non-substituted JJ I-NP
lower JJR I-NP
alkyl NN I-NP
, , O
substituted VBN B-NP
or CC I-NP
non-substituted JJ I-NP
cycloalkyl NN I-NP
, , O
substituted VBN B-NP
or CC I-NP
non FW I-NP
- : I-NP
substituted VBN I-NP
benzyl NN I-NP
, , O
substituted VBN B-NP
or CC I-NP
non-substituted JJ I-NP
aryl NN I-NP
or CC O
mono-, JJ B-NP
bi-, JJ I-NP
or CC I-NP
tricyclic JJ I-NP
unsubstituted JJ I-NP
or CC I-NP
substituted VBN I-NP
heteroaromatic JJ I-NP
ring( NN I-NP
s VBZ O
) -RRB- O
with IN O
one CD O
or CC O
more JJR O
heteroatoms NNS B-NP
and CC I-NP
non-aromatic JJ I-NP
heterocycles NNS I-NP
, , O
the DT O
substituents NNS O
of IN O
the DT O
substituted VBN O
groups NNS O
being VBG O
selected VBN O
from IN O
lower JJR B-NP
alkyl NN I-NP
, , O
halogens NNS B-NP
, , O
substituted VBN B-NP
or CC I-NP
non-substituted JJ I-NP
aryl NN I-NP
, , O
substituted VBN B-NP
or CC I-NP
non-substituted JJ I-NP
hetero-aromatic JJ I-NP
compounds NNS I-NP
, , O
non-aromatic JJ B-NP
heterocycles NNS I-NP
, , O
alkyloxy RB B-NP
, , O
alkylamino RB B-NP
; : O
or CC O
a DT O
pharmaceutically RB O
acceptable JJ O
salt NN O
thereof '' O
. . O

Accordingly RB O
, , O
in IN O
some DT O
embodiments NNS O
, , O
stabilizing VBG O
agent NN O
M NNP O
is VBZ O
a DT O
compound NN O
of IN O
formula NN O
III NNP O
: : O

[0034] . O

EMI10.1 . O

wherein WRB O

R<5> PRP O
is VBZ O
-CH2-R<6> JJ B-NP
or CC O
P-Q JJ O
; : O

P NNP O
is VBZ O
selected VBN O
from IN O
-(CH2)m JJ B-NP
- : I-NP
or CC O
- : B-NP
( -LRB- I-NP
CH2 NN I-NP
) -RRB- I-NP
m-Y- FW I-NP
( -LRB- I-NP
CH2 NN I-NP
) -RRB- I-NP
m-, , I-NP
wherein WRB O
m NN O
is VBZ O
1-6 JJ O
and CC O
Y PRP O
is VBZ O
0, JJ B-NP
NH NNP B-NP
or CC O
S NNP B-NP
; : O

Q NN O
is VBZ O
selected VBN O
from IN O
H NNP B-NP
, , O
-SO3 JJ B-NP
, , O
-COOH NNP B-NP
, , O
-NH2 NNP B-NP
, , O
-OH NNP B-NP
and CC O
-CONH2 NNP B-NP
. . O

each DT O
R<6> JJ O
individually RB O
being VBG O
selected VBN O
from IN O
substituted VBN B-NP
or CC I-NP
non-substituted JJ I-NP
lower JJR I-NP
alkyl NN I-NP
, , O
substituted VBN B-NP
or CC I-NP
non FW I-NP
- : I-NP
substituted VBN I-NP
cycloalkyl NN I-NP
, , O
substituted VBN B-NP
or CC I-NP
non-substituted JJ I-NP
benzyl NN I-NP
, , O
substituted VBN B-NP
or CC I-NP
non-substituted JJ I-NP
aryl NN I-NP
, , O
the DT O
substituents NNS O
of IN O
the DT O
substituted VBN O
groups NNS O
being VBG O
selected VBN O
from IN O
lower JJR B-NP
alkyl NN I-NP
, , O
halogens NNS B-NP
, , O
substituted VBN B-NP
or CC I-NP
non FW I-NP
- : I-NP
substituted VBN I-NP
aryl NN I-NP
, , O
substituted VBN B-NP
or CC I-NP
non-substituted JJ I-NP
hetero-aromatic JJ I-NP
compounds NNS I-NP
, , O
non-aromatic JJ B-NP
heterocycles NNS I-NP
, , O
alkyloxy RB B-NP
, , O
alkylamino RB B-NP
; : O
or CC O
a DT O
pharmaceutically RB O
acceptable JJ O
salt NN O
thereof '' O
. . O

In IN O
some DT O
embodiments NNS O
of IN O
the DT O
invention NN O
, , O
stabilizing VBG O
agent NN O
M NNP O
is VBZ O
selected VBN O
from IN O
the DT O
group NN O
consisting VBG O
of IN O
morpholine NN B-NP
, , O
3- CD B-NP
(N-morpholino NN I-NP
) -RRB- I-NP
propanesulfonic JJ I-NP
acid NN I-NP
( -LRB- O
MOPS) NNP B-NP
, , O
morpholino NN B-NP
butyl NN I-NP
sulphonic JJ I-NP
acid NN I-NP
, , O
morpholino NN B-NP
propyl NN I-NP
carboxylic NN I-NP
acid NN I-NP
, , O
morpholino NN B-NP
ethyl NN I-NP
alcohol NN I-NP
and CC O
morpholino NN B-NP
ethyl NN I-NP
sulphonic JJ I-NP
acid NN I-NP
. . O

Thus RB O
, , O
examples NNS O
of IN O
compounds NNS O
M NNP O
for IN O
use NN O
in IN O
the DT O
compositions NNS O
of IN O
this DT O
aspect NN O
of IN O
the DT O
invention NN O
are VBP O
morpholine NN B-NP
and CC O
3- CD B-NP
(N-morpholino NN I-NP
) -RRB- I-NP
propanesulfonic JJ I-NP
acid NN I-NP
( -LRB- O
MOPS) NNP B-NP
. . O

In IN O
a DT O
specific JJ O
embodiment NN O
of IN O
the DT O
invention NN O
, , O
stabilizing VBG O
agent NN O
M NNP O
is VBZ O
morpholine NN B-NP
. . O

A DT O
composition NN O
according VBG O
to TO O
the DT O
invention NN O
which WDT O
shows VBZ O
the DT O
stabilization NN O
effect NN O
is VBZ O
one CD O
in IN O
which WDT O
the DT O
serine NN O
protease NN O
is VBZ O
thrombin RB O
, , O
the DT O
reversible JJ O
inhibitor NN O
is VBZ O
N- NNP B-NP
( -LRB- I-NP
2' FW I-NP
- : I-NP
phenoxy NN I-NP
) -RRB- I-NP
-4-aminopyridin NN I-NP
, , O
and CC O
stabilizing VBG O
agent NN O
M NNP O
is VBZ O
morpholine NN B-NP
. . O

Another DT O
composition NN O
according VBG O
to TO O
the DT O
invention NN O
which WDT O
shows VBZ O
the DT O
stabilization NN O
effect NN O
is VBZ O
one CD O
in IN O
which WDT O
the DT O
serine NN O
protease NN O
is VBZ O
thrombin RB O
, , O
the DT O
reversible JJ O
inhibitor NN O
is VBZ O
N- NNP B-NP
( -LRB- I-NP
2' FW I-NP
- : I-NP
phenoxy NN I-NP
) -RRB- I-NP
-4-aminopyridin NN I-NP
, , O
and CC O
stabilizing VBG O
agent NN O
M NNP O
is VBZ O
3- CD B-NP
(N- : I-NP
morpholino NN I-NP
) -RRB- I-NP
propanesulfonic JJ I-NP
acid NN I-NP
( -LRB- O
MOPS) NNP B-NP
. . O

Another DT O
composition NN O
according VBG O
to TO O
the DT O
invention NN O
which WDT O
shows VBZ O
the DT O
stabilization NN O
effect NN O
is VBZ O
one CD O
in IN O
which WDT O
the DT O
serine NN O
protease NN O
is VBZ O
thrombin RB O
, , O
the DT O
reversible JJ O
inhibitor NN O
is VBZ O
aminobenzamidine JJ B-NP
, , O
and CC O
stabilizing VBG O
agent NN O
M NNP O
is VBZ O
morpholine NN B-NP
. . O

Another DT O
composition NN O
according VBG O
to TO O
the DT O
invention NN O
which WDT O
shows VBZ O
the DT O
stabilization NN O
effect NN O
is VBZ O
one CD O
in IN O
which WDT O
the DT O
serine NN O
protease NN O
is VBZ O
plasmin NN O
, , O
the DT O
reversible JJ O
inhibitor NN O
is VBZ O
N,N-di- NNP B-NP
ethylethylenediamine NN I-NP
and CC O
stabilizing VBG O
agent NN O
M NNP O
is VBZ O
morpholine NN B-NP
. . O

Another DT O
composition NN O
according VBG O
to TO O
the DT O
invention NN O
which WDT O
shows VBZ O
the DT O
stabilization NN O
effect NN O
is VBZ O
one CD O
in IN O
which WDT O
the DT O
serine NN O
protease NN O
is VBZ O
plasmin NN O
, , O
the DT O
reversible JJ O
inhibitor NN O
is VBZ O
aminobenzamidine JJ B-NP
and CC O
stabilizing VBG O
agent NN O
M NNP O
is VBZ O
morpholine NN B-NP
. . O

In IN O
serine NN O
protease NN O
compositions NNS O
for IN O
topical JJ O
administration NN O
, , O
e NN O
g NN O
to TO O
a DT O
wound NN O
site NN O
, , O
it PRP O
has VBZ O
been VBN O
a DT O
problem NN O
that IN O
the DT O
composition NN O
can MD O
easily RB O
flow VB O
or CC O
be VB O
rinsed VBN O
from IN O
the DT O
site NN O
where WRB O
it PRP O
is VBZ O
applied VBN O
. . O

In IN O
order NN O
to TO O
solve VB O
this DT O
problem NN O
, , O
it PRP O
is VBZ O
possible JJ O
to TO O
add VB O
to TO O
the DT O
enzyme NN O
composition NN O
an DT O
adhesive JJ O
polymer NN O
, , O
which WDT O
then RB O
serves VBZ O
the DT O
purpose NN O
of IN O
making VBG O
the DT O
composition NN O
more RBR O
viscous JJ O
and CC O
adherent NN O
to TO O
skin NN O
or CC O
wound VB O
sites NNS O
. . O

As IN O
an DT O
embodiment NN O
of IN O
the DT O
present JJ O
invention NN O
, , O
such JJ O
an DT O
addition NN O
of IN O
an DT O
adhesive JJ O
polymer NN O
to TO O
the DT O
inventive JJ O
composition NN O
may MD O
have VB O
an DT O
additional JJ O
unexpected JJ O
and CC O
beneficial JJ O
effect NN O
on IN O
its PRP$ O
stability NN O
. . O

The DT O
addition NN O
of IN O
a DT O
polymer NN B-NP
then RB O
serves VBZ O
the DT O
double JJ O
purpose NN O
of IN O
increasing VBG O
the DT O
viscosity NN O
and CC O
adhesiveness NN O
of IN O
the DT O
composition NN O
, , O
at IN O
the DT O
same JJ O
time NN O
as IN O
it PRP O
helps VBZ O
the DT O
stabilization NN O
of IN O
the DT O
enzyme NN O
even RB O
further RBR O
. . O

In IN O
some DT O
embodiments NNS O
of IN O
the DT O
invention NN O
, , O
the DT O
composition NN O
further RB O
comprises VBZ O
a DT O
viscous JJ O
and CC O
adhesive JJ O
polymer NN O
selected VBN O
from IN O
polysaccharides NNS B-NP
and CC O
gelatin NN B-NP
. . O

Thus RB O
, , O
the DT O
polymer NN O
may MD O
for IN O
example NN O
be VB O
a DT O
polysaccharide NN B-NP
, , O
such JJ O
as IN O
selected VBN O
from IN O
starch NN B-NP
, , O
its PRP$ O
derivatives NNS O
, , O
cellulose NN B-NP
, , O
its PRP$ O
derivatives NNS O
, , O
and CC O
mixtures NNS O
thereof RB O
. . O

Specific NNP O
, , O
non-limiting JJ O
examples NNS O
of IN O
starches NNS O
useful JJ O
as IN O
additives NNS O
to TO O
the DT O
composition NN O
according VBG O
to TO O
the DT O
invention NN O
include VBP O
corn NN O
starch NN B-NP
and CC O
potato NN O
starch NN B-NP
and CC O
mixtures NNS O
thereof RB O
, , O
whereas IN O
non-limiting JJ O
examples NNS O
of IN O
useful JJ O
cellulose NN B-NP
derivatives NNS O
are VBP O
carboxymethyl NN B-NP
cellulose NN I-NP
and CC O
ethyl NN B-NP
hydroxyethyl NN I-NP
cellulose NN I-NP
and CC O
mixtures NNS O
thereof RB O
. . O

In IN O
a DT O
specific JJ O
embodiment NN O
the DT O
polysaccharide NN B-NP
is VBZ O
carboxymethyl NN B-NP
chitosan NN I-NP
. . O

In IN O
further JJ O
embodiments NNS O
of IN O
the DT O
invention NN O
, , O
said VBD O
polysaccharide NN B-NP
is VBZ O
present JJ O
in IN O
a DT O
concentration NN O
of IN O
0.1-5 CD O
% NN O
. . O

However RB O
, , O
it PRP O
is VBZ O
also RB O
envisaged VBN O
that IN O
the DT O
polymer NN O
is VBZ O
gelatin JJ B-NP
, , O
such JJ O
as IN O
gelatin NN B-NP
from IN O
a DT O
cold JJ O
water NN B-NP
fish NN O
. . O

In IN O
some DT O
embodiments NNS O
of IN O
the DT O
invention NN O
, , O
said VBD O
gelatin NNP B-NP
is VBZ O
present JJ O
in IN O
a DT O
concentration NN O
of IN O
0.5-20 CD O
% NN O
. . O

In IN O
one CD O
embodiment NN O
of IN O
the DT O
invention NN O
, , O
said VBD O
serine NN O
protease NN O
is VBZ O
present JJ O
in IN O
a DT O
concentration NN O
of IN O
0.001-2 CD O
mg/ml NN O
. . O

In IN O
a DT O
more RBR O
specific JJ O
embodiment NN O
, , O
said VBD O
serine NN O
protease NN O
is VBZ O
present JJ O
in IN O
a DT O
concentration NN O
of IN O
0.01-1 JJ O
mg/ml NN O
. . O

In IN O
one CD O
embodiment NN O
of IN O
the DT O
invention NN O
, , O
in IN O
which WDT O
the DT O
serine NN O
protease NN O
is VBZ O
thrombin RB O
, , O
the DT O
concentration NN O
of IN O
thrombin NN O
is VBZ O
between IN O
5-3500 CD O
activity NN O
units/ml NN O
. . O

In IN O
one CD O
embodiment NN O
of IN O
the DT O
invention NN O
, , O
in IN O
which WDT O
the DT O
serine NN O
protease NN O
is VBZ O
thrombin RB O
, , O
the DT O
concentration NN O
of IN O
thrombin NN O
is VBZ O
between IN O
200-1000 CD O
activity NN O
units/ml NN O
. . O

In IN O
one CD O
embodiment NN O
of IN O
the DT O
invention NN O
, , O
in IN O
which WDT O
the DT O
serine NN O
protease NN O
is VBZ O
thrombin RB O
, , O
the DT O
concentration NN O
of IN O
thrombin NN O
is VBZ O
between IN O
5- CD O
20 CD O
activity NN O
units/ml NN O
. . O

In IN O
one CD O
embodiment NN O
of IN O
the DT O
invention NN O
, , O
said VBD O
reversible JJ O
inhibitor NN O
of IN O
said VBD O
serine NN O
protease NN O
is VBZ O
present JJ O
in IN O
a DT O
concentration NN O
of IN O
0.1-10 CD O
mM. . O

In IN O
a DT O
more RBR O
specific JJ O
embodiment NN O
, , O
said VBD O
reversible JJ O
inhibitor NN O
of IN O
said VBD O
serine NN O
protease NN O
is VBZ O
present JJ O
in IN O
a DT O
concentration NN O
of IN O
0.5-2 CD O
mM. . O

In IN O
one CD O
embodiment NN O
of IN O
the DT O
invention NN O
, , O
said VBD O
stabilizing VBG O
agent NN O
M NNP O
is VBZ O
present JJ O
in IN O
a DT O
concentration NN O
of IN O
0.02-0.5 CD O
M. NNP O
In IN O
a DT O
more RBR O
specific JJ O
embodiment NN O
, , O
said VBD O
stabilizing VBG O
agent NN O
M NNP O
is VBZ O
present JJ O
in IN O
a DT O
concentration NN O
of IN O
0.1-0.3 CD O

M. NNP O

According VBG O
to TO O
another DT O
aspect NN O
thereof RB O
, , O
the DT O
present JJ O
invention NN O
provides VBZ O
use NN O
of IN O
a DT O
composition NN O
as IN O
described VBN O
above IN O
as IN O
a DT O
medicament NN O
. . O

Another DT O
aspect NN O
of IN O
the DT O
invention NN O
concerns NNS O
use NN O
of IN O
said VBD O
composition NN O
, , O
in IN O
which WDT O
the DT O
serine NN O
protease NN O
is VBZ O
thrombin IN O
, , O
for IN O
the DT O
preparation NN O
of IN O
a DT O
medicament NN O
for IN O
establishing VBG O
haemostasis NN O
in IN O
a DT O
subject JJ O
suffering NN O
from IN O
a DT O
bleeding NN O
. . O

A DT O
related JJ O
aspect NN O
of IN O
the DT O
invention NN O
provides VBZ O
a DT O
method NN O
for IN O
establishing VBG O
haemostasis NN O
in IN O
a DT O
subject JJ O
suffering NN O
from IN O
a DT O
bleeding NN O
, , O
comprising VBG O
applying VBG O
a DT O
composition NN O
according VBG O
to TO O
the DT O
invention NN O
, , O
in IN O
which WDT O
composition NN O
the DT O
serine NN O
protease NN O
is VBZ O
thrombin RB O
, , O
to TO O
the DT O
site NN O
of IN O
bleeding VBG O
in IN O
an DT O
amount NN O
sufficient JJ O
to TO O
diminish VB O
or CC O
stop VB O
said VBD O
bleeding NN O
. . O

In IN O
connection NN O
with IN O
such JJ O
a DT O
use NN O
or CC O
method NN O
employing VBG O
a DT O
thrombin NN O
composition NN O
according VBG O
to TO O
the DT O
invention NN O
as IN O
a DT O
medicament NN O
, , O
the DT O
stability NN O
of IN O
the DT O
inventive JJ O
composition NN O
offers VBZ O
benefits NNS O
in IN O
the DT O
circumstances NNS O
in IN O
which WDT O
it PRP O
is VBZ O
used VBN O
. . O

Often RB O
, , O
thrombin IN O
compositions NNS O
are VBP O
used VBN O
in IN O
the DT O
context NN O
of IN O
emergency NN O
situations NNS O
, , O
wherein WRB O
it PRP O
is VBZ O
crucial JJ O
to TO O
stop VB O
subjects NNS O
from IN O
bleeding VBG O
. . O

In IN O
these DT O
same JJ O
situations NNS O
, , O
the DT O
use NN O
of IN O
conventional JJ O
, , O
haemostatic JJ O
thrombin IN O
preparations NNS O
is VBZ O
difficult JJ O
, , O
since IN O
they PRP O
often RB O
require VBP O
cumbersome JJ O
and CC O
time NN O
- : O
consuming JJ O
steps NNS O
of IN O
thawing DT O
( -LRB- O
if IN O
frozen VBN O
) -RRB- O
and/or NN O
dissolution NN O
( -LRB- O
if IN O
lyophilized VBN O
) -RRB- O
. . O

The DT O
present JJ O
invention NN O
enables VBZ O
the DT O
production NN O
of IN O
e NN O
g VBG O
such JJ O
haemostatic JJ O
agents NNS O
in IN O
the DT O
form NN O
of IN O
solutions NNS O
, , O
whose WP$ O
stability NN O
is VBZ O
such JJ O
that IN O
they PRP O
can MD O
readily RB O
be VB O
stored VBN O
during IN O
extended VBN O
periods NNS O
of IN O
time NN O
, , O
for IN O
example NN O
in IN O
an DT O
ambulance NN O
or CC O
an DT O
emergency NN O
helicopter NN O
, , O
until IN O
needed VBN O
at IN O
the DT O
site NN O
of IN O
an DT O
accident NN O
or CC O
the DT O
like JJ O
. . O

At IN O
this DT O
time NN O
, , O
they PRP O
may MD O
be VB O
used VBN O
as RB O
is VBZ O
, , O
without IN O
any DT O
delay NN O
due JJ O
to TO O
preparation NN O
. . O

The DT O
conventional JJ O
preparations NNS O
used VBN O
to TO O
stop VB O
bleeding VBG O
contain VBP O
fairly RB O
high JJ O
concentrations NNS O
of IN O
thrombin NN O
, , O
between IN O
200-1000 CD O
activity NN O
units/ml NN O
. . O

In IN O
connection NN O
with IN O
plastic NN O
surgery NN O
applications NNS O
, , O
this DT O
is VBZ O
seen VBN O
as IN O
a DT O
risk NN O
for IN O
increased JJ O
scar NN O
formation NN O
. . O

Low NNP O
thrombin IN O
concentration NN O
solutions NNS O
are VBP O
presently RB O
prepared VBN O
in IN O
the DT O
clinic NN O
by IN O
dilution NN O
of IN O
concentrated JJ O
thrombin IN O
solutions NNS O
. . O

No DT O
ready JJ O
to TO O
use VB O
preparation NN O
is VBZ O
available JJ O
. . O

Therefore RB O
, , O
in IN O
a DT O
further JJ O
aspect NN O
thereof RB O
, , O
the DT O
present JJ O
invention NN O
provides VBZ O
a DT O
stabilized VBN O
thrombin IN O
composition NN O
with IN O
a DT O
considerably RB O
lower JJR O
concentration NN O
of IN O
thrombin NN O
, , O
between IN O
5-20 CD O
activity NN O
units/ml NN O
, , O
and CC O
use NN O
thereof , O
in IN O
plastic NN O
surgery NN O
. . O

Another DT O
aspect NN O
of IN O
the DT O
invention NN O
exploits VBZ O
the DT O
known VBN O
properties NNS O
of IN O
plasmin NN O
, , O
urokinase NN O
or CC O
tPA NN O
as IN O
thrombolytic JJ O
agents NNS O
. . O

Thus RB O
, , O
the DT O
invention NN O
provides VBZ O
use NN O
of IN O
a DT O
composition NN O
as IN O
described VBN O
above IN O
, , O
in IN O
which WDT O
the DT O
serine NN O
protease NN O
is VBZ O
selected VBN O
from IN O
plasmin NN O
, , O
urokinase JJ O
and CC O
tissue NN O
plasminogen NN O
activator NN O
, , O
for IN O
the DT O
preparation NN O
of IN O
a DT O
medicament NN O
for IN O
thrombolytic JJ O
treatment NN O
. . O

A DT O
related JJ O
aspect NN O
provides VBZ O
a DT O
method NN O
for IN O
thrombolytic JJ O
treatment NN O
in IN O
a DT O
subject NN O
in IN O
need NN O
thereof RB O
, , O
comprising VBG O
administering VBG O
a DT O
composition NN O
as IN O
described VBN O
above IN O
, , O
in IN O
which WDT O
composition NN O
the DT O
serine NN O
protease NN O
is VBZ O
selected VBN O
from IN O
plasmin NN O
, , O
urokinase JJ O
and CC O
tissue NN O
plasminogen NN O
activator NN O
, , O
to TO O
the DT O
subject NN O
in IN O
an DT O
amount NN O
sufficient JJ O
for IN O
said VBD O
treatment NN O
. . O

In IN O
these DT O
two CD O
related JJ O
aspects NNS O
, , O
the DT O
thrombolytic JJ O
treatment NN O
in IN O
question NN O
may MD O
, , O
as IN O
non-limiting JJ O
examples NNS O
, , O
be VB O
performed VBN O
in IN O
order NN O
to TO O
treat VB O
myocardial JJ O
infarction NN O
or CC O
in IN O
order NN O
to TO O
treat VB O
stroke NN O
. . O

As IN O
mentioned VBN O
in IN O
the DT O
context NN O
of IN O
the DT O
composition NN O
aspect NN O
of IN O
the DT O
invention NN O
, , O
the DT O
increase NN O
in IN O
stabilization NN O
due JJ O
to TO O
the DT O
combination NN O
of IN O
the DT O
reversible JJ O
serine NN O
protease NN O
inhibitor NN O
and CC O
stabilizing VBG O
agent NN O
M NNP O
is VBZ O
not RB O
regarded VBN O
as IN O
an DT O
additional JJ O
inhibitory JJ O
effect NN O
provided VBN O
by IN O
M. NNP O
In IN O
fact NN O
M NNP O
, , O
as IN O
described VBN O
in IN O
Illustrative NNP O
Example NNP O
A NNP O
, , O
may MD O
lack VB O
any DT O
serine NN O
protease NN O
inhibiting VBG O
capacity NN O
. . O

Without IN O
wishing NN O
to TO O
be VB O
bound VBN O
by IN O
theory NN O
, , O
the DT O
present JJ O
inventors NNS O
believe VBP O
that IN O
the DT O
surprisingly RB O
increased VBN O
stabilizing VBG O
effect NN O
observed VBN O
is VBZ O
achieved VBN O
through IN O
a DT O
beneficial JJ O
synergy NN O
between IN O
reversible JJ O
serine NN O
protease NN O
inhibitors NNS O
and CC O
stabilizing VBG O
agents NNS O
M NNP O
of IN O
the DT O
inventive JJ O
composition NN O
. . O

Therefore RB O
, , O
in IN O
another DT O
aspect NN O
thereof RB O
, , O
the DT O
invention NN O
provides VBZ O
the DT O
use NN O
of IN O
a DT O
combination NN O
of IN O
a DT O
) -RRB- O
a DT O
reversible JJ O
serine NN O
protease NN O
inhibitor NN O
and CC O
b NN O
) -RRB- O
a DT O
stabilizing VBG O
agent NN O
M NNP O
of IN O
formula NN O
I PRP O
: : O

[0053] . O

EMI15.1 . O

wherein WRB O
n NN O
is VBZ O
0 CD O
, , O
1 CD O
or CC O
2 CD O
; : O

X NNP O
is VBZ O
0, JJ B-NP
N NNP B-NP
or CC O
CH2 NNP B-NP
; : O
R<1>--^<4> NNP O
are VBP O
the DT O
same JJ O
or CC O
different JJ O
, , O
and CC O
selected VBN O
from IN O
H NNP B-NP
, , O
-CH2-R<6> JJ B-NP
, , O
-CH2-O-R<6> JJ B-NP
, , O
-CH2-S-R<6> JJ B-NP
, , O
-CH2-NH-R<6> JJ B-NP
, , O
-CO-O-R<6> JJ B-NP
, , O
-CO-NH-R<6> JJ B-NP
, , O
-CH2-NH-CO-R<6> JJ B-NP
, , O
-CH2-O-CO-R<6> JJ B-NP
, , O
-CH2-NH-CO-NHR<6> JJ B-NP
, , O
-CH2-NH-CO-OR<6> JJ B-NP
, , O
-CH2-NH-CS-NHR<6> JJ B-NP
and CC O
-CH2-O-CO-NHR<6> JJ B-NP
; : O

R<5> NN O
is VBZ O
as IN O
R-R<4> JJ O
or CC O
P-Q JJ O
; : O
P NNP O
is VBZ O
selected VBN O
from IN O
- : B-NP
( -LRB- I-NP
CH2 NN I-NP
) -RRB- I-NP
m NN I-NP
- : I-NP
and CC O
- : B-NP
( -LRB- I-NP
CH2 NN I-NP
) -RRB- I-NP
m-Y- FW I-NP
( -LRB- I-NP
CH2 NN I-NP
) -RRB- I-NP
m-, , I-NP
wherein WRB O
m NN O
is VBZ O
1-6 JJ O
and CC O
Y PRP O
is VBZ O
0, JJ B-NP
NH NNP B-NP
or CC O
S NNP B-NP
; : O

Q NN O
is VBZ O
selected VBN O
from IN O
H NNP B-NP
, , O
-SO3 JJ B-NP
, , O
-COOH NNP B-NP
, , O
-NH2 NNP B-NP
, , O
-OH NNP B-NP
and CC O
-CONH2 NNP B-NP
; : O
each DT O
R<6> JJ O
individually RB O
being VBG O
selected VBN O
from IN O
H NNP B-NP
, , O
substituted VBN B-NP
or CC I-NP
non-substituted JJ I-NP
lower JJR I-NP
alkyl NN I-NP
, , O
substituted VBN B-NP
or CC I-NP
non-substituted JJ I-NP
cycloalkyl NN I-NP
, , O
substituted VBN B-NP
or CC I-NP
non FW I-NP
- : I-NP
substituted VBN I-NP
benzyl NN I-NP
, , O
substituted VBN B-NP
or CC I-NP
non-substituted JJ I-NP
aryl NN I-NP
or CC O
mono-, JJ B-NP
bi-, JJ I-NP
or CC I-NP
tricyclic JJ I-NP
unsubstituted JJ I-NP
or CC I-NP
substituted VBN I-NP
heteroaromatic JJ I-NP
ring( NN I-NP
s VBZ O
) -RRB- O
with IN O
one CD O
or CC O
more JJR O
heteroatoms NNS B-NP
and CC I-NP
non-aromatic JJ I-NP
heterocycles NNS I-NP
, , O
the DT O
substituents NNS O
of IN O
the DT O
substituted VBN O
groups NNS O
being VBG O
selected VBN O
from IN O
lower JJR B-NP
alkyl NN I-NP
, , O
halogens NNS B-NP
, , O
substituted VBN B-NP
or CC I-NP
non-substituted JJ I-NP
aryl NN I-NP
, , O
substituted VBN B-NP
or CC I-NP
non-substituted JJ I-NP
hetero-aromatic JJ I-NP
compounds NNS I-NP
, , O
non-aromatic JJ B-NP
heterocycles NNS I-NP
, , O
alkyloxy RB B-NP
, , O
alkylamino RB B-NP
; : O
or CC O
a DT O
pharmaceutically RB O
acceptable JJ O
salt NN O
thereof , O
; : O
for IN O
stabilizing VBG O
a DT O
serine NN O
protease NN O
composition NN O
, , O
wherein WRB O
the DT O
reversible JJ O
serine NN O
protease NN O
inhibitor NN O
and CC O
the DT O
stabilizing VBG O
agent NN O
M NNP O
act NN O
in IN O
synergy NN O
to TO O
provide VB O
a DT O
serine NN O
protease NN O
stabilizing VBG O
effect NN O
. . O

In IN O
this DT O
inventive JJ O
use NN O
of IN O
a DT O
combination NN O
of IN O
a DT O
reversible JJ O
serine NN O
protease NN O
inhibitor NN O
and CC O
a DT O
stabilizing VBG O
agent NN O
for IN O
stabilization NN O
of IN O
a DT O
serine NN O
protease NN O
composition NN O
, , O
the DT O
choices NNS O
of IN O
particular JJ O
components NNS O
that WDT O
may MD O
be VB O
used VBN O
and CC O
substituents NNS O
for IN O
compounds NNS O
M NNP O
are VBP O
as IN O
discussed VBN O
above IN O
in IN O
relation NN O
to TO O
the DT O
composition NN O
aspect NN O
of IN O
the DT O
invention NN O
. . O

In IN O
yet RB O
another DT O
aspect NN O
, , O
the DT O
invention NN O
provides VBZ O
a DT O
method NN O
for IN O
the DT O
stabilization NN O
of IN O
a DT O
serine NN O
protease NN O
, , O
which WDT O
comprises VBZ O
admixing VBG O
the DT O
serine NN O
protease NN O
with IN O
a DT O
) -RRB- O
a DT O
reversible JJ O
inhibitor NN O
of IN O
said VBD O
serine NN O
protease NN O
; : O
and CC O
b NN O
) -RRB- O
a DT O
stabilizing VBG O
agent NN O
M NNP O
of IN O
formula NN O
I PRP O
: : O

[0058] . O

EMI16.1 . O

wherein WRB O
n NN O
is VBZ O
0, CD O
1 CD O
or CC O
2 CD O
; : O

X NNP O
is VBZ O
O UH B-NP
, , O
N NNP B-NP
or CC O
CH2 NNP B-NP
; : O

R<3->-R<4> JJ O
are VBP O
the DT O
same JJ O
or CC O
different JJ O
, , O
and CC O
selected VBN O
from IN O
H NNP B-NP
, , O
-CH2-R<6> JJ B-NP
, , O
-CH2-O-R<6> JJ B-NP
, , O
-CH2-S-R<6> JJ B-NP
, , O
-CH2-NH-R<6> JJ B-NP
, , O
-CO-O-R<6> JJ B-NP
, , O
-CO-NH-R<6> JJ B-NP
, , O
-CH2-NH-CO-R<6> JJ B-NP
, , O
-CH2-O-CO-R<6> JJ B-NP
, , O
-CH2-NH-CO-NHR<6> JJ B-NP
, , O
-CH2-NH-CO-OR<6> JJ B-NP
, , O
-CH2-NH-CS-NHR<6> JJ B-NP
and CC O
-CH2-O-CO-NHR<6> JJ B-NP
; : O
R<5> NNP O
is VBZ O
as IN O
R-R<4> JJ O
or CC O
P-Q JJ O
; : O

P NNP O
is VBZ O
selected VBN O
from IN O
- : B-NP
( -LRB- I-NP
CH2 NN I-NP
) -RRB- I-NP
m NN I-NP
- : I-NP
and CC O
- : B-NP
( -LRB- I-NP
CH2 NN I-NP
) -RRB- I-NP
m-Y- FW I-NP
( -LRB- I-NP
CH2 NN I-NP
) -RRB- I-NP
m-, , I-NP
wherein WRB O
m NN O
is VBZ O
1-6 JJ O
and CC O
Y PRP O
is VBZ O
0, JJ B-NP
NH NNP B-NP
or CC O
S NNP B-NP
; : O

Q NN O
is VBZ O
selected VBN O
from IN O
H NNP B-NP
, , O
-SO3 JJ B-NP
, , O
-COOH NNP B-NP
, , O
-NH2 NNP B-NP
, , O
-OH NNP B-NP
and CC O
-CONH2 NNP B-NP
; : O
each DT O
R<6> JJ O
individually RB O
being VBG O
selected VBN O
from IN O
H NNP B-NP
, , O
substituted VBN B-NP
or CC I-NP
non-substituted JJ I-NP
lower JJR I-NP
alkyl NN I-NP
, , O
substituted VBN B-NP
or CC I-NP
non-substituted JJ I-NP
cycloalkyl NN I-NP
, , O
substituted VBN B-NP
or CC I-NP
non FW I-NP
- : I-NP
substituted VBN I-NP
benzyl NN I-NP
, , O
substituted VBN B-NP
or CC I-NP
non-substituted JJ I-NP
aryl NN I-NP
or CC O
mono-, JJ B-NP
bi-, JJ I-NP
or CC I-NP
tricyclic JJ I-NP
unsubstituted JJ I-NP
or CC I-NP
substituted VBN I-NP
heteroaromatic JJ I-NP
ring( NN I-NP
s VBZ O
) -RRB- O
with IN O
one CD O
or CC O
more JJR O
heteroatoms NNS B-NP
and CC I-NP
non-aromatic JJ I-NP
heterocycles NNS I-NP
, , O
the DT O
substituents NNS O
of IN O
the DT O
substituted VBN O
groups NNS O
being VBG O
selected VBN O
from IN O
lower JJR B-NP
alkyl NN I-NP
, , O
halogens NNS B-NP
, , O
substituted VBN B-NP
or CC I-NP
non-substituted JJ I-NP
aryl NN I-NP
, , O
substituted VBN B-NP
or CC I-NP
non-substituted JJ I-NP
hetero-aromatic JJ I-NP
compounds NNS I-NP
, , O
non-aromatic JJ B-NP
heterocycles NNS I-NP
, , O
alkyloxy RB B-NP
, , O
alkylamino RB B-NP
; : O
or CC O
a DT O
pharmaceutically RB O
acceptable JJ O
salt NN O
thereof '' O
. . O

In IN O
this DT O
inventive JJ O
method NN O
for IN O
stabilization NN O
of IN O
a DT O
serine NN O
protease NN O
composition NN O
, , O
the DT O
choices NNS O
of IN O
particular JJ O
components NNS O
that WDT O
may MD O
be VB O
used VBN O
and CC O
substituents NNS O
for IN O
compounds NNS O
M NNP O
are VBP O
as IN O
discussed VBN O
above IN O
in IN O
relation NN O
to TO O
the DT O
composition NN O
aspect NN O
of IN O
the DT O
invention NN O
. . O

A DT O
further JJ O
aspect NN O
of IN O
the DT O
invention NN O
concerns VBZ O
the DT O
use NN O
of IN O
the DT O
composition NN O
as IN O
described VBN O
above IN O
for IN O
adsorption NN O
onto IN O
a DT O
solid JJ O
object NN O
, , O
in IN O
order NN O
that IN O
this DT O
solid JJ O
object NN O
may MD O
provide VB O
the DT O
enzymatic JJ O
activity NN O
in IN O
question NN O
. . O

In IN O
particular JJ O
, , O
it PRP O
is VBZ O
of IN O
interest NN O
in IN O
many JJ O
surgical JJ O
applications NNS O
to TO O
enter VB O
and CC O
, , O
in IN O
particular JJ O
, , O
exit NN O
arteries NNS O
while IN O
inflicting VBG O
as IN O
little JJ O
damage NN O
from IN O
bleeding VBG O
as IN O
possible JJ O
. . O

In IN O
order NN O
to TO O
stop VB O
bleeding VBG O
from IN O
an DT O
artery NN O
, , O
it PRP O
has VBZ O
previously RB O
been VBN O
suggested VBN O
to TO O
use VB O
a DT O
form NN O
of IN O
"arterial JJ O
plug" NN O
( -LRB- O
such JJ O
objects NNS O
are VBP O
also RB O
known VBN O
as IN O
vascular JJ O
sealing NN O
devices NNS O
, , O
femoral JJ O
access NN O
closure NN O
devices NNS O
( -LRB- O
when WRB O
the DT O
femoral JJ O
artery NN O
is VBZ O
used VBN O
for IN O
entry NN O
, , O
e NN O
g NN O
in IN O
angiography NN O
) -RRB- O
, , O
vascular JJ O
hemostasis NN O
devices NNS O
and CC O
puncture NN O
closure NN O
devices NNS O
) -RRB- O
, , O
for IN O
example NN O
made VBN O
from IN O
collagen NN O
or CC O
another DT O
biodegradable JJ O
material NN O
. . O

According VBG O
to TO O
the DT O
present JJ O
aspect NN O
of IN O
the DT O
invention NN O
, , O
such JJ O
a DT O
plug NN O
may MD O
advantageously RB O
be VB O
coated VBN O
with IN O
a DT O
composition NN O
according VBG O
to TO O
the DT O
invention NN O
, , O
in IN O
which WDT O
the DT O
serine NN O
protease NN O
is VBZ O
thrombin RB O
. . O

Such JJ O
a DT O
plug NN O
achieves VBZ O
faster JJR O
sealing NN O
of IN O
the DT O
opening NN O
of IN O
the DT O
artery NN O
, , O
in IN O
that IN O
the DT O
thrombin NN O
of IN O
the DT O
composition NN O
aids NNS O
in IN O
blood NN O
clotting NN O
around IN O
the DT O
plug. NN O

Thus RB O
, , O
the DT O
invention NN O
provides VBZ O
, , O
in IN O
this DT O
aspect NN O
, , O
a DT O
vascular JJ O
haemostasis NN O
device NN O
having VBG O
an DT O
amount NN O
of IN O
the DT O
composition NN O
according VBG O
to TO O
the DT O
invention NN O
, , O
in IN O
which WDT O
the DT O
serine NN O
protease NN O
is VBZ O
thrombin IN O
, , O
adsorbed VBN O
on IN O
it PRP O
. . O

The DT O
vascular JJ O
haemostasis NN O
device NN O
is VBZ O
preferably RB O
made VBN O
from IN O
a DT O
biodegradable JJ O
solid JJ O
or CC O
semi-solid JJ O
material NN O
, , O
such JJ O
as IN O
collagen NN O
, , O
chitosan NN B-NP
or CC O
other JJ O
biological JJ O
polymer NN O
. . O

Another DT O
aspect NN O
of IN O
the DT O
invention NN O
concerns VBZ O
the DT O
novel NN O
identification NN O
of IN O
N,N-diethylethylenediamine NN B-NP
as IN O
a DT O
serine NN O
protease NN O
inhibitor NN O
. . O

Thus RB O
, , O
in IN O
this DT O
aspect NN O
, , O
the DT O
invention NN O
provides VBZ O
use NN O
of IN O
N NNP B-NP
, , I-NP
N-diethylethylenediamine NNP I-NP
as IN O
an DT O
inhibitor NN O
of IN O
a DT O
serine NN O
protease NN O
, , O
as RB O
well RB O
as IN O
a DT O
method NN O
of IN O
inhibiting VBG O
a DT O
serine NN O
protease NN O
, , O
comprising VBG O
admixing NN O
therewith , O
an DT O
inhibitory JJ O
amount NN O
of IN O
N NNP B-NP
, , I-NP
N-diethylethylenediamine NNP I-NP
. . O

In IN O
some DT O
embodiments NNS O
of IN O
this DT O
aspect NN O
of IN O
the DT O
invention NN O
, , O
the DT O
serine NN O
protease NN O
is VBZ O
plasmin NN O
. . O

In IN O
other JJ O
embodiments NNS O
of IN O
this DT O
aspect NN O
of IN O
the DT O
invention NN O
, , O
the DT O
serine NN O
protease NN O
is VBZ O
thrombin RB O
. . O

It PRP O
is VBZ O
generally RB O
preferred VBN O
, , O
for IN O
the DT O
realization NN O
of IN O
all DT O
the DT O
advantages NNS O
of IN O
the DT O
invention NN O
's POS O
different JJ O
aspects NNS O
, , O
that IN O
the DT O
composition NN O
according VBG O
to TO O
the DT O
invention NN O
is VBZ O
in IN O
a DT O
form NN O
selected VBN O
from IN O
a DT O
solution NN O
and CC O
a DT O
gel NN O
. . O

In IN O
this DT O
regard NN O
, , O
aqueous JJ O
solutions NNS O
and CC O
aqueous JJ O
gels NNS O
are VBP O
more RBR O
preferred VBN O
. . O

Definitions NNS O

As IN O
used VBN O
herein RB O
, , O
the DT O
term NN O
"lower NN O
alkyl NN B-NP
" '' O
means VBZ O
an DT O
unbranched JJ O
or CC O
branched JJ O
, , O
cyclic JJ O
, , O
saturated JJ O
or CC O
unsaturated JJ O
( -LRB- O
alkenyl NN B-NP
or CC O
alkynyl NN B-NP
) -RRB- O
hydrocarbyl NN B-NP
radical JJ I-NP
which WDT O
may MD O
be VB O
substituted VBN O
or CC O
unsubstituted VBN O
. . O

Where WRB O
cyclic NN O
, , O
the DT O
alkyl NN B-NP
group NN O
is VBZ O
preferably RB O
C3-C12 JJ O
, , O
more RBR O
preferably RB O
C5-C10 JJ O
, , O
most RBS O
preferably RB O
C5-C7 NN O
. . O

Where WRB O
acyclic NN O
, , O
the DT O
alkyl NN B-NP
group NN O
is VBZ O
preferably RB O
Cl-ClO NN O
, , O
more RBR O
preferably RB O
Cl-C[beta] JJ O
, , O
more RBR O
preferably RB O
methyl NN B-NP
, , O
ethyl NN B-NP
, , O
propyl NN B-NP
(n-propyl NN O
, , O
isopropyl NN B-NP
) -RRB- O
, , O
butyl FW B-NP
( -LRB- O
branched NN O
or CC O
unbranched JJ O
) -RRB- O
or CC O
pentyl NN B-NP
, , O
most JJS O
preferably RB O
methyl NN B-NP
. . O

As IN O
used VBN O
herein RB O
, , O
the DT O
term NN O
"aryl NN O
" '' O
means VBZ O
an DT O
aromatic JJ O
group NN O
, , O
such JJ O
as IN O
phenyl NN B-NP
or CC O
naphthyl NN B-NP
, , O
or CC O
a DT O
mono-, JJ O
bi-, JJ O
or CC O
tricyclic JJ O
heteroaromatic JJ O
group NN O
containing VBG O
one CD O
or CC O
ore NN O
heteroatom( NN O
s VBZ O
) -RRB- O
preferably RB O
selected VBN O
from IN O
N NNP B-NP
, , O
0 CD B-NP
and CC O
S NNP B-NP
, , O
such JJ O
as IN O
pyridyl NN B-NP
, , O
pyrrolyl NN B-NP
, , O
quinolinyl NN B-NP
, , O
furanyl NN B-NP
, , O
thienyl NN B-NP
, , O
oxadiazolyl NN B-NP
, , O
thiadiazolyl NN B-NP
, , O
thiazolyl NN B-NP
, , O
oxazolyl NN B-NP
, , O
pyrazolyl NN B-NP
, , O
triazolyl NN B-NP
, , O
tetrazolyl NN B-NP
, , O
isoxazolyl NN B-NP
, , O
isothiazolyl NN B-NP
, , O
imidazolyl NN B-NP
, , O
pyrimidinyl NN B-NP
, , O
indolyl NN B-NP
, , O
pyrazinyl NN B-NP
, , O
indazolyl NN B-NP
, , O
pyrimidinyl NN B-NP
, , O
thiophenetyl NN B-NP
, , O
pyranyl NN B-NP
, , O
carbazolyl NN B-NP
, , O
acridinyl NN B-NP
, , O
quinolinyl NN B-NP
, , O
benzoimidazolyl NN B-NP
, , O
benzthiazolyl NN B-NP
, , O
purinyl NN B-NP
, , O
cinnolinyl NN B-NP
, , O
pterdinyl NN B-NP
. . O

As IN O
used VBN O
herein RB O
, , O
the DT O
term NN O
"functional JJ O
group NN O
" '' O
means VBZ O
, , O
in IN O
the DT O
case NN O
of IN O
unprotected JJ O
: : O
hydroxy-, JJ B-NP
thiolo-, JJ B-NP
aminofunction NN O
, , O
carboxylic JJ B-NP
acid NN I-NP
, , O
and CC O
in IN O
the DT O
case NN O
of IN O
protected JJ O
: : O
lower JJR B-NP
alkoxy NN I-NP
, , O
N-, NNP B-NP
O-, NNP B-NP
S- NNP B-NP
acetyl NN I-NP
, , O
carboxylic JJ B-NP
acid NN I-NP
ester NN I-NP
. . O

As IN O
used VBN O
herein RB O
, , O
the DT O
term NN O
"heteroaryl NN O
" '' O
means VBZ O
an DT O
aromatic JJ O
group NN O
containing VBG O
one CD O
or CC O
more JJR O
heteroatom( NN O
s VBZ O
) -RRB- O
preferably RB O
selected VBN O
from IN O
N NNP B-NP
, , O
O NNP B-NP
and CC O
S NNP B-NP
, , O
such JJ O
as IN O
pyridyl NN B-NP
, , O
pyrrolyl NN B-NP
, , O
quinolinyl NN B-NP
, , O
furanyl NN B-NP
, , O
thienyl NN B-NP
, , O
oxadiazolyl NN B-NP
, , O
thiadiazolyl NN B-NP
, , O
thiazolyl NN B-NP
, , O
oxazolyl NN B-NP
, , O
pyrazolyl NN B-NP
, , O
triazolyl NN B-NP
, , O
imidazolyl NN B-NP
, , O
pyrimidinyl NN B-NP
, , O
indolyl NN B-NP
, , O
pyrazinyl NN B-NP
or CC O
indazolyl NN B-NP
. . O

As IN O
used VBN O
herein RB O
, , O
the DT O
term NN O
"non-aromatic JJ O
heterocycle NN B-NP
" '' O
means VBZ O
a DT O
non-aromatic JJ O
cyclic NN O
group NN O
containing VBG O
one CD O
or CC O
more JJR O
heteroatom NN O
( -LRB- O
s PRP O
) -RRB- O
preferably RB O
selected VBN O
from IN O
N NNP B-NP
, , O
0 CD O
and CC O
S NNP B-NP
, , O
such JJ O
as IN O
a DT O
cyclic NN B-NP
amino IN I-NP
group NN I-NP
such JJ O
as IN O
pyrrolidinyl NN B-NP
, , O
piperidyl NN B-NP
, , O
piperazinyl NN B-NP
, , O
morpholinyl NN B-NP
or CC O
a DT O
cyclic JJ B-NP
ether NN I-NP
such JJ O
as IN O
tetrahydrofuranyl NN B-NP
, , O
monosaccharide NN B-NP
. . O

As IN O
used VBN O
herein RB O
, , O
the DT O
term NN O
"halogen NN O
" '' O
means VBZ O
fluorine NN B-NP
, , O
chlorine NN B-NP
, , O
bromine NN B-NP
or CC O
iodine NN B-NP
. . O

As IN O
used VBN O
herein RB O
, , O
the DT O
term NN O
" `` O
substituted VBN O
" '' O
means VBZ O
that IN O
the DT O
groups NNS O
concerned VBN O
are VBP O
substituted VBN O
with IN O
a DT O
functional JJ O
group NN O
such JJ O
as IN O
hydroxyl JJ B-NP
, , O
amine JJ B-NP
, , O
sulf^e JJ B-NP
, , O
silyl JJ B-NP
, , O
carboxylic JJ B-NP
acid NN I-NP
, , O
halogen NN B-NP
, , O
aryl NN B-NP
, , O
etc FW O
. . O

Examples NNS O
of IN O
pharmaceutically RB O
acceptable JJ O
addition NN O
salts NNS O
for IN O
use NN O
in IN O
the DT O
compositions NNS O
of IN O
the DT O
present JJ O
invention NN O
include VBP O
those DT O
derived VBN O
from IN O
mineral NN O
acids NNS O
, , O
such JJ O
as IN O
hydrochlorid JJ B-NP
, , O
hydrobromic JJ B-NP
, , O
phosphoric JJ B-NP
, , O
metaphosphoric JJ B-NP
, , O
nitric JJ B-NP
and CC O
sulphuric JJ B-NP
acids NNS I-NP
, , O
and CC O
organic JJ O
acids NNS O
, , O
such JJ O
as IN O
tartaric JJ B-NP
, , O
acetic JJ B-NP
, , O
citric JJ B-NP
, , O
malic JJ B-NP
, , O
lactic JJ B-NP
, , O
fumaric JJ B-NP
, , O
benzoic JJ B-NP
, , O
glycolic JJ B-NP
, , O
gluconic JJ B-NP
, , O
succinic JJ B-NP
, , O
and CC O
arylsulphonic JJ B-NP
acids NNS I-NP
. . O

Pharmaceutically RB O
acceptable JJ O
excipients NNS O
described VBN O
herein RB O
, , O
for IN O
example NN O
, , O
vehicles NNS O
, , O
adjuvants NNS O
, , O
carriers NNS O
or CC O
diluents NNS O
, , O
are VBP O
well RB O
known VBN O
to TO O
those DT O
who WP O
are VBP O
skilled JJ O
in IN O
the DT O
art NN O
and CC O
are VBP O
readily RB O
available JJ O
to TO O
the DT O
public NN O
. . O

A DT O
pharmaceutically RB O
acceptable JJ O
carrier NN O
may MD O
be VB O
one CD O
which WDT O
is VBZ O
chemically RB O
inert JJ O
to TO O
the DT O
active JJ O
compounds NNS O
and CC O
which WDT O
have VBP O
no DT O
detrimental JJ O
side NN O
effects NNS O
or CC O
toxicity NN O
under IN O
the DT O
conditions NNS O
of IN O
use NN O
. . O

Pharmaceutical NNP O
formulations NNS O
may MD O
be VB O
found VBN O
e NN O
g VBG O
in IN O
Remington NNP O
: : O
The DT O
Science NNP O
and CC O
Practice NNP O
of IN O
Pharmacy NNP O
, , O
19 CD O
edition NN O
, , O
Mack NNP O
Printing NNP O
Company NNP O
, , O
Easton NNP O
, , O
Pennsylvania NNP O
( -LRB- O
1995 CD O
) -RRB- O
. . O

As IN O
detailed VBN O
in IN O
the DT O
description NN O
of IN O
the DT O
invention NN O
, , O
a DT O
possible JJ O
choice NN O
of IN O
inhibitor NN O
for IN O
use NN O
in IN O
the DT O
composition NN O
and CC O
methods NNS O
according VBG O
to TO O
the DT O
invention NN O
is VBZ O
"N- DT O
( -LRB- B-NP
2' FW I-NP
- : I-NP
phenoxy NN I-NP
) -RRB- I-NP
-4-aminopyridin . I-NP
and CC O
derivatives VBZ O
there RB O
.of" RB O
. . O

By IN O
this DT O
is VBZ O
meant VBN O
a DT O
compound NN O
having VBG O
the DT O
formula NN O
IV NNP O
: : O

[0075 CD O
] NN O

EMI20.1 . O

wherein WRB O

R<1> NN O
is VBZ O
selected VBN O
from IN O
H NNP B-NP
, , O
Cl-C[beta]-alkyl NNP B-NP
, , O
C3-C7-cyclo NNP B-NP
alkyl NN I-NP
, , O
phenyl NN B-NP
, , O
benzyl NN B-NP
acetyl NN I-NP
and CC O
benzoyl NN B-NP
; : O
X NNP O
is VBZ O
selected VBN O
from IN O
oxygen NN B-NP
, , O
nitrogen NN B-NP
and CC O
sulfur NN B-NP
; : O

R<2> NNP O
and CC O
R<3> NNP O
is VBZ O
each DT O
individually RB O
selected VBN O
from IN O
H NNP B-NP
, , O
halogen NN B-NP
, , O
hydroxyl NN B-NP
, , O
Cl-C[beta]-alkyl NNP B-NP
, , O
C3-C7-cyclo NNP B-NP
alkyl NN I-NP
, , O
C1-C6- DT B-NP
alkyloxy NN I-NP
; : O
and CC O
R<4> NNP O
is VBZ O
selected VBN O
from IN O
H NNP B-NP
, , O
Cl-C[beta]-alkyl NNP B-NP
, , O
arylalkyl NN B-NP
and CC O
acyl NN B-NP
. . O

Preferred VBN O
such JJ O
inhibitors NNS O
have VBP O
the DT O
formula NN O
V NNP O
: : O

[0079] . O

EMI21.1 . O

wherein WRB O

R<1> NN O
is VBZ O
selected VBN O
from IN O
Cl-C[beta]-alkyl NNP B-NP
, , O
C3-C7-cyclo NNP B-NP
alkyl NN I-NP
, , O
phenyl NN B-NP
and CC O
benzyl NN B-NP
; : O

R<2> NNP O
and CC O
R<3> NNP O
is VBZ O
each DT O
individually RB O
selected VBN O
from IN O
H NNP B-NP
, , O
halogen NN B-NP
, , O
hydroxyl NN B-NP
, , O
Cl-C[beta]-alkyl NNP B-NP
, , O
C3-C7-cyclo NNP B-NP
alkyl NN I-NP
and CC O
Cl- NNP B-NP
C6-alkyloxy JJ I-NP
. . O

Examples NNS O

The DT O
following VBG O
examples NNS O
illustrate VBP O
the DT O
invention NN O
, , O
and CC O
are VBP O
not RB O
to TO O
be VB O
interpreted VBN O
as IN O
limiting VBG O
. . O

In IN O
the DT O
following JJ O
description NN O
of IN O
experiments NNS O
conducted VBN O
in IN O
accordance NN O
with IN O
the DT O
present JJ O
invention NN O
, , O
the DT O
time NN O
it PRP O
takes VBZ O
to TO O
reach VB O
70 CD O
% NN O
of IN O
the DT O
initial JJ O
activity NN O
is VBZ O
used VBN O
as IN O
a DT O
numerical JJ O
value NN O
for IN O
the DT O
stability NN O
of IN O
an DT O
enzyme JJ O
solution NN O
. . O

This DT O
value NN O
, , O
denoted VBN O
" `` O
T NNP O
70 CD O
% NN O
" `` O
, , O
is VBZ O
chosen VBN O
since IN O
it PRP O
corresponds VBZ O
to TO O
what WP O
could MD O
be VB O
accepted VBN O
as IN O
a DT O
maximum NN O
permitted VBD O
loss NN O
in IN O
activity NN O
during IN O
a DT O
life NN O
span NN O
of IN O
a DT O
commercial JJ O
product NN O
. . O

In IN O
the DT O
experimental JJ O
studies NNS O
, , O
a DT O
high JJ O
temperature NN O
( -LRB- O
37 CD O
<0>C NN O
) -RRB- O
has VBZ O
been VBN O
used VBN O
, , O
as RB O
well RB O
as IN O
a DT O
high JJ O
concentration NN O
of IN O
enzyme NN O
. . O

This DT O
has VBZ O
been VBN O
made VBN O
in IN O
order NN O
to TO O
obtain VB O
stability NN O
data NNS O
in IN O
reasonably RB O
short JJ O
times NNS O
, , O
and CC O
not RB O
have VB O
to TO O
wait VB O
for IN O
months NNS O
or CC O
years NNS O
. . O

The DT O
stability NN O
's POS O
dependency NN O
on IN O
temperature NN O
has VBZ O
been VBN O
studied VBN O
, , O
and CC O
the DT O
results NNS O
given VBN O
in IN O
Example NNP O
1 CD O
. . O

This DT O
study NN O
showed VBD O
that IN O
the DT O
inactivation NN O
process NN O
is VBZ O
about IN O
3 CD O
times NNS O
slower JJR O
at IN O
room NN O
temperature NN O
, , O
and CC O
around IN O
20 CD O
times NNS O
slower JJR O
at IN O
refrigerator NN O
temperature NN O
, , O
than IN O
the DT O
process NN O
actually RB O
measured VBN O
( -LRB- O
at IN O
37 CD O
<0>C NN O
) -RRB- O
. . O

Furthermore RB O
, , O
the DT O
inactivation NN O
process NN O
is VBZ O
concentration NN O
dependent JJ O
, , O
and CC O
is VBZ O
more RBR O
rapid JJ O
at IN O
higher JJR O
concentrations NNS O
of IN O
the DT O
enzyme NN O
. . O

The DT O
concentration NN O
of IN O
thrombin NN O
used VBN O
in IN O
Example NNP O
1 CD O
was VBD O
1 CD O
mg/ml NN O
( -LRB- O
or CC O
3300 CD O
units/ml NN O
) -RRB- O
, , O
i FW O
e NN O
higher JJR O
than IN O
the DT O
0.1-0.3 CD O

mg/ml NN O
used VBN O
in IN O
present JJ O
commercially RB O
available JJ O
preparations NNS O
and/or JJ O
devices NNS O
. . O

Studies NNS O
of IN O
the DT O
concentration NN O
dependency NN O
has VBZ O
shown VBN O
that IN O
the DT O
inactivation NN O
process NN O
is VBZ O
3-4 CD O
times NNS O
slower JJR O
at IN O
those DT O
concentrations NNS O
as IN O
compared VBN O
to TO O
the DT O
concentration NN O
used VBN O
in IN O
Example NNP O
1 CD O
. . O

Taking VBG O
this DT O
together RB O
would MD O
give VB O
a DT O
factor NN O
of IN O
between IN O
10-12 CD O
, , O
with IN O
which WDT O
to TO O
multiply VB O
the DT O
T NNP O
70 CD O
% NN O
value NN O
in IN O
order NN O
to TO O
arrive VB O
at IN O
what WP O
corresponds NNS O
to TO O
room NN O
temperature NN O
storage NN O
conditions NNS O
for IN O
a DT O
commercial JJ O
product NN O
containing VBG O
a DT O
serine NN O
protease NN O
, , O
such JJ O
as IN O
a DT O
haemostatic JJ O
preparation NN O
containing VBG O
thrombin NN O
. . O

In IN O
Table NN O
1 CD O
, , O
the DT O
composition NN O
with IN O
N- NNP B-NP
( -LRB- I-NP
2'-phenoxy JJ I-NP
) -RRB- I-NP
-4-aminopyridine JJ I-NP
and CC O
MOPS NNP B-NP
has VBZ O
a DT O
T NNP O
70 CD O
% NN O
of IN O
120 CD O
days NNS O
. . O

That DT O
would MD O
correspond VB O
to TO O
a DT O
value NN O
, , O
for IN O
a DT O
0.1-0.3 CD O

mg/ml JJ O
product NN O
, , O
of IN O
more JJR O
than IN O
1200 CD O
days NNS O
in IN O
room NN O
temperature NN O
conditions NNS O
, , O
i IN O
e NN O
more JJR O
than IN O
three CD O
years NNS O
. . O

This DT O
clearly RB O
exceeds VBZ O
anything NN O
previously RB O
accomplished VBN O
, , O
regarding VBG O
the DT O
stabilization NN O
of IN O
thrombin NN O
in IN O
solution NN O
. . O

Example NNP O
1 CD O
- : O
Stabilization NN O
of IN O
human JJ O
thrombin NN O

To TO O
determine VB O
the DT O
coagulant NN O
activity NN O
of IN O
thrombin DT O
solutions NNS O
, , O
the DT O
time NN O
to TO O
clotting NN O
of IN O
a DT O
fibrinogen NN O
solution NN O
( -LRB- O
1.3 CD O
mg/ml NN O
) -RRB- O
after IN O
additions NNS O
of IN O
various JJ O
dilutions NNS O
of IN O
a DT O
solution NN O
of IN O
a DT O
particular JJ O
human NN O
thrombin IN O
( -LRB- O
derived VBN O
from IN O
plasma NN O
, , O
3300 CD O
units/mg NN O
, , O
Biovitrum NNP O
AB NNP O
, , O
Sweden NNP O
) -RRB- O
was VBD O
measured VBN O
. . O

The DT O
clotting NN O
times NNS O
were VBD O
measured VBN O
using VBG O
an DT O
Amelungen NNP O
Kc NNP O
1 CD O
coagulometer NN O
( -LRB- O
Amelungen NNP O
, , O
Germany NNP O
) -RRB- O
. . O

To TO O
study VB O
the DT O
stabilities NNS O
of IN O
thrombin DT O
solutions NNS O
with IN O
different JJ O
additives NNS O
, , O
the DT O
samples NNS O
were VBD O
incubated VBN O
in IN O
a DT O
thermostat JJ O
chamber NN O
kept VBD O
at IN O
37 CD O
<0>C. . O

Aliquots NNS O
were VBD O
taken VBN O
out RP O
at IN O
various JJ O
time NN O
intervals NNS O
, , O
and CC O
the DT O
remaining VBG O
thrombin NN O
activity NN O
in IN O
these DT O
aliquots NNS O
was VBD O
measured VBN O
. . O

From IN O
the DT O
values NNS O
obtained VBN O
, , O
activity NN O
decay NN O
curves NNS O
could MD O
be VB O
constructed VBN O
. . O

Activity NN O
decay NN O
curves NNS O
of IN O
1 CD O
mg/ml JJ O
thrombin IN O
solutions NNS O
in IN O
10 CD O
mM JJ O
HEPES NNP B-NP
, , O
0.13 CD O
M NNP O
NaCl NNP B-NP
buffer NN O
, , O
pH IN O
7.4 CD O
, , O
showed VBD O
T NNP O
70 CD O
% NN O
values NNS O
around IN O
1.6 CD O
days NNS O
at IN O
37 CD O
<0>C. . O

Corresponding VBG O
experiments NNS O
at IN O
room NN O
temperature NN O
(around NN O
21 CD O
<0>C NNP O
) -RRB- O
showed VBD O
a DT O
T NNP O
70 CD O
% NN O
value NN O
of IN O
5.4 CD O
days NNS O
, , O
whereas IN O
after IN O
refrigerator NN O
storage NN O
(around NN O
5 CD O
<0>C NN O
) -RRB- O
, , O
the DT O
T NNP O
70 CD O
% NN O
value NN O
was VBD O
36 CD O
days NNS O
. . O

Thus RB O
, , O
as IN O
expected VBN O
, , O
there EX O
is VBZ O
a DT O
strong JJ O
temperature NN O
dependency NN O
. . O

Solutions NNS O
containing VBG O
1 CD O
mg/ml NN O
of IN O
thrombin NN O
in IN O
10 CD O
mM NNS O
HEPES NNP B-NP
and CC O
0.13 CD O
M NNP O
NaCl NNP B-NP
at IN O
pH DT O
7.4 CD O
with IN O
the DT O
indicated VBN O
stabilizing VBG O
additive JJ O
( -LRB- O
s PRP O
) -RRB- O
were VBD O
put VBN O
in IN O
the DT O
thermostat JJ O
chamber NN O
, , O
and CC O
their PRP$ O
activity NN O
decay NN O
curves NNS O
were VBD O
determined VBN O
. . O

The DT O
results NNS O
obtained VBN O
are VBP O
shown VBN O
in IN O
Table NN O
1 CD O
. . O

Data NNP O
on IN O
the DT O
corresponding JJ O
1 CD O
mg/ml JJ O
thrombin NN O
solution NN O
without IN O
additives NNS O
is VBZ O
included VBN O
for IN O
comparison NN O
. . O

[0092 CD O
] NN O

EMI24.1 . O

It PRP O
is VBZ O
evident JJ O
that IN O
the DT O
tested VBN O
compounds NNS O
all DT O
have VBP O
a DT O
stabilizing VBG O
effect NN O
. . O

However RB O
, , O
there EX O
is VBZ O
a DT O
synergistic JJ O
effect NN O
of IN O
combinations NNS O
of IN O
inhibitor NN O
and CC O
morpholine NN B-NP
- : O
containing VBG O
compound NN O
in IN O
accordance NN O
with IN O
the DT O
invention NN O
, , O
as IN O
evidenced VBN O
by IN O
the DT O
superior JJ O
results NNS O
obtained VBN O
with IN O
such JJ O
combinations NNS O
. . O

As IN O
the DT O
table NN O
above IN O
illustrates VBZ O
, , O
the DT O
addition NN O
of IN O
0.20 CD O
M NNP O
MOPS NNP B-NP
alone RB O
gives VBZ O
an DT O
increase NN O
in IN O
stabilization NN O
by IN O
a DT O
factor NN O
of IN O
4.7 CD O
, , O
and CC O
the DT O
addition NN O
of IN O
0.5 CD O
mM NNS O
of IN O
the DT O
reversible JJ O
thrombin NN O
inhibitor NN O
aminobenzamidine IN B-NP
gives VBZ O
a DT O
stabilization NN O
increase NN O
by IN O
a DT O
factor NN O
of IN O
12.5 CD O
. . O

The DT O
inventive JJ O
combination NN O
, , O
however RB O
, , O
stabilizes VBZ O
the DT O
thrombin NN O
composition NN O
much RB O
better RB O
, , O
by IN O
a DT O
factor NN O
of IN O
42.5 CD O
. . O

The DT O
inventive JJ O
combination NN O
of IN O
MOPS NNP B-NP
and CC O
N,N-diethylethylenediamine NNP B-NP
is VBZ O
also RB O
better JJR O
at IN O
stabilizing VBG O
the DT O
enzyme NN O
than IN O
the DT O
individual JJ O
components NNS O
. . O

Likewise RB O
, , O
the DT O
combination NN O
of IN O
0.20 CD O
M NNP O
MOPS NNP B-NP
and CC O
1.9 CD O
mM JJ O
N- NNP B-NP
( -LRB- I-NP
2<r JJ I-NP
> NN I-NP
-phenoxy NN I-NP
) -RRB- I-NP
-4-aminopyridin . I-NP
is VBZ O
seen VBN O
to TO O
confer VB O
a DT O
very RB O
high JJ O
stabilization NN O
increase NN O
, , O
a DT O
factor NN O
of IN O
75 CD O
, , O
whereas IN O
the DT O
individual JJ O
components NNS O
increase NN O
stability NN O
by IN O
a DT O
factor NN O
of IN O
4.7 CD O
and CC O
22 CD O
, , O
respectively RB O
. . O

The DT O
thrombin NN O
used VBD O
in IN O
the DT O
study NN O
is VBZ O
human JJ O
thrombin IN O
derived VBN O
from IN O
plasma NN O
. . O

Recombinant JJ O
human JJ O
thrombin NN O
has VBZ O
also RB O
been VBN O
studied VBN O
and CC O
has VBZ O
essentially RB O
shown VBN O
the DT O
same JJ O
behavior NN O
. . O

Example NNP O
2 CD O
- : O
Stabilization NN O
of IN O
bovine NN O
thrombin IN O

Stabilization NN O
of IN O
bovine JJ O
thrombin NN O
was VBD O
studied VBN O
. . O

The DT O
experimental JJ O
setup NN O
was VBD O
the DT O
same JJ O
as IN O
in IN O
Example NNP O
1 CD O
, , O
but CC O
the DT O
concentration NN O
of IN O
bovine JJ O
thrombin NN O
( -LRB- O
Baxter NNP O
) -RRB- O
used VBN O
was VBD O
0.4 CD O
mg/ml NN O
. . O

Upon IN O
storage NN O
at IN O
37 CD O
[deg.]C NN O
, , O
the DT O
thrombin NN O
solution NN O
in IN O
HEPES NNP B-NP
buffer NN O
showed VBD O
a DT O
T NNP O
70 CD O
% NN O
value NN O
of IN O
1.3 CD O
days NNS O
. . O

The DT O
thrombin IN O
solution NN O
in IN O
HEPES NNP B-NP
buffer NN O
plus CC O
3.0 CD O
mM JJ O
N- NNP B-NP
( -LRB- I-NP
2' FW I-NP
- : I-NP
phenoxy NN I-NP
) -RRB- I-NP
-4-aminopyridin : I-NP
and CC O
0.20 CD O
M NNP O
MOPS NNP B-NP
showed VBD O
a DT O
T NNP O
70 CD O
% NN O
value NN O
of IN O
54 CD O
days NNS O
. . O

The DT O
results NNS O
obtained VBD O
show NN O
that IN O
bovine JJ O
thrombin NN O
is VBZ O
somewhat RB O
more JJR O
labile NN O
than IN O
the DT O
preparations NNS O
of IN O
human JJ O
thrombin NN O
studied VBD O
, , O
but CC O
that IN O
a DT O
very RB O
good JJ O
stabilizing VBG O
effect NN O
is VBZ O
nevertheless RB O
obtained VBN O
by IN O
the DT O
compositions NNS O
of IN O
the DT O
invention NN O
. . O

Example NNP O
3 CD O
- : O
Low NNP O
concentrations NNS O
of IN O
thrombin NN O

Stabilization NN O
of IN O
thrombin NN O
in IN O
compositions NNS O
containing VBG O
low JJ O
concentrations NNS O
of IN O
thrombin NN O
was VBD O
studied VBN O
. . O

The DT O
stabilizing VBG O
effect NN O
of IN O
the DT O
compositions NNS O
according VBG O
to TO O
the DT O
invention NN O
was VBD O
demonstrated VBN O
to TO O
work VB O
also RB O
for IN O
comparatively RB O
low JJ O
concentrations NNS O
of IN O
thrombin NN O
. . O

A DT O
15.0 CD O
activity NN O
units/ml IN O
solution NN O
of IN O
human NN O
thrombin NN O
( -LRB- O
derived VBN O
from IN O
plasma NN O
, , O
3300 CD O
units/mg NN O
, , O
Biovitrum NNP O
AB NNP O
, , O
Sweden NNP O
) -RRB- O
in IN O
HEPES NNP B-NP
buffer NN O
, , O
pH IN O
7.4 CD O
, , O
showed VBD O
a DT O
T NNP O
70 CD O
% NN O
value NN O
of IN O
23 CD O
days NNS O
. . O

The DT O
corresponding JJ O
solution NN O
in IN O
HEPES NNP B-NP
buffer NN O
, , O
pH IN O
7.4 CD O
, , O
plus CC O
2.0 CD O
mM JJ O
N- NNP B-NP
( -LRB- I-NP
2' JJ I-NP
-phenoxy NN I-NP
) -RRB- I-NP
-4-aminopyridin : I-NP
and CC O
0.20 CD O
M NNP O
MOPS NNP B-NP
exhibited VBD O
a DT O
T NNP O
70 CD O
% NN O
value NN O
of IN O
92 CD O
days NNS O
. . O

Example NNP O
4 CD O
- : O
Stabilization NN O
of IN O
plasmin NN O

The DT O
stabilization NN O
of IN O
solutions NNS O
of IN O
plasmin NN O
in IN O
accordance NN O
with IN O
the DT O
invention NN O
was VBD O
tested VBN O
. . O

The DT O
activity NN O
of IN O
plasmin NN O
was VBD O
determined VBN O
using VBG O
chromogenic NN O
peptide NN O
substrate NN O
Chromozym NNP O
TH IN O
( -LRB- O
Pentapharm NNP O
, , O
Switzerland NNP O
) -RRB- O
and CC O
measurement NN O
of IN O
absorbance NN O
change NN O
at IN O
405 CD O
nm NN O
in IN O
a DT O
spectrophotometer NN O
. . O

Solutions NNS O
containing VBG O
100 CD O
[mu]g/ml NN O
of IN O
plasmin NN O
( -LRB- O
specific JJ O
activity NN O
3.2 CD O
units/mg NN O
, , O
Sigma-Aldrich NNP O
) -RRB- O
in IN O
10 CD O
mM NNS O
HEPES NNP B-NP
and CC O
0.13 CD O
M NNP O
NaCl NNP B-NP
, , O
pH RB O
7.4 CD O
, , O
as RB O
well RB O
as IN O
stabilizers NNS O
as IN O
indicated VBN O
in IN O
Table NN O
2 CD O
below IN O
were VBD O
incubated VBN O
at IN O
37 CD O
<0>C CD O
, , O
and CC O
samples NNS O
were VBD O
taken VBN O
out RP O
at IN O
various JJ O
time NN O
intervals NNS O
for IN O
activity NN O
determination NN O
. . O

The DT O
results NNS O
obtained VBN O
are VBP O
shown VBN O
in IN O
Table NN O
2. . O

[0102 CD O
] NN O

EMI26.1 . O

From IN O
these DT O
results NNS O
, , O
it PRP O
is VBZ O
evident JJ O
that IN O
a DT O
very RB O
strong JJ O
stabilization NN O
is VBZ O
obtained VBN O
using VBG O
the DT O
combination NN O
in IN O
accordance NN O
with IN O
the DT O
invention NN O
. . O

0.20 CD O
M NNP O
morpholine NN B-NP
increases VBZ O
the DT O
stability NN O
of IN O
the DT O
plasmin NN O
composition NN O
by IN O
a DT O
factor NN O
of IN O
4 CD O
, , O
0.13 CD O
M NNP O
N,N-diethylethylenediamine NNP B-NP
by IN O
a DT O
factor NN O
of IN O
2.7 CD O
and CC O
1.3 CD O
mM NNS O
aminobenzamidine VBN B-NP
by IN O
a DT O
factor NN O
of IN O
17 CD O
. . O

However RB O
, , O
the DT O
combination NN O
of IN O
morpholine NN B-NP
and CC O
N NNP B-NP
, , I-NP
N- NNP I-NP
diethylethylenediamine NN I-NP
increases VBZ O
the DT O
stability NN O
of IN O
the DT O
plasmin NN O
composition NN O
by IN O
a DT O
factor NN O
of IN O
7.3 CD O
, , O
and CC O
the DT O
combination NN O
of IN O
morpholine NN B-NP
and CC O
aminobenzamidine JJ B-NP
increases NNS O
the DT O
stability NN O
by IN O
a DT O
factor NN O
of IN O
72 CD O
. . O

Example NNP O
5 CD O
- : O
Stabilization NN O
of IN O
trypsin NN O

The DT O
stabilization NN O
of IN O
solutions NNS O
of IN O
trypsin NN O
in IN O
accordance NN O
with IN O
the DT O
invention NN O
was VBD O
tested VBN O
. . O

The DT O
activity NN O
of IN O
trypsin NN O
was VBD O
determined VBN O
using VBG O
tosyl NN B-NP
arginine IN I-NP
methyl NN I-NP
ester NN I-NP
( -LRB- O
TAME) JJ B-NP
as IN O
substrate JJ O
and CC O
measuring VBG O
the DT O
absorbance NN O
change NN O
at IN O
247 CD O
nm NN O
in IN O
a DT O
spectrophotometer NN O
. . O

Solutions NNS O
containing VBG O
100 CD O
[mu]g/ml NN O
of IN O
trypsin NN O
( -LRB- O
TPCK-treated NNP O
, , O
Sigma-Aldrich NNP O
) -RRB- O
in IN O
10 CD O
mM NNS O
HEPES NNP B-NP
and CC O
0.13 CD O
M NNP O
NaCl NNP B-NP
, , O
pH RB O
7.4 CD O
, , O
as RB O
well RB O
as IN O
stabilizers NNS O
as IN O
indicated VBN O
in IN O
Table NN O
3 CD O
below IN O
were VBD O
incubated VBN O
at IN O
37 CD O
[deg.]C NNS O
, , O

and CC O
samples NNS O
were VBD O
taken VBN O
out RP O
at IN O
various JJ O
time NN O
intervals NNS O
for IN O
activity NN O
determination NN O
. . O

The DT O
results NNS O
obtained VBN O
are VBP O
shown VBN O
in IN O
Table NN O
3. . O

[0105 CD O
] NN O

EMI27.1 . O

Again RB O
, , O
the DT O
stabilizing VBG O
effect NN O
is VBZ O
the DT O
greatest JJS O
in IN O
the DT O
composition NN O
according VBG O
to TO O
the DT O
invention NN O
. . O

Thus RB O
, , O
0.5 CD O
M NNP O
morpholine NN B-NP
alone RB O
gives VBZ O
an DT O
increase NN O
in IN O
stabilization NN O
by IN O
a DT O
factor NN O
of IN O
13 CD O
, , O
and CC O
1 CD O
mM JJ O
benzamidine NN B-NP
alone RB O
gives VBZ O
an DT O
increase NN O
in IN O
stabilization NN O
by IN O
a DT O
factor NN O
of IN O
72 CD O
. . O

The DT O
inventive JJ O
combination NN O
, , O
on IN O
the DT O
other JJ O
hand NN O
, , O
gives VBZ O
an DT O
increase NN O
in IN O
stabilization NN O
by IN O
a DT O
factor NN O
of IN O
147 CD O
. . O

Example NNP O
6 CD O
- : O
Stabilization NN O
of IN O
thrombin NN O
with IN O
CMC NNP O
Tests NNS O
of IN O
thrombin NN O
solutions NNS O
containing VBG O
between IN O
1.0 CD O
and CC O
2.0 CD O
% NN O
carboxymethyl NN B-NP
cellulose NN I-NP
( -LRB- O
CMC) NNP O
for IN O
their PRP$ O
adhesiveness NN O
to TO O
human JJ O
skin NN O
showed VBD O
that IN O
the DT O
addition NN O
of IN O
CMC NNP O
increased VBD O
both DT O
viscosity NN O
and CC O
adhesiveness NN O
strongly RB O
. . O

Surprisingly RB O
, , O
however RB O
, , O
it PRP O
was VBD O
also RB O
found VBN O
that IN O
the DT O
stability NN O
of IN O
these DT O
thrombin IN O
solutions NNS O
was VBD O
further JJ O
increased VBN O
. . O

A DT O
1 CD O
mg/ml JJ O
human JJ O
thrombin NN O
( -LRB- O
derived VBN O
from IN O
plasma NN O
, , O
3300 CD O
units/mg NN O
, , O
Biovitrum NNP O
AB NNP O
, , O
Sweden NNP O
) -RRB- O
solution NN O
in IN O
0.5 CD O
mM NNS O
aminobenzamidine RB B-NP
, , O
0.20 CD O
M NNP O
MOPS NNP B-NP
, , O
10 CD O
mM NNS O
HEPES NNP B-NP
, , O
0.13 CD O
M NNP O
NaCl NNP B-NP
being VBG O
2.0 CD O
% NN O
with IN O
respect NN O
to TO O
CMC NNP O
was VBD O
incubated VBN O
at IN O
37 CD O
[deg.]C NNS O
, , O

and CC O
the DT O
activity NN O
decay NN O
curve NN O
was VBD O
determined VBN O
. . O

The DT O
T NNP O
70 CD O
% NN O
value NN O
obtained VBN O
was VBD O
175 CD O
days NNS O
. . O

Example NN O
7 CD O
- : O
Stabilization NN O
with IN O
other JJ O
adhesive NN O
polymers NNS O
Four CD O
other JJ O
polymers NNS O
were VBD O
also RB O
studied VBN O
: : O
ethyl NN B-NP
hydroxyethyl NN I-NP
cellulose NN I-NP
( -LRB- O
EHEC NNP B-NP
) -RRB- O
, , O
potato NN O
starch NN B-NP
, , O
corn NN O
starch NN B-NP
and CC O
cold JJ O
water NN B-NP
fish NN O
gelatin NN B-NP
. . O

All DT O
four CD O
of IN O
these DT O
polymers NNS O
increased VBD O
the DT O
adhesiveness NN O
and CC O
viscosity NN O
of IN O
thrombin DT O
solutions NNS O
. . O

The DT O
compatibility NN O
and CC O
stability NN O
of IN O
thrombin DT O
solutions NNS O
with IN O
the DT O
polymers NNS O
were VBD O
further RB O
studied VBN O
by IN O
incubation NN O
at IN O
37 CD O
<0>C NNP O
of IN O
1 CD O
mg/ml JJ O
human JJ O
thrombin NN O
( -LRB- O
derived VBN O
from IN O
plasma NN O
, , O
3300 CD O
units/mg NN O
, , O
Biovitrum NNP O
AB NNP O
, , O
Sweden NNP O
) -RRB- O
solutions NNS O
in IN O
0.20 CD O
M NNP O
MOPS NNP B-NP
, , O
0.5 CD O
mM NNS O
aminobenzamidine VBP B-NP
, , O
10 CD O
mM JJ O
HEPES NNP B-NP
, , O
0.13 CD O
M NNP O
NaCl NNP B-NP
, , O
pH RB O
7.4 CD O
, , O
containing VBG O
the DT O
various JJ O
polymers NNS O
. . O

The DT O
concentrations NNS O
of IN O
the DT O
polymers NNS O
used VBN O
were VBD O
: : O
EHEC NNP B-NP
, , O
0.6 CD O
% NN O
; : O
the DT O
two CD O
different JJ O
starches NNS O
, , O
4.0 CD O
% NN O
; : O
and CC O
gelatin NNP B-NP
, , O
12.8 CD O
% NN O
. . O

EHEC NNP B-NP
was VBD O
fully RB O
compatible JJ O
with IN O
thrombin NN O
, , O
and CC O
the DT O
same JJ O
T NNP O
70 CD O
% NN O
value NN O
, , O
i IN O
.e NN O
. . O
around IN O
65 CD O
days NNS O
, , O
was VBD O
obtained VBN O
as IN O
with IN O
the DT O
corresponding JJ O
solution NN O
without IN O
EHEC NNP B-NP
. . O

The DT O
starch NN B-NP
containing VBG O
solutions NNS O
had VBD O
T NNP O
70 CD O
% NN O
values NNS O
of IN O
22 CD O
and CC O
26 CD O
days NNS O
. . O

The DT O
stability NN O
of IN O
thrombin NN O
was VBD O
very RB O
good JJ O
in IN O
gelatin NN B-NP
with IN O
a DT O
T NNP O
70 CD O
% NN O
value NN O
of IN O
more JJR O
than IN O
90 CD O
days NNS O
, , O
which WDT O
demonstrates VBZ O
additional JJ O
stabilizing VBG O
effect NN O
of IN O
cold JJ O
water NN B-NP
fish NN O
gelatin NN B-NP
. . O

Example NNP O
8 CD O
- : O
Bleeding NN O
experiments NNS O

The DT O
ability NN O
of IN O
inventive JJ O
compositions NNS O
to TO O
stop VB O
bleeding VBG O
was VBD O
tested VBN O
in IN O
a DT O
series NN O
of IN O
experiments NNS O
on IN O
rabbits NNS O
. . O

The DT O
model NN O
chosen VBN O
was VBD O
incisions NNS O
in IN O
the DT O
liver NN O
which WDT O
is VBZ O
a DT O
frequently RB O
used VBN O
model NN O
. . O

The DT O
abdomen NN O
of IN O
the DT O
rabbit NN O
was VBD O
opened VBN O
and CC O
the DT O
liver NN O
exposed VBN O
. . O

Standardized VBN O
cuts NNS O
of IN O
3 CD O
mm CD O
length NN O
were VBD O
made VBN O
in IN O
the DT O
liver NN O
surface NN O
and CC O
an DT O
0.10 CD O
ml JJ O
amount NN O
of IN O
test NN O
solution NN O
was VBD O
applied VBN O
to TO O
the DT O
wound NN O
using VBG O
a DT O
syringe NN O
. . O

The DT O
time NN O
to TO O
haemostasis NN O
was VBD O
measured VBN O
. . O

10-12 CD O
experiments NNS O
were VBD O
performed VBN O
with IN O
each DT O
solution NN O
. . O

An DT O
average JJ O
value NN O
of IN O
bleeding VBG O
time NN O
was VBD O
calculated VBN O
after IN O
removal NN O
of IN O
the DT O
highest JJS O
and CC O
the DT O
lowest JJS O
value NN O
in IN O
each DT O
series NN O
of IN O
experiments NNS O
. . O

For IN O
comparison NN O
, , O
the DT O
commonly RB O
used VBN O
haemostatic JJ O
agent NN O
Tisseel NNP O
( -LRB- O
Baxter NNP O
) -RRB- O
, , O
a DT O
fibrin NN O
glue NN O
, , O
was VBD O
also RB O
included VBN O
in IN O
the DT O
study NN O
. . O

Tisseel NNP O
was VBD O
used VBN O
essentially RB O
according VBG O
to TO O
the DT O
manufacturer NN O
's POS O
recommendations NNS O
. . O

0.2 CD O
ml NN O
of IN O
solution NN O
was VBD O
applied VBN O
to TO O
each DT O
wound NN O
using VBG O
a DT O
double JJ O
syringe NN O
with IN O
a DT O
mixing JJ O
chamber NN O
. . O

The DT O
results NNS O
obtained VBN O
are VBP O
given VBN O
in IN O
Table NN O
4 CD O
below RB O
. . O

[0110] . O

EMI30.1 . O

As IN O
is VBZ O
evident JJ O
from IN O
these DT O
results NNS O
, , O
the DT O
thrombin NN O
solution NN O
stabilized VBD O
according VBG O
to TO O
the DT O
invention NN O
is VBZ O
the DT O
5 CD O
most RBS O
effective JJ O
in IN O
quickly RB O
establishing VBG O
haemostasis NN O
in IN O
a DT O
bleeding NN O
subject NN O
, , O
comparable JJ O
to TO O
or CC O
better RB O
than IN O
a DT O
commonly RB O
used VBN O
agent NN O
. . O

Example NN O
9 CD O
- : O
Compatibility NN O
with IN O
porous JJ O
materials NNS O
0 CD O
A DT O
solution NN O
containing VBG O
0.4 CD O
mg/ml JJ O
human JJ O
thrombin NN O
( -LRB- O
derived VBN O
from IN O
plasma NN O
, , O
3300 CD O
units/mg NN O
, , O
Biovitrum NNP O
AB NNP O
, , O
Sweden NNP O
) -RRB- O
in IN O
10 CD O
mM JJ O
HEPES NNP B-NP
, , O
0.14 CD O
M NNP O
NaCl NNP B-NP
, , O
0.5 CD O
mM NNS O
aminobenzamidine RB B-NP
, , O
0.20 CD O
M NNP O
MOPS NNP B-NP
of IN O
pH DT O
7.4 CD O
was VBD O
adsorbed VBN O
into IN O
a DT O
piece NN O
of IN O
polyurethane NN B-NP
plaster NN O
( -LRB- O
marketed VBN O
as IN O
Ligasone NN O
by IN O
5 CD O
Hartmann NNP O
Scandicare NNP O
AB NNP O
, , O
Anderstorp NNP O
, , O
Sweden NNP O
) -RRB- O
. . O

An DT O
amount NN O
of IN O
solution NN O
sufficient JJ O
to TO O
saturate VB O
the DT O
polyurethane NN B-NP
piece NN O
was VBD O
used VBN O
. . O

The DT O
piece NN O
was VBD O
transferred VBN O
to TO O
a DT O
tube NN O
, , O
which WDT O
was VBD O
then RB O
closed VBN O
to TO O
prevent VB O
evaporation NN O
. . O

The DT O
tube NN O
was VBD O
kept VBN O
at IN O
37 CD O
<0>C CD O
, , O
and CC O
samples NNS O
of IN O
solution NN O
were VBD O
taken VBN O
out RP O
at IN O
0 CD O
intervals NNS O
by IN O
a DT O
slight JJ O
pressure NN O
on IN O
the DT O
polyurethane NN B-NP
piece NN O
. . O

The DT O
activity NN O
decay NN O
curve NN O
showed VBD O
a DT O
T NNP O
70 CD O
% NN O
value NN O
of IN O
74 CD O
days NNS O
, , O
corresponding JJ O
to TO O
a DT O
stability NN O
increase NN O
by IN O
a DT O
factor NN O
of IN O
46 CD O
. . O

Example NNP O
10 CD O
- : O
Adsorption NN O
of IN O
enzyme NN O
onto IN O
a DT O
solid JJ O
phase NN O

Adsorption NN O
of IN O
thrombin NN O
in IN O
stabilizing VBG O
solutions NNS O
to TO O
surfaces NNS O
was VBD O
tested VBN O
. . O

Solid JJ O
flakes NNS O
of IN O
chitosan NN B-NP
( -LRB- O
at IN O
least JJS O
85 CD O
% NN O
deacetylated VBN O
, , O
Sigma-Aldrich NNP O
) -RRB- O
, , O
around IN O
3 CD O
x NN O
3 CD O
mm CD O
, , O
were VBD O
incubated VBN O
for IN O
10 CD O
minutes NNS O
in IN O
solutions NNS O
of IN O
400 CD O
units/ml NN O
human JJ O
thrombin NN O
( -LRB- O
derived VBN O
from IN O
plasma NN O
, , O
3300 CD O
units/mg NN O
, , O
Biovitrum NNP O
AB NNP O
, , O
Sweden NNP O
) -RRB- O
in IN O
10 CD O
mM JJ O
HEPES NNP B-NP
, , O
0.13 CD O
M NNP O
NaCl NNP B-NP
, , O
pH RB O
7.4. . O

The DT O
solutions NNS O
had VBD O
the DT O
following VBG O
additions NNS O
: : O
1 CD O
) -RRB- O
none NN O
, , O
2 CD O
) -RRB- O
0.10 CD O
M NNP O
morpholine NN B-NP
, , O
2 CD O
mM NN O
N- : B-NP
( -LRB- I-NP
2' JJ I-NP
-phenoxy NN I-NP
) -RRB- I-NP
-4-amino FW I-NP
- : I-NP
pyridine NN I-NP
, , O
3 CD O
) -RRB- O
0.10 CD O
M NNP O
morpholine NN B-NP
, , O
2 CD O
mM JJ O
N- NNP B-NP
[ NNP I-NP
2' JJ I-NP
-phenoxy NN I-NP
) -RRB- I-NP
-4- : I-NP
aminopyridine JJ I-NP
, , O
0.5 CD O
% NN O
carboxymethyl NN B-NP
cellulose NN I-NP
. . O

The DT O
flakes NNS O
were VBD O
then RB O
taken VBN O
up RB O
and CC O
dried VBD O
on IN O
filter NN O
paper NN O
. . O

To TO O
get VB O
a DT O
measure NN O
of IN O
thrombin DT O
clotting NN O
activity NN O
, , O
a DT O
flake NN O
was VBD O
put VBN O
in IN O
a DT O
test NN O
tube NN O
and CC O
0.4 CD O
ml NN O
of IN O
1.3 CD O
mg/ml JJ O
fibrinogen NN O
solution NN O
was VBD O
added VBN O
. . O

To TO O
improve VB O
clot NN O
detection NN O
, , O
the DT O
tube NN O
also RB O
contained VBD O
a DT O
small JJ O
steel NN O
ball NN O
. . O

The DT O
clotting NN O
times NNS O
obtained VBD O
initially RB O
on IN O
flakes NNS O
from IN O
the DT O
various JJ O
incubation NN O
mixtures NNS O
varied VBN O
between IN O
1 CD O
to TO O
4 CD O
minutes NNS O
. . O

After IN O
incubation NN O
in IN O
Eppendorf NNP O
tubes NNS O
at IN O
37 CD O
[deg.]C NNS O

for IN O
7 CD O
days NNS O
, , O
the DT O
clotting NN O
times NNS O
for IN O
flakes NNS O
incubated VBN O
in IN O
solution NN O
1 CD O
) -RRB- O
were VBD O
strongly RB O
prolonged VBN O
. . O

The DT O
values NNS O
were VBD O
between IN O
24 CD O
and CC O
27 CD O
minutes NNS O
. . O

In IN O
contrast NN O
, , O
the DT O
clotting NN O
times NNS O
for IN O
flakes NNS O
incubated VBN O
in IN O
solutions NNS O
2 CD O
) -RRB- O
and CC O
3 CD O
) -RRB- O
were VBD O
in IN O
the DT O
range NN O
of IN O
from IN O
1 CD O
to TO O
2.5 CD O
minutes NNS O
, , O
i IN O
e NN O
the DT O
same JJ O
as IN O
the DT O
starting VBG O
values NNS O
. . O

Evidently RB O
, , O
a DT O
strong JJ O
stabilization NN O
of IN O
thrombin NN O
activity NN O
is VBZ O
obtained VBN O
by IN O
using VBG O
solutions NNS O
2 CD O
) -RRB- O
and CC O
3 CD O
) -RRB- O
. . O

To TO O
test VB O
the DT O
in IN O
vivo JJ O
haemostatic JJ O
activity NN O
chitosan IN B-NP
flakes NNS O
incubated VBN O
in IN O
solution NN O
3 CD O
) -RRB- O
were VBD O
applied VBN O
to TO O
wounds NNS O
in IN O
rabbit NN O
liver NN O
according VBG O
to TO O
the DT O
animal NN O
model NN O
described VBD O
in IN O
Example NNP O
8. . O

The DT O
average JJ O
time NN O
to TO O
haemostasis NN O
was VBD O
27 CD O
seconds NNS O
( -LRB- O
based VBN O
on IN O
six CD O
experiments NNS O
) -RRB- O
. . O

Illustrative NNP O
Example NNP O
A DT O
- : O
Morpholine NNP B-NP
is VBZ O
not RB O
a DT O
thrombin NN O
inhibitor IN O
The DT O
possibility NN O
that IN O
morpholine NN B-NP
is VBZ O
an DT O
inhibitor NN O
of IN O
thrombin NN O
was VBD O
evaluated VBN O
. . O

The DT O
fibrinogen NN O
clotting NN O
activity NN O
of IN O
thrombin NN O
is VBZ O
usually RB O
measured VBN O
by IN O
clotting VBG O
tests NNS O
, , O
wherein WRB O
the DT O
time NN O
to TO O
coagulation NN O
of IN O
a DT O
fibrinogen NN O
solution NN O
is VBZ O
detected VBN O
by IN O
mechanical JJ O
or CC O
optical JJ O
devices NNS O
. . O

The DT O
clotting NN O
tests NNS O
in IN O
this DT O
experimental JJ O
setup NN O
were VBD O
performed VBN O
in IN O
0.01 CD O
M NNP O
HEPES NNP B-NP
, , O
0.13 CD O
M NNP O
NaCl NNP B-NP
buffer NN O
of IN O
pH DT O
7.4 CD O
, , O
which WDT O
is VBZ O
according VBG O
to TO O
standard JJ O
procedure NN O
( -LRB- O
EU JJ O
Pharmacopeia NN O
) -RRB- O
. . O

A DT O
human JJ O
thrombin NN O
( -LRB- O
derived VBN O
from IN O
plasma NN O
, , O
3300 CD O
units/mg NN O
, , O
Biovitrum NNP O
AB NNP O
, , O
Sweden NNP O
) -RRB- O
solution NN O
containing VBG O
89 CD O
units/ml NN O
was VBD O
used VBN O
and CC O
dilutions NNS O
of IN O
1/5 CD O
, , O
1/10 CD O
and CC O
1/16 CD O
were VBD O
tested VBN O
. . O

Solutions NNS O
of IN O
various JJ O
concentrations NNS O
of IN O
morpholine NN B-NP
were VBD O
prepared VBN O
in IN O
the DT O
HEPES NNP B-NP
buffer NN O
by IN O
adding VBG O
a DT O
concentrated JJ O
morpholine NN B-NP
solution NN O
adjusted VBN O
to TO O
pH VB O
7.4. . O

When WRB O
morpholine NN B-NP
is VBZ O
dissolved VBN O
in IN O
water NN B-NP
, , O
the DT O
pH NN O
goes VBZ O
up RP O
to TO O
9-10 CD O
, , O
so RB O
HCl NNP B-NP
was VBD O
added VBN O
to TO O
get VB O
a DT O
pH NN O
of IN O
7.4. VBG O

That DT O
also RB O
increased VBN O
the DT O
ionic JJ O
strength NN O
of IN O
the DT O
solution NN O
. . O

Table NN O
I PRP O
shows VBZ O
the DT O
results NNS O
obtained VBD O
. . O

Observed NNP O
clotting NN O
times NNS O
were VBD O
converted VBN O
to TO O
concentrations NNS O
of IN O
thrombin NN O
using VBG O
a DT O
standard JJ O
curve NN O
. . O

[0115 CD O
] NN O

EMI32.1 . O

As IN O
evident JJ O
from IN O
these DT O
results NNS O
, , O
there EX O
was VBD O
a DT O
prolongation NN O
of IN O
clotting VBG O
times NNS O
with IN O
increasing VBG O
concentration NN O
of IN O
morpholine NN B-NP
up IN O
to TO O
a DT O
certain JJ O
level NN O
. . O

However RB O
, , O
the DT O
same JJ O
thing NN O
was VBD O
observed VBN O
when WRB O
the DT O
ionic JJ O
strength NN O
was VBD O
increased VBN O
with IN O
NaCl NNP B-NP
, , O
and CC O
a DT O
similar JJ O
profile NN O
was VBD O
exhibited VBN O
. . O

Thus RB O
, , O
the DT O
prolongation NN O
effect NN O
was VBD O
, , O
in IN O
all DT O
likelihood NN O
, , O
caused VBN O
by IN O
the DT O
increase NN O
in IN O
ionic JJ O
strength NN O
. . O

Further RB O
, , O
it PRP O
is VBZ O
known VBN O
that IN O
an DT O
increase NN O
of IN O
ionic JJ O
strength NN O
from IN O
0.15 CD O
M NNP O
to TO O
0.22 CD O
M NNP O
causes VBZ O
a DT O
change NN O
in IN O
the DT O
polymerization NN O
of IN O
fibrin NN O
( -LRB- O
B. NNP O

Blomback NNP O
, , O

Thrombosis NNP O
Research NNP O
, , O
vol NN O
. . O

83 CD O
, , O
( -LRB- O
1996 CD O
) -RRB- O
, , O
p.1-75 -RRB- O
, , O
especially RB O
p.18 NNS O
) -RRB- O
. . O

This DT O
actually RB O
corresponds VBZ O
to TO O
the DT O
range NN O
studied VBN O
in IN O
this DT O
experimental JJ O
series NN O
, , O
in IN O
which WDT O
the DT O
initial JJ O
concentration NN O
of IN O
NaCl NNP B-NP
was VBD O
0.13 CD O
M NNP O
and CC O
then RB O
increased VBD O
to TO O
0.18 CD O
M NNP O
and CC O
onwards NNS O
up IN O
to TO O
0.33 CD O
M. NNP O

This DT O
also RB O
corresponds VBZ O
to TO O
the DT O
plateau NN O
level NN O
observed VBD O
. . O

In IN O
conclusion NN O
, , O
morpholine NN B-NP
itself PRP O
is VBZ O
not RB O
an DT O
inhibitor NN O
of IN O
thrombin NN O
. . O

CLAIMS NNS O

1 CD O
. . O
Stabilized NNP O
serine NN O
protease NN O
composition NN O
comprising NN O
a DT O
) -RRB- O
a DT O
serine NN O
protease NN O
; : O
b NN O
) -RRB- O
a DT O
reversible JJ O
inhibitor NN O
of IN O
said VBD O
serine NN O
protease NN O
; : O
and CC O
c NNS O
) -RRB- O
a DT O
stabilizing VBG O
agent NN O
M NNP O
having VBG O
the DT O
formula NN O
I PRP O
: : O

EMI34.1 . O

wherein WRB O
n NN O
is VBZ O
0, CD O
1 CD O
or CC O
2 CD O
; : O
X NNP O
is VBZ O
O UH B-NP
, , O
N NNP B-NP
or CC O
CH2 NNP B-NP
; : O

R^R<4> PRP O
are VBP O
the DT O
same JJ O
or CC O
different JJ O
, , O
and CC O
selected VBN O
from IN O
H NNP B-NP
, , O
-CH2-R<6> JJ B-NP
, , O
-CH2-O-R<6> JJ B-NP
, , O
-CH2-S-R<6> JJ B-NP
, , O
-CH2-NH-R<6> JJ B-NP
, , O
-CO-O-R<6> JJ B-NP
, , O
-CO-NH-R<6> JJ B-NP
, , O
-CH2-NH-CO-R<6> JJ B-NP
, , O
-CH2-O-CO-R<6> JJ B-NP
, , O
-CH2-NH-CO-NHR<6> JJ B-NP
, , O
-CH2-NH-CO-OR<6> JJ B-NP
, , O
-CH2-NH-CS-NHR<6> JJ B-NP
and CC O
-CH2-O-CO-NHR<6> JJ B-NP
; : O
R<5> NNP O
is VBZ O
as IN O
R<3^>-R<4> JJ O
or CC O
P-Q JJ O
; : O

P NNP O
is VBZ O
selected VBN O
from IN O
- : B-NP
( -LRB- I-NP
CH2 NN I-NP
) -RRB- I-NP
m NN I-NP
- : I-NP
and CC O
- : B-NP
( -LRB- I-NP
CH2 NN I-NP
) -RRB- I-NP
m-Y- FW I-NP
( -LRB- I-NP
CH2 NN I-NP
) -RRB- I-NP
m-, , I-NP
wherein WRB O
m NN O
is VBZ O
1-6 JJ O
and CC O
Y PRP O
is VBZ O
0, JJ O
NH NNP B-NP
or CC O
S NNP B-NP
; : O

Q NN O
is VBZ O
selected VBN O
from IN O
H NNP B-NP
, , O
-SO3 JJ B-NP
, , O
-COOH NNP B-NP
, , O
-NH2 NNP B-NP
, , O
-OH NNP B-NP
and CC O
-CONH2 NNP B-NP
; : O
each DT O
R<6> JJ O
individually RB O
being VBG O
selected VBN O
from IN O
H NNP B-NP
, , O
substituted VBN B-NP
or CC I-NP
non-substituted JJ I-NP
lower JJR I-NP
alkyl NN I-NP
, , O
substituted VBN B-NP
or CC I-NP
non-substituted JJ I-NP
cycloalkyl NN I-NP
, , O
substituted VBN B-NP
or CC I-NP
non FW I-NP
- : I-NP
substituted VBN I-NP
benzyl NN I-NP
, , O
substituted VBN B-NP
or CC I-NP
non-substituted JJ I-NP
aryl NN I-NP
or CC O
mono-, JJ B-NP
bi-, JJ I-NP
or CC I-NP
tricyclic JJ I-NP
unsubstituted JJ I-NP
or CC I-NP
substituted VBN I-NP
heteroaromatic JJ I-NP
ring( NN I-NP
s VBZ O
) -RRB- O
with IN O
one CD O
or CC O
more JJR O
heteroatoms NNS B-NP
and CC I-NP
non-aromatic JJ I-NP
heterocycles NNS I-NP
, , O
the DT O
substituents NNS O
of IN O
the DT O
substituted VBN O
groups NNS O
being VBG O
selected VBN O
from IN O
lower JJR B-NP
alkyl NN I-NP
, , O
halogens NNS B-NP
, , O
substituted VBN B-NP
or CC I-NP
non-substituted JJ I-NP
aryl NN I-NP
, , O
substituted VBN B-NP
or CC I-NP
non-substituted JJ I-NP
hetero-aromatic JJ I-NP
compounds NNS I-NP
, , O
non-aromatic JJ B-NP
heterocycles NNS I-NP
, , O
alkyloxy RB B-NP
, , O
alkylamino RB B-NP
; : O
or CC O
a DT O
pharmaceutically RB O
acceptable JJ O
salt NN O
thereof '' O
. . O

2. . O
Composition NNP O
according VBG O
to TO O
claim NN O
1 CD O
, , O
in IN O
which WDT O
the DT O
serine NN O
protease NN O
is VBZ O
selected VBN O
from IN O
the DT O
group NN O
consisting VBG O
of IN O
trypsin NN O
, , O
kallikrein NN O
, , O
thrombin NN O
, , O
plasmin NN O
, , O
urokinase JJ O
, , O
tissue NN O
plasminogen NN O
activator NN O
, , O
active JJ O
form NN O
of IN O
factor NN O
IX NNP O
, , O
active JJ O
form NN O
of IN O
factor NN O
X NNP O
and CC O
active JJ O
form NN O
of IN O
factor NN O
XI NNS O
. . O

3. . O
Composition NNP O
according VBG O
to TO O
any DT O
one CD O
of IN O
the DT O
preceding VBG O
claims NNS O
, , O
in IN O
which WDT O
the DT O
reversible JJ O
inhibitor NN O
exhibits NNS O
a DT O
Ki NNP O
value NN O
of IN O
between IN O
0.01 CD O
and CC O
2 CD O
mM NN O
, , O
for IN O
example NN O
between IN O
0.04 CD O
mM NN O
and CC O
0.5 CD O
mM. . O

4 CD O
. . O
Composition NNP O
according VBG O
to TO O
any DT O
one CD O
of IN O
the DT O
preceding VBG O
claims NNS O
, , O
in IN O
which WDT O
the DT O
serine NN O
protease NN O
is VBZ O
thrombin RB O
. . O

5 CD O
. . O
Composition NNP O
according VBG O
to TO O
claim VB O
4 CD O
, , O
in IN O
which WDT O
the DT O
reversible JJ O
inhibitor NN O
is VBZ O
selected VBN O
from IN O
N- NNP B-NP
( -LRB- I-NP
2' JJ I-NP
-phenoxy NN I-NP
) -RRB- I-NP
-4- : I-NP
aminopyridin IN I-NP
and CC O
derivatives VBZ O
thereof RB O
, , O
benzamidine NN B-NP
, , O
N NNP B-NP
, , I-NP
N- NNP I-NP
diethylethylenediamine NN I-NP
, , O
aminobenzamidine JJ B-NP
, , O
amidinopyridin IN B-NP
and CC O
tert-butylamidin NN B-NP
. . O

6 CD O
. . O
Composition NNP O
according VBG O
to TO O
claim VB O
4 CD O
, , O
in IN O
which WDT O
the DT O
reversible JJ O
inhibitor NN O
is VBZ O
selected VBN O
from IN O
N- NNP B-NP
( -LRB- I-NP
2' JJ I-NP
-phenoxy NN I-NP
) -RRB- I-NP
-4- : I-NP
aminopyridin IN I-NP
and CC O
derivatives VBZ O
thereof RB O
, , O
N,N-diethyl- NNP B-NP
ethylenediamine NN I-NP
, , O
amidinopyridin IN B-NP
and CC O
tert-butylamidin NN B-NP
. . O

7. . O
Composition NNP O
according VBG O
to TO O
claim VB O
4 CD O
, , O
in IN O
which WDT O
the DT O
reversible JJ O
inhibitor NN O
is VBZ O
N- NNP B-NP
( -LRB- I-NP
2' JJ I-NP
-phenoxy NN I-NP
) -RRB- I-NP
-4-aminopyridin NN I-NP
or CC O
a DT O
derivative JJ O
thereof NN O
. . O

8. . O
Composition NNP O
according VBG O
to TO O
any DT O
one CD O
of IN O
claims NNS O
1-3 JJ O
, , O
in IN O
which WDT O
the DT O
serine NN O
protease NN O
is VBZ O
plasmin NN O
. . O

9 CD O
. . O
Composition NNP O
according VBG O
to TO O
claim VB O
8 CD O
, , O
in IN O
which WDT O
the DT O
reversible JJ O
inhibitor NN O
is VBZ O
selected VBN O
from IN O
N,N-diethyl- NNP B-NP
ethylenediamine NN I-NP
, , O
aminobenzamidine JJ B-NP
and CC O
benzamidine JJ B-NP
. . O

10 CD O
. . O
Composition NNP O
according VBG O
to TO O
any DT O
one CD O
of IN O
claims NNS O
1-3 JJ O
, , O
in IN O
which WDT O
the DT O
serine NN O
protease NN O
is VBZ O
trypsin RB O
. . O

11 CD O
. . O
Composition NNP O
according VBG O
to TO O
claim NN O
10 CD O
, , O
in IN O
which WDT O
the DT O
reversible JJ O
inhibitor NN O
is VBZ O
selected VBN O
from IN O
aminobenzamidine JJ B-NP
and CC O
benzamidine JJ B-NP
. . O

12 CD O
. . O
Composition NNP O
according VBG O
to TO O
any DT O
one CD O
of IN O
the DT O
preceding VBG O
claims NNS O
, , O
in IN O
which WDT O
n NN O
in IN O
formula NN O
I PRP O
is VBZ O
1 CD O
or CC O
2. CD O

13 CD O
. . O
Composition NNP O
according VBG O
to TO O
any DT O
one CD O
of IN O
the DT O
preceding VBG O
claims NNS O
, , O
in IN O
which WDT O
n NN O
in IN O
formula NN O
I PRP O
is VBZ O
1 CD O
. . O

14 CD O
. . O
Composition NNP O
according VBG O
to TO O
any DT O
one CD O
of IN O
the DT O
preceding VBG O
claims NNS O
, , O
in IN O
which WDT O
stabilizing VBG O
agent NN O
M NNP O
is VBZ O
a DT O
compound NN O
of IN O
formula NN O
II NNP O
: : O

EMI36.1 . O

wherein WRB O

R<1>-R<4> JJ O
are VBP O
the DT O
same JJ O
or CC O
different JJ O
, , O
and CC O
selected VBN O
from IN O
H NNP B-NP
, , O
-CH2-R<6> JJ B-NP
; : O

R<5> NN O
is VBZ O
as IN O
R<3^>-R<4> JJ O
or CC O
P-Q JJ O
; : O

P NNP O
is VBZ O
selected VBN O
from IN O
- : B-NP
( -LRB- I-NP
CH2 NN I-NP
) -RRB- I-NP
m NN I-NP
- : I-NP
and CC O
- : B-NP
( -LRB- I-NP
CH2 NN I-NP
) -RRB- I-NP
m-Y- FW I-NP
( -LRB- I-NP
CH2 NN I-NP
) -RRB- I-NP
m-, , I-NP
wherein WRB O
m NN O
is VBZ O
1-6 JJ O
and CC O
Y PRP O
is VBZ O
0, JJ B-NP
NH NNP B-NP
or CC O
S NNP B-NP
; : O

Q NN O
is VBZ O
selected VBN O
from IN O
H NNP B-NP
, , O
-SO3 JJ B-NP
, , O
-COOH NNP B-NP
, , O
-NH2 NNP B-NP
, , O
-OH NNP B-NP
and CC O
-CONH2 NNP B-NP
; : O
each DT O
R<6> JJ O
individually RB O
being VBG O
selected VBN O
from IN O
H NNP B-NP
, , O
substituted VBN B-NP
or CC I-NP
non-substituted JJ I-NP
lower JJR I-NP
alkyl NN I-NP
, , O
substituted VBN B-NP
or CC I-NP
non-substituted JJ I-NP
cycloalkyl NN I-NP
, , O
substituted VBN B-NP
or CC I-NP
non FW I-NP
- : I-NP
substituted VBN I-NP
benzyl NN I-NP
, , O
substituted VBN B-NP
or CC I-NP
non-substituted JJ I-NP
aryl NN I-NP
or CC O
mono-, JJ B-NP
bi-, JJ I-NP
or CC I-NP
tricyclic JJ I-NP
unsubstituted JJ I-NP
or CC I-NP
substituted VBN I-NP
heteroaromatic JJ I-NP
ring( NN I-NP
s VBZ O
) -RRB- O
with IN O
one CD O
or CC O
more JJR O
heteroatoms NNS B-NP
and CC I-NP
non-aromatic JJ I-NP
heterocycles NNS I-NP
, , O
the DT O
substituents NNS O
of IN O
the DT O
substituted VBN O
groups NNS O
being VBG O
selected VBN O
from IN O
lower JJR B-NP
alkyl NN I-NP
, , O
halogens NNS B-NP
, , O
substituted VBN B-NP
or CC I-NP
non-substituted JJ I-NP
aryl NN I-NP
, , O
substituted VBN B-NP
or CC I-NP
non-substituted JJ I-NP
hetero-aromatic JJ I-NP
compounds NNS I-NP
, , O
non-aromatic JJ B-NP
heterocycles NNS I-NP
, , O
alkyloxy RB B-NP
, , O
alkylamino RB B-NP
; : O
or CC O
a DT O
pharmaceutically RB O
acceptable JJ O
salt NN O
thereof '' O
. . O

15 CD O
. . O
Composition NNP O
according VBG O
to TO O
claim NN O
14 CD O
, , O
in IN O
which WDT O
stabilizing VBG O
agent NN O
M NNP O
is VBZ O
a DT O
compound NN O
of IN O
formula NN O
III NNP O
: : O

EMI37.1 . O

wherein WRB O
R<5> NNP O
is VBZ O
-CH2-R<6> JJ B-NP
or CC O
P-Q JJ O
; : O

P NNP O
is VBZ O
selected VBN O
from IN O
- : B-NP
( -LRB- I-NP
CH2 NN I-NP
) -RRB- I-NP
m NN I-NP
- : I-NP
or CC O
- : B-NP
( -LRB- I-NP
CH2 NN I-NP
) -RRB- I-NP
m-Y- FW I-NP
( -LRB- I-NP
CH2 NN I-NP
) -RRB- I-NP
m-, , I-NP
wherein WRB O
m NN O
is VBZ O
1-6 JJ O
and CC O
Y PRP O
is VBZ O
0, JJ B-NP
NH NNP B-NP
or CC O
S NNP B-NP
; : O

Q NN O
is VBZ O
selected VBN O
from IN O
H NNP B-NP
, , O
-SO3 JJ B-NP
, , O
-COOH NNP B-NP
, , O
-NH2 NNP B-NP
, , O
-OH NNP B-NP
and CC O
-CONH2 NNP B-NP
. . O

each DT O
R<6> JJ O
individually RB O
being VBG O
selected VBN O
from IN O
substituted VBN B-NP
or CC I-NP
non-substituted JJ I-NP
lower JJR I-NP
alkyl NN I-NP
, , O
substituted VBN B-NP
or CC I-NP
non FW I-NP
- : I-NP
substituted VBN I-NP
cycloalkyl NN I-NP
, , O
substituted VBN B-NP
or CC I-NP
non-substituted JJ I-NP
benzyl NN I-NP
, , O
substituted VBN B-NP
or CC I-NP
non-substituted JJ I-NP
aryl NN I-NP
, , O
the DT O
substituents NNS O
of IN O
the DT O
substituted VBN O
groups NNS O
being VBG O
selected VBN O
from IN O
lower JJR B-NP
alkyl NN I-NP
, , O
halogens NNS B-NP
, , O
substituted VBN B-NP
or CC I-NP
non FW I-NP
- : I-NP
substituted VBN I-NP
aryl NN I-NP
, , O
substituted VBN B-NP
or CC I-NP
non-substituted JJ I-NP
hetero- , I-NP
aromatic JJ I-NP
compounds NNS I-NP
, , O
non-aromatic JJ B-NP
heterocycles NNS I-NP
, , O
alkyloxy RB B-NP
, , O
alkylamino RB B-NP
; : O
or CC O
a DT O
pharmaceutically RB O
acceptable JJ O
salt NN O
thereof '' O
. . O

16 CD O
. . O
Composition NNP O
according VBG O
to TO O
claim NN O
15 CD O
, , O
in IN O
which WDT O
stabilizing VBG O
agent NN O
M NNP O
is VBZ O
selected VBN O
from IN O
the DT O
group NN O
consisting VBG O
of IN O
morpholine NN B-NP
, , O
3- CD B-NP
(N-morpholino NN I-NP
) -RRB- I-NP
propanesulfonic JJ I-NP
acid NN I-NP
( -LRB- O
MOPS) NNP B-NP
, , O
morpholino NN B-NP
butyl NN I-NP
sulphonic JJ I-NP
acid NN I-NP
, , O
morpholino NN B-NP
propyl NN I-NP
carboxylic NN I-NP
acid NN I-NP
, , O
morpholino NN B-NP
ethyl NN I-NP
alcohol NN I-NP
and CC O
morpholino NN B-NP
ethyl NN I-NP
sulphonic JJ I-NP
acid NN I-NP
. . O

17 CD O
. . O
Composition NNP O
according VBG O
to TO O
claim NN O
16 CD O
, , O
in IN O
which WDT O
stabilizing VBG O
agent NN O
M NNP O
is VBZ O
selected VBN O
from IN O
morpholine NN B-NP
and CC O
3- CD B-NP
(N- NNS I-NP
morpholino)propanesulfonic JJ I-NP
acid NN I-NP
. . O

18 CD O
. . O
Composition NNP O
according VBG O
to TO O
claim NN O
17 CD O
, , O
in IN O
which WDT O
stabilizing VBG O
agent NN O
M NNP O
is VBZ O
morpholine NN B-NP
. . O

19 CD O
. . O
Composition NNP O
according VBG O
to TO O
any DT O
one CD O
of IN O
the DT O
preceding VBG O
claims NNS O
, , O
in IN O
which WDT O
the DT O
serine NN O
protease NN O
is VBZ O
thrombin RB O
, , O
the DT O
reversible JJ O
inhibitor NN O
is VBZ O
N- DT B-NP
( -LRB- I-NP
2<f JJ I-NP
> NN I-NP
-phenoxy NN I-NP
) -RRB- I-NP
-4- : I-NP
aminopyridin IN I-NP
, , O
and CC O
stabilizing VBG O
agent NN O
M NNP O
is VBZ O
morpholine NN B-NP
. . O

20 CD O
. . O
Composition NNP O
according VBG O
to TO O
any DT O
one CD O
of IN O
the DT O
preceding VBG O
claims NNS O
, , O
in IN O
which WDT O
the DT O
serine NN O
protease NN O
is VBZ O
thrombin RB O
, , O
the DT O
reversible JJ O
inhibitor NN O
is VBZ O
N- NNP B-NP
( -LRB- I-NP
2' JJ I-NP
-phenoxy NN I-NP
) -RRB- I-NP
-4- : I-NP
aminopyridin IN I-NP
, , O
and CC O
stabilizing VBG O
agent NN O
M NNP O
is VBZ O
3- CD B-NP
(N- : I-NP
morpholino NN I-NP
) -RRB- I-NP
propanesulfonic JJ I-NP
acid NN I-NP
. . O

21 CD O
. . O
Composition NNP O
according VBG O
to TO O
any DT O
one CD O
of IN O
the DT O
preceding VBG O
claims NNS O
, , O
which WDT O
further RB O
comprises VBZ O
a DT O
viscous JJ O
and CC O
adhesive JJ O
polymer NN O
selected VBN O
from IN O
polysaccharides NNS B-NP
and CC O
gelatin NN B-NP
. . O

22 CD O
. . O
Composition NNP O
according VBG O
to TO O
claim NN O
21 CD O
, , O
in IN O
which WDT O
the DT O
viscous JJ O
and CC O
adhesive JJ O
polymer NN O
is VBZ O
a DT O
polysaccharide NN B-NP
. . O

23 CD O
. . O
Composition NNP O
according VBG O
to TO O
claim NN O
22 CD O
, , O
in IN O
which WDT O
the DT O
polysaccharide NN B-NP
is VBZ O
selected VBN O
from IN O
starch NN B-NP
, , O
its PRP$ O
derivatives NNS O
, , O
cellulose NN B-NP
, , O
its PRP$ O
derivatives NNS O
, , O
and CC O
mixtures NNS O
thereof RB O
. . O

24 CD O
. . O
Composition NNP O
according VBG O
to TO O
claim NN O
23 CD O
, , O
in IN O
which WDT O
the DT O
polysaccharide NN B-NP
is VBZ O
selected VBN O
from IN O
carboxymethyl NN B-NP
cellulose NN I-NP
, , O
ethyl NN B-NP
hydroxyethyl NN I-NP
cellulose NN I-NP
and CC O
mixtures NNS O
thereof RB O
. . O

25 CD O
. . O
Composition NNP O
according VBG O
to TO O
claim NN O
22 CD O
, , O
in IN O
which WDT O
the DT O
polysaccharide NN B-NP
is VBZ O
carboxymethyl NN B-NP
chitosan NN I-NP
. . O

26 CD O
. . O
Composition NNP O
according VBG O
to TO O
any DT O
one CD O
of IN O
claims NNS O
22- CD O
25 CD O
, , O
in IN O
which WDT O
said VBD O
polysaccharide NN B-NP
is VBZ O
present JJ O
in IN O
a DT O
concentration NN O
of IN O
0.1-5 CD O
% NN O
. . O

27 CD O
. . O
Composition NNP O
according VBG O
to TO O
claim NN O
21 CD O
, , O
in IN O
which WDT O
the DT O
viscous JJ O
and CC O
adhesive JJ O
polymer NN O
is VBZ O
gelatin VBG B-NP
. . O

28 CD O
. . O
Composition NNP O
according VBG O
to TO O
claim NN O
27 CD O
, , O
in IN O
which WDT O
the DT O
gelatin NN B-NP
is VBZ O
cold JJ O
water NN B-NP
fish NN O
gelatin NN B-NP
. . O

29 CD O
. . O
Composition NNP O
according VBG O
to TO O
any DT O
one CD O
of IN O
claims NNS O
27 CD O
- : O
28 CD O
, , O
in IN O
which WDT O
said VBD O
gelatin NN B-NP
is VBZ O
present JJ O
in IN O
a DT O
concentration NN O
of IN O
0.5-20 CD O
% NN O
. . O

30 CD O
. . O

Composition NNP O
according VBG O
to TO O
any DT O
one CD O
of IN O
the DT O
preceding VBG O
claims NNS O
, , O
in IN O
which WDT O
said VBD O
serine NN O
protease NN O
is VBZ O
present JJ O
in IN O
a DT O
concentration NN O
of IN O
0.001-2 CD O
mg/ml NN O
. . O

31 CD O
. . O

Composition NNP O
according VBG O
to TO O
any DT O
one CD O
of IN O
the DT O
preceding VBG O
claims NNS O
, , O
in IN O
which WDT O
the DT O
serine NN O
protease NN O
is VBZ O
thrombin IN O
and CC O
the DT O
concentration NN O
of IN O
thrombin NN O
is VBZ O
5-3500 CD O
activity NN O
units/ml NN O
. . O

32 CD O
. . O
Composition NNP O
according VBG O
to TO O
any DT O
one CD O
of IN O
the DT O
preceding VBG O
claims NNS O
, , O
in IN O
which WDT O
the DT O
serine NN O
protease NN O
is VBZ O
thrombin IN O
and CC O
the DT O
concentration NN O
of IN O
thrombin NN O
is VBZ O
200-1000 CD O
activity NN O
units/ml NN O
. . O

33 CD O
. . O
Composition NNP O
according VBG O
to TO O
any DT O
one CD O
of IN O
the DT O
preceding VBG O
claims NNS O
, , O
in IN O
which WDT O
the DT O
serine NN O
protease NN O
is VBZ O
thrombin IN O
and CC O
the DT O
concentration NN O
of IN O
thrombin NN O
is VBZ O
5-20 JJ O
activity NN O
units/ml NN O
. . O

34. . O
Composition NNP O
according VBG O
to TO O
any DT O
one CD O
of IN O
the DT O
preceding VBG O
claims NNS O
, , O
in IN O
which WDT O
said VBD O
reversible JJ O
inhibitor NN O
of IN O
said VBD O
serine NN O
protease NN O
is VBZ O
present JJ O
in IN O
a DT O
concentration NN O
of IN O
0.1-10 CD O
inM. . O

35 CD O
. . O

Composition NNP O
according VBG O
to TO O
any DT O
one CD O
of IN O
the DT O
preceding VBG O
claims NNS O
, , O
in IN O
which WDT O
said VBD O
stabilizing VBG O
agent NN O
is VBZ O
present JJ O
in IN O
a DT O
concentration NN O
of IN O
0.02-0.5 CD O
M. NNP O

36 CD O
. . O

Composition NNP O
according VBG O
to TO O
any DT O
one CD O
of IN O
the DT O
preceding VBG O
claims NNS O
, , O
which WDT O
is VBZ O
in IN O
a DT O
form NN O
selected VBN O
from IN O
a DT O
solution NN O
and CC O
a DT O
gel NN O
, , O
for IN O
example NN O
an DT O
aqueous JJ O
solution NN O
or CC O
an DT O
aqueous JJ O
gel NN O
. . O

37 CD O
. . O
Use NNP O
of IN O
a DT O
composition NN O
according VBG O
to TO O
any DT O
one CD O
of IN O
the DT O
preceding VBG O
claims NNS O
as IN O
a DT O
medicament NN O
. . O

38 CD O
. . O
Use NNP O
of IN O
a DT O
composition NN O
according VBG O
to TO O
any DT O
one CD O
of IN O
claims NNS O
1-36 CD O
, , O
in IN O
which WDT O
the DT O
serine NN O
protease NN O
is VBZ O
thrombin IN O
, , O
for IN O
the DT O
preparation NN O
of IN O
a DT O
medicament NN O
for IN O
establishing VBG O
haemostasis NN O
in IN O
a DT O
subject JJ O
suffering NN O
from IN O
a DT O
bleeding NN O
. . O

39 CD O
. . O
Method NNP O
for IN O
establishing VBG O
haemostasis NN O
in IN O
a DT O
subject JJ O
suffering NN O
from IN O
a DT O
bleeding NN O
, , O
comprising VBG O
applying VBG O
a DT O
composition NN O
according VBG O
to TO O
any DT O
one CD O
of IN O
claims NNS O
1-36 CD O
, , O
in IN O
which WDT O
composition NN O
the DT O
serine NN O
protease NN O
is VBZ O
thrombin RB O
, , O
to TO O
the DT O
site NN O
of IN O
bleeding VBG O
in IN O
an DT O
amount NN O
sufficient JJ O
to TO O
diminish VB O
or CC O
stop VB O
said VBD O
bleeding NN O
. . O

40 CD O
. . O

Use NN O
of IN O
a DT O
composition NN O
according VBG O
to TO O
claim NN O
33 CD O
in IN O
plastic NN O
surgery NN O
. . O

41 CD O
. . O
Use NNP O
of IN O
a DT O
composition NN O
according VBG O
to TO O
any DT O
one CD O
of IN O
claims NNS O
1-36 CD O
, , O
in IN O
which WDT O
the DT O
serine NN O
protease NN O
is VBZ O
selected VBN O
from IN O
plasmin NN O
, , O
urokinase JJ O
and CC O
tissue NN O
plasminogen NN O
activator NN O
, , O
for IN O
the DT O
preparation NN O
of IN O
a DT O
medicament NN O
for IN O
thrombolytic JJ O
treatment NN O
. . O

42 CD O
. . O
Method NNP O
for IN O
thrombolytic DT O
treatment NN O
in IN O
a DT O
subject NN O
in IN O
need NN O
thereof RB O
, , O
comprising VBG O
administering VBG O
a DT O
composition NN O
according VBG O
to TO O
any DT O
one CD O
of IN O
claims NNS O
1-36 CD O
, , O
in IN O
which WDT O
composition NN O
the DT O
serine NN O
protease NN O
is VBZ O
selected VBN O
from IN O
plasmin NN O
, , O
urokinase JJ O
and CC O
tissue NN O
plasminogen NN O
activator NN O
, , O
to TO O
the DT O
subject NN O
in IN O
an DT O
amount NN O
sufficient JJ O
for IN O
said VBD O
treatment NN O
. . O

43 CD O
. . O
Use NNP O
of IN O
a DT O
combination NN O
of IN O
a DT O
reversible JJ O
serine NN O
protease NN O
inhibitor NN O
and CC O
a DT O
stabilizing VBG O
agent NN O
M NNP O
as IN O
defined VBN O
in IN O
claim NN O
I1 IN O
for IN O
stabilizing VBG O
a DT O
serine NN O
protease NN O
composition NN O
, , O
wherein WRB O
said VBD O
reversible JJ O
serine NN O
protease NN O
inhibitor NN O
and CC O
said VBD O
stabilizing VBG O
agent NN O
M NNP O
act NN O
in IN O
synergy NN O
to TO O
provide VB O
a DT O
serine NN O
protease NN O
stabilizing VBG O
effect NN O
. . O

44 CD O
. . O
Use NNP O
according VBG O
to TO O
claim NN O
43 CD O
, , O
in IN O
which WDT O
the DT O
serine NN O
protease NN O
is VBZ O
as IN O
defined VBN O
in IN O
any DT O
one CD O
of IN O
claims NNS O
2 CD O
, , O
4 CD O
, , O
8 CD O
, , O
10 CD O
, , O
30 CD O
, , O
31 CD O
, , O
32 CD O
and CC O
33 CD O
. . O

45 CD O
. . O
Use VB O
according VBG O
to TO O
any DT O
one CD O
of IN O
claims NNS O
43-44 CD O
, , O
in IN O
which WDT O
the DT O
reversible JJ O
inhibitor NN O
is VBZ O
as IN O
defined VBN O
in IN O
any DT O
one CD O
of IN O
claims NNS O
3 CD O
, , O
5 CD O
, , O
6 CD O
, , O
7 CD O
, , O
9 CD O
, , O
11 CD O
and CC O
34. CD O

46 CD O
. . O
Use NNP O
according VBG O
to TO O
any DT O
one CD O
of IN O
claims NNS O
43-45 CD O
, , O
in IN O
which WDT O
the DT O
stabilizing VBG O
agent NN O
M NNP O
is VBZ O
as IN O
defined VBN O
in IN O
any DT O
one CD O
of IN O
claims NNS O
12-18 CD O
and CC O
35 CD O
. . O

47 CD O
. . O
Use NNP O
according VBG O
to TO O
any DT O
one CD O
of IN O
claims NNS O
43-46 CD O
, , O
in IN O
which WDT O
said VBD O
combination NN O
further RB O
comprises VBZ O
a DT O
viscous JJ O
and CC O
adhesive JJ O
polymer NN O
selected VBN O
from IN O
polysaccharides NNS B-NP
and CC O
gelatin NN B-NP
. . O

48 CD O
. . O
Use NNP O
according VBG O
to TO O
claim NN O
47 CD O
, , O
in IN O
which WDT O
the DT O
viscous JJ O
and CC O
adhesive JJ O
polymer NN O
is VBZ O
as IN O
defined VBN O
in IN O
any DT O
one CD O
of IN O
claims NNS O

22-29 CD O
. . O

49 CD O
. . O
Use NNP O
according VBG O
to TO O
any DT O
one CD O
of IN O
claims NNS O
43-48 CD O
, , O
in IN O
which WDT O
said VBD O
reversible JJ O
serine NN O
protease NN O
inhibitor NN O
is VBZ O
N- DT B-NP
{ JJ I-NP
2<r JJ I-NP
> NNS I-NP
- : I-NP
phenoxy NN I-NP
) -RRB- I-NP
-4-aminopyridin NN I-NP
and CC O
said VBD O
stabilizing VBG O
agent NN O
M NNP O
is VBZ O
3- CD B-NP
(N-morpholino NN I-NP
) -RRB- I-NP
propanesulfonic JJ I-NP
acid NN I-NP
. . O

50 CD O
. . O

Method NNP O
for IN O
the DT O
stabilization NN O
of IN O
a DT O
serine NN O
protease NN O
composition NN O
, , O
which WDT O
comprises VBZ O
admixing VBG O
the DT O
serine NN O
protease NN O
with IN O
a DT O
) -RRB- O
a DT O
reversible JJ O
inhibitor NN O
of IN O
said VBD O
serine NN O
protease NN O
; : O
and CC O
b NN O
) -RRB- O
a DT O
stabilizing VBG O
agent NN O
M NNP O
of IN O
formula NN O
I PRP O
: : O

EMI42.1 . O

wherein WRB O
n NN O
is VBZ O
0 CD O
, , O
1 CD O
or CC O
2 CD O
/ . O

X NNP O
i FW O
s PRP O
0, IN B-NP
N NNP B-NP
or CC O
CH2 NNP B-NP
; : O

R<3->-R<4> JJ O
are VBP O
the DT O
same JJ O
or CC O
different JJ O
, , O
and CC O
selected VBN O
from IN O
H NNP B-NP
, , O
-CH2-R<6> JJ B-NP
, , O
-CH2-O-R<6> JJ B-NP
, , O
-CH2-S-R<6> JJ B-NP
, , O
-CH2-NH-R<6> JJ B-NP
, , O
-CO-O-R<6> JJ B-NP
, , O

-CO-NH-R<6> JJ B-NP
, , O
-CH2-NH-CO-R<6> JJ B-NP
, , O
-CH2-O-CO-R<6> JJ B-NP
, , O
-CH2-NH-CO-NHR<6> JJ B-NP
, , O
-CH2-NH-CO-OR<6> JJ B-NP
, , O
-CH2-NH-CS-NHR<6> JJ B-NP
and CC O
-CH2-O-CO-NHR<6> JJ B-NP
; : O

R<5> NN O
is VBZ O
as IN O
R<1->-R<4> JJ O
or CC O
P-Q JJ O
; : O

P NNP O
is VBZ O
selected VBN O
from IN O
-(CH2)m JJ B-NP
- : I-NP
and CC O
- : B-NP
( -LRB- I-NP
CH2 NN I-NP
) -RRB- I-NP
m-Y- FW I-NP
( -LRB- I-NP
CH2 NN I-NP
) -RRB- I-NP
m-, , I-NP
wherein WRB O
m NN O
is VBZ O
1-6 JJ O
and CC O
Y PRP O
is VBZ O
0, JJ O
NH NNP B-NP
or CC O
S NNP B-NP
; : O

Q NN O
is VBZ O
selected VBN O
from IN O
H NNP B-NP
, , O
-SO3 JJ B-NP
, , O
-COOH NNP B-NP
, , O
-NH2 NNP B-NP
, , O
-OH NNP B-NP
and CC O
-CONH2 NNP B-NP
; : O
each DT O
R<6> JJ O
individually RB O
being VBG O
selected VBN O
from IN O
H NNP B-NP
, , O
substituted VBN B-NP
or CC I-NP
non-substituted JJ I-NP
lower JJR I-NP
alkyl NN I-NP
, , O
substituted VBN B-NP
or CC I-NP
non-substituted JJ I-NP
cycloalkyl NN I-NP
, , O
substituted VBN B-NP
or CC I-NP
non FW I-NP
- : I-NP
substituted VBN I-NP
benzyl NN I-NP
, , O
substituted VBN B-NP
or CC I-NP
non-substituted JJ I-NP
aryl NN I-NP
or CC O
mono-, JJ B-NP
bi-, JJ I-NP
or CC I-NP
tricyclic JJ I-NP
unsubstituted JJ I-NP
or CC I-NP
substituted VBN I-NP
heteroaromatic JJ I-NP
ring( NN I-NP
s VBZ O
) -RRB- O
with IN O
one CD O
or CC O
more JJR O
heteroatoms NNS B-NP
and CC I-NP
non-aromatic JJ I-NP
heterocycles NNS I-NP
; : O
the DT O
substituents NNS O
of IN O
the DT O
substituted VBN O
groups NNS O
being VBG O
selected VBN O
from IN O
lower JJR B-NP
alkyl NN I-NP
, , O
halogens NNS B-NP
, , O
substituted VBN B-NP
or CC I-NP
non FW I-NP
- : I-NP
substituted VBN I-NP
aryl NN I-NP
, , O
substituted VBN O
or CC O
non-substituted JJ O
heteroaromatic JJ B-NP
compounds NNS I-NP
, , O
non-aromatic JJ B-NP
heterocycles NNS I-NP
, , O
alkyloxy RB B-NP
, , O
alkylamino RB B-NP
; : O
or CC O
a DT O
pharmaceutically RB O
acceptable JJ O
salt NN O
thereof '' O
. . O

51 CD O
. . O
Method NNP O
according VBG O
to TO O
claim NN O
50 CD O
, , O
in IN O
which WDT O
the DT O
serine NN O
protease NN O
is VBZ O
as IN O
defined VBN O
in IN O
any DT O
one CD O
of IN O
claims NNS O
2 CD O
, , O
4 CD O
, , O
8 CD O
, , O
10 CD O
, , O
30 CD O
, , O
31 CD O
, , O
32 CD O
and CC O
33 CD O
. . O

52 CD O
. . O
Method NNP O
according VBG O
to TO O
any DT O
one CD O
of IN O
claims NNS O
50-51 JJ O
, , O
in IN O
which WDT O
the DT O
reversible JJ O
inhibitor NN O
is VBZ O
as IN O
defined VBN O
in IN O
any DT O
one CD O
of IN O
claims NNS O
3 CD O
, , O
5 CD O
, , O
6 CD O
, , O
7 CD O
, , O
9 CD O
, , O
11 CD O
and CC O
34. CD O

53 CD O
. . O
Method NNP O
according VBG O
to TO O
any DT O
one CD O
of IN O
claims NNS O
50-52 CD O
, , O
in IN O
which WDT O
the DT O
stabilizing VBG O
agent NN O
M NNP O
is VBZ O
as IN O
defined VBN O
in IN O
any DT O
one CD O
of IN O
claims NNS O
12-18 CD O
and CC O
35 CD O
. . O

54 CD O
. . O
Method NNP O
according VBG O
to TO O
any DT O
one CD O
of IN O
claims NNS O
50-53 CD O
, , O
which WDT O
further RB O
comprises VBZ O
admixing VBG O
the DT O
serine NN O
protease NN O
with IN O
a DT O
viscous JJ O
and CC O
adhesive JJ O
polymer NN O
selected VBN O
from IN O
polysaccharides NNS B-NP
and CC O
gelatin NN B-NP
. . O

55 CD O
. . O
Method NNP O
according VBG O
to TO O
claim NN O
54 CD O
, , O
in IN O
which WDT O
the DT O
viscous JJ O
and CC O
adhesive JJ O
polymer NN O
is VBZ O
as IN O
defined VBN O
in IN O
any DT O
one CD O
of IN O
claims NNS O
22-29 CD O
. . O

56 CD O
. . O
Method NNP O
according VBG O
to TO O
any DT O
one CD O
of IN O
claims NNS O
50-55 CD O
, , O
in IN O
which WDT O
said VBD O
reversible JJ O
serine NN O
protease NN O
inhibitor NN O
is VBZ O
N- DT B-NP
( -LRB- I-NP
2<r JJ I-NP
> NN I-NP
- : I-NP
phenoxy NN I-NP
) -RRB- I-NP
-4-aminopyridin NN I-NP
and CC O
said VBD O
stabilizing VBG O
agent NN O
M NNP O
is VBZ O
3- CD B-NP
(N-morpholino NN I-NP
) -RRB- I-NP
propanesulfonic JJ I-NP
acid NN I-NP
. . O

57 CD O
. . O
Vascular NNP O
haemostasis VBD O
device NN O
having VBG O
adsorbed VBN O
thereupon RB O
a DT O
composition NN O
according VBG O
to TO O
any DT O
one CD O
of IN O
claims NNS O
1- CC O
36 CD O
, , O
in IN O
which WDT O
composition NN O
the DT O
serine NN O
protease NN O
is VBZ O
thrombin RB O
, , O

58 CD O
. . O
Vascular NNP O
haemostasis VBD O
device NN O
according VBG O
to TO O
claim NN O
57 CD O
, , O
which WDT O
comprises VBZ O
a DT O
biodegradable JJ O
material NN O
, , O
such JJ O
as IN O
selected VBN O
from IN O
chitosan NN B-NP
and CC O
collagen NN O
. . O

59 CD O
. . O
Use NNP O
of IN O
N,N-diethylethylenediamine NNP B-NP
as IN O
an DT O
inhibitor NN O
of IN O
a DT O
serine NN O
protease NN O
. . O

60 CD O
. . O
Use NNP O
according VBG O
to TO O
claim NN O
59 CD O
, , O
in IN O
which WDT O
the DT O
serine NN O
protease NN O
is VBZ O
selected VBN O
from IN O
thrombin NN O
and CC O
plasmin NN O
. . O

61 CD O
. . O
Method NNP O
of IN O
inhibiting VBG O
a DT O
serine NN O
protease NN O
, , O
comprising VBG O
admixing NN O
therewith , O
an DT O
inhibitory JJ O
amount NN O
of IN O
N NNP B-NP
, , I-NP
N-diethylethylenediamine NNP I-NP
. . O

62 CD O
. . O
Method NNP O
according VBG O
to TO O
claim NN O
61 CD O
, , O
in IN O
which WDT O
the DT O
serine NN O
protease NN O
is VBZ O
selected VBN O
from IN O
thrombin NN O
and CC O
plasmin NN O
. . O

-DOCSTART- X X O

[0001] JJ O
GOSMETIC NNP O
COMPOSITIONS NNP O
COMPRISING NNP O
HYDROXYFATTY NNP B-NP
ACIDS NNP I-NP

The DT O
present JJ O
invention NN O
is VBZ O
concerned VBN O
with IN O
novel NN O
cosmetic NN O
or CC O
pharmaceutical JJ O
compositions NNS O
. . O

More RBR O
particularly RB O
, , O
the DT O
invention NN O
is VBZ O
concerned VBN O
with IN O
novel NN O
cosmetic NN O
or CC O
pharmaceutical JJ O
compositions NNS O
for IN O
treating VBG O
or CC O
preventing VBG O
any DT O
symptoms NNS O
caused VBN O
by IN O
negative JJ O
developments NNS O
of IN O
the DT O
physiological JJ O
homeostasis NN O
of IN O
healthy JJ O
skin NN O
, , O
as RB O
well RB O
as IN O
for IN O
the DT O
promotion NN O
of IN O
hair NN O
growth NN O
and CC O
protection NN O
from IN O
hair NN O
loss NN O
. . O

Thus RB O
, , O
in IN O
one CD O
aspect NN O
, , O
the DT O
present JJ O
invention NN O
is VBZ O
concerned VBN O
with IN O
cosmetic JJ O
or CC O
pharmaceutical JJ O
compositions NNS O
comprising VBG O
a DT O
fatty NN B-NP
acid NN I-NP
containing VBG O
6 CD O
to TO O
18 CD O
carbon NN B-NP
atoms NNS O
, , O
which WDT O
carries VBZ O
one CD O
or CC O
two CD O
hydroxyl JJ B-NP
, , O
alkoxy JJ B-NP
, , O
preferably RB O
methoxy NN B-NP
or CC O
ethoxy JJ B-NP
, , O
C2-C4-acyl JJ B-NP
protected JJ O
amino NN B-NP
, , O
preferably RB O
C2 NN O
, , O
or CC O
oxo NN B-NP
group NN O
, , O
preferably RB O
between IN O
the DT O
positions NNS O
C6 . O
and CC O
C12 JJ O
; : O
or CC O
a DT O
salt NN O
, , O
ester NN B-NP
or CC O
amide IN B-NP
of IN O
such JJ O
acids NNS B-NP
or CC O
a DT O
mixture NN O
of IN O
these DT O
acids NNS B-NP
; : O
and CC O
a DT O
carrier NN O
conventionally RB O
used VBD O
in IN O
cosmetic JJ O
or CC O
pharmaceutical JJ O
compositions NNS O
. . O

The DT O
ester NN B-NP
or CC O
amide NN B-NP
are VBP O
, , O
preferably RB O
, , O
an DT O
alkyl NN B-NP
ester NN I-NP
or CC O
alkyl NN B-NP
amide IN I-NP
, , O
wherein WRB O
the DT O
term NN O
"alkyl NN O
" '' O
encompasses VBZ O
straight JJ O
chain NN O
as RB O
well RB O
as IN O
branched JJ O
alkyl NN B-NP
groups NNS O
, , O
i IN O
.e NN O
. . O
that WDT O
" `` O
C^-alkyl JJ B-NP
" '' O
encompasses NNS O
straight JJ O
chain NN O
Ci-4-alkyl NNP B-NP
( -LRB- O
methyl NN B-NP
, , O
ethyl NN B-NP
, , O
n-propyl JJ B-NP
, , B-NP
n-butyl JJ I-NP
) -RRB- O
as RB O
well RB O
as IN O
branched JJ O
C3-4-alkyl JJ B-NP
( -LRB- O
iso-propyl NN B-NP
, , O
iso-butyl NN B-NP
, , O
tert-butyl NN B-NP
) -RRB- O
. . O

The DT O
salt NN O
may MD O
by IN O
formed VBN O
by IN O
any DT O
cosmetically NN O
acceptable JJ O
cation NN O
which WDT O
means VBZ O
any DT O
metal NN B-NP
cation NN I-NP
as RB O
well RB O
as IN O
any DT O
organic JJ O
cation NN O
that WDT O
is VBZ O
not RB O
toxic JJ O
to TO O
the DT O
skin NN O
and/or CC O
does VBZ O
not RB O
cause VB O
allergic JJ O
reactions NNS O
. . O

Examples NNS O
of IN O
such JJ O
cations NNS O
are VBP O
ammonium NN B-NP
salts NNS I-NP
and CC O
alkyl NN B-NP
ammonium NN I-NP
salts NNS O
, , O
alkali VBP B-NP
cations NNS I-NP
such JJ O
as IN O
sodium NN B-NP
and CC O
potassium NN B-NP
ions NNS I-NP
and CC O
alkaline NN B-NP
earth NN I-NP
metal NN I-NP
cations NNS I-NP
such JJ O
as IN O
calcium NN B-NP
und IN O
magnesium NN B-NP
ions NNS O
. . O

In IN O
one CD O
embodiment NN O
of IN O
the DT O
present JJ O
invention NN O
the DT O
aliphatic JJ B-NP
fatty JJ I-NP
acid NN I-NP
is VBZ O
a DT O
saturated JJ B-NP
straight- NNS I-NP
chain NN I-NP
fatty JJ I-NP
acid NN I-NP
or CC O
[omega] VB B-NP
- : I-NP
branched-chain NN I-NP
fatty NN I-NP
acid NN I-NP
which WDT O
preferably RB O
has VBZ O
6 CD O
to TO O
18 CD O
carbon NN B-NP
atoms NNS O
. . O

In IN O
another DT O
embodiment NN O
the DT O
aliphatic JJ B-NP
fatty JJ I-NP
acid NN I-NP
is VBZ O
a DT O
saturated JJ O
straight-chain JJ O
or CC O
[omega] JJ B-NP
- : I-NP
branched JJ I-NP
chain NN I-NP
fatty NN I-NP
acid NN I-NP
which WDT O
has VBZ O
6 CD O
to TO O
18 CD O
carbon NN B-NP
atoms NNS O
and CC O
is VBZ O
substituted VBN O
, , O
preferably RB O
by IN O
hydroxy JJ B-NP
, , O
between IN O
the DT O
positions NNS O
C6 . O
and CC O
C12 PRP O
. . O

A DT O
particularly RB O
preferred VBN O
fatty JJ B-NP
acid NN I-NP
is VBZ O
9- CD B-NP
hydroxy JJ I-NP
stearic JJ I-NP
acid NN I-NP
. . O

In IN O
a DT O
further JJ O
aspect NN O
, , O
the DT O
invention NN O
is VBZ O
concerned VBN O
with IN O
cosmetic JJ O
or CC O
pharmaceutical JJ O
compositions NNS O
comprising VBG O
a DT O
fatty JJ B-NP
acid NN I-NP
or CC O
a DT O
salt NN O
, , O
ester NN B-NP
or CC O
amide IN B-NP
with IN O
the DT O
definitions NNS O
and CC O
preferences NNS O
as IN O
given VBN O
above IN O
, , O
and CC O
a DT O
retinoid NN B-NP
. . O

Retinoids NNS B-NP
for IN O
use NN O
in IN O
the DT O
invention NN O
are VBP O
, , O
e.g. FW O
, , O
retinoic JJ B-NP
acid NN I-NP
or CC O
retinol NN B-NP
and CC O
isomers NNS O
, , O
e.g NN O
. . O

9-, JJ O
11- CD O
or CC O
13-cis CD O
isomers NNS O
thereof RB O
, , O
and CC O
derivatives NNS O
thereof , O
which WDT O
comprise VBP O
retinyl NN B-NP
esters NNS I-NP
such JJ O
as IN O
the DT O
acetate NN B-NP
, , O
phenylbutyrate NN B-NP
, , O
propanoate NN B-NP
, , O
laurate NN B-NP
, , O
palmitate NN B-NP
, , O
oleate NN B-NP
, , O
linoleate NN B-NP
; : O
or CC O
retinyl NN B-NP
alkyl NN I-NP
carbonate NN I-NP
; : O
or CC O
ethers NNS B-NP
such JJ O
as IN O
retinoxytrimethylsilane NN B-NP
; : O
or CC O
( -LRB- B-NP
all DT I-NP
trans)-retinal JJ I-NP
or CC O
its PRP$ O
acetals NNS B-NP
; : O
or CC O
retinoic JJ B-NP
acid NN I-NP
or CC O
amides NNS O
thereof , O
such JJ O
as IN O
methoxy NN B-NP
PEG-12 NN I-NP
retinamide NN I-NP
( -LRB- O
"PEG-12 NN O
" '' O
= SYM O
-(CH2-CH2-O-)12 JJ O
) -RRB- O
. . O

More RBR O
specifically RB O
, , O
the DT O
invention NN O
is VBZ O
concerned VBN O
with IN O
cosmetic JJ O
or CC O
pharmaceutical JJ O
compositions NNS O
comprising VBG O
at IN O
least JJS O
one CD O
fatty JJ B-NP
acid NN I-NP
or CC O
a DT O
salt NN O
, , O
ester NN B-NP
or CC O
amide IN B-NP
with IN O
the DT O
definitions NNS O
and CC O
preferences NNS O
as IN O
given VBN O
above IN O
, , O
and CC O
optionally RB O
one CD O
retinoid NN B-NP
, , O
for IN O
the DT O
treatment NN O
or CC O
prevention NN O
of IN O
symptoms NNS O
caused VBN O
by IN O
negative JJ O
developments NNS O
of IN O
the DT O
physiological JJ O
homeostasis NN O
of IN O
healthy JJ O
skin NN O
, , O
as RB O
well RB O
as IN O
for IN O
the DT O
promotion NN O
of IN O
hair NN O
growth NN O
and CC O
protection NN O
from IN O
hair NN O
loss NN O
. . O

Treatment NNP O
or CC O
prevention NN O
of IN O
symptoms NNS O
caused VBN O
by IN O
negative JJ O
developments NNS O
of IN O
the DT O
physiological JJ O
homeostasis NN O
of IN O
healthy JJ O
skin NN O
comprises VBZ O
treatment NN O
or CC O
prevention NN O
of IN O
wrinkles NNS O
or CC O
dry JJ O
skin NN O
or CC O
sensitive JJ O
skin NN O
, , O
thickening NN O
of IN O
the DT O
epidermis NN O
, , O
inhibition NN O
of IN O
senescence NN O
of IN O
skin NN O
cells NNS O
, , O
prevention NN O
or CC O
treatment NN O
of IN O
photodamage NN O
, , O
prevention NN O
or CC O
treatment NN O
of IN O
oxidative JJ O
stress NN O
phenomena NNS O
, , O
prevention NN O
or CC O
treatment NN O
of IN O
cellulite NN O
, , O
prevention NN O
and CC O
treatment NN O
of IN O
disturbances NNS O
in IN O
ceramide JJ O
and CC O
lipid JJ O
synthesis NN O
, , O
prevention NN O
of IN O
excess JJ O
sebum JJ O
production NN O
, , O
reduction NN O
of IN O
activities NNS O
of IN O
matrix NN O
metallo NN O
proteases NNS O
or CC O
other JJ O
proteases NNS O
in IN O
the DT O
skin NN O
, , O
treatment NN O
and CC O
prevention NN O
of IN O
inflammatory JJ O
skin NN O
conditions NNS O
including VBG O
acne NN O
( -LRB- O
= SYM O
anti-acne JJ O
) -RRB- O
, , O
atopic JJ O
eczema NN O
, , O
polymorphic JJ O
light NN O
eruption NN O
, , O
psoriasis NN O
and CC O
vertiligo NN O
. . O

In IN O
still RB O
another DT O
aspect NN O
, , O
the DT O
invention NN O
is VBZ O
concerned VBN O
with IN O
a DT O
method NN O
of IN O
treatment NN O
or CC O
prevention NN O
of IN O
symptoms NNS O
caused VBN O
by IN O
negative JJ O
developments NNS O
of IN O
the DT O
physiological JJ O
homeostasis NN O
of IN O
healthy JJ O
skin NN O
as RB O
well RB O
as IN O
treatment NN O
or CC O
prevention NN O
of IN O
itchy NN O
or CC O
irritated JJ O
skin NN O
and CC O
of IN O
promotion NN O
of IN O
hair NN O
growth NN O
and CC O
of IN O
protection NN O
from IN O
hair NN O
loss NN O
which WDT O
method NN O
provides VBZ O
topically RB O
administering VBG O
to TO O
a DT O
person NN O
in IN O
need NN O
of IN O
such JJ O
treatment NN O
or CC O
prevention NN O
an DT O
effective JJ O
amount NN O
of IN O
a DT O
fatty JJ B-NP
acid NN I-NP
or CC O
a DT O
salt NN O
, , O
ester NN B-NP
or CC O
amide IN B-NP
with IN O
the DT O
definitions NNS O
and CC O
preferences NNS O
as IN O
given VBN O
above IN O
, , O
optionally RB O
and CC O
preferably RB O
in IN O
combination NN O
with IN O
a DT O
retinoid JJ B-NP
and CC O
preferably RB O
in IN O
the DT O
form NN O
of IN O
a DT O
cosmetic JJ O
or CC O
pharmaceutical JJ O
composition NN O
according VBG O
to TO O
the DT O
invention NN O
. . O

A DT O
preferred JJ O
embodiment NN O
of IN O
the DT O
present JJ O
invention NN O
is VBZ O
a DT O
method NN O
of IN O
treating VBG O
or CC O
preventing VBG O
wrinkles NNS O
or CC O
human JJ O
dry JJ O
skin NN O
or CC O
sensitive JJ O
skin NN O
, , O
of IN O
promoting VBG O
hair NN O
growth NN O
, , O
of IN O
protecting VBG O
from IN O
hair NN O
loss NN O
and CC O
of IN O
thickening VBG O
the DT O
epidermis NN O
, , O
which WDT O
method NN O
comprises VBZ O
the DT O
step NN O
of IN O
topically RB O
administering VBG O
to TO O
a DT O
person NN O
in IN O
need NN O
of IN O
such JJ O
treatment NN O
or CC O
prevention NN O
an DT O
effective JJ O
amount NN O
of IN O
a DT O
fatty JJ B-NP
acid NN I-NP
or CC O
a DT O
salt NN O
, , O
ester NN B-NP
or CC O
amide IN B-NP
with IN O
the DT O
definitions NNS O
and CC O
preferences NNS O
as IN O
given VBN O
above IN O
, , O
optionally RB O
and CC O
preferably RB O
in IN O
combination NN O
with IN O
a DT O
retinoid NN B-NP
. . O

A DT O
further JJ O
object NN O
of IN O
the DT O
present JJ O
invention NN O
is VBZ O
a DT O
method NN O
for IN O
the DT O
prevention NN O
or CC O
treatment NN O
of IN O
pigmentation NN O
disorders NNS O
and/or CC O
for IN O
providing VBG O
an DT O
even JJ O
skin NN O
tone NN O
, , O
which WDT O
method NN O
comprises VBZ O
the DT O
step NN O
of IN O
topically RB O
administering VBG O
to TO O
a DT O
person NN O
in IN O
need NN O
of IN O
such JJ O
prevention NN O
or CC O
treatment NN O
an DT O
effective JJ O
amount NN O
of IN O
a DT O
composition NN O
according VBG O
to TO O
the DT O
present JJ O
invention NN O
as IN O
defined VBN O
above IN O
, , O
wherein WRB O
the DT O
composition NN O
contains VBZ O
a DT O
retinoid NN B-NP
. . O

Another DT O
object NN O
of IN O
the DT O
present JJ O
invention NN O
is VBZ O
a DT O
method NN O
for IN O
fortifying VBG O
the DT O
pigmentation NN O
which WDT O
method NN O
comprises VBZ O
the DT O
step NN O
of IN O
topically RB O
administering VBG O
to TO O
a DT O
person NN O
in IN O
need NN O
of IN O
such JJ O
fortification IN O
an DT O
effective JJ O
amount NN O
of IN O
a DT O
composition NN O
according VBG O
to TO O
the DT O
present JJ O
invention NN O
as IN O
defined VBN O
above IN O
and CC O
topically RB O
administering VBG O
a DT O
tanning NN O
active JJ O
, , O
wherein WRB O
the DT O
tanning NN O
active JJ O
may MD O
be VB O
administered VBN O
before IN O
, , O
after IN O
or CC O
simultaneously RB O
with IN O
the DT O
administration NN O
of IN O
the DT O
effective JJ O
amount NN O
of IN O
the DT O
composition NN O
according VBG O
to TO O
the DT O
present JJ O
invention NN O
, , O
and CC O
wherein WRB O
any DT O
retinoid NN B-NP
is VBZ O
essentially RB O
absent JJ O
in IN O
such JJ O
a DT O
composition NN O
. . O

The DT O
term NN O
'an VBZ O
effective JJ O
amount NN O
' '' O
refers VBZ O
to TO O
an DT O
amount NN O
necessary JJ O
to TO O
obtain VB O
a DT O
physiological JJ O
effect NN O
. . O

The DT O
physiological JJ O
effect NN O
may MD O
be VB O
achieved VBN O
by IN O
one CD O
application NN O
dose NN O
or CC O
by IN O
repeated VBN O
applications NNS O
. . O

The DT O
dosage NN O
administered VBN O
may MD O
, , O
of IN O
course NN O
, , O
vary VBP O
depending VBG O
upon IN O
known VBN O
factors NNS O
, , O
such JJ O
as IN O
the DT O
physiological JJ O
characteristics NNS O
of IN O
the DT O
particular JJ O
composition NN O
comprising VBG O
the DT O
fatty JJ B-NP
acid NN I-NP
or CC O
a DT O
salt NN O
, , O
ester NN B-NP
or CC O
amide IN B-NP
with IN O
the DT O
definitions NNS O
and CC O
preferences NNS O
as IN O
given VBN O
above IN O
, , O
optionally RB O
in IN O
combination NN O
with IN O
a DT O
retinoid NN B-NP
and CC O
its PRP$ O
mode NN O
and CC O
route NN O
of IN O
administration NN O
; : O
the DT O
age NN O
, , O
health NN O
and CC O
weight NN O
of IN O
the DT O
recipient NN O
; : O
the DT O
nature NN O
and CC O
extent NN O
of IN O
the DT O
symptoms NNS O
; : O
the DT O
kind NN O
of IN O
concurrent JJ O
treatment NN O
; : O
the DT O
frequency NN O
of IN O
treatment NN O
; : O
and CC O
the DT O
effect NN O
desired VBN O
and CC O
can MD O
be VB O
adjusted VBN O
by IN O
a DT O
person NN O
skilled JJ O
in IN O
the DT O
art NN O
. . O

In IN O
another DT O
embodiment NN O
, , O
the DT O
compositions NNS O
according VBG O
to TO O
the DT O
present JJ O
invention NN O
can MD O
be VB O
used VBN O
for IN O
the DT O
treatment NN O
or CC O
prevention NN O
of IN O
symptoms NNS O
caused VBN O
by IN O
negative JJ O
developments NNS O
of IN O
the DT O
physiological JJ O
homeostasis NN O
of IN O
healthy JJ O
skin NN O
as IN O
defined VBN O
above RB O
, , O
as RB O
well RB O
as IN O
for IN O
the DT O
promotion NN O
of IN O
hair NN O
growth NN O
and CC O
protection NN O
from IN O
hair NN O
loss NN O
. . O

The DT O
compositions NNS O
according VBG O
to TO O
the DT O
present JJ O
invention NN O
can MD O
further RB O
be VB O
used VBN O
for IN O
the DT O
treatment NN O
or CC O
prevention NN O
of IN O
itchy NN O
or CC O
irritated JJ O
skin NN O
or CC O
for IN O
fortifying VBG O
the DT O
pigmentation NN O
( -LRB- O
the DT O
latter NN O
, , O
however RB O
, , O
only RB O
, , O
if IN O
no DT O
retinoid NN B-NP
but CC O
a DT O
tanning NN O
active JJ O
is VBZ O
present JJ O
. . O
) -RRB- O
. . O

If IN O
retinoid NN B-NP
is VBZ O
, , O
however RB O
, , O
present JJ O
in IN O
the DT O
composition NN O
of IN O
this DT O
invention NN O
the DT O
composition NN O
can MD O
be VB O
used VBN O
for IN O
the DT O
prevention NN O
or CC O
treatment NN O
of IN O
pigmentation NN O
disorders NNS O
and/or CC O
for IN O
providing VBG O
an DT O
even RB O
skin NN O
tone NN O
, , O
since IN O
the DT O
boosting VBG O
of IN O
retinoids NNS B-NP
by IN O
the DT O
fatty JJ B-NP
acids NNS I-NP
or CC O
a DT O
salt NN O
, , O
ester NN B-NP
or CC O
amide JJ B-NP
thereof , O
as IN O
defined VBN O
above IN O
may MD O
lead VB O
to TO O
a DT O
depigmentation NN O
. . O

Preverably RB O
the DT O
compositions NNS O
of IN O
the DT O
present JJ O
invention NN O
are VBP O
used VBN O
for IN O
the DT O
treatment NN O
or CC O
prevention NN O
of IN O
wrinkles NNS O
or CC O
dry JJ O
skin NN O
or CC O
sensitive JJ O
skin NN O
, , O
for IN O
the DT O
promotion NN O
of IN O
hair NN O
growth NN O
, , O
for IN O
the DT O
protection NN O
from IN O
hair NN O
loss NN O
, , O
for IN O
thickening VBG O
the DT O
epidermis NN O
, , O
( -LRB- O
if IN O
retinoid NN B-NP
is VBZ O
present JJ O
) -RRB- O
for IN O
the DT O
prevention NN O
or CC O
treatment NN O
of IN O
pigmentation NN O
disorders NNS O
and/or CC O
for IN O
providing VBG O
an DT O
even JJ O
skin NN O
tone NN O
, , O
and/or CC O
( -LRB- O
if IN O
retinoid NN B-NP
is VBZ O
absent JJ O
and CC O
a DT O
tanning NN O
active JJ O
is VBZ O
present JJ O
) -RRB- O
for IN O
fortifying VBG O
the DT O
pigmentation NN O
. . O

Thus RB O
the DT O
composition NN O
according VBG O
to TO O
the DT O
present JJ O
invention NN O
, , O
i IN O
.e NN O
. . O
the DT O
fatty NN B-NP
acids NNS I-NP
or CC O
a DT O
salt NN O
, , O
ester NN B-NP
or CC O
amide JJ B-NP
thereof , O
with IN O
the DT O
definitions NNS O
and CC O
preferences NNS O
as IN O
defined VBN O
above IN O
may MD O
fortify VB O
the DT O
pigmentation NN O
by IN O
enhancing VBG O
the DT O
effect NN O
of IN O
a DT O
tanning NN O
active JJ O
. . O

While IN O
, , O
typically RB O
, , O
the DT O
cosmetic NN O
or CC O
pharmaceutical JJ O
compositions NNS O
according VBG O
to TO O
the DT O
present JJ O
invention NN O
contain VBP O
one CD O
of IN O
the DT O
fatty JJ B-NP
acids NNS I-NP
as IN O
defined VBN O
above IN O
, , O
the DT O
invention NN O
is VBZ O
not RB O
limited VBN O
to TO O
that DT O
particular JJ O
aspect NN O
and CC O
two CD O
or CC O
more JJR O
fatty JJ B-NP
acids NNS I-NP
or CC O
a DT O
salt NN O
, , O
ester NN B-NP
or CC O
amide JJ B-NP
thereof , O
as IN O
defined VBN O
above IN O
may MD O
be VB O
present JJ O
. . O

As IN O
stated VBN O
above IN O
, , O
a DT O
retinoid NN B-NP
may MD O
be VB O
additionally VBG O
present JJ O
, , O
providing VBG O
an DT O
additive JJ O
or CC O
synergistic JJ O
cosmetic JJ O
effect NN O
, , O
i IN O
.e NN O
. . O
an DT O
improvement NN O
or CC O
prevention NN O
of IN O
symptoms NNS O
caused VBN O
by IN O
negative JJ O
developments NNS O
of IN O
the DT O
physiological JJ O
homeostasis NN O
of IN O
healthy JJ O
skin NN O
, , O
as RB O
well RB O
as IN O
promotion NN O
of IN O
hair NN O
growth NN O
and CC O
protection NN O
from IN O
hair NN O
loss NN O
. . O

Again RB O
, , O
two CD O
or CC O
more JJR O
retinoids NNS B-NP
may MD O
be VB O
present JJ O
. . O

If IN O
a DT O
retinoid NN B-NP
is VBZ O
present JJ O
in IN O
the DT O
compositions NNS O
of IN O
the DT O
present JJ O
invention NN O
, , O
the DT O
ratio NN O
of IN O
the DT O
fatty JJ B-NP
acid NN I-NP
or CC O
a DT O
salt NN O
, , O
ester NN B-NP
or CC O
amide IN B-NP
with IN O
the DT O
definitions NNS O
and CC O
preferences NNS O
as IN O
given VBN O
above IN O
) -RRB- O
to TO O
the DT O
retinoid NN B-NP
is VBZ O
suitably RB O
from IN O
about IN O
1000:1 CD O
to TO O
1 CD O
:1000 CD O
, , O
more RBR O
preferably RB O
from IN O
about IN O
100:1 CD O
to TO O
1 CD O
:100 CD O
and CC O
in IN O
particular JJ O
from IN O
about IN O
30 CD O
:1 CD O
to TO O
1 CD O
:30 CD O
by IN O
weight NN O
. . O

The DT O
fatty JJ B-NP
acids NNS I-NP
or CC O
a DT O
salt NN O
, , O
ester NN B-NP
or CC O
amide JJ B-NP
thereof , O
as IN O
defined VBN O
above IN O
show NN O
also RB O
an DT O
additive JJ O
or CC O
synergistic JJ O
effect NN O
with IN O
retinoids NNS B-NP
which WDT O
are VBP O
already RB O
present JJ O
in IN O
the DT O
human JJ O
skin NN O
. . O

In IN O
the DT O
compositions NNS O
provided VBN O
by IN O
the DT O
present JJ O
invention NN O
, , O
the DT O
amount NN O
of IN O
the DT O
fatty JJ B-NP
acid NN I-NP
or CC O
a DT O
salt NN O
, , O
ester NN B-NP
or CC O
amide IN B-NP
with IN O
the DT O
definitions NNS O
and CC O
preferences NNS O
as IN O
given VBN O
above IN O
is VBZ O
suitably RB O
from IN O
about IN O
0.0001 CD O
to TO O
about IN O
50 CD O
% NN O
, , O
preferably RB O
from IN O
about IN O
0.001 CD O
to TO O
about IN O
20 CD O
% NN O
by IN O
weight NN O
of IN O
the DT O
total JJ O
composition NN O
. . O

More RBR O
preferably RB O
, , O
the DT O
fatty JJ B-NP
acid NN I-NP
as IN O
defined VBN O
above IN O
are VBP O
contained VBN O
in IN O
the DT O
composition NN O
in IN O
an DT O
amount NN O
of IN O
about IN O
0.01 CD O
% NN O
by IN O
weight NN O
to TO O
about IN O
1 CD O
% NN O
by IN O
weight NN O
, , O
most JJS O
preferably RB O
in IN O
an DT O
amount NN O
of IN O
about RB O
0.5 CD O
% NN O
by IN O
weight NN O
. . O

If IN O
a DT O
retinoid NN B-NP
or CC O
derivative JJ O
thereof , O
is VBZ O
present JJ O
, , O
the DT O
amount NN O
of IN O
the DT O
latter NN O
is VBZ O
suitably RB O
from IN O
about IN O
0.0001 CD O
to TO O
about IN O
50 CD O
% NN O
by IN O
weight NN O
, , O
preferably RB O
from IN O
about IN O
0.001 CD O
to TO O
about IN O
20 CD O
% NN O
by IN O
weight NN O
, , O
most JJS O
preferably RB O
in IN O
an DT O
amount NN O
of IN O
about IN O
0.01 CD O
to TO O
about IN O
1 CD O
weight NN O
% NN O
, , O
in IN O
particular JJ O
in IN O
an DT O
amount NN O
of IN O
about RB O
0.1 CD O
% NN O
by IN O
weight NN O
, , O
based VBN O
on IN O
the DT O
total JJ O
amount NN O
of IN O
the DT O
composition NN O
. . O

Preferred VBN O
according VBG O
to TO O
the DT O
invention NN O
is VBZ O
a DT O
composition NN O
comprising VBG O
the DT O
fatty JJ B-NP
acid NN I-NP
or CC O
a DT O
salt NN O
, , O
ester NN B-NP
or CC O
amide IN B-NP
with IN O
the DT O
definitions NNS O
and CC O
preferences NNS O
as IN O
given VBN O
above IN O
in IN O
an DT O
amount NN O
of IN O
about RB O
0.5 CD O
% NN O
by IN O
weight NN O
and CC O
a DT O
retinoid NN B-NP
or CC O
derivative JJ O
thereof , O
in IN O
an DT O
amount NN O
of IN O
about RB O
0.1 CD O
% NN O
by IN O
weight NN O
, , O
based VBN O
on IN O
the DT O
total JJ O
amount NN O
of IN O
the DT O
composition NN O
. . O

The DT O
term NN O
" `` O
cosmetic JJ O
composition NN O
" '' O
as IN O
used VBN O
herein IN O
e.g NN O
. . O

refers VBZ O
to TO O
topical JJ O
compositions NNS O
for IN O
care NN O
of IN O
the DT O
human JJ O
skin NN O
, , O
see VBP O
also RB O
the DT O
heading VBG O
" `` O
Kosmetika NNP O
" '' O
in IN O
Rompp NNP O
Lexikon NNP O
Chemie NNP O
, , O
10th JJ O
edition NN O
1997 CD O
, , O
Georg NNP O
Thieme NNP O
Verlag NNP O
Stuttgart NNP O
, , O
New NNP O
York NNP O
. . O

Regarding VBG O
the DT O
kind NN O
of IN O
the DT O
topical JJ O
( -LRB- O
cosmetic NN O
or CC O
pharmaceutical JJ O
) -RRB- O
compositions NNS O
and CC O
the DT O
preparation NN O
of IN O
the DT O
topical JJ O
compositions NNS O
as RB O
well RB O
as IN O
for IN O
further JJ O
suitable JJ O
additives NNS O
, , O
it PRP O
can MD O
be VB O
referred VBN O
to TO O
the DT O
pertinent JJ O
literature NN O
, , O
e.g NN O
. . O
to TO O
Novak NNP O
G.A. NNP O
, , O
Die NNP O
kosmetischen NN O
Praparate NNP O
- : O
Band NNP O
2 CD O
, , O
Die FW O
kosmetischen FW O
Praparate FW O
- : O
Rezeptur NN O
, , O
Rohstoffe NNP O
, , O
wissenschaftliche NN O
Grundlagen NNP O
( -LRB- O
Verlag NNP O
fur NN O
Chem NNP O
. . O

Industrie NNP O
H. NNP O
Ziolkowski NNP O
KG NNP O
, , O
Augsburg NNP O
) -RRB- O
. . O

The DT O
amount NN O
of IN O
the DT O
cosmetic NN O
or CC O
pharmaceutical JJ O
composition NN O
according VBG O
to TO O
the DT O
invention NN O
, , O
which WDT O
is VBZ O
to TO O
be VB O
applied VBN O
to TO O
the DT O
skin NN O
depends VBZ O
on IN O
the DT O
concentration NN O
of IN O
the DT O
active JJ O
ingredients NNS O
in IN O
the DT O
compositions NNS O
and CC O
the DT O
desired VBN O
cosmetic NN O
or CC O
pharmaceutical JJ O
effect NN O
. . O

For IN O
example NN O
, , O
application NN O
can MD O
be VB O
such JJ O
that IN O
a DT O
creme NN O
is VBZ O
applied VBN O
to TO O
the DT O
skin NN O
. . O

A DT O
creme NN O
is VBZ O
usually RB O
applied VBN O
in IN O
an DT O
amount NN O
of IN O
2 CD O
mg NN O
creme/cm<2> VBG O
skin NN O
. . O

The DT O
amount NN O
of IN O
the DT O
composition NN O
which WDT O
is VBZ O
applied VBN O
to TO O
the DT O
skin NN O
is VBZ O
, , O
however RB O
, , O
not RB O
critical JJ O
, , O
and CC O
if IN O
with IN O
a DT O
certain JJ O
amount NN O
of IN O
applied VBN O
composition NN O
the DT O
desired VBN O
effect NN O
cannot MD O
be VB O
achieved VBN O
, , O
a DT O
higher JJR O
concentration NN O
of IN O
the DT O
active JJ O
ingredients NNS O
can MD O
be VB O
used VBN O
e.g RB O
. . O
by IN O
applying VBG O
more JJR O
of IN O
the DT O
composition NN O
or CC O
by IN O
applying VBG O
compositions NNS O
which WDT O
contain VBP O
more JJR O
active JJ O
ingredient NN O
. . O

The DT O
cosmetic JJ O
or CC O
pharmaceutical JJ O
composition NN O
according VBG O
to TO O
the DT O
invention NN O
is VBZ O
preferably RB O
applied VBN O
at IN O
least JJS O
once RB O
per IN O
day NN O
, , O
e.g NN O
. . O

twice RB O
or CC O
three CD O
times NNS O
a DT O
day NN O
. . O

Usually RB O
it PRP O
takes VBZ O
at IN O
least JJS O
two CD O
weeks NNS O
until IN O
the DT O
desired VBN O
effect NN O
is VBZ O
achieved VBN O
. . O

However RB O
, , O
it PRP O
can MD O
take VB O
several JJ O
weeks NNS O
or CC O
even RB O
months NNS O
until IN O
the DT O
desired VBN O
effect NN O
is VBZ O
fully RB O
maximized VBN O
. . O

The DT O
compositions NNS O
of IN O
the DT O
present JJ O
invention NN O
contain VBP O
the DT O
fatty NN B-NP
acids NNS I-NP
or CC O
a DT O
salt NN O
, , O
ester NN B-NP
or CC O
amide JJ B-NP
thereof , O
with IN O
the DT O
definitions NNS O
and CC O
preferences NNS O
as IN O
defined VBN O
above IN O
with IN O
cosmetically NN O
or CC O
pharmaceutically RB O
acceptable JJ O
excipients NNS O
or CC O
diluents NNS O
. . O

If IN O
nothing NN O
else RB O
is VBZ O
stated VBN O
, , O
the DT O
excipients NNS O
, , O
additives NNS O
, , O
diluents NNS O
, , O
etc FW O
. . O
mentioned VBN O
in IN O
the DT O
following VBG O
are VBP O
suitable JJ O
for IN O
cosmetic JJ O
compositions NNS O
. . O

If IN O
nothing NN O
else RB O
is VBZ O
stated VBN O
, , O
in IN O
this DT O
application NN O
parts NNS O
and CC O
percentages NNS O
are VBP O
per IN O
weight NN O
and CC O
are VBP O
based VBN O
on IN O
the DT O
total JJ O
weight NN O
of IN O
the DT O
composition NN O
. . O

Preferably RB O
, , O
the DT O
cosmetic NN O
or CC O
pharmaceutical JJ O
compositions NNS O
of IN O
the DT O
present JJ O
invention NN O
are VBP O
topical JJ O
compositions NNS O
in IN O
the DT O
form NN O
of IN O
a DT O
suspension NN O
or CC O
dispersion NN O
in IN O
solvents NNS O
or CC O
fatty JJ O
substances NNS O
, , O
or CC O
alternatively RB O
in IN O
the DT O
form NN O
of IN O
an DT O
emulsion NN O
or CC O
micro JJ O
emulsion NN O
( -LRB- O
in IN O
particular JJ O
of IN O
O/W NNP O
or CC O
VWO NNP O
type NN O
, , O
0/W/O NNP O
or CC O
W/O/W-type JJ O
) -RRB- O
, , O
PET-emulsions NNS O
, , O
multiple JJ O
emulsions NNS O
, , O
bickering VBG O
emulsions NNS O
, , O
hydrogels NNS O
, , O
alcoholic JJ O
gels NNS O
, , O
lipogels NNS O
, , O
one CD O
or CC O
multiphase VB O
solutions NNS O
or CC O
a DT O
vesicular JJ O
dispersion NN O
and CC O
other JJ O
usual JJ O
compositions NNS O
, , O
which WDT O
can MD O
also RB O
be VB O
applied VBN O
by IN O
pens NNS O
, , O
as IN O
masks NNS O
or CC O
as IN O
sprays NNS O
. . O

The DT O
emulsions NNS O
can MD O
also RB O
contain VB O
anionic JJ O
, , O
nonionic JJ O
, , O
cationic JJ O
or CC O
amphoteric JJ O
surfactant( NN O
s VBZ O
) -RRB- O
. . O

Preferred VBN O
compositions NNS O
according VBG O
to TO O
the DT O
invention NN O
are VBP O
skin NN O
care NN O
preparations NNS O
, , O
hair-care JJ O
preparations NNS O
, , O
decorative JJ O
preparations NNS O
, , O
light JJ O
protection NN O
preparations NNS O
and CC O
functional JJ O
preparations NNS O
. . O

Examples NNS O
of IN O
skin NN O
care NN O
preparations NNS O
are VBP O
, , O
in IN O
particular JJ O
, , O
body NN O
oils NNS O
, , O
body NN O
lotions NNS O
, , O
body NN O
gels NNS O
, , O
treatment NN O
creams NNS O
, , O
skin NN O
protection NN O
ointments NNS O
, , O
shaving VBG O
preparations NNS O
, , O
such JJ O
as IN O
shaving NN O
foams NNS O
or CC O
gels NNS O
, , O
skin NN O
powders NNS O
such JJ O
as IN O
baby NN O
powder NN O
, , O
moisturizing JJ O
gels NNS O
, , O
moisturizing JJ O
sprays NNS O
, , O
revitalizing VBG O
body NN O
sprays NNS O
, , O
cellulite JJ O
gels NNS O
, , O
anti NNS O
acne VBP O
preparations NNS O
and CC O
peeling JJ O
preparations NNS O
. . O

Examples NNS O
of IN O
hair NN O
care NN O
preparations NNS O
are VBP O
, , O
for IN O
example NN O
, , O
hair-washing JJ O
preparations NNS O
in IN O
the DT O
form NN O
of IN O
shampoos NNS O
, , O
hair NN O
conditioners NNS O
, , O
hair-care JJ O
preparations NNS O
, , O
e NN O
. . O
g NN O
. . O
treatment NN O
preparations NNS O
, , O
pre-treatment JJ O
preparations NNS O
, , O
hair NN O
tonics NNS O
, , O
styling VBG O
creams NNS O
, , O
styling VBG O
gels NNS O
, , O
pomades NNS O
, , O
hair NN O
rinses NNS O
, , O
treatment NN O
packs NNS O
, , O
intensive JJ O
hair NN O
treatments NNS O
, , O
hair-straightening JJ O
preparations NNS O
, , O
liquid JJ O
hair NN O
- : O
setting NN O
preparations NNS O
, , O
hair NN O
foams NNS O
and CC O
hairsprays NNS O
and CC O
lacquers NNS O
, , O
perming VBG O
agents NNS O
, , O
hair NN O
gels NNS O
, , O
hair NN O
fixatives NNS O
and CC O
hair NN O
dying VBG O
or CC O
bleaching VBG O
agents NNS O
. . O

Examples NNS O
of IN O
decorative JJ O
preparations NNS O
are VBP O
in IN O
particular JJ O
lipstick NN O
, , O
eye NN O
shadow NN O
, , O
mascaras NNS O
, , O
dry JJ O
and CC O
moist JJ O
make-up NN O
, , O
rouge JJ O
, , O
powders NNS O
, , O
and CC O
suntan JJ O
lotions NNS O
. . O

Examples NNS O
of IN O
functional JJ O
preparations NNS O
are VBP O
cosmetic JJ O
or CC O
pharmaceutical JJ O
compositions NNS O
containing VBG O
active JJ O
ingredients NNS O
such JJ O
as IN O
hormone NN O
preparations NNS O
, , O
vitamin NN O
preparations NNS O
, , O
vegetable NN O
extract VB O
preparations NNS O
, , O
anti-ageing JJ O
preparations NNS O
, , O
and CC O
antimicrobial JJ O
( -LRB- O
antibacterial JJ O
or CC O
antifungal JJ O
) -RRB- O
preparations NNS O
without IN O
being VBG O
limited JJ O
thereto NN O
. . O

Cosmetic JJ O
compositions NNS O
in IN O
accordance NN O
with IN O
the DT O
invention NN O
can MD O
be VB O
in IN O
the DT O
form NN O
of IN O
a DT O
liquid NN O
, , O
a DT O
lotion NN O
, , O
a DT O
thickened JJ O
lotion NN O
, , O
a DT O
gel NN O
, , O
a DT O
cream NN O
, , O
a DT O
milk NN O
, , O
an DT O
ointment NN O
, , O
a DT O
paste NN O
, , O
a DT O
powder NN O
, , O
a DT O
makeup NN O
, , O
or CC O
a DT O
solid JJ O
tube NN O
stick NN O
and CC O
can MD O
be VB O
optionally RB O
be VB O
packaged VBN O
as IN O
an DT O
aerosol NN O
and CC O
can MD O
be VB O
provided VBN O
in IN O
the DT O
form NN O
of IN O
a DT O
mousse NN O
such JJ O
as IN O
a DT O
aerosol NN O
mousse NN O
, , O
a DT O
foam NN O
or CC O
a DT O
spray NN O
foams NNS O
, , O
sprays NNS O
, , O
sticks NNS O
, , O
a DT O
gel NN O
, , O
a DT O
plaster NN O
, , O
a DT O
powder NN O
, , O
a DT O
cleanser NN O
, , O
a DT O
soap NN O
or CC O
aerosols NNS O
or CC O
wipes NNS O
. . O

The DT O
compositions NNS O
of IN O
the DT O
invention NN O
can MD O
also RB O
contain VB O
usual JJ O
cosmetic NN O
or CC O
pharmaceutical JJ O
adjuvants NNS O
and CC O
additives NNS O
, , O
such JJ O
as IN O
preservatives NNS O
/ IN O
antioxidants NNS O
, , O
fatty JJ O
substances NNS O
/ IN O
oils NNS O
, , O
water NN B-NP
, , O
organic JJ O
solvents NNS O
, , O
silicones NNS B-NP
, , O
thickeners NNS O
, , O
softeners NNS O
, , O
emulsifiers NNS O
, , O
sunscreens NNS O
, , O
antifoaming VBG O
agents NNS O
, , O
moisturizers NNS O
, , O
fragrances NNS O
, , O
surfactants NNS O
, , O
fillers NNS O
, , O
sequestering VBG O
agents NNS O
, , O
anionic JJ O
, , O
cationic JJ O
, , O
nonionic JJ O
or CC O
amphoteric JJ O
polymers NNS O
or CC O
mixtures NNS O
thereof RB O
, , O
propellents NNS O
, , O
acidifying VBG O
or CC O
basifying VBG O
agents NNS O
, , O
dyes NNS O
, , O
colorants NNS O
, , O
pigments NNS O
or CC O
nanopigments NNS O
, , O
e.g NN O
. . O

those DT O
suited VBN O
for IN O
providing VBG O
a DT O
photoprotective JJ O
effect NN O
by IN O
physically RB O
blocking VBG O
out IN O
ultraviolet NN O
radiation NN O
, , O
or CC O
any DT O
other JJ O
ingredients NNS O
usually RB O
formulated VBN O
into IN O
cosmetics NNS O
or CC O
medicaments NNS O
. . O

An DT O
additional JJ O
amount NN O
of IN O
antioxidants NNS O
/ IN O
preservatives NNS O
is VBZ O
generally RB O
preferred VBN O
. . O

Based VBN O
on IN O
the DT O
invention NN O
all DT O
known VBN O
antioxidants NNS O
usually RB O
formulated VBN O
into IN O
cosmetics NNS O
or CC O
medicaments NNS O
can MD O
be VB O
used VBN O
. . O

Especially RB O
preferred JJ O
are VBP O
antioxidants NNS O
chosen VBN O
from IN O
the DT O
group NN O
consisting VBG O
of IN O
amino NN B-NP
acids NNS I-NP
( -LRB- O
e NN O
.g NN O
. . O

glycine NN B-NP
, , O
histidine NN B-NP
, , O
tyrosine NN B-NP
, , O
tryptophane NN B-NP
) -RRB- O
and CC O
their PRP$ O
derivatives NNS O
, , O
imidazole NN B-NP
( -LRB- O
e NN O
.g NN O
. . O

urocanic JJ B-NP
acid NN I-NP
) -RRB- O
and CC O
derivatives VBZ O
, , O
peptides NNS B-NP
such JJ O
as IN O
D,L-carnosine NNP B-NP
, , O
D- NNP B-NP
carnosine NN I-NP
, , O
L-carnosine NNP B-NP
and CC O
derivatives NNS O
( -LRB- O
e NN O
.g NN O
. . O

anserine NN B-NP
) -RRB- O
, , O
carotenoids VBZ B-NP
, , O
carotenes NNS B-NP
( -LRB- O
e NN O
.g NN O
. . O

[alpha] SYM B-NP
- : I-NP
carotene NN I-NP
, , O
[beta]-carotene NN B-NP
, , O
lycopene NN B-NP
) -RRB- O
and CC O
derivatives VBZ O
, , O
chlorogenic JJ B-NP
acid NN I-NP
and CC O
derivatives NNS O
, , O
lipoic JJ B-NP
acid NN I-NP
and CC O
derivatives NNS O
( -LRB- O
e NN O
.g NN O
. . O

dihydrolipoic JJ B-NP
acid NN I-NP
) -RRB- O
, , O
aurothioglucose NN B-NP
, , O
propylthiouracil NN B-NP
and CC O
other JJ O
thiols NNS B-NP
( -LRB- O
e NN O
.g NN O
. . O

thioredoxine NN B-NP
, , O
glutathione NN B-NP
, , O
cysteine NN B-NP
, , O
cystine NN B-NP
, , O
cystamine NN B-NP
and CC O
its PRP$ O
glycosyl-, JJ B-NP
N- NNP B-NP
acetyl-, NNS I-NP
methyl-, , B-NP
ethyl-, JJ B-NP
propyl-, JJ B-NP
amyl-, JJ B-NP
butyl- NNS B-NP
and CC O
lauryl-, NN B-NP
palmitoyl-; NN B-NP
oleyl-, JJ B-NP
y-linoleyl-, JJ O
cholesteryl- NNS B-NP
and CC O
glycerylester NN B-NP
) -RRB- O
and CC O
the DT O
salts NNS O
thereof RB O
, , O
dilaurylthiodipropionate JJ B-NP
, , O
distearylthiodipropionate JJ B-NP
, , O
thiodipropionic JJ B-NP
acid NN I-NP
and CC O
its PRP$ O
derivatives NNS O
(ester NN O
, , O
ether NN B-NP
, , O
peptides NNS B-NP
, , O
lipids NNS B-NP
, , O
nucleotides NNS B-NP
, , O
nucleosides NNS B-NP
and CC O
salts NNS O
) -RRB- O
as RB O
well RB O
as IN O
sulfoximine NN B-NP
compounds NNS O
( -LRB- O
such JJ O
as IN O
buthioninsulfoximine NN B-NP
, , O
homocysteinsulfoximine NN B-NP
, , O
buthioninsulfone NN B-NP
, , O
penta-, JJ B-NP
hexa-, JJ B-NP
heptathioninsulfoximine NN B-NP
) -RRB- O
in IN O
very RB O
low JJ O
compatible JJ O
doses NNS O
( -LRB- O
e NN O
.g NN O
. . O

pmol NN O
to TO O
[mu]mol/kg NNP O
) -RRB- O
, , O
additionally RB O
( -LRB- B-NP
metal)-chelators NNS I-NP
( -LRB- O
such JJ O
as IN O
[alpha]-hydroxyfatty JJ B-NP
acids NNS I-NP
, , O
palmic-, JJ B-NP
phytinic JJ B-NP
acid NN I-NP
, , O
lactoferrin VBG O
) -RRB- O
, , O
[beta]-hydroxyacids FW B-NP
( -LRB- O
such JJ O
as IN O
citric JJ B-NP
acid NN I-NP
, , O
lactic JJ B-NP
acid NN I-NP
, , O
malic JJ B-NP
acid NN I-NP
) -RRB- O
, , O
huminic JJ B-NP
acid NN I-NP
, , O
gallic JJ B-NP
acid NN I-NP
, , O
gallic JJ O
extracts NNS O
, , O
bilirubin NN B-NP
, , O
biliverdin NN B-NP
, , O
EDTA NNP B-NP
, , O
EGTA NNP B-NP
and CC O
its PRP$ O
derivatives NNS O
, , O
unsaturated JJ O
fatty NN B-NP
acids NNS I-NP
and CC O
their PRP$ O
derivatives NNS O
( -LRB- O
such JJ O
as IN O
[gamma]-linoleic JJ B-NP
acid NN I-NP
, , O
linolic JJ B-NP
acid NN I-NP
, , O
oleic JJ B-NP
acid NN I-NP
) -RRB- O
, , O
folic JJ B-NP
acid NN I-NP
and CC O
its PRP$ O
derivatives NNS O
, , O
ubiquinone NN B-NP
and CC O
ubiquinol NN B-NP
and CC O
their PRP$ O
derivatives NNS O
, , O
vitamin NN B-NP
C NNP I-NP
and CC O
derivatives NNS O
( -LRB- O
such JJ O
as IN O
ascorbylpalmitate NN B-NP
and CC O
ascorbyltetraisopalmitate NN B-NP
, , O
Mg- NNP B-NP
ascorbylphosphate NN I-NP
, , O
Na-ascorbylphosphate NNP B-NP
, , O
Na-ascorbylacetate NNP B-NP
) -RRB- O
, , O
tocopherol NN B-NP
and CC O
derivatives NNS O
( -LRB- O
such JJ O
as IN O
vitamin-E-acetate JJ B-NP
) -RRB- O
, , O
mixtures NNS O
of IN O
natural JJ O
or CC O
synthetic JJ O
vitamin NN B-NP
E NNP I-NP
, , O
vitamin NN B-NP
A NNP I-NP
and CC O
derivatives VBZ O
(vitamin-A-palmitate NNP O
and CC O
-acetate NN O
) -RRB- O
as RB O
well RB O
as IN O
coniferylbenzoat NN B-NP
, , O
rutinic JJ B-NP
acid NN I-NP
and CC O
derivatives NNS O
, , O
[alpha]-glycosylrutin NNP B-NP
, , O
ferulic JJ B-NP
acid NN I-NP
, , O

furfurylidenglucitol NN B-NP
, , O
carnosine NN B-NP
, , O
butylhydroxytoluene NN B-NP
, , O
butylhydroxyanisole NN B-NP
, , O
trihydroxybutyrophenone NN B-NP
, , O
urea NN B-NP
and CC O
its PRP$ O
derivatives NNS O
, , O
mannose NN B-NP
and CC O
derivatives NNS O
, , O
zinc NN B-NP
and CC O
derivatives NNS O
( -LRB- O
e NN O
.g NN O
. . O

ZnO NNP B-NP
, , O
ZnSO4 NNP B-NP
) -RRB- O
, , O
selenium NN B-NP
and CC O
derivatives NNS O
( -LRB- O
e NN O
.g NN O
. . O

selenomethionin NN B-NP
) -RRB- O
, , O
stilbenes NNS B-NP
and CC O
derivatives NNS O
( -LRB- O
such JJ O
as IN O
stilbenoxide NN B-NP
, , O
trans-stilbenoxide NN B-NP
) -RRB- O
and CC O
suitable JJ O
derivatives NNS O
( -LRB- O
salts NNS O
, , O
esters NNS B-NP
, , O
ethers NNS B-NP
, , O
sugars NNS O
, , O
nucleotides NNS B-NP
, , O
nucleosides NNS B-NP
, , O
peptides NNS B-NP
and CC O
lipids NNS B-NP
) -RRB- O
of IN O
the DT O
named VBN O
active JJ O
ingredients NNS O
. . O

One CD O
or CC O
more JJR O
pre NN O
- : O
servatives/antioxidants NNS O
may MD O
be VB O
present JJ O
in IN O
an DT O
amount NN O
about IN O
0.01 CD O
weight NN O
% NN O
to TO O
about IN O
10 CD O
weight NN O
% NN O
of IN O
the DT O
total JJ O
weight NN O
of IN O
the DT O
composition NN O
of IN O
the DT O
present JJ O
invention NN O
. . O

Preferably RB O
, , O
one CD O
or CC O
more JJR O
preservatives/antioxidants NNS O
are VBP O
present JJ O
in IN O
an DT O
amount NN O
about IN O
0.1 CD O
weight NN O
% NN O
to TO O
about IN O
1 CD O
weight NN O
% NN O
. . O

Typically RB O
topical JJ O
formulations NNS O
also RB O
contain VBP O
surface NN O
active JJ O
ingredients NNS O
like IN O
emulsifiers NNS O
, , O
solubilizers NNS O
and CC O
the DT O
like JJ O
. . O

An DT O
emulsifier NN O
enables VBZ O
two CD O
or CC O
more JJR O
immiscible JJ O
components NNS O
to TO O
be VB O
combined VBN O
homogeneously RB O
. . O

Moreover RB O
, , O
the DT O
emulsifier NN O
acts VBZ O
to TO O
stabilize VB O
the DT O
composition NN O
. . O

Emulsifiers NNS O
that WDT O
may MD O
be VB O
used VBN O
in IN O
the DT O
present JJ O
invention NN O
in IN O
order NN O
to TO O
form VB O
O/W NNP O
, , O
W/O NNP O
, , O
0/W/O NNP O
or CC O
W/O/W NNP O
emulsions NNS O
/ VBP O
microemulsions NNS O
include VBP O
sorbitan JJ B-NP
oleate NN I-NP
, , O
sorbitan JJ B-NP
sesquioleate NN I-NP
, , O
sorbitan JJ B-NP
isostearate NN I-NP
, , O
sorbitan JJ B-NP
trioleate NN I-NP
, , O
polyglyceryl-3-diisostearate JJ B-NP
, , O
polyglycerol NN B-NP
esters NNS I-NP
of IN O
oleic/isostearic JJ B-NP
acid NN B-NP
, , O
polyglyceryl-6 NN B-NP
hexaricinolate NN I-NP
, , O
polyglyceryl-4-oleate NN B-NP
, , O
polyglyceryl- NNS B-NP
4 CD I-NP
oleate/PEG-8 NNS I-NP
propylene NN B-NP
glycol NN I-NP
cocoate NN I-NP
, , O
oleamide JJ B-NP
DEA NNP I-NP
, , O
TEA NNP B-NP
myristate NN I-NP
, , O
TEA NNP B-NP
stearate NN I-NP
, , O
magnesium NN B-NP
stearate NN I-NP
, , O
sodium NN B-NP
stearate NN I-NP
, , O
potassium NN B-NP
laurate NN I-NP
, , O
potassium NN B-NP
ricinoleate NN I-NP
, , O
sodium NN B-NP
cocoate NN I-NP
, , O
sodium NN B-NP
tallowate NN I-NP
, , O
potassium NN B-NP
castorate NN I-NP
, , O
sodium NN B-NP
oleate NN I-NP
, , O
and CC O
mixtures NNS O
thereof RB O
. . O

Further RB O
suitable JJ O
emulsifiers NNS O
are VBP O
phosphate JJ B-NP
esters NNS I-NP
and CC O
the DT O
salts NNS O
thereof , O
such JJ O
as IN O
cetyl NN B-NP
phosphate NN I-NP
( -LRB- O
Amphisol<( JJ B-NP
R NN I-NP
) -RRB- I-NP
> IN I-NP
A) NNP I-NP
, , O
diethanolamine NN B-NP
cetyl NN I-NP
phosphate NN I-NP
( -LRB- O
Amphisol<( NNP B-NP
R NN I-NP
)> NN I-NP
) -RRB- O
, , O
potassium NN B-NP
cetyl NN I-NP
phosphate NN I-NP
( -LRB- O
Amphisol<( JJ B-NP
R NN I-NP
) -RRB- I-NP
> IN I-NP
K) NNP I-NP
, , O
sodium NN B-NP
glyceryl NN I-NP
oleate NN I-NP
phosphate NN I-NP
, , O
hydrogenated JJ O
vegetable NN O
glyceride NN B-NP
phosphates NNS I-NP
and CC O
mixtures NNS O
thereof RB O
. . O

Furthermore RB O
, , O
one CD O
or CC O
more JJR O
synthetic JJ O
polymers NNS O
may MD O
be VB O
used VBN O
as IN O
an DT O
emulsifier NN O
. . O

For IN O
example NN O
, , O
PVP NNP B-NP
eicosene , I-NP
copolymer NN O
, , O
acrylates/C1O-3o JJ B-NP
alkyl NN B-NP
acrylate NN I-NP
crosspolymer NN O
, , O
acrylates/steareth-20 DT B-NP
methacrylate NN B-NP
copolymer NN O
, , O
PEG-22/dodecyl JJ B-NP
glycol NN I-NP
copolymer NN O
, , O
PEG-45/dodecyl JJ B-NP
glycol NN I-NP
copolymer NN O
, , O
and CC O
mixtures NNS O
thereof RB O
. . O

The DT O
preferred JJ O
emulsifiers NNS O
are VBP O
cetyl JJ B-NP
phosphate NN I-NP
( -LRB- O
Amphisol<( JJ B-NP
R NN I-NP
) -RRB- I-NP
> IN I-NP
A) NNP I-NP
, , O
diethanolamine NN B-NP
cetyl NN I-NP
phosphate NN I-NP
( -LRB- O
Amphisol<( NNP B-NP
R NN I-NP
)> NN I-NP
) -RRB- O
, , O
potassium NN B-NP
cetyl NN I-NP
phosphate NN I-NP
( -LRB- O
Amphisol<( JJ B-NP
R NN I-NP
) -RRB- I-NP
> IN I-NP
K) NNP I-NP
, , O
PVP NNP B-NP
Eicosene NNP I-NP
copolymer NN O
, , O
acrylates/CiO-3o-alkyl JJ B-NP
acrylate NN B-NP
crosspolymer NN O
, , O
PEG-20 DT B-NP
sorbitan JJ I-NP
isostearate NN I-NP
, , O
sorbitan JJ B-NP
isostearate NN I-NP
, , O
and CC O
mixtures NNS O
thereof RB O
. . O

The DT O
one CD O
or CC O
more JJR O
emulsifiers NNS O
are VBP O
present JJ O
in IN O
a DT O
total JJ O
amount NN O
about IN O
0.01 CD O
weight NN O
% NN O
to TO O
about IN O
20 CD O
weight NN O
% NN O
of IN O
the DT O
total JJ O
weight NN O
of IN O
the DT O
composition NN O
of IN O
the DT O
present JJ O
invention NN O
. . O

Preferably RB O
, , O
about IN O
0.1 CD O
weight NN O
% NN O
to TO O
about IN O
10 CD O
weight NN O
% NN O
of IN O
emulsifiers NNS O
is VBZ O
used VBN O
. . O

The DT O
lipid JJ O
phase NN O
of IN O
the DT O
topical JJ O
compositions NNS O
can MD O
advantageously RB O
be VB O
chosen VBN O
from IN O
: : O
mineral NN O
oils NNS O
and CC O
mineral NN O
waxes NNS B-NP
; : O
oils NNS O
such JJ O
as IN O
triglycerides NNS B-NP
of IN O
caprinic JJ B-NP
acid NN I-NP
or CC O
caprylic JJ B-NP
acid NN I-NP
and CC O
castor NN O
oil NN O
; : O

oils NNS O
or CC O
waxes NNS B-NP
and CC O
other JJ O
natural JJ O
or CC O
synthetic JJ O
oils NNS O
, , O
in IN O
a DT O
preferred JJ O
embodiment NN O
esters NNS B-NP
of IN O
fatty JJ B-NP
acids NNS I-NP
with IN O
alcohols NNS B-NP
e.g RB O
. . O

isopropanol NN B-NP
, , O
propylene NN B-NP
glycol NN I-NP
, , O
glycerin NN B-NP
or CC O
esters NNS B-NP
of IN O
fatty JJ O
alcohols NNS B-NP
with IN O
carboxylic NN B-NP
acids NNS I-NP
or CC O
fatty JJ B-NP
acids NNS I-NP
; : O
alkylbenzoates NNS B-NP
; : O
and/or CC O
silicone NN O
oils NNS O
such JJ O
as IN O
dimethylpolysiloxane NN B-NP
, , O
diethylpolysiloxane NN B-NP
, , O
diphenylpolysiloxane NN B-NP
, , O
cyclomethicones NNS B-NP
and CC O
mixtures NNS O
thereof RB O
. . O

Exemplary NNP O
fatty NN O
substances NNS O
which WDT O
can MD O
be VB O
incorporated VBN O
in IN O
the DT O
oil NN O
phase NN O
of IN O
the DT O
emulsion NN O
, , O
microemulsion NN O
, , O
oleo NNP O
gel NNP O
, , O
hydrodispersion NN O
or CC O
lipodispersion NN O
of IN O
the DT O
present JJ O
invention NN O
are VBP O
advantageously RB O
chosen VBN O
from IN O
esters NNS B-NP
of IN O
saturated JJ O
and/or CC O
unsaturated JJ O
, , O
linear JJ O
or CC O
branched JJ O
alkyl NN B-NP
carboxylic NN B-NP
acids NNS I-NP
with IN O
3 CD O
to TO O
30 CD O
carbon NN B-NP
atoms NNS O
, , O
and CC O
saturated VBD O
and/or IN O
unsaturated JJ O
, , O
linear JJ O
and/or CC O
branched JJ O
alcohols NNS B-NP
with IN O
3 CD O
to TO O
30 CD O
carbon NN B-NP
atoms NNS O
as RB O
well RB O
as IN O
esters NNS B-NP
of IN O
aromatic JJ O
carboxylic NN B-NP
acids NNS I-NP
and CC O
of IN O
saturated JJ O
and/or CC O
unsaturated JJ O
, , O
linear JJ O
or CC O
branched JJ O
alcohols NNS B-NP
of IN O
3- CD O
30 CD O
carbon NN B-NP
atoms NNS O
. . O

Such JJ O
esters NNS B-NP
can MD O
advantageously RB O
be VB O
selected VBN O
from IN O
octylpalmitate NN B-NP
, , O
octylcocoate NN B-NP
, , O
octylisostearate NN B-NP
, , O
octyldodecylmyristate NN B-NP
, , O
cetearylisononanoate NN B-NP
, , O
isopropylmyristate VBP B-NP
, , O
isopropylpalmitate VBP B-NP
, , O
isopropylstearate VBP B-NP
, , O
isopropyloleate VBP B-NP
, , O
n- DT B-NP
butylstearate NN I-NP
, , O
n-hexyllaureate JJ B-NP
, , O
n-decyloleat JJ B-NP
, , O
isooctylstearate JJ B-NP
, , O
isononylstearate JJ B-NP
, , O
isononylisononanoate JJ B-NP
, , O
2- CD B-NP
ethyl NN I-NP
hexylpalmitate NN I-NP
, , O
2-ethylhexyllaurate JJ B-NP
, , O
2- CD B-NP
hexyldecylstearate NN I-NP
, , O
2-octyldodecylpalmitate JJ B-NP
, , O
stearylheptanoate JJ B-NP
, , O
oleyloleate JJ B-NP
, , O
oleylerucate JJ B-NP
, , O
erucyloleate JJ B-NP
, , O
erucylerucate JJ B-NP
, , O
tridecylstearate JJ B-NP
, , O
tridecyltrimellitate NN B-NP
, , O
as RB O
well RB O
as IN O
synthetic JJ O
, , O
half-synthetic JJ O
or CC O
natural JJ O
mixtures NNS O
of IN O
such JJ O
esters NNS B-NP
e.g NN O
. . O

jojoba FW O
oil NN O
. . O

Other JJ O
fatty JJ O
components NNS O
suitable JJ O
for IN O
use NN O
in IN O
the DT O
topical JJ O
compositions NNS O
of IN O
the DT O
present JJ O
invention NN O
include VBP O
polar JJ O
oils NNS O
such JJ O
as IN O
lecithines NNS B-NP
and CC O
fatty JJ B-NP
acid NN I-NP
triglycerides VBZ B-NP
, , O
namely RB O
tri- , B-NP
glycerol NN I-NP
esters NNS B-NP
of IN O
saturated JJ O
and/or CC O
unsaturated JJ O
, , O
straight JJ O
or CC O
branched JJ O
carboxylic JJ B-NP
acid NN I-NP
with IN O
8 CD O
to TO O
24 CD O
carbon NN B-NP
atoms NNS O
, , O
preferably RB O
of IN O
12 CD O
to TO O
18 CD O
carbon-atoms NNS B-NP
whereas IN O
the DT O
fatty JJ B-NP
acid NN I-NP
triglycerides NNS B-NP
are VBP O
preferably RB O
chosen VBN O
from IN O
synthetic JJ O
, , O
half DT O
synthetic JJ O
or CC O
natural JJ O
oils NNS O
( -LRB- O
e NN O
.g NN O
. . O

cocoglyceride NN O
, , O
olive JJ O
oil NN O
, , O
sun NN O
flower NN O
oil NN O
, , O
soybean NN O
oil NN O
, , O
peanut NN O
oil NN O
, , O
rape NN O
seed NN O
oil NN O
, , O
sweet JJ O
almond NN O
oil NN O
, , O
palm NN O
oil NN O
, , O
coconut NN O
oil NN O
, , O
castor NN O
oil NN O
, , O
hydrogenated JJ O
castor NN O
oil NN O
, , O
wheat NN O
oil NN O
, , O
grape NN O
seed NN O
oil NN O
, , O
macadamia NN O
nut NN O
oil NN O
and CC O
others NNS O
) -RRB- O
; : O
apolar JJ O
oils NNS O
such JJ O
as IN O
linear JJ O
and/ NNS O
or CC O
branched JJ O
hydrocarbons NNS B-NP
and CC O
waxes NNS B-NP
e.g NN O
. . O

mineral NN O
oils NNS O
, , O
vaseline NN O
( -LRB- O
petrolatum NN O
) -RRB- O
; : O
paraffins NNS O
, , O
squalane NN B-NP
and CC O
squalene NN B-NP
, , O
polyolefines NNS B-NP
, , O
hydrogenated JJ O
polyisobutenes NNS B-NP
and CC O
isohexadecanes NNS B-NP
, , O
favored VBN O
polyolefines NNS B-NP
are VBP O
polydecenes NNS B-NP
; : O
dialkyl NN B-NP
ethers NNS I-NP
such JJ O
as IN O
dicaprylylether NN B-NP
; : O
linear NN O
or CC O
cyclic JJ B-NP
silicone NN I-NP
oils NNS O
such JJ O
as IN O
preferably RB O
cyclomethicones NNS B-NP
(octamethylcyclotetrasiloxane JJ O
; : O
cetyldimethicone NN B-NP
, , O
hexamethylcyclotrisiloxane NN B-NP
, , O
polydimethylsiloxane NN B-NP
, , O
poly(methylphenylsiloxane NN B-NP
) -RRB- I-NP
and CC O
mixtures VBZ O
thereof RB O
. . O

Still RB O
other JJ O
fatty JJ O
components NNS O
which WDT O
can MD O
advantageously RB O
be VB O
incorporated VBN O
in IN O
topical JJ O
com- NNS O
positions NNS O
of IN O
the DT O
present JJ O
invention NN O
are VBP O
isoeikosane JJ B-NP
; : O
neopentylglykoldiheptanoate NN B-NP
; : O
pro- : B-NP
pyleneglykoldicaprylate/ NN I-NP
dicaprate NN B-NP
; : O
caprylic/ NN B-NP
capric/ NN B-NP
diglycerylsuccinate NN B-NP
; : O
butyleneglycol NN B-NP
caprylat/caprat NN I-NP
; : O
Ci2-i3-alkyllactate NNP B-NP
; : O
di-C12.-3 JJ B-NP
alkyltartrate NN I-NP
; : O
triisostearin NN B-NP
; : O
dipentaerythrityl NN B-NP
hexacaprylat/hexacaprate NN B-NP
; : O
propylenglycolmonoisostearate NN B-NP
; : O
tricaprylin NN B-NP
; : O
dimethylisosorbid NN B-NP
. . O

Especially RB O
beneficial JJ O
is VBZ O
the DT O
use NN O
of IN O
mixtures NNS O
C12-i5-alkylbenzoate JJ B-NP
and CC O
2-ethylhexylisostearate JJ B-NP
, , O
mixtures NNS O
C12-i5-alkylbenzoate JJ B-NP
and CC O
isotridecylisononanoate JJ B-NP
as RB O
well RB O
as IN O
mixtures NNS O
of IN O
C12-15-alkylbenzoate JJ B-NP
, , O
2-ethylhexylisostearate JJ B-NP
and CC O
isotridecylisononanoate JJ B-NP
. . O

The DT O
oily JJ O
phase NN O
of IN O
the DT O
compositions NNS O
of IN O
the DT O
present JJ O
invention NN O
can MD O
also RB O
contain VB O
natural JJ O
vegetable NN O
or CC O
animal NN O
waxes NNS B-NP
such JJ O
as IN O
bee NN O
wax NN O
, , O
china NN O
wax NN O
, , O
bumblebee NN O
wax NN O
and CC O
other JJ O
waxes NNS B-NP
of IN O
insects NNS O
as RB O
well RB O
as IN O
shea NN O
butter NN O
and CC O
cocoa NN O
butter NN O
. . O

A DT O
moisturizing JJ O
agent NN O
may MD O
be VB O
incorporated VBN O
into IN O
a DT O
topical JJ O
composition NN O
of IN O
the DT O
present JJ O
invention NN O
to TO O
maintain VB O
hydration NN O
or CC O
rehydrate VB O
the DT O
skin NN O
. . O

Moisturizers NNS O
that DT O
prevent VBP O
water NN B-NP
from IN O
evaporating VBG O
from IN O
the DT O
skin NN O
by IN O
providing VBG O
a DT O
protective JJ O
coating NN O
are VBP O
called VBN O
emollients NNS O
. . O

Additionally RB O
an DT O
emollient NN O
provides VBZ O
a DT O
softening NN O
or CC O
soothing JJ O
effect NN O
on IN O
the DT O
skin NN O
surface NN O
and CC O
is VBZ O
generally RB O
considered VBN O
safe JJ O
for IN O
topical JJ O
use NN O
. . O

Preferred JJ O
emollients NNS O
include VBP O
mineral NN O
oils NNS O
, , O
lanolin NN O
, , O
petrolatum NN O
, , O
capric/caprylic JJ B-NP
triglyceraldehydes NNS B-NP
, , O
cholesterol NN B-NP
, , O
silicones NNS B-NP
such JJ O
as IN O
dimeticone NN B-NP
, , O
cyclometicone NN B-NP
, , O
almond DT O
oil NN O
, , O
jojoba FW O
oil NN O
, , O
avocado IN O
oil NN O
, , O
castor NN O
oil NN O
, , O
sesame JJ O
oil NN O
, , O
sunflower NN O
oil NN O
, , O
coconut NN O
oil NN O
and CC O
grape NN O
seed NN O
oil NN O
, , O
cocoa NN O
butter NN O
, , O
olive JJ O
oil NN O
aloe NN O
extracts NNS O
, , O
fatty JJ B-NP
acids NNS I-NP
such JJ O
as IN O
oleic JJ B-NP
and CC O
stearic JJ B-NP
, , O
fatty JJ B-NP
alcohols NNS I-NP
such JJ O
as IN O
cetyl NN B-NP
and CC O
hexadecyl NN B-NP
( -LRB- O
ENJAY NNP O
) -RRB- O
, , O
diisopropyl JJ B-NP
adipate NN I-NP
, , O
hydroxybenzoate JJ B-NP
esters NNS I-NP
, , O
benzoic JJ B-NP
acid NN I-NP
esters NNS I-NP
of IN I-NP
C9.i5-alcohols NNP I-NP
, , O
isononyl NN B-NP
iso-nonanoate NN I-NP
, , O
ethers NNS B-NP
such JJ O
as IN O
polyoxypropylene NN B-NP
butyl NN I-NP
ethers NNS I-NP
and CC O
polyoxypropylene NN B-NP
cetyl NN I-NP
ethers NNS I-NP
, , O
and CC O
C12-is-alkyl JJ B-NP
benzoates NNS I-NP
, , O
and CC O
mixtures NNS O
thereof RB O
. . O

The DT O
most RBS O
preferred JJ O
emollients NNS O
are VBP O
hydroxybenzoate JJ B-NP
esters NNS I-NP
, , O
aloe NN O
vera NN O
, , O
C12.15-alkyl JJ B-NP
benzoates NNS I-NP
, , O
and CC O
mixtures NNS O
thereof RB O
. . O

An DT O
emollient NN O
is VBZ O
present JJ O
in IN O
an DT O
amount NN O
of IN O
about IN O
1 CD O
weight NN O
% NN O
to TO O
about IN O
20 CD O
weight NN O
% NN O
of IN O
the DT O
total JJ O
weight NN O
of IN O
the DT O
composition NN O
. . O

The DT O
preferred JJ O
amount NN O
of IN O
emollient NN O
is VBZ O
about IN O
2 CD O
weight NN O
% NN O
to TO O
about IN O
15 CD O
weight NN O
% NN O
, , O
and CC O
most RBS O
preferably RB O
about IN O
4 CD O
weight NN O
% NN O
to TO O
about IN O
10 CD O
weight NN O
% NN O
. . O

Moisturizers NNS O
that WP O
bind VBP O
water NN B-NP
, , O
thereby RB O
retaining VBG O
it PRP O
on IN O
the DT O
skin NN O
surface NN O
are VBP O
called VBN O
humectants NNS O
. . O

Suitable JJ O
humectants NNS B-NP
can MD O
be VB O
incorporated VBN O
into IN O
a DT O
topical JJ O
composition NN O
of IN O
the DT O
present JJ O
invention NN O
such JJ O
as IN O
glycerin NN B-NP
, , O
polypropylene NN B-NP
glycol NN I-NP
, , O
polyethylene NN B-NP
glycol NN I-NP
, , O
lactic JJ B-NP
acid NN I-NP
, , O
pyrrolidon NN B-NP
carboxylic NN I-NP
acid NN I-NP
, , O
urea NN B-NP
, , O
phopholipids NNS B-NP
, , O
collagen NN O
, , O
elastin RB O
, , O
ceramides NNS O
, , O
lecithin JJ B-NP
sorbitol NN I-NP
, , O
PEG-4 NN B-NP
, , O
and CC O
mixtures NNS O
thereof RB O
. . O

Additional JJ O
suitable JJ O
moisturizers NNS O
are VBP O
polymeric JJ O
moisturizers NNS O
of IN O
the DT O
family NN O
of IN O
water NN B-NP
soluble JJ O
and/ NNS O
or CC O
swellable/ JJ O
and/ NNS O
or CC O
with IN O
water NN B-NP
gelating VBG O
polysaccharides NNS B-NP
such JJ O
as IN O
hyaluronic JJ B-NP
acid NN I-NP
, , O
chitosan NN B-NP
and/or CC O
a DT O
fucose JJ B-NP
rich JJ O
polysaccharide NN O
which WDT O
is VBZ O
e.g RB O
. . O

available JJ O
as IN O
Fucogel( JJ O
R)1000 CD O
( -LRB- O
CAS-Nr NNP B-NP
. . I-NP
178463-23-5 CD I-NP
) -RRB- O
by IN O
SOLABIA NNP O
S. NNP O
One CD O
or CC O
more JJR O
humectants NNS O
are VBP O
optionally RB O
present JJ O
at IN O
about RB O
0.5 CD O
weight NN O
% NN O
to TO O
about IN O
8 CD O
weight NN O
% NN O
in IN O
a DT O
composition NN O
of IN O
the DT O
present JJ O
invention NN O
, , O
preferably RB O
about IN O
1 CD O
weight NN O
% NN O
to TO O
about IN O
5 CD O
weight NN O
% NN O
. . O

The DT O
aqueous JJ O
phase NN O
of IN O
the DT O
preferred JJ O
topical JJ O
compositions NNS O
of IN O
the DT O
present JJ O
invention NN O
can MD O
contain VB O
the DT O
usual JJ O
cosmetic NN O
or CC O
pharmaceutical JJ O
additives NNS O
such JJ O
as IN O
alcohols NNS B-NP
, , O
especially RB O
lower JJR O
alcohols NNS B-NP
, , O
preferably RB O
ethanol NN B-NP
and/ NNS O
or CC O
isopropanol NN B-NP
, , O
low JJ O
diols NNS B-NP
or CC O
polyols NNS B-NP
and CC O
their PRP$ O
ethers NNS B-NP
, , O
preferably RB O
propyleneglycol NN B-NP
, , O
glycerin NN B-NP
, , O
ethyleneglycol NN B-NP
, , O
ethyleneglycol NN B-NP
monoethyl- NNS B-NP
or CC O
monobutylether NN B-NP
, , O
propyleneglycol NN B-NP
monomethyl- NNS B-NP
or CC O
-monoethyl- DT O
or-monobutylether JJ O
, , O
diethyleneglycol NN B-NP
monomethyl-or NN B-NP
monoethylether NN B-NP
and CC O
analogue NN O
products NNS O
, , O
polymers NNS O
, , O
foam NN O
stabilisators NNS O
; : O
electrolytes NNS O
and CC O
especially RB O
one CD O
or CC O
more JJR O
thickeners NNS O
. . O

Thickeners NNS O
that WDT O
may MD O
be VB O
used VBN O
in IN O
formulations NNS O
of IN O
the DT O
present JJ O
invention NN O
to TO O
assist VB O
in IN O
making VBG O
the DT O
consistency NN O
of IN O
a DT O
product NN O
suitable JJ O
include VBP O
carbomer NN B-NP
, , O
siliciumdioxide NN B-NP
, , O
magnesium NN B-NP
and/ NNS O
or CC O
aluminium NN B-NP
silicates NNS I-NP
, , O
beeswax NN O
, , O
stearic JJ B-NP
acid NN I-NP
, , O
stearyl NN B-NP
alcohol NN I-NP
polysaccharides NNS I-NP
and CC O
their PRP$ O
derivatives NNS O
such JJ O
as IN O
xanthan NNP B-NP
gum NN I-NP
, , O
hydroxypropyl NN B-NP
cellulose NN I-NP
, , O
polyacrylamides NNS B-NP
, , O
acrylate VB B-NP
crosspolymers NNS O
preferably RB O
a DT O
carbomer NN B-NP
, , O
such JJ O
as IN O
carbopole NN O
of IN O
type NN O
980 CD O
, , O
981 CD O
, , O
1382 CD O
, , O
2984 CD O
, , O
5984 CD O
alone JJ O
or CC O
mixtures NNS O
thereof RB O
. . O

Suitable JJ O
neutralizing JJ O
agents NNS O
which WDT O
may MD O
be VB O
included VBN O
in IN O
the DT O
composition NN O
of IN O
the DT O
present JJ O
invention NN O
to TO O
neutralize VB O
components NNS O
such JJ O
as IN O
e.g NN O
. . O
an DT O
emulsifier NN O
or CC O
a DT O
foam NN O
builder/stabilizer NN O
include VBP O
but CC O
are VBP O
not RB O
limited VBN O
to TO O
alkali JJ B-NP
hydroxides NNS I-NP
such JJ O
as IN O
a DT O
sodium NN B-NP
and CC O
potassium NN B-NP
hydroxide NN I-NP
; : O
organic JJ O
bases NNS O
such JJ O
as IN O
diethanolamine NN B-NP
( -LRB- O
DEA NNP B-NP
) -RRB- O
, , O
triethanolamine NN B-NP
( -LRB- O
TEA NNP B-NP
) -RRB- O
, , O
aminomethyl JJ B-NP
propanol NN I-NP
, , O
and CC O
mixtures NNS O
thereof , O
; : O
amino IN B-NP
acids NNS I-NP
such JJ O
as IN O
arginine NN B-NP
and CC O
lysine NN B-NP
and CC O
any DT O
combination NN O
of IN O
any DT O
foregoing NN O
. . O

The DT O
neutralizing JJ O
agent NN O
can MD O
be VB O
present JJ O
in IN O
an DT O
amount NN O
of IN O
about IN O
0.01 CD O
weight NN O
% NN O
to TO O
about IN O
8 CD O
weight NN O
% NN O
in IN O
the DT O
composition NN O
of IN O
the DT O
present JJ O
invention NN O
, , O
preferably RB O
, , O
1 CD O
weight NN O
% NN O
to TO O
about IN O
5 CD O
weight NN O
% NN O
. . O

The DT O
addition NN O
of IN O
electrolytes NNS O
into IN O
the DT O
composition NN O
of IN O
the DT O
present JJ O
invention NN O
may MD O
be VB O
necessary JJ O
to TO O
change VB O
the DT O
behavior NN O
of IN O
a DT O
hydrophobic JJ O
emulsifier NN O
. . O

Thus RB O
, , O
the DT O
emulsions NNS O
/ IN O
microemulsions NNS O
of IN O
this DT O
invention NN O
may MD O
contain VB O
preferably RB O
electrolytes NNS O
of IN O
one CD O
or CC O
several JJ O
salts NNS O
including VBG O
anions NNS O
such JJ O
as IN O
chloride NN B-NP
, , O
sulfates NNS B-NP
, , O
carbonate NN B-NP
, , O
borate NN B-NP
and CC O
aluminate NN B-NP
, , O
without IN O
being VBG O
limited JJ O
thereto NN O
. . O

Other JJ O
suitable JJ O
electrolytes NNS O
can MD O
be VB O
on IN O
the DT O
basis NN O
of IN O
organic JJ O
anions NNS O
such JJ O
as IN O
, , O
but CC O
not RB O
limited JJ O
to TO O
, , O
lactate NN B-NP
, , O
acetate NN B-NP
, , O
benzoate NN B-NP
, , O
propionate JJ B-NP
, , O
tartrate JJ B-NP
and CC O
citrate JJ B-NP
. . O

As IN O
cations NNS O
preferably RB O
ammonium NN B-NP
, , O
alkylammonium NN B-NP
, , O
alkali- . B-NP
or CC O
alkaline JJ B-NP
earth NN I-NP
metals NNS I-NP
, , O
magnesium-, VBN B-NP
iron NN B-NP
- : O
or CC O
zinc-ions NNS B-NP
are VBP O
selected VBN O
. . O

Especially RB O
preferred JJ O
salts NNS O
are VBP O
potassium NN B-NP
and CC O
sodium NN B-NP
chloride NN I-NP
, , O
magnesium NN B-NP
sulfate NN I-NP
, , O
zinc NN B-NP
sulfate NN I-NP
and CC O
mixtures NNS O
thereof RB O
. . O

Electrolytes NNP O
can MD O
be VB O
present JJ O
in IN O
an DT O
amount NN O
of IN O
about IN O
0.01 CD O
weight NN O
% NN O
to TO O
about IN O
8 CD O
weight NN O
% NN O
in IN O
the DT O
composition NN O
of IN O
the DT O
present JJ O
invention NN O
. . O

According VBG O
to TO O
the DT O
invention NN O
for IN O
preparing VBG O
the DT O
compositions NNS O
of IN O
the DT O
invention NN O
the DT O
active JJ O
ingredients NNS O
can MD O
be VB O
used VBN O
as IN O
such JJ O
or CC O
in IN O
an DT O
encapsulated JJ O
form NN O
, , O
for IN O
example NN O
in IN O
a DT O
liposomal JJ O
form NN O
. . O

Liposomes NNS O
are VBP O
preferably RB O
formed VBN O
with IN O
lecithins NNS B-NP
with IN O
or CC O
without IN O
addition NN O
of IN O
sterols NNS O
or CC O
phytosterols NNS B-NP
. . O

The DT O
encapsulation NN O
of IN O
the DT O
active JJ O
ingredients NNS O
can MD O
be VB O
alone RB O
or CC O
together RB O
with IN O
other JJ O
active JJ O
ingredients NNS O
. . O

It PRP O
is VBZ O
possible JJ O
to TO O
encapsulate VB O
only RB O
the DT O
fatty JJ B-NP
acid NN I-NP
or CC O
a DT O
salt NN O
, , O
ester NN B-NP
or CC O
amide JJ B-NP
thereof , O
with IN O
the DT O
preferences NNS O
and CC O
definitions NNS O
as IN O
defined VBN O
above IN O
or CC O
only RB O
the DT O
retinoid NN B-NP
, , O
but CC O
it PRP O
is VBZ O
also RB O
possible JJ O
to TO O
encapsulate VB O
both DT O
ingredients NNS O
either CC O
together RB O
or CC O
in IN O
separate JJ O
capsules NNS O
. . O

Other JJ O
embodiments NNS O
include VBP O
solid JJ O
or CC O
semisolid JJ O
capsules NNS O
aiming VBG O
to TO O
protect VB O
the DT O
retinoid NN B-NP
from IN O
degradation NN O
or CC O
for IN O
controlled JJ O
delivery NN O
. . O

The DT O
capsule NN O
may MD O
contain VB O
the DT O
retinoid NN B-NP
alone RB O
or CC O
together RB O
with IN O
the DT O
fatty JJ B-NP
acid NN I-NP
or CC O
a DT O
salt NN O
, , O
ester NN B-NP
or CC O
amide JJ B-NP
thereof , O
with IN O
the DT O
preferences NNS O
and CC O
definitions NNS O
as IN O
defined VBN O
above IN O
. . O

Suitable JJ O
encapsulation NN O
technologies NNS O
are VBP O
for IN O
example NN O
described VBN O
in IN O
WO NN O
0180823 CD O
, , O
WO NN O
9903450 CD O
, , O
WO NN O
9317784 CD O
or CC O
in IN O
Fragrance NNP O
Journal NNP O
( -LRB- O
2001 CD O
) -RRB- O
, , O
29( JJ O
2 CD O
) -RRB- O
, , O
83-90 CD O
. . O

The DT O
composition NN O
of IN O
the DT O
present JJ O
invention NN O
can MD O
also RB O
contain VB O
one CD O
or CC O
more JJR O
additional JJ O
pharmaceutically RB O
or CC O
cosmetically RB O
active JJ O
ingredients NNS O
, , O
in IN O
particular JJ O
for IN O
preventing VBG O
or CC O
reducing VBG O
acne NN O
, , O
wrinkles NNS O
, , O
lines NNS O
, , O
atrophy NN O
, , O
inflammation NN O
, , O
as RB O
well RB O
as IN O
topical JJ O
anesthetics NNS O
, , O
artificial JJ O
tanning NN O
agents NNS O
and CC O
accelerators NNS O
, , O
antimicrobial JJ O
agents NNS O
, , O
antifungal JJ O
agents NNS O
and CC O
sun NN O
screening VBG O
additives NNS O
without IN O
being VBG O
limited VBN O
thereto RB O
. . O

Examples NNS O
of IN O
such JJ O
ingredients NNS O
are VBP O
peptides NNS B-NP
( -LRB- O
e NN O
.g. NNP O
, , O
Matrixyl( NNP O
TM) NNP O
[pentapeptide NN O
derivative] NN O
) -RRB- O
, , O
oligopeptides VBZ B-NP
, , O
wax-based JJ O
synthetic JJ O
peptides NNS B-NP
( -LRB- O
e NN O
.g. NNP O
, , O
octyl NN B-NP
palmitate NN I-NP
and CC O
tribehenin NN B-NP
and CC O
sorbitan JJ B-NP
isostearate NN I-NP
and CC O
palmitoyl-oligopeptide NN B-NP
) -RRB- O
, , O
glycerol NN B-NP
, , O
urea NN B-NP
, , O
guanidine NN B-NP
( -LRB- O
e NN O
.g NN O
. . O

amino JJ B-NP
guanidine NN I-NP
) -RRB- O
; : O
vitamins NNS O
and CC O
derivatives NNS O
thereof , O
such JJ O
as IN O
vitamin NN B-NP
C NNP I-NP
( -LRB- O
ascorbic JJ B-NP
acid NN I-NP
) -RRB- O
, , O
vitamin NN B-NP
A DT I-NP
( -LRB- O
e NN O
.g. NNP O
, , O
retinoid JJ B-NP
derivatives NNS O
such JJ O
as IN O
retinyl NN B-NP
palmitate NN I-NP
or CC O
retinyl NN B-NP
propionate NN I-NP
) -RRB- O
, , O
vitamin NN B-NP
E NNP I-NP
( -LRB- O
e NN O
.g. NNP O
, , O
tocopherol NN B-NP
acetate NN I-NP
) -RRB- O
, , O
vitamin NN B-NP
B3 CC I-NP
( -LRB- O
e NN O
.g NN O
. . O

niacinamide NN B-NP
) -RRB- O
and CC O
vitamin NN B-NP
B5 IN I-NP
( -LRB- O
e NN O
.g NN O
. . O

panthenol NN B-NP
) -RRB- O
, , O
vitamin NN B-NP
B6 NNS I-NP
and CC O
vitamin NN B-NP
B12 NN I-NP
, , O
biotin NN B-NP
, , O
folic JJ B-NP
acid NN I-NP
; : O
anti-acne JJ O
actives NNS O
or CC O
medicaments NNS O
( -LRB- O
e NN O
.g NN O
. . O

resorcinol NN B-NP
, , O
salicylic JJ B-NP
acid NN I-NP
, , O
and CC O
the DT O
like JJ O
) -RRB- O
; : O
antioxidants NNS O
( -LRB- O
e NN O
.g NN O
. . O

phytosterols NNS B-NP
, , O
lipoic JJ B-NP
acid NN I-NP
) -RRB- O
; : O
flavonoids NNS B-NP
( -LRB- O
e NN O
.g NN O
. . O

isoflavones NNS B-NP
, , O
phytoestrogens NNS B-NP
) -RRB- O
; : O
skin NN O
soothing VBG O
and CC O
healing VBG O
agents NNS O
such JJ O
as IN O
aloe NN O
vera NN O
extract VB O
, , O
allantoin RB B-NP
and CC O
the DT O
like JJ O
; : O

agents NNS O
suitable JJ O
for IN O
aesthetic JJ O
purposes NNS O
such JJ O
as IN O
essential JJ O
oils NNS O
, , O
fragrances NNS O
, , O
skin NN O
sensates NNS O
, , O
opacifiers NNS O
, , O
aromatic JJ O
compounds NNS O
( -LRB- O
e NN O
.g. NNP O
, , O
clove NN O
oil NN O
, , O
menthol NN B-NP
, , O
camphor NN B-NP
, , O
eucalyptus NN O
oil NN O
, , O
and CC O
eugenol NN B-NP
) -RRB- O
, , O
desquamatory JJ O
actives NNS O
, , O
hydroxy JJ B-NP
acids NNS I-NP
such JJ O
as IN O
AHA NNP B-NP
acids NNS I-NP
, , O
radical JJ O
scavengers NNS O
, , O
farnesol NN B-NP
, , O
antifungal JJ O
actives NNS O
in IN O
particular JJ O
bisabolol NN B-NP
, , O
alkyldiols NNS B-NP
such JJ O
as IN O
1 CD B-NP
,2-pentanediol JJ I-NP
, , O
hexanediol JJ B-NP
or CC O
1 CD B-NP
,2-octanediol JJ I-NP
, , O
phytol NN B-NP
, , O
polyols NNS B-NP
such JJ O
as IN O
phytanetriol NN B-NP
, , O
ceramides NNS O
and CC O
pseudoceramides NNS O
, , O
amino IN B-NP
acids NNS I-NP
, , O
protein NN O
hydrolysates NNS O
, , O
polyunsaturated VBN O
fatty JJ B-NP
acids NNS I-NP
, , O
plant NN O
extracts NNS O
like IN O
kinetin NN O
, , O
DNA NNP O
or CC O
RNA NNP O
and CC O
their PRP$ O
fragmentation NN O
products NNS O
, , O
carbohydrates NNS B-NP
, , O
conjugated VBN O
fatty JJ B-NP
acids NNS I-NP
, , O
carnitin NN B-NP
, , O
carnosine NN B-NP
, , O
biochinonen NN B-NP
, , O
phytofluen NN B-NP
, , O
phytoen NN B-NP
, , O
and CC O
their PRP$ O
corresponding JJ O
derivatives NNS O
. . O

Additionally RB O
the DT O
cosmetic NN O
and CC O
pharmaceutical JJ O
topical JJ O
composition NN O
of IN O
the DT O
present JJ O
invention NN O
may MD O
contain VB O
UV-screening JJ O
agents NNS O
( -LRB- O
UV-filter NN O
) -RRB- O
. . O

The DT O
additional JJ O
UV-screening NN O
agents NNS O
are VBP O
advantageously RB O
selected VBN O
from IN O
IR NNP O
, , O
UV-A NNP O
, , O
UV-B NN O
, , O
UV-C JJ O
and/ NN O
or CC O
broadband NN O
filters NNS O
. . O

Examples NNS O
of IN O
UV-B NN O
or CC O
broad JJ O
spectrum NN O
screening VBG O
agents NNS O
, , O
i IN O
.e NNP O
. . O
substances NNS O
having VBG O
absorption NN O
maximums NNS O
between IN O
about IN O
290 CD O
nm NN O
and CC O
340 CD O
nm NN O
may MD O
be VB O
organic JJ O
or CC O
inorganic JJ O
compounds NNS O
. . O

Organic NNP O
UV-B NN O
or CC O
broadband JJ O
screening NN O
agents NNS O
are VBP O
e.g JJ O
. . O

acrylates NNS B-NP
such JJ O
as IN O
2- CD B-NP
ethylhexyl NN I-NP
2-cyano-3,3-diphenylacrylate JJ I-NP
(octocrylene NN O
, , O
PARSOL<( JJ B-NP
R NN I-NP
) -RRB- I-NP
> NN I-NP
340 CD I-NP
) -RRB- O
, , O
ethyl NN B-NP
2-cyano-3,3- CD I-NP
diphenylacrylate NN I-NP
and CC O
the DT O
like JJ O
; : O
camphor NN B-NP
derivatives NNS O
such JJ O
as IN O
4-methyl JJ B-NP
benzylidene NN I-NP
camphor NN I-NP
( -LRB- O
PARSOL<( NN B-NP
R NN I-NP
) -RRB- I-NP
> JJ I-NP
5000 CD I-NP
) -RRB- O
, , O
3-benzylidene JJ B-NP
camphor NN I-NP
, , O
camphor NN B-NP
benzalkonium NN I-NP
methosulfate NN I-NP
, , O
polyacrylamidomethyl NN B-NP
benzylidene NN I-NP
camphor NN I-NP
, , O
sulfo VB B-NP
benzylidene NN I-NP
camphor NN I-NP
, , O
sulphomethyl NN B-NP
benzylidene NN I-NP
camphor NN I-NP
, , O
therephthalidene DT B-NP
dicamphor NN I-NP
sulfonic JJ I-NP
acid NN I-NP
and CC O
the DT O
like JJ O
; : O
Cinnamate NNP B-NP
derivatives VBZ O
such JJ O
as IN O
ethylhexyl NN B-NP
methoxycinnamate NN I-NP
( -LRB- O
PARSOL<( NN B-NP
R NN I-NP
) -RRB- I-NP
> IN I-NP
MCX) NNP I-NP
, , O
ethoxyethyl NN B-NP
methoxycinnamate NN I-NP
, , O
diethanolamine NN B-NP
methoxycinnamate NN I-NP
( -LRB- O
PARSOL<( NN B-NP
R NN I-NP
) -RRB- I-NP
> NN I-NP
Hydro NNP I-NP
) -RRB- O
, , O
isoamyl JJ B-NP
methoxycinnamate NN I-NP
and CC O
the DT O
like JJ O
as RB O
well RB O
as IN O
cinnamic JJ B-NP
acid NN I-NP
derivatives VBZ O
bond NN O
to TO O
siloxanes NNS B-NP
; : O
p NN B-NP
- : I-NP
aminobenzoic JJ I-NP
acid NN I-NP
derivatives NNS O
, , O
such JJ O
as IN O
p-aminobenzoic JJ B-NP
acid NN I-NP
, , O
2-ethylhexyl JJ B-NP
p NN I-NP
- : I-NP
dimethylaminobenzoate NN I-NP
, , O
N-oxypropylenated JJ B-NP
ethyl NN I-NP
p-aminobenzoate NN I-NP
, , O
glyceryl NN B-NP
p NN I-NP
- : I-NP
aminobenzoate JJ I-NP
; : O
benzophenones NNS B-NP
such JJ O
as IN O
benzophenone-3 NN B-NP
, , O
benzophenone-4 NN B-NP
, , O
2 CD B-NP
, , I-NP
2' CD I-NP
, , I-NP
4,4' CD I-NP
- : I-NP
tetrahydroxy-benzophenone NN I-NP
, , O
2,2'-dihydroxy-4,4'-dimethoxybenzophenone CD B-NP
and CC O
the DT O
like JJ O
; : O
esters NNS B-NP
of IN O
benzalmalonic JJ B-NP
acid NN I-NP
such JJ O
as IN O
di-(2-ethylhexyl JJ B-NP
) -RRB- I-NP
4-methoxybenzalmalonate JJ I-NP
; : O
esters NNS B-NP
of IN O
2-(4-ethoxy-anilinomethylene)propandioic JJ B-NP
acid NN I-NP
such JJ O
as IN O
2-(4-ethoxy JJ B-NP
anilinomethylene NN I-NP
) -RRB- I-NP
propandioic JJ I-NP
acid NN I-NP
diethyl NN I-NP
ester NN I-NP
as IN O
described VBN O
in IN O
the DT O
European JJ O
Patent NN O
Publication NN O
EP NNP O
0895 CD O
776 CD O
; : O
organosiloxane NN B-NP
compounds NNS O
containing VBG O
benzmalonate JJ B-NP
groups NNS I-NP
as IN O
described VBN O
in IN O
the DT O
European JJ O
Patent NNP O
Publications NNPS O
EP NNP O
0358584 CD O
B1 NNP O
, , O
EP NNP O
0538431 CD O
B1 NNP O
and CC O
EP NNP O
0709080 IN O
A1 DT O
such JJ O
as IN O
PARSOL NNP O
SLX NNP O
; : O
drometrizole NN B-NP
trisiloxane NN I-NP
( -LRB- O
Mexoryl JJ O
XL NNP O
) -RRB- O
; : O
imidazole JJ B-NP
derivatives NNS O
such JJ O
as IN O
e.g NN O
. . O

2-phenyl JJ B-NP
benzimidazole NN I-NP
sulfonic JJ I-NP
acid NN I-NP
and CC O
its PRP$ O
salts NNS O
( -LRB- O
PARSOLHS) NN O
. . O

Salts NNS O
of IN O
2-phenyl JJ B-NP
benzimidazole NN I-NP
sulfonic JJ I-NP
acid NN I-NP
are VBP O
e.g RB O
. . O

alkali VBP B-NP
salts NNS O
such JJ O
as IN O
sodium NN B-NP
- : O
or CC O
potassium NN B-NP
salts NNS I-NP
, , O
ammonium NN O
salts NNS O
, , O
morpholine NN B-NP
salts NNS I-NP
, , O
salts NNS O
of IN O
primary JJ O
, , O
sec. . O

and CC O
tert NN O
. . O

amines NNS B-NP
like IN O
monoethanolamine NN B-NP
salts NNS O
, , O
diethanolamine NN B-NP
salts NNS O
and CC O
the DT O
like JJ O
; : O
salicylate JJ B-NP
derivatives NNS O
such JJ O
as IN O
isopropylbenzyl NN B-NP
salicylate NN I-NP
, , O
benzyl NN B-NP
salicylate NN I-NP
, , O
butyl NN B-NP
salicylate NN I-NP
, , O
ethylhexyl NN B-NP
salicylate NN I-NP
( -LRB- O
PARSOL NNP O
EHS NNP O
, , O
Neo NNP O
Heliopan NNP O
OS) NNP O
, , O
isooctyl NN B-NP
salicylate NN I-NP
or CC O
homomenthyl NN B-NP
salicylate NN I-NP
( -LRB- O
homosalate NN O
, , O
PARSOL NNP O
HMS NNP O
, , O
Neo NNP O
Heliopan NNP O
HMS NNP O
) -RRB- O
and CC O
the DT O
like JJ O
; : O
triazine NN B-NP
derivatives NNS O
such JJ O
as IN O
ethylhexyl NN B-NP
triazone NN I-NP
( -LRB- O
Uvinul JJ O
T-150 NN O
) -RRB- O
, , O
diethylhexyl NN B-NP
butamido NN I-NP
triazone NN I-NP
( -LRB- O
Uvasorb JJ O
HEB NN O
) -RRB- O
and CC O
the DT O
like JJ O
. . O

Encapsulated VBN O
UV-filters NNS O
such JJ O
as IN O
encapsulated JJ O
ethylhexyl NN B-NP
methoxycinnamate NN I-NP
( -LRB- O
Eusolex JJ O
UV-pearls NNS O
) -RRB- O
or CC O
microcapsules NNS O
loaded VBN O
with IN O
UV-filters NNS O
as IN O
e.g NN O
. . O

dislosed VBN O
in IN O
EP NNP O
1471995 CD O
and CC O
the DT O
like JJ O
; : O

Examples NNS O
of IN O
broad JJ O
spectrum NN O
or CC O
UV NN O
A DT O
screening VBG O
agents NNS O
i IN O
.e JJ O
. . O
substances NNS O
having VBG O
absorption NN O
maximums NNS O
between IN O
about IN O
320 CD O
nm NN O
and CC O
400 CD O
nm NN O
may MD O
be VB O
organic JJ O
or CC O
inorganic JJ O
compounds NNS O
. . O

Organic NNP O
broad JJ O
spectrum NN O
or CC O
UV NN O
A DT O
screening VBG O
agents NNS O
include VBP O
e.g JJ O
. . O

dibenzoylmethane NN B-NP
derivatives NNS O
such JJ O
as IN O
4-tert.-butyl-4'-methoxydibenzoyl-methane JJ B-NP

( -LRB- O
PARSOL NN O
1789 CD O
) -RRB- O
, , O
dimethoxydibenzoylmethane NN B-NP
, , O
isopropyldibenzoylmethane NN B-NP
and CC O
the DT O
like JJ O
; : O
benzotriazole JJ B-NP
derivatives NNS O
such JJ O
as IN O
2,2'-methylene-bis-(6-(2H-benzotriazole-2-yl)-4-( JJ B-NP
1 CD I-NP
, , I-NP
1 CD I-NP
,3,3,- CD I-NP
tetramethylbutyl)-phenol NN I-NP
( -LRB- O
Tinosorb NNP B-NP
M NNP I-NP
) -RRB- O
and CC O
the DT O
like JJ O
; : O
bis-ethylhexyloxyphenol JJ B-NP
methoxyphenyl NN I-NP
triazine NN I-NP
( -LRB- O
Tinosorb NNP B-NP
S NNP I-NP
) -RRB- O
and CC O
the DT O
like JJ O
; : O
phenylene-1 NN B-NP
,4-bis-benzimidazolsulfonic JJ I-NP
acids NNS I-NP
or CC O
salts NNS O
such JJ O
as IN O
2,2-( CD B-NP
1 CD I-NP
,4-phenylene)bis-( JJ I-NP
1 CD I-NP
H-benzimidazol-4,6-disulfonic JJ I-NP
acid NN I-NP
) -RRB- I-NP
( -LRB- O
Neoheliopan NN B-NP
AP NNP I-NP
) -RRB- O
; : O
amino IN B-NP
substituted VBN O
hydroxybenzophenones NNS B-NP
such JJ O
as IN O
2-(4-Diethylamino JJ B-NP
- : I-NP
2-hydroxy-benzoyl)-benzoic JJ I-NP
acid NN I-NP
hexylester NN I-NP
( -LRB- O
Uvinul JJ B-NP
A DT I-NP
plus NN I-NP
) -RRB- O
as IN O
described VBN O
in IN O
the DT O
European JJ O
Patent NN O
Publication NN O
EP NNP O
1046391 CD O
; : O
Ionic NNP O
UV-A NNP O
filters VBZ O
as IN O
described VBN O
in IN O
the DT O
International NNP O
Patent NNP O
Publication NNP O
WO2005080341 NNP O
A1 NNP O
; : O

As IN O
dibenzoylmethane NN B-NP
derivatives NNS O
have VBP O
limited VBN O
photostability NN O
it PRP O
may MD O
be VB O
desirable JJ O
to TO O
photostabilize VB O
these DT O
UV-A JJ O
screening NN O
agents NNS O
. . O

Thus RB O
, , O
the DT O
term NN O
" `` O
conventional JJ O
UV-A JJ O
screening NN O
agent NN O
" '' O
also RB O
refers VBZ O
to TO O
dibenzoylmethane NN B-NP
derivatives NNS O
such JJ O
as IN O
e.g NN O
. . O

PARSOL NNP O
1789 CD O
stabilized VBN O
by IN O
, , O
e.g NN O
. . O

3,3-Diphenylacrylate JJ B-NP
derivatives NNS O
as IN O
described VBN O
in IN O
the DT O
European JJ O
Patent NNP O
Publications NNPS O
EP NNP O
0 CD O
514 CD O
491 CD O
B1 NNP O
and CC O
EP NNP O
0 CD O
780 CD O
119 CD O
A1 NNP O
; : O
Benzylidene NNP B-NP
camphor NN I-NP
derivatives NNS O
as IN O
described VBN O
in IN O
the DT O
US NNP O
Patent NNP O
No. NN O
5,605,680 CD O
; : O
Organosiloxanes NNP B-NP
containing VBG O
benzmalonate JJ B-NP
groups NNS I-NP
as IN O
described VBN O
in IN O
the DT O
European JJ O
Patent NN O
Publications NNP O
EP NNP O
0358584 CD O
B1 NNP O
, , O
EP NNP O
0538431 CD O
B1 NNP O
and CC O
EP NNP O
0709080 CD O
A1 NNP O
. . O

A DT O
good JJ O
overview NN O
of IN O
UV-A- NNP O
and CC O
UV-B JJ O
screening NN O
agents NNS O
which WDT O
can MD O
be VB O
added VBN O
to TO O
the DT O
compositions NNS O
of IN O
the DT O
present JJ O
invention NN O
can MD O
also RB O
be VB O
found VBN O
in IN O
DE-A NNP O
103 CD O
27 CD O
432 CD O
. . O

All DT O
UV- JJ O
screening NN O
agents NNS O
disclosed VBN O
in IN O
this DT O
document NN O
are VBP O
also RB O
useful JJ O
as IN O
components NNS O
for IN O
the DT O
compositions NNS O
of IN O
the DT O
present JJ O
invention NN O
and CC O
are VBP O
included VBN O
herein RB O
by IN O
reference NN O
. . O

Additionally RB O
the DT O
composition NN O
of IN O
the DT O
present JJ O
invention NN O
may MD O
contain VB O
UV-A NNP O
and CC O
UV-B NNP O
filters NNS O
. . O

Further JJ O
examples NNS O
of IN O
UV- NNP O
filters NNS O
or CC O
screening VBG O
agents NNS O
are VBP O
disclosed VBN O
, , O
e.g. FW O
, , O
in IN O
WO NN O
04/000256 CD O
, , O
see VBP O
especially RB O
pages NNS O
10-12 CD O
which WDT O
are VBP O
included VBN O
herein RB O
by IN O
reference NN O
. . O

A DT O
safe JJ O
and CC O
effective JJ O
amount NN O
of IN O
the DT O
UV-screening JJ O
agent NN O
is VBZ O
used VBN O
, , O
typically RB O
from IN O
about IN O
1 CD O
wt NN O
. . O

-% NN O
to TO O
about IN O
20 CD O
wt.-% NN O
, , O
more RBR O
typically RB O
from IN O
about IN O
2 CD O
wt.-% NN O
to TO O
about IN O
10 CD O
wt.-% JJ O
based VBN O
on IN O
the DT O
total JJ O
weight NN O
of IN O
the DT O
composition NN O
. . O

Other JJ O
suitable JJ O
UV-screening NN O
agents NNS O
which WDT O
may MD O
be VB O
incorporated VBN O
into IN O
the DT O
cosmetic NN O
or CC O
pharmaceutical JJ O
topical JJ O
compositions NNS O
of IN O
the DT O
present JJ O
invention NN O
are VBP O
inorganic JJ O
pigments NNS O
such JJ O
as IN O
microparticulated JJ O
metal NN B-NP
oxides NNS I-NP
( -LRB- O
e NN O
.g NN O
. . O

PARSOL NN O
TX NNP O
) -RRB- O
. . O

Examples NNS O
of IN O
such JJ O
compounds NNS O
include VBP O
e.g NN O
. . O

titanium NN B-NP
dioxide NN I-NP
having VBG O
an DT O
average JJ O
primary JJ O
particle NN O
size NN O
of IN O
from IN O
about IN O
15 CD O
nm NN O
to TO O
about IN O
100 CD O
nm NN O
, , O
zinc NN B-NP
oxide NN I-NP
having VBG O
an DT O
average JJ O
primary JJ O
particle NN O
size NN O
of IN O
from IN O
about IN O
15 CD O
nm NN O
to TO O
about IN O
150 CD O
nm NN O
, , O
zirconium NN B-NP
oxide NN I-NP
having VBG O
an DT O
average JJ O
primary JJ O
particle NN O
size NN O
of IN O
from IN O
about IN O
15 CD O
nm NN O
to TO O
about IN O
150 CD O
nm NN O
, , O
iron NN B-NP
oxide NN I-NP
having VBG O
an DT O
average JJ O
primary JJ O
particle NN O
size NN O
of IN O
from IN O
about IN O
15 CD O
nm NN O
to TO O
about IN O
500 CD O
nm NN O
, , O
and CC O
mixtures NNS O
thereof RB O
. . O

The DT O
metal NN B-NP
oxide NN I-NP
particles NNS O
may MD O
also RB O
be VB O
coated VBN O
by IN O
metal NN B-NP
oxides NNS I-NP
such JJ O
as IN O
e.g NN O
. . O

aluminum NN B-NP
or CC O
zirconium NN B-NP
oxides NNS O
or CC O
by IN O
organic JJ O
coatings NNS O
such JJ O
as IN O
e.g NN O
. . O

polyols NNS B-NP
, , O
methicone NN B-NP
, , O
aluminum NN B-NP
stearate NN I-NP
, , O
alkyl NN B-NP
silane NN I-NP
. . O

Such JJ O
coatings NNS O
are VBP O
well RB O
known VBN O
in IN O
the DT O
art NN O
. . O

When WRB O
used VBN O
herein RB O
, , O
the DT O
inorganic JJ O
sunscreens NNS O
are VBP O
present JJ O
in IN O
the DT O
amount NN O
of IN O
from IN O
about IN O
0.1 CD O
wt.-% NN O
to TO O
about IN O
20 CD O
wt.-% NN O
, , O
preferably RB O
from IN O
about RB O
0.5 CD O
wt.-% NN O
to TO O
about IN O
10 CD O
wt.-% NN O
, , O
more JJR O
preferably RB O
from IN O
about IN O
1wt.-% JJ O
to TO O
about IN O
5 CD O
wt.-% NN O
based VBN O
on IN O
the DT O
total JJ O
weight NN O
of IN O
the DT O
composition NN O
. . O

The DT O
fatty JJ B-NP
acids NNS I-NP
or CC O
a DT O
salt NN O
, , O
ester NN B-NP
or CC O
amide JJ B-NP
thereof , O
with IN O
the DT O
preferences NNS O
and CC O
definitions NNS O
as IN O
given VBN O
above IN O
are VBP O
known VBN O
or CC O
belong VBP O
to TO O
a DT O
known JJ O
class NN O
of IN O
compounds NNS O
and CC O
as IN O
such JJ O
can MD O
be VB O
prepared VBN O
by IN O
known VBN O
methods NNS O
or CC O
in IN O
analogy NN O
thereto NN O
. . O

In IN O
another DT O
embodiment NN O
the DT O
invention NN O
relates VBZ O
to TO O
the DT O
use NN O
of IN O
a DT O
fatty JJ B-NP
acid NN I-NP
or CC O
a DT O
salt NN O
, , O
ester NN B-NP
or CC O
amide IN B-NP
with IN O
the DT O
definitions NNS O
and CC O
preferences NNS O
as IN O
given VBN O
above IN O
for IN O
boosting VBG O
the DT O
cosmetic JJ O
effects NNS O
of IN O
retinoids NNS B-NP
and/or CC O
tanning NN O
actives NNS O
. . O

The DT O
efficacy NN O
of IN O
the DT O
compositions NNS O
of IN O
the DT O
invention NN O
comprising VBG O
fatty JJ B-NP
acid NN I-NP
or CC O
a DT O
salt NN O
, , O
ester NN B-NP
or CC O
amide IN B-NP
with IN O
the DT O
definitions NNS O
and CC O
preferences NNS O
as IN O
given VBN O
above IN O
, , O
optionally RB O
in IN O
combination NN O
with IN O
a DT O
retinoid NN B-NP
as RB O
well RB O
as IN O
the DT O
concept NN O
of IN O
a DT O
synergistic JJ O
effect NN O
between IN O
a DT O
retinoid NN B-NP
and CC O
a DT O
fatty JJ B-NP
acid NN I-NP
as IN O
defined VBN O
above IN O
may MD O
be VB O
demonstrated VBN O
in IN O
an DT O
in IN O
vitro NN O
test NN O
system NN O
using VBG O
human JJ O
primary JJ O
keratinocytes NNS O
as IN O
outlined VBN O
below IN O
. . O

The DT O
marker NN O
may MD O
be VB O
the DT O
enzyme NN O
Transglutaminase NNP O
1 CD O
, , O
which WDT O
is VBZ O
a DT O
well-known JJ O
and CC O
common JJ O
differentiation NN O
marker NN O
in IN O
human JJ O
epidermal NN O
cells NNS O
. . O

Epidermal JJ O
keratinocytes NNS O
are VBP O
isolated VBN O
from IN O
human JJ O
foreskin NN O
biopsies NNS O
and CC O
cultured VBD O
in IN O
keratinocyte NN O
serum NN O
free JJ O
medium NN O
( -LRB- O
KSFM NNP O
, , O
GIBCO NNP O
) -RRB- O
in IN O
a DT O
growth NN O
chamber NN O
with IN O
37<0>C NN O
and CC O
5 CD O
% NN O
CO2 NN O
. . O

At IN O
the DT O
second JJ O
passage NN O
, , O
cells NNS O
are VBP O
transferred VBN O
to TO O
6 CD O
well RB O
plates NNS O
and CC O
allowed VBD O
to TO O
reach VB O
approximately RB O
50 CD O
% NN O
surface NN O
confluence NN O
. . O

The DT O
active JJ O
ingredient( NN O
s VBZ O
) -RRB- O
are VBP O
solubilized VBN O
in IN O
ethanol NN B-NP
or CC O
ethanol/ NN B-NP
tetrahydrofuran NN B-NP
. . O

Retinoic JJ B-NP
acid NN I-NP
solutions NNS O
are VBP O
handled VBN O
under IN O
yellow JJ O
light NN O
conditions NNS O
only RB O
. . O

When WRB O
keratinocyte NN O
cultures NNS O
reaches VBZ O
the DT O
appropriate JJ O
confluence NN O
, , O
the DT O
KSFM NNP O
medium NN O
is VBZ O
supplemented VBN O
with IN O
1.3 CD O
mM JJ O
calcium NN B-NP
, , O
in IN O
order NN O
to TO O
induce VB O
keratinocyte NN O
differentiation NN O
and CC O
thus RB O
also RB O
induce VB O
TG1 DT O
expression NN O
, , O
and CC O
treatment NN O
is VBZ O
started VBN O
by IN O
adding VBG O
either CC O
a DT O
retinoid NN B-NP
such JJ O
as IN O
retinoic JJ B-NP
acid NN I-NP
or CC O
a DT O
fatty JJ B-NP
acid NN I-NP
or CC O
a DT O
salt NN O
, , O
ester NN B-NP
or CC O
amide IN B-NP
with IN O
the DT O
definitions NNS O
and CC O
preferences NNS O
as IN O
given VBN O
above IN O
or CC O
both DT O
substances NNS O
in IN O
combination NN O
. . O

For IN O
every DT O
sample NN O
, , O
medium JJ O
and/or CC O
treatment NN O
substances NNS O
are VBP O
changed VBN O
twice RB O
daily RB O
. . O

Seventy-two CD O
hours NNS O
after IN O
the DT O
beginning NN O
of IN O
the DT O
treatment NN O
, , O
cells NNS O
are VBP O
harvested VBN O
and CC O
the DT O
RNA NNP O
extracted VBD O
. . O

RNA NNP O
is VBZ O
reverse RB O
transcribed VBN O
into IN O
cDNA NN O
. . O

Relative JJ O
quantification NN O
of IN O
TG1 DT O
mRNA NN O
transcript NN O
levels NNS O
in IN O
control NN O
versus IN O
treatment NN O
cultures NNS O
are VBP O
determined VBN O
using VBG O
multiplexed JJ O
real JJ O
time NN O
PCR NN O
analysis NN O
. . O

The DT O
ability NN O
of IN O
the DT O
cosmetic NN O
or CC O
pharmaceutical JJ O
compositions NNS O
of IN O
the DT O
present JJ O
invention NN O
to TO O
reduce VB O
skin NN O
wrinkles NNS O
may MD O
be VB O
assessed VBN O
by IN O
profilometric JJ O
methods NNS O
described VBN O
in IN O
"Skin NNP O
topography NN O
measurement NN O
by IN O
interference NN O
fringe NN O
projection NN O
: : O
a DT O
technical JJ O
validation NN O
" '' O
. . O

( -LRB- O
Lagarde NNP O
J NNP O
M NNP O
; : O
Rouvrais NNP O
C NNP O
; : O
Black NNP O
D NNP O
; : O
Diridollou NNP O
S NNP O
; : O
Gall NNP O
Y NNP O
, , O
Skin NNP O
research NN O
and CC O
technology NN O
: : O
official JJ O
journal NN O
of IN O
International NNP O
Society NNP O
for IN O
Bioengineering NNP O
and CC O
the DT O
Skin NNP O
( -LRB- O
ISBS NNP O
) -RRB- O
[and CC O
] SYM O
International NNP O
Society NNP O
for IN O
Digital NNP O
Imaging NNP O
of IN O
Skin NNP O
( -LRB- O
ISDIS NNP O
) -RRB- O
[and CC O
] SYM O
International NNP O
Society NNP O
for IN O
Skin NNP O
Imaging NNP O
( -LRB- O
ISSI) NN O
( -LRB- O
2001 CD O
May NNP O
) -RRB- O
, , O
7( JJ O
2 CD O
) -RRB- O
, , O
112-21 CD O
or CC O
" `` O
Direct NNP O
and CC O
non-direct JJ O
measurement NN O
techniques NNS O
for IN O
analysis NN O
of IN O
skin NN O
surface NN O
topography" NN O
. . O

Fischer NNP O
T NNP O
W; NNP O
Wigger-Alberti NNP O
W; NNP O
Eisner NNP O
P. NNP O
, , O
Skin NNP O
pharmacology NN O
and CC O
applied VBD O
skin NN O
physiology NN O
( -LRB- O
1999 CD O
Jan-Apr NNP O
) -RRB- O
, , O
12(1-2 JJ O
) -RRB- O
, , O
1-11 JJ O
. . O

The DT O
ability NN O
of IN O
the DT O
compounds NNS O
and CC O
compositions NNS O
of IN O
the DT O
present JJ O
invention NN O
to TO O
stimulate VB O
or CC O
protect VB O
hair NN O
growth NN O
may MD O
be VB O
determined VBN O
with IN O
a DT O
mouse NN O
model NN O
described VBD O
for IN O
example NN O
in IN O
WO NN O
9817273 CD O
. . O

Instead RB O
of IN O
using VBG O
Cyclophosphamide NNP B-NP
( -LRB- O
Neostar NNP O
, , O
Pharmacia NNP O
) -RRB- O
to TO O
damage VB O
hair NN O
follicle NN O
Mitomycin NNP O
, , O
or CC O
Methotrexate NNP B-NP
can MD O
be VB O
used VBN O
. . O

It PRP O
is VBZ O
also RB O
possible JJ O
to TO O
detect VB O
hair NN O
growth NN O
acceleration NN O
with IN O
newborn JJ O
mice NNS O
. . O

They PRP O
have VBP O
a DT O
synchronized JJ O
hair NN O
cycle NN O
and CC O
approximately RB O
after IN O
3 CD O
weeks NNS O
all DT O
hair NN O
follicles VBZ O
go VB O
into IN O
the DT O
telogen NN O
phase NN O
. . O

Then RB O
the DT O
animals NNS O
are VBP O
treated VBN O
and CC O
it PRP O
is VBZ O
evaluated VBN O
how WRB O
fast RB O
and CC O
to TO O
what WP O
extend VB O
the DT O
hair NN O
is VBZ O
growing VBG O
Similar JJ O
tests NNS O
using VBG O
in IN O
vitro NN O
or CC O
in IN O
vivo JJ O
setups NNS O
can MD O
also RB O
be VB O
found VBN O
in IN O
J. NNP O
Invest NNP O
. . O

Dermato NNP O
. . O

symposium NN O
proceedings NNS O
3rd VBD O
Int NNP O
. . O

Meeting VBG O
of IN O
Hair NNP O
Research NNP O
Societies NNP O
, , O
8/1 CD O
, , O
p.39 FW O
- : O
45 CD O
( -LRB- O
2003 CD O
) -RRB- O
. . O

The DT O
following VBG O
examples NNS O
exemplify VBP O
the DT O
invention NN O
, , O
but CC O
they PRP O
should MD O
not RB O
be VB O
construed VBN O
as IN O
limiting VBG O
the DT O
invention NN O
. . O

Example NNP O
1 CD O
An DT O
anti-aging NN O
formulation NN O
containing VBG O
the DT O
ingredients NNS O
indicated VBN O
below IN O
can MD O
be VB O
prepared VBN O
in IN O
a DT O
manner NN O
known VBN O
per IN O
se NN O
. . O

Example JJ O
formulation NN O
number NN O
1 CD O

Ingredients NNS O
% NN O
( -LRB- O
w/w NN O
) -RRB- O

Glyceryl NNP B-NP
Myristate NNP I-NP
4.00 CD O

Cetyl NNP B-NP
Alcohol NNP I-NP
2.00 CD O

Steareth-2 NNP B-NP
2.00 CD O

Steareth-21 NNP B-NP
2.00 CD O
lsopropyl NN B-NP
Myristate NNP I-NP
5.00 CD O

Tocopherol NNP B-NP
Acetate NNP B-NP
0.50 CD O

Ethylhexyl NNP B-NP
Methoxycinnamate NNP I-NP
4.00 CD O

Ethylhexyl NNP B-NP
Salicylate NNP I-NP
2.00 CD O

Butyl NNP B-NP
Methoxydibenzoylmethane NNP I-NP
1.00 CD O

Almond NNP O
Oil NNP O
2.00 CD O

BHT NNP O
0.05 CD O

Phenoxyethanol NNP B-NP
& CC O
Methylparaben NNP B-NP
& CC O
Ethylparaben NNP B-NP
& CC O
Propylparaben NNP B-NP
& CC O
0.80 CD O
Butylparaben NNP B-NP
& CC O
lsopropylparaben RB B-NP

Disodium NNP B-NP
EDTA NNP I-NP
0.10 CD O

D-Panthenol NNP B-NP
0.30 CD O

Propylene NNP B-NP
Glycol NNP I-NP
4.00 CD O

Polyacrylamide NNP B-NP
& CC O
C13-14 NNP O
lsoparaffin IN B-NP
& CC O
Laureth-7 NNP B-NP
0.50 CD O

9-hydroxy JJ B-NP
stearic JJ I-NP
acid NN I-NP
0.50 CD O

Retinol NNP B-NP
15D CD O
( -LRB- O
Caprylic/Capric NNP B-NP
Triglyceride NNP B-NP
& CC O
Retinol NNP B-NP
) -RRB- O
0.50 CD O

Water NNP B-NP
Ad NNP O
100 CD O

Triethanolamine NNP B-NP
q.s NNS O
. . O

Example NN O
2 CD O

An DT O
anti-aging NN O
formulations NNS O
containing VBG O
the DT O
ingredients NNS O
indicated VBN O
below IN O
can MD O
be VB O
prepared VBN O
in IN O
a DT O
manner NN O
known VBN O
per IN O
se NN O
. . O

Example JJ O
formulation NN O
number NN O
2 CD O

Ingredients NNS O
% NN O
( -LRB- O
w/w NN O
) -RRB- O

Glyceryl NNP B-NP
Myristate NNP I-NP
4.00 CD O

Cetyl NNP B-NP
Alcohol NNP I-NP
2.00 CD O

Steareth-2 NNP B-NP
2.00 CD O

Steareth-21 NNP B-NP
2.00 CD O
lsopropyl NN B-NP
Myristate NNP I-NP
5.00 CD O

Tocopheryl NNP B-NP
Acetate NNP I-NP
0.50 CD O

Ethylhexyl NNP B-NP
Methoxycinnamate NNP I-NP
4.00 CD O

Ethylhexyl NNP B-NP
Salicylate NNP I-NP
2.00 CD O

Butyl NNP B-NP
Methoxydibenzoylmethane NNP I-NP
1.00 CD O

Almond NNP O
Oil NNP O
2.00 CD O

BHT NNP O
0.05 CD O
Phenoxyethanol NNP B-NP
& CC O
Methylparaben NNP B-NP
& CC O
Ethylparaben NNP B-NP
& CC O
Propylparaben NNP B-NP
& CC O
0.80 CD O
Butylparaben NNP B-NP
& CC O
lsopropylparaben RB B-NP

Disodium NNP B-NP
EDTA NNP I-NP
0.10 CD O

D-Panthenol NNP B-NP
0.30 CD O

Propylene NNP B-NP
Glycol NNP I-NP
4.00 CD O

Polyacrylamide NNP B-NP
& CC O
C13-14 NNP O
lsoparaffin IN B-NP
& CC O
Laureth-7 NNP B-NP
0.50 CD O

Water NNP B-NP
Ad NNP O
100 CD O

9-hydroxy-stearic JJ B-NP
acid NN I-NP
0.50 CD O

Retinol NNP B-NP
Acetate NNP I-NP
2.8 CD O
Ml NNP O
0.10 CD O

Triethanolamine NNP B-NP
q.s NNS O
. . O

Example NN O
3 CD O

A DT O
facial JJ O
treatment NN O
formulation NN O
containing VBG O
the DT O
ingredients NNS O
indicated VBN O
below IN O
can MD O
be VB O
prepared VBN O
in IN O
a DT O
manner NN O
known VBN O
per IN O
se NN O

Formulation NNP O
No. NN O
3 CD O

Inqredients NNS O
% NN O
( -LRB- O
w/w NN O
) -RRB- O

Glyceryl NNP B-NP
Myristate NNP I-NP
5.00 CD O

Cetyl NNP B-NP
Alcohol NNP I-NP
2.00 CD O

Cetyl NNP B-NP
Phosphate NNP I-NP
2.00 CD O
lsopropyl NN B-NP
Myristate NNP I-NP
10.00 CD O

Tocopheryl NNP B-NP
Acetate NNP I-NP
0.30 CD O

Almond NNP O
Oil NNP O
2.00 CD O

BHT NNP O
0.05 CD O

Phenoxyethanol NNP B-NP
& CC O
Methylparaben NNP B-NP
& CC O
Ethylparaben NNP B-NP
& CC O
Propylparaben NNP B-NP
& CC O
0.60 CD O

Butylparaben NNP B-NP
& CC O
lsopropylparaben RB B-NP

Tromethamine NN B-NP
0.90 CD O

Water NNP B-NP
Ad NNP O
. . O
100 CD O

D-Panthenol NNP B-NP
0.20 CD O

Disodium NNP B-NP
EDTA NNP I-NP
0.10 CD O

Propylene NNP B-NP
Glycol NNP I-NP
4.00 CD O

Polyacrylamide NNP B-NP
& CC O
C13-14 NNP O
lsoparaffin IN O
& CC O
Laureth-7 NNP O
2.00 CD O

9-hydroxy JJ B-NP
stearic JJ I-NP
acid NN I-NP
0.50 CD O

Retinol NNP B-NP
15D CD O
( -LRB- O
Caprylic/Capric NNP B-NP
Triglyceride NNP B-NP
& CC O
Retinol NNP B-NP
) -RRB- O
0.50 CD O

Triethanolamine NNP B-NP
q.s NNS O
. . O

Example NNP O
4 CD O

A DT O
facial JJ O
treatment NN O
formulation NN O
containing VBG O
the DT O
ingredients NNS O
indicated VBN O
below IN O
can MD O
be VB O
prepared VBN O
in IN O
a DT O
manner NN O
known VBN O
per IN O
se NN O

Formulation NNP O
No. NN O
4 CD O

Ingredients NNS O
% NN O
( -LRB- O
w/w NN O
) -RRB- O

Glyceryl NNP B-NP
Myristate NNP I-NP
5.00 CD O

Cetyl NNP B-NP
Alcohol NNP I-NP
2.00 CD O

Cetyl NNP B-NP
Phosphate NNP I-NP
2.00 CD O
lsopropyl NN B-NP
Myristate NNP I-NP
10.00 CD O

Tocopheryl NNP B-NP
Acetate NNP I-NP
0.30 CD O

Almond NNP O
Oil NNP O
2.00 CD O

BHT NNP O
0.05 CD O

Phenoxyethanol NNP B-NP
& CC O
Methylparaben NNP B-NP
& CC O
Ethylparaben NNP B-NP
& CC O
Propylparaben NNP B-NP
& CC O
0.60 CD O

Butylparaben NNP B-NP
& CC O
lsopropylparaben RB B-NP

Tromethamine NN B-NP
0.90 CD O

Water NNP B-NP
Ad NNP O
. . O
100 CD O

D-Panthenol NNP B-NP
0.20 CD O

Disodium NNP B-NP
EDTA NNP I-NP
0.10 CD O

Propylene NNP B-NP
Glycol NNP I-NP
4.00 CD O

Polyacrylamide NNP B-NP
& CC O
C13-14 NNP B-NP
lsoparaffin IN I-NP
& CC O
Laureth-7 NNP B-NP
2.00 CD O

9-hydroxy JJ B-NP
stearic JJ I-NP
acid NN I-NP
0.50 CD O

Retinol NNP B-NP
Acetate NNP I-NP
2.8 CD O
Ml NNP O
0.10 CD O

Triethanolamine NNP B-NP
q.s NNS O
. . O

Example NNP O
5 CD O

Hair NN O
loss NN O
sera NN O
containing VBG O
the DT O
ingredients NNS O
indicated VBD O
below IN O
can MD O
be VB O
prepared VBN O
in IN O
a DT O
manner NN O
known VBN O
per IN O
se NN O

Formulation NN O
No DT O
5 CD O

Ingredients NNS O
% NN O
( -LRB- O
w/w NN O
) -RRB- O

Water NNP B-NP
Ad NNP O
. . O
100 CD O

Ethanol NNP B-NP
8.00 CD O
lsopropanol NN B-NP
4.00 CD O

Propylene NNP B-NP
Glycol NNP I-NP
5.00 CD O

D-Panthenol NNP B-NP
0.20 CD O

PEG-12 NN B-NP
Dimethicone NNP I-NP
0.20 CD O

PEG-40 DT B-NP
Hydrogenated NNP O
Castor NNP O
Oil NNP O
4.00 CD O

Phytantriol NNP B-NP
0.05 CD O

Vitamin NNP B-NP
E NNP I-NP
Acetate NNP I-NP
0.10 CD O

9-hydroxy JJ B-NP
stearic JJ I-NP
acid NN I-NP
0.50 CD O

Retinol NNP B-NP
15D CD O
( -LRB- O
Caprylic/Capric NNP B-NP
Triglyceride NNP B-NP
& CC O
Retinol NNP B-NP
) -RRB- O
0.50 CD O

NaOH NNP B-NP
10 CD O
% NN O
q.s NNS O
. . O

Example NNP O
6 CD O

Hair NN O
loss NN O
sera NN O
containing VBG O
the DT O
ingredients NNS O
indicated VBD O
below IN O
can MD O
be VB O
prepared VBN O
in IN O
a DT O
manner NN O
known VBN O
per IN O
se NN O

Formulation IN O
No DT O
6 CD O

Ingredients NNS O
% NN O
( -LRB- O
w/w NN O
) -RRB- O

Water NNP B-NP
Ad NNP O
. . O
100 CD O

Ethanol NNP B-NP
8.00 CD O
lsopropanol NN B-NP
4.00 CD O

Propylene NNP B-NP
Glycol NNP I-NP
5.00 CD O

D-Panthenol NNP B-NP
0.20 CD O

PEG-12 NN B-NP
Dimethicone NNP I-NP
0.20 CD O

PEG-40 DT B-NP
Hydrogenated NNP O
Castor NNP O
Oil NNP O
4.00 CD O

Phytantriol NNP B-NP
0.05 CD O

Vitamin NNP B-NP
E NNP I-NP
Acetate NNP B-NP
0.10 CD O

9-hydroxyy JJ B-NP
stearic JJ I-NP
acid NN I-NP
0.50 CD O

Retinol NNP B-NP
Acetate NNP I-NP
2.8 CD O
Ml NNP O
0.10 CD O

NaOH NNP B-NP
10 CD O
% NN O
q.s NNS O
. . O

Example NN O
7 CD O

A DT O
skin NN O
fortifier NN O
lotion NN O
containing VBG O
the DT O
ingredients NNS O
indicated VBN O
below IN O
can MD O
be VB O
prepared VBN O
in IN O
a DT O
manner NN O
known VBN O
per IN O
se NN O

Formulation NNP O
No. NN O
7 CD O

Ingredients NNS O
% NN O
( -LRB- O
w/w NN O
) -RRB- O

Water NNP B-NP
Ad NNP O
. . O
100 CD O

D- NNP B-NP
Panthenol NNP I-NP
0.05 CD O

Sodium NNP B-NP
Ascorbyl NNP I-NP
Phosphate NNP I-NP
0.20 CD O

Propylene NNP B-NP
Glycol NNP I-NP
5.00 CD O

Acrylates/C NNP B-NP
10-30 CD B-NP
Alkyl NNP I-NP
Acrylate NNP I-NP
Crosspolymer NNP O
0.50 CD O

Sodium NNP B-NP
Hydroxide NNP I-NP
30 CD O
% NN O
0.40 CD O

Disodium NNP B-NP
EDTA NNP I-NP
0.10 CD O

Squalane NNP B-NP
2.00 CD O

Phenoxyethanol NNP B-NP
& CC O
Methylparaben NNP B-NP
& CC O
Ethylparaben NNP B-NP
& CC O
Propylparaben NNP B-NP
& CC O
0.80 CD O

Butylparaben NNP B-NP
& CC O
lsopropylparaben RB B-NP

Coco-Caprylate/Caprate JJ O
4.00 CD O

BHT NNP O
0.05 CD O

Tocopheryl NNP B-NP
Acetate NNP I-NP
0.10 CD O

Cyclomethicone NN B-NP
3.00 CD O

Glycerin NNP B-NP
3.00 CD O

9-hydroxy JJ B-NP
stearic JJ I-NP
acid NN I-NP
0.50 CD O

Retinol NNP B-NP
15D CD O
( -LRB- O
Caprylic/Capric NNP B-NP
Triglyceride NNP B-NP
& CC O
Retinol NNP B-NP
) -RRB- O
0.50 CD O

Sodium NNP B-NP
Hydroxide NNP I-NP
10 CD O
% NN O
q.s NNS O
. . O

Example NNP O
8 CD O

A DT O
skin NN O
fortifier NN O
lotion NN O
containing VBG O
the DT O
ingredients NNS O
indicated VBN O
below IN O
can MD O
be VB O
prepared VBN O
in IN O
a DT O
manner NN O
known VBN O
per IN O
se NN O

Formulation NN O
No. NN O
8 CD O

Inqredients NNS O
% NN O
( -LRB- O
w/w NN O
) -RRB- O

Water NNP B-NP
Ad NNP O
. . O
100 CD O

D- NNP B-NP
Panthenol NNP I-NP
0.05 CD O

Sodium NNP B-NP
Ascorbyl NNP I-NP
Phosphate NNP I-NP
0.20 CD O

Propylene NNP B-NP
Glycol NNP I-NP
5.00 CD O

Acrylates/C NNP B-NP
10-30 CD O
Alkyl NNP B-NP
Acrylate NNP B-NP
Crosspolymer NNP O
0.50 CD O

Sodium NNP B-NP
Hydroxide NNP I-NP
30 CD O
% NN O
0.40 CD O

Disodium NNP B-NP
EDTA NNP I-NP
0.10 CD O

Squalane NNP B-NP
2.00 CD O

Phenoxyethanol NNP B-NP
& CC O
Methylparaben NNP B-NP
& CC O
Ethylparaben NNP B-NP
& CC O
Propylparaben NNP B-NP
& CC O
0.80 CD O

Butylparaben NNP B-NP
& CC O
lsopropylparaben RB B-NP

Coco-Caprylate/Caprate JJ O
4.00 CD O

BHT NNP O
0.05 CD O

Tocopheryl NNP B-NP
Acetate NNP I-NP
0.10 CD O

Cyclomethicone NN B-NP
3.00 CD O

Glycerin NNP B-NP
3.00 CD O

9-hydroxy JJ B-NP
stearic JJ I-NP
acid NN I-NP
0.50 CD O

Retinol NNP B-NP
Acetate NNP I-NP
2.8 CD O
Ml NNP O
0.10 CD O

Sodium NNP B-NP
Hydroxide NNP I-NP
10 CD O
% NN O
q.s NNS O
. . O

Example NNP O
9 CD O

A DT O
formulation NN O
to TO O
treat VB O
age NN O
spots NNS O
containing VBG O
the DT O
ingredients NNS O
indicated VBN O
below IN O
can MD O
be VB O
prepared VBN O
in IN O
a DT O
manner NN O
known VBN O
per IN O
se NN O

Formulation NNP O
No. NN O
9 CD O

Ingredients NNS O
% NN O
( -LRB- O
w[ JJ O
Lambda]v NN O
) -RRB- O

Water NNP B-NP
Ad NNP O
. . O
100 CD O

Polyquaternium-10 NNP B-NP
0.10 CD O

D- NNP B-NP
Panthenol NNP I-NP
0.50 CD O

Sodium NNP B-NP
Ascorbyl NNP I-NP
Phosphate NNP I-NP
1.00 CD O

Niacinamid NNP B-NP
0.50 CD O

Propylene NNP B-NP
Glycol NNP I-NP
4.00 CD O

Glycerin NNP B-NP
3.00 CD O

PEG-12 NN B-NP
Dimethicone NNP B-NP
0.20 CD O

Disodium NNP B-NP
EDTA NNP I-NP
0.10 CD O

Polysorbate NNP B-NP
20 CD O
5.00 CD O

Phenoxyethanol NNP B-NP
& CC O
Methylparaben NNP B-NP
& CC O
Ethylparaben NNP B-NP
& CC O
Propylparaben NNP B-NP
& CC O
0.80 CD O

Butylparaben NNP B-NP
& CC O
lsopropylparaben RB B-NP

9-hydroxy JJ B-NP
stearic JJ I-NP
acid NN I-NP
0.50 CD O

Retinol NNP B-NP
15D CD O
( -LRB- O
Caprylic/Capric NNP B-NP
Triglyceride NNP B-NP
& CC O
Retinol NNP B-NP
) -RRB- O
0.50 CD O

Sodium NNP B-NP
Hydroxide NNP I-NP
10 CD O
% NN O
q.s NNS O
. . O

Example NNP O
10 CD O

A DT O
formulation NN O
to TO O
treat VB O
age NN O
spots NNS O
containing VBG O
the DT O
ingredients NNS O
indicated VBN O
below IN O
can MD O
be VB O
prepared VBN O
in IN O
a DT O
manner NN O
known VBN O
per IN O
se NN O

Formulation NNP O
No. NN O
10 CD O

Inqredients NNS O
% NN O
( -LRB- O
w/w NN O
) -RRB- O

Water NNP B-NP
Ad NNP O
. . O
100 CD O
. . O

Polyquaternium-10 NNP B-NP
0.10 CD O

D- NNP B-NP
Panthenol NNP I-NP
0.50 CD O

Sodium NNP B-NP
Ascorbyl NNP I-NP
Phosphate NNP I-NP
1.00 CD O

Niacinamid NNP B-NP
0.50 CD O

Propylene NNP B-NP
Glycol NNP I-NP
4.00 CD O

Glycerin NNP B-NP
3.00 CD O

PEG-12 NN B-NP
Dimethicone NNP B-NP
0.20 CD O

Disodium NNP B-NP
EDTA NNP I-NP
0.10 CD O

Polysorbate NNP B-NP
20 CD O
5.00 CD O

Phenoxyethanol NNP B-NP
& CC O
Methylparaben NNP B-NP
& CC O
Ethylparaben NNP B-NP
& CC O
Propylparaben NNP B-NP
& CC O
0.80 CD O

Butylparaben NNP B-NP
& CC O
lsopropylparaben RB B-NP

9-hydroxy JJ B-NP
stearic JJ I-NP
acid NN I-NP
0.50 CD O

Retinol NNP B-NP
Acetate NNP I-NP
2.8 CD O
Ml NNP O
0.10 CD O

Sodium NNP B-NP
Hydroxide NNP I-NP
10 CD O
% NN O
q.s NNS O
. . O

Example NNP O
11 CD O

Anti-cellulite JJ O
formulations NNS O
containing VBG O
the DT O
ingredients NNS O
indicated VBN O
below IN O
can MD O
be VB O
prepared VBN O
in IN O
a DT O
manner NN O
known VBN O
per IN O
se NN O

Formulation NNP O
No. NN O
11 CD O

Inqredients NNS O
% NN O
( -LRB- O
w/w NN O
) -RRB- O

Water NNP B-NP
Ad NNP O
. . O
100 CD O

Caffeine NNP B-NP
1.00 CD O

D-Panthenol NNP B-NP
0.50 CD O

Glycerin NNP B-NP
4.00 CD O

Butylene NNP B-NP
Glycol NNP I-NP
2.00 CD O

Acrylates/C NNP B-NP
10-30 CD B-NP
Alkyl NNP I-NP
Acrylate NNP I-NP
Crosspolymer NNP O
0.20 CD O

Disodium NNP B-NP
EDETA NNP I-NP
0.10 CD O

Arachidyl NNP B-NP
Alcohol NNP I-NP
& CC O
Behenyl NNP B-NP
Alcohol NNP I-NP
& CC O
Arachidyl NNP B-NP
Glucoside NNP I-NP
5.00 CD O

Squalane NNP B-NP
2.00 CD O

Mineral NNP O
Oil NNP O
4.00 CD O

Phenoxyethanol NNP B-NP
& CC O
Methylparaben NNP B-NP
& CC O
Ethylparaben NNP B-NP
& CC O
Propylparaben NNP B-NP
& CC O
0.80 CD O

Butylparaben NNP B-NP
& CC O
lsopropylparaben VBN B-NP
lsononyl NN B-NP
lsononanoate NN I-NP
4.00 CD O

BHT NNP O
0.05 CD O

Cetyl NNP B-NP
Alcohol NNP I-NP
2.00 CD O

Dimethicone NNP B-NP
0.50 CD O

Tocopheryl NNP B-NP
Acetate NNP I-NP
0.10 CD O

9-hydroxy JJ B-NP
stearic JJ I-NP
acid NN I-NP
0.50 CD O

Retinol NNP B-NP
15D CD O
( -LRB- O
Caprylic/Capric NNP B-NP
Triglyceride NNP B-NP
& CC O
Retinol NNP B-NP
) -RRB- O
0.50 CD O

Triethanolamine NNP B-NP
q.s NNS O
. . O

Example NNP O
12 CD O

An DT O
anti-cellulite JJ O
formulation NN O
containing VBG O
the DT O
ingredients NNS O
indicated VBN O
below IN O
can MD O
be VB O
prepared VBN O
in IN O
a DT O
manner NN O
known VBN O
per IN O
se NN O

Formulation NNP O
No. NN O
12 CD O

Inqredients NNS O
% NN O
( -LRB- O
w/w NN O
) -RRB- O

Water NNP B-NP
Ad NNP O
100 CD O

Caffeine NNP B-NP
1 CD O
00 CD O

D-Panthenol NNP B-NP
0 CD O
50 CD O

Glycerin NNP B-NP
4 CD O
00 CD O

Butylene NNP B-NP
Glycol NNP I-NP
2 CD O
00 CD O

Acrylates/C NNP B-NP
10-30 CD O
Alkyl NNP B-NP
Acrylate NNP B-NP
Crosspolymer NNP O
0 CD O
20 CD O

Disodium NNP B-NP
EDETA NNP I-NP
0 CD O
10 CD O

Arachidyl NNP B-NP
Alcohol NNP I-NP
& CC O
Behenyl NNP B-NP
Alcohol NNP I-NP
& CC O
Arachidyl NNP B-NP
Glucoside NNP I-NP
5 CD O
00 CD O

Squalane NNP B-NP
2 CD O
00 CD O

Mineral NNP O
Oil NNP O
4 CD O
00 CD O

Phenoxyethanol NNP B-NP
& CC O
Methylparaben NNP B-NP
& CC O
Ethylparaben NNP B-NP
& CC O
Propylparaben NNP B-NP
& CC O
0 CD O
80 CD O

Butylparaben NNP B-NP
& CC O
lsopropylparaben VBN B-NP
lsononyl NN B-NP
lsononanoate NN I-NP
4 CD O
00 CD O

BHT NNP O
0 CD O
05 CD O

Cetyl NNP B-NP
Alcohol NNP I-NP
2 CD O
00 CD O

Dimethicone NNP B-NP
0 CD O
50 CD O

Tocopherol NNP B-NP
Acetate NNP B-NP
0 CD O
10 CD O

9-hydroxy JJ B-NP
stearic JJ I-NP
acid NN I-NP
0 CD O
50 CD O

Retinol NNP B-NP
Acetate NNP I-NP
2 CD O
8 CD O
Ml NN O
0 CD O
10 CD O

Triethanolamine NN B-NP
q NN O
s VBZ O

Example NNP O
13 CD O

A DT O
skin NN O
repair NN O
formulation NN O
containing VBG O
the DT O
ingredients NNS O
indicated VBN O
below IN O
can MD O
be VB O
prepared VBN O
in IN O
a DT O
manner NN O
known VBN O
per IN O
se NN O

Formulation NNP O
No. NN O
13 CD O

Inqredients NNS O
% NN O
( -LRB- O
w/w NN O
) -RRB- O

Polyglyceryl-2 NN B-NP
Dipolyhydroxystearate NNP I-NP
4.00 CD O

Polyglyceryl-3 NN B-NP
Diisostearate NNP I-NP
2.00 CD O

Beeswax NNP O
2.00 CD O

Zinc NNP B-NP
Stearate NNP I-NP
2.00 CD O

Caprylic/Capric NNP B-NP
Triglyceride NNP B-NP
3.00 CD O

Cetearyl NNP B-NP
lsononanoate NN I-NP
8.00 CD O

Dicaprylyl NNP B-NP
Ether NNP I-NP
5.00 CD O

BHT NNP O
0.05 CD O

Phenoxyethanol NNP B-NP
& CC O
Methylparaben NNP B-NP
& CC O
Ethylparaben NNP B-NP
& CC O
Propylparaben NNP B-NP
& CC O
0.60 CD O

Butylparaben NNP B-NP
& CC O
lsopropylparaben RB B-NP

Water NNP B-NP
Ad NNP O
. . O
100 CD O

D-Panthenol NNP B-NP
0.20 CD O

Disodium NNP B-NP
EDTA NNP I-NP
0.10 CD O

Propylene NNP B-NP
Glycol NNP I-NP
4.00 CD O

9-hydroxy JJ B-NP
stearic JJ I-NP
acid NN I-NP
0.55 CD O

Retinol NNP B-NP
15D CD O
( -LRB- O
Caprylic/Capric NNP B-NP
Triglyceride NNP B-NP
& CC O
Retinol NNP B-NP
) -RRB- O
0.50 CD O

Example NNP O
14 CD O

A DT O
skin NN O
repair NN O
formulation NN O
containing VBG O
the DT O
ingredients NNS O
indicated VBN O
below IN O
can MD O
be VB O
prepared VBN O
in IN O
a DT O
manner NN O
known VBN O
per IN O
se NN O

Formulation NNP O
No. NN O
14 CD O

Inqredients NNS O
% NN O
( -LRB- O
w/w NN O
) -RRB- O

Polyglyceryl-2 NN B-NP
Dipolyhydroxystearate NNP I-NP
4.00 CD O

Polyglyceryl-3 NN B-NP
Diisostearate NNP I-NP
2.00 CD O

Beeswax NNP O
2.00 CD O

Zinc NNP B-NP
Stearate NNP I-NP
2.00 CD O

Caprylic/Capric NNP B-NP
Triglyceride NNP B-NP
3.00 CD O

Cetearyl NNP B-NP
lsononanoate NN I-NP
8.00 CD O

Dicaprylyl NNP B-NP
Ether NNP I-NP
5.00 CD O

BHT NNP O
0.05 CD O

Phenoxyethanol NNP B-NP
& CC O
Methylparaben NNP B-NP
& CC O
Ethylparaben NNP B-NP
& CC O
Propylparaben NNP B-NP
& CC O
0.60 CD O

Butylparaben NNP B-NP
& CC O
lsopropylparaben RB B-NP

Water NNP B-NP
Ad NNP O
. . O
100 CD O

D-Panthenol NNP B-NP
0.20 CD O

Disodium NNP B-NP
EDTA NNP I-NP
0.10 CD O

Propylene NNP B-NP
Glycol NNP I-NP
4.00 CD O

9-hydroxy JJ B-NP
stearic JJ I-NP
acid NN I-NP
0.50 CD O

Retinol NNP B-NP
Acetate NNP I-NP
2.8 CD O
Ml NNP O
0.10 CD O

What WP O
is VBZ O
claimed VBN O
is VBZ O
: : O

1 CD O
. . O

A DT O
cosmetic JJ O
or CC O
pharmaceutical JJ O
composition NN O
comprising VBG O
a DT O
fatty NN B-NP
acid NN I-NP
containing VBG O
6 CD O
to TO O
18 CD O
carbon NN B-NP
atoms NNS O
, , O
which WDT O
carries VBZ O
one CD O
or CC O
two CD O
hydroxy JJ B-NP
, , O
alkoxy JJ B-NP
, , O
preferably RB O
methoxy NN B-NP
or CC O
ethoxy NN B-NP
, , O
C2-C4-acylprotected JJ O
amino NN B-NP
, , O
preferably RB O
C2 NN O
, , O
or CC O
oxo NN B-NP
group NN O
, , O
or CC O
a DT O
salt NN O
, , O
ester NN B-NP
or CC O
amide IN B-NP
of IN O
such JJ O
acids NNS B-NP
or CC O
a DT O
mixture NN O
of IN O
these DT O
acids NNS B-NP
; : O
and CC O
a DT O
carrier NN O
conventionally RB O
used VBD O
in IN O
cosmetic JJ O
or CC O
pharmaceutical JJ O
compositions NNS O
. . O

2. VBG O
The DT O
composition NN O
as IN O
in IN O
claim NN O
1 CD O
, , O
wherein WRB O
the DT O
aliphatic JJ B-NP
fatty JJ I-NP
acid NN I-NP
is VBZ O
a DT O
saturated JJ B-NP
straight- NNS I-NP
chain NN I-NP
fatty JJ I-NP
acid NN I-NP
or CC O
[omega]-branched-chain JJ B-NP
fatty JJ I-NP
acid NN I-NP
. . O

3. VBG O
The DT O
composition NN O
as IN O
in IN O
claim NN O
2 CD O
wherein WRB O
the DT O
saturated JJ O
straight-chain NN O
or CC O
[omega] SYM B-NP
- : I-NP
branched JJ I-NP
chain NN I-NP
fatty JJ I-NP
acid NN I-NP
is VBZ O
substituted VBN O
between IN O
the DT O
positions NNS O
6 CD O
and CC O
12 CD O
. . O

4 LS O
. . O
The DT O
composition NN O
as IN O
in IN O
claim NN O
3 CD O
wherein WRB O
the DT O
saturated JJ O
straight-chain JJ O
or CC O
[omega] SYM O
- : O
branched JJ O
fatty JJ B-NP
acid NN I-NP
is VBZ O
substituted VBN O
by IN O
hydroxy JJ B-NP
. . O

5 CD O
. . O
The DT O
composition NN O
as IN O
in IN O
claim NN O
4 CD O
wherein WRB O
the DT O
fatty JJ B-NP
acid NN I-NP
is VBZ O
9-hydroxy JJ B-NP
stearic JJ I-NP
acid NN I-NP
. . O

6 CD O
. . O

The DT O
composition NN O
as IN O
in IN O
any DT O
one CD O
of IN O
claims NNS O
1 CD O
to TO O
5 CD O
comprising NN O
additionally RB O
a DT O
retinoid NN B-NP
. . O

7. VBG O
The DT O
composition NN O
as IN O
in IN O
any DT O
one CD O
of IN O
claims NNS O
1 CD O
to TO O
6 CD O
wherein WRB O
the DT O
retinoid NN B-NP
is VBZ O
retinoic JJ B-NP
acid NN I-NP
or CC O
a DT O
derivative JJ O
thereof NN O
. . O

8. VBG O
The DT O
composition NN O
as IN O
in IN O
any DT O
one CD O
of IN O
claims NNS O
1 CD O
to TO O
6 CD O
wherein WRB O
the DT O
retinoid NN B-NP
is VBZ O
retinyl JJ B-NP
acetate NN I-NP
, , O
phenylbutyrate NN B-NP
, , O
propionate JJ B-NP
, , O
octanoate JJ B-NP
, , O
laurate NN B-NP
, , O
palmitate NN B-NP
, , O
oleate JJ B-NP
, , O
linoleate JJ B-NP
; : O
retinyl NN B-NP
alkyl NN I-NP
carbonate NN I-NP
; : O
retinoxytrimethylsilane NN B-NP
; : O
( -LRB- B-NP
all DT I-NP
trans)-retinal JJ I-NP
or CC O
its PRP$ O
acetals NNS B-NP
; : O
or CC O
methoxy JJ B-NP
PEG-12 NN I-NP
retinamide NN I-NP
. . O

9 CD O
. . O
The DT O
composition NN O
according VBG O
to TO O
any DT O
of IN O
claims NNS O
1 CD O
to TO O
8 CD O
, , O
wherein WRB O
the DT O
amount NN O
of IN O
the DT O
fatty JJ B-NP
acid NN I-NP
is VBZ O
from IN O
about IN O
0.0001 CD O
to TO O
about IN O
50 CD O
% NN O
by IN O
weight NN O
of IN O
the DT O
total JJ O
composition NN O
. . O

10 CD O
. . O

The DT O
composition NN O
according VBG O
to TO O
any DT O
of IN O
claims NNS O
1 CD O
to TO O
8 CD O
, , O
wherein WRB O
the DT O
amount NN O
of IN O
the DT O
fatty JJ B-NP
acid NN I-NP
is VBZ O
from IN O
about IN O
0.001 CD O
to TO O
about IN O
20 CD O
% NN O
by IN O
weight NN O
of IN O
the DT O
total JJ O
composition NN O
. . O

11 CD O
. . O

The DT O
composition NN O
according VBG O
to TO O
any DT O
of IN O
claims NNS O
1 CD O
to TO O
8 CD O
, , O
wherein WRB O
the DT O
amount NN O
of IN O
the DT O
compound NN O
of IN O
the DT O
fatty JJ B-NP
acid NN I-NP
is VBZ O
from IN O
about IN O
0.01 CD O
to TO O
about IN O
1 CD O
% NN O
by IN O
weight NN O
of IN O
the DT O
total JJ O
composition NN O
. . O

12 CD O
. . O
The DT O
composition NN O
according VBG O
to TO O
any DT O
of IN O
claims NNS O
6 CD O
to TO O
11 CD O
, , O
wherein WRB O
the DT O
amount NN O
of IN O
the DT O
retinoid NN B-NP
or CC O
derivative JJ O
thereof , O
is VBZ O
from IN O
about IN O
0.001 CD O
to TO O
about IN O
50 CD O
% NN O
by IN O
weight NN O
of IN O
the DT O
total JJ O
composition NN O
. . O

13 CD O
. . O

The DT O
composition NN O
according VBG O
to TO O
any DT O
of IN O
claims NNS O
6 CD O
to TO O
11 CD O
wherein WRB O
the DT O
amount NN O
of IN O
the DT O
retinoid NN B-NP
or CC O
derivative JJ O
thereof , O
is VBZ O
from IN O
about IN O
0.001 CD O
to TO O
about IN O
20 CD O
% NN O
by IN O
weight NN O
of IN O
the DT O
total JJ O
composition NN O
. . O

14 CD O
. . O

The DT O
composition NN O
according VBG O
to TO O
any DT O
of IN O
claims NNS O
6 CD O
to TO O
11 CD O
, , O
wherein WRB O
the DT O
amount NN O
of IN O
the DT O
retinoid NN B-NP
or CC O
derivative JJ O
thereof , O
is VBZ O
from IN O
about IN O
0.01 CD O
to TO O
about IN O
1 CD O
% NN O
by IN O
weight NN O
of IN O
the DT O
total JJ O
composition NN O
. . O

15 CD O
. . O

The DT O
composition NN O
according VBG O
to TO O
any DT O
of IN O
claims NNS O
6 CD O
to TO O
14 CD O
, , O
wherein WRB O
the DT O
ratio NN O
of IN O
the DT O
fatty JJ B-NP
acid NN I-NP
to TO O
the DT O
retinoid NN B-NP
or CC O
derivative JJ O
thereof , O
is VBZ O
from IN O
about IN O
1000 CD O
: : O
1 CD O
to TO O
about IN O
1 CD O
: : O
1000 CD O
by IN O
weight NN O
. . O

16 CD O
. . O

The DT O
composition NN O
according VBG O
to TO O
any DT O
of IN O
claims NNS O
6 CD O
to TO O
14 CD O
, , O
wherein WRB O
the DT O
ratio NN O
of IN O
the DT O
fatty JJ B-NP
acid NN I-NP
to TO O
the DT O
retinoid NN B-NP
or CC O
derivative JJ O
thereof , O
is VBZ O
from IN O
about IN O
100 CD O
: : O
1 CD O
to TO O
about IN O
1 CD O
: : O
100 CD O
by IN O
weight NN O
. . O

17 CD O
. . O

The DT O
composition NN O
according VBG O
to TO O
any DT O
of IN O
claims NNS O
6 CD O
to TO O
14 CD O
, , O
wherein WRB O
the DT O
ratio NN O
of IN O
the DT O
fatty JJ B-NP
acid NN I-NP
to TO O
the DT O
retinoid NN B-NP
or CC O
derivative JJ O
thereof , O
is VBZ O
from IN O
about IN O
30 CD O
: : O
1 CD O
to TO O
about IN O
1 CD O
: : O
30 CD O
by IN O
weight NN O
. . O

18 CD O
. . O

A DT O
composition NN O
as IN O
in IN O
any DT O
one CD O
of IN O
claims NNS O
1 CD O
to TO O
17 CD O
, , O
which WDT O
is VBZ O
for IN O
prevention NN O
or CC O
treatment NN O
of IN O
symptoms NNS O
caused VBN O
by IN O
negative JJ O
developments NNS O
of IN O
the DT O
physiological JJ O
homeostasis NN O
of IN O
healthy JJ O
skin NN O
, , O
promotion NN O
of IN O
hair NN O
growth NN O
, , O
protection NN O
from IN O
hair NN O
loss NN O
, , O
prevention NN O
and CC O
treatment NN O
of IN O
itchy NN O
or CC O
irritated JJ O
skin NN O
. . O

19 CD O
. . O

A DT O
composition NN O
as IN O
in IN O
any DT O
one CD O
of IN O
claims NNS O
1 CD O
to TO O
17 CD O
which WDT O
is VBZ O
for IN O
the DT O
prevention NN O
or CC O
treatment NN O
of IN O
pigmentation NN O
disorders NNS O
and/or CC O
for IN O
providing VBG O
an DT O
even JJ O
skin NN O
tone NN O
. . O

20 CD O
. . O

A DT O
composition NN O
as IN O
in IN O
any DT O
one CD O
of IN O
claims NNS O
1 CD O
to TO O
5 CD O
and CC O
9 CD O
to TO O
11 CD O
which WDT O
is VBZ O
for IN O
fortifying VBG O
the DT O
pigmentation NN O
by IN O
enhancing VBG O
the DT O
effect NN O
of IN O
a DT O
tanning JJ O
active JJ O
. . O

21 CD O
. . O

A DT O
composition NN O
as IN O
in IN O
claim NN O
1 CD O
to TO O
17 CD O
, , O
which WDT O
is VBZ O
for IN O
the DT O
treatment NN O
or CC O
prevention NN O
of IN O
wrinkles NNS O
or CC O
dry JJ O
skin NN O
or CC O
sensitive JJ O
skin NN O
, , O
for IN O
the DT O
promotion NN O
of IN O
hair NN O
growth NN O
, , O
for IN O
the DT O
protection NN O
from IN O
hair NN O
loss NN O
, , O
and CC O
for IN O
thickening VBG O
the DT O
epidermis NN O
. . O

22 CD O
. . O
A DT O
method NN O
of IN O
treatment NN O
or CC O
prevention NN O
of IN O
symptoms NNS O
caused VBN O
by IN O
negative JJ O
developments NNS O
of IN O
the DT O
physiological JJ O
homeostasis NN O
of IN O
healthy JJ O
skin NN O
as RB O
well RB O
as IN O
treatment NN O
or CC O
prevention NN O
of IN O
itchy NN O
or CC O
irritated JJ O
skin NN O
and CC O
of IN O
promotion NN O
of IN O
hair NN O
growth NN O
and CC O
of IN O
protection NN O
from IN O
hair NN O
loss NN O
, , O
which WDT O
method NN O
comprises VBZ O
the DT O
step NN O
of IN O
topically RB O
administering VBG O
to TO O
a DT O
person NN O
in IN O
need NN O
of IN O
such JJ O
treatment NN O
or CC O
prevention NN O
an DT O
effective JJ O
amount NN O
of IN O
a DT O
fatty JJ B-NP
acid NN I-NP
or CC O
a DT O
salt NN O
, , O
ester NN B-NP
or CC O
amide JJ B-NP
, , O
optionally RB O
in IN O
combination NN O
with IN O
a DT O
retinoid NN B-NP
. . O

-DOCSTART- X X O

[0001] JJ O
Novel NNP O
carboxylic NN B-NP
acid NN I-NP
derivatives NNS O

The DT O
present JJ O
invention NN O
is VBZ O
concerned VBN O
with IN O
novel NN O
arylalkyl NN B-NP
carboxylic NN I-NP
acid NN I-NP
derivatives VBZ O
, , O
more RBR O
specifically RB O
, , O
with IN O
acylates NNS B-NP
of IN O
arylalkyl NN B-NP
carboxylic NN I-NP
acids NNS I-NP
with IN O
naturally RB O
occurring VBG O
, , O
non-toxic JJ O
hydroxy NN B-NP
, , O
sulfhydryl NN B-NP
, , O
amino IN B-NP
or CC O
imino VB B-NP
compounds NNS O
, , O
and CC O
to TO O
compositions NNS O
containing VBG O
them PRP O
. . O

The DT O
compositions NNS O
are VBP O
preferably RB O
cosmetic JJ O
preparations NNS O
. . O

More RBR O
particularly RB O
, , O
the DT O
invention NN O
is VBZ O
concerned VBN O
with IN O
compounds NNS O
of IN O
the DT O
general JJ O
formula NN O

[ NN B-NP
Ph-(CH2 NNP I-NP
)n-CO]m NNP I-NP
-X NNP I-NP
( -LRB- O
I PRP O
) -RRB- O

wherein WRB O
Ph NNP O
is VBZ O
phenyl NN B-NP
or CC O
substituted VBN O
phenyl NN B-NP
, , O
n NN O
is VBZ O
1 CD O
or CC O
3 CD O
, , O
m NN O
is VBZ O
an DT O
integer NN O
of IN O
at IN O
least JJS O
1 CD O
, , O
and CC O
X NNP O
is VBZ O
a DT O
moiety NN O
from IN O
a DT O
naturally RB O
occurring VBG O
, , O
non-toxic JJ O
compound NN O
carrying VBG O
at IN O
least JJS O
one CD O
hydroxyl NN B-NP
, , O
sulfhydryl NN B-NP
, , O
amino IN B-NP
or CC O
imino NN B-NP
group NN O
which WDT O
moiety NN O
is VBZ O
formed VBN O
by IN O
removal NN O
of IN O
a DT O
hydrogen NN B-NP
atom NN O
from IN O
said VBD O
hydroxyl NN B-NP
, , O
sulfhydryl NN B-NP
, , O
amino IN B-NP
or CC O
imino VB B-NP
group NN O
; : O
except IN O
that DT O
X NNP O
is VBZ O
not RB O
an DT O
amino JJ B-NP
acid NN I-NP
or CC O
peptide NN B-NP
comprising NN O
up IN O
to TO O
6 CD O
amino IN B-NP
acids NNS I-NP
. . O

The DT O
term NN O
'naturally RB O
occurring VBG O
, , O
non-toxic JJ O
hydroxyl NN B-NP
, , O
sulfhydryl NN B-NP
, , O
amino IN B-NP
or CC O
imino VB B-NP
compounds NNS O
' POS O
comprises VBZ O
natural JJ O
occurring VBG O
compounds NNS O
such JJ O
as IN O
vitamins NNS O
, , O
terpenes NNS B-NP
, , O
chromanes NNS B-NP
, , O
flavones NNS B-NP
, , O
catechols NNS B-NP
, , O
pyrimidines NNS B-NP
as RB O
well RB O
as IN O
synthetic JJ O
derivatives NNS O
or CC O
analogues NNS O
thereof , O
which WDT O
have VBP O
been VBN O
modified VBN O
in IN O
order NN O
to TO O
make VB O
them PRP O
susceptible JJ O
for IN O
an DT O
attachment NN O
to TO O
the DT O
[ NN B-NP
Ph-(CH2 . I-NP
)n-CO]m JJ I-NP
moiety NN O
. . O

It PRP O
has VBZ O
been VBN O
found VBN O
that IN O
the DT O
compounds NNS O
provided VBN O
by IN O
the DT O
present JJ O
invention NN O
are VBP O
particularly RB O
useful JJ O
for IN O
treating VBG O
wrinkles NNS O
but CC O
also RB O
for IN O
thickening VBG O
the DT O
epidermis NN O
, , O
repairing VBG O
the DT O
skins NNS O
lipid JJ B-NP
barrier NN O
, , O
for IN O
protection NN O
against IN O
hair NN O
loss NN O
and CC O
for IN O
improving VBG O
hair NN O
growth NN O
. . O

Human JJ O
skin NN O
undergoes VBZ O
certain JJ O
normal JJ O
cornification NN O
processes NNS O
which WDT O
give VBP O
the DT O
skin NN O
its PRP$ O
characteristic JJ O
appearance NN O
. . O

Casual JJ O
factors NNS O
or CC O
external JJ O
factors NNS O
such JJ O
as IN O
a DT O
raw JJ O
climate NN O
, , O
wind NN O
, , O
photo-damage JJ O
and CC O
irritation NN O
triggered VBN O
by IN O
the DT O
sun NN O
, , O
rain NN O
and CC O
snow NN O
, , O
however RB O
, , O
disturb VBP O
this DT O
normal JJ O
condition NN O
of IN O
the DT O
skin NN O
, , O
and CC O
there EX O
appears VBZ O
a DT O
roughness NN O
, , O
a DT O
formation NN O
of IN O
scales NNS O
( -LRB- O
for IN O
example NN O
on IN O
the DT O
scalp NN O
) -RRB- O
, , O
an DT O
excessive JJ O
keratinization NN O
and CC O
similar JJ O
phenomena NNS O
. . O

Furthermore RB O
, , O
in IN O
the DT O
course NN O
of IN O
aging VBG O
of IN O
the DT O
skin NN O
various JJ O
signs NNS O
appear VBP O
that IN O
are VBP O
especially RB O
reflected VBN O
by IN O
a DT O
change NN O
in IN O
the DT O
structure NN O
and CC O
function NN O
of IN O
the DT O
skin NN O
. . O

One CD O
of IN O
these DT O
signs NNS O
is VBZ O
the DT O
appearance NN O
of IN O
fine JJ O
lines NNS O
and CC O
deep JJ O
wrinkles NNS O
, , O
the DT O
size NN O
and CC O
number NN O
of IN O
which WDT O
increases NNS O
with IN O
age NN O
. . O

The DT O
micro JJ O
relief NN O
of IN O
the DT O
skin NN O
becomes VBZ O
less RBR O
uniform JJ O
and CC O
is VBZ O
of IN O
anisotropic JJ O
nature NN O
. . O

In IN O
parallel RB O
with IN O
age NN O
the DT O
skin NN O
becomes VBZ O
more RBR O
sensitive JJ O
towards IN O
disturbing VBG O
influences NNS O
, , O
either CC O
intrinsic JJ O
or CC O
extrinsic JJ O
, , O
which WDT O
may MD O
result VB O
in IN O
itch NN O
, , O
redness NN O
or CC O
even RB O
darker JJR O
spots NNS O
, , O
particular JJ O
on IN O
hands NNS O
and CC O
the DT O
facial JJ O
area NN O
due JJ O
to TO O
pigmentation NN O
disorders NNS O
. . O

These DT O
unwanted JJ O
signs NNS O
may MD O
lead VB O
to TO O
an DT O
undesired JJ O
age NN O
judgment NN O
of IN O
a DT O
person NN O
. . O

Cosmetic JJ O
preparations NNS O
are VBP O
essentially RB O
useful JJ O
for IN O
skin NN O
care NN O
. . O

One CD O
aim NN O
of IN O
skin NN O
care NN O
in IN O
the DT O
cosmetic JJ O
sense NN O
is VBZ O
to TO O
strengthen VB O
or CC O
rebuild VB O
the DT O
skin NN O
's POS O
natural JJ O
function NN O
as IN O
a DT O
barrier NN O
against IN O
environmental JJ O
influences NNS O
( -LRB- O
e NN O
.g NN O
. . O

UV-light NN O
, , O
dirt NN O
, , O
chemicals NNS O
, , O
microorganisms NNS O
) -RRB- O
and CC O
against IN O
the DT O
loss NN O
of IN O
endogenous JJ O
substances NNS O
( -LRB- O
e NN O
.g NN O
. . O

water NN B-NP
, , O
natural JJ O
lipids NNS B-NP
, , O
electrolytes NNS O
) -RRB- O
. . O

If IN O
this DT O
function NN O
becomes VBZ O
impaired VBN O
, , O
increased VBN O
resorption NN O
of IN O
toxic JJ O
or CC O
allergenic JJ O
substances NNS O
or CC O
attack NN O
by IN O
microorganisms NNS O
may MD O
result VB O
, , O
leading VBG O
to TO O
toxic JJ O
or CC O
allergic JJ O
skin NN O
reactions NNS O
. . O

Another DT O
aim NN O
of IN O
skin NN O
care NN O
is VBZ O
to TO O
compensate VB O
for IN O
the DT O
loss NN O
by IN O
the DT O
skin NN O
of IN O
lipids NNS B-NP
and CC O
water NN B-NP
caused VBN O
by IN O
daily JJ O
washing NN O
. . O

This DT O
is VBZ O
particularly RB O
important JJ O
, , O
if IN O
the DT O
natural JJ O
regeneration NN O
ability NN O
is VBZ O
inadequate JJ O
. . O

Furthermore RB O
, , O
skin NN O
care VB O
products NNS O
should MD O
protect VB O
against IN O
environmental JJ O
influences NNS O
, , O
in IN O
particular JJ O
against IN O
sun NN O
and CC O
wind NN O
, , O
and CC O
delay VBP O
skin NN O
aging VBG O
. . O

Strengthening VBG O
or CC O
thickening VBG O
of IN O
the DT O
epidermis NN O
together RB O
with IN O
an DT O
optimized JJ O
skin NN O
barrier NN O
lipid JJ B-NP
synthesis NN O
can MD O
rebuild VB O
the DT O
skin NN O
's POS O
barrier NN O
ability NN O
and CC O
is VBZ O
therefore RB O
of IN O
significant JJ O
cosmetic JJ O
value NN O
. . O

Reduced VBN O
transepidermal JJ O
water NN B-NP
loss NN O
( -LRB- O
TEWL NNP O
) -RRB- O
is VBZ O
a DT O
sign NN O
of IN O
an DT O
intact JJ O
lipid JJ B-NP
barrier NN O
, , O
which WDT O
acts VBZ O
also RB O
as IN O
first JJ O
defense NN O
line NN O
to TO O
protect VB O
against IN O
the DT O
appearance NN O
of IN O
skin NN O
wrinkles NNS O
. . O

Another DT O
strategy NN O
to TO O
fight VB O
wrinkles NNS O
is VBZ O
to TO O
stimulate VB O
the DT O
collagen NN O
synthesis NN O
in IN O
the DT O
dermis NN O
. . O

A DT O
number NN O
of IN O
degenerative JJ O
processes NNS O
act NN O
on IN O
the DT O
collagen NN O
matrix NN O
and CC O
is VBZ O
triggered VBN O
by IN O
extrinsic JJ O
factors NNS O
like IN O
UV NN O
radiation NN O
, , O
pollution NN O
in IN O
general JJ O
and CC O
particular JJ O
cigarette NN O
smoke NN O
or CC O
intrinsic JJ O
factors NNS O
leading VBG O
to TO O
any DT O
chronic NN O
or CC O
sub NN O
chronic NN O
inflammation NN O
. . O

Destruction NNP O
and/or CC O
impaired VBN O
repair NN O
efficacy NN O
leads VBZ O
to TO O
a DT O
denser NN O
and CC O
less JJR O
elastic JJ O
macro NN O
structure NN O
of IN O
the DT O
dermis NN O
, , O
which WDT O
in IN O
turn NN O
leads VBZ O
to TO O
the DT O
formation NN O
of IN O
deep JJ O
wrinkles NNS O
. . O

Enhancing VBG O
the DT O
de FW O
novo FW O
synthesis NN O
of IN O
collagen NN O
or CC O
other JJ O
structural JJ O
proteins NNS O
of IN O
the DT O
dermis NN O
is VBZ O
considered VBN O
a DT O
valuable JJ O
therapy NN O
to TO O
reduce VB O
the DT O
existing VBG O
wrinkles NNS O
and CC O
to TO O
protect VB O
against IN O
the DT O
appearance NN O
of IN O
new JJ O
wrinkles NNS O
. . O

Of IN O
particular JJ O
importance NN O
for IN O
anti-aging JJ O
cosmetics NNS O
is VBZ O
to TO O
inhibit VB O
the DT O
senescence NN O
of IN O
skin NN O
cells NNS O
in IN O
order NN O
to TO O
keep VB O
their PRP$ O
regular JJ O
metabolic JJ O
level NN O
on IN O
a DT O
constant JJ O
and CC O
beneficial JJ O
level NN O
. . O

Hair NN O
loss NN O
or CC O
alopecia NN O
is VBZ O
a DT O
common JJ O
affliction NN O
of IN O
humans NNS O
. . O

The DT O
most RBS O
common JJ O
form NN O
of IN O
hair NN O
loss NN O
in IN O
both DT O
males NNS O
and CC O
females NNS O
is VBZ O
patterned VBN O
baldness NN O
or CC O
androgenic JJ O
alopecia NN O
. . O

Hair JJ O
follicles NNS O
range VBP O
in IN O
size NN O
from IN O
small JJ O
, , O
superficial JJ O
, , O
vellus JJ O
follicles NNS O
to TO O
large JJ O
, , O
deep JJ O
, , O
terminal JJ O
follicles NNS O
. . O

The DT O
cyclic JJ O
growth NN O
phases NNS O
of IN O
hair NN O
follicles NNS O
are VBP O
telogen NN O
( -LRB- O
resting VBG O
) -RRB- O
, , O
anagen NN O
l-lll NN O
( -LRB- O
developing VBG O
) -RRB- O
, , O
anagen NN O
IV-VI NNP O
( -LRB- O
growing VBG O
) -RRB- O
and CC O
catagen NN O
( -LRB- O
involuting VBG O
) -RRB- O
. . O

In IN O
the DT O
development NN O
of IN O
androgenic JJ O
alopecia NN O
there RB O
is VBZ O
the DT O
gradual JJ O
diminution NN O
of IN O
follicle NN O
size NN O
, , O
with IN O
conversion NN O
of IN O
large JJ O
, , O
terminal JJ O
follicles NNS O
, , O
producing VBG O
thick JJ O
, , O
pigmented JJ O
hair NN O
fibers NNS O
(terminal JJ O
hair NN O
) -RRB- O
to TO O
small JJ O
vellus NN O
follicles VBZ O
producing VBG O
fine JJ O
, , O
non-pig JJ O
mented JJ O
hair NN O
fibers NNS O
(vellus JJ O
hair NN O
) -RRB- O
. . O

In IN O
addition NN O
, , O
the DT O
proportion NN O
of IN O
growing VBG O
anagen NN O
follicles VBZ O
declines NNS O
. . O

There EX O
exists VBZ O
a DT O
wide JJ O
variety NN O
of IN O
literature NN O
regarding VBG O
cosmetic JJ O
preparations NNS O
, , O
in IN O
particular JJ O
regarding VBG O
cosmetic JJ O
preparations NNS O
for IN O
treating VBG O
wrinkles NNS O
and CC O
for IN O
promoting VBG O
hair NN O
growth NN O
. . O

As IN O
examples NNS O
of IN O
the DT O
extensive JJ O
literature NN O
it PRP O
can MD O
be VB O
referred VBN O
e.g RB O
. . O
to TO O
GB NNP O
906,000 CD O
, , O
EP-A NNP O
699 CD O
429 CD O
or CC O
WO NN O
03/086342 NN O
. . O

While IN O
a DT O
variety NN O
of IN O
technologies NNS O
exist VBP O
to TO O
prevent VB O
and CC O
to TO O
fight VB O
the DT O
signs NNS O
of IN O
skin NN O
aging VBG O
, , O
to TO O
improve VB O
the DT O
appearance NN O
of IN O
the DT O
skin NN O
or CC O
to TO O
treat VB O
or CC O
prevent VB O
hair NN O
loss NN O
, , O
there EX O
is VBZ O
still RB O
a DT O
demand NN O
for IN O
more JJR O
efficacious JJ O
ingredients NNS O
. . O

The DT O
problem NN O
to TO O
be VB O
solved VBN O
by IN O
the DT O
present JJ O
invention NN O
is VBZ O
the DT O
provision NN O
of IN O
novel NN O
compounds NNS O
, , O
of IN O
compositions NNS O
containing VBG O
these DT O
novel JJ O
compounds NNS O
, , O
in IN O
particular JJ O
of IN O
cosmetic JJ O
preparations NNS O
which WDT O
are VBP O
particularly RB O
useful JJ O
for IN O
treating VBG O
and/or CC O
preventing VBG O
wrinkles NNS O
, , O
thickening VBG O
of IN O
the DT O
epidermis NN O
, , O
and CC O
preventing VBG O
and/or IN O
treating VBG O
of IN O
hair NN O
loss NN O
, , O
but CC O
also RB O
preparations NNS O
which WDT O
are VBP O
useful JJ O
against IN O
other JJ O
conditions NNS O
which WDT O
are VBP O
observed VBN O
with IN O
skin NN O
aging VBG O
due JJ O
to TO O
environmental JJ O
or CC O
other JJ O
external JJ O
influences NNS O
or CC O
due JJ O
to TO O
age NN O
. . O

The DT O
new JJ O
compounds NNS O
should MD O
have VB O
an DT O
activity NN O
which WDT O
is VBZ O
comparable JJ O
to TO O
the DT O
activity NN O
of IN O
known JJ O
cosmetically , O
active JJ O
compounds NNS O
but CC O
preferably RB O
is VBZ O
better JJR O
than IN O
the DT O
activity NN O
of IN O
the DT O
prior JJ O
art NN O
compounds NNS O
. . O

This DT O
problem NN O
is VBZ O
solved VBN O
on IN O
the DT O
basis NN O
of IN O
the DT O
unexpected JJ O
finding NN O
that IN O
certain JJ O
arylalkyl NN B-NP
carboxylic NN I-NP
acylates NNS I-NP
with IN O
naturally RB O
occurring VBG O
, , O
non-toxic JJ O
hydroxyl NN B-NP
, , O
sulfhydryl NN B-NP
, , O
amino IN B-NP
or CC O
imino VBP B-NP
compounds NNS O
show VBP O
activity NN O
in IN O
cosmetic JJ O
applications NNS O
and CC O
related VBN O
pharmaceutical JJ O
applications NNS O
, , O
in IN O
particular JJ O
for IN O
treating VBG O
and CC O
preventing VBG O
wrinkles NNS O
and CC O
hair NN O
loss NN O
and CC O
thickening VBG O
the DT O
epidermis NN O
, , O
but CC O
also RB O
for IN O
ameliorating VBG O
the DT O
effects NNS O
of IN O
aging VBG O
of IN O
the DT O
skin NN O
, , O
which WDT O
may MD O
be VB O
caused VBN O
by IN O
external JJ O
or CC O
environmental JJ O
hazards NNS O
or CC O
by IN O
the DT O
natural JJ O
aging NN O
of IN O
the DT O
skin NN O
. . O

Accordingly RB O
, , O
in IN O
one CD O
aspect NN O
, , O
the DT O
present JJ O
invention NN O
is VBZ O
concerned VBN O
with IN O
compounds NNS O
represented VBN O
by IN O
general JJ O
formula NN O
( -LRB- O
I PRP O
) -RRB- O
as IN O
shown VBN O
above IN O
. . O

In IN O
another DT O
aspect NN O
, , O
the DT O
invention NN O
is VBZ O
concerned VBN O
with IN O
compositions NNS O
, , O
particularly RB O
cosmetic JJ O
preparations NNS O
comprising VBG O
a DT O
compound NN O
of IN O
the DT O
formula NN O
( -LRB- O
I PRP O
) -RRB- O
. . O

In IN O
still RB O
another DT O
aspect NN O
, , O
the DT O
invention NN O
is VBZ O
concerned VBN O
with IN O
the DT O
use NN O
of IN O
the DT O
compounds NNS O
of IN O
formula NN O
( -LRB- O
I PRP O
) -RRB- O
for IN O
treating VBG O
and CC O
preventing VBG O
wrinkles NNS O
and CC O
hair NN O
loss NN O
and CC O
thickening VBG O
the DT O
epidermis NN O
, , O
but CC O
also RB O
for IN O
ameliorating VBG O
the DT O
effects NNS O
of IN O
aging VBG O
of IN O
the DT O
skin NN O
, , O
which WDT O
may MD O
be VB O
caused VBN O
by IN O
external JJ O
or CC O
environmental JJ O
hazards NNS O
or CC O
by IN O
the DT O
natural JJ O
aging NN O
of IN O
the DT O
skin NN O
, , O
and CC O
with IN O
a DT O
method NN O
of IN O
treating VBG O
and CC O
preventing VBG O
the DT O
aforesaid NN O
conditions NNS O
by IN O
administering VBG O
an DT O
effective JJ O
amount NN O
of IN O
a DT O
topical JJ O
composition NN O
comprising VBG O
a DT O
compound NN O
of IN O
formula NN O
( -LRB- O
I PRP O
) -RRB- O
on IN O
the DT O
appropriate JJ O
portions NNS O
of IN O
the DT O
skin NN O
of IN O
an DT O
individual JJ O
in IN O
need NN O
of IN O
such JJ O
treatment NN O
. . O

In IN O
another DT O
embodiment NN O
, , O
the DT O
invention NN O
relates VBZ O
to TO O
a DT O
method NN O
of IN O
treatment NN O
or CC O
prophylaxis NNS O
of IN O
wrinkles NNS O
or CC O
dry JJ O
skin NN O
or CC O
sensitive JJ O
skin NN O
or CC O
any DT O
symptoms NNS O
caused VBN O
by IN O
negative JJ O
developments NNS O
of IN O
the DT O
physiological JJ O
homeostasis NN O
of IN O
healthy JJ O
skin NN O
, , O
promotion NN O
of IN O
hair NN O
growth NN O
, , O
protection NN O
from IN O
hair NN O
loss NN O
, , O
a DT O
thickening NN O
of IN O
the DT O
epidermis NN O
, , O
anti-acne JJ O
, , O
the DT O
inhibition NN O
of IN O
senescence NN O
of IN O
skin NN O
cells NNS O
, , O
prevention NN O
or CC O
treatment NN O
of IN O
photo NN O
damage NN O
, , O
prevention NN O
or CC O
treatment NN O
of IN O
oxidative JJ O
stress NN O
phenomena NNS O
, , O
prevention NN O
or CC O
treatment NN O
of IN O
cellulite NN O
, , O
prevention NN O
or CC O
treatment NN O
of IN O
pigmentation NN O
disorders NNS O
and/or CC O
even RB O
the DT O
skin NN O
tone NN O
, , O
prevention NN O
and CC O
treatment NN O
of IN O
disturbances NNS O
in IN O
ceramide JJ B-NP
and CC O
lipid JJ B-NP
synthesis NN O
, , O
prevention NN O
of IN O
excess JJ O
sebum JJ O
production NN O
, , O
reduction NN O
of IN O
activities NNS O
of IN O
matrix NN O
metallo NN O
proteases NNS O
or CC O
other JJ O
proteases NNS O
in IN O
the DT O
skin NN O
, , O
treatment NN O
and CC O
prevention NN O
of IN O
inflammatory JJ O
skin NN O
conditions NNS O
including VBG O
atopic JJ O
eczema NN O
, , O
polymorphic JJ O
light NN O
eruption NN O
, , O
psoriasis NN O
, , O
vertiligo RB O
, , O
prevention NN O
and CC O
treatment NN O
of IN O
itchy NN O
or CC O
irritated JJ O
skin NN O
, , O
which WDT O
comprises VBZ O
applying VBG O
an DT O
effective JJ O
amount NN O
of IN O
composition NN O
comprising VBG O
a DT O
compound NN O
of IN O
formula NN O
( -LRB- O
I PRP O
) -RRB- O
on IN O
the DT O
appropriate JJ O
portions NNS O
of IN O
the DT O
skin NN O
of IN O
the DT O
individual JJ O
in IN O
need NN O
of IN O
such JJ O
treatment NN O
. . O

The DT O
term NN O
'an VBZ O
effective JJ O
amount NN O
' '' O
refers VBZ O
to TO O
an DT O
amount NN O
necessary JJ O
to TO O
obtain VB O
a DT O
physiological JJ O
effect NN O
. . O

The DT O
physiological JJ O
effect NN O
may MD O
be VB O
achieved VBN O
by IN O
one CD O
single JJ O
application NN O
or CC O
by IN O
repeated VBN O
applications NNS O
. . O

The DT O
dosage NN O
applied VBN O
may MD O
, , O
of IN O
course NN O
, , O
vary VBP O
depending VBG O
upon IN O
known VBN O
factors NNS O
, , O
such JJ O
as IN O
the DT O
physiological JJ O
characteristics NNS O
of IN O
the DT O
particular JJ O
composition NN O
and CC O
its PRP$ O
mode NN O
and CC O
route NN O
of IN O
administration NN O
; : O
the DT O
age NN O
, , O
health NN O
and CC O
weight NN O
of IN O
the DT O
recipient NN O
; : O
the DT O
nature NN O
and CC O
extent NN O
of IN O
the DT O
symptoms NNS O
; : O
the DT O
kind NN O
of IN O
concurrent JJ O
treatment NN O
; : O
the DT O
frequency NN O
of IN O
treatment NN O
; : O
the DT O
concentration NN O
of IN O
the DT O
compound NN O
of IN O
formula NN O
( -LRB- O
I PRP O
) -RRB- O
in IN O
the DT O
topical JJ O
composition NN O
; : O
and CC O
the DT O
effect NN O
desired VBN O
and CC O
can MD O
be VB O
adjusted VBN O
by IN O
a DT O
person NN O
skilled JJ O
in IN O
the DT O
art NN O
. . O

The DT O
amount NN O
of IN O
the DT O
topical JJ O
composition NN O
which WDT O
is VBZ O
to TO O
be VB O
applied VBN O
to TO O
the DT O
skin NN O
depends VBZ O
on IN O
the DT O
concentration NN O
of IN O
the DT O
active JJ O
ingredients NNS O
, , O
i IN O
.e NN O
. . O
the DT O
compound NN O
of IN O
formula NN O
( -LRB- O
I PRP O
) -RRB- O
, , O
in IN O
the DT O
compositions NNS O
and CC O
the DT O
desired VBN O
cosmetic NN O
or CC O
pharmaceutical JJ O
effect NN O
. . O

For IN O
example NN O
, , O
application NN O
can MD O
be VB O
such JJ O
that IN O
a DT O
creme NN O
is VBZ O
applied VBN O
to TO O
the DT O
skin NN O
. . O

A DT O
creme NN O
is VBZ O
usually RB O
applied VBN O
in IN O
an DT O
amount NN O
of IN O
2 CD O
mg NN O
creme/cm<2> VBG O
skin NN O
. . O

The DT O
amount NN O
of IN O
the DT O
composition NN O
which WDT O
is VBZ O
applied VBN O
to TO O
the DT O
skin NN O
is VBZ O
, , O
however RB O
, , O
not RB O
critical JJ O
, , O
and CC O
if IN O
with IN O
a DT O
certain JJ O
amount NN O
of IN O
applied VBN O
composition NN O
the DT O
desired VBN O
effect NN O
cannot MD O
be VB O
achieved VBN O
, , O
a DT O
higher JJR O
concentration NN O
of IN O
the DT O
active JJ O
ingredients NNS O
can MD O
be VB O
used VBN O
e.g RB O
. . O
by IN O
applying VBG O
more JJR O
of IN O
the DT O
composition NN O
or CC O
by IN O
applying VBG O
compositions NNS O
which WDT O
contain VBP O
more JJR O
active JJ O
ingredient NN O
. . O

A DT O
preferred JJ O
group NN O
of IN O
compounds NNS O
within IN O
the DT O
scope NN O
of IN O
formula NN O
( -LRB- O
I PRP O
) -RRB- O
are VBP O
those DT O
wherein IN O
Ph NNP O
is VBZ O
unsubstituted JJ O
phenyl NN B-NP
. . O

If IN O
Ph NNP O
is VBZ O
substituted VBN O
phenyl NN B-NP
, , O
the DT O
phenyl NN B-NP
ring NN O
may MD O
be VB O
substituted VBN O
by IN O
up RB O
to TO O
three CD O
substituents NNS O
which WDT O
are VBP O
selected VBN O
, , O
independently RB O
, , O
from IN O
hydroxyl NN B-NP
, , O
C1-C6 DT B-NP
alkyl NN I-NP
, , O
C2-C6 DT B-NP
alkenyl NN I-NP
, , O
C1-C6 DT B-NP
alkoxy JJ I-NP
and CC O
C2-C6 JJ B-NP
alkenyloxy NN I-NP
. . O

Preferred NNP O
substituted VBD O
phenyl NN B-NP
moieties NNS O
are VBP O
phenyl JJ B-NP
mono-substituted JJ O
by IN O
C^-alkoxy JJ B-NP
, , O
especially RB O
methoxyphenyl NN B-NP
. . O

In IN O
all DT O
embodiments NNS O
of IN O
the DT O
invention NN O
compounds NNS O
within IN O
the DT O
scope NN O
of IN O
formula NN O
( -LRB- O
I PRP O
) -RRB- O
wherein WRB O
m NN O
is VBZ O
1 CD O
are VBP O
preferred VBN O
. . O

Most JJS O
preferred JJ O
according VBG O
to TO O
the DT O
invention NN O
are VBP O
compounds NNS O
within IN O
the DT O
scope NN O
of IN O
formula NN O
( -LRB- O
I PRP O
) -RRB- O
wherein WRB O
the DT O
residue JJ O
[ NN B-NP
Ph-(CH2 NNP I-NP
)n-CO]m NNP I-NP
is VBZ O
derived VBN O
from IN O
phenyl JJ B-NP
butyric JJ I-NP
acid NN I-NP
and CC O
m NN O
is VBZ O
1 CD O
. . O

The DT O
naturally RB O
occurring VBG O
, , O
non-toxic JJ O
compound NN O
carrying VBG O
at IN O
least JJS O
one CD O
hydroxyl NN B-NP
, , O
sulfhydryl NN B-NP
, , O
amino VBP B-NP
or CC O
imino VBP B-NP
group NN O
from IN O
which WDT O
the DT O
moiety NN O
X NNP O
in IN O
formula NN O
( -LRB- O
I PRP O
) -RRB- O
is VBZ O
derived VBN O
may MD O
be VB O
any DT O
such JJ O
compound NN O
that WDT O
can MD O
be VB O
used VBN O
in IN O
cosmetic JJ O
applications NNS O
. . O

Examples NNS O
of IN O
such JJ O
compounds NNS O
are VBP O
fat- NNS O
soluble JJ O
vitamin NN O
derivatives NNS O
and CC O
analogues NNS O
thereof RB O
, , O
water-soluble JJ O
vitamins NNS O
, , O
derivatives NNS O
or CC O
analogues NNS O
thereof RB O
, , O
carbohydrates NNS B-NP
, , O
[alpha]-hydroxy-carboxylic JJ B-NP
acids NNS I-NP
, , O
aliphatic JJ B-NP
alcohols NNS I-NP
and CC O
polyols NNS B-NP
, , O
amino IN B-NP
alcohols NNS I-NP
, , O
chromanes NNS B-NP
and CC O
flavones NNS B-NP
, , O
derivatives NNS O
and CC O
analogues NNS O
thereof RB O
, , O
pyrimidines NNS B-NP
or CC O
purines NNS B-NP
or CC O
analogues NNS O
thereof RB O
, , O
terpenes NNS B-NP
, , O
and CC O
catechols NNS B-NP
; : O
particular JJ O
examples NNS O
being VBG O
( -LRB- O
CAS NNP O
numbers NNS O
given VBN O
in IN O
parenthesis NN O
) -RRB- O
glucoses VBZ B-NP
with IN I-NP
open JJ I-NP
or CC I-NP
ring NN I-NP
form NN I-NP
( -LRB- O
50-99-7 JJ O
) -RRB- O
, , O
Tocopherols NNP B-NP
like IN O
DL-[alpha]-tocopherol NNP B-NP
( -LRB- O
10191-41-0 CD O
) -RRB- O
, , O
Panthenol NNP B-NP
( -LRB- O
81-13-0 NN O
) -RRB- O
, , O
Pantothenic JJ B-NP
acid NN I-NP
(79-83-4) NN O
, , O
Pyridoxines NNS B-NP
such JJ O
as IN O
vitamin NN B-NP
B6 IN I-NP
( -LRB- O
65-23-6 NN O
) -RRB- O
, , O
Kinetin NNP B-NP
( -LRB- O
525-79-1 JJ O
) -RRB- O
, , O
Vanillin NNP B-NP
( -LRB- O
121-33-5 CD O
) -RRB- O
, , O
Fenchol NNP B-NP
( -LRB- O
1632-73-1 JJ O
) -RRB- O
, , O
Quercetin NNP B-NP
( -LRB- O
117-39-5 CD O
) -RRB- O
, , O
Wogonin FW B-NP
( -LRB- O
632-85-9) NN O
, , O
Delphinidin NNP B-NP
( -LRB- O
528-53-0 CD O
) -RRB- O
, , O
Silymarin NNP B-NP
( -LRB- O
65666-07-1 NN O
) -RRB- O
, , O
Gossypin NNP B-NP
( -LRB- O
652-78-8 CD O
) -RRB- O
, , O
Equol NNP B-NP
( -LRB- O
531-95-3 JJ O
) -RRB- O
, , O
Shikimic NNP B-NP
Acid NNP I-NP
( -LRB- O
138-59-0 CD O
) -RRB- O
, , O
Gramin NNP B-NP
(87-52-5 CD O
) -RRB- O
, , O
Carnitin NNP B-NP
( -LRB- O
461-06-3 JJ O
) -RRB- O
, , O
Glutathion NNP B-NP
( -LRB- O
70-18-8 CD O
) -RRB- O
, , O
Ginkgetin NNP B-NP
( -LRB- O
481-46-9) JJ O
, , O
Insulin NNP O
( -LRB- O
11061-68-0 CD O
) -RRB- O
, , O
Farnesol NNP B-NP
( -LRB- O
106-28-5 CD O
) -RRB- O
, , O
Thiamine NNP B-NP
( -LRB- O
67-03-8 CD O
) -RRB- O
, , O
Riboflavin NNP B-NP
(83-88-5 CD O
) -RRB- O
, , O
Bisabolol FW B-NP
( -LRB- O
23089-26-1 JJ O
) -RRB- O
, , O
Ascorbic NNP B-NP
Acid NNP I-NP
( -LRB- O
50-81-7 CD O
) -RRB- O
, , O
Stay-C JJ O
50 CD O
( -LRB- O
66170-10-3 NN O
) -RRB- O
, , O
Folic NNP B-NP
Acid NNP I-NP
( -LRB- O
59-30-3 JJ O
) -RRB- O
, , O
Daidzein NNP B-NP
( -LRB- O
486-66-8 CD O
) -RRB- O
, , O
Genistein NNP B-NP
( -LRB- O
446-72-0 CD O
) -RRB- O
, , O
Resveratrol NNP B-NP
( -LRB- O
501-36-0 CD O
) -RRB- O
, , O
Betanin FW B-NP
( -LRB- O
7659-95-2 NN O
) -RRB- O
, , O
Phytantriol NNP B-NP
( -LRB- O
74563-64-7 CD O
) -RRB- O
, , O
Retinol NNP B-NP
( -LRB- O
68-26-8 CD O
) -RRB- O
, , O
Vitamin NNP B-NP
D3 NNP I-NP
( -LRB- O
67-97-0 CD O
) -RRB- O
, , O
Hy-D NNP O
( -LRB- O
63283-36-3 NN O
) -RRB- O
, , O
Astaxanthin NNP B-NP
( -LRB- O
7542-45-2 CD O
) -RRB- O
, , O
Lutein NNP B-NP
( -LRB- O
127-40-2 CD O
) -RRB- O
, , O
Zeaxanthin NNP B-NP
( -LRB- O
144-68-3 JJ O
) -RRB- O
, , O
alpha-hydroxy JJ B-NP
phytanic JJ I-NP
acid NN I-NP
( -LRB- O
14721-68-7 CD O
) -RRB- O
, , O
beta-Sitosterol JJ B-NP
( -LRB- O
64997-52-0 CD O
) -RRB- O
, , O
Menthol NNP B-NP
(89-78-1 NN O
) -RRB- O
, , O
Allantoin NNP B-NP
(97-59-6 NN O
) -RRB- O
, , O
epigallocatechin NN B-NP
gallate NN I-NP
( -LRB- O
EGCG) JJ B-NP
(989-51-5 NN O
) -RRB- O
, , O
Glycerol NNP B-NP
( -LRB- O
56-81-5 CD O
) -RRB- O
, , O
Phytol NNP B-NP
( -LRB- O
150-86-7 CD O
) -RRB- O
, , O
lactic JJ B-NP
acid NN I-NP
( -LRB- O
50-21-5 CD O
) -RRB- O
, , O
Biotin NNP B-NP
( -LRB- O
58-85-5 CD O
) -RRB- O
, , O
phytanic JJ B-NP
acid NN I-NP
( -LRB- O
14721-66-5 CD O
) -RRB- O
and CC O
tetradecylthioacetic JJ B-NP
acid NN I-NP
( -LRB- O
2921-20-2 CD O
) -RRB- O
. . O

Preferably RB O
, , O
the DT O
naturally RB O
occurring VBG O
, , O
non-toxic JJ O
compound NN O
carrying VBG O
at IN O
least JJS O
one CD O
hydroxyl NN B-NP
, , O
sulfhydryl NN B-NP
, , O
amino VBP B-NP
or CC O
imino VBP B-NP
group NN O
from IN O
which WDT O
the DT O
moiety NN O
X NNP O
in IN O
formula NN O
( -LRB- O
I PRP O
) -RRB- O
is VBZ O
derived VBN O
is VBZ O
a DT O
fat-soluble JJ O
vitamin NN O
or CC O
derivative JJ O
or CC O
analogue NN O
, , O
in IN O
particular JJ O
a DT O
tocopherol NN B-NP
, , O
a DT O
carotenoid NN B-NP
and CC O
vitamin NN B-NP
D3 NNS I-NP
or CC O
a DT O
hydroxyl JJ B-NP
derivative JJ O
thereof , O
; : O
a DT O
water-soluble JJ O
vitamin NN O
, , O
derivatives NNS O
or CC O
analogues NNS O
thereof , O
belonging VBG O
to TO O
the DT O
vitamin NN O
B NNP O
or CC O
vitamin NN B-NP
C NNP I-NP
group NN O
, , O
in IN O
particular JJ O
panthenol NN B-NP
, , O
pantothenic JJ B-NP
acid NN I-NP
, , O
pyridoxines NNS B-NP
, , O
thiamine NN B-NP
, , O
riboflavin NNP B-NP
, , O
nicotinamide JJ B-NP
, , O
2-hydroxyethylnicotinamide JJ B-NP
, , O
folic JJ B-NP
acid NN I-NP
, , O
ascorbic JJ B-NP
acid NN I-NP
or CC O
ascorbic JJ B-NP
acid NN I-NP
phosphate NN I-NP
, , O
more RBR O
in IN O
particular JJ O
nicotinamide NN B-NP
, , O
2-hydroxyethylnicotinamide JJ B-NP
, , O
panthenol NN B-NP
, , O
ascorbic JJ B-NP
acid NN I-NP
or CC O
ascorbic JJ B-NP
acid NN I-NP
phosphate NN I-NP
; : O
a DT O
chromane NN B-NP
, , O
flavone NN B-NP
, , O
derivatives NNS O
and CC O
analogues NNS O
thereof RB O
, , O
in IN O
particular JJ O
equol NN B-NP
, , O
quercetin NN B-NP
, , O
delphinidine NN B-NP
, , O
silymarin NN B-NP
, , O
daidzein NN B-NP
, , O
or CC O
genistein NN B-NP
; : O
a DT O
pyrimidine NN B-NP
or CC O
purine NN O
or CC O
analogue NN O
thereof RB O
, , O
in IN O
particular JJ O
kinetin NN B-NP
or CC O
allantoin RB B-NP
; : O
a DT O
terpene NN B-NP
preferably RB O
farnesol NN B-NP
, , O
bisabolol NN B-NP
, , O
phytol NN B-NP
and CC O
menthol NN B-NP
, , O
in IN O
particular JJ O
bisabolol NN B-NP
; : O
or CC O
a DT O
catechol NN B-NP
, , O
in IN O
particular JJ O
epigallocatechingallate NN B-NP
. . O

Of IN O
particular JJ O
interest NN O
as IN O
compounds NNS O
from IN O
which WDT O
the DT O
moiety NN O
X NNP O
is VBZ O
derived VBN O
, , O
i IN O
.e NN O
. . O
compounds NNS O
of IN O
the DT O
formula NN O
XH NNP O
, , O
are VBP O
panthenol NN B-NP
, , O
bisabolol NN B-NP
, , O
kinetin NN B-NP
and CC O
2-hydroxyethylnicotinamide JJ B-NP
. . O

Further JJ O
examples NNS O
of IN O
compounds NNS O
of IN O
formula NN O
( -LRB- O
I PRP O
) -RRB- O
are VBP O
the DT O
phenyl NN B-NP
butyric CC I-NP
acid NN I-NP
ester NN I-NP
of IN O
nicotinic JJ B-NP
acid NN I-NP
2-hydroxyethylamide JJ I-NP
, , O
glycerol-1-phenylbutyrate-3-nicotinate JJ B-NP
and CC O
the DT O
phenyl NN B-NP
acetic JJ I-NP
acid NN I-NP
ester NN I-NP
of IN O
phytanic JJ B-NP
acid NN I-NP
2-hydroxyethylamide JJ I-NP
. . O

Especially RB O
preferred JJ O
according VBG O
to TO O
the DT O
invention NN O
are VBP O
the DT O
following VBG O
compounds NNS O
of IN O
formula NN O
( -LRB- O
I PRP O
) -RRB- O
: : O
4-phenylbutyric JJ B-NP
acid NN I-NP
2-[( JJ I-NP
pyridine-3-carbonyl NN I-NP
)amino]-ethyl NN I-NP
ester NN I-NP
4-phenylbutyric JJ B-NP
acid NN I-NP
3-(2,4-dihydroxy-3,3-dimethyl-butyrylamino)-propyl JJ I-NP
ester NN I-NP
. . O

N-furan-2-yl-methyl-4-phenyl-N-(9H-purin-6-yl)-butyramide . B-NP

4-phenylbutyric JJ B-NP
acid NN I-NP
1 CD I-NP
,5-dimethyl-1-(4-methyl-cyclohex-3-enyl)-hex-4-enyl NN I-NP
ester NN I-NP
. . O

In IN O
accordance NN O
of IN O
the DT O
present JJ O
invention NN O
, , O
the DT O
compounds NNS O
of IN O
formula NN O
( -LRB- O
I PRP O
) -RRB- O
can MD O
be VB O
prepared VBN O
in IN O
a DT O
manner NN O
known VBN O
per IN O
se NN O
, , O
e.g RB O
. . O
as IN O
disclosed VBN O
in IN O
the DT O
Examples NNS O
or CC O
in IN O
analogy NN O
thereto NN O
. . O

Generally RB O
, , O
the DT O
compounds NNS O
of IN O
formula NN O
( -LRB- O
I PRP O
) -RRB- O
can MD O
be VB O
prepared VBN O
by IN O
acylating VBG O
a DT O
compound NN O
of IN O
the DT O
formula NN O
XH NNP O
, , O
wherein WRB O
X NNP O
is VBZ O
as IN O
defined VBN O
above IN O
, , O
with IN O
a DT O
compound NN O
of IN O
the DT O
formula NN O
Ph-(CH2 NNP B-NP
)n-COOH NNP I-NP
or CC O
a DT O
reactive JJ O
derivative JJ O
thereof PRP O
. . O

The DT O
acylation NN O
of IN O
the DT O
present JJ O
invention NN O
can MD O
be VB O
carried VBN O
out RP O
in IN O
a DT O
manner NN O
known VBN O
per IN O
se NN O
. . O

Suitably RB O
, , O
the DT O
acylation NN O
is VBZ O
carried VBN O
out RP O
using VBG O
a DT O
reactive JJ O
derivate JJ O
such JJ O
as IN O
a DT O
halogenide NN B-NP
, , O
e.g NN O
. . O
the DT O
chloride NN B-NP
or CC O
bromide NN B-NP
, , O
in IN O
the DT O
presence NN O
of IN O
an DT O
organic JJ O
base NN O
, , O
e.g NN O
. . O

pyridine NN B-NP
or CC O
an DT O
aliphatic JJ B-NP
amine NN I-NP
such JJ O
as IN O
triethylamine NN B-NP
, , O
or CC O
an DT O
inorganic JJ O
base NN O
such JJ O
as IN O
sodium NN B-NP
hydride NN I-NP
or CC O
an DT O
alkali JJ B-NP
carbonate NN I-NP
. . O

If IN O
required VBN O
, , O
any DT O
groups NNS O
reactive VBP O
to TO O
the DT O
acylating NN O
agent NN O
which WDT O
are VBP O
not RB O
intended VBN O
to TO O
be VB O
acylated VBN O
have VBP O
to TO O
be VB O
protected VBN O
. . O

Therefore CC O
the DT O
acylation NN O
of IN O
polyfunctional JJ O
molecules NNS O
requires VBZ O
versatile JJ O
protecting VBG O
groups NNS O
that WDT O
can MD O
be VB O
easily RB O
introduced VBN O
which WDT O
are VBP O
orthogonally RB O
stable JJ O
to TO O
each DT O
other JJ O
and CC O
can MD O
be VB O
selectively RB O
removed VBN O
under IN O
mild JJ O
conditions NNS O
. . O

A DT O
good JJ O
selection NN O
of IN O
the DT O
most RBS O
useful JJ O
protecting VBG O
groups NNS O
for IN O
functional JJ O
and CC O
potentially RB O
reactive JJ O
groups NNS O
which WDT O
can MD O
be VB O
easily RB O
applied VBN O
for IN O
the DT O
above RB O
mentioned VBN O
purpose NN O
by IN O
people NNS O
skilled JJ O
in IN O
the DT O
art NN O
can MD O
be VB O
found VBN O
e.g JJ O
. . O
in IN O
P. NNP O
J. NNP O
Kocienski NNP O
, , O
Protecting NNP O
Groups NNP O
, , O
2000 CD O
, , O
Corrected VBN O
Edition NNP O
, , O
Georg NNP O
Thieme NNP O
Verlag NNP O
, , O
Stuttgart NNP O
, , O
New NNP O
York NNP O
and CC O
T. NNP O
W. NNP O
Greene NNP O
, , O
P. NNP O
G. NNP O
M. NNP O
Wuts NNP O
, , O
Protective NNP O
Groups NNP O
in IN O
Organic NNP O
Synthesis NNP O
, , O
3 CD O
Edition NNP O
, , O
1999 CD O
, , O
John NNP O
Wiley NNP O
& CC O
Sons NNP O
, , O
Inc. NNP O
, , O
New NNP O
York NNP O
. . O

For IN O
instance NN O
, , O
when WRB O
acylating VBG O
panthenol NN B-NP
, , O
the DT O
primary JJ O
and CC O
secondary JJ O
hydroxy JJ B-NP
groups NNS O
located VBN O
in IN O
the DT O
carboxylic JJ B-NP
acid NN I-NP
portion NN O
of IN O
the DT O
molecule NN O
may MD O
be VB O
protected VBN O
by IN O
forming VBG O
an DT O
acetonide NN B-NP
, , O
thus RB O
allowing VBG O
a DT O
selective JJ O
acylation NN O
of IN O
the DT O
hydroxy JJ B-NP
group NN O
located VBN O
in IN O
the DT O
amide JJ O
portion NN O
of IN O
the DT O
molecule NN O
. . O

On IN O
the DT O
other JJ O
hand NN O
, , O
the DT O
acylation NN O
of IN O
compounds NNS O
of IN O
the DT O
formula NN O
XH NNP O
which WDT O
carry VBP O
more JJR O
than IN O
one CD O
reactive NN O
OH NNP B-NP
, , O
SH NNP B-NP
, , O
amino IN B-NP
or CC O
imino VBP B-NP
group NN O
may MD O
be VB O
carried VBN O
out RP O
without IN O
intermediary JJ O
protection NN O
of IN O
individual JJ O
reactive NN O
groups NNS O
, , O
thus RB O
leading VBG O
to TO O
compounds NNS O
of IN O
the DT O
formula NN O
( -LRB- O
I PRP O
) -RRB- O
wherein WRB O
m NN O
is VBZ O
an DT O
integer NN O
of IN O
greater JJR O
than IN O
1 CD O
with IN O
m NN O
corresponding JJ O
to TO O
the DT O
number NN O
of IN O
reactive JJ O
OH NNP B-NP
, , O
SH NNP B-NP
, , O
amino IN B-NP
or CC O
imino VB B-NP
groups NNS O
in IN O
the DT O
starting VBG O
compound NN O
of IN O
formula NN O
XH. . O

For IN O
the DT O
purposes NNS O
of IN O
the DT O
present JJ O
invention NN O
, , O
the DT O
compounds NNS O
of IN O
formula NN O
( -LRB- O
I PRP O
) -RRB- O
can MD O
be VB O
used VBN O
alone RB O
or CC O
in IN O
mixtures NNS O
. . O

The DT O
present JJ O
invention NN O
also RB O
provides VBZ O
compositions NNS O
, , O
in IN O
particular JJ O
topical JJ O
compositions NNS O
comprising VBG O
at IN O
least JJS O
one CD O
compound NN O
represented VBN O
by IN O
general JJ O
formula NN O
( -LRB- O
I PRP O
) -RRB- O
, , O
and CC O
a DT O
cosmetically NN O
acceptable JJ O
excipient JJ O
or CC O
diluent JJ O
. . O

In IN O
case NN O
that IN O
the DT O
compounds NNS O
of IN O
formula NN O
I PRP O
bear VBP O
one CD O
or CC O
more JJR O
chiral NN O
centers NNS O
the DT O
compounds NNS O
represented VBN O
by IN O
general JJ O
formula NN O
( -LRB- O
I PRP O
) -RRB- O
may MD O
be VB O
present JJ O
in IN O
a DT O
racemic JJ O
mixture NN O
, , O
in IN O
a DT O
mixture NN O
of IN O
diastereomers NNS O
or CC O
in IN O
excess NN O
of IN O
an DT O
enantiomer NN O
and/or CC O
diastereomer NN O
. . O

If IN O
one CD O
or CC O
more JJR O
chiral NN O
centers NNS O
are VBP O
present JJ O
the DT O
optical JJ O
purity NN O
of IN O
the DT O
mixture NN O
is VBZ O
preferably RB O
> VBN O
= SYM O
80 CD O
% NN O
ee NN O
, , O
more JJR O
preferably RB O
> RB O
90 CD O
% NN O
ee NN O
, , O
most JJS O
preferably RB O
> VBP O
95 CD O
% NN O
de FW O
. . O

If IN O
two CD O
or CC O
more JJR O
chiral NN O
centers NNS O
are VBP O
present JJ O
the DT O
purity NN O
of IN O
the DT O
mixture NN O
is VBZ O
preferably RB O
> VBN O
= SYM O
80 CD O
% NN O
de FW O
, , O
more RBR O
preferably RB O
> VBN O
= SYM O
90 CD O
% NN O
de IN O
, , O
most RBS O
preferably RB O
> NN O
= SYM O
95 CD O
% NN O
de FW O
. . O

The DT O
compositions NNS O
of IN O
the DT O
present JJ O
invention NN O
are VBP O
pharmaceutical JJ O
or CC O
cosmetic JJ O
compositions NNS O
, , O
preferably RB O
cosmetic JJ O
compositions NNS O
or CC O
cosmetic JJ O
preparations NNS O
. . O

The DT O
term NN O
" `` O
cosmetic JJ O
preparation NN O
" '' O
or CC O
" `` O
cosmetic JJ O
composition NN O
" '' O
as IN O
used VBN O
in IN O
the DT O
present JJ O
application NN O
refers VBZ O
to TO O
cosmetic JJ O
compositions NNS O
as IN O
defined VBN O
under IN O
the DT O
heading VBG O
" `` O
Kosmetika NNP O
" '' O
in IN O
Rompp NNP O
Lexikon NNP O
Chemie NNP O
, , O
10th JJ O
edition NN O
1997 CD O
, , O
Georg NNP O
Thieme NNP O
Verlag NNP O
Stuttgart NNP O
, , O
New NNP O
York NNP O
. . O

The DT O
compositions NNS O
of IN O
the DT O
present JJ O
invention NN O
contain VBP O
the DT O
compound NN O
represented VBN O
by IN O
general JJ O
formula NN O
( -LRB- O
I PRP O
) -RRB- O
with IN O
cosmetically NN O
acceptable JJ O
excipients NNS O
or CC O
diluents NNS O
. . O

If IN O
nothing NN O
else RB O
is VBZ O
stated VBN O
, , O
the DT O
excipients NNS O
, , O
additives NNS O
, , O
diluents NNS O
, , O
etc FW O
. . O
mentioned VBN O
in IN O
the DT O
following VBG O
are VBP O
suitable JJ O
for IN O
cosmetic JJ O
compositions NNS O
. . O

If IN O
nothing NN O
else RB O
is VBZ O
stated VBN O
, , O
in IN O
this DT O
application NN O
parts NNS O
and CC O
percentages NNS O
are VBP O
per IN O
weight NN O
and CC O
are VBP O
based VBN O
on IN O
the DT O
weight NN O
of IN O
the DT O
composition NN O
. . O

Preferably RB O
, , O
the DT O
cosmetic NN O
or CC O
pharmaceutical JJ O
compositions NNS O
of IN O
the DT O
present JJ O
invention NN O
are VBP O
topical JJ O
compositions NNS O
in IN O
the DT O
form NN O
of IN O
a DT O
suspension NN O
or CC O
dispersion NN O
in IN O
solvents NNS O
or CC O
fatty JJ O
substances NNS O
, , O
or CC O
alternatively RB O
in IN O
the DT O
form NN O
of IN O
an DT O
emulsion NN O
or CC O
micro JJ O
emulsion NN O
( -LRB- O
in IN O
particular JJ O
of IN O
O/W NNP O
or CC O
VWO NNP O
type NN O
, , O
0/W/O NNP O
or CC O
W/O/W-type JJ O
) -RRB- O
, , O
PET-emulsions NNS O
, , O
multiple JJ O
emulsions NNS O
, , O
bickering VBG O
emulsions NNS O
, , O
hydrogels NNS O
, , O
alcoholic JJ O
gels NNS O
, , O
lipogels NNS O
, , O
one CD O
or CC O
multiphase VB O
solutions NNS O
or CC O
a DT O
vesicular JJ O
dispersion NN O
and CC O
other JJ O
usual JJ O
compositions NNS O
, , O
which WDT O
can MD O
also RB O
be VB O
applied VBN O
by IN O
pens NNS O
, , O
as IN O
masks NNS O
or CC O
as IN O
sprays NNS O
. . O

The DT O
emulsions NNS O
can MD O
also RB O
contain VB O
anionic JJ O
, , O
nonionic JJ O
, , O
cationic JJ O
or CC O
amphoteric JJ O
surfactant( NN O
s VBZ O
) -RRB- O
. . O

Preferred VBN O
compositions NNS O
according VBG O
to TO O
the DT O
invention NN O
are VBP O
skin NN O
care NN O
preparations NNS O
, , O
hair-care JJ O
preparations NNS O
, , O
decorative JJ O
preparations NNS O
, , O
light JJ O
protection NN O
preparations NNS O
and CC O
functional JJ O
preparations NNS O
. . O

Examples NNS O
of IN O
skin NN O
care NN O
preparations NNS O
are VBP O
, , O
in IN O
particular JJ O
, , O
body NN O
oils NNS O
, , O
body NN O
lotions NNS O
, , O
body NN O
gels NNS O
, , O
treatment NN O
creams NNS O
, , O
skin NN O
protection NN O
ointments NNS O
, , O
shaving VBG O
preparations NNS O
, , O
such JJ O
as IN O
shaving NN O
foams NNS O
or CC O
gels NNS O
, , O
skin NN O
powders NNS O
such JJ O
as IN O
baby NN O
powder NN O
, , O
moisturizing JJ O
gels NNS O
, , O
moisturizing JJ O
sprays NNS O
, , O
revitalizing VBG O
body NN O
sprays NNS O
, , O
cellulite JJ O
gels NNS O
, , O
anti NNS O
acne VBP O
preparations NNS O
and CC O
peeling JJ O
preparations NNS O
. . O

Examples NNS O
of IN O
hair NN O
care NN O
preparations NNS O
are VBP O
, , O
for IN O
example NN O
, , O
hair-washing JJ O
preparations NNS O
in IN O
the DT O
form NN O
of IN O
shampoos NNS O
, , O
hair NN O
conditioners NNS O
, , O
hair-care JJ O
preparations NNS O
, , O
e NN O
. . O
g NN O
. . O
treatment NN O
preparations NNS O
, , O
pre JJ O
- : O
treatment NN O
preparations NNS O
, , O
hair NN O
tonics NNS O
, , O
styling VBG O
creams NNS O
, , O
styling VBG O
gels NNS O
, , O
pomades NNS O
, , O
hair NN O
rinses NNS O
, , O
treatment NN O
packs NNS O
, , O
intensive JJ O
hair NN O
treatments NNS O
, , O
hair-straightening JJ O
preparations NNS O
, , O
liquid JJ O
hair NN O
- : O
setting NN O
preparations NNS O
, , O
hair NN O
foams NNS O
and CC O
hairsprays NNS O
and CC O
lacquers NNS O
, , O
perming VBG O
agents NNS O
, , O
hair NN O
gels NNS O
, , O
hair NN O
fixatives NNS O
and CC O
hair NN O
dying VBG O
or CC O
bleaching VBG O
agents NNS O
. . O

Examples NNS O
of IN O
decorative JJ O
preparations NNS O
are VBP O
in IN O
particular JJ O
lipstick NN O
, , O
eye NN O
shadow NN O
, , O
mascaras NNS O
, , O
dry JJ O
and CC O
moist JJ O
make-up NN O
, , O
rouge JJ O
, , O
powders NNS O
, , O
and CC O
suntan JJ O
lotions NNS O
. . O

Examples NNS O
of IN O
functional JJ O
preparations NNS O
are VBP O
cosmetic JJ O
or CC O
pharmaceutical JJ O
compositions NNS O
containing VBG O
active JJ O
ingredients NNS O
such JJ O
as IN O
hormone NN O
preparations NNS O
, , O
vitamin NN O
preparations NNS O
, , O
vegetable NN O
extract VB O
preparations NNS O
, , O
anti-ageing JJ O
preparations NNS O
, , O
and CC O
antimicrobial JJ O
( -LRB- O
antibacterial JJ O
or CC O
antifungal JJ O
) -RRB- O
preparations NNS O
without IN O
being VBG O
limited JJ O
thereto NN O
. . O

Cosmetic JJ O
compositions NNS O
in IN O
accordance NN O
with IN O
the DT O
invention NN O
can MD O
be VB O
in IN O
the DT O
form NN O
of IN O
a DT O
liquid JJ O
, , O
lotion NN O
, , O
a DT O
thickened JJ O
lotion NN O
, , O
a DT O
gel NN O
, , O
a DT O
cream NN O
, , O
a DT O
milk NN O
, , O
an DT O
ointment NN O
, , O
a DT O
paste NN O
, , O
a DT O
powder NN O
, , O
a DT O
make-up NN O
, , O
or CC O
a DT O
solid JJ O
tube NN O
stick NN O
and CC O
can MD O
be VB O
optionally RB O
be VB O
packaged VBN O
as IN O
an DT O
aerosol NN O
and CC O
can MD O
be VB O
provided VBN O
in IN O
the DT O
form NN O
of IN O
a DT O
mousse NN O
such JJ O
as IN O
a DT O
aerosol NN O
mousse NN O
, , O
a DT O
foam NN O
or CC O
a DT O
spray NN O
foams NNS O
, , O
sprays NNS O
, , O
sticks NNS O
, , O
a DT O
gel NN O
, , O
a DT O
plaster NN O
, , O
a DT O
powder NN O
, , O
a DT O
cleanser NN O
, , O
a DT O
soap NN O
or CC O
aerosols NNS O
or CC O
wipes NNS O
. . O

The DT O
compositions NNS O
of IN O
the DT O
invention NN O
can MD O
also RB O
contain VB O
usual JJ O
cosmetic JJ O
adjuvants NNS O
and CC O
additives NNS O
, , O
such JJ O
as IN O
preservatives NNS O
/ IN O
antioxidants NNS O
, , O
fatty JJ O
substances NNS O
/ IN O
oils NNS O
, , O
water NN B-NP
, , O
organic JJ O
solvents NNS O
, , O
silicones NNS B-NP
, , O
thickeners NNS O
, , O
softeners NNS O
, , O
emulsifiers NNS O
, , O
sunscreens NNS O
, , O
cosmetic JJ O
actives NNS O
antifoaming VBG O
agents NNS O
, , O
moisturizers NNS O
, , O
fragrances NNS O
, , O
surfactants NNS O
, , O
fillers NNS O
, , O
sequestering VBG O
agents NNS O
, , O
anionic JJ O
, , O
cationic JJ O
, , O

nonionic JJ O
or CC O
amphoteric JJ O
polymers NNS B-NP
or CC O
mixtures NNS O
thereof RB O
, , O
propellants NNS O
, , O
acidifying VBG O
or CC O
basifying VBG O
agents NNS O
, , O
dyes NNS O
, , O
colorants NNS O
, , O
pigments NNS O
or CC O
nanopigments NNS O
, , O
e.g NN O
. . O

those DT O
suited VBN O
for IN O
providing VBG O
a DT O
photoprotective JJ O
effect NN O
by IN O
physically RB O
blocking VBG O
out IN O
ultraviolet NN O
radiation NN O
, , O
or CC O
any DT O
other JJ O
ingredients NNS O
usually RB O
formulated VBN O
into IN O
cosmetics NNS O
. . O

A DT O
good JJ O
overview NN O
of IN O
suitable JJ O
additives NNS O
for IN O
cosmetic JJ O
compositions NNS O
can MD O
also RB O
be VB O
found VBN O
e.g JJ O
. . O
in IN O
WO NN O
03/082232 CD O
. . O

The DT O
additives NNS O
disclosed VBD O
in IN O
this DT O
document NN O
, , O
in IN O
particular JJ O
the DT O
waxes NNS O
, , O
thickeners NNS O
, , O
structuring VBG O
agents NNS O
, , O
film NN O
forming VBG O
agents NNS O
and CC O
conditioning NN O
ingredients NNS O
are VBP O
also RB O
suitable JJ O
for IN O
the DT O
compositions NNS O
of IN O
the DT O
present JJ O
invention NN O
and CC O
included VBD O
herein RB O
by IN O
reference NN O
. . O

Of IN O
course NN O
, , O
the DT O
stabilizing VBG O
compositions NNS O
disclosed VBN O
in IN O
this DT O
document NN O
can MD O
also RB O
be VB O
used VBN O
for IN O
preparing VBG O
the DT O
compositions NNS O
of IN O
the DT O
present JJ O
invention NN O
. . O

The DT O
composition NN O
of IN O
the DT O
present JJ O
invention NN O
can MD O
also RB O
contain VB O
one CD O
or CC O
more JJR O
additional JJ O
pharmaceutically RB O
or CC O
cosmetically RB O
active JJ O
ingredients NNS O
, , O
in IN O
particular JJ O
for IN O
preventing VBG O
or CC O
reducing VBG O
acne NN O
, , O
wrinkles NNS O
, , O
lines NNS O
, , O
pigmentation NN O
, , O
atrophy NN O
, , O
inflammation NN O
, , O
as RB O
well RB O
as IN O
topical JJ B-NP
anesthetics NNS I-NP
, , O
artificial JJ O
tanning NN O
agents NNS O
and CC O
accelerators NNS O
, , O
antimicrobial JJ O
agents NNS O
, , O
and CC O
antifungal JJ O
agents NNS O
and CC O
sun NN O
screening VBG O
additives NNS O
without IN O
being VBG O
limited VBN O
thereto RB O
. . O

Examples NNS O
of IN O
such JJ O
ingredients NNS O
are VBP O
peptides NNS B-NP
( -LRB- O
e NN O
.g. NNP O
, , O
Matrixyl( NNP O
TM) NNP O
[pentapeptide NN O
derivative] NN O
) -RRB- O
, , O
oligopeptides VBZ B-NP
, , O
wax-based JJ O
synthetic JJ O
peptides NNS B-NP
( -LRB- O
e NN O
.g. NNP O
, , O
octyl NN B-NP
palmitate NN I-NP
and CC O
tribehenin NN B-NP
and CC O
sorbitan JJ B-NP
isostearate NN I-NP
and CC O
palmitoyl-oligopeptide NN B-NP
) -RRB- O
, , O
glycerol NN B-NP
, , O
urea NN B-NP
, , O
guanidine NN B-NP
( -LRB- O
e NN O
.g NN O
. . O

amino JJ B-NP
guanidine NN B-NP
) -RRB- O
; : O
vitamins NNS O
and CC O
derivatives NNS O
thereof , O
such JJ O
as IN O
vitamin NN B-NP
C NNP I-NP
( -LRB- O
ascorbic JJ B-NP
acid NN I-NP
) -RRB- O
, , O
vitamin NN B-NP
A DT I-NP
( -LRB- O
e NN O
.g. NNP O
, , O
retinoid JJ B-NP
derivatives NNS O
such JJ O
as IN O
retinyl NN B-NP
palmitate NN I-NP
or CC O
retinyl NN B-NP
propionate NN I-NP
) -RRB- O
, , O
vitamin NN B-NP
E NNP I-NP
( -LRB- O
e NN O
.g. NNP O
, , O
tocopherol NN B-NP
acetate NN I-NP
) -RRB- O
, , O
vitamin NN B-NP
B3 CC I-NP
( -LRB- O
e NN O
.g NN O
. . O

nicotinamide NN B-NP
) -RRB- O
and CC O
vitamin NN B-NP
B5 IN I-NP
( -LRB- O
e NN O
.g NN O
. . O

panthenol NN B-NP
) -RRB- O
, , O
vitamin NN B-NP
B6 NNS I-NP
and CC O
vitamin NN B-NP
B12 NN I-NP
, , O
biotin NN B-NP
, , O
folic JJ B-NP
acid NN I-NP
; : O
anti-acne JJ O
actives NNS O
or CC O
medicaments NNS O
( -LRB- O
e NN O
.g NN O
. . O

resorcinol NN B-NP
, , O
salicylic JJ B-NP
acid NN I-NP
, , O
and CC O
the DT O
like JJ O
) -RRB- O
; : O
antioxidants NNS O
( -LRB- O
e NN O
.g NN O
. . O

phytosterols NNS B-NP
, , O
lipoic JJ B-NP
acid NN I-NP
) -RRB- O
; : O
flavonoids NNS B-NP
( -LRB- O
e NN O
.g NN O
. . O

isoflavones NNS B-NP
, , O
phytoestrogens NNS B-NP
) -RRB- O
; : O
skin NN O
soothing VBG O
and CC O
healing VBG O
agents NNS O
such JJ O
as IN O
aloe NN O
vera NN O
extract VB O
, , O
allantoin RB B-NP
and CC O
the DT O
like JJ O
; : O

agents NNS O
suitable JJ O
for IN O
aesthetic JJ O
purposes NNS O
such JJ O
as IN O
essential JJ O
oils NNS O
, , O
fragrances NNS O
, , O
skin NN O
sensates NNS O
, , O
opacifiers NNS O
, , O
aromatic JJ O
compounds NNS O
( -LRB- O
e NN O
.g. NNP O
, , O
clove NN O
oil NN O
, , O
menthol NN B-NP
, , O
camphor NN B-NP
, , O
eucalyptus NN O
oil NN O
, , O
and CC O
eugenol NN B-NP
) -RRB- O
, , O
desquamatory JJ O
actives NNS O
, , O
hydroxy JJ B-NP
acids NNS I-NP
such JJ O
as IN O
AHA NNP O
acids NNS O
, , O
radical JJ O
scavengers NNS O
, , O
farnesol NN B-NP
, , O
antifungal JJ O
actives NNS O
in IN O
particular JJ O
bisabolol NN B-NP
, , O
alkyldiols NNS B-NP
such JJ O
as IN O
1 CD B-NP
,2-pentanediol JJ I-NP
, , O
hexanediol JJ B-NP
or CC O
1 CD B-NP
,2-octanediol JJ I-NP
, , O
phytol NN B-NP
, , O
polyols NNS B-NP
such JJ O
as IN O
phytanetriol NN B-NP
, , O
ceramides NNS O
and CC O
pseudoceramides NNS B-NP
, , O
amino IN B-NP
acids NNS I-NP
, , O
protein NN O
hydrolysates NNS O
, , O
polyunsaturated VBN B-NP
fatty JJ I-NP
acids NNS I-NP
, , O
plant NN O
extracts NNS O
like IN O
kinetin NN B-NP
, , O
DNA NNP O
or CC O
RNA NNP O
and CC O
their PRP$ O
fragmentation NN O
products NNS O
, , O
carbohydrates NNS B-NP
, , O
conjugated VBN B-NP
fatty JJ I-NP
acids NNS I-NP
, , O
carnitin NN B-NP
, , O
carnosine NN B-NP
, , O
biochinonen NN B-NP
, , O
phytofluen NN B-NP
, , O
phytoen NN B-NP
, , O
and CC O
their PRP$ O
corresponding JJ O
derivatives NNS O
. . O

Additionally RB O
the DT O
cosmetic NN O
and CC O
pharmaceutical JJ O
topical JJ O
composition NN O
of IN O
the DT O
present JJ O
invention NN O
may MD O
contain VB O
UV-screening JJ O
agents NNS O
( -LRB- O
UV-filter NN O
) -RRB- O
. . O

The DT O
additional JJ O
UV-screening NN O
agents NNS O
are VBP O
advantageously RB O
selected VBN O
from IN O
IR NNP O
, , O
UV-A NNP O
, , O
UV-B NN O
, , O
UV-C JJ O
and/ NN O
or CC O
broadband NN O
filters NNS O
. . O

Examples NNS O
of IN O
UV-B NN O
or CC O
broad JJ O
spectrum NN O
screening VBG O
agents NNS O
, , O
i IN O
.e NNP O
. . O
substances NNS O
having VBG O
absorption NN O
maximums NNS O
between IN O
about IN O
290 CD O
nm NN O
and CC O
340 CD O
nm NN O
may MD O
be VB O
organic JJ O
or CC O
inorganic JJ O
compounds NNS O
. . O

Organic NNP O
UV-B NN O
or CC O
broadband JJ O
screening NN O
agents NNS O
are VBP O
e.g JJ O
. . O

acrylates NNS B-NP
such JJ O
as IN O
2-ethylhexyl JJ B-NP
2-cyano-3,3- CC I-NP
diphenylacrylate JJ I-NP
(octocrylene NN O
, , O
PARSOL NNP O
340 CD O
) -RRB- O
, , O
ethyl NN B-NP
2-cyano-3,3-diphenylacrylate JJ I-NP
and CC O
the DT O
like JJ O
; : O
camphor NN B-NP
derivatives NNS O
such JJ O
as IN O
4-methyl JJ B-NP
benzylidene NN I-NP
camphor NN I-NP
( -LRB- O
PARSOL NN O
5000 CD O
) -RRB- O
, , O
3- CD B-NP
benzylidene NN I-NP
camphor NN I-NP
, , O
camphor NN B-NP
benzalkonium NN I-NP
methosulfate NN I-NP
, , O
polyacrylamidomethyl NN B-NP
benzylidene NN I-NP
camphor NN I-NP
, , O
sulfo VB B-NP
benzylidene NN I-NP
camphor NN I-NP
, , O
sulphomethyl NN B-NP
benzylidene NN I-NP
camphor NN I-NP
, , O
therephthalidene DT B-NP
dicamphor NN I-NP
sulfonic JJ I-NP
acid NN I-NP
and CC O
the DT O
like JJ O
; : O
Cinnamate NNP B-NP
derivatives VBZ O
such JJ O
as IN O
ethylhexyl NN B-NP
methoxycinnamate NN I-NP
( -LRB- O
PARSOL NNP O
MCX) NNP O
, , O
ethoxyethyl NN B-NP
methoxycinnamate NN I-NP
, , O
diethanolamine NN B-NP
methoxycinnamate NN I-NP
( -LRB- O
PARSOL NN O
Hydro NNP O
) -RRB- O
, , O
isoamyl JJ B-NP
methoxycinnamate NN I-NP
and CC O
the DT O
like JJ O
as RB O
well RB O
as IN O
cinnamic JJ B-NP
acid NN I-NP
derivatives VBZ O
bond NN O
to TO O
siloxanes NNS B-NP
; : O
p-aminobenzoic JJ B-NP
acid NN I-NP
derivatives NNS O
, , O
such JJ O
as IN O
p-aminobenzoic JJ B-NP
acid NN I-NP
, , O
2-ethylhexyl JJ B-NP
p-dimethylaminobenzoate JJ I-NP
, , O
N-oxypropylenated JJ B-NP
ethyl NN I-NP
p-aminobenzoate NN I-NP
, , O
glyceryl NN B-NP
p-aminobenzoate NN I-NP
; : O
benzophenones NNS B-NP
such JJ O
as IN O
benzophenone NN B-NP
- : I-NP
3 CD I-NP
, , O
benzophenone-4 CD B-NP
, , O
2,2<l> CD B-NP
,4,4'-tetrahydroxy-benzophenone NN I-NP
, , O
2,2'-dihydroxy-4,4' JJ B-NP
- : I-NP
dimethoxybenzophenone NN I-NP
and CC O
the DT O
like JJ O
; : O
esters NNS B-NP
of IN O
benzalmalonic JJ B-NP
acid NN I-NP
such JJ O
as IN O
di-(2 JJ B-NP
- : I-NP
ethylhexyl NN I-NP
) -RRB- I-NP
4-methoxybenzalmalonate JJ I-NP
; : O
esters NNS B-NP
of IN O
2-(4-ethoxy-anilinomethylene)propandioic JJ B-NP
acid NN I-NP
such JJ O
as IN O
2-(4-ethoxy JJ B-NP
anilinomethylene NN I-NP
) -RRB- I-NP
propandioic JJ I-NP
acid NN I-NP
diethyl NN I-NP
ester NN I-NP
as IN O
described VBN O
in IN O
the DT O
European JJ O
Patent NN O
Publication NN O
EP NNP O
0895 CD O
776 CD O
; : O
organosiloxane NN B-NP
compounds NNS O
containing VBG O
benzmalonate JJ B-NP
groups NNS O
as IN O
described VBN O
in IN O
the DT O
European JJ O
Patent NN O
Publications NNP O
EP NNP O
0358584 CD O
B1 NNP O
, , O
EP NNP O
0538431 CD O
B1 NNP O
and CC O
EP NNP O
0709080 CD O
A1 . O
such JJ O
as IN O
PARSOL NNP O
SLX NNP O
; : O
drometrizole NN B-NP
trisiloxane NN I-NP
( -LRB- O
Mexoryl JJ O
XL NNP O
) -RRB- O
; : O
imidazole JJ B-NP
derivatives NNS O
such JJ O
as IN O
e.g NN O
. . O

2-phenyl JJ B-NP
benzimidazole NN I-NP
sulfonic JJ I-NP
acid NN I-NP
and CC O
its PRP$ O
salts NNS O
( -LRB- O
PARSOLHS) NN O
. . O

Salts NNS O
of IN O
2-phenyl JJ B-NP
benzimidazole NN I-NP
sulfonic JJ I-NP
acid NN I-NP
are VBP O
e.g RB O
. . O

alkali VBP B-NP
salts NNS I-NP
such JJ O
as IN O
sodium NN B-NP
- : O
or CC O
potassium NN B-NP
salts NNS O
, , O
ammonium NN B-NP
salts NNS O
, , O
morpholine NN B-NP
salts NNS I-NP
, , O
salts NNS O
of IN O
primary JJ O
, , O
sec. . O

and CC O
tert NN O
. . O

amines NNS B-NP
like IN O
monoethanolamine NN B-NP
salts NNS O
, , O
diethanolamine NN B-NP
salts NNS O
and CC O
the DT O
like JJ O
; : O
salicylate JJ B-NP
derivatives NNS O
such JJ O
as IN O
isopropylbenzyl NN B-NP
salicylate NN I-NP
, , O
benzyl NN B-NP
salicylate NN I-NP
, , O
butyl NN B-NP
salicylate NN I-NP
, , O
ethylhexyl NN B-NP
salicylate NN I-NP
( -LRB- O
PARSOL NNP O
EHS NNP O
, , O
Neo NNP O
Heliopan NNP O
OS) NNP O
, , O
isooctyl NN B-NP
salicylate NN I-NP
or CC O
homomenthyl NN B-NP
salicylate NN I-NP
( -LRB- O
homosalate NN O
, , O
PARSOL NNP O
HMS NNP O
, , O
Neo NNP O
Heliopan NNP O
HMS NNP O
) -RRB- O
and CC O
the DT O
like JJ O
; : O
triazine NN B-NP
derivatives NNS O
such JJ O
as IN O
ethylhexyl NN B-NP
triazone NN I-NP
( -LRB- O
Uvinul JJ O
T-150 NN O
) -RRB- O
, , O
diethylhexyl NN B-NP
butamido NN I-NP
triazone NN I-NP
( -LRB- O
Uvasorb JJ O
HEB NN O
) -RRB- O
and CC O
the DT O
like JJ O
. . O

Encapsulated VBN O
UV-filters NNS O
such JJ O
as IN O
encapsulated JJ O
ethylhexyl NN B-NP
methoxycinnamate NN I-NP
( -LRB- O
Eusolex JJ O
UV-pearls NNS O
) -RRB- O
or CC O
microcapsules NNS O
loaded VBN O
with IN O
UV-filters NNS O
as IN O
e.g NN O
. . O

dislosed VBN O
in IN O
EP NNP O
1471995 CD O
and CC O
the DT O
like JJ O
; : O

Examples NNS O
of IN O
broad JJ O
spectrum NN O
or CC O
UV NN O
A DT O
screening VBG O
agents NNS O
i IN O
.e JJ O
. . O
substances NNS O
having VBG O
absorption NN O
maximums NNS O
between IN O
about IN O
320 CD O
nm NN O
and CC O
400 CD O
nm NN O
may MD O
be VB O
organic JJ O
or CC O
inorganic JJ O
compounds NNS O
. . O

Organic NNP O
broad JJ O
spectrum NN O
or CC O
UV NN O
A DT O
screening VBG O
agents NNS O
include VBP O
e.g JJ O
. . O

dibenzoylmethane NN B-NP
derivatives NNS O
such JJ O
as IN O
4-tert.-butyl-4'-methoxydibenzoyl-methane JJ B-NP

( -LRB- O
PARSOL NN O
1789 CD O
) -RRB- O
, , O
dimethoxydibenzoylmethane NN B-NP
, , O
isopropyldibenzoylmethane NN B-NP
and CC O
the DT O
like JJ O
; : O
benzotriazole JJ B-NP
derivatives NNS I-NP
such JJ O
as IN O
2,2'-methylene-bis-(6-(2H-benzotriazole-2-yl)-4-( JJ B-NP
1 CD I-NP
,1 CD I-NP
,3,3,- CC I-NP
tetramethylbutyl)-phenol JJ I-NP
( -LRB- O
Tinosorb JJ O
M NNP O
) -RRB- O
and CC O
the DT O
like JJ O
; : O
bis-ethylhexyloxyphenol JJ B-NP
methoxyphenyl NN I-NP
triazine NN I-NP
( -LRB- O
Tinosorb NNP O
S NNP O
) -RRB- O
and CC O
the DT O
like JJ O
; : O
phenylene-1 NN B-NP
,4-bis-benzimidazolsulfonic JJ I-NP
acids NNS I-NP
or CC O
salts NNS O
such JJ O
as IN O
2,2-( CD B-NP
1 CD I-NP
,4-phenylene)bis-( JJ I-NP
1 CD I-NP
H-benzimidazol-4,6-disulfonic JJ I-NP
acid NN I-NP
) -RRB- O
( -LRB- O
Neoheliopan NN O
AP NNP O
) -RRB- O
; : O
amino IN B-NP
substituted VBN O
hydroxybenzophenones NNS B-NP
such JJ O
as IN O
2-(4-Diethylamino-2-hydroxy-benzoyl) JJ B-NP
- : I-NP
benzoic JJ I-NP
acid NN I-NP
hexylester NN I-NP
( -LRB- O
Uvinul JJ O
A DT O
plus NN O
) -RRB- O
as IN O
described VBN O
in IN O
the DT O
European JJ O
Patent NN O
Publication NN O
EP NNP O
1046391 CD O
; : O
Ionic NNP O
UV-A NNP O
filters VBZ O
as IN O
described VBN O
in IN O
the DT O
International NNP O
Patent NNP O
Publication NNP O
WO2005080341 NNP O
A1 NNP O
; : O

As IN O
dibenzoylmethane NN B-NP
derivatives NNS O
have VBP O
limited VBN O
photostability NN O
it PRP O
may MD O
be VB O
desirable JJ O
to TO O
photostabilize VB O
these DT O
UV-A JJ O
screening NN O
agents NNS O
. . O

Thus RB O
, , O
the DT O
term NN O
" `` O
conventional JJ O
UV- '' O
A DT O
screening NN O
agent NN O
" '' O
also RB O
refers VBZ O
to TO O
dibenzoylmethane NN B-NP
derivatives NNS O
such JJ O
as IN O
e.g NN O
. . O

PARSOL NNP O
1789 CD O
stabilized VBN O
by IN O
, , O
e.g NN O
. . O

3,3-Diphenylacrylate JJ B-NP
derivatives NNS O
as IN O
described VBN O
in IN O
the DT O
European JJ O
Patent NNP O
Publications NNPS O
EP NNP O
0 CD O
514 CD O
491 CD O
B1 NNP O
and CC O
EP NNP O
0 CD O
780 CD O
119 CD O
A1 NNP O
; : O
Benzylidene NNP B-NP
camphor NN B-NP
derivatives NNS O
as IN O
described VBN O
in IN O
the DT O
US NNP O
Patent NNP O
No. NN O
5,605,680 CD O
; : O
Organosiloxanes NNP B-NP
containing VBG O
benzmalonate JJ B-NP
groups NNS O
as IN O
described VBN O
in IN O
the DT O
European JJ O
Patent NN O
Publications NNP O
EP NNP O
0358584 CD O
B1 NNP O
, , O
EP NNP O
0538431 CD O
B1 NNP O
and CC O
EP NNP O
0709080 CD O
A1 NNP O
. . O

A DT O
good JJ O
overview NN O
of IN O
UV-A- NNP O
and CC O
UV-B JJ O
screening NN O
agents NNS O
which WDT O
can MD O
be VB O
added VBN O
to TO O
the DT O
compositions NNS O
of IN O
the DT O
present JJ O
invention NN O
can MD O
also RB O
be VB O
found VBN O
in IN O
DE-A NNP O
103 CD O
27 CD O
432 CD O
. . O

All DT O
UV- JJ O
screening NN O
agents NNS O
disclosed VBN O
in IN O
this DT O
document NN O
are VBP O
also RB O
useful JJ O
as IN O
components NNS O
for IN O
the DT O
compositions NNS O
of IN O
the DT O
present JJ O
invention NN O
and CC O
are VBP O
included VBN O
herein RB O
by IN O
reference NN O
. . O

A DT O
safe JJ O
and CC O
effective JJ O
amount NN O
of IN O
the DT O
UV-screening JJ O
agent NN O
is VBZ O
used VBN O
, , O
typically RB O
from IN O
about IN O
1 CD O
wt NN O
. . O

-% NN O
to TO O
about IN O
20 CD O
wt.-% NN O
, , O
more RBR O
typically RB O
from IN O
about IN O
2 CD O
wt.-% NN O
to TO O
about IN O
10 CD O
wt.-% NN O
. . O

Other JJ O
suitable JJ O
UV-screening NN O
agents NNS O
which WDT O
may MD O
be VB O
incorporated VBN O
into IN O
the DT O
cosmetic NN O
or CC O
pharmaceutical JJ O
topical JJ O
compositions NNS O
of IN O
the DT O
present JJ O
invention NN O
are VBP O
inorganic JJ O
pigments NNS O
such JJ O
as IN O
microparticulated JJ O
metal NN B-NP
oxides NNS I-NP
( -LRB- O
e NN O
.g NN O
. . O

PARSOL NN O
TX NNP O
) -RRB- O
. . O

Examples NNS O
of IN O
such JJ O
compounds NNS O
include VBP O
e.g NN O
. . O

titanium NN B-NP
dioxide NN I-NP
having VBG O
an DT O
average JJ O
primary JJ O
particle NN O
size NN O
of IN O
from IN O
about IN O
15 CD O
nm NN O
to TO O
about IN O
100 CD O
nm NN O
, , O
zinc NN B-NP
oxide NN O
having VBG O
an DT O
average JJ O
primary JJ O
particle NN O
size NN O
of IN O
from IN O
about IN O
15 CD O
nm NN O
to TO O
about IN O
150 CD O
nm NN O
, , O
zirconium NN B-NP
oxide NN I-NP
having VBG O
an DT O
average JJ O
primary JJ O
particle NN O
size NN O
of IN O
from IN O
about IN O
15 CD O
nm NN O
to TO O
about IN O
150 CD O
nm NN O
, , O
iron NN B-NP
oxide NN O
having VBG O
an DT O
average JJ O
primary JJ O
particle NN O
size NN O
of IN O
from IN O
about IN O
15 CD O
nm NN O
to TO O
about IN O
500 CD O
nm NN O
, , O
and CC O
mixtures NNS O
thereof RB O
. . O

The DT O
metal NN O
oxide NN O
particles NNS O
may MD O
also RB O
be VB O
coated VBN O
by IN O
metal NN B-NP
oxides NNS I-NP
such JJ O
as IN O
e.g NN O
. . O

aluminum NN O
or CC O
zirconium NN O
oxides NNS O
or CC O
by IN O
organic JJ O
coatings NNS O
such JJ O
as IN O
e.g NN O
. . O

polyols NNS B-NP
, , O
methicone NN B-NP
, , O
aluminum NN B-NP
stearate NN I-NP
, , O
alkyl NN B-NP
silane NN I-NP
. . O

Such JJ O
coatings NNS O
are VBP O
well RB O
known VBN O
in IN O
the DT O
art NN O
. . O

When WRB O
used VBN O
herein RB O
, , O
the DT O
inorganic JJ O
sunscreens NNS O
are VBP O
present JJ O
in IN O
the DT O
amount NN O
of IN O
from IN O
about IN O
0.1 CD O
wt.-% NN O
to TO O
about IN O
20 CD O
wt.-% NN O
, , O
preferably RB O
from IN O
about RB O
0.5 CD O
wt.-% NN O
to TO O
about IN O
10 CD O
wt.-% NN O
, , O
more JJR O
preferably RB O
from IN O
about IN O
1wt.-% JJ O
to TO O
about IN O
5 CD O
wt.-% NN O
. . O

The DT O
compositions NNS O
of IN O
the DT O
present JJ O
invention NN O
preferably RB O
contain VBP O
one CD O
or CC O
more JJR O
antioxidants/preservatives NNS O
. . O

Based VBN O
on IN O
the DT O
invention NN O
all DT O
known VBN O
antioxidants NNS O
usually RB O
formulated VBN O
into IN O
cosmetics NNS O
can MD O
be VB O
used VBN O
. . O

Especially RB O
preferred JJ O
are VBP O
antioxidants NNS O
chosen VBN O
from IN O
the DT O
group NN O
consisting VBG O
of IN O
amino NN B-NP
acids NNS I-NP
( -LRB- O
e NN O
.g NN O
. . O

glycine NN B-NP
, , O
histidine NN B-NP
, , O
tyrosine FW B-NP
, , O
tryptophan FW B-NP
) -RRB- O
and CC O
their PRP$ O
derivatives NNS O
, , O
imidazole NN B-NP
( -LRB- O
e NN O
.g NN O
. . O

urocanic JJ B-NP
acid NN I-NP
) -RRB- O
and CC O
derivatives VBZ O
, , O
peptides NNS B-NP
such JJ O
as IN O
D1L- NNP B-NP
carnosine NN I-NP
, , O
D-carnosine NNP B-NP
, , O
L-carnosine NNP B-NP
and CC O
derivatives NNS O
( -LRB- O
e NN O
.g NN O
. . O

anserine NN B-NP
) -RRB- O
, , O
carotenoids VBZ B-NP
, , O
carotenes NNS B-NP
( -LRB- O
e NN O
.g NN O
. . O

[alpha]-carotene NN B-NP
, , O
[beta]-carotene NN B-NP
, , O
lycopene NN B-NP
) -RRB- O
and CC O
derivatives VBZ O
, , O
chlorogenic JJ B-NP
acid NN I-NP
and CC O
derivatives NNS O
, , O
lipoic JJ B-NP
acid NN I-NP
and CC O
derivatives NNS O
( -LRB- O
e NN O
.g NN O
. . O

dihydrolipoic JJ B-NP
acid NN I-NP
) -RRB- O
, , O
aurothioglucose NN B-NP
, , O
propylthiouracil NN B-NP
and CC O
other JJ O
thiols NNS B-NP
( -LRB- O
e NN O
.g NN O
. . O

thioredoxine NN B-NP
, , O
glutathione NN B-NP
, , O
cysteine NN B-NP
, , O
cystine NN B-NP
, , O
cystamine NN B-NP
and CC O
its PRP$ O
glycosyl-, NN B-NP
N-acetyl-, JJ B-NP
methyl-, NN B-NP
ethyl-, NN B-NP
propyl-, JJ B-NP
amyl-, JJ B-NP
butyl- NNS B-NP
and CC O
lauryl-, NN B-NP
palmitoyl-; NN B-NP
oleyl-, JJ B-NP
y-linoleyl-, JJ B-NP
cholesteryl- NNS B-NP
and CC O
glycerylester NN B-NP
) -RRB- O
and CC O
the DT O
salts NNS O
thereof RB O
, , O
dilaurylthiodipropionate JJ B-NP
, , O
distearylthiodipropionate JJ B-NP
, , O
thiodipropionic JJ B-NP
acid NN I-NP
and CC O
its PRP$ O
derivatives NNS O
(ester NN O
, , O
ether NN O
, , O
peptides NNS B-NP
, , O
lipids NNS B-NP
, , O
nucleotides NNS B-NP
, , O
nucleosides NNS B-NP
and CC O
salts NNS O
) -RRB- O
as RB O
well RB O
as IN O
sulfoximine NN B-NP
compounds NNS O
( -LRB- O
such JJ O
as IN O
buthioninsulfoximine NN B-NP
, , O
homocysteinsulfoximine NN B-NP
, , O
buthioninsulfone NN B-NP
, , O
penta-, JJ O
hexa-, JJ O
heptathioninsulfoximine NN B-NP
) -RRB- O
in IN O
very RB O
low JJ O
compatible JJ O
doses NNS O
( -LRB- O
e NN O
.g NN O
. . O

pmol NN O
to TO O
[mu]mol/kg NNP O
) -RRB- O
, , O
additionally RB O
( -LRB- O
metal)-chelators NNS O
( -LRB- O
such JJ O
as IN O
[alpha]-hydroxyfatty JJ B-NP
acids NNS I-NP
, , O
palmic-, JJ B-NP
phytinic JJ B-NP
acid NN I-NP
, , O
lactoferrin VBG B-NP
) -RRB- O
, , O
[alpha]-hydroxyacids FW B-NP
( -LRB- O
such JJ O
as IN O
citric JJ B-NP
acid NN I-NP
, , O
lactic JJ B-NP
acid NN I-NP
, , O
malic JJ B-NP
acid NN I-NP
) -RRB- O
, , O
huminic JJ B-NP
acid NN I-NP
, , O
gallic JJ B-NP
acid NN I-NP
, , O
gallic JJ O
extracts NNS O
, , O
bilirubin NN B-NP
, , O
biliverdin NN B-NP
, , O
EDTA NNP B-NP
, , O
EGTA NNP B-NP
and CC O
its PRP$ O
derivatives NNS O
, , O
unsaturated JJ B-NP
fatty NN I-NP
acids NNS I-NP
and CC O
their PRP$ O
derivatives NNS O
( -LRB- O
such JJ O
as IN O
[gamma]-linoleic JJ B-NP
acid NN I-NP
, , O
linolic JJ B-NP
acid NN I-NP
, , O
oleic JJ B-NP
acid NN I-NP
) -RRB- O
, , O
folic JJ B-NP
acid NN I-NP
and CC O
its PRP$ O
derivatives NNS O
, , O
ubiquinone NN B-NP
and CC O
ubiquinol NN B-NP
and CC O
their PRP$ O
derivatives NNS O
, , O
vitamin NN B-NP
C NNP I-NP
and CC O
derivatives NNS O
( -LRB- O
such JJ O
as IN O
ascorbylpalmitate NN B-NP
and CC O
ascorbyltetraisopalmitate NN B-NP
, , O
Mg- NNP B-NP
ascorbylphosphate NN I-NP
, , O
Na-ascorbylphosphate NNP B-NP
, , O
ascorbylacetate NN B-NP
, , O
ascorbylglucoside NN B-NP
) -RRB- O
, , O
tocopherol NN B-NP
and CC O
derivates NNS O
( -LRB- O
such JJ O
as IN O
vitamin-E-acetate NN B-NP
) -RRB- O
, , O
mixtures NNS O
of IN O
nat NN O
. . O

vitamin NN B-NP
E NNP I-NP
, , O
vitamin NN B-NP
A NNP I-NP
and CC O
derivatives NNS O
(vitamin-A-palmitate NN O
and CC O
-acetate NN O
) -RRB- O
as RB O
well RB O
as IN O
coniferylbenzoate NN B-NP
, , O
rutinic JJ B-NP
acid NN I-NP
and CC O
derivatives NNS O
, , O
[alpha]-glycosylrutin NNP B-NP
, , O
ferulic JJ B-NP
acid NN I-NP
, , O
furfurylidenglucitol NN B-NP
, , O
carnosin NN B-NP
, , O
butylhydroxytoluene NN B-NP
, , O
butylhydroxyanisole NN B-NP
, , O
trihydroxybutyrophenone NN B-NP
, , O
urea NN B-NP
and CC O
its PRP$ O
derivatives NNS O
, , O
mannose NN B-NP
and CC O
derivatives NNS O
, , O
zinc NN B-NP
and CC O
derivatives NNS O
( -LRB- O
e NN O
.g NN O
. . O

ZnO NNP B-NP
, , O
ZnSO4 NNP B-NP
) -RRB- O
, , O
selenium NN B-NP
and CC O
derivatives NNS O
( -LRB- O
e NN O
.g NN O
. . O

selenomethionine NN B-NP
) -RRB- O
, , O
stilbenes NNS B-NP
and CC O
derivatives NNS O
( -LRB- O
such JJ O
as IN O
stilbenoxide NN B-NP
, , O
trans-stilbenoxide NN B-NP
) -RRB- O
and CC O
suitable JJ O
derivatives NNS O
( -LRB- O
salts NNS O
, , O
esters NNS B-NP
, , O
ethers NNS B-NP
, , O
sugars NNS B-NP
, , O
nucleotides NNS B-NP
, , O
nucleosides NNS B-NP
, , O
peptides NNS B-NP
and CC O
lipids NNS B-NP
) -RRB- O
of IN O
the DT O
named VBN O
active JJ O
ingredients NNS O
. . O

One CD O
or CC O
more JJR O
preservatives/antioxidants NNS O
may MD O
be VB O
present JJ O
in IN O
an DT O
amount NN O
about IN O
0.01 CD O
wt NN O
. . O
% NN O
to TO O
about IN O
10 CD O
wt NN O
. . O

% NN O
of IN O
the DT O
total JJ O
weight NN O
of IN O
the DT O
composition NN O
of IN O
the DT O
present JJ O
invention NN O
. . O

Preferably RB O
, , O
one CD O
or CC O
more JJR O
preservatives/antioxidants NNS O
are VBP O
present JJ O
in IN O
an DT O
amount NN O
about IN O
0.1 CD O
wt NN O
. . O
% NN O
to TO O
about IN O
1 CD O
wt NN O
. . O
% NN O
. . O

Typically RB O
topical JJ O
compositions NNS O
also RB O
contain VBP O
surface NN O
active JJ O
ingredients NNS O
like IN O
emulsifiers NNS O
, , O
solubilizers NNS O
and CC O
the DT O
like JJ O
. . O

An DT O
emulsifier NN O
enables VBZ O
two CD O
or CC O
more JJR O
not RB O
miscible JJ O
components NNS O
to TO O
be VB O
combined VBN O
homogeneously RB O
. . O

Moreover RB O
, , O
the DT O
emulsifier NN O
acts VBZ O
to TO O
stabilize VB O
the DT O
composition NN O
. . O

Emulsifiers NNS O
that WDT O
may MD O
be VB O
used VBN O
in IN O
the DT O
present JJ O
invention NN O
in IN O
order NN O
to TO O
form VB O
O/W NNP O
, , O
W/O NNP O
, , O
0/W/O NNP O
or CC O
W/O/W NNP O
emulsions/microemulsions NNS O
include VBP O
sorbitan JJ B-NP
oleate NN I-NP
, , O
sorbitan JJ B-NP
sesquioleate NN I-NP
, , O
sorbitan JJ B-NP
isostearate NN I-NP
, , O
sorbitan JJ B-NP
trioleate NN I-NP
, , O
polyglyceryl-3-diisostearate JJ B-NP
, , O
polyglycerol NN B-NP
esters NNS I-NP
of IN O
oleic/isostearic JJ B-NP
acid NN B-NP
, , O
polyglyceryl-6 NN B-NP
hexaricinolate NN I-NP
, , O
polyglyceryl-4-oleate NN B-NP
, , O
polyglyceryl-4 NN B-NP
oleate/PEG-8 NNS I-NP
propylene NN B-NP
glycol NN I-NP
cocoate NN I-NP
, , O
oleamide JJ B-NP
DEA NNP I-NP
, , O
TEA NNP B-NP
myristate NN I-NP
, , O
TEA NNP B-NP
stearate NN I-NP
, , O
magnesium NN B-NP
stearate NN I-NP
, , O
sodium NN B-NP
stearate NN I-NP
, , O
potassium NN B-NP
laurate NN I-NP
, , O
potassium NN B-NP
ricinoleate NN I-NP
, , O
sodium NN B-NP
cocoate NN I-NP
, , O
sodium NN B-NP
tallowate NN I-NP
, , O
potassium NN B-NP
castorate NN I-NP
, , O
sodium NN B-NP
oleate NN I-NP
, , O
and CC O
mixtures NNS O
thereof RB O
. . O

Further RB O
suitable JJ O
emulsifiers NNS O
are VBP O
phosphate JJ B-NP
esters NNS I-NP
and CC O
the DT O
salts NNS O
thereof , O
such JJ O
as IN O
cetyl NN B-NP
phosphate NN I-NP
( -LRB- O
Amphisol NNP O
A) NNP O
, , O
diethanolamine NN B-NP
cetyl NN I-NP
phosphate NN I-NP
( -LRB- O
Amphisol NNP O
) -RRB- O
, , O
potassium NN B-NP
cetyl NN I-NP
phosphate NN I-NP
( -LRB- O
Amphisol NNP O
K) NNP O
, , O
sodium NN B-NP
glyceryl NN I-NP
oleate NN I-NP
phosphate NN I-NP
, , O
hydrogenated JJ O
vegetable NN O
glycerides NNS O
phosphate NN O
and CC O
mixtures NNS O
thereof RB O
. . O

Furthermore RB O
, , O
one CD O
or CC O
more JJR O
synthetic JJ O
polymers NNS B-NP
may MD O
be VB O
used VBN O
as IN O
an DT O
emulsifier NN O
. . O

For IN O
example NN O
, , O
PVP NNP O
eicosene , B-NP
copolymer NN O
, , O
acrylates/C1O-3o JJ B-NP
alkyl NN B-NP
acrylate NN I-NP
crosspolymer NN O
, , O
acrylates/steareth-20 DT B-NP
methacrylate NN B-NP
copolymer NN O
, , O
PEG- NNP B-NP
22/dodecyl CD I-NP
glycol NN O
copolymer NN O
, , O
PEG-45/dodecyl JJ B-NP
glycol NN O
copolymer NN O
, , O
and CC O
mixtures NNS O
thereof RB O
. . O

The DT O
preferred JJ O
emulsifiers NNS O
are VBP O
cetyl JJ B-NP
phosphate NN I-NP
( -LRB- O
Amphisol NNP O
A) NNP O
, , O
diethanolamine NN B-NP
cetyl NN I-NP
phosphate NN I-NP
( -LRB- O
Amphisol NNP O
) -RRB- O
, , O
potassium NN B-NP
cetyl NN I-NP
phosphate NN I-NP
( -LRB- O
Amphisol NNP O
K) NNP O
, , O
PVP NNP O
Eicosene NNP B-NP
copolymer NN O
, , O
acrylates/C10-30-alkyl JJ B-NP
acrylate NN B-NP
crosspolymer NN O
, , O
PEG-20 DT B-NP
sorbitan JJ B-NP
isostearate NN I-NP
, , O
sorbitan JJ B-NP
isostearate NN I-NP
, , O
and CC O
mixtures NNS O
thereof RB O
. . O

The DT O
one CD O
or CC O
more JJR O
emulsifiers NNS O
are VBP O
present JJ O
in IN O
a DT O
total JJ O
amount NN O
about IN O
0.01 CD O
wt NN O
. . O
% NN O
to TO O
about IN O
20 CD O
wt NN O
. . O
% NN O
of IN O
the DT O
total JJ O
weight NN O
of IN O
the DT O
composition NN O
of IN O
the DT O
present JJ O
invention NN O
. . O

Preferably RB O
, , O
about IN O
0.1 CD O
wt NN O
. . O
% NN O
to TO O
about IN O
10 CD O
wt NN O
. . O
% NN O
of IN O
emulsifiers NNS O
are VBP O
used VBN O
. . O

The DT O
lipid JJ B-NP
phase NN O
of IN O
the DT O
topical JJ O
compositions NNS O
can MD O
advantageously RB O
be VB O
chosen VBN O
from IN O
mineral NN O
oils NNS O
and CC O
mineral NN O
waxes NNS O
;oils NNS O
such JJ O
as IN O
triglycerides NNS O
of IN O
caprinic JJ B-NP
acid NN I-NP
or CC O
caprylic JJ B-NP
acid NN I-NP
, , O
preferable JJ O
castor NN O
oil NN O
; : O
oils NNS O
or CC O
waxes NNS O
and CC O
other JJ O
natural JJ O
or CC O
synthetic JJ O
oils NNS O
, , O
in IN O
an DT O
preferred JJ O
embodiment NN O
esters NNS B-NP
of IN O
fatty JJ B-NP
acids NNS I-NP
with IN O
alcohols NNS B-NP
e.g RB O
. . O

isopropanol NN B-NP
, , O
propylene NN B-NP
glycol NN I-NP
, , O
glycerin NN B-NP
or CC O
esters NNS B-NP
of IN O
fatty JJ B-NP
alcohols NNS I-NP
with IN O
carboxylic NN B-NP
acids NNS I-NP
or CC O
fatty JJ B-NP
acids NNS I-NP
; : O
alkylbenzoates NNS B-NP
; : O
and/or CC O
silicone NN O
oils NNS O
such JJ O
as IN O
dimethylpolysiloxane NN B-NP
, , O
diethylpolysiloxane NN B-NP
, , O
diphenylpolysiloxane NN B-NP
, , O
cyclomethicones NNS B-NP
and CC O
mixtures NNS O
thereof RB O
. . O

Exemplary NNP O
fatty NN O
substances NNS O
which WDT O
can MD O
be VB O
incorporated VBN O
in IN O
the DT O
oil NN O
phase NN O
of IN O
the DT O
emulsion NN O
, , O
micro-emulsion NN O
, , O
oleo NNP O
gel NNP O
, , O
hydrodispersion NN O
or CC O
lipodispersion NN O
of IN O
the DT O
present JJ O
invention NN O
are VBP O
advantageously RB O
chosen VBN O
from IN O
esters NNS B-NP
of IN O
saturated JJ O
and/or CC O
unsaturated JJ O
, , O
linear JJ O
or CC O
branched JJ O
alkyl NN O
carboxylic NN B-NP
acids NNS I-NP
with IN O
3 CD O
to TO O
30 CD O
carbon NN O
atoms NNS O
, , O
and CC O
saturated VBD O
and/or IN O
unsaturated JJ O
, , O
linear JJ O
and/or CC O
branched JJ O
alcohols NNS B-NP
with IN O
3 CD O
to TO O
30 CD O
carbon NN O
atoms NNS O
as RB O
well RB O
as IN O
esters NNS B-NP
of IN O
aromatic JJ O
carboxylic NN B-NP
acids NNS I-NP
and CC O
of IN O
saturated JJ O
and/or CC O
unsaturated JJ O
, , O
linear JJ O
or CC O
branched JJ O
alcohols NNS B-NP
of IN O
3-30 CD O
carbon NN O
atoms NNS O
. . O

Such JJ O
esters NNS B-NP
can MD O
advantageously RB O
be VB O
selected VBN O
from IN O
octylpalmitate NN B-NP
, , O
octylcocoate NN B-NP
, , O
octylisostearate NN B-NP
, , O
octyldodecylmyristate NN B-NP
, , O
cetearylisononanoate NN B-NP
, , O
isopropyl- DT B-NP
myristate NN I-NP
, , O
isopropylpalmitate VBP B-NP
, , O
isopropylstearate VBP B-NP
, , O
isopropyloleate VBP B-NP
, , O
n-butylstearate JJ B-NP
, , O
n- DT B-NP
hexyllaureate NN I-NP
, , O
n-decyloleat JJ B-NP
, , O
isooctylstearate JJ B-NP
, , O
isononylstearate JJ B-NP
, , O
isononylisononanoate JJ B-NP
, , O
2- CD B-NP
ethyl NN I-NP
hexylpalmitate NN I-NP
, , O
2-ethylhexyllaurate JJ B-NP
, , O
2-hexyldecylstearate JJ B-NP
, , O
2-octyldodecylpalmitate JJ B-NP
, , O
stearylheptanoate JJ B-NP
, , O
oleyloleate JJ B-NP
, , O
oleylerucate JJ B-NP
, , O
erucyloleate JJ B-NP
, , O
erucylerucate JJ B-NP
, , O
thdecylstearate JJ B-NP
, , O
tridecyltrimellitate NN B-NP
, , O
as RB O
well RB O
as IN O
synthetic JJ O
, , O
half-synthetic JJ O
or CC O
natural JJ O
mixtures NNS O
of IN O
such JJ O
esters NNS B-NP
e.g NN O
. . O

jojoba FW O
oil NN O
. . O

Other JJ O
fatty JJ O
components NNS O
suitable JJ O
for IN O
use NN O
in IN O
the DT O
topical JJ O
compositions NNS O
of IN O
the DT O
present JJ O
invention NN O
include VBP O
polar JJ O
oils NNS O
such JJ O
as IN O
lecithins NNS O
and CC O
fatty JJ B-NP
acid NN I-NP
triglycerides VBZ I-NP
, , O
namely RB O
triglycerol JJ O
esters NNS B-NP
of IN O
saturated JJ O
and/or CC O
unsaturated JJ O
, , O
straight JJ O
or CC O
branched JJ O
carboxylic JJ B-NP
acid NN I-NP
with IN O
8 CD O
to TO O
24 CD O
carbon NN O
atoms NNS O
, , O
preferably RB O
of IN O
12 CD O
to TO O
18 CD O
carbon-atoms NNS O
whereas IN O
the DT O
fatty JJ B-NP
acid NN I-NP
triglycerides NNS I-NP
are VBP O
preferably RB O
chosen VBN O
from IN O
synthetic JJ O
, , O
half DT O
synthetic JJ O
or CC O
natural JJ O
oils NNS O
( -LRB- O
e NN O
.g NN O
. . O

cocoglyceride NN B-NP
, , O
olive JJ O
oil NN O
, , O
sun NN O
flower NN O
oil NN O
, , O
soybean NN O
oil NN O
, , O
peanut NN O
oil NN O
, , O
rape NN O
seed NN O
oil NN O
, , O
sweet JJ O
almond NN O
oil NN O
, , O
palm NN O
oil NN O
, , O
coconut NN O
oil NN O
, , O
castor NN O
oil NN O
, , O
hydrogenated JJ O
castor NN O
oil NN O
, , O
wheat NN O
oil NN O
, , O
grape NN O
seed NN O
oil NN O
, , O
macadamia NN O
nut NN O
oil NN O
and CC O
others NNS O
) -RRB- O
; : O
apolar JJ O
oils NNS O
such JJ O
as IN O
linear JJ O
and/ NNS O
or CC O
branched JJ B-NP
hydrocarbons NNS I-NP
and CC O
waxes NNS O
e.g NN O
. . O

mineral NN O
oils NNS O
, , O
vaseline NN O
( -LRB- O
petrolatum NN O
) -RRB- O
; : O

paraffins NNS O
, , O
squalane NN B-NP
and CC O
squalene NN B-NP
, , O
polyolefins NNS B-NP
, , O
hydrogenated JJ O
polyisobutenes NNS O
and CC O
isohexadecanes NNS B-NP
, , O
favored VBN O
polyolefins NNS B-NP
are VBP O
polydecenes NNS B-NP
; : O
dialkyl NN B-NP
ethers NNS I-NP
such JJ O
as IN O
dicaprylylether NN B-NP
; : O
linear NN O
or CC O
cyclic JJ B-NP
silicone NN I-NP
oils NNS O
such JJ O
as IN O
preferably RB O
cyclomethicone NN B-NP
(octamethylcyclotetrasiloxane NN O
; : O
cetyldimethicone NN B-NP
, , O
hexamethylcyclotri- CC B-NP
siloxane NN I-NP
, , O
polydimethylsiloxane NN B-NP
, , O
poly(methylphenylsiloxane NN B-NP
) -RRB- I-NP
and CC O
mixtures VBZ O
thereof RB O
. . O

Other JJ O
fatty JJ O
components NNS O
which WDT O
can MD O
advantageously RB O
be VB O
incorporated VBN O
in IN O
topical JJ O
compositions NNS O
of IN O
the DT O
present JJ O
invention NN O
are VBP O
isoeikosane JJ B-NP
; : O
neopentylglycoldiheptanoate NN B-NP
; : O
propyleneglycol- : B-NP
dicaprylate/ NN O
dicaprate NN O
; : O
caprylic/capric/diglycerylsuccinate JJ O
; : O
butyleneglycol NN O
caprylat/caprat NN O
; : O
C12-i3-alkyllactate : O
; : O
di-Ci2-i3 JJ O
alkyltartrate NN B-NP
; : O
triisostearin NN B-NP
; : O
dipentaerythrityl NN B-NP
hexacaprylat- CC I-NP
/hexacaprate NN O
; : O
propylenglycolmonoisostearate NN B-NP
; : O
tricaprylin NN B-NP
; : O
dimethylisosorbid NN B-NP
. . O

Especially RB O
beneficial JJ O
is VBZ O
the DT O
use NN O
of IN O
mixtures NNS O
Ci2-i5-alkylbenzoate JJ O
and CC O
2-ethylhexylisostearate JJ B-NP
, , O
mixtures NNS O
C12-i5-alkylbenzoate JJ O
and CC O
isotridecylisononanoate JJ B-NP
as RB O
well RB O
as IN O
mixtures NNS O
of IN O
C1M5- DT O
alkylbenzoate NN B-NP
, , O
2-ethylhexylisostearate JJ B-NP
and CC O
isotridecylisononanoate JJ B-NP
. . O

The DT O
oily JJ O
phase NN O
of IN O
the DT O
compositions NNS O
of IN O
the DT O
present JJ O
invention NN O
can MD O
also RB O
contain VB O
natural JJ O
vegetable NN O
or CC O
animal NN O
waxes NNS O
such JJ O
as IN O
bee NN O
wax NN O
, , O
china NN O
wax NN O
, , O
bumblebee NN O
wax NN O
and CC O
other JJ O
waxes NNS O
of IN O
insects NNS O
as RB O
well RB O
as IN O
shea NN O
butter NN O
and CC O
cocoa NN O
butter NN O
. . O

A DT O
moisturizing JJ O
agent NN O
may MD O
be VB O
incorporated VBN O
into IN O
a DT O
topical JJ O
composition NN O
of IN O
the DT O
present JJ O
invention NN O
to TO O
maintain VB O
hydration NN O
or CC O
rehydrate VB O
the DT O
skin NN O
. . O

Moisturizers NNS O
that DT O
prevent VBP O
water NN B-NP
from IN O
evaporating VBG O
from IN O
the DT O
skin NN O
by IN O
providing VBG O
a DT O
protective JJ O
coating NN O
are VBP O
called VBN O
emollients NNS O
. . O

Additionally RB O
an DT O
emollient NN O
provides VBZ O
a DT O
softening NN O
or CC O
soothing JJ O
effect NN O
on IN O
the DT O
skin NN O
surface NN O
and CC O
is VBZ O
generally RB O
considered VBN O
safe JJ O
for IN O
topical JJ O
use NN O
. . O

Preferred JJ O
emollients NNS O
include VBP O
mineral NN O
oils NNS O
, , O
lanolin NN O
, , O
petrolatum NN O
, , O
capric/caprylic JJ O
triglyceraldehydes NNS B-NP
, , O
cholesterol NN B-NP
, , O
silicones NNS B-NP
such JJ O
as IN O
dimethicone NN B-NP
, , O
cyclomethicone NN B-NP
, , O
almond DT O
oil NN O
, , O
jojoba FW O
oil NN O
, , O
avocado IN O
oil NN O
, , O
castor NN O
oil NN O
, , O
sesame JJ O
oil NN O
, , O
sunflower NN O
oil NN O
, , O
coconut NN O
oil NN O
and CC O
grape NN O
seed NN O
oil NN O
, , O
cocoa NN O
butter NN O
, , O
olive JJ O
oil NN O
aloe NN O
extracts NNS O
, , O
fatty JJ B-NP
acids NNS I-NP
such JJ O
as IN O
oleic JJ B-NP
and CC O
stearic JJ B-NP
, , O
fatty JJ B-NP
alcohols NNS I-NP
such JJ O
as IN O
cetyl NN B-NP
and CC O
hexadecyl NN B-NP
( -LRB- O
ENJAY NNP O
) -RRB- O
, , O
diisopropyl JJ B-NP
adipate NN I-NP
, , O
hydroxybenzoate JJ B-NP
esters NNS I-NP
, , O
benzoic JJ B-NP
acid NN I-NP
esters NNS I-NP
of IN O

EMI17.1 . O

isononyl NN B-NP
iso-nonanoate JJ I-NP
, , O
ethers NNS B-NP
such JJ O
as IN O
polyoxypropylene NN B-NP
butyl NN I-NP
ethers NNS I-NP
and CC O
polyoxypropylene NN B-NP
cetyl NN I-NP
ethers NNS I-NP
, , O
and CC O
C12-i5-alkyl JJ B-NP
benzoates NNS I-NP
, , O
and CC O
mixtures NNS O
thereof RB O
. . O

The DT O
most RBS O
preferred JJ O
emollients NNS O
are VBP O
hydroxybenzoate JJ B-NP
esters NNS I-NP
, , O
aloe NN O
vera NN O
, , O
C12-i5-alkyl JJ B-NP
benzoates NNS I-NP
, , O
and CC O
mixtures NNS O
thereof RB O
. . O

An DT O
emollient NN O
is VBZ O
present JJ O
in IN O
an DT O
amount NN O
of IN O
about IN O
1 CD O
wt NN O
. . O
% NN O
to TO O
about IN O
20 CD O
wt NN O
. . O
% NN O
of IN O
the DT O
total JJ O
weight NN O
of IN O
the DT O
composition NN O
. . O

The DT O
preferred JJ O
amount NN O
of IN O
emollient NN O
is VBZ O
about IN O
2 CD O
wt NN O
. . O
% NN O
to TO O
about IN O
15 CD O
wt NN O
. . O
% NN O
, , O
and CC O
most RBS O
preferably RB O
about IN O
4 CD O
wt NN O
. . O
% NN O
to TO O
about IN O
10 CD O
wt NN O
. . O
% NN O
. . O

Moisturizers NNS O
that WP O
bind VBP O
water NN B-NP
, , O
thereby RB O
retaining VBG O
it PRP O
on IN O
the DT O
skin NN O
surface NN O
are VBP O
called VBN O
humectants NNS O
. . O

Suitable JJ O
humectants NNS O
can MD O
be VB O
incorporated VBN O
into IN O
a DT O
topical JJ O
composition NN O
of IN O
the DT O
present JJ O
invention NN O
such JJ O
as IN O
glycerin NN B-NP
, , O
polypropylene NN B-NP
glycol NN I-NP
, , O
1,2-pentandiol CD B-NP
, , O
polyethylene NN B-NP
glycol NN I-NP
, , O
lactic JJ B-NP
acid NN I-NP
, , O
pyrrolidone VBG B-NP
carboxylic JJ I-NP
acid NN I-NP
, , O
urea NN B-NP
, , O
phospholipids NNS B-NP
, , O
collagen NN O
, , O
elastin RB O
, , O
ceramides NNS O
, , O
lecithin JJ B-NP
sorbitol NN I-NP
, , O
PEG-4 NN B-NP
, , O
and CC O
mixtures NNS O
thereof RB O
. . O

Additional JJ O
suitable JJ O
moisturizers NNS O
are VBP O
polymeric JJ O
moisturizers NNS O
of IN O
the DT O
family NN O
of IN O
water NN B-NP
soluble JJ O
and/ NNS O
or CC O
swellable/ JJ O
and/ NNS O
or CC O
with IN O
water NN B-NP
gelating VBG O
polysaccharides NNS O
such JJ O
as IN O
hyaluronic JJ B-NP
acid NN I-NP
, , O
chitosan NN B-NP
and/or CC O
a DT O
fucose JJ O
rich JJ O
polysaccharide NN B-NP
which WDT O
is VBZ O
e.g RB O
. . O

available JJ O
as IN O
Fucogel( JJ O
R)1000 CD O
( -LRB- O
CAS-Nr NN O
. . O

178463-23-5 CD O
) -RRB- O
by IN O
SOLABIA NNP O
S. NNP O
One CD O
or CC O
more JJR O
humectants NNS O
are VBP O
optionally RB O
present JJ O
at IN O
about RB O
0.5 CD O
wt NN O
. . O
% NN O
to TO O
about IN O
8 CD O
wt NN O
. . O
% NN O
in IN O
a DT O
composition NN O
of IN O
the DT O
present JJ O
invention NN O
, , O
preferably RB O
about IN O
1 CD O
wt NN O
. . O
% NN O
to TO O
about IN O
5 CD O
wt NN O
. . O
% NN O
. . O

The DT O
aqueous JJ O
phase NN O
of IN O
the DT O
preferred JJ O
topical JJ O
compositions NNS O
of IN O
the DT O
present JJ O
invention NN O
can MD O
contain VB O
the DT O
usual JJ O
cosmetic NN O
or CC O
pharmaceutical JJ O
additives NNS O
such JJ O
as IN O
alcohols NNS B-NP
, , O
especially RB O
lower JJR B-NP
alcohols NNS I-NP
, , O
preferably RB O
ethanol NN B-NP
and/ NNS O
or CC O
isopropanol NN B-NP
, , O
low JJ O
diols NNS O
or CC O
polyols NNS B-NP
and CC O
their PRP$ O
ethers NNS B-NP
, , O
preferably RB O
propyleneglycol NN B-NP
, , O
glycerin NN B-NP
, , O
ethyleneglycol NN B-NP
, , O
ethyleneglycol NN B-NP
monoethyl- NNS I-NP
or CC O
monobutylether NN O
, , O
propyleneglycol NN B-NP
monomethyl- NNS O
or CC O
-monoethyl- NNS O
or CC O
-monobutylether JJ O
, , O
diethyleneglycol NN B-NP
monomethyl- NNS I-NP
or CC O
-monoethylether JJ O
and CC O
analogue JJ O
products NNS O
, , O
polymers NNS B-NP
, , O
foam NN O
stabilizers NNS O
; : O
electrolytes NNS O
and CC O
especially RB O
one CD O
or CC O
more JJR O
thickeners NNS O
. . O

Thickeners NNS O
that WDT O
may MD O
be VB O
used VBN O
in IN O
compositions NNS O
of IN O
the DT O
present JJ O
invention NN O
to TO O
assist VB O
in IN O
making VBG O
the DT O
consistency NN O
of IN O
a DT O
product NN O
suitable JJ O
include VBP O
carbomer NN O
, , O
siliciumdioxide NN O
, , O
magnesium NN B-NP
and/ NN O
or CC O
aluminum NN O
silicates NNS O
, , O
beeswax NN O
, , O
stearic JJ B-NP
acid NN I-NP
, , O
stearyl NN O
alcohol NN O
polysaccharides NNS O
and CC O
their PRP$ O
derivatives NNS O
such JJ O
as IN O
xanthan NNP O
gum NN O
, , O
hydroxypropyl NN B-NP
cellulose NN I-NP
, , O
polyacrylamides NNS B-NP
, , O
acrylate VB B-NP
crosspolymers NNS I-NP
preferably RB O
a DT O
carbomer NN O
, , O
such JJ O
as IN O
carbopole NN O
of IN O
type NN O
980 CD O
, , O
981 CD O
, , O
1382 CD O
, , O
2984 CD O
, , O
5984 CD O
alone JJ O
or CC O
mixtures NNS O
thereof RB O
. . O

Suitable JJ O
neutralizing JJ O
agents NNS O
which WDT O
may MD O
be VB O
included VBN O
in IN O
the DT O
composition NN O
of IN O
the DT O
present JJ O
invention NN O
to TO O
neutralize VB O
components NNS O
such JJ O
as IN O
e.g NN O
. . O
an DT O
emulsifier NN O
or CC O
a DT O
foam NN O
builder/stabilizer NN O
include VBP O
but CC O
are VBP O
not RB O
limited VBN O
to TO O
alkali JJ B-NP
hydroxides NNS O
such JJ O
as IN O
a DT O
sodium NN B-NP
and CC O
potassium NN B-NP
hydroxide NN I-NP
; : O
organic JJ O
bases NNS O
such JJ O
as IN O
diethanolamine NN B-NP
( -LRB- O
DEA NNP B-NP
) -RRB- O
, , O
triethanolamine NN B-NP
( -LRB- O
TEA NNP B-NP
) -RRB- O
, , O
aminomethyl JJ B-NP
propanol NN I-NP
, , O
and CC O
mixtures NNS O
thereof , O
; : O
amino IN B-NP
acids NNS I-NP
such JJ O
as IN O
arginin NN B-NP
and CC O
lysine NN B-NP
and CC O
any DT O
combination NN O
of IN O
any DT O
foregoing NN O
. . O

The DT O
neutralizing JJ O
agent NN O
can MD O
be VB O
present JJ O
in IN O
an DT O
amount NN O
of IN O
about IN O
0.01 CD O
wt NN O
. . O
% NN O
to TO O
about IN O
8 CD O
wt NN O
. . O
% NN O
in IN O
the DT O
composition NN O
of IN O
the DT O
present JJ O
invention NN O
, , O
preferably RB O
, , O
1 CD O
wt NN O
. . O
% NN O
to TO O
about IN O
5 CD O
wt NN O
. . O
% NN O
. . O

The DT O
addition NN O
of IN O
electrolytes NNS O
into IN O
the DT O
composition NN O
of IN O
the DT O
present JJ O
invention NN O
may MD O
be VB O
necessary JJ O
to TO O
change VB O
the DT O
behavior NN O
of IN O
a DT O
hydrophobic JJ O
emulsifier NN O
. . O

Thus RB O
, , O
the DT O
emulsions NNS O
/ IN O
microemulsions NNS O
of IN O
this DT O
invention NN O
may MD O
contain VB O
preferably RB O
electrolytes NNS O
of IN O
one CD O
or CC O
several JJ O
salts NNS O
including VBG O
anions NNS B-NP
such JJ O
as IN O
chloride NN B-NP
, , O
sulfates NNS B-NP
, , O
carbonate NN B-NP
, , O
borate NN B-NP
and CC O
aluminate NN B-NP
, , O
without IN O
being VBG O
limited JJ O
thereto NN O
. . O

Other JJ O
suitable JJ O
electrolytes NNS O
can MD O
be VB O
on IN O
the DT O
basis NN O
of IN O
organic JJ O
anions NNS O
such JJ O
as IN O
, , O
but CC O
not RB O
limited JJ O
to TO O
, , O
lactate NN B-NP
, , O
acetate NN B-NP
, , O
benzoate NN B-NP
, , O
propionate JJ B-NP
, , O
tartrate JJ B-NP
and CC O
citrate JJ B-NP
. . O

As IN O
cations NNS B-NP
preferably RB O
ammonium NN B-NP
, , O
alkylammonium NN B-NP
, , O
alkali- . B-NP
or CC O
alkaline JJ B-NP
earth NN I-NP
metals NNS I-NP
, , O
magnesium-, VBN B-NP
iron NN B-NP
- : O
or CC O
zinc-ions NNS B-NP
are VBP O
selected VBN O
. . O

Especially RB O
preferred JJ O
salts NNS O
are VBP O
potassium NN B-NP
and CC O
sodium NN B-NP
chloride NN I-NP
, , O
magnesium NN B-NP
sulfate NN I-NP
, , O
zinc NN B-NP
sulfate NN I-NP
and CC O
mixtures NNS O
thereof RB O
. . O

Electrolytes NNP O
can MD O
be VB O
present JJ O
in IN O
an DT O
amount NN O
of IN O
about IN O
0.01 CD O
wt NN O
. . O
% NN O
to TO O
about IN O
8 CD O
wt NN O
. . O
% NN O
in IN O
the DT O
composition NN O
of IN O
the DT O
present JJ O
invention NN O
. . O

The DT O
topical JJ O
compositions NNS O
of IN O
the DT O
invention NN O
can MD O
preferably RB O
be VB O
provided VBN O
in IN O
the DT O
form NN O
of IN O
a DT O
lotion NN O
, , O
a DT O
thickened JJ O
lotion NN O
, , O
a DT O
gel NN O
, , O
a DT O
cream NN O
, , O
a DT O
milk NN O
, , O
an DT O
ointment NN O
, , O
a DT O
powder NN O
or CC O
a DT O
solid JJ O
tube NN O
stick NN O
and CC O
can MD O
be VB O
optionally RB O
be VB O
packaged VBN O
as IN O
an DT O
aerosol NN O
and CC O
can MD O
be VB O
provided VBN O
in IN O
the DT O
form NN O
of IN O
a DT O
mousse NN O
, , O
foam NN O
or CC O
a DT O
spray NN O
. . O

The DT O
compositions NNS O
according VBG O
to TO O
the DT O
invention NN O
can MD O
also RB O
be VB O
in IN O
the DT O
form NN O
of IN O
a DT O
suspension NN O
or CC O
dispersion NN O
in IN O
solvents NNS O
or CC O
fatty JJ O
substances NNS O
, , O
or CC O
alternatively RB O
in IN O
the DT O
form NN O
of IN O
an DT O
emulsion NN O
or CC O
microemulsion NN O
( -LRB- O
in IN O
particular JJ O
of IN O
O[Lambda]/V NNP O
or CC O
W/O NNP O
type NN O
, , O
0/W/O NNP O
or CC O
W/O/W-type JJ O
) -RRB- O
, , O
such JJ O
as IN O
a DT O
cream NN O
or CC O
a DT O
milk NN O
, , O
a DT O
vesicular JJ O
dispersion NN O
, , O
in IN O
the DT O
form NN O
of IN O
an DT O
ointment NN O
, , O
a DT O
gel NN O
, , O
a DT O
solid JJ O
tube NN O
stick NN O
or CC O
an DT O
aerosol JJ O
mousse NN O
. . O

The DT O
emulsions NNS O
can MD O
also RB O
contain VB O
anionic JJ O
, , O
nonionic JJ O
, , O
cationic JJ O
or CC O
amphoteric JJ O
surfactants NNS O
. . O

The DT O
topical JJ O
application NN O
is VBZ O
preferably RB O
applied VBN O
at IN O
least JJS O
once RB O
per IN O
day NN O
, , O
e.g NN O
. . O
two CD O
or CC O
three CD O
times NNS O
a DT O
day NN O
. . O

Usually RB O
it PRP O
takes VBZ O
at IN O
least JJS O
two CD O
days NNS O
until IN O
the DT O
desired VBN O
effect NN O
is VBZ O
achieved VBN O
. . O

However RB O
, , O
it PRP O
can MD O
take VB O
several JJ O
weeks NNS O
or CC O
even RB O
months NNS O
until IN O
the DT O
desired VBN O
effect NN O
is VBZ O
achieved VBN O
. . O

According VBG O
to TO O
the DT O
invention NN O
for IN O
preparing VBG O
the DT O
compositions NNS O
the DT O
active JJ O
ingredients NNS O
can MD O
be VB O
used VBN O
as IN O
such JJ O
or CC O
in IN O
an DT O
encapsulated JJ O
form NN O
, , O
for IN O
example NN O
in IN O
a DT O
liposomal JJ O
form NN O
. . O

Liposomes NNS O
are VBP O
preferably RB O
formed VBN O
with IN O
lecithins NNS O
with IN O
or CC O
without IN O
addition NN O
of IN O
sterols NNS O
or CC O
phytosterols NNS B-NP
. . O

The DT O
encapsulation NN O
of IN O
the DT O
active JJ O
ingredients NNS O
can MD O
be VB O
alone RB O
or CC O
together RB O
with IN O
other JJ O
active JJ O
ingredients NNS O
. . O

In IN O
the DT O
composition NN O
of IN O
the DT O
invention NN O
, , O
in IN O
particular JJ O
the DT O
topical JJ O
compositions NNS O
of IN O
the DT O
invention NN O
, , O
the DT O
compound NN O
of IN O
formula NN O
( -LRB- O
I PRP O
) -RRB- O
is VBZ O
contained VBN O
in IN O
an DT O
amount NN O
of IN O
preferably RB O
0.0001 CD O
wt.-% JJ O
to TO O
about IN O
50 CD O
wt.-% NN O
, , O

based VBN O
on IN O
the DT O
total JJ O
weight NN O
of IN O
the DT O
composition NN O
. . O

More RBR O
preferably RB O
, , O
the DT O
compound NN O
is VBZ O
contained VBN O
in IN O
the DT O
composition NN O
in IN O
an DT O
amount NN O
of IN O
about IN O
0.01 CD O
wt.-% NN O
to TO O
about IN O
20 CD O
wt.-% NN O
, , O
more JJR O
preferably RB O
in IN O
an DT O
amount NN O
of IN O
about RB O
0.1 CD O
wt.-% NN O
to TO O
about IN O
5 CD O
wt.-% NN O
, , O
in IN O
particular JJ O
in IN O
an DT O
amount NN O
of IN O
about IN O
0.2wt-% CD O
to TO O
1 CD O
wt.-% NN O
, , O
based VBN O
on IN O
the DT O
total JJ O
amount NN O
of IN O
the DT O
composition NN O
. . O

In IN O
case NN O
that IN O
the DT O
( -LRB- O
preferably RB O
topical NN O
) -RRB- O
composition NN O
of IN O
the DT O
invention NN O
contains VBZ O
a DT O
further RBR O
active JJ O
ingredient NN O
, , O
this DT O
further JJ O
active JJ O
ingredient NN O
is VBZ O
contained VBN O
in IN O
an DT O
amount NN O
of IN O
preferably RB O
0.0001 CD O
wt. NN O
- : O

% NN O
to TO O
about IN O
50 CD O
wt.-% NN O
, , O

based VBN O
on IN O
the DT O
total JJ O
weight NN O
of IN O
the DT O
composition NN O
. . O

More RBR O
preferably RB O
, , O
the DT O
further JJ O
active JJ O
ingredient NN O
is VBZ O
contained VBN O
in IN O
the DT O
composition NN O
in IN O
an DT O
amount NN O
of IN O
about IN O
0.01 CD O
wt.-% NN O
to TO O
about IN O
20 CD O
wt.-% NN O
, , O
more JJR O
preferably RB O
in IN O
an DT O
amount NN O
of IN O
about IN O
0.01 CD O
wt.-% NN O
to TO O
about IN O
1 CD O
wt.-% NN O
, , O
in IN O
particular JJ O
in IN O
an DT O
amount NN O
of IN O
about RB O
0.1 CD O
wt.-% NN O
to TO O
1 CD O
wt NN O
. . O

% NN O
, , O
based VBN O
on IN O
the DT O
total JJ O
amount NN O
of IN O
the DT O
composition NN O
. . O

Regarding VBG O
the DT O
kind NN O
of IN O
the DT O
topical JJ O
composition NN O
and CC O
the DT O
preparation NN O
of IN O
the DT O
topical JJ O
compositions NNS O
as RB O
well RB O
as IN O
for IN O
further JJ O
suitable JJ O
additives NNS O
, , O
it PRP O
can MD O
be VB O
referred VBN O
to TO O
the DT O
pertinent JJ O
literature NN O
, , O
e.g NN O
. . O
to TO O
Novak NNP O
G.A. NNP O
, , O
Die NNP O
kosmetischen NN O
Praparate NNP O
- : O
Band NNP O
2 CD O
, , O
Die FW O
kosmetischen FW O
Praparate FW O
- : O
Rezeptur NN O
, , O
Rohstoffe NNP O
, , O
wissenschaftliche NN O
Grundlagen NNP O
( -LRB- O
Verlag NNP O
f[upsilon]r IN O
Chem NNP O
. . O

Industrie NNP O
H. NNP O
Ziolkowski NNP O
KG NNP O
, , O
Augsburg NNP O
) -RRB- O
. . O

It PRP O
is VBZ O
furthermore RB O
possible JJ O
to TO O
provide VB O
the DT O
compositions NNS O
of IN O
the DT O
present JJ O
invention NN O
as IN O
oral JJ O
composition NN O
, , O
e.g RB O
. . O
in IN O
the DT O
form NN O
of IN O
pills NNS O
, , O
tablets NNS O
, , O
capsules NNS O
which WDT O
may MD O
contain VB O
granules NNS O
or CC O
pellets NNS O
, , O
as IN O
a DT O
liquid JJ O
, , O
oral JJ O
composition NN O
or CC O
as IN O
an DT O
additive JJ O
to TO O
foodstuff NN O
as IN O
is VBZ O
generally RB O
known VBN O
to TO O
a DT O
skilled JJ O
person NN O
. . O

Useful JJ O
procedures NNS O
and CC O
useful JJ O
additives NNS O
for IN O
preparing VBG O
the DT O
oral JJ O
compositions NNS O
of IN O
the DT O
present JJ O
invention NN O
are VBP O
e.g JJ O
. . O

disclosed VBN O
in IN O
the DT O
standard JJ O
literature NN O
Remington NNP O
: : O
The DT O
Science NNP O
and CC O
Practice NNP O
of IN O
Pharmacy NNP O
, , O
Lippincot NNP O
, , O
Williams NNP O
& CC O
Wilking NNP O
( -LRB- O
Editors NNP O
) -RRB- O
2000 CD O
, , O
which WDT O
is VBZ O
included VBN O
herein RB O
by IN O
reference NN O
. . O

As IN O
usual JJ O
additives NNS O
for IN O
oral JJ O
compositions NNS O
, , O
in IN O
particular JJ O
for IN O
tablets NNS O
, , O
usual JJ O
excipients NNS O
such JJ O
as IN O
micro-crystalline JJ O
cellulose NN O
, , O
sodium NN B-NP
citrate NN I-NP
, , O
calcium NN B-NP
carbonate NN I-NP
, , O
disodium NN O
or CC O
dipotassium NN B-NP
phosphate NN I-NP
, , O
sodium NN B-NP
or CC O
potassium NN B-NP
phosphate NN I-NP
, , O
glycine NN B-NP
, , O
disintegration NN O
agents NNS O
such JJ O
as IN O
starch NN O
or CC O
alginic JJ B-NP
acid NN I-NP
, , O
binders NNS O
such JJ O
as IN O
polyvinylpyrolidone NN B-NP
, , O
saccharose NN B-NP
, , O
gelatin NN O
and CC O
gum NN O
arabicum NN O
lubricants NNS O
such JJ O
as IN O
magnesium NN B-NP
stearate NN I-NP
, , O
sodium NN B-NP
lauryl NN I-NP
sulfate NN I-NP
or CC O
talcum NN O
can MD O
be VB O
used VBN O
. . O

If IN O
the DT O
compositions NNS O
are VBP O
filed VBN O
into IN O
gelatin NN O
capsules NNS O
, , O
usual JJ O
additives NNS O
for IN O
the DT O
preparation NN O
of IN O
granules NNS O
are VBP O
lactose JJ B-NP
or CC O
lactate NN B-NP
as RB O
well RB O
as IN O
polyethylene NN B-NP
glycols NNS I-NP
with IN O
a DT O
high JJ O
molecular JJ O
weight NN O
. . O

Further RB O
additives NNS O
and CC O
excipients NNS O
as RB O
well RB O
as IN O
additives NNS O
and CC O
excipients NNS O
for IN O
other JJ O
oral JJ O
compositions NNS O
and CC O
for IN O
food NN O
additives NNS O
are VBP O
known VBN O
to TO O
a DT O
skilled JJ O
person NN O
, , O
and CC O
it PRP O
can MD O
be VB O
referred VBN O
to TO O
the DT O
pertinent JJ O
literature NN O
such JJ O
as IN O
" `` O
Grundz[upsilon]ge NNP O
der FW O
Lebensmitteltechnik" NNP O
, , O
Horst NNP O
Dieter NNP O
Tscheuschner NNP O
( -LRB- O
Editor NNP O
) -RRB- O
, , O
2. DT O
Edition NNP O
, , O
Hamburg NNP O
, , O
Beers NNP O
1996 CD O
. . O

The DT O
total JJ O
content NN O
of IN O
the DT O
active JJ O
ingredients NNS O
in IN O
the DT O
oral JJ O
compositions NNS O
of IN O
the DT O
present JJ O
invention NN O
is VBZ O
usually RB O
about IN O
1 CD O
% NN O
to TO O
90 CD O
% NN O
, , O
preferably RB O
about IN O
10 CD O
% NN O
to TO O
80 CD O
% NN O
, , O
e.g NN O
. . O
about IN O
50 CD O
% NN O
or CC O
more JJR O
. . O

The DT O
application NN O
is VBZ O
such JJ O
that IN O
the DT O
desired VBN O
effect NN O
occurs VBZ O
and CC O
depends VBZ O
on IN O
the DT O
patient NN O
and CC O
the DT O
desired VBN O
effect NN O
. . O

A DT O
usual JJ O
daily JJ O
dosage NN O
can MD O
be VB O
in IN O
a DT O
range NN O
from IN O
about IN O
0.1 CD O
[mu]g/day NN O
to TO O
50 CD O
mg/day NN O
, , O
e.g NN O
. . O
about IN O
20 CD O
[mu]g/day NN O
to TO O
2 CD O
mg/day NN O
. . O

The DT O
ability NN O
of IN O
the DT O
compounds NNS O
and CC O
compositions NNS O
of IN O
the DT O
present JJ O
invention NN O
to TO O
reduce VB O
skin NN O
wrinkles NNS O
can MD O
be VB O
assessed VBN O
by IN O
profilometric JJ O
methods NNS O
described VBN O
in IN O
"Skin NNP O
topography NN O
measurement NN O
by IN O
interference NN O
fringe NN O
projection NN O
: : O
a DT O
technical JJ O
validation NN O
" '' O
. . O

( -LRB- O
Lagarde NNP O
J NNP O
M NNP O
; : O
Rouvrais NNP O
C NNP O
; : O
Black NNP O
D NNP O
; : O
Diridollou NNP O
S NNP O
; : O
Gall NNP O
Y NNP O
, , O
Skin NNP O
research NN O
and CC O
technology NN O
: : O
official JJ O
journal NN O
of IN O

International NNP O
Society NNP O
for IN O
Bioengineering NNP O
and CC O
the DT O
Skin NNP O
( -LRB- O
ISBS NNP O
) -RRB- O
[and CC O
] SYM O
International NNP O
Society NNP O
for IN O

Digital NNP O
Imaging NNP O
of IN O
Skin NNP O
( -LRB- O
ISDIS NNP O
) -RRB- O
[and CC O
] SYM O
International NNP O
Society NNP O
for IN O
Skin NNP O
Imaging NNP O
( -LRB- O
ISSI) NN O
( -LRB- O
2001 CD O

May NNP O
) -RRB- O
, , O
7( JJ O
2 CD O
) -RRB- O
, , O
112-21 CD O
or CC O
" `` O
Direct NNP O
and CC O
non-direct JJ O
measurement NN O
techniques NNS O
for IN O
analysis NN O
of IN O
skin NN O
surface NN O
topography" NN O
. . O

Fischer NNP O
T NNP O
W; NNP O
Wigger-Alberti NNP O
W; NNP O
Eisner NNP O
P. NNP O
, , O
Skin NNP O
pharmacology NN O
and CC O
applied VBD O
skin NN O
physiology NN O
( -LRB- O
1999 CD O
Jan-Apr NNP O
) -RRB- O
, , O
12( VBD O
1 CD O
-2 NN O
) -RRB- O
, , O
1 CD O
-11 NN O
. . O

The DT O
ability NN O
of IN O
the DT O
compounds NNS O
and CC O
compositions NNS O
of IN O
the DT O
present JJ O
invention NN O
to TO O
stimulate VB O
or CC O
protect VB O
hair NN O
growth NN O
can MD O
be VB O
determined VBN O
with IN O
a DT O
mouse NN O
model NN O
described VBD O
for IN O
example NN O
in IN O
WO NN O
9817273 CD O
. . O

Instead RB O
of IN O
using VBG O
Cyclophosphamide NNP O
( -LRB- O
Neostar NNP O
, , O
Pharmacia NNP O
) -RRB- O
to TO O
damage VB O
hair NN O
follicle NN O
Mitomycin NNP O
, , O
or CC O
Methotrexate NNP O
can MD O
be VB O
used VBN O
. . O

It PRP O
is VBZ O
also RB O
possible JJ O
to TO O
detect VB O
hair NN O
growth NN O
acceleration NN O
with IN O
newborn JJ O
mice NNS O
. . O

They PRP O
have VBP O
a DT O
synchronized JJ O
hair NN O
cycle NN O
and CC O
approximately RB O
after IN O
3 CD O
weeks NNS O
all DT O
hair NN O
follicles VBZ O
go VB O
into IN O
the DT O
telogen NN O
phase NN O
. . O

Then RB O
the DT O
animals NNS O
are VBP O
treated VBN O
and CC O
it PRP O
is VBZ O
evaluated VBN O
how WRB O
fast RB O
and CC O
to TO O
what WP O
extend VB O
the DT O
hair NN O
is VBZ O
growing VBG O
Similar JJ O
tests NNS O
using VBG O
in IN O
vitro NN O
or CC O
in IN O
vivo JJ O
setups NNS O
can MD O
also RB O
be VB O
found VBN O
in IN O
J. NNP O
Invest NNP O
. . O

Dermato NNP O
. . O

symposium NN O
proceedings NNS O
3rd VBD O
Int NNP O
. . O

Meeting VBG O
of IN O
Hair NNP O
Research NNP O
Societies NNP O
, , O
8/1 CD O
, , O
p.39 FW O
- : O
45 CD O
( -LRB- O
2003 CD O
) -RRB- O
. . O

It PRP O
also RB O
is VBZ O
possible JJ O
to TO O
perform VB O
a DT O
clinical JJ O
study NN O
including VBG O
males NNS O
suffering VBG O
from IN O
alopecia DT O
using VBG O
the DT O
TrichoScan NNP O
analysis NN O
tool NN O
described VBN O
in IN O
R. NNP O
Hoffmann NNP O
, , O
J. NNP O
Invest NNP O
. . O

Dermato NNP O
. . O

symposium NN O
proceedings NNS O
3rd VBD O
Int NNP O
. . O

Meeting VBG O
of IN O
Hair NNP O
Research NNP O
Societies NNP O
, , O
8/1 CD O
, , O
p.109-115 FW O
( -LRB- O
2003 CD O
) -RRB- O
. . O

The DT O
compositions NNS O
of IN O
the DT O
present JJ O
invention NN O
can MD O
also RB O
be VB O
in IN O
the DT O
form NN O
of IN O
injectable JJ O
compositions NNS O
, , O
in IN O
particular JJ O
if IN O
the DT O
compositions NNS O
are VBP O
for IN O
promoting VBG O
hair NN O
growth NN O
. . O

The DT O
preparation NN O
of IN O
injectable JJ O
compositions NNS O
is VBZ O
known VBN O
to TO O
a DT O
skilled JJ O
person NN O
, , O
and CC O
it PRP O
can MD O
be VB O
referred VBN O
to TO O
the DT O
pertinent JJ O
literature NN O
, , O
in IN O
particular JJ O
to TO O
Remington NNP O
already RB O
cited VBD O
above JJ O
. . O

The DT O
compounds NNS O
of IN O
formula NN O
( -LRB- O
I PRP O
) -RRB- O
can MD O
also RB O
be VB O
present JJ O
as IN O
hydrates NNS O
or CC O
solvates NNS O
, , O
and CC O
the DT O
hydrates NNS O
and CC O
solvates NNS O
of IN O
the DT O
active JJ O
ingredients NNS O
are VBP O
also RB O
encompassed VBN O
by IN O
the DT O
present JJ O
invention NN O
. . O

The DT O
following VBG O
examples NNS O
exemplify VBP O
the DT O
invention NN O
, , O
but CC O
they PRP O
should MD O
not RB O
be VB O
construed VBN O
as IN O
limiting VBG O
the DT O
invention NN O
. . O

Example NNP O
1 CD O
: : O
Synthesis NN O
of IN O
4-Phenyl-Butyric JJ B-NP
Acid NNP I-NP
3-(2,4-Dihydroxy-3,3-Dimethyl- CD I-NP
Butyrylamino)-Propyl NNP I-NP
Ester NNP I-NP

[0083] . O

EMI22.1 . O

To TO O
a DT O
solution NN O
of IN O
D-Panthenol NNP B-NP
( -LRB- O
20.5 CD O
g NN O
, , O
100.0 CD O
mmol NN O
, , O
1.0 CD O
eq NN O
. . O
) -RRB- O
in IN O
dry JJ O
acetone NN B-NP
( -LRB- O
400 CD O
ml NN O
. . O
) -RRB- O
were VBD O
added VBN O
sodium NN B-NP
sulphate NN I-NP
anhydrous . O
( -LRB- O
50.0 JJ O
g NN O
) -RRB- O
and CC O
p-TsOH JJ B-NP
monohydrate NN I-NP
( -LRB- O
1.0 CD O
g NN O
, , O
4.0 CD O
mmol NN O
, , O
0.04 CD O
eq NN O
. . O
) -RRB- O
. . O

The DT O
reaction NN O
mixture NN O
was VBD O
stirred VBN O
at IN O
room NN O
temperature NN O
overnight RB O
. . O

p-TsOH JJ B-NP
monohydrate NN I-NP
( -LRB- O
500 CD O
mg NN O
, , O
2.63 CD O
mmol NN O
, , O
0.03 CD O
eq NN O
. . O
) -RRB- O
was VBD O
added VBN O
again RB O
and CC O
the DT O
reaction NN O
mixture NN O
stirred VBD O
at IN O
room NN O
temperature NN O
for IN O
6 CD O
days NNS O
until IN O
the DT O
reaction NN O
showed VBD O
nearly RB O
no DT O
starting VBG O
material NN O
and CC O
no DT O
further JJ O
conversion NN O
anymore RB O
. . O

Most JJS O
of IN O
the DT O
acetone NN B-NP
was VBD O
removed VBN O
under IN O
low JJ O
pressure NN O
and CC O
the DT O
residue NN O
was VBD O
suspended VBN O
in IN O
a DT O
saturated JJ O
aqueous JJ O
solution NN O
of IN O
NaHCO3 NNP B-NP
( -LRB- O
150 CD O
ml NN O
. . O
) -RRB- O
and CC O
extracted VBD O
five CD O
times NNS O
with IN O
ethyl NN B-NP
acetate NN I-NP
( -LRB- O
200 CD O
ml_ NN O
) -RRB- O
. . O

The DT O
organic JJ O
layers NNS O
were VBD O
combined VBN O
and CC O
washed VBN O
with IN O
brine VB O
( -LRB- O
100 CD O
ml_ NN O
) -RRB- O
once RB O
. . O

The DT O
organic JJ O
layer NN O
was VBD O
dried VBN O
over IN O
Na2SO4 NNP B-NP
, , O
filtered VBN O
and CC O
the DT O
solvent NN O
was VBD O
removed VBN O
under IN O
low JJ O
pressure NN O
. . O

The DT O
colourless JJ O
and CC O
oily JJ O
residue NN O
was VBD O
dried VBN O
under IN O
high-vacuum JJ O
at IN O
room NN O
temperature NN O
to TO O
yield VB O
22.7 CD O
g NN O
( -LRB- O
93 CD O
% NN O
) -RRB- O
of IN O
the DT O
product NN O
as IN O
a DT O
white JJ O
solid JJ O
. . O

<1>H JJ O
NMR NNP O
( -LRB- O
CDCI3 NN B-NP
) -RRB- O
[delta NN O
] SYM O
= SYM O
1.01 CD O
( -LRB- O
s VBZ O
3H) JJ O
, , O
1.05 CD O
( -LRB- O
s VBZ O
, , O
3H) CC O
, , O
1.44 CD O
( -LRB- O
s VBZ O
, , O
3H) CC O
, , O
1.47 CD O
( -LRB- O
s VBZ O
, , O
3H) CC O
, , O
1.70-1.73 CD O

( -LRB- O
m NN O
, , O
2H) JJ O
, , O
3.27-3.71 CD O

( -LRB- O
m NN O
, , O
9H) NNP O
, , O
4.11 CD O
( -LRB- O
s VBZ O
, , O
1H) CC O
, , O
6.85 CD O
( -LRB- O
s VBZ O
, , O
1H) UH O
. . O

<13>C JJ O
NMR NNP O
( -LRB- O
CDCI3 NN B-NP
) -RRB- O
<5 VBZ O
= SYM O
18.7 CD O
, , O
18.9 CD O
, , O
22.1 CD O
, , O
29.4 CD O
, , O
32.4 CD O
, , O

33.0, CD O
35.3 CD O
, , O
59.1 CD O
, , O
71.5 CD O
, , O
76.6 CD O
, , O
99.1 CD O
, , O
171.0. . O

Panthenolacetonide NNP B-NP
( -LRB- O
15.0 CD O
g NN O
, , O
61.2 CD O
mmol NN O
, , O
1.0 CD O
eq NN O
. . O
) -RRB- O
was VBD O
dissolved VBN O
in IN O
DCM NNP B-NP
( -LRB- O
250 CD O
ml_ NN O
) -RRB- O
and CC O
cooled VBD O
to TO O
0<0>C VB O
with IN O
an DT O
ice NN O
bath NN O
. . O

Pyridine NNP B-NP
( -LRB- O
12.1 CD O
g NN O
, , O
153 CD O
mmol NN O
, , O
2.5 CD O
eq NN O
. . O
) -RRB- O
was VBD O
first RB O
added VBN O
and CC O
then RB O
4-Phenylbutanoylchloride JJ B-NP
( -LRB- O
11.7 CD O
g NN O
, , O
64.2 CD O
mmol NN O
, , O
1.05 CD O
eq NN O
. . O
) -RRB- O
in IN O
DCM NNP B-NP
( -LRB- O
70 CD O
ml_ NN O
) -RRB- O
. . O

The DT O
reaction NN O
was VBD O
exothermic JJ O
, , O
therefore RB O
the DT O
temperature NN O
was VBD O
held VBN O
in IN O
a DT O
range NN O
of IN O
-5[deg.]C JJ O
to TO O
5[deg.]C. . O

The DT O
ice-bath NN O
was VBD O
removed VBN O
after IN O
complete JJ O
addition NN O
and CC O
the DT O
reaction NN O
mixture NN O
was VBD O
allowed VBN O
to TO O
warm VB O
up RP O
to TO O
room NN O
temperature NN O
overnight RB O
. . O

The DT O
reaction NN O
was VBD O
quenched VBN O
with IN O
a DT O
saturated JJ O
aqueous JJ O
solution NN O
of IN O
Na2CO3 NNP B-NP
( -LRB- O
150 CD O
ml_ NN O
) -RRB- O
and CC O
ethyl NN B-NP
acetate NN I-NP
( -LRB- O
200 CD O
mL NN O
) -RRB- O
was VBD O
added VBN O
. . O

The DT O
layers NNS O
were VBD O
separated VBN O
and CC O
the DT O
aqueous JJ O
layer NN O
was VBD O
extracted VBN O
twice RB O
with IN O
of IN O
ethyl NN B-NP
acetate NN I-NP
( -LRB- O
150 CD O
mL NN O
) -RRB- O
. . O

The DT O
combined VBN O
organic JJ O
layers NNS O
were VBD O
washed VBN O
once RB O
with IN O
a DT O
saturated JJ O
aqueous JJ O
solution NN O
of IN O
Na2CO3 NNP B-NP
( -LRB- O
150 CD O
mL NN O
) -RRB- O
and CC O
once RB O
with IN O
brine NN O
( -LRB- O
150 CD O
mL NN O
) -RRB- O
. . O

The DT O
organic JJ O
layer NN O
was VBD O
dried VBN O
over IN O
Na2SO4 NNP B-NP
, , O
the DT O
solvent NN O
was VBD O
removed VBN O
under IN O
low JJ O
pressure NN O
and CC O
the DT O
residue JJ O
dried VBN O
under IN O
high JJ O
vacuum NN O
at IN O
room NN O
temperature NN O
. . O

24.95 CD O
g NN O
( -LRB- O
104.2 CD O
% NN O
) -RRB- O
of IN O
a DT O
pale JJ O
yellow JJ O
oil NN O
were VBD O
obtained VBN O
. . O

The DT O
crude JJ O
product NN O
was VBD O
purified VBN O
by IN O
flash NN O
chromatography NN O
over IN O
silica NN O
gel NN O
with IN O
a DT O
mixture NN O
of IN O
tBME/DIPE NN B-NP
( -LRB- O
1 CD O
:2 CD O
, , O
+ RB O
0.5 CD O
% NN O
triethylamine NN B-NP
) -RRB- O
. . O

24.1 CD O
g NN O
( -LRB- O
100 CD O
% NN O
) -RRB- O
of IN O
the DT O
acylated JJ O
Panthenolacetonide NNP B-NP
as IN O
a DT O
colourless JJ O
oil NN O
were VBD O
obtained VBN O
. . O

<1>H JJ O
NMR NNP O
( -LRB- O
CDCI3 NN B-NP
) -RRB- O
[delta NN O
] SYM O
= SYM O
0.99 CD O
( -LRB- O
s VBZ O
, , O
3H)1 CC O
1.05 CD O
( -LRB- O
s VBZ O
, , O
3H) CC O
, , O
1.41 CD O
( -LRB- O
s VBZ O
, , O
3H) CC O
, , O
1.46 CD O
( -LRB- O
s VBZ O
, , O
3H) CC O
, , O
1.82 CD O
- : O
1.86 CD O
( -LRB- O
m NN O
, , O
2H) JJ O
, , O
1.92-2.00 CD O

( -LRB- O
m NN O
, , O
2H) JJ O
, , O
2.30-2.35 CD O

(q NN O
, , O
2H) JJ O
, , O
2.61-2.67 CD O

( -LRB- O
t NN O
, , O
2H) JJ O
, , O
3.19-3.43 CD O

( -LRB- O
m NN O
, , O
3H) NNP O
, , O
3.65-3.69 CD O

( -LRB- O
d NN O
, , O
1 CD O
H) NNP O
, , O
4.08-4.15 CD O

( -LRB- O
m NN O
, , O
3H) NNP O
, , O
6.71-6.74 CD O

( -LRB- O
t NN O
, , O
1 CD O
H) NNP O
, , O
7.15-7.19 CD O

( -LRB- O
m NN O
, , O
3H)1 CD O
7.24-7.31 CD O

( -LRB- O
m NN O
, , O
2H) JJ O
. . O

<13>C JJ O
NMR NNP O
( -LRB- O
CDCI3 NN B-NP
) -RRB- O
[delta VBZ O
] VBN O
= SYM O
18.7 CD O
, , O
18.9 CD O
, , O
22.1 CD O
, , O
22.9 CD O
, , O
26.4 CD O
, , O

27.0, CD O
28.8 CD O
, , O
29.5 CD O
, , O
32.7 CD O
, , O
32.9 CD O
, , O
33.2 CD O
, , O
33.5 CD O
, , O
35.1 CD O
, , O
35.6 CD O
, , O
49.4 CD O
, , O

61.9 CD O
, , O
68.2 CD O
, , O
71.4 CD O
, , O

76.8 CD O
, , O
99.0, CD O
126.0, CD O
128.3 CD O
, , O
128.4 CD O
, , O

141.2 CD O
, , O
169.7 CD O
, , O
173.3 CD O
. . O

DC NNP O
( -LRB- O
silica NN O
gel/tBME/DIPE NN O
( -LRB- O
1 CD O
:2 CD O
, , O
+ RB O
0.5 CD O
% NN O
triethylamine NN B-NP
) -RRB- O
) -RRB- O
Rf NNP O
= SYM O
0.41 CD O
and CC O
0.25 CD O
. . O

The DT O
acylated JJ O
Panthenolacetonide NNP B-NP
( -LRB- O
24.1 CD O
g NN O
, , O
61.2 CD O
mmol NN O
, , O
1.0 CD O
eq NN O
. . O
) -RRB- O
was VBD O
suspended VBN O
in IN O
a DT O
mixture NN O
of IN O
methanol NN B-NP
( -LRB- O
150 CD O
ml NN O
. . O
) -RRB- O
and CC O
water NN B-NP
( -LRB- O
100 CD O
ml_ NN O
, , O
deionised VBD O
) -RRB- O
. . O

p-TsOH JJ B-NP
monohydrate NN I-NP
( -LRB- O
500 CD O
mg NN O
, , O
2.63 CD O
mmol NN O
, , O
0.04 CD O
eq NN O
. . O
) -RRB- O
was VBD O
added VBN O
and CC O
the DT O
reaction NN O
mixture NN O
was VBD O
stirred VBN O
overnight RB O
at IN O
room NN O
temperature NN O
. . O

The DT O
reaction NN O
mixture NN O
was VBD O
quenched VBN O
with IN O
a DT O
saturated JJ O
aqueous JJ O
solution NN O
of IN O
NaHCO3 NNP B-NP
( -LRB- O
40 CD O
ml NN O
. . O
) -RRB- O
and CC O
the DT O
methanol NN B-NP
was VBD O
distilled VBN O
of IN O
under IN O
reduced JJ O
pressure NN O
. . O

The DT O
residue NN O
, , O
a DT O
white JJ O
suspension NN O
, , O
was VBD O
extracted VBN O
five CD O
times NNS O
with IN O
ethyl NN B-NP
acetate NN I-NP
( -LRB- O
200 CD O
ml_ NN O
) -RRB- O
. . O

The DT O
organic JJ O
layers NNS O
were VBD O
combined VBN O
and CC O
washed VBN O
once RB O
with IN O
a DT O
saturated JJ O
aqueous JJ O
solution NN O
of IN O
NaHCO3 NNP B-NP
( -LRB- O
100 CD O
ml NN O
. . O
) -RRB- O
and CC O
once RB O
with IN O
brine NN O
( -LRB- O
150 CD O
ml_ NN O
) -RRB- O
. . O

The DT O
organic JJ O
layer NN O
was VBD O
dried VBN O
over IN O
Na2SO4 NNP B-NP
, , O
filtered VBN O
and CC O
the DT O
solvent NN O
was VBD O
removed VBN O
under IN O
reduced JJ O
pressure NN O
. . O

The DT O
oily JJ O
residue NN O
was VBD O
dried VBN O
under IN O
high JJ O
vacuum NN O
at IN O
room NN O
temperature NN O
overnight RB O
. . O

21.3 CD O
g VBG O
(99 CD O
% NN O
) -RRB- O
of IN O
pale JJ O
yellow JJ O
oil NN O
were VBD O
obtained VBN O
. . O

The DT O
crude JJ O
product NN O
was VBD O
purified VBN O
by IN O
flash NN O
chromatography NN O
over IN O
silica NN O
gel NN O
with IN O
tBME NN B-NP
as IN O
solvent NN O
. . O

14.9 CD O
g VBG O
(69 CD O
% NN O
) -RRB- O
of IN O
4-phenyl-butyric JJ B-NP
acid NN I-NP
3-(2,4-dihydroxy-3,3-dimethyl-butyrylamino)-propyl JJ I-NP
ester NN I-NP
as IN O
a DT O
colourless JJ O
oil NN O
were VBD O
obtained VBN O
. . O

<1>H JJ B-NP
NMR NNP O
( -LRB- O
CDCI3 NN B-NP
) -RRB- O
[delta NN O
] SYM O
= SYM O
0.90 FW O
( -LRB- O
s PRP O
, , O
3H) CC O
, , O
0.98 CD O
( -LRB- O
s VBZ O
, , O
3H) CC O
, , O
1.79- CD O
1.99 CD O
( -LRB- O
m NN O
, , O
4H) JJ O
, , O
2.3-2.36 CD O
( -LRB- O
t NN O
, , O
2H) JJ O
, , O
2.61-2.66 CD O

( -LRB- O
t NN O
, , O
2H) JJ O
, , O
3.23-3.42 CD O

( -LRB- O
m NN O
, , O
2H) JJ O
, , O
3.47 CD O
( -LRB- O
s VBZ O
, , O
2H) CC O
, , O
3.99-4.00 CD O

( -LRB- O
d NN O
, , O
1 CD O
H) NNP O
, , O
4.07-4.13 CD O

( -LRB- O
m NN O
, , O
3H) NNP O
, , O
4.64-4.65 CD O
( -LRB- O
d NN O
, , O
1 CD O
H) NNP O
, , O
7.15-7.30 CD O

( -LRB- O
m NN O
, , O
5H) JJ O
. . O

<13>C JJ O
NMR NNP O
( -LRB- O
CDCI3 NN B-NP
) -RRB- O
5 CD O
= SYM O
20.3 CD O
, , O

21.2 CD O
, , O
26.4 CD O
, , O

28.7 CD O
, , O
33.5 CD O
, , O
35.1 CD O
, , O
39.3 CD O
, , O
60.5 CD O
, , O
62.0 CD O
71.2 CD O
76.7 CD O
77.1-77.6 CD O
( -LRB- O
CDCI3 NN B-NP
) -RRB- O
, , O
126.0, CD O
128.4 CD O
, , O

128.5 CD O
, , O
141.3 CD O
, , O
141.6 CD O
, , O
173.7 CD O
, , O
173.7. . O

MS NNP O
( -LRB- O
ESI) NNP O
m/z , O
= SYM O
352.2 CD O

( -LRB- O
100 CD O
) -RRB- O
[ IN O
M+H] NNP O
, , O
374.2 CD O
( -LRB- O
5 CD O
) -RRB- O
[ , O
M+Na] NNP O
, , O
188 CD O
( -LRB- O
5 CD O
) -RRB- O
[M-(4-Phenylbutyric JJ O
acid NN O
)+H] NN O
, , O
DC NNP O
( -LRB- O
silica NN O
gel/tBME) NN O
R, IN O
= SYM O
0.25 CD O
. . O

Example NNP O
2 CD O
: : O
Synthesis NN O
of IN O
4-Phenyl-Butyric JJ B-NP
Acid NNP I-NP
2-[( CD I-NP
Pyridine-3-Carbonyl)Amino]-Ethyl NNP I-NP
Ester NNP I-NP

[0088 CD O
] NN O

EMI23.1 . O

Ethyl NNP B-NP
nicotinate JJ I-NP
( -LRB- O
15.1 CD O
g NN O
, , O
100.0 CD O
mmol NN O
, , O
1.0 CD O
eq NN O
. . O
) -RRB- O
and CC O
Ethanolamine NNP B-NP
( -LRB- O
6.1 CD O
g NN O
, , O
100.0 CD O
rnrnol NN O
, , O
1.0 CD O
eq NN O
. . O
) -RRB- O
were VBD O
dissolved VBN O
in IN O
toluene NN B-NP
( -LRB- O
80 CD O
ml_ NN O
) -RRB- O
. . O

The DT O
reaction NN O
mixture NN O
was VBD O
heated VBN O
to TO O
80 CD O
<0>C JJ O
and CC O
stirred VBD O
for IN O
48 CD O
h NN O
. . O

During IN O
the DT O
reaction NN O
the DT O
mixture NN O
changed VBD O
into IN O
a DT O
sticky JJ O
emulsion NN O
. . O

The DT O
emulsion NN O
was VBD O
cooled VBN O
down RB O
to TO O
room NN O
temperature NN O
and CC O
the DT O
lower JJR O
phase NN O
became VBD O
solid JJ O
. . O

The DT O
upper JJ O
liquid JJ O
phase NN O
was VBD O
decanted VBN O
and CC O
the DT O
orange JJ O
solid JJ O
was VBD O
crystallised VBN O
twice RB O
, , O
first JJ O
from IN O
ethyl NN B-NP
acetate NN I-NP
and CC O
then RB O
from IN O
acetone NN B-NP
. . O

The DT O
crystals NNS O
were VBD O
dried VBN O
under IN O
high JJ O
vacuum NN O
at IN O
room NN O
temperature NN O
to TO O
give VB O
7.1 CD O
g NN O
( -LRB- O
42 CD O
% NN O
) -RRB- O
of IN O
the DT O
product NN O
as IN O
a DT O
white JJ O
, , O
free JJ O
flowing VBG O
powder NN O
. . O

The DT O
1 CD O
H NNP O
NMR NNP O
and CC O
the DT O
13C JJ O
NMR NNP O
corresponds NNS O
to TO O
the DT O
literature NN O
( -LRB- O
Ogawa NNP O
, , O
T. NNP O
; : O
Hatayama NNP O
, , O
K. NNP O
; : O
Maeda NNP O
, , O
H. NNP O
; : O
Kita NNP O
, , O
Y NNP O
. . O
Chem NNP O
. . O

Pharm NN O
. . O

Bull NNP O
. . O

1994 CD O
, , O
42 CD O
( -LRB- O
8 CD O
) -RRB- O
1579-1589 CD O
) -RRB- O
. . O

<1>H JJ O
NMR NNP O
( -LRB- O
CDCI3 NN B-NP
) -RRB- O
[delta NN O
] SYM O
= SYM O
3.60-3.64 CD O

(q NN O
, , O
2H) JJ O
, , O
3.82-3.85 CD O

( -LRB- O
t NN O
, , O
2H) JJ O
, , O
4.00 CD O
( -LRB- O
s VBZ O
, , O
1H) CC O
, , O
7.33-7.39 CD O

( -LRB- O
m NN O
, , O
2H) JJ O
, , O
8.10-8.14 CD O

( -LRB- O
m NN O
, , O
1H) JJ O
, , O
8.64-8.67 CD O

(q NN O
, , O
1 CD O
H)1 CD O
8.99-9.00 CD O

( -LRB- O
t NN O
, , O
1 CD O
H) NN O
. . O

<13>C JJ O
NMR NNP O
( -LRB- O
CDCI3 NN B-NP
) -RRB- O
[delta NN O
] SYM O
= SYM O
42.8 CD O
, , O

61.5 CD O
, , O
123.6 CD O
, , O
130.2 CD O
, , O
135.5 CD O
, , O
147.8 CD O
, , O
152.0, CD O
166.4 CD O
. . O

N-(2-Hydroxy-ethyl)-nicotinamide JJ B-NP
( -LRB- O
3.3 CD O
g NN O
, , O
20.0 CD O
mmol NN O
, , O
1.0 CD O
eq NN O
. . O
) -RRB- O
was VBD O
dissolved VBN O
in IN O
DCM NNP B-NP
( -LRB- O
100 CD O
ml_ NN O
) -RRB- O
and CC O
pyridine NN B-NP
( -LRB- O
20 CD O
ml_ NN O
) -RRB- O
. . O

The DT O
light JJ O
yellow JJ O
solution NN O
was VBD O
cooled VBN O
to TO O
2 CD O
<0>C. . O

A DT O
solution NN O
of IN O
4- CD B-NP
phenylbutanoylchloride NN I-NP
( -LRB- O
3.65 CD O
g NN O
of IN O
20 CD O
mmol NN O
, , O
1.0 CD O
eq NN O
. . O
) -RRB- O
in IN O
DCM NNP B-NP
( -LRB- O
25 CD O
ml_ NN O
) -RRB- O
was VBD O
slowly RB O
added VBN O
. . O

The DT O
reaction NN O
mixture NN O
was VBD O
stirred VBN O
for IN O
1 CD O
h NN O
at IN O
0<0>C. VBG O

The DT O
reaction NN O
mixture NN O
was VBD O
evaporated VBN O
under IN O
reduced JJ O
pressure NN O
and CC O
the DT O
residue NN O
was VBD O
dissolved VBN O
in IN O
water NN B-NP
( -LRB- O
100 CD O
ml_ NN O
) -RRB- O
and CC O
ethyl NN B-NP
acetate NN I-NP
( -LRB- O
100 CD O
ml_ NN O
) -RRB- O
. . O

The DT O
layers NNS O
were VBD O
separated VBN O
and CC O
the DT O
aqueous JJ O
phase NN O
was VBD O
extracted VBN O
with IN O
ethyl NN B-NP
acetate NN I-NP
( -LRB- O
75 CD O
ml_ NN O
) -RRB- O
. . O

The DT O
combined VBN O
organic JJ O
layers NNS O
were VBD O
washed VBN O
with IN O
a DT O
saturated JJ O
aqueous JJ O
solution NN O
of IN O
NaHCO3 NNP B-NP
( -LRB- O
50 CD O
mL NN O
) -RRB- O
and CC O
of IN O
brine NN O
( -LRB- O
50 CD O
ml_ NN O
) -RRB- O
. . O

The DT O
organic JJ O
layer NN O
was VBD O
dried VBN O
over IN O
Na2SO4 NNP B-NP
, , O
filtrated VBN O
and CC O
evaporated VBN O
under IN O
reduced JJ O
pressure NN O
. . O

The DT O
yellow JJ O
, , O
oily JJ O
residue NN O
was VBD O
dried VBN O
at IN O
high JJ O
vacuum NN O
at IN O
room NN O
temperature NN O
to TO O
give VB O
6.2 CD O
g NN O
( -LRB- O
100 CD O
% NN O
) -RRB- O
of IN O
the DT O
product NN O
as RB O
yellow JJ O
oil NN O
. . O

The DT O
crude JJ O
product NN O
was VBD O
purified VBN O
by IN O
flash NN O
chromatography NN O
over IN O
silica NN O
gel NN O
with IN O
ethyl NN B-NP
acetate NN I-NP
to TO O
yield VB O
the DT O
pure JJ O
A- NNP B-NP
phenyl-butyric JJ I-NP
acid NN I-NP
2-[( JJ I-NP
pyridine-3-carbonyl NN I-NP
)amino]-ethyl NN I-NP
ester NN I-NP
5.6 CD O
g NN O
( -LRB- O
89 CD O
% NN O
) -RRB- O
as IN O
a DT O
light NN O
yellow JJ O
oil NN O
. . O

<1>H JJ O
NMR NNP O
( -LRB- O
CDCI3 NN B-NP
) -RRB- O
[delta NN O
] SYM O
= SYM O
1.87-1.95 CD O

( -LRB- O
m NN O
, , O
2H) JJ O
, , O
2.29-2.34 CD O

( -LRB- O
m NN O
, , O
2H) JJ O
, , O
2.58-2.63 CD O

( -LRB- O
m NN O
, , O
2H) JJ O
, , O
3.67-3.72 CD O

( -LRB- O
m NN O
, , O
2H) JJ O
, , O
4.25-4.29 CD O
( -LRB- O
m NN O
, , O
2H) JJ O
, , O
7.11-7.41 CD O

( -LRB- O
m NN O
, , O
7H) NNP O
, , O
8.08-8.12 CD O

( -LRB- O
m NN O
, , O
1 CD O
H) NNP O
, , O
8.65-8.67 CD O

(q NN O
, , O
1 CD O
H) NNP O
, , O
8.99- CD O
9.00 CD O
( -LRB- O
d NN O
, , O
1 CD O
H) NN O
. . O

<13>C JJ O
NMR NNP O
( -LRB- O
CDCI3 NN B-NP
) -RRB- O
[delta NN O
] SYM O
= SYM O
26.3 CD O
, , O

33.4 CD O
, , O

35.0, CD O
39.6 CD O
, , O
62.9 CD O
, , O
123.5 CD O
, , O
126.0, CD O
128.4 CD O
, , O

128.4 CD O
, , O

130.0, CD O
135.2 CD O
, , O
141.1 CD O
, , O
148.1 CD O
, , O
152.1 CD O
, , O
165.8 CD O
, , O
173.9 CD O
. . O

MS NNP O
( -LRB- O
ESI) NNP O
m/z , O
= SYM O
313.2 CD O

( -LRB- O
100 CD O
) -RRB- O
[ IN O
M+H+] NNP O
. . O

DC NNP O
( -LRB- O
silica NN O
gel/ethyl NN O
acetate NN B-NP
) -RRB- O
: : O
RF NN O
= SYM O
0.32 CD O
. . O

Example NNP O
3 CD O
: : O
Synthesis NNP O
of IN O
4-Phenyl-butyric JJ B-NP
acid NN I-NP
1 CD I-NP
,5-dimethyl-1-(4-methyl-cyclohex-3-enyl) JJ I-NP
- : I-NP
hex-4-enyl JJ I-NP
ester NN I-NP

[0090 CD O
] NN O

EMI25.1 . O

To TO O
a DT O
solution NN O
of IN O
rac-alpha-Bisabolol NN B-NP
( -LRB- O
267 CD O
mg NN O
, , O
1.2 CD O
mmol NN O
, , O
1.2 CD O
eq NN O
. . O
) -RRB- O
in IN O
toluene NN B-NP
( -LRB- O
5 CD O
ml_ NN O
) -RRB- O
, , O
silver JJ B-NP
cyanide NN I-NP
( -LRB- O
268 CD O
mg NN O
, , O
2 CD O
mmol NN O
, , O
2.0 CD O
eq NN O
. . O
) -RRB- O
was VBD O
added VBN O
. . O

The DT O
reaction NN O
mixture NN O
was VBD O
heated VBN O
to TO O
80[deg.]C. . O

Then RB O
4-phenylbutanoylchloride JJ B-NP
( -LRB- O
182 CD O
mg NN O
, , O
1 CD O
mmol NN O
, , O
1.0 CD O
eq NN O
. . O
) -RRB- O
was VBD O
added VBN O
and CC O
the DT O
reaction NN O
mixture NN O
was VBD O
stirred VBN O
overnight RB O
at IN O
80<0>C. VBG O

A DT O
sample NN O
was VBD O
taken VBN O
and CC O
analyzed VBN O
by IN O
GC-MS. NNP O

The DT O
mass NN O
of IN O
the DT O
alpha-Bisabolol NN B-NP
was VBD O
found VBN O
: : O
( -LRB- O
El NNP O
) -RRB- O
m/z , O
= SYM O
204 CD O
, , O
147 CD O
, , O
119 CD O
, , O
109 CD O
, , O
104 CD O
, , O
91 CD O
, , O
69 CD O
, , O
41 CD O
. . O

The DT O
reaction NN O
mixture NN O
containing VBG O
4-phenyl-butyric JJ B-NP
acid NN I-NP
1 CD B-NP
,5-dimethyl-1-(4-methyl-cyclohex-3-enyl) JJ I-NP
- : I-NP
hex-4-enyl JJ I-NP
ester NN I-NP
can MD O
be VB O
worked VBN O
up RP O
by IN O
standard JJ O
procedures NNS O
. . O

Example NNP O
4 CD O
: : O
Synthesis NN O
of IN O
N-furan-2-yl-methyl-4-phenyl-N-(9H-purin-6-yl)-butyramide JJ B-NP

[0093] . O

EMI25.2 NN O

To TO O
a DT O
suspension NN O
of IN O
Kinetin NNP B-NP
( -LRB- O
1.26 CD O
g NN O
, , O
5.85 CD O
mmol NN O
, , O
1.0 CD O
eq NN O
. . O
) -RRB- O
in IN O
dry JJ O
DMF NN O
( -LRB- O
25 CD O
ml NN O
. . O
) -RRB- O
was VBD O
added VBN O
triethylamine NN B-NP
( -LRB- O
651 CD O
mg NN O
, , O
6.44 CD O
mmol NN O
, , O
1.1 CD O
eq NN O
. . O
) -RRB- O
. . O

Then RB O
trityl JJ B-NP
bromide NN I-NP
( -LRB- O
2.08 CD O
g NN O
, , O
6.44 CD O
mmol NN O
, , O
1.1 CD O
eq NN O
. . O
) -RRB- O
was VBD O
added VBN O
and CC O
the DT O
mixture NN O
was VBD O
stirred VBN O
at IN O
room NN O
temperature NN O
over IN O
night NN O
. . O

Reaction NN O
control NN O
by IN O
DC NNP O
( -LRB- O
hexane/ethyl NN B-NP
acetate NN B-NP
1 CD O
:1 CD O
) -RRB- O
showed VBD O
still RB O
Kinetin NNP B-NP
. . O

The DT O
reaction NN O
mixture NN O
was VBD O
stirred VBN O
further RB O
3 CD O
hours NNS O
at IN O
50 CD O
[deg.]C. . O

Reaction NN O
control NN O
by IN O
DC NNP O
( -LRB- O
hexane/ethyl NN B-NP
acetate NN B-NP
1 CD O
:1 CD O
) -RRB- O
showed VBD O
only RB O
small JJ O
traces NNS O
of IN O
remaining VBG O
Kinetin NNP B-NP
. . O

The DT O
reaction NN O
mixture NN O
was VBD O
quenched VBN O
with IN O
a DT O
saturated JJ O
aqueous JJ O
solution NN O
of IN O
NaHCO3 NNP B-NP
( -LRB- O
30 CD O
ml_ NN O
) -RRB- O
. . O

The DT O
yellow JJ O
solution NN O
was VBD O
extracted VBN O
three CD O
times NNS O
with IN O
ethyl NN B-NP
acetate NN I-NP
( -LRB- O
75 CD O
ml_ NN O
) -RRB- O
. . O

The DT O
combined VBN O
organic JJ O
layers NNS O
were VBD O
washed VBN O
with IN O
a DT O
saturated JJ O
aqueous JJ O
solution NN O
of IN O
NaHCO3 NNP B-NP
( -LRB- O
50 CD O
ml_ NN O
) -RRB- O
and CC O
once RB O
with IN O
brine NN O
( -LRB- O
50 CD O
ml_ NN O
) -RRB- O
. . O

The DT O
organic JJ O
layer NN O
was VBD O
dried VBN O
over IN O
Na2SO4 NNP B-NP
, , O
filtered VBN O
and CC O
the DT O
solvent NN O
was VBD O
removed VBN O
under IN O
reduced JJ O
pressure NN O
. . O

The DT O
residue NN O
was VBD O
dried VBN O
in IN O
high-vacuum JJ O
at IN O
room NN O
temperature NN O
to TO O
yield VB O
3.21 CD O
g NN O
( -LRB- O
120 CD O
% NN O
) -RRB- O
of IN O
a DT O
brown JJ O
amorphous JJ O
solid JJ O
. . O

The DT O
crude JJ O
product NN O
was VBD O
purified VBN O
by IN O
flash-chromatography NN O
with IN O
ethyl NN B-NP
acetate/hexane NN I-NP
1 CD O
:2 NN O
as IN O
eluent JJ O
. . O

1.41 CD O
g NN O
( -LRB- O
53 CD O
% NN O
) -RRB- O
of IN O
a DT O
light NN O
beige NN O
solid JJ O
were VBD O
obtained VBN O
. . O

- : O
<1>H JJ B-NP
NMR NN O
( -LRB- O
CDCI3 NN B-NP
) -RRB- O
[delta NN O
] SYM O
= SYM O
4.82 CD O
- : O
4.83 CD O
( -LRB- O
d NN O
, , O
2H) JJ O
, , O
6.29 CD O
( -LRB- O
s VBZ O
, , O
2H)1 CC O
6.45-6.49 CD O

( -LRB- O
t NN O
, , O
1 CD O
H) NNP O
, , O
7.14-7.31 CD O

( -LRB- O
m NN O
, , O
16H) JJ O
, , O
7.71 CD O
( -LRB- O
s VBZ O
, , O
1 CD O
H)1 CD O
8.14 CD O
( -LRB- O
s VBZ O
, , O
1 CD O
H) NN O
. . O
- : O
<13>C JJ B-NP
NMR NN O
( -LRB- O
CDCI3 NN B-NP
) -RRB- O
[delta NN O
] SYM O
= SYM O
75.8 CD O
, , O

107.5 CD O
, , O
110.4 CD O
, , O

121.3 CD O
, , O
127.9 CD O
, , O
128.0, CD O
129.8 CD O
, , O
141.4 CD O
, , O

142.2 CD O
, , O
151.8 CD O
, , O
152.4 CD O
, , O

154.6 CD O
. . O

- : O
DC NNP O
(ethyl NNP O
acetate/hexane NN B-NP
1 CD O
:2 NN O
) -RRB- O
: : O
Rf JJ O
= SYM O
0.33 CD O
. . O

A DT O
suspension NN O
of IN O
furane-2-ylmethyl-(9-trityl-9H-purine-6-yl)-arnine DT B-NP
( -LRB- O
1.00 CD O
g NN O
, , O
2.186 CD O
mmol,1.0 CD O

eq NN O
. . O
) -RRB- O
in IN O
toluene NN B-NP
( -LRB- O
40 CD O
ml NN O
. . O
) -RRB- O
was VBD O
heated VBN O
to TO O
65<0>C VB O
and CC O
a DT O
clear JJ O
pale JJ O
yellow JJ O
solution NN O
was VBD O
obtained VBN O
. . O

Then RB O
silver JJ B-NP
cyanide NN I-NP
( -LRB- O
585 CD O
mg NN O
, , O
4.371 CD O
mmol NN O
, , O
2.0 CD O
eq. NN O
) -RRB- O
, , O
triethylamine NN B-NP
( -LRB- O
266 CD O
mg NN O
, , O
2.633 CD O
mmol NN O
, , O
1.2 CD O
eq NN O
. . O
) -RRB- O
and CC O
4-phenylbutanoyl JJ B-NP
chloride NN I-NP
( -LRB- O
439 CD O
mg NN O
, , O
2.404 CD O
mmol NN O
, , O
1.1 CD O
eq NN O
. . O
) -RRB- O
were VBD O
added VBN O
. . O

The DT O
reaction NN O
mixture NN O
was VBD O
stirred VBN O
for IN O
3 CD O
hours NNS O
at IN O
65[deg.]C. PRP$ O

Reaction NN O
control NN O
by IN O
DC NNP O
showed VBD O
still RB O
starting VBG O
material NN O
. . O

Another DT O
portion NN O
of IN O
triethylamine NN B-NP
( -LRB- O
266 CD O
mg NN O
, , O
2.633 CD O
mmol NN O
, , O
1.2 CD O
eq NN O
. . O
) -RRB- O
and CC O
4- JJ B-NP
phenylbutanoyl NN I-NP
chloride NN I-NP
( -LRB- O
439 CD O
mg NN O
, , O
2.404 CD O
mmol NN O
, , O
1.1 CD O
eq NN O
. . O
) -RRB- O
were VBD O
added VBN O
. . O

The DT O
reaction NN O
mixture NN O
was VBD O
stirred VBN O
for IN O
1 CD O
hour NN O
at IN O
70<0>C. PRP$ O

Reaction NN O
control NN O
by IN O
DC NNP O
showed VBD O
no DT O
more JJR O
starting VBG O
material NN O
. . O

The DT O
reaction NN O
mixture NN O
was VBD O
cooled VBN O
to TO O
room NN O
temperature NN O
, , O
ethyl NN B-NP
acetate NN I-NP
( -LRB- O
100 CD O
mL NN O
) -RRB- O
was VBD O
added VBN O
and CC O
the DT O
solution NN O
was VBD O
washed VBN O
with IN O
a DT O
saturated JJ O
aqueous JJ O
solution NN O
of IN O
NaHCO3 NNP B-NP
( -LRB- O
50 CD O
mL NN O
) -RRB- O
and CC O
brine VB O
( -LRB- O
50 CD O
mL NN O
) -RRB- O
. . O

The DT O
organic JJ O
layer NN O
was VBD O
dried VBN O
over IN O
Na2SO4 NNP B-NP
, , O
the DT O
solvent NN O
was VBD O
removed VBN O
under IN O
reduced JJ O
pressure NN O
and CC O
the DT O
residue NN O
was VBD O
dried VBN O
in IN O
high JJ O
vacuum NN O
at IN O
room NN O
temperature NN O
to TO O
yield VB O
1.93 CD O
g NN O
( -LRB- O
146 CD O
% NN O
) -RRB- O
of IN O
a DT O
brown JJ O
oil NN O
. . O

The DT O
crude JJ O
product NN O
was VBD O
purified VBN O
by IN O
flash-chromatography NN O
with IN O
a DT O
mixture NN O
of IN O
hexane/ethyl NN B-NP
acetate NN B-NP
4:1 VBD O
to TO O
give VB O
720 CD O
mg NN O
( -LRB- O
55 CD O
% NN O
) -RRB- O
of IN O
a DT O
pale JJ O
yellow JJ O
solid JJ O
. . O

- : O
<1>H JJ B-NP
NMR NN O
( -LRB- O
CDCI3 CC B-NP
) -RRB- O
" `` O
5 CD O
= SYM O
1.95-2.05 CD O

( -LRB- O
m NN O
, , O
2H) JJ O
, , O
2.56-2.63 CD O

( -LRB- O
m NN O
, , O
4H) JJ O
, , O
5.50 CD O
( -LRB- O
s VBZ O
, , O
2H) CC O
, , O
6.14-6.19 CD O

( -LRB- O
m NN O
, , O
2H) JJ O
, , O
7.06-7.42 CD O

( -LRB- O
m NN O
, , O
21 CD O
H) NNP O
, , O
8.00 CD O
( -LRB- O
s VBZ O
, , O
1 CD O
H)1 CD O
8.41 CD O
( -LRB- O
s VBZ O
, , O
1 CD O
H) NN O
. . O
- : O
<13>C JJ B-NP
NMR NN O
( -LRB- O
CDCI3 NN B-NP
) -RRB- O
[delta NN O
] SYM O
= SYM O
26.9 CD O
, , O

35.1 CD O
, , O
35.2 CD O
, , O
43.6 CD O
, , O
76.4 CD O
, , O
108.0, CD O
110.2 CD O
, , O
125.7 CD O
, , O
128.1 CD O
, , O
128.2 CD O
, , O
128.5 CD O
, , O
129.7 CD O
, , O
140.9 CD O
, , O
141.8 CD O
, , O
145.0, CD O
151.3 CD O
, , O
153.1 CD O
, , O
154.4 CD O
, , O

173.8. CD O
- : O
DC NN O
( -LRB- O
hexane/ethyl NN B-NP
acetate NN B-NP
4:1 IN O
) -RRB- O
: : O
R, JJ O
= SYM O
0.40 CD O
. . O

N-furane-2-ylmethyl-4-phenyl-N-(9-trityl-9H-purine-6-yl)-butyramide JJ B-NP
( -LRB- O
650 CD O
mg NN O
, , O
1.11 CD O
mmol NN O
) -RRB- O
was VBD O
dissolved VBN O
in IN O
a DT O
mixture NN O
of IN O
DCM NNP B-NP
with IN O
1 CD O
% NN O
deionised JJ O
water NN B-NP
and CC O
0.2 CD O
% NN O
TFA NN B-NP
( -LRB- O
55 CD O
mL NN O
) -RRB- O
. . O

The DT O
clear JJ O
pale JJ O
brown JJ O
solution NN O
was VBD O
stirred VBN O
for IN O
2 CD O
hours NNS O
at IN O
room NN O
temperature NN O
. . O

Reaction NN O
control NN O
by IN O
DC NNP O
showed VBD O
no DT O
more JJR O
starting VBG O
material NN O
. . O

To TO O
the DT O
reaction NN O
mixture NN O
was VBD O
added VBN O
ethyl NN B-NP
acetate NN I-NP
( -LRB- O
100 CD O
mL NN O
) -RRB- O
and CC O
the DT O
solution NN O
was VBD O
washed VBN O
twice RB O
with IN O
a DT O
saturated JJ O
aqueous JJ O
solution NN O
of IN O
NaHCO3 NNP B-NP
solution NN O
( -LRB- O
50 CD O
mL NN O
) -RRB- O
. . O

The DT O
combined VBN O
aqueous JJ O
layers NNS O
were VBD O
extracted VBN O
twice RB O
with IN O
ethyl NN B-NP
acetate NN I-NP
( -LRB- O
50 CD O
mL NN O
) -RRB- O
. . O

The DT O
combined VBN O
organic JJ O
layers NNS O
were VBD O
washed VBN O
once RB O
with IN O
brine NN O
( -LRB- O
75 CD O
mL NN O
) -RRB- O
and CC O
dried VBD O
over IN O
Na2SO4 NNP B-NP
. . O

The DT O
solvent NN O
was VBD O
removed VBN O
under IN O
reduced JJ O
pressure NN O
and CC O
the DT O
residue NN O
was VBD O
dried VBN O
in IN O
high JJ O
vacuum NN O
at IN O
room NN O
temperature NN O
to TO O
yield VB O
700 CD O
mg JJ O
( -LRB- O
175 CD O
% NN O
) -RRB- O
of IN O
a DT O
pale JJ O
brown JJ O
solid JJ O
. . O

The DT O
crude JJ O
product NN O
was VBD O
purified VBN O
by IN O
flash-chromatography NN O
using VBG O
hexane/ethyl NN B-NP
acetate NN B-NP
1:1 VBD O
to TO O
give VB O
260 CD O
mg NN O
( -LRB- O
65 CD O
% NN O
) -RRB- O
of IN O
N-furan-2-yl-methyl-4-phenyl-N-(9H-purin-6-yl)-butyramide NNP B-NP
as IN O
a DT O
colourless JJ O
gum NN O
. . O

- : O
<1>H JJ B-NP
NMR NN O
( -LRB- O
MeOH-d4 NNP B-NP
) -RRB- O
[delta NNP O
] SYM O
= SYM O
1.76-1.86 CD O

( -LRB- O
m NN O
, , O
2H) JJ O
, , O
2.37-2.45 CD O

( -LRB- O
m NN O
, , O
4H) JJ O
, , O
4.78 CD O
( -LRB- O
s VBZ O
, , O
2H) CC O
, , O
5.23 CD O
( -LRB- O
s VBZ O
, , O
2H) CC O
, , O
6.00-6.06 CD O

( -LRB- O
t NN O
, , O
1 CD O
H) NNP O
, , O
6.06-6.07 CD O

( -LRB- O
t NN O
, , O
1 CD O
H) NNP O
, , O
6.89-7.05 CD O

( -LRB- O
m NN O
, , O
4H) JJ O
, , O
7.11-7.12 CD O

( -LRB- O
d NN O
, , O
1 CD O
H) NNP O
, , O
8.31 CD O
( -LRB- O
s VBZ O
, , O
1 CD O
H) NNP O
, , O
8.63 CD O
( -LRB- O
s VBZ O
, , O
1 CD O
H) NN O
. . O
- : O
<13>C JJ B-NP
NMR NN O
( -LRB- O
MeOH-d4 NNP B-NP
) -RRB- O
[delta NNP O
] SYM O
= SYM O
28.2 CD O
, , O

35.5 CD O
, , O
35.9 CD O
, , O
44.5 CD O
, , O
109.4 CD O
, , O

111.2 CD O
, , O
126.9 CD O
, , O
129.3 CD O
, , O
129.4 CD O
, , O
142.7 CD O
, , O
143.4 CD O
, , O

146.2 CD O
, , O
152.0, CD O
153.0, CD O
175.5 CD O
. . O

- : O
DC NN O
( -LRB- O
hexane/ethyl NN B-NP
acetate NN B-NP
1:1 CD O
) -RRB- O
: : O
R, JJ O
= SYM O
0.20 CD O
. . O

Example NNP O
5 CD O
Anti-aging JJ O
cream NN O

[0098] . O

EMI27.1 . O

Example NNP O
6 CD O
Anti-aging JJ O
cream NN O

[0099] . O

EMI28.1 . O

Example NN O
7 CD O

Anti-aging JJ O
cream NN O

[0102 CD O
] NN O

EMI28.2 NN O

EMI29.1 . O

What WP O
is VBZ O
claimed VBN O
is VBZ O
: : O

1 CD O
. . O

A DT O
compound NN O
of IN O
the DT O
general JJ O
formula NN O

[ NN B-NP
Ph-(CH2 NNP I-NP
)n-CO]m NNP I-NP
-X NNP I-NP
( -LRB- O
I PRP O
) -RRB- O
wherein WRB O
Ph NNP O
is VBZ O
phenyl NN B-NP
or CC O
substituted VBN O
phenyl NN B-NP
, , O
n NN O
is VBZ O
1 CD O
or CC O
3 CD O
, , O
m NN O
is VBZ O
an DT O
integer NN O
of IN O
at IN O
least JJS O
1 CD O
, , O
and CC O
X NNP O
is VBZ O
a DT O
moiety NN O
from IN O
a DT O
naturally RB O
occurring VBG O
, , O
non-toxic JJ O
compound NN O
carrying VBG O
at IN O
least JJS O
one CD O
hydroxy NN B-NP
, , O
sulfhydryl NN B-NP
, , O
amino IN B-NP
or CC O
imino NN B-NP
group NN O
which WDT O
moiety NN O
is VBZ O
formed VBN O
by IN O
removal NN O
of IN O
a DT O
hydrogen NN B-NP
atom NN O
from IN O
said VBD O
hydroxyl NN B-NP
, , O
sulfhydryl NN B-NP
, , O
amino IN B-NP
or CC O
imino VB B-NP
group NN O
; : O
except IN O
that DT O
X NNP O
is VBZ O
not RB O
an DT O
amino JJ B-NP
acid NN I-NP
or CC O
peptide NN B-NP
comprising NN O
up IN O
to TO O
6 CD O
amino IN B-NP
acids NNS I-NP
. . O

2. DT O
The DT O
compound NN O
as RB O
in IN O
claim NN O
1 CD O
wherein WRB O
Ph NNP O
is VBZ O
phenyl NN B-NP
. . O

3. DT O
The DT O
compound NN O
as RB O
in IN O
claim NN O
1 CD O
wherein WRB O
Ph NNP O
is VBZ O
phenyl RB B-NP
substituted VBN O
by IN O
up RB O
to TO O
three CD O
substituents NNS O
which WDT O
are VBP O
selected VBN O
, , O
independently RB O
, , O
from IN O
hydroxy JJ B-NP
, , O
C1-C6 DT B-NP
alkyl NN I-NP
C2-C6 CC B-NP
alkenyl NN I-NP
, , O
Ci-C6 NNP B-NP
alkoxy NN I-NP
and CC O
C2-C6 DT B-NP
alkenyloxy NN I-NP
. . O

4 LS O
. . O
The DT O
compound NN O
as RB O
in IN O
any DT O
one CD O
of IN O
claims NNS O
1 CD O
- : O
3 CD O
wherein WRB O
X NNP O
is VBZ O
a DT O
moiety NN O
from IN O
a DT O
naturally RB O
occurring VBG O
, , O
non-toxic JJ O
compound NN O
carrying VBG O
at IN O
least JJS O
one CD O
hydroxyl JJ B-NP
group NN O
. . O

5 CD O
. . O
The DT O
compound NN O
as RB O
in IN O
any DT O
one CD O
of IN O
claims NNS O
1 CD O
- : O
4 CD O
wherein WRB O
the DT O
naturally RB O
occurring VBG O
, , O
non-toxic JJ O
compound NN O
carrying VBG O
at IN O
least JJS O
one CD O
hydroxyl NN B-NP
group NN O
is VBZ O
selected VBN O
from IN O
fat-soluble JJ O
vitamin NN O
derivatives NNS O
and CC O
analoga NN O
thereof RB O
, , O
water-soluble JJ O
vitamins NNS O
, , O
derivatives NNS O
or CC O
analogues NNS O
thereof RB O
, , O
carbohydrates NNS B-NP
, , O
[alpha]-hydroxy-carboxylic JJ B-NP
acids NNS I-NP
, , O
aliphatic JJ B-NP
alcohols NNS I-NP
and CC O
polyols NNS B-NP
, , O
aminoalcohols NNS B-NP
, , O
chromanes NNS B-NP
and CC O
flavones NNS B-NP
, , O
derivatives NNS O
and CC O
analogues NNS O
thereof RB O
, , O
pyrimidines NNS B-NP
or CC O
purines NNS B-NP
or CC O
metabolites NNS O
or CC O
analogues NNS O
thereof RB O
, , O
terpenes NNS B-NP
, , O
and CC O
catechols NNS B-NP
; : O

6 CD O
. . O

The DT O
compound NN O
as RB O
in IN O
claim NN O
5 CD O
wherein WRB O
the DT O
naturally RB O
occurring VBG O
, , O
non-toxic JJ O
compound NN O
carrying VBG O
at IN O
least JJS O
one CD O
hydroxyl NN B-NP
group NN O
is VBZ O
selected VBN O
from IN O
a DT O
fat-soluble JJ O
vitamin NN O
, , O
derivatives NNS O
and CC O
analogues NNS O
thereof RB O
. . O

7. DT O
The DT O
compound NN O
as RB O
in IN O
claim NN O
6 CD O
wherein WRB O
the DT O
fat-soluble JJ O
vitamin NN O
or CC O
derivative JJ O
or CC O
analogue JJ O
thereof , O
is VBZ O
selected VBN O
from IN O
a DT O
tocopherol NN B-NP
, , O
a DT O
carotenoid NN B-NP
, , O
and CC O
vitamin NN B-NP
D3 NNS I-NP
or CC O
a DT O
hydroxyl JJ B-NP
derivative JJ O
thereof PRP O
. . O

8. DT O
The DT O
compound NN O
as RB O
in IN O
claim NN O
5 CD O
wherein WRB O
the DT O
naturally RB O
occurring VBG O
, , O
non-toxic JJ O
compound NN O
carrying VBG O
at IN O
least JJS O
one CD O
hydroxyl NN B-NP
group NN O
is VBZ O
selected VBN O
from IN O
a DT O
water-soluble JJ O
vitamin NN O
, , O
derivatives NNS O
or CC O
analogues NNS O
thereof RB O
. . O

9 CD O
. . O
The DT O
compound NN O
as RB O
in IN O
claim NN O
8 CD O
wherein WRB O
the DT O
water-soluble JJ O
vitamin NN O
or CC O
derivative JJ O
or CC O
analogue JJ O
thereof , O
is VBZ O
one CD O
belonging VBG O
to TO O
the DT O
vitamin NN O
B NNP O
group NN O
. . O

10 CD O
. . O

The DT O
compound NN O
as RB O
in IN O
claim NN O
9 CD O
wherein WRB O
the DT O
water-soluble JJ O
vitamin NN O
or CC O
derivative JJ O
or CC O
analogue JJ O
thereof , O
is VBZ O
selected VBN O
from IN O
panthenol NN B-NP
, , O
pantothenic JJ B-NP
acid NN I-NP
, , O
pyridoxines NNS B-NP
, , O
thiamine NN B-NP
, , O
riboflavin VBG B-NP
, , O
nicotinamide JJ B-NP
, , O
2-hydroxyethylnicotinamide JJ B-NP
and CC O
folic JJ B-NP
acid NN I-NP
, , O
preferably RB O
panthenol NN B-NP
, , O
nicotinamide JJ B-NP
, , O
or CC O
2-hydroxyethylnicotinamide JJ B-NP
. . O

11 CD O
. . O

The DT O
compound NN O
of IN O
claim NN O
10 CD O
which WDT O
is VBZ O
4-phenylbutyric JJ B-NP
acid NN I-NP
2-[( JJ I-NP
pyridine-3-carbonyl JJ I-NP
)amino] SYM I-NP
- : I-NP
ethyl NN I-NP
ester NN I-NP
. . O

12 CD O
. . O
The DT O
compound NN O
of IN O
claim NN O
10 CD O
, , O
which WDT O
is VBZ O
4-phenylbutyric JJ B-NP
acid NN I-NP
3-(2,4-dihydroxy-3,3-dimethyl- CD I-NP
butyrylamino)-propyl NN I-NP
ester NN I-NP
. . O

13 CD O
. . O

The DT O
compound NN O
as RB O
in IN O
claim NN O
8 CD O
wherein WRB O
the DT O
water-soluble JJ O
vitamin NN O
or CC O
derivative NN O
is VBZ O
ascorbic JJ B-NP
acid NN I-NP
or CC O
ascorbic JJ B-NP
acid NN I-NP
phosphate NN I-NP
. . O

14 CD O
. . O

The DT O
compound NN O
as RB O
in IN O
claim NN O
5 CD O
wherein WRB O
the DT O
naturally RB O
occurring VBG O
, , O
non-toxic JJ O
compound NN O
carrying VBG O
at IN O
least JJS O
one CD O
hydroxyl NN B-NP
group NN O
is VBZ O
selected VBN O
from IN O
chromanes NNS B-NP
and CC O
flavones NNS B-NP
, , O
derivatives NNS O
and CC O
analogues NNS O
thereof RB O
. . O

15 CD O
. . O

The DT O
compound NN O
as RB O
in IN O
claim NN O
14 CD O
wherein WRB O
the DT O
chromane NN B-NP
, , O
flavone NN B-NP
, , O
derivative JJ O
and CC O
analogue JJ O
thereof , O
is VBZ O
selected VBN O
from IN O
equol NN B-NP
, , O
quercetin NN B-NP
, , O
delphinidin NN B-NP
, , O
silymarin NN B-NP
, , O
daidzein NN B-NP
, , O
or CC O
genistein NN B-NP
. . O

16 CD O
. . O

The DT O
compound NN O
as RB O
in IN O
claim NN O
5 CD O
wherein WRB O
the DT O
naturally RB O
occurring VBG O
, , O
non-toxic JJ O
compound NN O
carrying VBG O
at IN O
least JJS O
one CD O
hydroxyl NN B-NP
group NN O
is VBZ O
a DT O
pyrimidine NN B-NP
or CC O
purine NN O
or CC O
metabolite NN O
or CC O
analogue NN O
thereof RB O
. . O

17 CD O
. . O

The DT O
compound NN O
as RB O
in IN O
claim NN O
16 CD O
wherein WRB O
the DT O
pyrimidine NN B-NP
or CC O
purine NN O
or CC O
analogue NN O
thereof , O
is VBZ O
kinetin NN B-NP
or CC O
allantoin VB B-NP
, , O
preferably RB O
kinetin NN B-NP
. . O

18 CD O
. . O

The DT O
compound NN O
of IN O
claim NN O
17 CD O
which WDT O
is VBZ O
N-furan-2-yl-methyl-4-phenyl-N-(9H-purin-6-yl) JJ B-NP
- : I-NP
butyramide NN I-NP
. . O

19 CD O
. . O

A DT O
compound NN O
as RB O
in IN O
claim NN O
5 CD O
wherein WRB O
the DT O
naturally RB O
occurring VBG O
, , O
non-toxic JJ O
compound NN O
carrying VBG O
at IN O
least JJS O
one CD O
hydroxyl NN B-NP
group NN O
is VBZ O
a DT O
terpene NN B-NP
. . O

20 CD O
. . O

A DT O
compound NN O
as RB O
in IN O
claim NN O
19 CD O
wherein WRB O
the DT O
terpene NN B-NP
is VBZ O
selected VBN O
from IN O
farnesol NN B-NP
, , O
bisabolol NN B-NP
, , O
phytol NN B-NP
and CC O
menthol NN B-NP
, , O
preferably RB O
bisabolol NN B-NP
. . O

21 CD O
. . O

The DT O
compound NN O
of IN O
claim NN O
20 CD O
which WDT O
is VBZ O
4-phenylbutyric JJ B-NP
acid NN I-NP
1 CD I-NP
,5-dimethyl-1-(4-methyl- CC I-NP
cyclohex-3-enyl)-hex-4-enyl JJ I-NP
ester NN I-NP
. . O

22 CD O
. . O
The DT O
compound NN O
as RB O
in IN O
claim NN O
5 CD O
wherein WRB O
the DT O
naturally RB O
occurring VBG O
, , O
non-toxic JJ O
compound NN O
carrying VBG O
at IN O
least JJS O
one CD O
hydroxyl NN B-NP
group NN O
is VBZ O
a DT O
catechol NN B-NP
. . O

23 CD O
. . O

The DT O
compound NN O
as RB O
in IN O
claim NN O
22 CD O
wherein WRB O
the DT O
catechol NN B-NP
is VBZ O
epigallocatechin JJ B-NP
gallate NN I-NP
. . O

24 CD O
. . O

A DT O
topical JJ O
composition NN O
comprising VBG O
at IN O
least JJS O
one CD O
compound NN O
as IN O
in IN O
any DT O
of IN O
claims NNS O
1 CD O
to TO O
23 CD O
and CC O
a DT O
cosmetically NN O
or CC O
pharmaceutically RB O
acceptable JJ O
excipient JJ O
or CC O
diluent JJ O
. . O

25 CD O
. . O

The DT O
composition NN O
as IN O
in IN O
claim NN O
24 CD O
wherein WRB O
the DT O
compound NN O
of IN O
formula NN O
( -LRB- O
I PRP O
) -RRB- O
is VBZ O
present JJ O
in IN O
a DT O
concentration NN O
of IN O
0.001 CD O
to TO O
50 CD O
wt.-% NN O
, , O

based VBN O
on IN O
the DT O
total JJ O
weight NN O
of IN O
the DT O
composition NN O
. . O

26 CD O
. . O

The DT O
composition NN O
as IN O
in IN O
claim NN O
24 CD O
wherein WRB O
the DT O
compound NN O
of IN O
formula NN O
( -LRB- O
I PRP O
) -RRB- O
is VBZ O
present JJ O
in IN O
a DT O
concentration NN O
of IN O
0.01 CD O
to TO O
1 CD O
wt.-% NN O
, , O
based VBN O
on IN O
the DT O
total JJ O
weight NN O
of IN O
the DT O
composition NN O
. . O

-DOCSTART- X X O

[0001] FW O
( -LRB- B-NP
S)-[omicron]-METHYLOXAALKYL NN I-NP
EXEMESTANE VB I-NP
COMPOUNDS NNPS O
AND CC O
RELATED VBN O
METHODS NNS O
OF IN O
USE NNP O

This DT O
application NN O
claims VBZ O
priority NN O
benefit NN O
from IN O
application NN O
serial NN O
no NN O
. . O

60/722,204 CD O
filed VBD O
September NNP O
30 CD O
, , O
2005 CD O
, , O
the DT O
entirety NN O
of IN O
which WDT O
is VBZ O
incorporated JJ O
herein RB O
by IN O
reference NN O
. . O

Background NN O
of IN O
the DT O
Invention NNP O
. . O

Abnormal JJ O
cell NN O
proliferation NN O
is VBZ O
usually RB O
characterized VBN O
by IN O
an DT O
increased VBN O
rate NN O
of IN O
division NN O
and CC O
in IN O
some DT O
cases NNS O
uncontrolled JJ O
growth NN O
. . O

One CD O
example NN O
of IN O
a DT O
proliferative JJ O
cell NN O
disorder NN O
is VBZ O
a DT O
tumor NN O
. . O

In IN O
addition NN O
to TO O
posing VBG O
a DT O
serious JJ O
health NN O
risk NN O
in IN O
and CC O
of IN O
themselves PRP O
, , O
primary JJ O
malignant JJ O
tumors NNS O
are VBP O
particularly RB O
problematic JJ O
given VBN O
their PRP$ O
tendency NN O
to TO O
invade VB O
surrounding VBG O
tissues NNS O
and CC O
metastasize NN O
to TO O
distant JJ O
organs NNS O
in IN O
the DT O
body NN O
. . O

To TO O
date NN O
, , O
the DT O
most RBS O
frequently RB O
used VBN O
methods NNS O
for IN O
treating VBG O
neoplasia NN O
, , O
especially RB O
solid JJ O
tumor NN O
forms NNS O
of IN O
neoplasia NN O
, , O
include VBP O
surgical JJ O
procedures NNS O
, , O
radiation NN O
therapy NN O
, , O
drug NN O
therapies NNS O
, , O
and CC O
combinations NNS O
of IN O
the DT O
foregoing NN O
. . O

Drug NN O
therapy NN O
for IN O
breast NN O
cancer NN O
may MD O
include VB O
the DT O
administration NN O
of IN O
exemestane NN B-NP
to TO O
a DT O
patient NN O
. . O

Product NN O
information NN O
available JJ O
on-line NN O
from IN O
the DT O
U.S. NNP O
Food NNP O
and CC O
Drug NNP O
Administration NNP O
describes VBZ O
exemestane NN B-NP
as IN O
an DT O
irreversible JJ O
, , O
steroidal JJ O
aromatase NN O
inactivator NN O
. . O

Exemestane NN B-NP
( -LRB- O
which WDT O
is VBZ O
sold VBN O
as IN O
Aromasin NNP O
( -LRB- O
R NN O
) -RRB- O
, , O
is VBZ O
chemically RB O
described VBN O
as IN O
6-methylenandrosta-l,4-diene-3,17 JJ B-NP
-dione NN I-NP
. . O

Its PRP$ O
molecular JJ O
formula NN O
is VBZ O
C20H24O2 NNP B-NP
and CC O
its PRP$ O
structural JJ O
formula NN O
is VBZ O
as IN O
follows VBZ O
: : O

[0004 CD O
] NN O

EMI2.1 . O

Among IN O
other JJ O
things NNS O
, , O
exemestane JJ B-NP
lowers NNS O
circulating VBG O
estrogen NN B-NP
concentrations NNS O
in IN O
postmenopausal JJ O
women NNS O
thereby RB O
providing VBG O
a DT O
treatment NN O
for IN O
some DT O
postmenopausal JJ O
patients NNS O
with IN O
hormone-dependent JJ O
breast NN O
cancer NN O
. . O

U.S. NNP O

Patent NN O
Nos NNP O
. . O

4,808,616 CD O
, , O
and CC O
4,904,650 CD O
describe VBP O
6-alkylidenandrosta-l,4- CD B-NP
diene-3,17-dione NN I-NP
derivatives NNS O
, , O
such JJ O
as IN O
exemestane NN B-NP
, , O
and CC O
methods NNS O
of IN O
making VBG O
them PRP O
. . O

U.S. NNP O
Patent NNP O
No. NN O
4,876,045 CD O
teaches VBZ O
a DT O
method NN O
of IN O
preparing VBG O
6-methylene JJ B-NP
derivatives NNS O
of IN O
androsta-l,4-diene-3,17-diones NNS B-NP
by IN O
reacting VBG O
a DT O
17-hydroxy JJ B-NP
precursor NN O
with IN O
formaldehyde NN B-NP
and CC O
an DT O
amine JJ B-NP
, , O
and CC O
then RB O
oxidizing VBG O
the DT O
resulting VBG O
compound NN O
. . O

U.S. NNP O
Patent NNP O
No. NN O
4,990,635 CD O
teaches VBZ O
a DT O
process NN O
for IN O
making VBG O
6-methylene JJ B-NP
derivatives NNS O
of IN O
androsta-l,4-diene-3,17 DT B-NP
- : I-NP
diones NNS I-NP
by IN O
reacting VBG O
androsta-3,5-diene-17-one JJ B-NP
with IN O
formaldehyde NN B-NP
and CC O
an DT O
amine JJ B-NP
, , O
and CC O
then RB O
dehydrogenating VBG O
the DT O
resulting VBG O
compound NN O
. . O

The DT O
preparation NN O
of IN O
intermediates NNS O
that WDT O
may MD O
be VB O
useful JJ O
in IN O
preparing VBG O
exemestane NN B-NP
is VBZ O
also RB O
described VBN O
in IN O
the DT O
literature NN O
. . O

In IN O
U.S. NNP O

Patent NN O
No. NN O
3,274,176 CD O
, , O
there EX O
is VBZ O
described VBN O
a DT O
process NN O
for IN O
making VBG O
l,3-dipyrrolidyl-[Delta]3 JJ B-NP
,5-androstadiene-17-one NN I-NP
in IN O
which WDT O
[ NNP B-NP
Delta]l NNP I-NP
,4- CC I-NP
androstadiene-3,17-dione DT I-NP
is VBZ O
refluxed VBN O
with IN O
pyrrolidine NN B-NP
and CC O
the DT O
residue NN O
is VBZ O
crystallized VBN O
in IN O
methanol NN B-NP
to TO O
obtain VB O
l,3-dipyrrolidyl-[Delta]3 JJ B-NP
,5-androstadiene-17-one NN I-NP
. . O

In IN O
German JJ O
patent NN O
DD NNP O
258820 CD O
, , O
6-hydroxymethyl-androsta-l,4-diene-3,17-dione CD B-NP
is VBZ O
prepared VBN O
from IN O
androsta-l,4-diene-3,17-dione DT B-NP
via IN O
l,3-dipyrrolidinoandrosta-3,5-dien-17-one JJ B-NP
. . O

A DT O
solution NN O
of IN O
l,3-dipyrrolidinoandrosta-3,5-dien-17-one NN B-NP
in IN O
benzene-ethanol NN B-NP
is VBZ O
stirred VBN O
with IN O
aqueous JJ O
formaldehyde NN B-NP
( -LRB- O
HCHO NNP B-NP
) -RRB- O
until IN O
the DT O
reaction NN O
is VBZ O
complete JJ O
. . O

Co-pending JJ O
international JJ O
application NN O
no NN O
. . O

PCT/US2005/001248 PRP O
filed VBD O
January NNP O
14 CD O
, , O
2005 CD O
(PCT NNP O
Publication NNP O
Number NNP O
WO NN O
2005/070951 CD O
) -RRB- O
also RB O
describes VBZ O
the DT O
preparation NN O
of IN O
intermediates NNS O
that WDT O
are VBP O
useful JJ O
in IN O
preparing VBG O
exemestane NN B-NP
, , O
such JJ O
application NN O
as IN O
is VBZ O
incorporated JJ O
herein RB O
by IN O
reference NN O
, , O
in IN O
its PRP$ O
entirety NN O
. . O

The DT O
clinical JJ O
pharmacology NN O
in IN O
this DT O
exemestane JJ B-NP
product NN O
information NN O
states NNS O
that IN O
the DT O
mechanism NN O
of IN O
action NN O
for IN O
breast NN O
cancer NN O
cell NN O
growth NN O
may MD O
be VB O
estrogen-dependent JJ B-NP
. . O

Aromatase NNP O
is VBZ O
described VBN O
as IN O
the DT O
principal JJ O
enzyme NN O
that WDT O
converts VBZ O
androgens NNS O
to TO O
estrogens VB B-NP
both DT O
in IN O
pre NN O
- : O
and CC O
postmenopausal JJ O
women NNS O
. . O

It PRP O
is VBZ O
reported VBN O
that IN O
the DT O
principal JJ O
source NN O
of IN O
circulating VBG O
estrogens NNS B-NP
in IN O
postmenopausal JJ O
women NNS O
is VBZ O
from IN O
conversion NN O
of IN O
adrenal JJ O
and CC O
ovarian JJ O
androgens NNS O
( -LRB- O
androstenedione NN B-NP
and CC O
testosterone NN B-NP
) -RRB- O
to TO O
estrogens NNS B-NP
(estrone , O
and CC O
estradiol NN B-NP
) -RRB- O
by IN O
the DT O
aromatese JJ O
enzyme NN O
. . O

Estrogen NN B-NP
deprivation NN O
through IN O
aromatase JJ O
inhibition NN O
is VBZ O
described VBN O
as IN O
an DT O
effective JJ O
and CC O
selective JJ O
treatment NN O
for IN O
some DT O
postmenopausal JJ O
patients NNS O
with IN O
hormone-dependent JJ O
breast NN O
cancer NN O
. . O

Exemestane NN B-NP
as IN O
an DT O
irreversible JJ O
, , O
steroidal JJ O
aromatase NN O
inactivator NN O
is VBZ O
believed VBN O
to TO O
act VB O
as IN O
a DT O
false JJ O
substrate NN O
for IN O
the DT O
aromatase JJ O
enzyme NN O
, , O
and CC O
processed VBD O
to TO O
an DT O
intermediate JJ O
that IN O
binds NNS O
irreversibly RB O
to TO O
the DT O
active JJ O
site NN O
of IN O
the DT O
enzyme NN O
causing VBG O
its PRP$ O
inactivation NN O
. . O

Exemestane NN B-NP
lowers NNS O
circulating VBG O
estrogen NN B-NP
concentrations NNS O
in IN O
postmenopausal JJ O
women NNS O
thereby RB O
providing VBG O
a DT O
treatment NN O
for IN O
some DT O
postmenopausal JJ O
patients NNS O
with IN O
hormone-dependent JJ O
breast NN O
cancer NN O
. . O

However RB O
, , O
a DT O
need NN O
still RB O
exists VBZ O
to TO O
identify VB O
new JJ O
and CC O
effective JJ O
agents NNS O
for IN O
treating VBG O
cancer NN O
. . O

Summary NNP O
of IN O
the DT O
Invention NNP O
. . O

In IN O
light NN O
of IN O
the DT O
foregoing NN O
, , O
it PRP O
is VBZ O
an DT O
object NN O
of IN O
the DT O
present JJ O
invention NN O
to TO O
provide VB O
chemotherapeutic JJ O
compounds NNS O
, , O
compositions NNS O
and/or CC O
methods NNS O
for IN O
their PRP$ O
use NN O
and CC O
preparation NN O
, , O
thereby RB O
overcoming VBG O
various JJ O
deficiencies NNS O
and CC O
shortcomings NNS O
of IN O
the DT O
prior JJ O
art NN O
, , O
including VBG O
those DT O
outlined VBN O
above IN O
. . O

It PRP O
will MD O
be VB O
understood VBN O
by IN O
those DT O
skilled JJ O
in IN O
the DT O
art NN O
that IN O
one CD O
or CC O
aspects NNS O
of IN O
this DT O
invention NN O
can MD O
meet VB O
certain JJ O
objectives NNS O
, , O
while IN O
one CD O
or CC O
more JJR O
other JJ O
aspects NNS O
can MD O
meet VB O
certain JJ O
other JJ O
objectives NNS O
. . O

Each DT O
objective NN O
may MD O
not RB O
apply VB O
equally RB O
, , O
in IN O
all DT O
its PRP$ O
respects NNS O
, , O
to TO O
every DT O
aspect NN O
of IN O
this DT O
invention NN O
. . O

As IN O
such JJ O
, , O
the DT O
following JJ O
objects NNS O
can MD O
be VB O
viewed VBN O
in IN O
the DT O
alternative NN O
with IN O
respect NN O
to TO O
any DT O
one CD O
aspect NN O
of IN O
this DT O
invention NN O
. . O

It PRP O
can MD O
be VB O
an DT O
object NN O
of IN O
the DT O
present JJ O
invention NN O
to TO O
provide VB O
one CD O
or CC O
more JJR O
compounds NNS O
, , O
compositions NNS O
, , O
and/or CC O
methods NNS O
to TO O
more RBR O
broadly RB O
treat VB O
a DT O
cancer NN O
disease NN O
state NN O
, , O
in IN O
particular JJ O
such JJ O
a DT O
state NN O
or CC O
condition NN O
not RB O
hormone NN O
and/or CC O
estrogen NN B-NP
dependent JJ O
. . O

It PRP O
can MD O
be VB O
another DT O
object NN O
of IN O
the DT O
present JJ O
invention NN O
to TO O
provide VB O
one CD O
or CC O
more JJR O
compounds NNS O
, , O
compositions NNS O
, , O
and/or CC O
methods NNS O
to TO O
deleteriously RB O
affect VB O
cancer NN O
cellular JJ O
growth NN O
or CC O
proliferation NN O
without IN O
restriction NN O
to TO O
aromatase DT O
inhibition NN O
. . O

It PRP O
can MD O
be VB O
another DT O
object NN O
of IN O
the DT O
present JJ O
invention NN O
to TO O
provide VB O
more JJR O
generally RB O
, , O
without IN O
restriction NN O
to TO O
any DT O
one CD O
compound NN O
or CC O
composition NN O
, , O
use NN O
of IN O
an DT O
exemestane NN B-NP
6-methylene NN B-NP
substituent JJ O
to TO O
effect VB O
results NNS O
of IN O
the DT O
sort NN O
described VBD O
herein RB O
. . O

Other JJ O
objects NNS O
, , O
features NNS O
, , O
benefits NNS O
and CC O
advantages NNS O
of IN O
the DT O
present JJ O
invention NN O
will MD O
be VB O
apparent JJ O
from IN O
this DT O
summary NN O
and CC O
the DT O
following VBG O
descriptions NNS O
of IN O
certain JJ O
embodiments NNS O
, , O
and CC O
will MD O
be VB O
readily RB O
apparent JJ O
to TO O
those DT O
skilled JJ O
in IN O
the DT O
art NN O
having VBG O
knowledge NN O
of IN O
various JJ O
chemotherapeutic NN O
compounds NNS O
, , O
methods NNS O
and/or CC O
modes NNS O
of IN O
operation NN O
. . O

Such JJ O
objects NNS O
, , O
features NNS O
, , O
benefits NNS O
, , O
and CC O
advantages NNS O
will MD O
be VB O
apparent JJ O
from IN O
the DT O
above JJ O
as IN O
taken VBN O
into IN O
conjunction NN O
with IN O
the DT O
accompanying JJ O
examples NNS O
, , O
data NNS O
, , O
figures NNS O
and CC O
all DT O
reasonable JJ O
inferences NNS O
to TO O
be VB O
drawn VBN O
therefrom RB O
, , O
alone RB O
or CC O
with IN O
consideration NN O
of IN O
the DT O
references NNS O
incorporated JJ O
herein RB O
. . O

In IN O
part NN O
, , O
the DT O
present JJ O
invention NN O
can MD O
be VB O
directed VBN O
to TO O
a DT O
chemotherapeutic JJ O
compound NN O
of IN O
a DT O
formula NN O

[0013] . O

EMI5.1 . O

R5 IN O
In IN O
such JJ O
a DT O
compound NN O
R1 NN O
, , O
R2 NNP O
, , O
R3 NNP O
and CC O
R4 NNP O
can MD O
be VB O
independently RB O
selected VBN O
from IN O
H NNP O
alkyl NN B-NP
, , O
substituted VBN O
alkyl NN B-NP
and CC O
halogen NN B-NP
moieties NNS O
. . O

Regardless RB O
, , O
R5 CD O
, , O
can MD O
be VB O
selected VBN O
from IN O
alkyl NN B-NP
and CC O
substituted VBD O
alkyl RB B-NP
moieties NNS O
. . O

Such JJ O
a DT O
compound NN O
can MD O
be VB O
selected VBN O
from IN O
any DT O
one CD O
or CC O
more JJR O
of IN O
the DT O
available JJ O
enantiomers NNS O
, , O
other JJ O
stereochemical JJ O
isomers NNS O
, , O
hydrates NNS B-NP
, , O
solvates NNS O
, , O
tautomers NNS O
and CC O
possible JJ O
salts NNS O
thereof '' O
. . O

In IN O
certain JJ O
embodiments NNS O
, , O
R5 PRP O
can MD O
be VB O
selected VBN O
from IN O
C1 NNP O
to TO O
about IN O
C6 DT B-NP
alkyl NN I-NP
and CC O
C1 NNP O
to TO O
about IN O
C6 DT O
substituted VBN O
alkyl NN B-NP
moieties NNS O
. . O

In IN O
certain JJ O
such JJ O
embodiments NNS O
, , O
R5 PRP O
can MD O
be VB O
methyl NN B-NP
and CC O
, , O
optionally RB O
such JJ O
a DT O
compound NN O
can MD O
be VB O
present JJ O
as IN O
the DT O
S NNP O
enantiomer NN O
. . O

In IN O
part NN O
, , O
the DT O
present JJ O
invention NN O
can MD O
also RB O
be VB O
directed VBN O
to TO O
a DT O
pharmaceutical JJ O
composition NN O
. . O

Such JJ O
a DT O
composition NN O
can MD O
comprise VB O
one CD O
or CC O
more JJR O
compounds NNS O
selected VBN O
from IN O
those DT O
discussed VBN O
above IN O
, , O
illustrated VBN O
below IN O
or CC O
otherwise RB O
inferred JJ O
herein RB O
, , O
and CC O
combinations NNS O
thereof RB O
. . O

In IN O
certain JJ O
embodiments NNS O
, , O
such JJ O
a DT O
composition NN O
can MD O
comprise VB O
a DT O
pharmaceutically-acceptable JJ O
carrier NN O
component NN O
. . O

Without IN O
limitation NN O
, , O
such JJ O
a DT O
composition NN O
can MD O
comprise VB O
a DT O
racemic JJ O
mixture NN O
of IN O
compounds NNS O
. . O

In IN O
certain JJ O
such JJ O
embodiments NNS O
, , O
such JJ O
a DT O
compound NN O
can MD O
be VB O
present JJ O
as IN O
the DT O
S NNP O
enantiomer NN O
, , O
and CC O
R5 PRP O
can MD O
be VB O
selected VBN O
from IN O
C1 NNP O
to TO O
about IN O
C6 DT O
alkyl NN B-NP
and CC O
C1 NNP O
to TO O
about IN O
C6 DT O
substituted VBN O
alkyl NN B-NP
moieties NNS O
. . O

In IN O
part NN O
, , O
this DT O
invention NN O
can MD O
also RB O
be VB O
directed VBN O
to TO O
a DT O
method NN O
of IN O
using VBG O
an DT O
exemestane NN B-NP
6-methylene NN B-NP
substituent JJ O
to TO O
affect VB O
cancer NN O
growth NN O
. . O

Such JJ O
a DT O
method NN O
can MD O
comprise VB O
providing VBG O
a DT O
compound NN O
with IN O
an DT O
exemestane JJ B-NP
core NN O
structure NN O
comprising VBG O
a DT O
methyloxaalkyl NN O
substituent NN O
at IN O
the DT O
6- CD O
position NN O
of IN O
such JJ O
a DT O
core NN O
structure NN O
; : O
and CC O
contacting VBG O
a DT O
cancer NN O
growth NN O
with IN O
such JJ O
a DT O
compound NN O
. . O

In IN O
certain JJ O
embodiments NNS O
the DT O
alkyl NN B-NP
moiety NN O
of IN O
the DT O
6-methylene JJ B-NP
substituent NN O
can MD O
be VB O
selected VBN O
from IN O
C1 NNP O
to TO O
about IN O
C6 DT O
alkyl NN B-NP
and CC O
C1 NNP O
to TO O
about IN O
C6 DT O
substituted VBN O
alkyl NN B-NP
moieties NNS O
. . O

In IN O
certain JJ O
such JJ O
embodiments NNS O
the DT O
alkyl NN B-NP
moiety NN O
can MD O
be VB O
methyl NN B-NP
, , O
and CC O
the DT O
compound NN O
can MD O
be VB O
present JJ O
as IN O
the DT O
S NNP O
enantiomer NN O
. . O

Regardless RB O
, , O
such JJ O
a DT O
method NN O
can MD O
comprise VB O
contact NN O
with IN O
and CC O
affect VB O
estrogen(-) JJ B-NP
and/or CC O
aromatase( JJ O
+ NN O
) -RRB- O
cell NN O
lines NNS O
. . O

For IN O
purposes NNS O
of IN O
the DT O
present JJ O
compounds NNS O
, , O
compositions NNS O
and/or CC O
methods NNS O
, , O
the DT O
following VBG O
, , O
unless IN O
otherwise RB O
indicated VBN O
, , O
will MD O
be VB O
understood VBN O
as IN O
having VBG O
the DT O
meaning NN O
ascribed VBN O
thereto , O
by IN O
those DT O
skilled JJ O
in IN O
the DT O
art NN O
or CC O
as IN O
otherwise RB O
indicated VBN O
with IN O
respect NN O
thereto , O
: : O
"exemestane NN O
core NN O
structure NN O
" '' O
means VBZ O
a DT O
structure NN O
comprising VBG O
a DT O
3,17-dione-3,5- CD O
diene NN O
fused VBN O
ring NN O
structure NN O
. . O

Representative JJ O
structures NNS O
, , O
without IN O
regard NN O
to TO O
substitution NN O
, , O
or CC O
to TO O
stereochemistry VB O
at IN O
the DT O
6-position NN O
include VBP O
but CC O
are VBP O
not RB O
limited VBN O
to TO O

[0017] . O

EMI6.1 . O

where WRB O
R1 NNP O
, , O
R2 NNP O
, , O
R3 NNP O
and CC O
R4 NNP O
can MD O
be VB O
H NNP B-NP
, , O
alkyl NN B-NP
, , O
substituted VBN O
alkyl NN B-NP
, , O
halogen NN B-NP
, , O
etc. FW O
, , O
together RB O
with IN O
tautomers NNS O
thereof RB O
. . O

In IN O
part NN O
, , O
this DT O
invention NN O
can MD O
also RB O
be VB O
directed VBN O
to TO O
a DT O
method NN O
of IN O
treating VBG O
a DT O
subject JJ O
and/or CC O
inhibiting JJ O
growth NN O
of IN O
cancer NN O
cells NNS O
. . O

Such JJ O
a DT O
method NN O
can MD O
comprise VB O
providing VBG O
a DT O
subject/growth NN O
of IN O
cancer NN O
cells NNS O
; : O
and CC O
contacting VBG O
such JJ O
a DT O
growth NN O
with IN O
one CD O
or CC O
more JJR O
compounds NNS O
selected VBN O
from IN O
compounds NNS O
discussed VBN O
above RB O
, , O
illustrated VBN O
below IN O
or CC O
otherwise RB O
inferred JJ O
herein RB O
, , O
and CC O
combinations NNS O
thereof RB O
. . O

Such JJ O
a DT O
compound NN O
can MD O
be VB O
in IN O
an DT O
amount NN O
at IN O
least JJS O
partially RB O
sufficient JJ O
to TO O
inhibit VB O
growth NN O
of IN O
such JJ O
cancer NN O
cells NNS O
, , O
such JJ O
inhibition NN O
substantially RB O
without IN O
aromatase DT O
inhibition NN O
and/or CC O
in IN O
an DT O
amount NN O
or CC O
at IN O
a DT O
concentration NN O
substantially RB O
insufficient JJ O
to TO O
inhibit VB O
aromatase JJ O
activity NN O
, , O
such JJ O
insufficiency NN O
as IN O
can MD O
be VB O
determined VBN O
by IN O
comparison NN O
with IN O
exemestane NN B-NP
. . O

In IN O
certain JJ O
embodiments NNS O
, , O
without IN O
limitation NN O
, , O
such JJ O
a DT O
compound NN O
can MD O
be VB O
of IN O
a DT O
formula NN O

EMI7.1 . O

wherein WRB O
R1 NNP O
, , O
R2 NNP O
, , O
R3 NNP O
and CC O
R4 NNP O
can MD O
be VB O
independently RB O
selected VBN O
from IN O
H5 CD O
alkyl NN B-NP
, , O
substituted VBN O
alkyl NN B-NP
and CC O
halogen NN B-NP
moieties NNS O
. . O

In IN O
certain JJ O
such JJ O
embodiments NNS O
, , O
R5 PRP O
can MD O
be VB O
selected VBN O
from IN O
alkyl NN B-NP
and CC O
substituted VBD O
alkyl RB B-NP
moieties NNS O
. . O

Regardless RB O
, , O
such JJ O
compounds NNS O
can MD O
be VB O
selected VBN O
from IN O
any DT O
one CD O
or CC O
combination NN O
of IN O
possible JJ O
enantiomers NNS O
, , O
hydrates NNS B-NP
, , O
solvates NNS O
, , O
tautomers NNS O
and CC O
salts NNS O
of IN O
such JJ O
compounds NNS O
. . O

In IN O
certain JJ O
embodiments NNS O
, , O
such JJ O
a DT O
method NN O
can MD O
be VB O
effected VBN O
with IN O
one CD O
or CC O
more JJR O
compounds NNS O
, , O
such JJ O
as IN O
wherein WRB O
R5 PRP O
can MD O
be VB O
selected VBN O
from IN O
C1 NNP O
to TO O
about IN O
C6 DT O
alkyl NN B-NP
and CC O
Cj NNP O
to TO O
about IN O
C6 DT O
substituted VBN O
alkyl NN B-NP
moieties NNS O
. . O

As IN O
illustrated VBN O
below IN O
, , O
R5 PRP O
can MD O
be VB O
methyl NN B-NP
. . O

Regardless RB O
, , O
any DT O
such JJ O
compound NN O
or CC O
combinations NNS O
thereof , O
can MD O
be VB O
present JJ O
in IN O
a DT O
pharmaceutical JJ O
composition NN O
. . O

As IN O
illustrated VBN O
below IN O
, , O
such JJ O
a DT O
method NN O
can MD O
be VB O
used VBN O
to TO O
inhibit VB O
breast NN O
, , O
lung NN O
, , O
colon NN O
, , O
prostate NN O
, , O
ovarian JJ O
and CC O
pancreatic JJ O
cancerous JJ O
growths NNS O
and/or CC O
cell NN O
lines NNS O
. . O

In IN O
part NN O
, , O
the DT O
present JJ O
invention NN O
can MD O
also RB O
be VB O
directed VBN O
to TO O
a DT O
method NN O
of IN O
using VBG O
a DT O
6-methyloxamethyl NN B-NP
exemestane NN I-NP
derivative JJ O
to TO O
inhibit VB O
growth NN O
of IN O
cancer NN O
cells NNS O
. . O

Such JJ O
a DT O
method NN O
can MD O
comprise VB O
providing VBG O
cancer NN O
cell NN O
growth NN O
; : O
and CC O
contacting VBG O
such JJ O
cells NNS O
or CC O
growth NN O
with IN O
a DT O
methyloxamethyl NN B-NP
compound NN O
selected VBN O
from IN O
one CD O
or CC O
more JJR O
compounds NNS O
discussed VBN O
above RB O
, , O
illustrated VBN O
below IN O
or CC O
otherwise RB O
inferred JJ O
herein RB O
, , O
and CC O
combinations NNS O
thereof RB O
. . O

Such JJ O
a DT O
compound NN O
can MD O
be VB O
in IN O
an DT O
amount NN O
at IN O
least JJS O
partially RB O
sufficient JJ O
to TO O
inhibit VB O
such JJ O
cellular JJ O
growth NN O
, , O
such JJ O
inhibition NN O
substantially RB O
without IN O
aromatase DT O
inhibition NN O
and/or CC O
in IN O
an DT O
amount NN O
or CC O
at IN O
a DT O
concentration NN O
substantially RB O
insufficient JJ O
to TO O
inhibit VB O
aromatase JJ O
activity NN O
, , O
such JJ O
insufficiency NN O
as IN O
can MD O
be VB O
determined VBN O
by IN O
comparison NN O
with IN O
exemestane NN B-NP
. . O

In IN O
certain JJ O
embodiments NNS O
, , O
such JJ O
a DT O
compound NN O
can MD O
be VB O
of IN O
a DT O
formula NN O

[0021] . O

EMI8.1 . O

O UH O

Such JJ O
a DT O
compound NN O
can MD O
be VB O
used VBN O
to TO O
inhibit VB O
cancer NN O
cellular JJ O
or CC O
tumor NN O
growth NN O
associated JJ O
with IN O
breast NN O
, , O
lung NN O
, , O
colon NN O
, , O
prostate NN O
, , O
ovarian JJ O
and CC O
pancreatic JJ O
cancers NNS O
. . O

In IN O
part NN O
, , O
the DT O
present JJ O
invention NN O
can MD O
also RB O
be VB O
directed VBN O
to TO O
a DT O
method NN O
for IN O
preparing VBG O
an DT O
oxaalkyl NN O
derivative NN O
of IN O
exemestane NN B-NP
. . O

Such JJ O
a DT O
method NN O
can MD O
comprise VB O
providing VBG O
a DT O
3 CD B-NP
, , I-NP
5-diene JJ I-NP
derivative NN O
of IN O
( -LRB- B-NP
+)-androsta-l,4-diene-3,17-dione NN I-NP
; : O
formylating VBG O
such JJ O
a DT O
diene NN B-NP
at IN O
the DT O
6- CD O
position NN O
thereof RB O
, , O
to TO O
provide VB O
a DT O
hydroxymethyl NN O
derivative JJ O
; : O
and CC O
alkylating VBG O
the DT O
hydroxymethyl NN O
derivative NN O
. . O

In IN O
certain JJ O
embodiments NNS O
, , O
the DT O
aforementioned JJ O
3 CD B-NP
, , I-NP
5-diene JJ I-NP
derivative NN O
can MD O
be VB O
prepared VBN O
by IN O
reaction NN O
of IN O
pyrrolidine NN B-NP
with IN O
the DT O
3,17-dione CD B-NP
under IN O
appropriate JJ O
catalytic NN O
and CC O
reaction NN O
conditions NNS O
. . O

Various JJ O
oxaalkyl NN O
derivatives NNS O
, , O
in IN O
accordance NN O
with IN O
this DT O
invention NN O
, , O
are VBP O
limited VBN O
only RB O
by IN O
choice NN O
of IN O
alkylating VBG O
agent NN O
, , O
such JJ O
derivatives NNS O
as IN O
would MD O
be VB O
understood VBN O
by IN O
those DT O
skilled JJ O
in IN O
art NN O
made VBD O
aware JJ O
of IN O
this DT O
invention NN O
, , O
as IN O
available JJ O
through IN O
synthetic JJ O
procedures NNS O
of IN O
the DT O
sort NN O
described VBD O
herein PRP O
or CC O
straight-forward JJ O
modifications NNS O
thereof RB O
, , O
such JJ O
modifications NNS O
as RB O
would MD O
also RB O
be VB O
understood VBN O
by IN O
those DT O
skilled JJ O
in IN O
the DT O
art NN O
. . O

Accordingly RB O
, , O
without IN O
limitation NN O
, , O
various JJ O
C1 NNP O
to TO O
about IN O
C6 DT O
alkyl NN B-NP
and CC O
substituted VBN O
alkyl NN B-NP
( -LRB- O
e NN O
.g. NNP O
, , O
C1 NNP O
to TO O
about IN O
C6 NNP O
linear NN O
, , O
substituted VBN O
linear NN O
, , O
branched VBD O
and CC O
substituted VBD O
branched JJ O
alkyl NN B-NP
, , O
such JJ O
substituents NNS O
as IN O
would MD O
be VB O
understood VBN O
in IN O
the DT O
art NN O
) -RRB- O
reagents VBZ O
can MD O
be VB O
used VBN O
as IN O
described VBN O
herein IN O
to TO O
prepare VB O
the DT O
corresponding JJ O
oxaalkyl NN B-NP
derivatives NNS O
. . O

Brief JJ O
Description NN O
of IN O
the DT O
Drawings NNP O
. . O

Figure NN O
1 CD O
shows VBZ O
a DT O
reaction NN O
scheme NN O
for IN O
preparing VBG O
one CD O
example NN O
exemestane NN B-NP
derivative JJ O
according VBG O
to TO O
the DT O
invention NN O
. . O

Figure NN O
2 CD O
shows VBZ O
a DT O
reaction NN O
scheme NN O
for IN O
preparing VBG O
another DT O
example NN O
exemestane NN B-NP
derivative JJ O
according VBG O
to TO O
the DT O
invention NN O
. . O

Detailed VBN O
Description NN O
of IN O
Certain NNP O
Embodiments NNP O
. . O

In IN O
one CD O
aspect NN O
, , O
this DT O
invention NN O
provides VBZ O
a DT O
method NN O
for IN O
inhibiting VBG O
growth NN O
of IN O
cells NNS O
of IN O
a DT O
cancer NN O
or CC O
a DT O
tumor NN O
. . O

In IN O
such JJ O
a DT O
method NN O
, , O
the DT O
cells NNS O
are VBP O
exposed VBN O
to TO O
or CC O
contacted VBN O
with IN O
a DT O
compound NN O
of IN O
Formula NNP O
( -LRB- O
A DT O
) -RRB- O
or CC O
pharmaceutically RB O
acceptable JJ O
salts NNS O
or CC O
hydrates NNS B-NP
thereof . O
: : O

[0027] . O

EMI9.1 . O

wherein WRB O
each DT O
Of IN O
R1 NNP O
, , O
R2 NNP O
, , O
R3 NNP O
, , O
and CC O
R4 NNP O
, , O
independently RB O
, , O
is VBZ O
hydrogen NN B-NP
, , O
halogen NN B-NP
or CC O
alkyl NN B-NP
, , O
and CC O
R5 NNP O
is VBZ O
alkyl RB B-NP
. . O

One CD O
specific JJ O
non-limiting JJ O
example NN O
compound NN O
of IN O
Formula NNP O
( -LRB- O
A DT O
) -RRB- O
has VBZ O
the DT O
Formula NN O

( -LRB- O
B NN O
) -RRB- O
below RB O
: : O

[0030] . O

EMI9.2 NN O

O UH O

More RBR O
specifically RB O
, , O
showing VBG O
various JJ O
stereochemical JJ O
relationships NNS O
, , O
such JJ O
a DT O
compound NN O
B NN O
can MD O
be VB O
represented VBN O
as IN O

[0033] . O

EMI10.1 . O

The DT O
compound NN O
of IN O
Formula NNP O
( -LRB- O
B NN O
) -RRB- O
can MD O
be VB O
referred VBN O
to TO O
as IN O
"6S" NN O
or CC O
" `` O
Exemestane NNP B-NP
6S" '' O
. . O

Looking VBG O
at IN O
Figure NN O
I5 IN O
the DT O
compound NN O
of IN O
formula NN O
( -LRB- O
B NN O
) -RRB- O
can MD O
be VB O
prepared VBN O
by IN O
first JJ O
preparing VBG O
l,3-dipyrrolidinoandrosta-3,5-diene-17-one FW B-NP
( -LRB- O
EX-I) NN O
from IN O
( -LRB- B-NP
+)-androsta-l NN I-NP
, , I-NP
A- NNP I-NP
diene-3 NN I-NP
, , I-NP
17-dione CD I-NP
( -LRB- O
ADD) NNP B-NP
. . O

One CD O
set VBN O
of IN O
conditions NNS O
utilizes NNS O
( -LRB- B-NP
+)-androsta-l,4-diene-3 NN I-NP
, , I-NP
17 CD I-NP
- : I-NP
dione NN I-NP
( -LRB- O
ADD) NNP B-NP
, , O
12.2 CD O
equivalents NNS O
pyrrolidine JJ B-NP
, , O
catalytic JJ O
acetic JJ B-NP
acid NN I-NP
, , O
denatured VBD O
ethanol NN B-NP
( -LRB- O
95/5 CD O
ethanol/methanol NN B-NP
) -RRB- O
and CC O
6-7 CD O
% NN O
tetrahydrofuran JJ B-NP
(volume NN O
basis NN O
of IN O
total JJ O
volume NN O
of IN O
ethanol NN B-NP
and CC O
pyrrolidine NN B-NP
) -RRB- O
with IN O
heating NN O
to TO O
30-40<0>C CD O
for IN O
a DT O
minimum NN O
of IN O
16 CD O
hours NNS O
. . O

Once RB O
the DT O
ADD NNP B-NP
content NN O
is VBZ O
less JJR O
than IN O
3 CD O
% NN O
by IN O
HPLC NNP O
area NN O
, , O
becomes VBZ O
static JJ O
or CC O
EX-I JJ O
begins VBZ O
to TO O
revert VB O
to TO O
ADD NNP B-NP
, , O
the DT O
reaction NN O
mixture NN O
is VBZ O
cooled VBN O
to TO O
5 CD O
+ CD O
- : O
5[deg.]C JJ O
, , O

collected VBN O
and CC O
washed VBN O
with IN O
cold JJ O
denatured VBN O
ethanol NN B-NP
. . O

Yields NNS O
are VBP O
typically RB O
70 CD O
- : O
80 CD O
% NN O
on IN O
a DT O
dry JJ O
basis NN O
with IN O
purities NNS O
typically RB O
90 CD O
- : O
95 CD O
% NN O
by IN O
HPLC NNP O
area NN O
percent NN O
. . O

Next JJ O
, , O
6-hydroxymethyl-androsta-l,4-diene-3 JJ B-NP
, , I-NP
17-dione JJ I-NP
( -LRB- O
EX-2 NN O
) -RRB- O
is VBZ O
prepared VBN O
from IN O
l,3-dipyrrolidinoandrosta-355-diene-17-one JJ B-NP
( -LRB- O
EX-I) NN O
. . O

One CD O
set VBN O
of IN O
conditions NNS O
for IN O
the DT O
preparation NN O
employ VBP O
1 CD O
equivalent JJ O
l,3-dipyrrolidinoandrosta-3,5-diene-17-one NN B-NP
( -LRB- O
EX-I) JJ O
and CC O
2.6 CD O
equivalents NNS O
formalin IN B-NP
( -LRB- O
formaldehyde NN B-NP
) -RRB- O
in IN O
10 CD O
mL JJ O
dichloromethane/g NN B-NP
of IN O
EX-I JJ O
at IN O
room NN O
temperature NN O
. . O

Workup NNP O
consists VBZ O
of IN O
acidification NN O
of IN O
the DT O
reaction NN O
mixture NN O
to TO O
a DT O
pH NN O
of IN O
about IN O
2 CD O
, , O
dilution NN O
with IN O
2 CD O
% NN O
sulfuric NN B-NP
acid NN I-NP
( -LRB- O
aqueous JJ O
, , O
volume/volume JJ O
basis NN O
) -RRB- O
and CC O
removal NN O
of IN O
the DT O
organic JJ O
layer NN O
which WDT O
is VBZ O
then RB O
washed VBN O
with IN O
2 CD O
% NN O
sulfuric NN B-NP
acid NN I-NP
(vol/vol NN O
) -RRB- O
and CC O
1 CD O
: : O
1 CD O
water/brine NN B-NP
. . O

Solvent NNP O
exchange NN O
into IN O
toluene NN B-NP
( -LRB- O
approximately RB O
10 CD O
mL/g NN O
theory NN O
EX-2 NN O
) -RRB- O
is VBZ O
then RB O
carried VBN O
out RB O
and CC O
the DT O
product NN O
crystallizes VBZ O
as IN O
toluene NN B-NP
exchange NN O
transpires NNS O
. . O

The DT O
product NN O
is VBZ O
collected VBN O
, , O
washed VBN O
and CC O
dried VBN O
to TO O
provide VB O
6-hydroxymethyl-androsta JJ B-NP
- : I-NP
1 CD I-NP
,A- NNP I-NP
diene-3 NN I-NP
, , I-NP
17-dione CD I-NP
( -LRB- O
EX-2 NN O
) -RRB- O
in IN O
yields NNS O
of IN O
typically RB O
75 CD O
- : O
80 CD O
% NN O
. . O

Purity NNP O
is VBZ O
usually RB O
96 CD O
% NN O
or CC O
greater JJR O
by IN O
HPLC NNP O
area NN O
percent NN O
. . O

Next NNP O
, , O
the DT O
6-hydroxymethyl-androsta-l,4-diene-3,17 CD B-NP
- : I-NP
dione NN I-NP
( -LRB- O
EX-2 NN O
) -RRB- O
may MD O
be VB O
treated VBN O
as IN O
shown VBN O
in IN O
Figure NN O
1 CD O
to TO O
prepare VB O
the DT O
6S JJ O
compound NN O
, , O
which WDT O
is VBZ O
Formula NNP O
( -LRB- O
B NN O
) -RRB- O
above RB O
. . O

In IN O
another DT O
aspect NN O
of IN O
such JJ O
a DT O
method NN O
the DT O
cells NNS O
are VBP O
exposed VBN O
to TO O
a DT O
compound NN O
of IN O
Formula NNP O
( -LRB- O
C NNP O
) -RRB- O
or CC O
pharmaceutically RB O
acceptable JJ O
salts NNS O
or CC O
hydrates NNS B-NP
thereof . O
: : O

[0037] . O

EMI11.1 . O

wherein WRB O
each DT O
OfR1 NNP O
, , O
R2 NNP O
, , O
R3 NNP O
, , O
R4 NNP O
, , O
independently RB O
, , O
is VBZ O
hydrogen NN B-NP
, , O
halogen NN B-NP
or CC O
alkyl NN B-NP
, , O
and CC O
R5 NNP O
is VBZ O
alkyl RB B-NP
. . O

One CD O
specific JJ O
non-limiting JJ O
example NN O
compound NN O
of IN O
Formula NNP O
( -LRB- O
C NNP O
) -RRB- O
has VBZ O
the DT O
Formula NNP O
( -LRB- O
D) NNP O
below IN O
: : O

[0040] . O

EMI11.2 NN O

More RBR O
specifically RB O
showing VBG O
various JJ O
stereochemical JJ O
relationships NNS O
, , O
such JJ O
a DT O
compound NN O
D NN O
can MD O
be VB O
represented VBN O
as IN O

[0042] . O

EMI12.1 . O

The DT O
compound NN O
of IN O
Formula NNP O
( -LRB- O
D) NN O
can MD O
be VB O
referred VBN O
to TO O
as IN O
"6R JJ O
" `` O
or CC O
" `` O
Exemestane NNP B-NP
6R" '' O
. . O

Looking VBG O
at IN O
Figure NN O
2 CD O
, , O
the DT O
compound NN O
of IN O
formula NN O
( -LRB- O
D) NN O
can MD O
be VB O
prepared VBN O
by IN O
reacting VBG O
6- CD B-NP
hydroxymethyl-androsta-l,4-diene-3,17-dione JJ I-NP
( -LRB- O
EX-2 NN O
) -RRB- O
as IN O
shown VBN O
in IN O
Figure NN O
2 CD O
to TO O
produce VB O
exemestane NN B-NP
and CC O
then RB O
reacting VBG O
the DT O
exemestane NN B-NP
as IN O
shown VBN O
in IN O
Figure NN O
2 CD O
to TO O
produce VB O
the DT O
6R JJ O
compound NN O
, , O
which WDT O
is VBZ O
Formula NNP O
( -LRB- O
D) NNP O
above IN O
. . O

To TO O
treat VB O
an DT O
individual/subject NN O
, , O
an DT O
effective JJ O
amount NN O
of IN O
one CD O
or CC O
more JJR O
of IN O
the DT O
present JJ O
compounds NNS O
, , O
or CC O
a DT O
pharmaceutically-acceptable JJ O
salt NN O
thereof RB O
, , O
is VBZ O
administered VBN O
so RB O
as IN O
to TO O
be VB O
exposed VBN O
to TO O
or CC O
contact NN O
cancer NN O
cells NNS O
or CC O
a DT O
tumor NN O
. . O

Effective JJ O
dosage NN O
forms NNS O
, , O
modes NNS O
of IN O
administration NN O
and CC O
dosage NN O
amounts NNS O
may MD O
be VB O
determined VBN O
empirically RB O
, , O
and CC O
making VBG O
such JJ O
determinations NNS O
is VBZ O
within IN O
the DT O
skill NN O
of IN O
the DT O
art NN O
. . O

It PRP O
is VBZ O
understood VBN O
by IN O
those DT O
skilled JJ O
in IN O
the DT O
art NN O
that IN O
the DT O
dosage NN O
amount NN O
will MD O
vary VB O
with IN O
the DT O
activity NN O
of IN O
the DT O
particular JJ O
compound NN O
employed VBN O
, , O
course NN O
and/or CC O
progression NN O
of IN O
the DT O
disease NN O
state NN O
, , O
the DT O
route NN O
of IN O
administration NN O
, , O
the DT O
rate NN O
of IN O
excretion NN O
of IN O
the DT O
compound NN O
, , O
the DT O
duration NN O
of IN O
the DT O
treatment NN O
, , O
the DT O
identity NN O
of IN O
any DT O
other JJ O
drugs NNS O
being VBG O
administered VBN O
to TO O
the DT O
subject NN O
, , O
age NN O
, , O
size NN O
and CC O
like IN O
factors NNS O
well RB O
known VBN O
in IN O
the DT O
medical JJ O
arts NNS O
. . O

In IN O
general JJ O
, , O
a DT O
suitable JJ O
daily JJ O
dose NN O
will MD O
be VB O
that DT O
amount NN O
which WDT O
is VBZ O
the DT O
lowest JJS O
dose NN O
effective JJ O
to TO O
produce VB O
a DT O
therapeutic JJ O
effect NN O
. . O

The DT O
total JJ O
daily JJ O
dosage NN O
will MD O
be VB O
determined VBN O
by IN O
an DT O
attending VBG O
physician NN O
within IN O
the DT O
scope NN O
of IN O
sound JJ O
medical JJ O
judgment NN O
. . O

If IN O
desired VBN O
, , O
the DT O
effective JJ O
daily JJ O
dose NN O
of IN O
such JJ O
a DT O
compound NN O
, , O
or CC O
a DT O
pharmaceutically- NNS O
acceptable JJ O
variation NN O
or CC O
salt NN O
thereof RB O
, , O
maybe RB O
administered VBN O
as IN O
two CD O
, , O
three CD O
, , O
four CD O
, , O
five CD O
, , O
six CD O
or CC O
more JJR O
sub-doses NNS O
, , O
administered VBN O
separately RB O
at IN O
appropriate JJ O
intervals NNS O
throughout IN O
the DT O
day NN O
. . O

Treatment NNP O
includes VBZ O
mitigation NN O
, , O
as RB O
well RB O
as IN O
elimination NN O
, , O
of IN O
the DT O
disease NN O
state NN O
. . O

Compounds NNS O
of IN O
this DT O
invention NN O
may MD O
be VB O
administered VBN O
to TO O
patient NN O
for IN O
therapy NN O
by IN O
any DT O
suitable JJ O
route NN O
of IN O
administration NN O
, , O
including VBG O
orally NNP O
, , O
nasally RB O
, , O
rectally RB O
, , O
intravaginally RB O
, , O
parenterally RB O
, , O
intracisternally RB O
and CC O
topically RB O
, , O
as IN O
by IN O
powders NNS O
, , O
ointments NNS O
or CC O
drops NNS O
, , O
including VBG O
buccally NN O
and CC O
sublingually RB O
. . O

The DT O
preferred JJ O
routes NNS O
of IN O
administration NN O
are VBP O
orally RB O
and CC O
parenterally RB O
. . O

While IN O
it PRP O
is VBZ O
possible JJ O
for IN O
the DT O
active JJ O
ingredient( NN O
s VBZ O
) -RRB- O
( -LRB- O
one CD O
or CC O
more JJR O
compounds NNS O
of IN O
this DT O
invention NN O
and/or CC O
pharmaceutically-acceptable JJ O
salts NNS O
thereof RB O
, , O
alone RB O
or CC O
in IN O
combination NN O
with IN O
another DT O
therapeutic JJ O
agent NN O
) -RRB- O
to TO O
be VB O
administered VBN O
alone RB O
, , O
it PRP O
is VBZ O
preferable JJ O
to TO O
administer VB O
the DT O
active JJ O
ingredient( NN O
s VBZ O
) -RRB- O
as IN O
a DT O
pharmaceutical JJ O
formulation NN O
( -LRB- O
composition NN O
) -RRB- O
. . O

The DT O
pharmaceutical JJ O
compositions NNS O
of IN O
the DT O
invention NN O
comprise NN O
the DT O
active JJ O
ingredient( NN O
s VBZ O
) -RRB- O
in IN O
admixture NN O
with IN O
one CD O
or CC O
more JJR O
pharmaceutically-acceptable JJ O
carriers NNS O
and CC O
, , O
optionally RB O
, , O
with IN O
one CD O
or CC O
more JJR O
other JJ O
compounds NNS O
, , O
drugs NNS O
or CC O
other JJ O
materials NNS O
. . O

Each DT O
carrier NN O
must MD O
be VB O
"acceptable JJ O
" '' O
in IN O
the DT O
sense NN O
of IN O
being VBG O
compatible JJ O
with IN O
the DT O
other JJ O
ingredients NNS O
of IN O
the DT O
formulation NN O
and CC O
not RB O
injurious JJ O
to TO O
the DT O
patient NN O
. . O

Pharmaceutical NNP O
formulations NNS O
of IN O
the DT O
present JJ O
invention NN O
include VBP O
those DT O
suitable JJ O
for IN O
oral JJ O
, , O
nasal JJ O
, , O
topical JJ O
( -LRB- O
including VBG O
buccal JJ O
and CC O
sublingual JJ O
) -RRB- O
, , O
rectal JJ O
, , O
vaginal JJ O
and/or CC O
parenteral JJ O
administration NN O
. . O

Regardless RB O
of IN O
the DT O
route NN O
of IN O
administration NN O
selected VBN O
, , O
the DT O
active JJ O
ingredient( NN O
s VBZ O
) -RRB- O
are VBP O
formulated VBN O
into IN O
pharmaceutically-acceptable JJ O
dosage NN O
forms NNS O
by IN O
conventional JJ O
methods NNS O
known VBN O
to TO O
those DT O
of IN O
skill NN O
in IN O
the DT O
art NN O
. . O

The DT O
amount NN O
of IN O
the DT O
active JJ O
ingredient( NN O
s VBZ O
) -RRB- O
which WDT O
will MD O
be VB O
combined VBN O
with IN O
a DT O
carrier NN O
material NN O
to TO O
produce VB O
a DT O
single JJ O
dosage NN O
form NN O
will MD O
vary VB O
depending VBG O
upon IN O
the DT O
host NN O
being VBG O
treated VBN O
, , O
the DT O
particular JJ O
mode NN O
of IN O
administration NN O
and CC O
all DT O
of IN O
the DT O
other JJ O
factors NNS O
described VBN O
above IN O
. . O

The DT O
amount NN O
of IN O
the DT O
active JJ O
ingredient( NN O
s VBZ O
) -RRB- O
which WDT O
will MD O
be VB O
combined VBN O
with IN O
a DT O
carrier NN O
material NN O
to TO O
produce VB O
a DT O
single JJ O
dosage NN O
form NN O
will MD O
generally RB O
be VB O
that DT O
amount NN O
of IN O
the DT O
active JJ O
ingredient( NN O
s VBZ O
) -RRB- O
which WDT O
is VBZ O
the DT O
lowest JJS O
dose NN O
effective JJ O
to TO O
produce VB O
a DT O
therapeutic JJ O
effect NN O
. . O

Methods NNS O
of IN O
preparing VBG O
pharmaceutical JJ O
formulations NNS O
or CC O
compositions NNS O
include VBP O
the DT O
step NN O
of IN O
bringing VBG O
the DT O
active JJ O
ingredient( NN O
s VBZ O
) -RRB- O
into IN O
association NN O
with IN O
the DT O
carrier NN O
and CC O
, , O
optionally RB O
, , O
one CD O
or CC O
more JJR O
accessory JJ O
ingredients NNS O
. . O

In IN O
general JJ O
, , O
the DT O
formulations NNS O
are VBP O
prepared VBN O
by IN O
uniformly RB O
and CC O
intimately RB O
bringing VBG O
the DT O
active JJ O
ingredient( NN O
s VBZ O
) -RRB- O
into IN O
association NN O
with IN O
liquid JJ O
carriers NNS O
, , O
or CC O
finely RB O
divided VBN O
solid JJ O
carriers NNS O
, , O
or CC O
both DT O
, , O
and CC O
then RB O
, , O
if IN O
necessary JJ O
, , O
shaping VBG O
the DT O
product NN O
. . O

Formulations NNS O
of IN O
the DT O
invention NN O
suitable JJ O
for IN O
oral JJ O
administration NN O
may MD O
be VB O
in IN O
the DT O
form NN O
of IN O
capsules NNS O
, , O
cachets NNS O
, , O
pills NNS O
, , O
tablets NNS O
, , O
lozenges NNS O
(using VBG O
a DT O
flavored JJ O
basis NN O
, , O
usually RB O
sucrose JJ B-NP
and CC O
acacia NN O
or CC O
tragacanth NN O
) -RRB- O
, , O
powders NNS O
, , O
granules NNS O
, , O
or CC O
as IN O
a DT O
solution NN O
or CC O
a DT O
suspension NN O
in IN O
an DT O
aqueous JJ O
or CC O
nonaqueous JJ O
liquid NN O
, , O
or CC O
as IN O
an DT O
oil-in-water NN O
or CC O
water-in-oil NN B-NP
liquid NN O
emulsion NN O
, , O
or CC O
as IN O
an DT O
elixir NN O
or CC O
syrup NN O
, , O
or CC O
as IN O
pastilles NNS O
(using VBG O
an DT O
inert JJ O
base NN O
, , O
such JJ O
as IN O
gelatin NN O
and CC O
glycerin NN B-NP
, , O
or CC O
sucrose NN B-NP
and CC O
acacia NN O
) -RRB- O
and/or CC O
as IN O
mouth NN O
washes NNS O
and CC O
the DT O
like JJ O
, , O
each DT O
containing VBG O
a DT O
predetermined JJ O
amount NN O
of IN O
the DT O
active JJ O
ingredient( NN O
s VBZ O
) -RRB- O
. . O

The DT O
active JJ O
ingredient( NN O
s VBZ O
) -RRB- O
may MD O
also RB O
be VB O
administered VBN O
as IN O
a DT O
bolus NN O
, , O
electuary JJ O
or CC O
paste NN O
. . O

In IN O
solid JJ O
dosage NN O
forms NNS O
of IN O
the DT O
invention NN O
for IN O
oral JJ O
administration NN O
( -LRB- O
capsules NNS O
, , O
tablets NNS O
, , O
pills NNS O
, , O
dragees NNS O
, , O
powders NNS O
, , O
granules NNS O
and CC O
the DT O
like JJ O
) -RRB- O
, , O
the DT O
active JJ O
ingredient( NN O
s VBZ O
) -RRB- O
is/are NN O
mixed JJ O
with IN O
one CD O
or CC O
more JJR O
pharmaceutically-acceptable JJ O
carriers NNS O
, , O
such JJ O
as IN O
sodium NN B-NP
citrate NN I-NP
or CC O
dicalcium NN B-NP
phosphate NN I-NP
, , O
and/or CC O
any DT O
of IN O
the DT O
following NN O
: : O
( -LRB- O
1 CD O
) -RRB- O
fillers NNS O
or CC O
extenders NNS O
, , O
such JJ O
as IN O
starches NNS B-NP
, , O
lactose NN B-NP
, , O
sucrose NN B-NP
, , O
glucose NN B-NP
, , O
mannitol NN B-NP
, , O
and/or CC O
silicic JJ B-NP
acid NN I-NP
; : O
( -LRB- O
2 CD O
) -RRB- O
binders NNS O
, , O
such JJ O
as IN O
, , O
for IN O
example NN O
, , O
carboxymethyl-cellulose NN B-NP
, , O
alginates NNS O
, , O
gelatin NN O
, , O
polyvinyl NN B-NP
pyrrolidone NN I-NP
, , O
sucrose VBD B-NP
and/or IN O
acacia NN O
; : O
( -LRB- O
3 CD O
) -RRB- O
humectants NNS O
, , O
such JJ O
as IN O
glycerol NN B-NP
; : O
( -LRB- O
4 CD O
) -RRB- O
disintegrating VBG O
agents NNS O
, , O
such JJ O
as IN O
agar-agar JJ O
, , O
calcium NN B-NP
carbonate NN I-NP
, , O
potato NN O
or CC O
tapioca NN O
starch NN B-NP
, , O
alginic JJ B-NP
acid NN I-NP
, , O
certain JJ O
silicates NNS B-NP
, , O
and CC O
sodium NN B-NP
carbonate NN I-NP
; : O
( -LRB- O
5 CD O
) -RRB- O
solution NN O
retarding VBG O
agents NNS O
, , O
such JJ O
as IN O
paraffin NN O
; : O

( -LRB- O
6 CD O
) -RRB- O
absorption NN O
accelerators NNS O
, , O
such JJ O
as IN O
quaternary JJ B-NP
ammonium NN I-NP
compounds NNS I-NP
; : O
( -LRB- O
7 CD O
) -RRB- O
wetting VBG O
agents NNS O
, , O
such JJ O
as IN O
, , O
for IN O
example NN O
, , O
cetyl JJ B-NP
alcohol NN I-NP
and CC O
glycerol NN B-NP
monostearate NN I-NP
; : O
( -LRB- O
8 CD O
) -RRB- O
absorbents NNS O
, , O
such JJ O
as IN O
kaolin NN O
and CC O
bentonite JJ B-NP
clay NN O
; : O
( -LRB- O
9 CD O
) -RRB- O
lubricants NNS O
, , O
such JJ O
as IN O
talc NN B-NP
, , O
calcium NN B-NP
stearate NN I-NP
, , O
magnesium NN B-NP
stearate NN I-NP
, , O
solid JJ O
polyethylene NN B-NP
glycols NNS I-NP
, , O
sodium NN B-NP
lauryl NN I-NP
sulfate NN I-NP
, , O
and CC O
mixtures NNS O
thereof , O
; : O
and CC O
( -LRB- O
10 CD O
) -RRB- O
coloring VBG O
agents NNS O
. . O

In IN O
the DT O
case NN O
of IN O
capsules NNS O
, , O
tablets NNS O
and CC O
pills NNS O
, , O
the DT O
pharmaceutical JJ O
compositions NNS O
may MD O
also RB O
comprise VB O
buffering VBG O
agents NNS O
. . O

Solid JJ O
compositions NNS O
of IN O
a DT O
similar JJ O
type NN O
may MD O
also RB O
be VB O
employed VBN O
as IN O
fillers NNS O
in IN O
soft JJ O
and CC O
hard-filled JJ O
gelatin NN O
capsules NNS O
using VBG O
such JJ O
excipients NNS O
as IN O
lactose NN B-NP
or CC O
milk NN O
sugars NNS B-NP
, , O
as RB O
well RB O
as IN O
high JJ O
molecular JJ O
weight NN O
polyethylene NN B-NP
glycols NNS I-NP
and CC O
the DT O
like JJ O
. . O

A DT O
tablet NN O
may MD O
be VB O
made VBN O
by IN O
compression NN O
or CC O
molding NN O
, , O
optionally RB O
with IN O
one CD O
or CC O
more JJR O
accessory JJ O
ingredients NNS O
. . O

Compressed VBN O
tablets NNS O
may MD O
be VB O
prepared VBN O
using VBG O
binder NN O
( -LRB- O
for IN O
example NN O
, , O
gelatin NN O
or CC O
hydroxypropylmethyl NN B-NP
cellulose NN I-NP
) -RRB- O
, , O
lubricant JJ O
, , O
inert JJ O
diluent JJ O
, , O
preservative JJ O
, , O
disintegrant JJ O
( -LRB- O
for IN O
example NN O
, , O
sodium NN B-NP
starch NN I-NP
glycolate NN I-NP
or CC O
cross-linked JJ O
sodium NN B-NP
carboxymethyl NN I-NP
cellulose NN I-NP
) -RRB- O
, , O
surface-active JJ O
or CC O
dispersing JJ O
agent NN O
. . O

Molded JJ O
tablets NNS O
may MD O
be VB O
made VBN O
by IN O
molding NN O
in IN O
a DT O
suitable JJ O
machine NN O
a DT O
mixture NN O
of IN O
the DT O
powdered JJ O
active JJ O
ingredient( NN O
s VBZ O
) -RRB- O
moistened VBN O
with IN O
an DT O
inert JJ O
liquid NN O
diluent NN O
. . O

The DT O
tablets NNS O
, , O
and CC O
other JJ O
solid JJ O
dosage NN O
forms NNS O
of IN O
the DT O
pharmaceutical JJ O
compositions NNS O
of IN O
the DT O
present JJ O
invention NN O
, , O
such JJ O
as IN O
dragees NNS O
, , O
capsules NNS O
, , O
pills NNS O
and CC O
granules NNS O
, , O
may MD O
optionally RB O
be VB O
scored VBN O
or CC O
prepared VBN O
with IN O
coatings NNS O
and CC O
shells NNS O
, , O
such JJ O
as IN O
enteric JJ O
coatings NNS O
and CC O
other JJ O
coatings NNS O
well RB O
known VBN O
in IN O
the DT O
pharmaceutical-formulating JJ O
art NN O
. . O

They PRP O
may MD O
also RB O
be VB O
formulated VBN O
so RB O
as RB O
to TO O
provide VB O
slow JJ O
or CC O
controlled JJ O
release NN O
of IN O
the DT O
active JJ O
ingredient( NN O
s VBZ O
) -RRB- O
therein RB O
using VBG O
, , O
for IN O
example NN O
, , O
hydroxypropylmethyl NN B-NP
cellulose NN I-NP
in IN O
varying VBG O
proportions NNS O
to TO O
provide VB O
the DT O
desired VBN O
release NN O
profile NN O
, , O
other JJ O
polymer NN O
matrices NNS O
, , O
liposomes NNS O
and/or CC O
microspheres NNS O
. . O

They PRP O
may MD O
be VB O
sterilized VBN O
by IN O
, , O
for IN O
example NN O
, , O
filtration NN O
through IN O
a DT O
bacteria NNS O
- : O
retaining VBG O
filter NN O
. . O

These DT O
compositions NNS O
may MD O
also RB O
optionally RB O
contain VBP O
opacifying VBG O
agents NNS O
and CC O
may MD O
be VB O
of IN O
a DT O
composition NN O
that IN O
they PRP O
release VBP O
the DT O
active JJ O
ingredient( NN O
s VBZ O
) -RRB- O
only RB O
, , O
or CC O
preferentially RB O
, , O
in IN O
a DT O
certain JJ O
portion NN O
of IN O
the DT O
gastrointestinal JJ O
tract NN O
, , O
optionally RB O
, , O
in IN O
a DT O
delayed JJ O
manner NN O
. . O

Examples NNS O
of IN O
embedding VBG O
compositions NNS O
which WDT O
can MD O
be VB O
used VBN O
include VBP O
polymeric JJ O
substances NNS O
and CC O
waxes NNS O
. . O

The DT O
active JJ O
ingredient( NN O
s VBZ O
) -RRB- O
can MD O
also RB O
be VB O
in IN O
microencapsulated JJ O
form NN O
. . O

Liquid JJ O
dosage NN O
forms NNS O
for IN O
oral JJ O
administration NN O
of IN O
the DT O
active JJ O
ingredient( NN O
s VBZ O
) -RRB- O
include VBP O
pharmaceutically-acceptable JJ O
emulsions NNS O
, , O
microemulsions NNS O
, , O
solutions NNS O
, , O
suspensions NNS O
, , O
syrups NNS O
and CC O
elixirs NNS O
. . O

In IN O
addition NN O
to TO O
the DT O
active JJ O
ingredient( NN O
s VBZ O
) -RRB- O
, , O
the DT O
liquid JJ O
dosage NN O
forms NNS O
may MD O
contain VB O
inert JJ O
diluents NNS O
commonly RB O
used VBN O
in IN O
the DT O
art NN O
, , O
such JJ O
as IN O
, , O
for IN O
example NN O
, , O
water NN B-NP
or CC O
other JJ O
solvents NNS O
, , O
solubilizing VBG O
agents NNS O
and CC O
emulsifiers NNS O
, , O
such JJ O
as IN O
ethyl NN B-NP
alcohol NN I-NP
, , O
isopropyl NN B-NP
alcohol NN I-NP
, , O
ethyl NN B-NP
carbonate NN I-NP
, , O
ethyl NN B-NP
acetate NN I-NP
, , O
benzyl JJ B-NP
alcohol NN I-NP
, , O
benzyl NN B-NP
benzoate NN I-NP
, , O
propylene NN B-NP
glycol NN I-NP
, , O
1,3-butylene JJ B-NP
glycol NN I-NP
, , O
oils NNS O
( -LRB- O
in IN O
particular JJ O
, , O
cottonseed JJ O
, , O
groundnut NN O
, , O
corn NN O
, , O
germ NN O
, , O
olive JJ O
, , O
castor NN O
and CC O
sesame JJ O
oils NNS O
) -RRB- O
, , O
glycerol NN B-NP
, , O
tetrahydrofuryl JJ B-NP
alcohol NN I-NP
, , O
polyethylene NN B-NP
glycols NNS I-NP
and CC O
fatty JJ B-NP
acid NN I-NP
esters NNS I-NP
of IN O
sorbitan JJ B-NP
, , O
and CC O
mixtures NNS O
thereof RB O
. . O

Besides IN O
inert JJ O
diluents NNS O
, , O
the DT O
oral JJ O
compositions NNS O
can MD O
also RB O
include VB O
adjuvants NNS O
such JJ O
as IN O
wetting VBG O
agents NNS O
, , O
emulsifying VBG O
and CC O
suspending VBG O
agents NNS O
, , O
sweetening VBG O
, , O
flavoring VBG O
, , O
coloring VBG O
, , O
perfuming VBG O
and CC O
preservative JJ O
agents NNS O
. . O

Suspensions NNS O
, , O
in IN O
addition NN O
to TO O
the DT O
active JJ O
ingredient( NN O
s VBZ O
) -RRB- O
, , O
may MD O
contain VB O
suspending VBG O
agents NNS O
as IN O
, , O
for IN O
example NN O
, , O
ethoxylated VBD O
isostearyl NN B-NP
alcohols NNS I-NP
, , O
polyoxyethylene NN B-NP
sorbitol NN B-NP
and CC O
sorbitan JJ B-NP
esters NNS O
, , O
microcrystalline NN O
cellulose NN B-NP
, , O
aluminum NN B-NP
metahydroxide NN I-NP
, , O
bentonite JJ B-NP
, , O
agar-agar JJ O
and CC O
tragacanth NN O
, , O
and CC O
mixtures NNS O
thereof RB O
. . O

Formulations NNS O
of IN O
the DT O
pharmaceutical JJ O
compositions NNS O
of IN O
the DT O
invention NN O
for IN O
rectal JJ O
or CC O
vaginal JJ O
administration NN O
may MD O
be VB O
presented VBN O
as IN O
a DT O
suppository NN O
, , O
which WDT O
may MD O
be VB O
prepared VBN O
by IN O
mixing VBG O
the DT O
active JJ O
ingredient( NN O
s VBZ O
) -RRB- O
with IN O
one CD O
or CC O
more JJR O
suitable JJ O
nonin[iota]tating NN O
excipients NNS O
or CC O
carriers NNS O
comprising NN O
, , O
for IN O
example NN O
, , O
cocoa NN O
butter NN O
, , O
polyethylene NN B-NP
glycol NN I-NP
, , O
a DT O
suppository NN O
wax NN O
or CC O
salicylate NN B-NP
and CC O
which WDT O
is VBZ O
solid JJ O
at IN O
room NN O
temperature NN O
, , O
but CC O
liquid JJ O
at IN O
body NN O
temperature NN O
and CC O
, , O
therefore RB O
, , O
will MD O
melt VB O
in IN O
the DT O
rectum NN O
or CC O
vaginal JJ O
cavity NN O
and CC O
release VB O
the DT O
active JJ O
ingredient( NN O
s VBZ O
) -RRB- O
. . O

Formulations NNS O
of IN O
the DT O
present JJ O
invention NN O
which WDT O
are VBP O
suitable JJ O
for IN O
vaginal JJ O
administration NN O
also RB O
include VBP O
pessaries NNS O
, , O
tampons NNS O
, , O
creams NNS O
, , O
gels NNS O
, , O
pastes NNS O
, , O
foams NNS O
or CC O
spray NN O
formulations NNS O
containing VBG O
such JJ O
carriers NNS O
as IN O
are VBP O
known VBN O
in IN O
the DT O
art NN O
to TO O
be VB O
appropriate JJ O
. . O

Dosage VB O
forms NNS O
for IN O
the DT O
topical JJ O
or CC O
transdermal JJ O
administration NN O
of IN O
the DT O
active JJ O
ingredient( NN O
s VBZ O
) -RRB- O
include VBP O
powders NNS O
, , O
sprays NNS O
, , O
ointments NNS O
, , O
pastes NNS O
, , O
creams NNS O
, , O
lotions NNS O
, , O
gels NNS O
, , O
solutions NNS O
, , O
patches NNS O
and CC O
inhalants NNS O
. . O

The DT O
active JJ O
ingredient( NN O
s VBZ O
) -RRB- O
may MD O
be VB O
mixed JJ O
under IN O
sterile JJ O
conditions NNS O
with IN O
a DT O
pharmaceutically-acceptable JJ O
carrier NN O
, , O
and CC O
with IN O
any DT O
buffers NNS O
, , O
or CC O
propellants NNS O
which WDT O
may MD O
be VB O
required VBN O
. . O

The DT O
ointments NNS O
, , O
pastes NNS O
, , O
creams NNS O
and CC O
gels NNS O
may MD O
contain VB O
, , O
in IN O
addition NN O
to TO O
the DT O
active JJ O
ingredient( NN O
s VBZ O
) -RRB- O
, , O
excipients NNS O
, , O
such JJ O
as IN O
animal NN O
and CC O
vegetable NN O
fats NNS O
, , O
oils NNS O
, , O
waxes NNS O
, , O
paraffins NNS O
, , O
starch NN B-NP
, , O
tragacanth NN O
, , O
cellulose JJ B-NP
derivatives NNS O
, , O
polyethylene NN B-NP
glycols NNS I-NP
, , O
silicones NNS B-NP
, , O
bentonites NNS B-NP
, , O
silicic JJ B-NP
acid NN I-NP
, , O
talc NN B-NP
and CC O
zinc NN B-NP
oxide NN I-NP
, , O
or CC O
mixtures NNS O
thereof RB O
. . O

Powders NNS O
and CC O
sprays NNS O
can MD O
contain VB O
, , O
in IN O
addition NN O
to TO O
the DT O
active JJ O
ingredient( NN O
s VBZ O
) -RRB- O
, , O
excipients NNS O
such JJ O
as IN O
lactose NN B-NP
, , O
talc NN B-NP
, , O
silicic JJ B-NP
acid NN I-NP
, , O
aluminum NN B-NP
hydroxide NN I-NP
, , O
calcium NN B-NP
silicates NNS I-NP
and CC O
polyamide NN B-NP
powder NN O
, , O
or CC O
mixtures NNS O
of IN O
these DT O
substances NNS O
. . O

Sprays NNS O
can MD O
additionally RB O
contain VB O
customary JJ O
propellants NNS O
such JJ O
as IN O
chlorofluorohydrocarbons NNS B-NP
and CC O
volatile JJ O
unsubstituted JJ O
hydrocarbons NNS B-NP
, , O
such JJ O
as IN O
butane NN B-NP
and CC O
propane NN B-NP
. . O

Transdermal JJ O
patches NNS O
have VBP O
the DT O
added VBN O
advantage NN O
of IN O
providing VBG O
controlled JJ O
delivery NN O
of IN O
the DT O
active JJ O
ingredient( NN O
s VBZ O
) -RRB- O
to TO O
the DT O
body NN O
. . O

Such JJ O
dosage NN O
forms NNS O
can MD O
be VB O
made VBN O
by IN O
dissolving VBG O
, , O
dispersing VBG O
or CC O
otherwise RB O
incorporating VBG O
the DT O
active JJ O
ingredient( NN O
s VBZ O
) -RRB- O
in IN O
a DT O
proper JJ O
medium NN O
, , O
such JJ O
as IN O
an DT O
elastomeric JJ O
matrix NN O
material NN O
. . O

Absorption NN O
enhancers NNS O
can MD O
also RB O
be VB O
used VBN O
to TO O
increase VB O
the DT O
flux NN O
of IN O
the DT O
active JJ O
ingredient( NN O
s VBZ O
) -RRB- O
across IN O
the DT O
skin NN O
. . O

The DT O
rate NN O
of IN O
such JJ O
flux NN O
can MD O
be VB O
controlled VBN O
by IN O
either DT O
providing VBG O
a DT O
rate-controlling NN O
membrane NN O
or CC O
dispersing VBG O
the DT O
active JJ O
ingredient( NN O
s VBZ O
) -RRB- O
in IN O
a DT O
polymer NN O
matrix NN O
or CC O
gel NN O
. . O

Pharmaceutical NNP O
compositions NNS O
of IN O
this DT O
invention NN O
suitable JJ O
for IN O
parenteral JJ O
administration NN O
comprise NN O
the DT O
active JJ O
ingredient( NN O
s VBZ O
) -RRB- O
in IN O
combination NN O
with IN O
one CD O
or CC O
more JJR O
pharmaceutically-acceptable JJ O
sterile JJ O
isotonic JJ O
aqueous JJ O
or CC O
nonaqueous JJ O
solutions NNS O
, , O
dispersions NNS O
, , O
suspensions NNS O
or CC O
emulsions NNS O
, , O
or CC O
sterile JJ O
powders NNS O
which WDT O
may MD O
be VB O
reconstituted VBN O
into IN O
sterile JJ O
injectable JJ O
solutions NNS O
or CC O
dispersions NNS O
just RB O
prior RB O
to TO O
use VB O
, , O
which WDT O
may MD O
contain VB O
antioxidants NNS O
, , O
buffers NNS O
, , O
solutes NNS O
which WDT O
render VBP O
the DT O
formulation NN O
isotonic JJ O
with IN O
the DT O
blood NN O
of IN O
the DT O
intended JJ O
recipient NN O
or CC O
suspending NN O
or CC O
thickening VBG O
agents NNS O
. . O

Examples NNS O
of IN O
suitable JJ O
aqueous JJ O
and CC O
nonaqueous JJ O
carriers NNS O
which WDT O
may MD O
be VB O
employed VBN O
in IN O
the DT O
pharmaceutical JJ O
compositions NNS O
of IN O
the DT O
invention NN O
include VBP O
water NN B-NP
, , O
ethanol NN B-NP
, , O
polyols NNS B-NP
( -LRB- O
such JJ O
as IN O
glycerol NN B-NP
, , O
propylene NN B-NP
glycol NN I-NP
, , O
polyethylene NN B-NP
glycol NN I-NP
, , O
and CC O
the DT O
like JJ O
) -RRB- O
, , O
and CC O
suitable JJ O
mixtures NNS O
thereof RB O
, , O
vegetable NN O
oils NNS O
, , O
such JJ O
as IN O
olive JJ O
oil NN O
, , O
and CC O
injectable JJ O
organic JJ O
esters NNS O
, , O

such JJ O
as IN O
ethyl NN B-NP
oleate NN I-NP
. . O

Proper NNP O
fluidity NN O
can MD O
be VB O
maintained VBN O
, , O
for IN O
example NN O
, , O
by IN O
the DT O
use NN O
of IN O
coating NN O
materials NNS O
, , O
such JJ O
as IN O
lecithin JJ B-NP
, , O
by IN O
the DT O
maintenance NN O
of IN O
the DT O
required JJ O
particle NN O
size NN O
in IN O
the DT O
case NN O
of IN O
dispersions NNS O
, , O
and CC O
by IN O
the DT O
use NN O
of IN O
surfactants NNS O
. . O

These DT O
compositions NNS O
may MD O
also RB O
contain VB O
adjuvants NNS O
such JJ O
as IN O
wetting VBG O
agents NNS O
, , O
emulsifying VBG O
agents NNS O
and CC O
dispersing VBG O
agents NNS O
. . O

It PRP O
may MD O
also RB O
be VB O
desirable JJ O
to TO O
include VB O
isotonic JJ O
agents NNS O
, , O
such JJ O
as IN O
sugars NNS B-NP
, , O
sodium NN B-NP
chloride NN I-NP
, , O
and CC O
the DT O
like JJ O
in IN O
the DT O
compositions NNS O
. . O

In IN O
addition NN O
, , O
prolonged VBN O
absorption NN O
of IN O
the DT O
injectable JJ O
pharmaceutical JJ O
form NN O
may MD O
be VB O
brought VBN O
about RB O
by IN O
the DT O
inclusion NN O
of IN O
agents NNS O
which WDT O
delay VBP O
absorption NN O
such JJ O
as IN O
aluminum NN B-NP
monostearate NN I-NP
and CC O
gelatin NN O
. . O

In IN O
some DT O
cases NNS O
, , O
in IN O
order NN O
to TO O
prolong VB O
the DT O
effect NN O
of IN O
the DT O
active JJ O
ingredient( NN O
s VBZ O
) -RRB- O
, , O
it PRP O
is VBZ O
desirable JJ O
to TO O
slow VB O
the DT O
absorption NN O
of IN O
the DT O
drag NN O
from IN O
subcutaneous JJ O
or CC O
intramuscular JJ O
injection NN O
. . O

This DT O
may MD O
be VB O
accomplished VBN O
by IN O
the DT O
use NN O
of IN O
a DT O
liquid JJ O
suspension NN O
of IN O
crystalline NN O
or CC O
amorphous JJ O
material NN O
having VBG O
poor JJ O
water NN B-NP
solubility NN O
. . O

The DT O
rate NN O
of IN O
absorption NN O
of IN O
the DT O
active JJ O
ingredient( NN O
s VBZ O
) -RRB- O
then RB O
depends VBZ O
upon IN O
its/their PRP$ O
rate NN O
of IN O
dissolution NN O
which WDT O
, , O
in IN O
turn NN O
, , O
may MD O
depend VB O
upon IN O
crystal NN O
size NN O
and CC O
crystalline NN O
form NN O
. . O

Alternatively RB O
, , O
delayed VBN O
absorption NN O
of IN O
parenterally-administered JJ O
active JJ O
ingredient( NN O
s VBZ O
) -RRB- O
is VBZ O
accomplished VBN O
by IN O
dissolving VBG O
or CC O
suspending VBG O
the DT O
active JJ O
ingredient( NN O
s VBZ O
) -RRB- O
in IN O
an DT O
oil NN O
vehicle NN O
. . O

Injectable JJ O
depot NN O
forms NNS O
are VBP O
made VBN O
by IN O
forming VBG O
microencapsule JJ O
matrices NNS O
of IN O
the DT O
active JJ O
ingredient( NN O
s VBZ O
) -RRB- O
in IN O
biodegradable JJ O
polymers NNS O
such JJ O
as IN O
polylactide-polyglycolide NN B-NP
. . O
Depending VBG O
on IN O
the DT O
ratio NN O
of IN O
the DT O
active JJ O
ingredient( NN O
s VBZ O
) -RRB- O
to TO O
polymer NN O
, , O
and CC O
the DT O
nature NN O
of IN O
the DT O
particular JJ O
polymer NN O
employed VBN O
, , O
the DT O
rate NN O
of IN O
release NN O
of IN O
the DT O
active JJ O
ingredient( NN O
s VBZ O
) -RRB- O
can MD O
be VB O
controlled VBN O
. . O

Examples NNS O
of IN O
other JJ O
biodegradable JJ O
polymers NNS O
include VBP O
poly(orthoesters NNS B-NP
) -RRB- I-NP
and CC O
poly(anhydrides NNS B-NP
) -RRB- I-NP
. . O

Depot NNP O
injectable JJ O
formulations NNS O
are VBP O
also RB O
prepared VBN O
by IN O
entrapping VBG O
the DT O
active JJ O
ingredient( NN O
s VBZ O
) -RRB- O
in IN O
liposomes NNS O
or CC O
microemulsions NNS O
which WDT O
are VBP O
compatible JJ O
with IN O
body NN O
tissue NN O
. . O

The DT O
injectable JJ O
materials NNS O
can MD O
be VB O
sterilized VBN O
for IN O
example NN O
, , O
by IN O
filtration NN O
through IN O
a DT O
bacterial-retaining JJ O
filter NN O
. . O

The DT O
formulations NNS O
may MD O
be VB O
presented VBN O
in IN O
unit-dose NN O
or CC O
multi-dose JJ O
sealed JJ O
containers NNS O
, , O
for IN O
example NN O
, , O
ampoules NNS O
and CC O
vials NNS O
, , O
and CC O
may MD O
be VB O
stored VBN O
in IN O
a DT O
lyophilized JJ O
condition NN O
requiring VBG O
only RB O
the DT O
addition NN O
of IN O
the DT O
sterile JJ O
liquid NN O
carrier NN O
, , O
for IN O
example NN O
water NN B-NP
for IN O
injection NN O
, , O
immediately RB O
prior RB O
to TO O
use VB O
. . O

Extemporaneous JJ O
injection NN O
solutions NNS O
and CC O
suspensions NNS O
maybe RB O
prepared VBN O
from IN O
sterile JJ O
powders NNS O
, , O
granules NNS O
and CC O
tablets NNS O
of IN O
the DT O
type NN O
described VBN O
above IN O
. . O

The DT O
pharmaceutical JJ O
compositions NNS O
of IN O
the DT O
present JJ O
invention NN O
may MD O
also RB O
be VB O
used VBN O
in IN O
the DT O
form NN O
of IN O
veterinary JJ O
formulations NNS O
, , O
including VBG O
those DT O
adapted VBN O
for IN O
the DT O
following NN O
: : O
( -LRB- O
1 CD O
) -RRB- O
oral JJ O
administration NN O
, , O
for IN O
example NN O
, , O
drenches NNS O
( -LRB- O
aqueous JJ O
or CC O
nonaqueous JJ O
solutions NNS O
or CC O
suspensions NNS O
) -RRB- O
, , O
tablets NNS O
, , O
boluses NNS O
, , O
powders NNS O
, , O
granules NNS O
or CC O
pellets NNS O
for IN O
admixture NN O
with IN O
feed NN O
stuffs NNS O
, , O
pastes NNS O
for IN O
application NN O
to TO O
the DT O
tongue NN O
; : O
( -LRB- O
2 CD O
) -RRB- O
parenteral JJ O
administration NN O
, , O
for IN O
example NN O
, , O
by IN O
subcutaneous JJ O
, , O
intramuscular JJ O
or CC O
intravenous JJ O
injection NN O
as IN O
, , O
for IN O
example NN O
, , O
a DT O
sterile JJ O
solution NN O
or CC O
suspension NN O
or CC O
, , O
when WRB O
appropriate JJ O
, , O
by IN O
intramammary JJ O
injection NN O
where WRB O
a DT O
suspension NN O
or CC O
solution NN O
is VBZ O
introduced VBN O
into IN O
the DT O
udder NN O
of IN O
the DT O
animal NN O
via IN O
its PRP$ O
teat NN O
; : O

( -LRB- O
3 CD O
) -RRB- O
topical JJ O
application NN O
, , O
for IN O
example NN O
, , O
as IN O
a DT O
cream NN O
, , O
ointment NN O
or CC O
spray NN O
applied VBD O
to TO O
the DT O
skin NN O
; : O
or CC O
( -LRB- O
4 CD O
) -RRB- O
intravaginally RB O
, , O
for IN O
example NN O
, , O
as IN O
a DT O
pessary NN O
, , O
cream NN O
or CC O
foam NN O
. . O

Examples NNS O
of IN O
the DT O
Invention NNP O
. . O

The DT O
following VBG O
non-limiting JJ O
examples NNS O
and CC O
data NNS O
illustrate VBP O
various JJ O
aspects NNS O
and CC O
features NNS O
relating VBG O
to TO O
the DT O
compounds NNS O
, , O
compositions NNS O
and/or CC O
methods NNS O
of IN O
the DT O
present JJ O
invention NN O
, , O
including VBG O
the DT O
use NN O
of IN O
a DT O
range NN O
of IN O
methyl NN B-NP
oxaaklyl NN I-NP
derivatives NNS O
of IN O
exemestane NN B-NP
, , O
as RB O
are VBP O
available JJ O
through IN O
the DT O
synthetic JJ O
methodologies NNS O
described VBD O
herein RB O
. . O

In IN O
comparison NN O
with IN O
the DT O
prior JJ O
art NN O
, , O
the DT O
present JJ O
compounds NNS O
, , O
compositions NNS O
and/or CC O
methods NNS O
provide VBP O
results NNS O
and CC O
data NNS O
which WDT O
are VBP O
surprising JJ O
, , O
unexpected JJ O
and CC O
contrary JJ O
thereto NN O
. . O

While IN O
the DT O
utility NN O
of IN O
this DT O
invention NN O
is VBZ O
illustrated VBN O
through IN O
the DT O
use NN O
of IN O
several JJ O
compounds NNS O
and CC O
moieties NNS O
incorporated VBN O
therein RB O
, , O
it PRP O
will MD O
understood VBN O
be VB O
those DT O
skilled JJ O
in IN O
the DT O
art NN O
that WDT O
comparable JJ O
results NNS O
are VBP O
obtainable JJ O
with IN O
various JJ O
other JJ O
compounds NNS O
, , O
compositions NNS O
and CC O
related VBN O
methods NNS O
, , O
as RB O
are VBP O
commensurate JJ O
with IN O
the DT O
scope NN O
of IN O
this DT O
invention NN O
. . O

Example NNP O
1 CD O

Activity NNP O
Of IN O
6-Methyloxamethyl JJ B-NP
Exemestane NNP I-NP
Compounds NNP O
Against IN O
Cancer NNP O
Cell NNP O
Lines NNP O
. . O

Cancer-derived JJ O
cell NN O
lines NNS O
were VBD O
used VBN O
for IN O
the DT O
following VBG O
growth NN O
inhibition IN O
assay NN O
. . O

The DT O
ability NN O
of IN O
the DT O
compound NN O
of IN O
Formula NNP O
( -LRB- O
B NN O
) -RRB- O
above RB O
and CC O
the DT O
compound NN O
of IN O
Formula NNP O
( -LRB- O
D) NN O
above IN O
to TO O
inhibit VB O
cancer-derived JJ O
cell NN O
growth NN O
was VBD O
compared VBN O
to TO O
exemestane NN B-NP
as IN O
a DT O
control NN O
. . O

Cell NNP O
viability NN O
is VBZ O
determined VBN O
using VBG O
the DT O
MTS NNP O
assay NN O
. . O

This DT O
colorimetric JJ O
procedure NN O
measures NNS O
conversion NN O
of IN O
the DT O
MTS NNP O
reagent NN O
( -LRB- O
a DT O
tetrazoleum NN O
salt NN O
) -RRB- O
to TO O
formazan VB B-NP
by IN O
living VBG O
cells NNS O
. . O

Formazan JJ B-NP
production NN O
is VBZ O
quantified VBN O
by IN O
spectrophotometric JJ O
measurement NN O
at IN O
490 CD O
nm NN O
and CC O
is VBZ O
proportional JJ O
to TO O
viable JJ O
cell NN O
number NN O
. . O

Cells NNP O
are VBP O
cultured VBN O
and CC O
treated VBN O
. . O

Following VBG O
treatment NN O
, , O
100 CD O
[mu]l NN O
of IN O
growth NN O
medium NN O
is VBZ O
removed VBN O
and CC O
cells NNS O
incubated VBN O
with IN O
20[mu]l JJ O
CellTiter NNP O
96 CD O
AQueous JJ O
One CD O
Solution NN O
Reagent NN O
( -LRB- O
1.9 CD O
mg/ml NN O
in IN O
PBS NNP O
, , O
pH RB O
6.0) CD O
for IN O
1-3 JJ O
hours NNS O
at IN O
37[deg.]C. PRP$ O

Absorbance NN O
( -LRB- O
OD NNP O
) -RRB- O
values NNS O
are VBP O
measured VBN O
using VBG O
a DT O
[mu] NN O
Quant NNP O
microplate JJ O
reader NN O
at IN O
a DT O
single JJ O
wavelength NN O
of IN O
490 CD O
nm NN O
. . O

The DT O
data NNS O
were VBD O
measured VBN O
as IN O
the DT O
50 CD O
% NN O
inhibitory JJ O
dose NN O
( -LRB- O
IC50 NN O
) -RRB- O
and CC O
are VBP O
reported VBN O
in IN O
Table NN O
1 CD O
below IN O
. . O

Table NN O
1 CD O

[0063] . O

EMI19.1 . O

All DT O
data NNS O
represent VBP O
the DT O
mean NN O
of IN O
2 CD O
independent JJ O
trials NNS O
. . O

Additional JJ O
assays NNS O
were VBD O
performed VBN O
to TO O
evaluate VB O
the DT O
growth-inhibiting JJ O
activity NN O
of IN O
the DT O
compound NN O
of IN O
Formula NNP O
( -LRB- O
B NN O
) -RRB- O
above RB O
and CC O
the DT O
compound NN O
of IN O
Formula NNP O
( -LRB- O
D) NN O
compared VBN O
to TO O
exemestane NN B-NP
as IN O
a DT O
control NN O
. . O

The DT O
percent NN O
of IN O
cell NN O
growth NN O
inhibited VBZ O
at IN O
a DT O
dose NN O
of IN O
200 CD O
[mu]M NNP O
is VBZ O
reported VBN O
in IN O
Table NN O
2 CD O
below IN O
. . O

Table NN O
2 CD O

[0066] . O

EMI20.1 . O

Table NN O
3 CD O
below IN O
provides VBZ O
the DT O
cell NN O
line NN O
information NN O
. . O

Table NN O
3 CD O

[0069] . O

EMI21.1 . O

The DT O
compound NN O
of IN O
Formula NNP O
( -LRB- O
B NN O
) -RRB- O
( -LRB- O
6S NNS O
) -RRB- O
demonstrates VBZ O
excellent JJ O
activity NN O
against IN O
a DT O
variety NN O
of IN O
cancer NN O
cell NN O
lines NNS O
( -LRB- O
95-98 CD O
% NN O
inhibition NN O
- : O
see VBP O
Table NN O
2 CD O
) -RRB- O
. . O

By IN O
comparison NN O
, , O
the DT O
exemestane NN B-NP
( -LRB- O
control NN O
) -RRB- O
shows VBZ O
marginal JJ O
activity NN O
against IN O
the DT O
same JJ O
cell NN O
lines NNS O
. . O

In IN O
addition NN O
, , O
under IN O
the DT O
conditions NNS O
and CC O
protocols NNS O
employed VBN O
, , O
the DT O
data NNS O
consistently RB O
shows VBZ O
that IN O
Formula NNP O
( -LRB- O
B NN O
) -RRB- O
( -LRB- O
exemestane NN B-NP
6S NNS I-NP
) -RRB- O
works VBZ O
best RBS O
against IN O
cell NN O
lines NNS O
that WDT O
are VBP O
estrogen(-) JJ B-NP
and/or CC O
aromatase JJ O
( -LRB- O
+ NN O
) -RRB- O
, , O
as IN O
compared VBN O
to TO O
cell NN O
lines NNS O
that WDT O
are VBP O
estrogen NN B-NP
( -LRB- O
+ NN O
) -RRB- O
and CC O
aromatase JJ O
(-) NN O
. . O

Thus RB O
, , O
the DT O
6-methylene NN B-NP
substituted VBN O
exemestane JJ B-NP
coumpounds NNS O
described VBD O
herein PRP O
have VBP O
been VBN O
discovered VBN O
to TO O
be VB O
able JJ O
to TO O
inhibit VB O
the DT O
growth NN O
of IN O
cancer NN O
cells NNS O
. . O

This DT O
indicates VBZ O
that IN O
the DT O
exemestane JJ B-NP
derivatives NNS O
described VBN O
herein RB O
are VBP O
useful JJ O
for IN O
cancer NN O
treatments NNS O
and CC O
therapies NNS O
when WRB O
provided VBN O
to TO O
a DT O
patient NN O
either CC O
individually RB O
or CC O
in IN O
various JJ O
combinations NNS O
with IN O
each DT O
other JJ O
or CC O
with IN O
other JJ O
compounds NNS O
which WDT O
have VBP O
anticancer NN O
or CC O
antitumor NN O
activity NN O
. . O

In IN O
light NN O
of IN O
the DT O
ability NN O
of IN O
the DT O
exemestane JJ B-NP
derivatives NNS O
described VBD O
herein IN O
to TO O
inhibit VB O
various JJ O
types NNS O
of IN O
cancer NN O
cells NNS O
, , O
exemestane JJ B-NP
derivatives NNS O
described VBN O
herein RB O
are VBP O
useful JJ O
as IN O
antitumor JJ O
or CC O
antiproliferative JJ O
agents NNS O
for IN O
cancer NN O
chemotherapeutic NN O
applications NNS O
. . O

Although IN O
the DT O
present JJ O
invention NN O
has VBZ O
been VBN O
described VBN O
with IN O
reference NN O
to TO O
certain JJ O
embodiments NNS O
, , O
one CD O
skilled JJ O
in IN O
the DT O
art NN O
will MD O
appreciate VB O
that IN O
the DT O
present JJ O
invention NN O
can MD O
be VB O
practiced VBN O
by IN O
other JJ O
than IN O
the DT O
described VBN O
embodiments NNS O
, , O
which WDT O
have VBP O
been VBN O
presented VBN O
for IN O
purposes NNS O
of IN O
illustration NN O
and CC O
not RB O
of IN O
limitation NN O
. . O

Therefore RB O
, , O
the DT O
scope NN O
of IN O
the DT O
appended VBN O
claims NNS O
should MD O
not RB O
be VB O
limited VBN O
to TO O
the DT O
description NN O
of IN O
the DT O
embodiments NNS O
contained VBD O
herein RB O
. . O

We PRP O
claim VBP O
: : O

1 CD O
. . O

A DT O
chemotherapeutic JJ O
compound NN O
of IN O
a DT O
formula NN O

EMI23.1 . O

R5 PRP O
wherein WRB O
each DT O
Of IN O
R1 NNP O
, , O
R2 NNP O
, , O
R3 NNP O
and CC O
R4 NNP O
is VBZ O
independently RB O
selected VBN O
from IN O
H NNP B-NP
, , O
alkyl NN B-NP
, , O
substituted VBN O
alkyl NN B-NP
and CC O
halogen NN B-NP
moieties NNS O
; : O
and CC O
R5 PRP O
is VBZ O
selected VBN O
from IN O
alkyl NN B-NP
and CC O
substituted VBD O
alkyl RB B-NP
moieties NNS O
; : O
enantiomers NNS O
, , O
hydrates NNS B-NP
, , O
solvates NNS O
, , O
tautomers NNS O
and CC O
salts NNS O
thereof RB O
. . O

2. DT O
The DT O
compound NN O
of IN O
claim NN O
1 CD O
wherein WRB O
R5 PRP O
is VBZ O
selected VBN O
from IN O
C1 NNP O
to TO O
about IN O
C6 DT B-NP
alkyl NN I-NP
and CC O
C1 NNP O
to TO O
about IN O
C6 DT O
substituted VBN O
alkyl NN B-NP
moieties NNS O
. . O

3. DT O
The DT O
compound NN O
of IN O
claim NN O
2 CD O
wherein WRB O
R5 PRP O
is VBZ O
methyl NN B-NP
. . O

4 LS O
. . O
The DT O
compound NN O
of IN O
claim NN O
3 CD O
where WRB O
said VBD O
compound NN O
is VBZ O
the DT O
S NNP O
enantiomer NN O
. . O

5 CD O
. . O
A DT O
pharmaceutical JJ O
composition NN O
comprising VBG O
a DT O
compound NN O
selected VBN O
from IN O
compounds NNS O
of IN O
claim NN O
1 CD O
and CC O
combinations NNS O
thereof RB O
, , O
and CC O
a DT O
pharmaceutically-acceptable JJ O
carrier NN O
. . O

6 CD O
. . O

The DT O
composition NN O
of IN O
claim NN O
5 CD O
wherein WRB O
said VBD O
compound NN O
comprises VBZ O
a DT O
racemic JJ O
mixture NN O
of IN O
said VBD O
compounds NNS O
. . O

7. VBG O
The DT O
composition NN O
of IN O
claim NN O
6 CD O
comprising VBG O
the DT O
S NNP O
enantiomer NN O
, , O
and CC O
R5 PRP O
is VBZ O
selected VBN O
from IN O
Ci NNP O
to TO O
about IN O
C6 DT B-NP
alkyl NN I-NP
and CC O
C1 NNP O
to TO O
about IN O
C6 DT O
substituted VBN O
alkyl NN B-NP
moieties NNS O
. . O

8. VBG O
The DT O
composition NN O
of IN O
claim NN O
7 CD O
wherein WRB O
R5 PRP O
is VBZ O
methyl NN B-NP
. . O

9 CD O
. . O
A DT O
method NN O
of IN O
using VBG O
an DT O
exemestane NN B-NP
6-methylene NN B-NP
substituent JJ O
to TO O
affect VB O
cancer NN O
growth NN O
, , O
said VBD O
method NN O
comprising NN O
: : O
providing VBG O
a DT O
compound NN O
with IN O
an DT O
exemestane JJ B-NP
core NN O
structure NN O
comprising VBG O
a DT O
methyloxaalkyl NN B-NP
substituent NN O
at IN O
the DT O
6-position NN O
of IN O
said VBD O
core NN O
structure NN O
; : O
and CC O
contacting VBG O
a DT O
cancer NN O
growth NN O
with IN O
said VBD O
compound NN O
. . O

10 CD O
. . O

The DT O
method NN O
of IN O
claim NN O
9 CD O
wherein WRB O
the DT O
alkyl NN B-NP
moiety NN O
of IN O
said VBD O
6-methylene JJ B-NP
substituent NN O
is VBZ O
selected VBN O
from IN O
C1 NNP O
to TO O
about IN O
C6 DT B-NP
alkyl NN I-NP
and CC O
Cj NNP O
to TO O
about IN O
C6 DT O
substituted VBN O
alkyl NN B-NP
moieties NNS O
. . O

11 CD O
. . O

The DT O
method NN O
of IN O
claim NN O
10 CD O
wherein WRB O
said VBD O
alkyl NN B-NP
moiety NN O
is VBZ O
methyl NN B-NP
. . O

12 CD O
. . O
The DT O
method NN O
of IN O
claim NN O
11 CD O
wherein WRB O
said VBD O
compound NN O
is VBZ O
the DT O
S NNP O
enantiomer NN O
. . O

13 CD O
. . O

The DT O
method NN O
of IN O
claim NN O
9 CD O
comprising NN O
contact NN O
with IN O
estrogen NN B-NP
(-) JJ O
and CC O
aromatase JJ O
( -LRB- O
+ NN O
) -RRB- O
cell NN O
lines NNS O
. . O

14 CD O
. . O

A DT O
method NN O
of IN O
inhibiting VBG O
growth NN O
of IN O
cancer NN O
cells NNS O
, , O
said VBD O
method NN O
comprising NN O
: : O
providing VBG O
a DT O
growth NN O
of IN O
cancer NN O
cells NNS O
; : O
and CC O
contacting VBG O
said VBD O
cells NNS O
with IN O
a DT O
compound NN O
selected VBN O
from IN O
compounds NNS O
of IN O
claim NN O
1 CD O
and CC O
combinations NNS O
thereof RB O
, , O
said VBD O
compound NN O
in IN O
an DT O
amount NN O
at IN O
least JJS O
partially RB O
sufficient JJ O
to TO O
inhibit VB O
said VBD O
growth NN O
. . O

15 CD O
. . O

The DT O
method NN O
of IN O
claim NN O
14 CD O
wherein WRB O
said VBD O
compound NN O
is VBZ O
of IN O
a DT O
formula NN O

EMI24.1 . O

wherein WRB O
each DT O
OfR1 NNP O
, , O
R2 NNP O
, , O
R3 NNP O
and CC O
R4 NNP O
is VBZ O
independently RB O
selected VBN O
from IN O
H NNP B-NP
, , O
alkyl NN B-NP
, , O
substituted VBN O
alkyl NN B-NP
and CC O
halogen NN B-NP
moieties NNS O
; : O
and CC O
R5 PRP O
is VBZ O
selected VBN O
from IN O
alkyl NN B-NP
and CC O
substituted VBD O
alkyl RB B-NP
moieties NNS O
; : O
enantiomers NNS O
, , O
hydrates NNS B-NP
, , O
solvates NNS O
, , O
tautomers NNS O
and CC O
salts NNS O
thereof RB O
. . O

16 CD O
. . O

The DT O
method NN O
of IN O
claim NN O
15 CD O
wherein WRB O
R5 PRP O
is VBZ O
selected VBN O
from IN O
C1 NNP O
to TO O
about IN O
C6 DT B-NP
alkyl NN I-NP
and CC O
Ci NNP O
to TO O
about IN O
C6 DT O
substituted VBN O
alkyl NN B-NP
moieties NNS O
. . O

17 CD O
. . O

The DT O
method NN O
of IN O
claim NN O
16 CD O
wherein WRB O
R5 PRP O
is VBZ O
methyl NN B-NP
. . O

18 CD O
. . O

The DT O
method NN O
of IN O
claim NN O
14 CD O
wherein WRB O
said VBD O
cancer NN O
growth NN O
is VBZ O
selected VBN O
from IN O
breast NN O
, , O
lung NN O
, , O
colon NN O
, , O
prostate NN O
, , O
ovarian JJ O
and CC O
pancreatic JJ O
growths NNS O
. . O

19 CD O
. . O

The DT O
method NN O
of IN O
claim NN O
14 CD O
wherein WRB O
said VBD O
compound NN O
is VBZ O
in IN O
a DT O
pharmaceutical JJ O
composition NN O
. . O

20 CD O
. . O

A DT O
method NN O
of IN O
using VBG O
a DT O
6-methyloxamethyl NN B-NP
exemestane NN I-NP
derivative JJ O
to TO O
inhibit VB O
growth NN O
of IN O
cancer NN O
cells NNS O
, , O
said VBD O
method NN O
comprising NN O
: : O
providing VBG O
a DT O
growth NN O
of IN O
cancer NN O
cells NNS O
; : O
and CC O
contacting VBG O
said VBD O
cells NNS O
with IN O
a DT O
methyloxamethyl NN B-NP
compound NN O
selected VBN O
from IN O
said VBD O
compounds NNS O
of IN O
claim NN O
1 CD O
, , O
said VBD O
compound NN O
in IN O
an DT O
amount NN O
at IN O
least JJS O
partially RB O
sufficient JJ O
to TO O
inhibit VB O
said VBD O
growth NN O
. . O

21 CD O
. . O

The DT O
method NN O
of IN O
claim NN O
20 CD O
wherein WRB O
said VBD O
compound NN O
is VBZ O
of IN O
a DT O
formula NN O

EMI25.1 . O

O UH O

22 CD O
. . O
The DT O
method NN O
of IN O
claim NN O
21 CD O
wherein WRB O
said VBD O
cancer NN O
growth NN O
is VBZ O
selected VBN O
from IN O
breast NN O
, , O
lung NN O
, , O
colon NN O
, , O
prostate NN O
, , O
ovarian JJ O
and CC O
pancreatic JJ O
growths NNS O
. . O

-DOCSTART- X X O

[0001] JJ O
AMINO NNP B-NP
ACID-CONTAINING NNP I-NP
COMPOUNDS NNPS O
AND CC O
DERIVATIVES NNPS O
LABELED VBD O
WITH IN O
HALIDES NNP B-NP
AND CC O
METHOD NNP O
OF IN O

MAKING NN O

BACKGROUND NN O
OF IN O
THE DT O
INVENTION NN O

The DT O
present JJ O
invention NN O
relates NNS O
to TO O
amino VB B-NP
acid-containing NN I-NP
compounds NNS O
and CC O
their PRP$ O
derivatives NNS O
labeled VBN O
with IN O
one CD O
or CC O
more JJR O
halogen NN B-NP
atoms NNS O
and CC O
to TO O
methods NNS O
of IN O
making VBG O
such JJ O
labeled VBN O
amino IN B-NP
acid-containing NN I-NP
compounds NNS O
and CC O
derivatives NNS O
. . O

The DT O
growing VBG O
need NN O
for IN O
the DT O
early JJ O
diagnosis NN O
and CC O
assessment NN O
and/or CC O
treatment NN O
of IN O
diseases NNS O
can MD O
potentially RB O
be VB O
addressed VBN O
by IN O
pharmaceuticals NNS O
that WDT O
preferentially RB O
accumulate VBP O
at IN O
the DT O
disease NN O
sites NNS O
. . O

In IN O
diagnostic JJ O
applications NNS O
, , O
these DT O
pharmaceuticals NNS O
can MD O
elucidate VB O
the DT O
state NN O
of IN O
the DT O
disease NN O
through IN O
its PRP$ O
distinctive JJ O
biology NN O
expressed VBN O
as IN O
disease NN O
markers NNS O
that WDT O
are VBP O
not RB O
present JJ O
, , O
or CC O
are VBP O
present JJ O
in IN O
diminished JJ O
levels NNS O
, , O
in IN O
healthy JJ O
tissues NNS O
. . O

In IN O
therapeutic JJ O
applications NNS O
, , O
these DT O
pharmaceuticals NNS O
can MD O
deliver VB O
an DT O
enhanced JJ O
dose NN O
of IN O
therapeutic JJ O
agents NNS O
to TO O
the DT O
disease NN O
sites NNS O
through IN O
specific JJ O
interactions NNS O
with IN O
the DT O
disease NN O
markers NNS O
. . O

By IN O
specifically RB O
targeting VBG O
physiological JJ O
or CC O
cellular JJ O
functions NNS O
that WDT O
are VBP O
present JJ O
only RB O
in IN O
disease NN O
states NNS O
, , O
these DT O
pharmaceuticals NNS O
can MD O
report VB O
exclusively RB O
on IN O
the DT O
scope NN O
and CC O
progress NN O
of IN O
that DT O
disease NN O
or CC O
exclusively RB O
target VB O
the DT O
diseased JJ O
tissue NN O
. . O

A DT O
signal-generating JJ O
moiety NN O
is VBZ O
a DT O
key JJ O
element NN O
of IN O
these DT O
diagnostic JJ O
pharmaceuticals NNS O
, , O
which WDT O
produce VBP O
differentiated JJ O
signals NNS O
at IN O
the DT O
disease NN O
sites NNS O
. . O

In IN O
certain JJ O
situations NNS O
, , O
these DT O
pharmaceuticals NNS O
are VBP O
based VBN O
on IN O
peptides NNS B-NP
or CC O
derivatives NNS O
thereof , O
that WDT O
bind VBP O
specifically RB O
to TO O
disease NN O
markers NNS O
. . O

The DT O
peptides NNS B-NP
or CC O
derivatives NNS O
thereof , O
are VBP O
labeled VBN O
with IN O
moieties NNS O
that WDT O
generate VBP O
a DT O
signal NN O
that WDT O
can MD O
be VB O
detected VBN O
by IN O
imaging VBG O
equipment NN O
for IN O
the DT O
purposes NNS O
of IN O
disease NN O
diagnosis NN O
. . O

Alternatively RB O
, , O
the DT O
moieties NNS O
can MD O
comprise VB O
a DT O
radioisotope NN O
for IN O
the DT O
purposes NNS O
of IN O
disease NN O
therapy NN O
. . O

Positron NNP O
emission NN O
tomography NN O
( -LRB- O
"PET" NN O
) -RRB- O
has VBZ O
gained VBN O
acceptance NN O
as IN O
a DT O
technique NN O
for IN O
diagnostic JJ O
imaging NN O
because IN O
of IN O
its PRP$ O
capability NN O
of IN O
providing VBG O
images NNS O
with IN O
high JJ O
resolution NN O
in IN O
addition NN O
to TO O
its PRP$ O
non-invasive JJ O
nature NN O
. . O

In IN O
PET NNP O
, , O
gamma NN O
photons NNS O
having VBG O
511 CD O
keV NN O
energy NN O
produced VBN O
during IN O
positron DT O
annihilation NN O
decay NN O
are VBP O
detected VBN O
. . O

In IN O
the DT O
clinical JJ O
setting NN O
, , O
fluorine-18 NN B-NP
(F-18 NN O
) -RRB- O
is VBZ O
one CD O
of IN O
the DT O
most RBS O
widely RB O
used VBN O
positron-emitting JJ O
nuclides NNS O
. . O

However RB O
, , O
its PRP$ O
relatively RB O
short JJ O
half JJ O
life NN O
of IN O
1 CD O
10 CD O
minutes NNS O
has VBZ O
limited VBN O
or CC O
precluded VBN O
its PRP$ O
use NN O
with IN O
constructs NNS O
( -LRB- O
such JJ O
as IN O
antibodies NNS O
, , O
antibody NN O
fragments NNS O
, , O
or CC O
receptor-targeted JJ O
peptides NNS B-NP
) -RRB- O
that WDT O
would MD O
require VB O
relatively RB O
long JJ O
time NN O
to TO O
accumulate VB O
sufficiently RB O
at IN O
the DT O
target NN O
. . O

Furthermore RB O
, , O
the DT O
relatively RB O
short JJ O
half JJ O
life NN O
of IN O
F-18 NN B-NP
would MD O
necessitate VB O
the DT O
manufacture NN O
of IN O
the DT O
F-18-labeled JJ B-NP
pharmaceutical JJ O
immediately RB O
before IN O
its PRP$ O
use NN O
and CC O
a DT O
short JJ O
time NN O
required VBN O
for IN O
such JJ O
manufacture NN O
. . O

However RB O
, , O
these DT O
requirements NNS O
are VBP O
inconsistent JJ O
with IN O
the DT O
currently RB O
known VBN O
complicated VBN O
chemistry NN O
that WDT O
is VBZ O
required VBN O
to TO O
link VB O
inorganic JJ O
fluoride NN O
species NNS O
to TO O
such JJ O
organic JJ O
targeting VBG O
vectors NNS O
. . O

Therefore RB O
, , O
a DT O
continued JJ O
need NN O
exists VBZ O
for IN O
a DT O
rapid JJ O
method NN O
of IN O
labeling VBG O
peptides NNS B-NP
and CC O
their PRP$ O
derivatives NNS O
with IN O
short-lived JJ O
radioisotopes NNS O
. . O

In IN O
particular JJ O
, , O
it PRP O
is VBZ O
very RB O
desirable JJ O
to TO O
provide VB O
a DT O
rapid JJ O
method NN O
for IN O
labeling VBG O
peptides NNS B-NP
and CC O
their PRP$ O
derivatives NNS O
with IN O
short-lived JJ O
halogen NN B-NP
radioisotopes NNS O
. . O

SUMMARY NN O
OF IN O
THE DT O
INVENTION NN O

The DT O
present JJ O
invention NN O
provides VBZ O
a DT O
method NN O
of IN O
labeling VBG O
an DT O
amino JJ B-NP
acid-containing NN I-NP
compound NN O
or CC O
a DT O
derivative JJ O
thereof , O
with IN O
a DT O
halide NN O
moiety NN O
. . O

The DT O
method NN O
comprises VBZ O
reacting VBG O
a DT O
halogenated JJ O
electrophilic JJ O
compound NN O
with IN O
a DT O
nucleophilic JJ O
moiety NN O
of IN O
the DT O
amino JJ B-NP
acid-containing NN I-NP
compound NN O
or CC O
a DT O
derivative JJ O
thereof NN O
. . O

In IN O
one CD O
aspect NN O
of IN O
the DT O
present JJ O
invention NN O
, , O
the DT O
halide NN O
moiety NN O
in IN O
the DT O
halogenated JJ O
electrophilic JJ O
compound NN O
is VBZ O
a DT O
radioactive JJ B-NP
halide NN I-NP
. . O

In IN O
another DT O
aspect NN O
of IN O
the DT O
present JJ O
invention NN O
, , O
the DT O
radioactive JJ B-NP
halide NN I-NP
is VBZ O
selected VBN O
from IN O
the DT O
group NN O
consisting VBG O
of IN O
halide NN O
radioisotopes NNS O
that WDT O
emit VBP O
positrons NNS O
. . O

In IN O
still RB O
another DT O
aspect NN O
, , O
the DT O
amino JJ B-NP
acid-containing NN I-NP
compound NN O
is VBZ O
a DT O
peptide NN B-NP
or CC O
a DT O
peptide NN B-NP
derivative JJ O
, , O
and CC O
the DT O
nucleophilic JJ O
moiety NN O
is VBZ O
conjugated VBN O
to TO O
a DT O
residue NN O
of IN O
the DT O
peptide NN B-NP
or CC O
peptide NN B-NP
derivative NN O
. . O

In IN O
still RB O
another DT O
aspect NN O
, , O
the DT O
amino-acid JJ B-NP
containing VBG O
compound NN O
comprises VBZ O
at IN O
least JJS O
one CD O
amino-acid JJ B-NP
residue NN I-NP
and CC O
at IN O
least JJS O
a DT O
residue NN O
of IN O
at IN O
least JJS O
another DT O
type NN O
of IN O
monomelic JJ O
units NNS O
in IN O
the DT O
backbone NN O
chain NN O
, , O
wherein WRB O
the DT O
nucleophilic JJ O
moiety NN O
is VBZ O
conjugated VBN O
to TO O
the DT O
at IN O
least JJS O
one CD O
amino-acid JJ B-NP
residue NN I-NP
. . O

In IN O
still RB O
another DT O
aspect NN O
, , O
the DT O
present JJ O
invention NN O
provides VBZ O
a DT O
pharmaceutical JJ O
labeled VBN O
with IN O
a DT O
radioactive JJ B-NP
halide NN I-NP
moiety NN O
, , O
wherein WRB O
the DT O
pharmaceutical NN O
comprises VBZ O
a DT O
peptide NN B-NP
or CC O
a DT O
peptide NN B-NP
derivative NN O
. . O

In IN O
still RB O
another DT O
aspect NN O
, , O
the DT O
present JJ O
invention NN O
provides VBZ O
a DT O
set NN O
of IN O
separate JJ O
compounds NNS O
comprising VBG O
a DT O
first JJ O
compound NN O
comprising VBG O
a DT O
peptide NN B-NP
or CC O
a DT O
peptide NN B-NP
derivative NN O
that WDT O
comprises VBZ O
a DT O
nucleophilic JJ O
moiety NN O
, , O
and CC O
a DT O
second JJ O
compound NN O
that WDT O
is VBZ O
electrophilic JJ O
and CC O
comprises VBZ O
a DT O
halide NN O
moiety NN O
. . O

The DT O
compounds NNS O
readily RB O
react VBP O
with IN O
one CD O
another DT O
to TO O
produce VB O
a DT O
halide-labeled JJ O
peptide NN B-NP
or CC O
peptide NN B-NP
derivative NN O
. . O

Other JJ O
features NNS O
and CC O
advantages NNS O
of IN O
the DT O
present JJ O
invention NN O
will MD O
be VB O
apparent JJ O
from IN O
a DT O
perusal NN O
of IN O
the DT O
following VBG O
detailed JJ O
description NN O
of IN O
the DT O
invention NN O
and CC O
the DT O
accompanying JJ O
drawings NNS O
in IN O
which WDT O
the DT O
same JJ O
numerals NNS O
refer VBP O
to TO O
like VB O
elements NNS O
. . O

BRIEF NN O
DESCRIPTION NN O
OF IN O
THE DT O
DRAWINGS NNS O

Figure NN O
1 CD O
shows VBZ O
the DT O
MALDI-TOF NNP O
( -LRB- O
matrix NN O
assisted VBN O
laser NN O
desorption NN O
ionisation NN O
time-of NN O
- : O
flight NN O
) -RRB- O
mass NN O
spectrum NN O
Of IN O
JiFLGFL-NH2 NNP O
, , O
wherein WRB O
Ji RB O
is VBZ O
3,4,5-trimethoxybenzyl JJ B-NP
glycine NN I-NP
, , O
and CC O
wherein WRB O
F NNP O
, , O
L, NNP O
and CC O
G NNP O
conventionally RB O
denote VBP O
phenylalanine NN B-NP
, , O
leucine NN B-NP
, , O
and CC O
glycine NN B-NP
, , O
respectively RB O
. . O

Figure NN O
2 CD O
shows VBZ O
the DT O
MALDI-TOF NNP O
mass NN O
spectrum NN O
of IN O
J2FLGFL-NH2 JJ O
, , O
wherein WRB O
J2 NNP O
is VBZ O
3- CD B-NP
( -LRB- I-NP
3,4,5-trimethoxyphenyl)propionic JJ I-NP
acid NN I-NP
. . O

DETAILED VBN O
DESCRIPTION NN O
OF IN O
THE DT O
INVENTION NN O

The DT O
present JJ O
invention NN O
provides VBZ O
a DT O
method NN O
of IN O
labeling VBG O
an DT O
amino JJ B-NP
acid-containing NN I-NP
compound NN O
or CC O
a DT O
derivative JJ O
thereof , O
with IN O
a DT O
halide NN O
moiety NN O
. . O

The DT O
method NN O
comprises VBZ O
reacting VBG O
a DT O
halogenated JJ O
electrophilic JJ O
compound NN O
with IN O
a DT O
nucleophilic JJ O
moiety NN O
of IN O
the DT O
amino JJ B-NP
acid-containing NN I-NP
compound NN O
or CC O
derivative JJ O
thereof '' O
. . O

In IN O
one CD O
aspect NN O
of IN O
the DT O
present JJ O
invention NN O
, , O
the DT O
halide NN O
moiety NN O
in IN O
the DT O
halogenated JJ O
electrophilic JJ O
compound NN O
is VBZ O
a DT O
radioactive JJ B-NP
halide NN I-NP
. . O

The DT O
radioactive JJ B-NP
halide-labeled JJ I-NP
amino NN B-NP
acid-containing NN I-NP
compounds NNS O
or CC O
derivatives NNS O
thereof , O
disclosed VBN O
in IN O
the DT O
present JJ O
invention NN O
are VBP O
useful JJ O
in IN O
diagnostic JJ O
and/or CC O
therapeutic JJ O
applications NNS O
. . O

For IN O
example NN O
, , O
the DT O
amino JJ B-NP
acid-containing NN I-NP
compound NN O
or CC O
derivative JJ O
thereof , O
can MD O
preferentially RB O
accumulate VB O
at IN O
a DT O
disease NN O
site NN O
by IN O
preferentially RB O
or CC O
specifically RB O
binding JJ O
to TO O
an DT O
epitope NN O
expressed VBN O
on IN O
the DT O
surface NN O
of IN O
cells NNS O
of IN O
the DT O
diseased JJ O
tissue NN O
. . O

Alternatively RB O
, , O
the DT O
amino JJ B-NP
acid-containing NN I-NP
compound NN O
or CC O
a DT O
derivative JJ O
thereof , O
can MD O
preferentially RB O
accumulate VB O
at IN O
a DT O
disease NN O
site NN O
by IN O
binding JJ O
to TO O
an DT O
enzyme NN O
overproduced VBN O
by IN O
the DT O
diseased JJ O
tissue NN O
. . O

Thus RB O
, , O
the DT O
radioactive JJ B-NP
halide-labeled JJ I-NP
amino JJ B-NP
acid-containing NN I-NP
compound NN O
carries VBZ O
the DT O
radioactive JJ B-NP
halide NN I-NP
label NN O
with IN O
it PRP O
to TO O
the DT O
disease NN O
site NN O
, , O
which WDT O
can MD O
then RB O
be VB O
imaged VBN O
by IN O
detecting VBG O
and CC O
measuring VBG O
the DT O
differentiated JJ O
level NN O
of IN O
radioactivity NN O
. . O

Alternatively RB O
, , O
the DT O
radioactive JJ B-NP
halide-labeled JJ I-NP
amino IN B-NP
acid NN I-NP
- : O
containing VBG O
compound NN O
or CC O
a DT O
derivative JJ O
thereof , O
can MD O
have VB O
a DT O
therapeutic JJ O
effect NN O
when WRB O
the DT O
emitted VBN O
radiation NN O
can MD O
kill VB O
the DT O
surrounding VBG O
diseased JJ O
tissue NN O
or CC O
otherwise RB O
stop VB O
its PRP$ O
growth NN O
. . O

Suitable JJ O
for IN O
halogen NN B-NP
radioisotopes NNS O
for IN O
labeling VBG O
a DT O
amino JJ B-NP
acid-containing NN I-NP
compound NN O
or CC O
derivative JJ O
thereof , O
in IN O
the DT O
present JJ O
invention NN O
to TO O
produce VB O
a DT O
diagnostic JJ O
or CC O
therapeutic JJ O
pharmaceutical JJ O
are VBP O
fluorine-18 NN B-NP
, , O
iodine-120 JJ B-NP
, , O
iodine-123 JJ B-NP
, , O
iodine-124 JJ B-NP
, , O
iodine-125 CC B-NP
, , O
iodine-126 -RRB- B-NP
, , O
iodine-131 JJ B-NP
, , O
iodine-133 JJ B-NP
, , O
bromine-75 CD B-NP
, , O
bromine-76 CD B-NP
, , O
bromine-77 CD B-NP
, , O
bromine NN B-NP
- : I-NP
78 CD I-NP
, , O
chlorine-34 NN B-NP
, , O
chlorine-38 NN B-NP
, , O
and CC O
chlorine-39 CD B-NP
. . O

It PRP O
should MD O
be VB O
noted VBN O
that IN O
any DT O
of IN O
these DT O
halogen NN B-NP
isotopes NNS O
is VBZ O
present JJ O
in IN O
the DT O
form NN O
of IN O
a DT O
combined VBN O
halide NN O
in IN O
a DT O
compound NN O
with IN O
an DT O
electrophilic JJ O
moiety NN O
. . O

Isotopes NNP O
preferred VBD O
for IN O
imaging VBG O
applications NNS O
include VBP O
: : O
fluorine-18 NN B-NP
, , O
iodine-123 JJ B-NP
, , O
iodine JJ B-NP
- : I-NP
125 CD I-NP
, , O
iodine-131 NN B-NP
, , O
bromine-75 CD B-NP
, , O
bromine-76 CD B-NP
, , O
and CC O
bromine-77 CD B-NP
. . O

In IN O
another DT O
aspect NN O
of IN O
the DT O
present JJ O
invention NN O
, , O
the DT O
radioactive JJ B-NP
halide NN I-NP
is VBZ O
selected VBN O
from IN O
the DT O
group NN O
consisting VBG O
of IN O
halide NN O
radioisotopes NNS O
that WDT O
emit VBP O
positrons NNS O
. . O

A DT O
preferred JJ O
radioisotope NN O
for IN O
PET NN O
is VBZ O
fluorine-18 NN B-NP
. . O

The DT O
nucleophilic JJ O
moiety NN O
of IN O
the DT O
amino JJ B-NP
acid-containing NN I-NP
compound NN O
or CC O
derivative JJ O
thereof , O
of IN O
the DT O
present JJ O
invention NN O
is VBZ O
preferably RB O
attached VBN O
to TO O
the DT O
amino JJ B-NP
acid-containing NN I-NP
compound NN O
or CC O
derivative JJ O
thereof , O
by IN O
a DT O
direct JJ O
covalent JJ O
bond NN O
or CC O
a DT O
linkage NN O
selected VBN O
from IN O
the DT O
group NN O
consisting VBG O
of IN O
divalent JJ O
saturated JJ O
or CC O
unsaturated JJ O
hydrocarbyl NN B-NP
groups NNS O
, , O
and CC O
derivatives VBZ O
thereof RB O
. . O

In IN O
one CD O
embodiment NN O
, , O
the DT O
divalent JJ O
saturated JJ O
or CC O
unsaturated JJ O
hydrocarbyl NN B-NP
group NN O
, , O
or CC O
a DT O
derivative JJ O
thereof NN O
, , O
is VBZ O
a DT O
chain NN O
having VBG O
from IN O
one CD O
to TO O
ten CD O
carbon NN B-NP
atoms NNS O
, , O
preferably RB O
from IN O
one CD O
to TO O
six CD O
carbon NN B-NP
atoms NNS O
, , O
inclusive JJ O
. . O

In IN O
another DT O
embodiment NN O
, , O
the DT O
linkage NN O
can MD O
be VB O
-(O-CH2-CH2 JJ B-NP
)n-, JJ I-NP
-(S-CH2-CH2 JJ B-NP
)n-, JJ I-NP
or CC O
-(NR'-CH2-CH2 JJ B-NP
)n-, NN I-NP
wherein WRB O
n NN O
is VBZ O
an DT O
integer NN O
such JJ O
that IN O
1 CD O
< VBD O
n RB O
< JJ O
5 CD O
, , O
preferably RB O
1 CD O
< JJ O
= SYM O
n RB O
< VB O
3 CD O
, , O
and CC O
R<1> NNP O
is VBZ O
-CmHm+i JJ O
, , O
and CC O
m NN O
is VBZ O
an DT O
integer NN O
such JJ O
that IN O
1 CD O
< NN O
m NN O
< IN O
5 CD O
, , O
preferably RB O
1 CD O
< JJ O
= SYM O
m NN O
< IN O
3. DT O
It PRP O
should MD O
be VB O
understood VBN O
that IN O
n NN O
and CC O
m NN O
are VBP O
independently RB O
selected VBN O
. . O

The DT O
nucleophilic JJ O
moiety NN O
comprises VBZ O
from IN O
one CD O
to TO O
three CD O
aromatic JJ O
rings NNS O
, , O
substituted VBN O
with IN O
one CD O
or CC O
more JJR O
electron-donating JJ O
groups NNS O
, , O
such JJ O
as IN O
-OR<1> JJ B-NP
, , O
or CC O
-SR<1> JJ B-NP
, , O
wherein WRB O
R<1> NNP O
is VBZ O
define VB O
above IN O
. . O

Thus RB O
, , O
in IN O
general JJ O
, , O
an DT O
amino JJ B-NP
acid-containing NN I-NP
compound NN O
or CC O
derivative JJ O
thereof , O
of IN O
the DT O
present JJ O
invention NN O
having VBG O
a DT O
nucleophilic JJ O
moiety NN O
can MD O
be VB O
represented VBN O
by IN O
formula NN O
( -LRB- O
I PRP O
) -RRB- O
: : O

[0028 CD O
] NN O

EMI6.1 . O

wherein WRB O
A DT O
is VBZ O
a DT O
first JJ O
group NN O
that WDT O
is VBZ O
capable JJ O
of IN O
forming VBG O
a DT O
bond NN O
with IN O
an DT O
amino JJ B-NP
acid NN I-NP
; : O
D NNP O
is VBZ O
a DT O
direct JJ O
covalent JJ O
bond NN O
or CC O
a DT O
divalent JJ O
saturated JJ O
or CC O
unsaturated JJ O
hydrocarbyl NN B-NP
group NN O
, , O
or CC O
a DT O
derivative JJ O
thereof , O
having VBG O
from IN O
one CD O
to TO O
ten CD O
carbon NN B-NP
atoms NNS O
, , O
preferably RB O
from IN O
one CD O
to TO O
five CD O
carbon NN B-NP
atoms NNS O
, , O
inclusive JJ O
; : O
E NNP O
is VBZ O
a DT O
nucleophilic JJ O
moiety NN O
defined VBN O
above IN O
; : O
and CC O
Q NNP O
is VBZ O
a DT O
second JJ O
group NN O
that WDT O
is VBZ O
capable JJ O
of IN O
forming VBG O
a DT O
bond NN O
with IN O
an DT O
amino JJ B-NP
acid NN I-NP
. . O

For IN O
example NN O
, , O
the DT O
first JJ O
group NN O
can MD O
be VB O
a DT O
chain NN O
comprising NN O
amino IN B-NP
acid NN I-NP
residues NNS I-NP
or CC O
derivatives NNS O
thereof RB O
. . O

The DT O
second JJ O
group NN O
can MD O
be VB O
another DT O
chain NN O
comprising VBG O
amino IN B-NP
acid NN I-NP
residues NNS I-NP
or CC O
derivatives NNS O
thereof RB O
, , O
-COOR<1> JJ O
, , O
-CONR<2>R<3> JJ B-NP
, , O
-SO3H JJ O
, , O
-SO2NR<2>R<3> JJ O
, , O
or CC O
a DT O
derivative JJ O
thereof CD O
, , O
wherein WRB O
R<1> NNP O
is VBZ O
disclosed VBN O
above IN O
, , O
R<2> NNP O
and CC O
R<3> NNP O
are VBP O
independently RB O
selected VBN O
from IN O
the DT O
group NN O
consisting VBG O
of IN O
hydrogen NN B-NP
, , O
alkyl NN B-NP
, , O
amino IN B-NP
protecting VBG O
groups NNS O
, , O
chelating VBG O
moieties NNS O
, , O
carbohydrates NNS B-NP
, , O
lipids NNS B-NP
, , O
and CC O
polymer NN O
chains NNS O
. . O

In IN O
other JJ O
embodiments NNS O
of IN O
the DT O
present JJ O
invention NN O
, , O
each DT O
of IN O
A DT O
and CC O
Q NN O
independently RB O
can MD O
be VB O
a DT O
chain NN O
of IN O
plurality NN O
of IN O
nucleotide JJ O
residues NNS O
( -LRB- O
"oligonucleotides NNS O
" '' O
) -RRB- O
or CC O
derivatives VBZ O
thereof . O
that WDT O
have VBP O
a DT O
terminal NN O
moiety NN O
capable JJ O
of IN O
forming VBG O
a DT O
bond NN O
with IN O
an DT O
amino JJ B-NP
acid NN I-NP
. . O

In IN O
one CD O
embodiment NN O
of IN O
the DT O
present JJ O
invention NN O
, , O
the DT O
chain NN O
comprising NN O
amino IN B-NP
acid NN I-NP
residues NNS I-NP
or CC O
a DT O
derivative JJ O
thereof , O
having VBG O
a DT O
nucleophilic JJ O
moiety NN O
has VBZ O
a DT O
formula NN O
( -LRB- O
II NNP O
) -RRB- O
or CC O
( -LRB- O
III NNP O
) -RRB- O
: : O

EMI7.1 . O

wherein WRB O
G NNP O
is VBZ O
an DT O
electron-donating JJ O
group NN O
, , O
such JJ O
as IN O
-OR JJ B-NP
, , O
or CC O
-SR NNP B-NP
, , O
wherein WRB O
R NN O
is VBZ O
define VB O
above IN O
. . O

In IN O
a DT O
preferred JJ O
embodiment NN O
, , O
the DT O
electron-donating JJ O
group NN O
is VBZ O
the DT O
methoxy NN B-NP
group NN O
, , O
the DT O
nucleophilic JJ O
moiety NN O
is VBZ O
3,4,5-trimethoxyphenyl JJ B-NP
or CC O
3,4,5-trimethoxybenzyl JJ B-NP
, , O
and CC O
D NNP O
is VBZ O
methylene NN B-NP
or CC O
ethylene NN B-NP
. . O

Halogenated NNP O
electrophilic JJ O
compounds NNS O
suitable JJ O
for IN O
a DT O
labeling NN O
reaction NN O
with IN O
a DT O
nucleophilic JJ O
moiety NN O
of IN O
a DT O
peptide NN B-NP
or CC O
peptide NN B-NP
derivative NN O
of IN O
the DT O
present JJ O
invention NN O
include VBP O
substituted VBN O
or CC O
unsubstituted JJ O
N-fluoropyridimium NN B-NP
salts NNS O
, , O
N-fluorobenzene NNP B-NP
sulfonamide NN I-NP
, , O
N-fluoro-N'-chloromethyl-l JJ B-NP
,4-diaza-bicyclo{2.2.2} JJ I-NP
octane NN I-NP
salts NNS I-NP
, , O
N-fluoro NNP B-NP
perfluoro NN I-NP
piperidines NNS I-NP
, , O
substituted VBN O
or CC O
unsubstituted JJ O
N-chloropyridimium NN B-NP
salts NNS I-NP
, , O
N-chlorobenzene NNP B-NP
sulfonamide NN I-NP
, , O
N-chloro-N'-chloromethyl-l JJ B-NP
,4-diaza-bicyclo{2.2.2} JJ I-NP
octane NN I-NP
salts NNS O
, , O
N- NNP B-NP
chloro NN I-NP
perchloro NN I-NP
piperidines NNS I-NP
, , O
substituted VBN O
or CC O
unsubstituted JJ O
N-bromopyridimium NN B-NP
salts NNS I-NP
, , O
N-bromobenzene NNP B-NP
sulfonamide NN I-NP
, , O
N-bromo-N'-chlorornethyl-l,4-diaza-bicyclo NNP B-NP
{2.2.2} VBD I-NP
octane NN I-NP
salts NNS O
, , O
and CC O
N-bromo NNP B-NP
perbromo NN I-NP
piperidines NNS I-NP
. . O

In IN O
one CD O
embodiment NN O
, , O
the DT O
aforementioned JJ O
salts NNS O
are VBP O
triflate JJ B-NP
salts NNS O
or CC O
tetrafluoroborate JJ O
salts NNS O
. . O

In IN O
particular JJ O
, , O
halogenated JJ O
electrophilic JJ O
compounds NNS O
suitable JJ O
for IN O
a DT O
labeling NN O
reaction NN O
with IN O
a DT O
nucleophilic JJ O
moiety NN O
of IN O
a DT O
peptide NN B-NP
or CC O
peptide NN B-NP
derivative NN O
of IN O
the DT O
present JJ O
invention NN O
have VBP O
the DT O
following VBG O
formulas NNS O
: : O

EMI8.1 . O

wherein WRB O
Me PRP O
is VBZ O
CH3 JJ B-NP
, , O
X NNP O
is VBZ O
-CF3SO3 JJ B-NP
( -LRB- O
triflate JJ B-NP
) -RRB- O
or CC O
BF4 NNP B-NP
, , O
and CC O
R NN O
is VBZ O
a DT O
substituted VBN O
or CC O
unsubstituted JJ O
alkyl NN B-NP
or CC O
alkenyl NN B-NP
group NN I-NP
having VBG O
up RP O
to TO O
and CC O
including VBG O
5 CD O
carbon NN B-NP
atoms NNS O
. . O

In IN O
one CD O
preferred JJ O
embodiment NN O
, , O
the DT O
halogenated JJ O
electrophilic JJ O
compound NN O
is VBZ O
N-fluoro- NNP B-NP
2,6-dichloro CD I-NP
pyridinium NN I-NP
triflate JJ I-NP
. . O

EXAMPLE NNP O
: : O
Direct JJ O
Labeling NNP O
of IN O
Peptide NNP B-NP
With IN O
Halogen NN B-NP

Solid-Phase JJ O
Peptide NNP B-NP
Synthesis NNPS O

First RB O
, , O
the DT O
solid-phase JJ O
synthesis NN O
technique NN O
was VBD O
employed VBN O
for IN O
the DT O
production NN O
of IN O
two CD O
peptide NN B-NP
sequences NNS O
, , O
each DT O
having VBG O
a DT O
nucleophilic JJ O
moiety NN O
. . O

The DT O
peptides NNS B-NP
sequences NNS O
were VBD O
JiFLGFL-NH2 NNP O
and CC O
J2FLGFL-NH2 NNP O
, , O
wherein WRB O
Jj NNP O
is VBZ O
3,4,5-trimethoxybenzyl JJ B-NP
glycine NN I-NP
and CC O
J2 NNP O
is VBZ O
3-(3,4,5-trimethoxyphenyl)propionic JJ B-NP
acid NN I-NP
. . O

The DT O
syntheses NNS O
of IN O
both DT O
sequences NNS O
were VBD O
equally RB O
successful JJ O
, , O
although IN O
the DT O
absence NN O
of IN O
the DT O
amino JJ B-NP
group NN O
in IN O
J2 NNP O
makes VBZ O
it PRP O
usable JJ O
as IN O
a DT O
terminus NN O
only RB O
. . O

On IN O
the DT O
other JJ O
hand NN O
, , O
Ji RB O
could MD O
be VB O
inserted VBN O
anywhere RB O
along IN O
the DT O
peptide NN B-NP
chain NN O
. . O

For IN O
these DT O
model NN O
compounds NNS O
, , O
the DT O
sequence NN O
was VBD O
chosen VBN O
to TO O
be VB O
chemically RB O
non FW O
- : O
reactive NN O
and CC O
with IN O
high JJ O
organic JJ O
solubility NN O
. . O

The DT O
J2 NNP O
peptide NN B-NP
was VBD O
synthesized VBN O
to TO O
evaluate VB O
relative JJ O
reactivity NN O
in IN O
comparison NN O
to TO O
the DT O
Ji NNP O
series NN O
and CC O
to TO O
gauge VB O
whether IN O
J2 JJ O
and CC O
Ji RB O
moieties NNS O
could MD O
be VB O
used VBN O
within IN O
the DT O
same JJ O
peptide NN B-NP
sequence NN O
. . O

Peptides NNS B-NP
were VBD O
synthesized VBN O
using VBG O
standard JJ O
solid JJ O
phase NN O
techniques NNS O
with IN O
TV^-Fmoc NNP O
- : O
protected VBD O
amino IN B-NP
acids NNS O
( -LRB- O
see VB O
; : O
e.g. FW O
, , O
W. NNP O
C. NNP O
Chan NNP O
and CC O
P.D. NNP O
White NNP O
(ed JJ O
. . O
) -RRB- O
, , O
" '' O
Fmoc NNP O
Solid JJ O
Phase NN O
Peptide NNP O
Synthesis NNP O
, , O
" `` O
pp RP O
. . O

9-40 CD O
, , O
Oxford NNP O
University NNP O
Press NNP O
, , O
New NNP O
York NNP O
, , O
New NNP O
York NNP O
( -LRB- O
2000 CD O
) -RRB- O
) -RRB- O
using VBG O
2,4-dimethoxybenzhydrylamine CD B-NP
resin NN O
( -LRB- O
Rink NNP O
Amide NNP O
AM VBP O
) -RRB- O
on IN O
a DT O
25 CD O
Dmole JJ O
scale NN O
( -LRB- O
Fmoc NNP B-NP
= SYM O
fluorenylmethoxycarbonyl NN B-NP
) -RRB- O
. . O

The DT O
peptides NNS B-NP
were VBD O
synthesized VBN O
using VBG O
a DT O
Rainin/Protein NNP O
Technology NN O
Symphony NNP O
solid JJ O
phase NN O
peptide NN B-NP
synthesizer NN O
( -LRB- O
Woburn NNP O
, , O
MA NNP O
) -RRB- O
. . O

Prior RB O
to TO O
any DT O
chemistry NN O
, , O
the DT O
resin NN O
was VBD O
swelled VBN O
for IN O
one CD O
hour NN O
in IN O
methylene NN B-NP
chloride NN I-NP
, , O
and CC O
subsequently RB O
exchanged VBD O
out RP O
with IN O
DMF NNP B-NP
( -LRB- O
dimethylformamide NN B-NP
) -RRB- O
over IN O
half DT O
- : O
hour NN O
or CC O
more JJR O
. . O

Each DT O
coupling NN O
reaction NN O
was VBD O
carried VBN O
out RP O
at IN O
room NN O
temperature NN O
in IN O
DMF NNP B-NP
with IN O
five CD O
equivalents NNS O
of IN O
amino JJ B-NP
acid NN I-NP
. . O

Reaction NN O
times NNS O
were VBD O
typically RB O
45 CD O
minutes NNS O
. . O

The DT O
coupling NN O
reagent NN O
used VBN O
was VBD O
HBTU NNP B-NP
( -LRB- O
C>-benzotriazolyl-l-yl-./V NN B-NP
, , I-NP
./VyvyV' NNP I-NP
- : I-NP
tetramethyluronium NN I-NP
hexafluorophosphate NN I-NP
) -RRB- O
, , O
with IN O
NMM JJ B-NP
(N-methylmorpholine NN O
) -RRB- O
as IN O
the DT O
base NN O
. . O

For IN O
each DT O
step NN O
the DT O
coupling NN O
agent NN O
was VBD O
delivered VBN O
at IN O
a DT O
scale NN O
of IN O
five CD O
equivalents NNS O
relative JJ O
to TO O
the DT O
estimated VBN O
resin NN O
capacity NN O
, , O
and CC O
reaction NN O
carried VBD O
out RP O
in IN O
2.5 CD O
ml NN O
of IN O
0.4 CD O
M NNP O
NMM NNP B-NP
solution NN O
in IN O
DMF. NNP B-NP

Following VBG O
each DT O
coupling VBG O
reaction NN O
, , O
the DT O
N-terminal JJ O
Fmoc-protected JJ B-NP
amine NN O
was VBD O
deprotected VBN O
by IN O
applying VBG O
20 CD O
% NN O
piperidine NN O
in IN O
DMF NNP B-NP
twice RB O
at IN O
room NN O
temperature NN O
for IN O
approximately RB O
15 CD O
minutes NNS O
. . O

After IN O
the DT O
addition NN O
of IN O
the DT O
last JJ O
residue NN O
the DT O
resin NN O
, , O
still RB O
on IN O
the DT O
peptide NN B-NP
synthesizer NN O
, , O
was VBD O
rinsed VBN O
thoroughly RB O
with IN O
DMF NNP B-NP
and CC O
methylene NN B-NP
chloride NN I-NP
. . O

To TO O
couple NN O
the DT O
Ji RB O
or CC O
J2 VB O
to TO O
the DT O
N-terminus NNP O
of IN O
the DT O
peptide NN B-NP
, , O
the DT O
amino JJ B-NP
acid NN I-NP
, , O
HBTU NNP B-NP
and CC O
NMM NNP B-NP
was VBD O
added VBN O
to TO O
the DT O
resin NN O
in IN O
the DT O
same JJ O
manner NN O
as IN O
the DT O
amino NN B-NP
acids NNS O
. . O

The DT O
reaction NN O
typically RB O
proceeded VBD O
for IN O
3 CD O
hours NNS O
, , O
at IN O
the DT O
end NN O
of IN O
which WDT O
period NN O
the DT O
Fmoc NNP B-NP
Group NNP O
was VBD O
removed VBN O
for IN O
Xj NNP O
. . O

After IN O
the DT O
reaction NN O
, , O
the DT O
N-terminal JJ O
amine JJ O
group NN O
of IN O
the DT O
peptide NN B-NP
was VBD O
capped VBN O
with IN O
an DT O
acyl NN B-NP
group NN O
by IN O
adding VBG O
0.05 CD O
M NNP O
acetic JJ B-NP
anhydride NN I-NP
, , O
0.2 CD O
M NNP O
NM NNP O
and CC O
0.05 CD O
M NNP O
HBTU NNP B-NP
in IN O
a DT O
total JJ O
volume NN O
of IN O
2.5 CD O
ml NN O
DMF. . B-NP

Post NNP O
reaction NN O
, , O
the DT O
resin NN O
was VBD O
thoroughly RB O
washed VBN O
with IN O
DMF NNP B-NP
and CC O
methylene NN B-NP
chloride NN I-NP
and CC O
dried VBD O
under IN O
a DT O
stream NN O
of IN O
nitrogen NN B-NP
. . O

Peptide NNP B-NP
Fluorination NNP O

A DT O
parallel JJ O
fluorination NN O
setup NN O
was VBD O
employed VBN O
in IN O
order NN O
to TO O
ensure VB O
similar JJ O
reaction NN O
conditions NNS O
for IN O
all DT O
the DT O
individual JJ O
peptide NN B-NP
compositions NNS O
within IN O
each DT O
fluorination NN O
experiment NN O
. . O

This DT O
was VBD O
accomplished VBN O
using VBG O
an DT O
array NN O
of IN O
Teflon NNP O
tubes NNS O
fritted VBN O
at IN O
the DT O
bottom NN O
, , O
arranged VBD O
such JJ O
that IN O
simultaneous JJ O
addition NN O
of IN O
a DT O
reagent NN O
or CC O
solvent NN O
can MD O
be VB O
achieved VBN O
from IN O
the DT O
top NN O
, , O
while IN O
simultaneous JJ O
removal NN O
of IN O
liquid NN O
can MD O
be VB O
made VBN O
by IN O
applying VBG O
vacuum NN O
below IN O
the DT O
frit NN O
. . O

Each DT O
fluorination NN O
tube NN O
was VBD O
loaded VBN O
with IN O
resin NN O
beads NNS O
containing VBG O
one CD O
of IN O
the DT O
peptide NN B-NP
to TO O
be VB O
fluorinated VBN O
, , O
amounting NN O
to TO O
6 CD O
[mu]mol NN O
peptide/tube NN B-NP
( -LRB- O
8.2 CD O
+/ NN O
- : O
0.1 CD O
mg NN O
beads/tube NN O
) -RRB- O
. . O

The DT O
tubes NNS O
were VBD O
kept VBN O
in IN O
a DT O
high JJ O
vacuum NN O
desiccator NN O
overnight RB O
. . O

Prior RB O
to TO O
fluorination NN O
, , O
the DT O
resins NNS O
were VBD O
swelled VBN O
for IN O
1 CD O
hr NN O
. . O

by IN O
adding VBG O
0.25 CD O
ml NN O
dry JJ O
dichloromethane NN B-NP
. . O

A DT O
0.1 CD O
M NNP O
solution NN O
of IN O
N-fluoro-2,6-dichloropyridinium NN B-NP
triflate( JJ I-NP
40 CD O
) -RRB- O
in IN O
dry JJ O
acetonitrile NN B-NP
was VBD O
prepared VBN O
prior RB O
to TO O
use VB O
. . O

The DT O
dichloromethane NN B-NP
solvent VBD O
used VBN O
for IN O
swelling VBG O
was VBD O
drawn VBN O
off RB O
, , O
replaced VBN O
with IN O
fresh JJ O
dry JJ O
solvent NN O
( -LRB- O
0.25 CD O
ml/tube NN O
) -RRB- O
and CC O
to TO O
each DT O
tube NN O
were VBD O
added VBN O
130 CD O
[mu]l NN O
of IN O
the DT O
fluorinating NN O
solution NN O
( -LRB- O
1.1 CD O
equivalents NNS O
vs. IN O
peptide NN B-NP
, , O
corrected VBN O
for IN O
the DT O
electron-rich JJ O
Rink NNP O
resin NN O
linker NN O
) -RRB- O
. . O

Upon IN O
a DT O
contact NN O
time NN O
of IN O
15 CD O
minutes NNS O
, , O
the DT O
liquids NNS O
were VBD O
drawn VBN O
off RB O
, , O
the DT O
beads NNS O
were VBD O
washed VBN O
with IN O
fresh JJ O
dichloromethane NN B-NP
and CC O
the DT O
resin NN O
was VBD O
submitted VBN O
to TO O
the DT O
cleavage JJ O
protocol NN O
. . O

Fluorinated NNP O
Peptide NNP B-NP
Cleavage NNP O
From IN O
Resin NN O

To TO O
cleave VB O
the DT O
peptides NNS B-NP
from IN O
the DT O
resin NN O
a DT O
cocktail NN O
consisting VBG O
of IN O
1 CD O
ml NN O
TFA NN B-NP
( -LRB- O
trifluoacetic JJ B-NP
acid NN I-NP
) -RRB- O
, , O
2.5 CD O
% NN O
TIS NNP B-NP
( -LRB- O
triisopropylsilane NN B-NP
) -RRB- O
and CC O
2.5 CD O
% NN O
water NN O
was VBD O
used VBN O
. . O

The DT O
resin NN O
and CC O
cocktail NN O
were VBD O
stirred VBN O
at IN O
room NN O
temperature NN O
for IN O
approximately RB O
3 CD O
to TO O
4 CD O
hours NNS O
. . O

The DT O
resin NN O
beads NNS O
were VBD O
filtered VBN O
off RP O
using VBG O
glass NN O
wool NN O
, , O
followed VBN O
by IN O
rinsing VBG O
with IN O
2-3 CD O
ml NN O
of IN O
TFA. NNP B-NP

The DT O
peptide NN B-NP
was VBD O
precipitated VBN O
with IN O
40 CD O
ml NN O
of IN O
ice-cold JJ O
ether NN O
and CC O
centrifuged VBD O
at IN O
3000-4000 CD O
rpm NN O
until IN O
the DT O
precipitate NN O
formed VBD O
a DT O
pellet NN O
at IN O
the DT O
bottom NN O
of IN O
the DT O
centrifuge JJ O
tube NN O
. . O

The DT O
ether NN O
was VBD O
decanted VBN O
, , O
and CC O
the DT O
pellet NN O
was VBD O
resuspended VBN O
in IN O
cold JJ O
ether NN O
( -LRB- O
40 CD O
ml NN O
) -RRB- O
and CC O
centrifuged VBD O
again RB O
; : O
the DT O
process NN O
was VBD O
repeated VBN O
two CD O
to TO O
three CD O
times NNS O
. . O

During IN O
the DT O
final JJ O
wash NN O
10 CD O
ml NN O
of IN O
Millipore NNP O
water NN O
was VBD O
added VBN O
to TO O
30 CD O
ml NN O
of IN O
cold JJ O
ether NN O
, , O
and CC O
the DT O
mixture NN O
was VBD O
centrifuged VBN O
again RB O
. . O

The DT O
ether NN O
was VBD O
decanted VBN O
. . O

The DT O
aqueous JJ O
layer NN O
, , O
containing VBG O
the DT O
crude JJ O
peptide NN B-NP
, , O
was VBD O
transferred VBN O
to TO O
a DT O
round JJ O
bottom NN O
flask NN O
for IN O
lyophilization NN O
. . O

Mass NNP O
Spectrometry NNP O
( -LRB- O
MALDI-TOF NN O
) -RRB- O
Characterization NN O

Peptide NNP B-NP
molecular JJ O
weight NN O
, , O
and CC O
hence RB O
fluorination NN O
, , O
were VBD O
analyzed VBN O
using VBG O
Time NNP O
of IN O
Flight NNP O
MALDI NNP O
mass NN O
spectrometry NN O
in IN O
the DT O
reflectron NN O
mode NN O
( -LRB- O
Applied NNP O
Biosystems NNP O
Voyager-DE NNP O
STR NNP O
, , O
Framingham NNP O
, , O
MA NNP O
) -RRB- O
. . O

Mass NNP O
Spectrometry NNP O
confirmed VBD O
that IN O
both DT O
series NN O
of IN O
compounds NNS O
, , O
JiFLGFL-NH2 NNP O
and CC O
J2FLGFL-NH2 NNP O
, , O
were VBD O
successfully RB O
fluorinated VBN O
. . O

Although IN O
the DT O
degree NN O
of IN O
fluorination NN O
was VBD O
not RB O
quantified VBN O
, , O
the DT O
predominant JJ O
peak NN O
in IN O
the DT O
MALDI NNP O
spectra NN O
was VBD O
that IN O
of IN O
the DT O
fluorinated JJ O
species NNS O
. . O

Figure NN O
1 CD O
shows VBZ O
the DT O
mass NN O
spectrum NN O
( -LRB- O
MALDI-TOF NN O
) -RRB- O
of IN O
JiFLGFL NNP O
- : O
NH2 NNP O
, , O
wherein WRB O
J] NNP O
is VBZ O
3,4,5-trimethoxybenzyl JJ B-NP
glycine NN I-NP
. . O

The DT O
expected JJ O
molecular JJ O
weight NN O
of IN O
about IN O
894 CD O
is VBZ O
seen VBN O
in IN O
the DT O
spectrum NN O
. . O

Figure NN O
2 CD O
shows VBZ O
the DT O
mass NN O
spectrum NN O
( -LRB- O
MALDI-TOF NN O
) -RRB- O
of IN O
J2FLGFL-NH2 NNP O
, , O
wherein WRB O
J2 NNP O
is VBZ O
3-(3,4,5-trimethoxyphenyl)propionic JJ B-NP
acid NN I-NP
. . O

The DT O
expected JJ O
molecular JJ O
weight NN O
of IN O
about IN O
836 CD O
is VBZ O
seen VBN O
in IN O
the DT O
spectrum NN O
. . O

Carboxyl NNP B-NP
hypofluorites NNS I-NP
are VBP O
another DT O
suitable JJ O
class NN O
of IN O
halogenated JJ O
electrophilic JJ O
compounds NNS O
when WRB O
the DT O
desired VBN O
halogen NN B-NP
is VBZ O
fluorine NN B-NP
. . O

Carboxyl NNP B-NP
hypofluorites NNS I-NP
can MD O
be VB O
generated VBN O
in-situ JJ O
by IN O
the DT O
method NN O
described VBD O
in IN O
S. NNP O
Rozen NNP O
et NNP O
al NN O
. . O
, , O
" '' O
Acetyl NNP O
Hypofluorite NNP O
, , O
the DT O
First NNP O
Member NNP O
of IN O
a DT O
New NNP O
Family NNP O
of IN O
Organic NNP O
Compounds NNP O
, , O
" '' O
J. NNP O
C. NNP O
S. NNP O
Chem NNP O
. . O

Comm. NNP O
, , O
pp RP O
. . O

443-44 CD O
( -LRB- O
1981 CD O
) -RRB- O
. . O

For IN O
example NN O
, , O
in IN O
one CD O
non-limiting JJ O
experiment NN O
demonstrating VBG O
the DT O
use NN O
of IN O
a DT O
hypofluorite NN O
to TO O
fluorinate VB O
a DT O
peptide NN B-NP
, , O
the DT O
procedure NN O
was VBD O
as IN O
follows VBZ O
. . O

Resin NN O
beads NNS O
on IN O
which WDT O
a DT O
peptide NN B-NP
was VBD O
synthesiezed VBN O
( -LRB- O
at IN O
a DT O
loading NN O
of IN O
0.45 CD O
micromoles NNS O
of IN O
peptide/mg NN B-NP
of IN O
beads NNS O
) -RRB- O
were VBD O
swollen VBN O
in IN O
fluorotrichloromethane NN B-NP
( -LRB- O
Freon-11 NN B-NP
) -RRB- O
for IN O
2 CD O
hours NNS O
at IN O
0 CD O
C NNP O
prior JJ O
to TO O
fiuorination NN O
. . O

To TO O
a DT O
Teflon NNP O
vial NN O
with IN O
cap NN O
and CC O
a DT O
teflon NN O
lined VBD O
septum NN O
was VBD O
added VBN O
a DT O
9/1 CD O
v/v NN O
mixture NN O
of IN O
Freon-1 NNP B-NP
1 CD I-NP
/acetic JJ O
acid NN B-NP
( -LRB- O
0.44 CD O
ml/micromole NN O
of IN O
peptide NN B-NP
) -RRB- O
, , O
and CC O
the DT O
mixture NN O
was VBD O
cooled VBN O
to TO O
-78C JJ O
with IN O
a DT O
dry JJ O
ice-acetone NN O
mixture NN O
. . O

A DT O
gaseous JJ O
mixture NN O
of IN O
1 CD O
% NN O
( -LRB- O
v/v NN O
) -RRB- O
F2 . B-NP
in IN O
N2 NNP B-NP
was VBD O
bubbled VBN O
through IN O
( -LRB- O
1 LS O
ml/ . O
micromole JJ O
peptide NN B-NP
) -RRB- O
, , O
and CC O
then RB O
the DT O
slurry NN O
was VBD O
sparged VBN O
with IN O
N2 NNP B-NP
. . O

A DT O
capillary NN O
passed VBD O
through IN O
a DT O
syringe NN O
needle NN O
was VBD O
used VBN O
both DT O
for IN O
dilute JJ O
F2 NNP B-NP
addition NN O
and CC O
for IN O
the DT O
N2 NNP B-NP
sparging NN O
. . O

To TO O
this DT O
mixture NN O
was VBD O
quickly RB O
added VBN O
a DT O
suspension NN O
of IN O
the DT O
beads NNS O
containing VBG O
the DT O
peptide NN B-NP
in IN O
Freon-11 NN B-NP
via IN O
canula NN O
. . O

The DT O
mixture NN O
was VBD O
stirred VBN O
at IN O
-78C JJ O
for IN O
5 CD O
minutes NNS O
, , O
then RB O
the DT O
solvent NN O
was VBD O
drawn VBN O
off RB O
and CC O
the DT O
beads NNS O
were VBD O
washed VBN O
with IN O
dichloromethane NN B-NP
. . O

Typically RB O
, , O
the DT O
reaction NN O
was VBD O
conducted VBN O
on IN O
7 CD O
-16 CD O
mg NN O
of IN O
resin-bound JJ O
peptide NN B-NP
( -LRB- O
3.15 CD O
- : O
7.2 CD O
micromoles NNS O
peptide NN B-NP
) -RRB- O
with IN O
the DT O
reagent JJ O
ratios NNS O
sateted VBD O
above RB O
. . O

Cleavage NN O
of IN O
the DT O
fluorinated JJ O
peptide NN B-NP
was VBD O
performed VBN O
as IN O
in IN O
the DT O
example NN O
disclosed VBN O
above IN O
, , O
and CC O
fiuorination NN O
was VBD O
confirmed VBN O
by IN O
MALDI-TOF. NNP O

Thus RB O
, , O
the DT O
method NN O
of IN O
the DT O
present JJ O
invention NN O
can MD O
be VB O
used VBN O
rapidly RB O
and CC O
conveniently RB O
to TO O
produce VB O
a DT O
radioactive JJ B-NP
halide NN I-NP
labeled VBN O
amino IN B-NP
acid-containing NN I-NP
compound NN O
. . O

For IN O
example NN O
, , O
an DT O
amino JJ B-NP
acid-containing NN I-NP
compound NN O
can MD O
be VB O
labeled VBN O
with IN O
a DT O
short-lived JJ O
radioactive JJ B-NP
halogen NN I-NP
, , O
such JJ O
as IN O
F NNP O
, , O
only RB O
a DT O
short JJ O
time NN O
before IN O
the DT O
labeled VBN O
compound NN O
is VBZ O
to TO O
be VB O
used VBN O
to TO O
avoid VB O
a DT O
substantial JJ O
decay NN O
of IN O
the DT O
radioactive JJ O
level NN O
, , O
from IN O
which WDT O
other JJ O
methods NNS O
typically RB O
suffer VBP O
. . O

Similarly RB O
, , O
an DT O
amino JJ B-NP
acid-containing NN I-NP
compound NN O
or CC O
a DT O
derivative JJ O
thereof , O
can MD O
be VB O
labeled VBN O
with IN O
a DT O
halogen NN B-NP
other JJ O
than IN O
fluorine NN B-NP
. . O

Moreover RB O
, , O
the DT O
procedure NN O
of IN O
the DT O
present JJ O
invention NN O
, , O
as IN O
disclosed VBN O
above IN O
, , O
is VBZ O
equally RB O
applicable JJ O
to TO O
a DT O
radioactive JJ B-NP
halogen NN I-NP
such JJ O
as IN O
any DT O
of IN O
the DT O
radioisotope NN O
of IN O
fluorine NN B-NP
, , O
chlorine NN B-NP
, , O
bromine NN B-NP
, , O
or CC O
iodine NN B-NP
disclosed VBN O
above IN O
. . O

In IN O
general JJ O
, , O
an DT O
amino JJ B-NP
acid-containing NN I-NP
compound NN O
or CC O
a DT O
derivative JJ O
thereof , O
that WDT O
can MD O
be VB O
labeled VBN O
with IN O
the DT O
method NN O
of IN O
the DT O
present JJ O
invention NN O
comprises VBZ O
at IN O
least JJS O
one CD O
amino IN B-NP
acid NN I-NP
residue NN I-NP
in IN O
a DT O
backbone NN O
chain NN O
. . O

For IN O
example NN O
, , O
such JJ O
an DT O
amino JJ B-NP
acid-containing NN I-NP
compound NN O
can MD O
be VB O
a DT O
protein NN O
or CC O
a DT O
fragment NN O
thereof RB O
. . O

Further RB O
, , O
such JJ O
a DT O
protein NN O
or CC O
fragment NN O
thereof , O
labeled VBN O
with IN O
a DT O
radioactive JJ B-NP
halogen NN I-NP
can MD O
be VB O
targeted VBN O
to TO O
disease NN O
site NN O
when WRB O
such JJ O
protein NN O
preferentially RB O
binds VBZ O
a DT O
marker NN O
substance NN O
that WDT O
is VBZ O
produced VBN O
by IN O
or CC O
associated VBN O
with IN O
the DT O
diseased JJ O
tissue NN O
. . O

Thus RB O
, , O
a DT O
labeled VBN O
protein NN O
or CC O
fragment NN O
thereof . O
produced VBD O
according VBG O
to TO O
the DT O
method NN O
of IN O
the DT O
present JJ O
invention NN O
can MD O
serve VB O
as IN O
a DT O
diagnostic JJ O
imaging NN O
or CC O
therapeutic JJ O
agent NN O
. . O

The DT O
amino JJ B-NP
acid-containing NN I-NP
compound NN O
may MD O
also RB O
be VB O
replaced VBN O
by IN O
a DT O
peptide NN B-NP
nucleic JJ O
acid NN O
( -LRB- O
"PNA" NN O
) -RRB- O
. . O

PNAs NNS O
are VBP O
oligomers NNS O
, , O
the DT O
backbone NN O
chains NNS O
of IN O
which WDT O
comprise NN O
repeating VBG O
units NNS O
of IN O
N-(2-aminoethyl)-glycine JJ B-NP
, , O
wherein WRB O
the DT O
amino JJ B-NP
nitrogen NN B-NP
of IN O
the DT O
glycine NN B-NP
moiety NN O
is VBZ O
linked VBN O
to TO O
one CD O
of IN O
five CD O
heterocyclic JJ O
bases NNS O
(adenine VBP O
, , O
guanine NNP B-NP
, , O
cytosine NN B-NP
, , O
thymine NN O
, , O
and CC O
uracil NN B-NP
) -RRB- O
through IN O
a DT O
methyl NN B-NP
carbonyl NN I-NP
linkage NN O
. . O

See VB O
; : O
e.g. FW O
, , O
U.S. NNP O
patent NN O
6,395,474 CD O
. . O

In IN O
still RB O
another DT O
embodiment NN O
, , O
the DT O
amino-acid JJ B-NP
containing VBG O
compound NN O
comprises VBZ O
at IN O
least JJS O
one CD O
amino-acid JJ B-NP
residue NN I-NP
and CC O
at IN O
least JJS O
a DT O
residue NN O
of IN O
at IN O
least JJS O
another DT O
type NN O
of IN O
monomelic JJ O
units NNS O
in IN O
the DT O
backbone NN O
chain NN O
, , O
wherein WRB O
the DT O
nucleophilic JJ O
moiety NN O
is VBZ O
conjugated VBN O
to TO O
the DT O
at IN O
least JJS O
one CD O
amino-acid JJ B-NP
residue NN I-NP
. . O

For IN O
example NN O
, , O
the DT O
at IN O
least RBS O
another DT O
type NN O
of IN O
monomeric JJ O
units NNS O
can MD O
comprise VB O
a DT O
chain NN O
of IN O
plurality NN O
of IN O
nucleotides NNS B-NP
( -LRB- O
"oligonucleotides NNS O
" '' O
) -RRB- O
or CC O
derivatives VBZ O
thereof TO O
having VBG O
an DT O
amine JJ O
functional JJ O
group NN O
at IN O
a DT O
terminus NN O
. . O

In IN O
one CD O
embodiment NN O
, , O
the DT O
at IN O
least JJS O
one CD O
amino-acid JJ B-NP
residue NN I-NP
is VBZ O
attached VBN O
to TO O
the DT O
terminal NN O
amine IN O
group NN O
of IN O
the DT O
chain NN O
of IN O
nucleotides NNS B-NP
or CC O
derivatives NNS O
thereof RB O
. . O

In IN O
one CD O
embodiment NN O
, , O
when WRB O
the DT O
radioactive JJ B-NP
halogen NN I-NP
is VBZ O
capable JJ O
of IN O
emitting VBG O
positrons NNS O
, , O
the DT O
labeled VBN O
compound NN O
is VBZ O
used VBN O
to TO O
image NN O
a DT O
portion NN O
of IN O
the DT O
body NN O
using VBG O
positron NN O
emission NN O
tomography NN O
( -LRB- O
"PET" NN O
) -RRB- O
. . O

In IN O
an DT O
embodiment NN O
, , O
the DT O
proteins NNS O
of IN O
interest NN O
in IN O
the DT O
present JJ O
invention NN O
are VBP O
antibodies NNS O
and CC O
antibody NN O
fragments NNS O
. . O

The DT O
terms NNS O
"antibodies VBZ O
" `` O
and CC O
"antibody NN O
fragments NNS O
" `` O
mean VB O
generally RB O
immunoglobulins NNS O
or CC O
fragments NNS O
thereof , O
that WDT O
specifically RB O
bind VBP O
to TO O
antigens NNS O
to TO O
form VB O
immune JJ O
complexes NNS O
. . O

The DT O
antibody NN O
may MD O
be VB O
a DT O
whole JJ O
immunoglobulin NN O
of IN O
any DT O
class NN O
; : O
e.g. FW O
, , O
IgG NNP O
, , O
IgM NNP O
, , O
IgA NNP O
, , O
IgD NNP O
, , O
IgE NNP O
, , O
chimeric JJ O
or CC O
hybrid JJ O
antibodies NNS O
with IN O
dual JJ O
or CC O
multiple JJ O
antigen NN O
or CC O
epitope NN O
specificities NNS O
. . O

It PRP O
can MD O
be VB O
a DT O
polyclonal JJ O
antibody NN O
, , O
preferably RB O
an DT O
affinity-purified JJ O
antibody NN O
from IN O
a DT O
human NN O
. . O

It PRP O
can MD O
be VB O
an DT O
antibody NN O
from IN O
an DT O
appropriate JJ O
animal NN O
; : O
e.g. FW O
, , O
a DT O
primate JJ O
, , O
goat NN O
, , O
rabbit NN O
, , O
mouse NN O
, , O
or CC O
the DT O
like JJ O
. . O

If IN O
the DT O
target NN O
site-binding NN O
region NN O
is VBZ O
obtained VBN O
from IN O
a DT O
non FW O
- : O
human JJ O
species NNS O
, , O
it PRP O
is VBZ O
preferred VBN O
that IN O
the DT O
target NN O
species NNS O
is VBZ O
humanized VBN O
to TO O
reduce VB O
immunogenicity NN O
of IN O
the DT O
non-human JJ O
antibodies NNS O
, , O
for IN O
use NN O
in IN O
human JJ O
diagnostic JJ O
or CC O
therapeutic JJ O
applications NNS O
. . O

Such JJ O
a DT O
humanized JJ O
antibody NN O
or CC O
fragment NN O
thereof , O
is VBZ O
also RB O
termed VBN O
" `` O
chimeric JJ O
. . O
" '' O

For IN O
example NN O
, , O
a DT O
chimeric JJ O
antibody NN O
comprises VBZ O
non-human JJ O
( -LRB- O
such JJ O
as IN O
murine NN O
) -RRB- O
variable JJ O
regions NNS O
and CC O
human JJ O
constant JJ O
regions NNS O
. . O

A DT O
chimeric JJ O
antibody NN O
fragment NN O
can MD O
comprise VB O
a DT O
variable JJ O
binding NN O
sequence NN O
or CC O
complementarity-determining NN O
regions NNS O
( -LRB- O
"CDR" NN O
) -RRB- O
derived VBN O
from IN O
a DT O
non-human JJ O
antibody NN O
within IN O
a DT O
human JJ O
variable JJ O
region NN O
framework NN O
domain NN O
. . O

Monoclonal NNP O
antibodies NNS O
are VBP O
also RB O
suitable JJ O
for IN O
use NN O
in IN O
the DT O
present JJ O
invention NN O
, , O
and CC O
are VBP O
preferred VBN O
because IN O
of IN O
their PRP$ O
high JJ O
specificities NNS O
. . O

They PRP O
are VBP O
readily RB O
prepared VBN O
by IN O
what WP O
are VBP O
now RB O
considered VBN O
conventional JJ O
procedures NNS O
of IN O
immunization NN O
of IN O
mammals NNS O
with IN O
an DT O
immunogenic JJ O
antigen JJ O
preparation NN O
, , O
fusion NN O
of IN O
immune JJ O
lymph NN O
or CC O
spleen JJ O
cells NNS O
with IN O
an DT O
immortal JJ O
myeloma NN O
cell NN O
line NN O
, , O
and CC O
isolation NN O
of IN O
specific JJ O
hybridoma NN O
clones NNS O
. . O

More JJR O
unconventional JJ O
methods NNS O
of IN O
preparing VBG O
monoclonal JJ O
antibodies NNS O
are VBP O
not RB O
excluded VBN O
, , O
such JJ O
as IN O
interspecies NNS O
fusions NNS O
and CC O
genetic JJ O
engineering NN O
manipulations NNS O
of IN O
hypervariable JJ O
regions NNS O
, , O
since IN O
it PRP O
is VBZ O
primarily RB O
the DT O
antigen JJ O
specificity NN O
of IN O
the DT O
antibodies NNS O
that WDT O
affects VBZ O
their PRP$ O
utility NN O
in IN O
the DT O
present JJ O
invention NN O
. . O

It PRP O
will MD O
be VB O
appreciated VBN O
that IN O
newer JJR O
techniques NNS O
for IN O
production NN O
of IN O
monoclonal JJ O
antibodies NNS O
( -LRB- O
"MAb" NN O
) -RRB- O
can MD O
also RB O
be VB O
used VBN O
; : O
e.g. FW O
, , O
human JJ O
MAbs NNS O
, , O
interspecies NNS O
MAbs NNS O
, , O
chimeric JJ O
( -LRB- O
e NN O
.g. NNP O
, , O
human/mouse NN O
) -RRB- O
MAbs NNS O
, , O
genetically RB O
engineered VBN O
antibodies NNS O
, , O
and CC O
the DT O
like JJ O
. . O

Antibody NNP O
fragments VBZ O
useful JJ O
in IN O
the DT O
present JJ O
invention NN O
include VBP O
F(ab')2 NNP O
, , O
F(ab)2 NNP O
, , O
Fab' NNP O
, , O
Fab NNP O
, , O
Fv NNP O
, , O
and CC O
the DT O
like JJ O
including VBG O
hybrid NN O
fragments NNS O
. . O

Preferred JJ O
fragments NNS O
are VBP O
Fab' NNP O
, , O
F(ab')2 NNP O
, , O
Fab NNP O
, , O
and CC O
F(ab)2 NNP O
. . O

Also RB O
useful JJ O
are VBP O
any DT O
subfragments NNS O
retaining VBG O
the DT O
hypervariable JJ O
, , O
antigen-binding JJ O
region NN O
of IN O
an DT O
immunoglobulin NN O
and CC O
having VBG O
a DT O
size NN O
similar JJ O
to TO O
or CC O
smaller JJR O
than IN O
a DT O
Fab NNP O
' POS O
fragment NN O
. . O

An DT O
antibody NN O
fragment NN O
can MD O
include VB O
genetically RB O
engineered VBN O
and/or CC O
recombinant JJ O
proteins NNS O
, , O
whether IN O
single-chain JJ O
or CC O
multiple-chain JJ O
, , O
which WDT O
incorporate VBP O
an DT O
antigen-binding JJ O
site NN O
and CC O
otherwise RB O
function VBP O
in IN O
vivo NN O
as IN O
targeting VBG O
species NNS O
in IN O
substantially RB O
the DT O
same JJ O
way NN O
as IN O
natural JJ O
immunoglobulin NN O
fragments NNS O
. . O

Such JJ O
single JJ O
- : O
chain NN O
binding NN O
molecules NNS O
are VBP O
disclosed VBN O
in IN O
U.S. NNP O
Pat NNP O
. . O

No. NN O
4,946,778 CD O
. . O

Fab NNP O
' POS O
antibody NN O
fragments NNS O
may MD O
be VB O
conveniently RB O
made VBN O
by IN O
reductive JJ O
cleavage NN O
of IN O
F(ab')2 NN O
fragments NNS O
, , O
' '' O
which WDT O
themselves PRP O
may MD O
be VB O
made VBN O
by IN O
pepsin NN O
digestion NN O
of IN O
intact JJ O
immunoglobulin NN O
. . O

Fab NNP O
antibody NN O
fragments NNS O
may MD O
be VB O
made VBN O
by IN O
papain NN O
digestion NN O
of IN O
intact JJ O
immunoglobulin NN O
, , O
under IN O
reducing VBG O
conditions NNS O
, , O
or CC O
by IN O
cleavage NN O
of IN O
F(ab)2 NN O
fragments NNS O
which WDT O
result VBP O
from IN O
careful JJ O
papain NN O
digestion NN O
of IN O
whole JJ O
immunoglobulin NN O
. . O

The DT O
fragments NNS O
may MD O
also RB O
be VB O
produced VBN O
by IN O
genetic JJ O
engineering NN O
. . O

It PRP O
should MD O
be VB O
noted VBN O
that IN O
mixtures NNS O
of IN O
antibodies NNS O
and CC O
immunoglobulin NN O
classes NNS O
can MD O
be VB O
used VBN O
, , O
as RB O
can MD O
hybrid JJ O
antibodies NNS O
. . O

Multispecific NNP O
, , O
including VBG O
bispecific JJ O
and CC O
hybrid JJ O
, , O
antibodies NNS O
and CC O
antibody NN O
fragments NNS O
are VBP O
sometimes RB O
desirable JJ O
in IN O
the DT O
present JJ O
invention NN O
for IN O
detecting VBG O
and CC O
treating VBG O
lesions NNS O
and CC O
comprise VB O
at IN O
least JJS O
two CD O
different JJ O
substantially RB O
monospecific JJ O
antibodies NNS O
or CC O
antibody NN O
fragments NNS O
, , O
wherein WRB O
at IN O
least JJS O
two CD O
of IN O
said VBD O
antibodies NNS O
or CC O
antibody NN O
fragments NNS O
specifically RB O
bind VBP O
to TO O
at IN O
least JJS O
two CD O
different JJ O
antigens NNS O
produced VBN O
or CC O
associated VBN O
with IN O
the DT O
targeted JJ O
lesion NN O
or CC O
at IN O
least JJS O
two CD O
different JJ O
epitopes NNS O
or CC O
molecules NNS O
of IN O
a DT O
marker NN O
substance NN O
produced VBN O
or CC O
associated VBN O
with IN O
the DT O
targeted JJ O
lesion NN O
. . O

Multispecific NNP O
antibodies NNS O
and CC O
antibody NN O
fragments NNS O
with IN O
dual JJ O
specificities NNS O
can MD O
be VB O
prepared VBN O
analogously RB O
to TO O
the DT O
anti-tumor JJ O
marker NN O
hybrids NNS O
disclosed VBN O
in IN O
U.S. NNP O
Patent NNP O
No. NN O
4,361 CD O
,544 CD O
. . O

Other JJ O
techniques NNS O
for IN O
preparing VBG O
hybrid JJ O
antibodies NNS O
are VBP O
disclosed VBN O
in IN O
; : O
e.g. FW O
, , O
U.S. NNP O
Patents NNP O
4,474,893 CD O
and CC O
4,479,895 CD O
, , O
and CC O
in IN O
Milstein NNP O
et NNP O
al NN O
. . O
, , O
Immunology NNP O
Today NNP O
, , O
Vol NNP O
. . O
5 CD O
, , O
299 CD O
( -LRB- O
1984 CD O
) -RRB- O
. . O

In IN O
another DT O
aspect NN O
, , O
the DT O
present JJ O
invention NN O
provides VBZ O
a DT O
set NN O
of IN O
separate JJ O
compounds NNS O
comprising VBG O
a DT O
first JJ O
compound NN O
comprising VBG O
an DT O
amino JJ B-NP
acid-containing NN I-NP
compound NN O
, , O
such JJ O
as IN O
a DT O
peptide NN B-NP
or CC O
peptide NN B-NP
derivative JJ O
, , O
that IN O
comprises VBZ O
a DT O
nucleophilic JJ O
moiety NN O
, , O
and CC O
a DT O
second JJ O
compound NN O
that WDT O
is VBZ O
electrophilic JJ O
and CC O
comprises VBZ O
a DT O
halide NN O
moiety NN O
. . O

The DT O
compounds NNS O
readily RB O
react VBP O
with IN O
one CD O
another DT O
to TO O
produce VB O
a DT O
halide-labeled JJ O
peptide NN B-NP
or CC O
peptide NN B-NP
derivative NN O
, , O
which WDT O
is VBZ O
produced VBN O
substantially RB O
at IN O
the DT O
time NN O
of IN O
use NN O
. . O

For IN O
example NN O
, , O
the DT O
first JJ O
compound NN O
may MD O
be VB O
stored VBN O
over IN O
an DT O
extended JJ O
period NN O
of IN O
time NN O
at IN O
the DT O
site NN O
of IN O
future JJ O
use NN O
. . O

The DT O
second JJ O
compound NN O
that WDT O
comprises VBZ O
a DT O
radioactive NN B-NP
halide NN I-NP
moiety NN O
is VBZ O
provided VBN O
shortly RB O
before IN O
or CC O
at IN O
the DT O
time NN O
a DT O
radioactive JJ B-NP
halide-labeled JJ I-NP
peptide NN B-NP
need MD O
be VB O
produced VBN O
. . O

Such JJ O
a DT O
set NN O
of IN O
compounds NNS O
can MD O
constitute VB O
a DT O
kit NN O
for IN O
the DT O
production NN O
of IN O
a DT O
radioactive JJ O
diagnostic JJ O
imaging NN O
agent NN O
or CC O
a DT O
radioactive JJ O
therapeutic JJ O
pharmaceutical JJ O
that DT O
is VBZ O
the DT O
product NN O
of IN O
the DT O
reaction NN O
of IN O
the DT O
compounds NNS O
. . O

While IN O
various JJ O
embodiments NNS O
are VBP O
described VBN O
herein RB O
, , O
it PRP O
will MD O
be VB O
appreciated VBN O
from IN O
the DT O
specification NN O
that IN O
various JJ O
combinations NNS O
of IN O
elements NNS O
, , O
variations NNS O
, , O
equivalents NNS O
, , O
or CC O
improvements NNS O
therein RB O
may MD O
be VB O
made VBN O
by IN O
those DT O
skilled JJ O
in IN O
the DT O
art NN O
, , O
and CC O
are VBP O
still RB O
within IN O
the DT O
scope NN O
of IN O
the DT O
invention NN O
as IN O
defined VBN O
in IN O
the DT O
appended JJ O
claims NNS O
. . O

WHAT WDT O
IS VBZ O
CLAIMED VBN O
IS VBZ O
: : O

1 CD O
. . O

A DT O
method NN O
for IN O
labeling VBG O
an DT O
amino JJ B-NP
acid-containing NN I-NP
compound NN O
with IN O
a DT O
halide NN O
moiety NN O
, , O
the DT O
method NN O
comprising NN O
reacting VBG O
a DT O
halogenated JJ O
electrophilic JJ O
compound NN O
with IN O
a DT O
nucleophilic JJ O
moiety NN O
of IN O
the DT O
amino JJ B-NP
acid-containing NN I-NP
compound NN O
, , O
wherein WRB O
the DT O
nucleophilic JJ O
moiety NN O
comprises VBZ O
at IN O
least JJS O
one CD O
aromatic JJ O
ring NN O
that WDT O
is VBZ O
substituted VBN O
with IN O
at IN O
least JJS O
one CD O
electron-donating JJ O
group NN O
, , O
and CC O
the DT O
halogenated JJ O
electrophilc JJ O
compound NN O
is VBZ O
selected VBN O
from IN O
the DT O
group NN O
consisting VBG O
of IN O
substituted VBN O
and CC O
unsubstituted JJ O
N-fluoropyridimium NNP B-NP
salts NNS O
, , O
N- NNP B-NP
fluorobenzene NN I-NP
sulfonamide NN I-NP
, , O
N-fluoro-N'-chloromethyl-l,4-diaza-bicyclo NNP B-NP
{2.2.2} VBD I-NP
octane NN I-NP
salts NNS I-NP
, , O
N-fluoro NNP B-NP
perfluoro NN I-NP
piperidines NNS I-NP
, , O
substituted VBN O
or CC O
unsubstituted JJ O
N- : B-NP
chloropyridimium NN I-NP
salts NNS I-NP
, , O
N-chlorobenzene NNP B-NP
sulfonamide NN I-NP
, , O
N-chloro-N'-chloromethyl- NNP B-NP
l JJ I-NP
,4-diaza-bicyclo{2.2.2} JJ I-NP
octane NN I-NP
salts NNS O
, , O
N-chloro NNP B-NP
perchloro NN I-NP
piperidines NNS I-NP
, , O
substituted VBN O
or CC O
unsubstituted JJ O
N-bromopyridimium NN B-NP
salts NNS I-NP
, , O
N-bromobenzene NNP B-NP
sulfonamide NN I-NP
, , O
N-bromo-N'- NNP B-NP
chloromethyl-l,4-diaza-bicyclo{2.2.2} NN I-NP
octane NN I-NP
salts NNS O
, , O
and CC O
N-bromo NNP B-NP
perbromo NN I-NP
piperidines NNS I-NP
. . O

2. DT O
The DT O
method NN O
according VBG O
to TO O
claim NN O
1 CD O
, , O
further JJ O
comprising NN O
providing VBG O
the DT O
nucleophilic JJ O
moiety NN O
to TO O
the DT O
amino JJ B-NP
acid-containing NN I-NP
compound NN O
before IN O
the DT O
step NN O
of IN O
reacting VBG O
. . O

3. DT O
The DT O
method NN O
according VBG O
to TO O
claim NN O
2 CD O
, , O
wherein WRB O
said VBD O
providing VBG O
the DT O
nucleophilic JJ O
moiety NN O
to TO O
the DT O
amino JJ B-NP
acid-containing NN I-NP
compound NN O
comprises VBZ O
linking VBG O
the DT O
nucleophilic JJ O
moiety NN O
to TO O
a DT O
residue NN O
of IN O
the DT O
amino JJ B-NP
acid-containing NN I-NP
compound NN O
. . O

4 LS O
. . O
The DT O
method NN O
according VBG O
to TO O
claim NN O
1 CD O
, , O
wherein WRB O
the DT O
nucleophilic JJ O
moiety NN O
comprises VBZ O
from IN O
one CD O
to TO O
three CD O
aromatic JJ O
rings NNS O
which WDT O
are VBP O
substituted VBN O
with IN O
at IN O
least JJS O
one CD O
electron NN O
- : O
donating VBG O
group NN O
selected VBN O
from IN O
the DT O
group NN O
consisting VBG O
of IN O
-OR<1> JJ B-NP
and CC O
-SR<1> JJ B-NP
, , O
wherein WRB O
R<1> NNP O
is VBZ O
- : O
CHmHm+[iota JJ O
] SYM O
and CC O
1 CD O
< JJ O
m NN O
< IN O
5 CD O
. . O

5 CD O
. . O
The DT O
method NN O
according VBG O
to TO O
claim VB O
4 CD O
, , O
wherein WRB O
the DT O
nucleophilic JJ O
moiety NN O
is VBZ O
selected VBN O
from IN O
the DT O
group NN O
consisting VBG O
of IN O
trimethoxyphenyl NN B-NP
and CC O
trimethoxybenzyl NN B-NP
. . O

6 CD O
. . O

The DT O
method NN O
according VBG O
to TO O
claim NN O
1 CD O
, , O
wherein WRB O
the DT O
halogenated JJ O
electrophilc JJ O
compound NN O
is VBZ O
selected VBN O
from IN O
the DT O
group NN O
consisting VBG O
of IN O
substituted VBN O
and CC O
unsubstituted JJ O
N- NNP B-NP
fluoropyridimium NN I-NP
salts NNS O
. . O

7. DT O
The DT O
method NN O
according VBG O
to TO O
claim NN O
6 CD O
, , O
wherein WRB O
the DT O
halogenated JJ O
electrophilc JJ O
compound NN O
is VBZ O
N-fluoro-2,6-dichloro JJ B-NP
pyridimium NN I-NP
triflate NN I-NP
. . O

8. DT O
The DT O
method NN O
according VBG O
to TO O
claim NN O
1 CD O
, , O
wherein WRB O
the DT O
halogenated JJ O
electrophilc JJ O
compound NN O
comprises VBZ O
a DT O
radioactive NN B-NP
halogen NN I-NP
. . O

9 CD O
. . O
The DT O
method NN O
according VBG O
to TO O
claim VB O
8 CD O
, , O
wherein WRB O
the DT O
radioactive JJ B-NP
halogen NN I-NP
is VBZ O
<18>F NNP B-NP
. . O

10 CD O
. . O

The DT O
method NN O
according VBG O
to TO O
claim NN O
1 CD O
, , O
wherein WRB O
the DT O
amino JJ B-NP
acid-containing NN I-NP
compound NN O
is VBZ O
selected VBN O
from IN O
the DT O
group NN O
consisting VBG O
of IN O
peptides NNS B-NP
, , O
peptides NNS B-NP
derivatives NNS O
, , O
proteins NNS O
, , O
antibodies NNS O
, , O
amino IN B-NP
acid-containing NN I-NP
oligonucleotides NNS B-NP
, , O
derivatives VBZ O
thereof RB O
, , O
and CC O
fragments NNS O
thereof RB O
. . O

11 CD O
. . O

A DT O
method NN O
for IN O
producing VBG O
a DT O
labeled VBN O
amino IN B-NP
acid-containing NN I-NP
compound NN O
, , O
the DT O
method NN O
comprising NN O
: : O

attaching VBG O
a DT O
group NN O
comprising VBG O
a DT O
nucleophilic JJ O
moiety NN O
to TO O
an DT O
unlabeled JJ O
amino IN B-NP
acid NN I-NP
- : O
containing VBG O
compound NN O
; : O
and CC O

reacting VBG O
a DT O
halogenated JJ O
electrophilic JJ O
compound NN O
with IN O
the DT O
nucleophilic JJ O
moiety NN O
that WDT O
is VBZ O
attached VBN O
to TO O
the DT O
amino JJ B-NP
acid-containing NN I-NP
compound NN O
; : O

wherein WRB O
the DT O
nucleophilic JJ O
moiety NN O
comprises VBZ O
at IN O
least JJS O
one CD O
aromatic JJ O
ring NN O
that WDT O
is VBZ O
substituted VBN O
with IN O
at IN O
least JJS O
one CD O
electron-donating JJ O
group NN O
, , O
and CC O
the DT O
halogenated JJ O
electrophilc JJ O
compound NN O
is VBZ O
selected VBN O
from IN O
the DT O
group NN O
consisting VBG O
of IN O
substituted VBN O
and CC O
unsubstituted JJ O
N- NNP B-NP
fluoropyridimium NN I-NP
salts NNS O
, , O
N-fluorobenzene NNP B-NP
sulfonamide NN I-NP
, , O
N-fiuoro-N'-chloromethyl- NNP B-NP
l JJ I-NP
,4-diaza-bicyclo{2.2.2} JJ I-NP
octane NN I-NP
salts NNS O
, , O
N-fluoro NNP B-NP
perfluoro NN I-NP
piperidines NNS I-NP
, , O
substituted VBN O
or CC O
unsubstituted JJ O
N-chloropyridimium NN B-NP
salts NNS I-NP
, , O
N-chlorobenzene NNP B-NP
sulfonamide NN I-NP
, , O
N-chloro-N'- NNP B-NP
chloromethyl-l NN I-NP
,4-diaza-bicyclo{2.2.2} JJ I-NP
octane NN I-NP
salts NNS O
, , O
N-chloro NNP B-NP
perchloro NN I-NP
piperidines NNS I-NP
, , O
substituted VBN O
or CC O
unsubstituted JJ O
N-bromopyridimium NN B-NP
salts NNS I-NP
, , O
N-bromobenzene NNP B-NP
sulfonamide NN I-NP
, , O
N-bromo-N'-chloromethyl-l JJ B-NP
,4-diaza-bicyclo{2.2.2} JJ I-NP
octane NN I-NP
salts NNS O
, , O
and CC O
N-bromo NNP B-NP
perbromo NN I-NP
piperidines NNS I-NP
. . O

12 CD O
. . O
The DT O
method NN O
according VBG O
to TO O
claim NN O
1 CD O
1 CD O
, , O
wherein WRB O
said VBD O
attaching NN O
comprising NN O
inserting VBG O
a DT O
residue NN O
of IN O
a DT O
derivative NN O
of IN O
an DT O
amino JJ B-NP
acid NN I-NP
in IN O
a DT O
chain NN O
of IN O
the DT O
amino JJ B-NP
acid NN I-NP
- : O
containing VBG O
compound NN O
, , O
said VBD O
residue JJ O
comprising NN O
said VBD O
nucleophilic JJ O
moiety NN O
. . O

13 CD O
. . O

A DT O
labeled VBN O
amino IN B-NP
acid-containing NN I-NP
compound NN O
having VBG O
a DT O
formula NN O
of IN O

o IN O

HN. NNP O
JL NNP O

wherein WRB O
at IN O
least JJS O
one CD O
of IN O
A NNP O
and CC O
Q NNP O
is VBZ O
independently RB O
selected VBN O
from IN O
the DT O
group NN O
consisting VBG O
of IN O
peptides NNS B-NP
, , O
proteins NNS O
, , O
antibodies NNS O
, , O
peptide NN B-NP
nucleic JJ O
acids NNS O
, , O
amino IN B-NP
acid-containing NN I-NP
oligonucleotides NNS B-NP
, , O
derivatives VBZ O
thereof RB O
, , O
and CC O
fragments NNS O
thereof , O
; : O
D NNP O
is VBZ O
selected VBN O
from IN O
the DT O
group NN O
consisting VBG O
of IN O
a DT O
direct JJ O
covalent JJ O
bond NN O
, , O
divalent JJ O
saturated JJ O
or CC O
unsaturated JJ O
hydrocarbyl NN B-NP
groups NNS O
, , O
and CC O
derivatives VBZ O
thereof RB O
having VBG O
from IN O
one CD O
to TO O
ten CD O
carbon NN B-NP
atoms NNS O
, , O
inclusive JJ O
; : O
and CC O
E NNP O
comprises VBZ O
a DT O
nucleophilic JJ O
moiety NN O
. . O

14 CD O
. . O

The DT O
labeled VBN O
amino IN B-NP
acid-containing NN I-NP
compound NN O
according VBG O
to TO O
claim NN O
13 CD O
, , O
wherein WRB O
at IN O
least JJS O
one CD O
of IN O
A NNP O
and CC O
Q NNP O
is VBZ O
a DT O
peptide NN B-NP
. . O

15 CD O
. . O

The DT O
labeled VBN O
amino IN B-NP
acid-containing NN I-NP
compound NN O
according VBG O
to TO O
claim NN O
13 CD O
, , O
wherein WRB O
A DT O
is VBZ O
a DT O
peptide NN B-NP
, , O
and CC O
Q NNP O
is VBZ O
selected VBN O
from IN O
the DT O
group NN O
consisting VBG O
of IN O
peptides NNS B-NP
, , O
amino IN B-NP
acid NN I-NP
- : O
containing VBG O
oligonucleotides NNS B-NP
, , O
-COOR<1> JJ O
, , O
-CONR<2>R<3> JJ B-NP
, , O
-SO3H JJ B-NP
, , O
-SO2NR<2>R<3> JJ B-NP
, , O
and CC O
derivatives VBZ O
thereof TO O
; : O
wherein WRB O
R<1> NNP O
is VBZ O
-CmHm+i JJ O
, , O
n RB O
and CC O
m PRP O
are VBP O
integers NNS O
independently RB O
selected VBN O
from IN O
the DT O
group NN O
consisting VBG O
of IN O
1 CD O
, , O
2 CD O
, , O
3 CD O
, , O
4 CD O
, , O
and CC O
5 CD O
; : O
and CC O
R<2> NNP O
and CC O
R<3> NNP O
are VBP O
independently RB O
selected VBN O
from IN O
the DT O
group NN O
consisting VBG O
of IN O
hydrogen NN B-NP
, , O
alkyl NN B-NP
, , O
amino IN B-NP
protecting VBG O
groups NNS O
, , O
chelating VBG O
moieties NNS O
, , O
carbohydrates NNS B-NP
, , O
lipids NNS B-NP
, , O
and CC O
polymer NN O
chains NNS O
. . O

16 CD O
. . O

The DT O
labeled VBN O
amino IN B-NP
acid-containing NN I-NP
compound NN O
according VBG O
to TO O
claim NN O
13 CD O
, , O
wherein WRB O
D NNP O
is VBZ O
selected VBN O
from IN O
the DT O
group NN O
consisting VBG O
of IN O
-(O-CH2-CH2 DT B-NP
)n-, JJ I-NP
-(S-CH2-CH2 NN B-NP
) -RRB- I-NP
,,-, , O
or CC O
- : B-NP
( -LRB- I-NP
NR NNP I-NP
-CH2-CH2)P-, : I-NP
R<1> NNP O
is VBZ O
-CItlHm+i JJ O
, , O
and CC O
n NN O
and CC O
m NN O
are VBP O
integers NNS O
independently RB O
selected VBN O
from IN O
the DT O
group NN O
consisting VBG O
of IN O
1 CD O
, , O
2 CD O
, , O
3 CD O
, , O
4 CD O
, , O
and CC O
5 CD O
. . O

17 CD O
. . O

The DT O
labeled VBN O
amino IN B-NP
acid-containing NN I-NP
compound NN O
according VBG O
to TO O
claim NN O
13 CD O
, , O
wherein WRB O
E NNP O
comprises VBZ O
from IN O
one CD O
to TO O
three CD O
aromatic JJ O
rings NNS O
, , O
substituted VBN O
with IN O
at IN O
least JJS O
one CD O
electron NN O
- : O
donating VBG O
group NN O
selected VBN O
from IN O
the DT O
group NN O
consisting VBG O
of IN O
-OR<1> JJ B-NP
and CC O
-SR<1> JJ B-NP
, , O
wherein WRB O
R<1> NNP O
is VBZ O
- : O
CmHm+i NN B-NP
and CC O
m NN O
is VBZ O
an DT O
integer NN O
such JJ O
that IN O
1 CD O
< NN O
m NN O
< IN O
5 CD O
. . O

18 CD O
. . O

The DT O
labeled VBN O
amino IN B-NP
acid-containing NN I-NP
compound NN O
according VBG O
to TO O
claim NN O
17 CD O
, , O
wherein WRB O
E NNP O
is VBZ O
selected VBN O
from IN O
the DT O
group NN O
consisting VBG O
of IN O
trimethoxyphenyl NN B-NP
and CC O
trimethoxybenzyl NN B-NP
. . O

19 CD O
. . O

The DT O
labeled VBN O
amino IN B-NP
acid-containing NN I-NP
compound NN O
according VBG O
to TO O
claim NN O
13 CD O
, , O
wherein WRB O
the DT O
amino JJ B-NP
acid-containing NN I-NP
compound NN O
is VBZ O
labeled VBN O
with IN O
a DT O
halide NN B-NP
moiety NN O
. . O

20 CD O
. . O

The DT O
labeled VBN O
amino IN B-NP
acid-containing NN I-NP
compound NN O
according VBG O
to TO O
claim NN O
19 CD O
, , O
wherein WRB O
the DT O
halide NN O
moiety NN O
is VBZ O
radioactive JJ O
. . O

21 CD O
. . O

The DT O
labeled VBN O
amino IN B-NP
acid-containing NN I-NP
compound NN O
according VBG O
to TO O
claim NN O
20 CD O
, , O
wherein WRB O
the DT O
radioactive JJ B-NP
halide NN I-NP
moiety NN O
emits VBZ O
positrons NNS O
. . O

22 CD O
. . O
The DT O
labeled VBN O
amino IN B-NP
acid-containing NN I-NP
compound NN O
according VBG O
to TO O
claim NN O
20 CD O
, , O
wherein WRB O
the DT O
halide NN B-NP
moiety NN O
is VBZ O
F. NNP B-NP

23 CD O
. . O

A DT O
kit NN O
comprising VBG O
a DT O
first JJ O
compound NN O
and CC O
a DT O
second JJ O
compound NN O
that WDT O
are VBP O
kept VBN O
separate JJ O
, , O
wherein WRB O
said VBD O
first JJ O
compound NN O
comprises VBZ O
an DT O
amino NN B-NP
acid-containing NN I-NP
compound NN O
comprising VBG O
a DT O
nucleophilic JJ O
moiety NN O
that WDT O
comprises VBZ O
at IN O
least JJS O
one CD O
aromatic JJ O
ring NN O
that WDT O
is VBZ O
substituted VBN O
with IN O
at IN O
least JJS O
one CD O
electron-donating JJ O
group NN O
, , O
and CC O
said VBD O
second JJ O
compound NN O
is VBZ O
an DT O
halogenated JJ O
electrophilic JJ O
compound NN O
that WDT O
is VBZ O
selected VBN O
from IN O
the DT O
group NN O
consisting VBG O
of IN O
substituted VBN O
and CC O
unsubstituted JJ O
N-fluoropyridimium NNP B-NP
salts NNS O
, , O
N-fluorobenzene NNP B-NP
sulfonamide NN I-NP
, , O
N-fluoro-N'-chloromethyl-l,4-diaza-bicyclo{2.2.2} JJ B-NP
octane NN I-NP
salts NNS I-NP
, , O
N- NNP B-NP
fluoro VBD I-NP
perfluoro RB I-NP
piperidines NNS I-NP
, , O
substituted VBN O
or CC O
unsubstituted JJ O
N-chloropyridimium NN B-NP
salts NNS I-NP
, , O
N-chlorobenzene NNP B-NP
sulfonamide NN I-NP
, , O
N-chloro-N'-chloromethyl-l JJ B-NP
,4-diaza-bicyclo JJ I-NP
{2.2.2] JJ I-NP
octane NN I-NP
salts NNS I-NP
, , O
N-chloro NNP B-NP
perchloro NN I-NP
piperidines NNS I-NP
, , O
substituted VBN O
or CC O
unsubstituted JJ O
N- NNP B-NP
bromopyridimium NN I-NP
salts NNS I-NP
, , O
N-bromobenzene NNP B-NP
sulfonamide NN I-NP
, , O
N-bromo-N'-chloromethyl- NNP B-NP
1 CD I-NP
,4-diaza-bicyclo . I-NP
{2.2.2} IN I-NP
octane NN I-NP
salts NNS I-NP
, , O
and CC O
N-bromo NNP B-NP
perbromo NN I-NP
piperidines NNS I-NP
. . O

24 CD O
. . O

The DT O
kit NN O
according VBG O
to TO O
claim NN O
23 CD O
, , O
wherein WRB O
the DT O
nucleophilic JJ O
moiety NN O
comprises VBZ O
from IN O
one CD O
to TO O
three CD O
aromatic JJ O
rings NNS O
which WDT O
are VBP O
substituted VBN O
with IN O
at IN O
least JJS O
one CD O
electron-donating JJ O
group NN O
selected VBN O
from IN O
the DT O
group NN O
consisting VBG O
of IN O
-OR<1> JJ B-NP
and CC O
SR<1> JJ B-NP
, , O
wherein WRB O
R<1> NNP O
is VBZ O
- : O
CH111H1n+ JJ O
, , O
and CC O
1 CD O
< JJ O
m NN O
< IN O
5 CD O
. . O

25 CD O
. . O

The DT O
kit NN O
according VBG O
to TO O
claim VB O
24 CD O
, , O
wherein WRB O
the DT O
nucleophilic JJ O
moiety NN O
is VBZ O
selected VBN O
from IN O
the DT O
group NN O
consisting VBG O
of IN O
trimethoxyphenyl NN B-NP
and CC O
trimethoxybenzyl NN B-NP
. . O

26 CD O
. . O

The DT O
kit NN O
according VBG O
to TO O
claim NN O
23 CD O
, , O
wherein WRB O
the DT O
halogenated JJ O
electrophilc JJ O
compound NN O
is VBZ O
selected VBN O
from IN O
the DT O
group NN O
consisting VBG O
of IN O
substituted VBN O
and CC O
unsubstituted JJ O
N- NNP B-NP
fluoropyridimium NN I-NP
salts NNS O
. . O

27 CD O
. . O

The DT O
kit NN O
according VBG O
to TO O
claim NN O
26 CD O
, , O
wherein WRB O
the DT O
halogenated JJ O
electrophilc JJ O
compound NN O
is VBZ O
N-fluoro-2,6-dichloro JJ B-NP
pyridimium NN I-NP
triflate NN I-NP
. . O

28 CD O
. . O

The DT O
kit NN O
according VBG O
to TO O
claim NN O
23 CD O
, , O
wherein WRB O
the DT O
halogenated JJ O
electrophilc JJ O
compound NN O
comprises VBZ O
a DT O
radioactive NN B-NP
halogen NN I-NP
. . O

29 CD O
. . O

The DT O
kit NN O
according VBG O
to TO O
claim NN O
28 CD O
, , O
wherein WRB O
the DT O
radioactive JJ B-NP
halogen NN I-NP
is VBZ O
<18>F NNP B-NP
. . O

30 CD O
. . O

The DT O
kit NN O
according VBG O
to TO O
claim NN O
23 CD O
, , O
wherein WRB O
at IN O
least JJS O
a DT O
portion NN O
of IN O
the DT O
amino JJ B-NP
acid NN I-NP
- : O
containing VBG O
compound NN O
is VBZ O
selected VBN O
from IN O
the DT O
group NN O
consisting VBG O
of IN O
peptides NNS B-NP
, , O
peptides NNS B-NP
derivatives NNS O
, , O
peptide NN B-NP
nucleic JJ O
acids NNS O
, , O
proteins NNS O
, , O
antibodies NNS O
, , O
amino IN B-NP
acid-containing NN I-NP
oligonucleotides NNS B-NP
, , O
derivatives VBZ O
thereof RB O
, , O
and CC O
fragments NNS O
thereof RB O
. . O

-DOCSTART- X X O

[0001] JJ O
Glucosaminylmuramic JJ B-NP
acid NN I-NP
derivatives NNS O

Technical NNP O
field NN O
of IN O
the DT O
invention NN O

The DT O
invention NN O
deals VBZ O
with IN O
glucosaminylmuramic JJ B-NP
acid NN I-NP
(2-amino-2-deoxy-[beta]-D-gluco : O
- : B-NP
pyranosyl-(l->4)-iV-acetylmuramic JJ I-NP
acid NN I-NP
) -RRB- O
derivatives VBZ O
, , O
method NN O
of IN O
their PRP$ O
synthesis NN O
, , O
and CC O
their PRP$ O
use NN O
for IN O
the DT O
synthesis NN O
of IN O
glucosaminylmuramyl NN B-NP
glycopeptides NNS O
, , O
i IN O
.e NN O
. . O
disaccharide VB B-NP
analogues NNS O
of IN O
muramyl NN B-NP
glycopeptides NNS I-NP
. . O

Background NN O
of IN O
the DT O
invention NN O

Immunopharmaceutics NNP O
represent VBP O
a DT O
new JJ O
group NN O
of IN O
drugs NNS O
that WDT O
already RB O
have VBP O
an DT O
irreplaceable JJ O
role NN O
in IN O
modern JJ O
clinical JJ O
practice NN O
. . O

Disorders NNS O
of IN O
the DT O
organism NN O
immune JJ O
capacity NN O
due RB O
to TO O
negative JJ O
changes NNS O
in IN O
the DT O
environment NN O
, , O
an DT O
increased VBN O
occurrence NN O
of IN O
pathogenic JJ O
microorganisms NNS O
resistant JJ O
to TO O
antibiotics NNS O
, , O
and CC O
infections NNS O
damaged VBN O
immunity NN O
( -LRB- O
e NN O
.g NN O
. . O

AIDS NNP O
) -RRB- O
as RB O
well RB O
as IN O
a DT O
frequent JJ O
application NN O
of IN O
immunosuppressive JJ O
therapeutic JJ O
procedures NNS O
such JJ O
as IN O
radio NN O
- : O
and CC O
chemotherapy NN O
of IN O
tumor NN O
diseases NNS O
, , O
just RB O
as IN O
following VBG O
transplantations NNS O
, , O
present VB O
a DT O
serious JJ O
medical JJ O
problem NN O
. . O

The DT O
present JJ O
tendency NN O
to TO O
replace VB O
live JJ O
vaccines NNS O
by IN O
safer JJR O
semi-synthetic JJ O
, , O
recombinant JJ O
, , O
and CC O
synthetic JJ O
ones NNS O
requires VBZ O
new JJ O
structurally RB O
defined VBN O
adjuvants NNS O
. . O

Therefore RB O
, , O
considerable JJ O
attention NN O
is VBZ O
devoted VBN O
to TO O
the DT O
development NN O
of IN O
substances NNS O
with IN O
immunostimulatory JJ O
activity NN O
with IN O
the DT O
aim NN O
to TO O
obtain VB O
a DT O
) -RRB- O
safe JJ O
, , O
structurally RB O
defined VBN O
adjuvants NNS O
for IN O
protein NN O
, , O
peptide NN B-NP
and CC O
DNA NNP O
vaccines NNS O
, , O
b NN O
) -RRB- O
stimulators NNS O
of IN O
nonspecific JJ O
antiinfectious JJ O
and CC O
antitumor JJ O
immunity NN O
, , O
and CC O
c NNS O
) -RRB- O
stimulators NNS O
of IN O
hemopoiesis NN O
. . O

Important JJ O
representatives NNS O
of IN O
such JJ O
compounds NNS O
are VBP O
muramyl NN B-NP
glycopeptides NNS I-NP
that WDT O
are VBP O
derived VBN O
from IN O
peptidoglycan JJ B-NP
fragments NNS O
of IN O
bacterial JJ O
cell NN O
wall NN O
, , O
i IN O
.e NN O
. . O
compounds NNS O
derived VBN O
from IN O
the DT O
minimal JJ O
immunoadjuvant JJ O
unit NN O
, , O
"muramyl NN O
dipeptide NN B-NP
" '' O
( -LRB- O
MDP NNP B-NP
) -RRB- O
, , O
and CC O
basic JJ O
repeating VBG O
disaccharide-dipeptide JJ B-NP
unit NN O
, , O
"glucosaminyl-muramyl-dipeptide JJ O
" `` O
( -LRB- O
GMDP NNP B-NP
) -RRB- O
. . O

During IN O
the DT O
past JJ O
three CD O
decades NNS O
many JJ O
analogues NNS O
of IN O
MDP NNP B-NP
and CC O
GMDP NNP B-NP
were VBD O
synthesized VBN O
in IN O
order NN O
to TO O
increase VB O
the DT O
specificity NN O
of IN O
therapeutic JJ O
activity NN O
and CC O
to TO O
suppress VB O
undesired JJ O
side NN O
effects NNS O
, , O
especially RB O
pyrogenicity NN O
. . O

This DT O
effort NN O
led VBD O
to TO O
compounds NNS O
interesting JJ O
for IN O
pharmaceutical JJ O
industry NN O
( -LRB- O
for IN O
review NN O
see VBP O
ref NN O
. . O
) -RRB- O
. . O

From IN O
MDP NNP B-NP
derived VBD O
compounds NNS O
, , O
therapeutic JJ O
Romurtid( NNP O
TM) NNP O
( -LRB- O
MDP-Lys-L-18 NN B-NP
) -RRB- O
, , O
based VBN O
on IN O
MDP NNP B-NP
molecule NN O
prolonged VBN O
in IN O
the DT O
peptide NN B-NP
part NN O
by IN O
Lys NNP O
substituted VBD O
with IN O
stearoyl NN B-NP
residue NN O
, , O
is VBZ O
in IN O
the DT O
most JJS O
progressed VBD O
phase NN O
of IN O
development NN O
. . O

Romurtid( NNP O
TM) NNP O
is VBZ O
less RBR O
pyrogenic JJ O
than IN O
MDP NNP B-NP
and CC O
successfully RB O
passed VBD O
clinical JJ O
trials NNS O
. . O

Principal JJ O
practical JJ O
application NN O
is VBZ O
stimulation NN O
of IN O
hemopoiesis NN O
in IN O
patients NNS O
after IN O
radiotherapy NNP O
or CC O
chemotherapy<3"5> NN O
. . O

Acceleration NNP O
of IN O
neutrophil JJ O
number NN O
normalization NN O
in IN O
periphery JJ O
blood NN O
is VBZ O
important JJ O
in IN O
order NN O
to TO O
suppress VB O
the DT O
risk NN O
of IN O
infection NN O
in IN O
immunosuppressed JJ O
patients<6 NNS O
>'<7> VBP O
. . O

Romurtid( NNP O
TM) NNP O
is VBZ O
also RB O
able JJ O
to TO O
increase VB O
natural JJ O
immunity NN O
against IN O
viral<8> JJ O
and CC O
bacterial<9 JJ O
> NNS O
'<10> VBP O
infections NNS O
and CC O
tumor NN O
growth<11> NN O
. . O

GMDP NNP B-NP
, , O
in IN O
comparison NN O
with IN O
MDP NNP B-NP
, , O
has VBZ O
higher JJR O
immunoadjuvant JJ O
activity NN O
and CC O
lower JJR O
pyrogenicity NN O
. . O

Hence RB O
, , O
the DT O
compounds NNS O
derived VBN O
from IN O
GMDP NNP B-NP
are VBP O
more JJR O
perspective NN O
potential NN O
immunotherapeutics NNS O
than IN O
compounds NNS O
derived VBN O
from IN O
MDP<2> NNP B-NP
. . O

GMDP-based JJ B-NP
compound NN O
Likopid( IN B-NP
TM) NNP O
is VBZ O
the DT O
first JJ O
immunotherapeutic NN O
of IN O
the DT O
muramyl NN O
glycopeptide NN B-NP
type NN O
introduced VBN O
to TO O
the DT O
clinical JJ O
practice NN O
. . O

Likopid( IN B-NP
TM) NNP O
was VBD O
developed VBN O
and CC O
registered VBN O
by IN O
a DT O
Russian JJ O
company NN O
Peptek NNP O
as IN O
an DT O
immunotherapeutic JJ O
with IN O
broad JJ O
applicability NN O
, , O
e.g NN O
. . O

immunostimulation NN O
and CC O
prevention NN O
of IN O
infections NNS O
complicating VBG O
post-traumatic JJ O
, , O
post-operative JJ O
, , O
post-chemotherapeutic JJ O
and CC O
post- NNS O
radiotherapeutic JJ O
patienthood<12> NN O
. . O

Other JJ O
areas NNS O
are VBP O
treatment NN O
of IN O
infectious JJ O
diseases NNS O
, , O
as IN O
tuberculosis NN O
, , O
human JJ O
cervical JJ O
papilomavirus NN O
, , O
ophthalmic JJ O
herpetic JJ O
infections NNS O
, , O
psoriasis NN O
and CC O
treatment NN O
of IN O
ulcerous JJ O
and CC O
inflammation NN O
processes NNS O
. . O

Likopid( IN B-NP
TM) NNP O
can MD O
be VB O
used VBN O
alone RB O
or CC O
in IN O
combination NN O
with IN O
antibiotics NNS O
and CC O
antivirotics<13> JJ O
for IN O
treatment NN O
of IN O
infectious JJ O
diseases NNS O
. . O

Side NNP O
effects NNS O
are VBP O
associated VBN O
with IN O
pyrogenicity NN O
that IN O
stems NNS O
from IN O
the DT O
active JJ O
component NN O
GMDP. . B-NP

Company NNP O
ImmunoTherapeutics NNP O
, , O
Inc. NNP O
, , O
North NNP O
Dacota NNP O
, , O
USA NNP O
, , O
is VBZ O
developing VBG O
lipophilic JJ O
analogues NNS O
of IN O
GMDP NNP B-NP
, , O
e.g NN O
. . O

"disaccharidetripeptide-glyceroldipalmitate NN O
" `` O
(DTP-GDP NNP O
) -RRB- O
, , O
modified VBN O
in IN O
the DT O
carboxy-terminal JJ O
part NN O
by IN O
glycerol-dipalmitate NN B-NP
residue NN I-NP
, , O
and CC O
structurally RB O
related VBN O
GMTP- NNP B-NP
N-DPG NNP I-NP
, , O
modified VBN O
in IN O
the DT O
carboxy-terminal JJ O
part NN O
of IN O
the DT O
peptide NN B-NP
chain NN O
by IN O
dipalmitoylpropylarnide JJ B-NP
residue NN O
. . O

DTP-GDP NNP B-NP
was VBD O
proposed VBN O
as IN O
potential JJ O
immunotherapeutic NN O
of IN O
tumor NN O
diseases<14> NN O
. . O

The DT O
compound NN O
applied VBD O
in IN O
liposomes NNS O
is VBZ O
active JJ O
in IN O
the DT O
therapy NN O
of IN O
liver NN O
tumors NNS O
metastases NNS O
<5> CD O
. . O

DTP-GDP NNP B-NP
passed VBD O
successfully RB O
phase VB O
II NNP O
of IN O
clinical JJ O
trials NNS O
, , O
but CC O
is VBZ O
strongly RB O
pyrogenic<15> JJ O
. . O

Its PRP$ O
main JJ O
side NN O
effects NNS O
, , O
besides IN O
pyrogenicity NN O
, , O
are VBP O
shivers NNS O
, , O
nausea NN O
and CC O
hypotension NN O
. . O

GMTP-N-DPG NNP B-NP
is VBZ O
a DT O
perspective NN O
adjuvans NNS O
for IN O
cellular JJ O
immunity NN O
usable NN O
for IN O
construction NN O
of IN O
new JJ O
generation NN O
vaccines NNS O
against IN O
some DT O
serious JJ O
infectious JJ O
diseases NNS O
( -LRB- O
AIDS NNP O
, , O
tuberculosis NN O
, , O
malaria NN O
)<16>'<17> NN O
. . O

Some DT O
of IN O
the DT O
above JJ O
mentioned VBN O
analogues NNS O
are VBP O
part NN O
of IN O
produced VBN O
adjuvants NNS O
. . O

As IN O
examples NNS O
can MD O
be VB O
given VBN O
Gerbu NNP O
Adjuvant( NNP O
TM) NNP O
, , O
containing VBG O
GMDP NNP B-NP
(CC NNP O
Biotech NNP O
Corporation NNP O
, , O
USA NNP O
) -RRB- O
, , O
ImmTher( NNP O
TM) NNP O
, , O
containing VBG O
DTP-GDP5 NNP O
and CC O
Theramide NNP O
( -LRB- O
TM) NN O
, , O
containing VBG O
DTP-DPP NNP B-NP
( -LRB- O
GMTP-N- NNP B-NP
DPG) NNP I-NP
( -LRB- O
ImmunoTherapeutics NNP O
, , O
USA NNP O
) -RRB- O
; : O
ref JJ O
.<18> NN O
. . O

The DT O
accessibility NN O
of IN O
the DT O
carbohydrate NN O
component NN O
is VBZ O
the DT O
main JJ O
problem NN O
in IN O
the DT O
synthesis NN O
of IN O
GMDP-derived JJ B-NP
murarnyl NN B-NP
glycopeptides NNS I-NP
. . O

The DT O
synthesis NN O
of IN O
oligosaccharides NNS O
represents VBZ O
a DT O
challenging JJ O
task NN O
, , O
especially RB O
as IN O
for IN O
the DT O
sequences NNS O
containing VBG O
D-glucose JJ B-NP
units NNS O
connected VBN O
with IN O
[beta](l->4 CD O
) -RRB- O
glycosidic NN O
bond NN O
due JJ O
to TO O
a DT O
low JJ O
reactivity NN O
of IN O
the DT O
OH( JJ O
4 CD O
) -RRB- O
group<19"23> NN O
. . O

Known VBN O
synthetic JJ O
approaches NNS O
of IN O
disaccharide NN B-NP
GMDP NNP B-NP
component NN O
represent VBP O
a DT O
challenging JJ O
process NN O
due JJ O
to TO O
many JJ O
synthetic JJ O
steps NNS O
and CC O
associated VBN O
low JJ O
affectivity NN O
. . O

These DT O
syntheses NNS O
can MD O
be VB O
divided VBN O
into IN O
three CD O
groups NNS O
( -LRB- O
according VBG O
to TO O
the DT O
glycosyl NN O
acceptor NN O
used VBN O
for IN O
glycosylation NN O
reaction NN O
representing VBG O
a DT O
key JJ O
step NN O
in IN O
disaccharide NN B-NP
unit NN O
synthesis NN O
) -RRB- O
: : O
a DT O
) -RRB- O
glycosylation NN O
with IN O
acyclic JJ O
precursor NN O
of IN O
muramic JJ B-NP
acid<24>'<25> NN I-NP
, , O
b NN O
) -RRB- O
glycosylation NN O
with IN O
cyclic JJ O
precursor NN O
of IN O
muramic JJ B-NP
acid<26"28> NN I-NP
, , O
and CC O
c NNS O
) -RRB- O
glycosylation NN O
with IN O
cyclic JJ O
derivative NN O
of IN O
muramic JJ B-NP
acid<29"33> NN I-NP
. . O

Therefore RB O
semisynthetic JJ O
, , O
in IN O
addition NN O
to TO O
de NNP O
novo RB O
synthetic JJ O
, , O
approach NN O
is VBZ O
applied VBN O
in IN O
the DT O
field NN O
of IN O
GMDP NNP B-NP
and CC O
its PRP$ O
analogues NNS O
synthesis NN O
, , O
too RB O
. . O

The DT O
sugar NN O
component NN O
preparation NN O
is VBZ O
based VBN O
on IN O
a DT O
biotechnological JJ O
process NN O
of IN O
preparation NN O
of IN O
bacterial JJ O
mass NN O
by IN O
fermentation NN O
, , O
by IN O
partial JJ O
enzymatic JJ O
hydrolysis NN O
of IN O
bacterial JJ O
walls NNS O
and CC O
difficult JJ O
isolation NN O
of IN O
disaccharide NN B-NP
unit NN O
by IN O
chromatographic JJ O
techniques NNS O
. . O

The DT O
obtained VBD O
2-acetamido-2- CD B-NP
deoxy-[beta]-D-glucopyranosyl(l->4)N-acetylmuramic JJ I-NP
acid NN I-NP
( -LRB- O
[beta]-D-Glc[Nu]Ac(l->4)Mur[Nu]Ac JJ B-NP
) -RRB- O
is VBZ O
then RB O
condensed VBN O
with IN O
the DT O
peptide NN B-NP
component<17>'<34"36> NN O
. . O

The DT O
semisynthetic JJ O
approach NN O
is VBZ O
applied VBN O
as IN O
by IN O
a DT O
Russian JJ O
company NN O
Peptek NNP O
for IN O
the DT O
preparation NN O
of IN O
the DT O
active JJ O
component NN O
of IN O
Likopid( NN B-NP
TM) NN O
( -LRB- O
GMDP NNP B-NP
) -RRB- O
and CC O
by IN O
ImmunoTherapeutics NNP O
, , O
Inc. NNP O
, , O
USA NNP O
, , O
for IN O
preparation NN O
of IN O
GMDP NNP B-NP
analogues NNS O
(DTP-GDP NNP O
and CC O
GMTP-N-DPG) NNP B-NP
modified VBN O
in IN O
carboxy NN O
terminal NN O
part NN O
of IN O
the DT O
peptide NN B-NP
chain NN O
by IN O
lipophilic JJ O
residue NN O
. . O

In IN O
spite NN O
of IN O
illusive JJ O
simple JJ O
semisynthetic JJ O
approach NN O
, , O
their PRP$ O
disadvantages NNS O
are VBP O
poor JJ O
reproducibility NN O
and CC O
necessity NN O
of IN O
standardization NN O
of IN O
the DT O
biotechnological JJ O
production NN O
process NN O
of IN O
disaccharide NN B-NP
component NN O
. . O

At IN O
the DT O
same JJ O
time NN O
, , O
reproducibility NN O
and CC O
standardization NN O
of IN O
production NN O
processes NNS O
are VBP O
the DT O
main JJ O
criteria NNS O
for IN O
the DT O
production NN O
of IN O
drugs NNS O
and CC O
their PRP$ O
substances NNS O
. . O

A DT O
limiting VBG O
factor NN O
for IN O
introduction NN O
of IN O
GMDP-based JJ B-NP
therapeutics NNS O
into IN O
the DT O
practice NN O
is VBZ O
complicated VBN O
accessibility NN O
of IN O
the DT O
disaccharide NN B-NP
component NN O
, , O
2-acetamido-2-deoxy-[beta]-D- DT B-NP
glucopyranosyl(l->4)iV-acetylmuraniic JJ I-NP
acid NN I-NP
( -LRB- O
[beta]-D-GlcNAc(l-"4)MurNAc JJ B-NP
) -RRB- O
, , O
and CC O
their PRP$ O
derivatives NNS O
, , O
respectively RB O
. . O

Present JJ O
invention NN O
solves VBZ O
this DT O
problem NN O
by IN O
elaboration NN O
of IN O
effective JJ O
synthesis NN O
of IN O
disaccharide NN B-NP
synthon NN O
enabling VBG O
reasonable JJ O
synthesis NN O
of IN O
GMDP-based JJ B-NP
muramyl NN B-NP
glycopeptides NNS I-NP
as RB O
well RB O
as IN O
2-acetamido-2-deoxy-[beta]-D-glucopyranosyl(l->4)N-acetylmuramic JJ B-NP
acid NN I-NP
itself PRP O
. . O

Detailed VBN O
description NN O
of IN O
the DT O
invention NN O

a DT O
) -RRB- O
One CD O
aspect NN O
of IN O
the DT O
invention NN O
relates VBZ O
to TO O
disaccharide VB B-NP
synthon NN O
of IN O
the DT O
following VBG O
formula NN O
I PRP O

[0014] . O

EMI5.1 . O

b NN O
) -RRB- O
Other JJ O
aspect NN O
of IN O
the DT O
invention NN O
relates VBZ O
to TO O
synthetic JJ O
pathway NN O
of IN O
preparation NN O
of IN O
disaccharide JJ B-NP
synthon NN O
of IN O
formula NN O
I. NN O

The DT O
synthesis NN O
of IN O
the DT O
compound NN O
I PRP O
starts VBP O
with IN O
glycosyl NN O
donor NN O
, , O
3,4,6-tri-0-acetyl-2- CD B-NP
deoxy-2-phthalimido-[beta]-D-glucopyranosyl JJ I-NP
bromide NN I-NP
, , O
obtained VBN O
in IN O
two CD O
steps NNS O
synthesis NN O
according VBG O
to TO O
art<37>'<38> NN O
, , O
from IN O
commercially RB O
available JJ O
D-glucosamine NN B-NP
hydrochloride NN I-NP
. . O

As IN O
glycosyl NN O
acceptor NN O
, , O
a DT O
muramic JJ B-NP
acid NN I-NP
derivative NN O
, , O
i IN O
.e NN O
. . O
benzyl-2-acetamido-6-O-benzoyl-2-deoxy-3-O-[l-(R)-(metho- -RRB- B-NP
xycarbonyl NN I-NP
)ethyl]-[alpha]-D-glucopyranoside NN I-NP
of IN O
formula NN O
II NNP O

[0017] . O

EMI5.2 NN O

the DT O
synthesis NN O
of IN O
which WDT O
is VBZ O
also RB O
a DT O
part NN O
of IN O
the DT O
invention NN O
, , O
is VBZ O
used VBN O
. . O

Glycosyl NNP O
acceptor NN O
II NNP O
synthesis NN O
starts VBZ O
from IN O
benzyl-2-acetamido-2-deoxy-4,6-O- DT B-NP
isopropylidene-[alpha]-D-glucopyranoside JJ I-NP
lll NN O

EMI6.1 . O

which WDT O
is VBZ O
obtained VBN O
in IN O
two CD O
synthetic JJ O
steps NNS O
as IN O
given VBN O
in IN O
the DT O
art<39> NN O
from IN O
commercially RB O
available JJ O
N- NNP B-NP
acetyl-D-glucosamine NN I-NP
. . O

3-0-Alkylation CD O
of IN O
compound NN O
III NNP O
on IN O
treatment NN O
with IN O
racemic JJ O
bromopropionic JJ B-NP
acid NN I-NP
or CC O
its PRP$ O
( -LRB- O
S)-stereoisomer NN O
in IN O
a DT O
polar JJ O
aprotic JJ O
solvent NN O
and CC O
in IN O
the DT O
presence NN O
of IN O
a DT O
strong JJ O
base NN O
( -LRB- O
with IN O
advantage NN O
in IN O
dioxan NN B-NP
or CC O
tetrahydrofurane NN B-NP
in IN O
the DT O
presence NN O
of IN O
sodium JJ B-NP
hydride NN I-NP
) -RRB- O
and CC O
the DT O
following VBG O
esterification NN O
of IN O
the DT O
produced VBN O
acid NN O
with IN O
diazomethane NN B-NP
or CC O
of IN O
its PRP$ O
salt NN O
with IN O
methyl NN B-NP
iodide NN I-NP
affords NNS O
benzyl-2-acetamido-2-deoxy-4,6-O-isopropylidene-3-O-[l-(R)-(methoxycarbonyl JJ B-NP
)ethyl]-[alpha] SYM I-NP
- : I-NP
D-glucopyranoside NN I-NP
IV. . O

[0022] . O

EMI6.2 NN O

IV NNP O

The DT O
acetal NN O
protecting VBG O
group NN O
in IN O
compound NN O
IV NNP O
is VBZ O
removed VBN O
by IN O
acidic NN O
hydrolysis NN O
, , O
advantageously RB O
by IN O
action NN O
of IN O
ion-exchanger NN O
Dowex NNP O
50 CD O
in IN O
H NNP O
cycle NN O
in IN O
anhydrous JJ O
methanol NN B-NP
or CC O
by IN O
heating NN O
in IN O
aqueous JJ O
acetic JJ B-NP
acid NN I-NP
, , O
affording VBG O
benzyl-2-acetamido-2-deoxy-3-O-[l-(R) JJ B-NP
- : I-NP
( -LRB- I-NP
methoxycarbonyl NN I-NP
)ethyl NN I-NP
] SYM I-NP
-[alpha]-D-glucopyranoside JJ I-NP
V. NNP O

[0025 CD O
] NN O

EMI6.3 . O

V NNP O

Partial JJ O
benzoylation NN O
of IN O
compound NN O
V NNP O
, , O
in IN O
advantage NN O
with IN O
benzoylimidazole NN B-NP
in IN O
dichloro- NNS B-NP
methane NN I-NP
, , O
affords NNS O
glycosyl NN O
acceptor NN O
of IN O
formula NN O
II NNP O
. . O

EMI7.1 . O

Reaction NN O
of IN O
3,4,6-tri-(9-acetyl-2-deoxy-2-phthalimido-[beta]-D-glucopyranosyl JJ B-NP
bromide NN I-NP
, , O
as IN O
glycosyl NN O
donor NN O
, , O
with IN O
glycosyl NN O
acceptor NN O
II NNP O
in IN O
aprotic JJ O
solvent NN O
promoted VBN O
by IN O
heavy JJ B-NP
metal NN I-NP
salts NNS I-NP
( -LRB- O
in IN O
advantage NN O
in IN O
dichloromethane NN B-NP
in IN O
the DT O
presence NN O
of IN O
silver JJ B-NP
trifluoromethanesulfonate JJ I-NP
as IN O
promotor NN O
) -RRB- O
afforded VBN O
benzyl-3 NN B-NP
,4,6-tri-O-acetyl-2-deoxy-2-phthalimido-[beta]-D-glucopyranosyl- . I-NP
( -LRB- I-NP
1 CD I-NP
->4)-2-acetamido-6-(9-benzoyl-2-deoxy-3 NN I-NP
-O- : I-NP
[ NN I-NP
1 CD I-NP
-(R)-(methoxycarbonyl NN I-NP
)ethyl NN I-NP
] SYM I-NP
-[alpha]-D-gluco FW I-NP
- : I-NP
pyranoside NN I-NP
VI. . O

[0029 CD O
] NN O

EMI7.2 NN O

Vl NN O

Sequential JJ O
removing VBG O
of IN O
protecting VBG O
groups NNS O
sensitive JJ O
to TO O
alkali DT B-NP
( -LRB- O
i NN O
.e NN O
. . O

acetyl NN B-NP
, , O
benzoyl NN B-NP
, , O
methyl NN B-NP
ester NN I-NP
and CC O
phthalimide NN B-NP
) -RRB- O
, , O
in IN O
advantage NN O
on IN O
treatment NN O
with IN O
sodium NN B-NP
methoxide NN I-NP
in IN O
methanol NN B-NP
, , O
sodium NN B-NP
hydroxide NN I-NP
in IN O
water NN B-NP
, , O
and CC O
n-butylamine NN B-NP
in IN O
methanol NN B-NP
, , O
respectively RB O
, , O
affords NNS O
benzyl-2- : B-NP
amino-2-deoxy-[beta]-D-glucopyranosyl-(l-->4)-2-acetamido-2-deoxy-3-O-[l-(R)-carboxyethyl] JJ I-NP
- : I-NP
[alpha]-D-glucopyranoside JJ I-NP
VII NNP O
. . O

[0031] . O

EMI7.3 . O

VIl NN O

iV-Acetylation NN O
of IN O
this DT O
compound NN O
VII NN O
with IN O
acetic JJ B-NP
acid NN I-NP
anhydride NN O
in IN O
water NN B-NP
affords NNS O
disaccharide VBP B-NP
synthon NN O
of IN O
formula NN O
I. NN O
c NN O
) -RRB- O
The DT O
next JJ O
aspect NN O
of IN O
the DT O
invention NN O
relates VBZ O
to TO O
the DT O
use NN O
of IN O
disaccharide NN B-NP
synthon NN O
I PRP O
for IN O
synthesis NN O
of IN O
2-acetamido-2-deoxy-[beta]-D-glucopyranosyl-(l->4)-JV-acetyl JJ B-NP
muramic JJ I-NP
acid NN I-NP
VIII NNP O
. . O

[0034] . O

EMI8.1 . O

2-Acetamido-2-deoxy-[beta]-D-glucopyranosyl-(l->4)-iV-acetyl JJ B-NP
muramic JJ I-NP
acid NN I-NP
VIII NNP O
is VBZ O
synthesized VBN O
on IN O
hydrogenolytic JJ O
removing VBG O
of IN O
ben2yl JJ B-NP
protecting VBG O
groups NNS O
, , O
in IN O
advantage NN O
with IN O
palladium NN B-NP
catalyst NN O
on IN O
charcoal NN O
in IN O
acetic JJ B-NP
acid NN I-NP
, , O
from IN O
disaccharide NN B-NP
synthon NN O
of IN O
formula NN O
I. NN O

d NN O
) -RRB- O
The DT O
next JJ O
aspect NN O
of IN O
the DT O
invention NN O
relates VBZ O
to TO O
the DT O
use NN O
of IN O
disaccharide NN B-NP
synthon NN O
I PRP O
for IN O
the DT O
synthesis NN O
of IN O
muramyl NN B-NP
glycopeptides NNS I-NP
based VBN O
on IN O
GMDP NNP B-NP
molecule NN O
of IN O
general JJ O
formula NN O
IX . O

[0037] . O

EMI8.2 NN O

in IN O
which WDT O
X NNP O
is VBZ O
peptide NN B-NP
residue NN O
. . O

Reaction NN O
of IN O
disaccharide NN B-NP
synthon NN O
I PRP O
with IN O
bis(pentafluorophenyl)carbonate JJ B-NP
in IN O
polar JJ O
aprotic JJ O
solvent NN O
in IN O
the DT O
presence NN O
of IN O
base NN O
, , O
with IN O
advantage NN O
in IN O
N NNP B-NP
,iV-dimethylformamide NN I-NP
in IN O
the DT O
presence NN O
of IN O
N-methylmorpholine NNP B-NP
, , O
leads VBZ O
to TO O
benzyl-2-acetamido-2-deoxy-[beta]-D-glucopyranosyl- VB B-NP
(l->-4)-2-acetamido-2-deoxy-3-O-[l-(R)-(pentafluorophenoxycarbonyl JJ I-NP
)ethyl]-[alpha]-D-glucopyra NNP I-NP
- : I-NP
noside NN I-NP
X NNP O
. . O

[0040] . O

EMI8.3 . O

Reaction NN O
of IN O
pentafluorophenyl JJ B-NP
ester NN I-NP
X NNP O
with IN O
peptide NN B-NP
component NN O
in IN O
polar JJ O
aprotic JJ O
solvent NN O
in IN O
the DT O
presence NN O
of IN O
base NN O
, , O
in IN O
advantage NN O
in IN O
N,N-dimethylformamide NNP B-NP
in IN O
the DT O
presence NN O
of IN O
tri- DT B-NP
ethylamine NN I-NP
or CC O
JV-methylmorpholine NN B-NP
, , O
affords NNS O
protected VBD O
glycopeptide NN B-NP
XI NNS O

[0041] . O

EMI9.1 . O

in IN O
which WDT O
X NNP O
is VBZ O
a DT O
peptide NN B-NP
residue NN O
. . O

For IN O
example NN O
, , O
reaction NN O
with IN O
benzyl NN B-NP
ester NN I-NP
of IN O
L-alanyl-D-isoglu- DT B-NP
tamine NN I-NP
(available JJ O
according VBG O
to TO O
the DT O
ref JJ O
.<40> NN O
) -RRB- O
affords NNS O
benzyl IN B-NP
ester NN I-NP
of IN O
iV-{2-O-[benzyl-2-acetamido NN B-NP
- : I-NP
2-deoxy-[beta]-D-glucopyranosyl-(l-->4)-2-acetamido-2,3-dideoxy-[alpha]-D-glucopyranosid-3-yl]-(R) JJ I-NP
- : I-NP
lactoyl}-L-alanyl-D-isoglutamine JJ I-NP
(X NN O
I PRP O
wherein WRB O
X NNP O
is VBZ O
L-Ala-D-iso-Gln-OBn JJ B-NP
) -RRB- O
. . O

Hydrogenolytic JJ O
removing VBG O
of IN O
benzyl NN B-NP
protecting VBG O
group NN O
from IN O
reducing VBG O
end NN O
of IN O
the DT O
saccharide NN O
part NN O
and CC O
protecting VBG O
groups NNS O
cleavable JJ O
under IN O
these DT O
conditions NNS O
from IN O
the DT O
peptide NN B-NP
chain NN O
( -LRB- O
benzyl NN B-NP
or CC O
benzyloxycarbonyl NN B-NP
groups NNS O
) -RRB- O
of IN O
glycopeptide NN B-NP
of IN O
general JJ O
formula NN O
XI NNS O
( -LRB- O
with IN O
advantage NN O
with IN O
the DT O
use NN O
of IN O
palladium NN B-NP
catalyst NN O
on IN O
charcoal NN O
in IN O
acetic JJ B-NP
acid NN I-NP
) -RRB- O
, , O
affords NNS O
glycopeptide NN B-NP
IX NNP O
. . O

For IN O
example NN O
, , O
hydrogenolysis NN O
of IN O
benzyl NN B-NP
groups NNS O
of IN O
benzyl JJ B-NP
ester NN I-NP
of IN O
iV-{2-O-[benzyl-2-acetamido-2- DT B-NP
deoxy-[beta]-D-glucopyranosyl-(l- NNS I-NP
>4)-2-acetamido-2,3-dideoxy-[alpha]-D-glucopyranosid-3-yl]-(R) JJ I-NP
- : I-NP
lactoyl}-L-alanyl-D-isoglutamine JJ I-NP
(XI NN O
, , O
wherein WRB O
X NNP O
is VBZ O
L-Ala-D-iso-Gln-OBn JJ B-NP
) -RRB- O
with IN O
palladium NN B-NP
catalyst NN O
on IN O
charcoal NN O
in IN O
acetic JJ B-NP
acid NN I-NP
affords NNS O
2-acetamido-2-deoxy-[beta]-D-glucopyranosyl-(l->4) JJ B-NP
- : I-NP
iV-acetylmuramyl-L-alanyl-D-isoglutamine NN I-NP
( -LRB- O
GMDP NNP B-NP
) -RRB- O
( -LRB- O
IX NNP O
, , O
wherein WRB O
X NNP O
is VBZ O
L-Ala-D-iso-Gln-OH) JJ B-NP
. . O

The DT O
present JJ O
invention NN O
is VBZ O
further RB O
illustrated VBN O
by IN O
the DT O
following VBG O
examples NNS O
that WDT O
are VBP O
only RB O
illustrative JJ O
and CC O
are VBP O
not RB O
meant VBN O
as IN O
any DT O
limitation NN O
of IN O
this DT O
invention NN O
. . O

Examples NNS O

Example NNP O
1 CD O

Sodium NN B-NP
hydride NN I-NP
( -LRB- O
9.0 CD O
g NN O
, , O
375 CD O
mmol NN O
) -RRB- O
was VBD O
added VBN O
to TO O
a DT O
stirred VBD O
solution NN O
of IN O
benzyl-2- CD B-NP
acetamido-2-deoxy-4,6-0-isopropyliden-a-D-glucopyranoside JJ I-NP
III NNP O
( -LRB- O
24.6 CD O
g NN O
, , O
70 CD O
mmol NN O
) -RRB- O
in IN O
anhydrous JJ O
dioxane NN B-NP
( -LRB- O
270 CD O
ml NN O
) -RRB- O
at IN O
room NN O
temperature NN O
and CC O
the DT O
mixture NN O
was VBD O
heated VBN O
for IN O
2 CD O
h NN O
at IN O
90 CD O
<0>C NNS O
under IN O
stirring VBG O
. . O

The DT O
mixture NN O
was VBD O
cooled VBN O
down RB O
to TO O
room NN O
temperature NN O
, , O
2-bromopropionic JJ B-NP
acid NN I-NP
( -LRB- O
9.0 CD O
ml NN O
, , O
100 CD O
mmol NN O
) -RRB- O
is VBZ O
added VBN O
and CC O
the DT O
mixture NN O
is VBZ O
heated VBN O
under IN O
stirring VBG O
for IN O
6 CD O
h NN O
at IN O
65 CD O
[deg.]C. . O

Excess NNP O
hydride NN O
after IN O
cooling VBG O
down RP O
to TO O
room NN O
temperature NN O
was VBD O
decomposed VBN O
with IN O
water NN B-NP
; : O
solid JJ O
carbon NN B-NP
dioxide NN I-NP
was VBD O
added VBN O
to TO O
the DT O
mixture NN O
under IN O
Stirling VBG O
followed VBN O
by IN O
adding VBG O
of IN O
water NN B-NP
( -LRB- O
20 CD O
ml NN O
) -RRB- O
. . O

The DT O
mixture NN O
was VBD O
evaporated VBN O
in IN O
vacuum NN O
. . O

The DT O
remaining VBG O
residue NN O
is VBZ O
dissolved VBN O
in IN O
water NN B-NP
( -LRB- O
450 CD O
ml NN O
) -RRB- O
, , O
and CC O
the DT O
solution NN O
obtained VBD O
was VBD O
with IN O
ice NN O
neutralized VBN O
with IN O
5 CD O
% NN O
water NN B-NP
solution NN O
of IN O
sodium NN B-NP
hydrogen NN I-NP
sulphate NN I-NP
under IN O
stirring VBG O
and CC O
cooling VBG O
. . O

Separated NNP O
product NN O
was VBD O
extracted VBN O
with IN O
ethyl NN B-NP
acetate NN I-NP
( -LRB- O
3 CD O
x NN O
200 CD O
ml NN O
) -RRB- O
, , O
the DT O
extract VB O
was VBD O
dried VBN O
with IN O
anhydrous JJ O
magnesium NN B-NP
sulphate NN I-NP
and CC O
evaporated VBD O
in IN O
vacuum NN O
to TO O
about IN O
100 CD O
ml NN O
. . O

A DT O
solution NN O
of IN O
diazomethane NN B-NP
in IN O
diethyl NN B-NP
ether NN I-NP
was VBD O
added VBN O
to TO O
evaporated DT O
residue NN O
under IN O
stirring VBG O
and CC O
cooling VBG O
with IN O
ice NN O
up RB O
to TO O
permanent JJ O
yellow JJ O
colour NN O
. . O

After IN O
30 CD O
minutes NNS O
, , O
the DT O
excess JJ O
diazomethane NN B-NP
was VBD O
decomposed VBN O
with IN O
acetic JJ B-NP
acid NN I-NP
, , O
the DT O
mixture NN O
was VBD O
evaporated VBN O
in IN O
vacuum NN O
, , O
and CC O
evaporated VBD O
residue NN O
was VBD O
chromatographed VBN O
on IN O
silica NN B-NP
gel NN I-NP
column NN O
in IN O
ethyl NN B-NP
acetate-toluen JJ I-NP
mixture NN O
( -LRB- O
2:1 CD O
) -RRB- O
. . O

Homogenous NNP O
fraction NN O
with IN O
higher JJR O
RF NN O
was VBD O
evaporated VBN O
in IN O
vacuum NN O
, , O
and CC O
the DT O
obtained VBN O
crystalline NN O
residue NN O
( -LRB- O
19.6 CD O
g NN O
, , O
64,0 CD O
% NN O
) -RRB- O
, , O
benzyl-2-acetamido-2-deoxy-4,6-O-isopropyliden-3-O- . B-NP
[l-(R)-(methoxykarbonyl NNP I-NP
)ethyl]-[alpha]-D-glucopyranoside NNP I-NP
IV5 NNP O
is VBZ O
without IN O
next JJ O
purification NN O
deprotected VBD O
( -LRB- O
isopropylidendioxy NN B-NP
group NN O
is VBZ O
removed VBN O
; : O
see VB O
Examples NNS O
3 CD O
and CC O
4) CD O
. . O

Crystallization NN O
of IN O
the DT O
residue NN O
from IN O
toluene-diethyl NN B-NP
ether-petrolether JJ B-NP
mixture NN O
afforded VBN O
an DT O
analytical JJ O
sample NN O
of IN O
compound NN O
IV NNP O
in IN O
the DT O
yield NN O
76.5 CD O
% NN O
; : O
m.p NN O
. . O
123 CD O
[deg.]C NNP O
, , O

[[alpha]] NN O
D NNP O
+ . O
139 CD O
( -LRB- O
c NN O
0.5 CD O
, , O
chloroform NN B-NP
) -RRB- O
. . O

For IN O
C22H31NOg JJ B-NP
calculated VBN O
: : O
relative JJ O
molecular JJ O
mass NN O
437.5 CD O
, , O
monoisotopic JJ O
mass NN O
437.2 CD O
. . O

FAB NNP O
MS NNP O
, , O
mlz NN O
: : O
438.4 CD O
[ NN O
M NNP O
+ NNP O
H] NNP O
, , O
460.3 CD O
[ NN O
M NNP O
+ NNP O
Na] NNP O
. . O

For IN O
C22H3iNO8 DT B-NP
( -LRB- O
437.5 CD O
) -RRB- O

calculated VBN O
: : O
60.40 CD O
% NN O
C NNP O
; : O
7.14 CD O
% NN O
H NNP O
; : O
3.20 CD O
% NN O
N NNP O
; : O
found VBD O
: : O
60.23 CD O
% NN O
C5 IN O
7.28 CD O
% NN O
H NNP O
, , O
3.27 CD O
% NN O
N. NNP O

Evaporation NN O
of IN O
homogenous JJ O
fraction NN O
with IN O
lower JJR O
Rp NN O
value NN O
afforded VBN O
9.0 CD O
g NN O
( -LRB- O
29.4 CD O
% NN O
) -RRB- O
treacly NN O
residue NN O
, , O
benzyl-2-acetamido-2-deoxy-4,6-<9-isopropyliden-3-0-[ JJ B-NP
1 CD I-NP
-(S)-(methoxycar-bonyl JJ I-NP
)ethyl]-[alpha]-D-glucopyranoside JJ I-NP
, , O
that IN O
crystallized VBN O
on IN O
standing VBG O
; : O
m.p JJ O
. . O
83 CD O
[deg.]C NNP O
; : O
[[alpha]]o NNP O
+ CD O
77 CD O
( -LRB- O
c NN O
0.5 CD O
, , O
chloroform NN B-NP
) -RRB- O
. . O

For IN O
C22H3INOs NNS B-NP
calculated VBN O
: : O
relative JJ O
molecular JJ O
mass NN O
437.5 CD O
, , O
monoisotopic JJ O
mass NN O
437 CD O
. . O

FAB NNP O
MS NNP O
, , O
mlz NN O
: : O
438.3 CD O
[ NN O
M NNP O
+ NNP O
H] NNP O
, , O
460.3 CD O
[ NN O
M NNP O
+ NNP O
Na] NNP O
. . O

For IN O
C22H31NO8 DT B-NP
( -LRB- O
437.5 CD O
) -RRB- O

calculated VBN O
: : O
60.40 CD O
% NN O
C NNP O
; : O
7.14 CD O
% NN O
H NNP O
; : O
3.20 CD O
% NN O
N NNP O
; : O
found VBD O
: : O
60.51 CD O
% NN O
C NNP O
, , O
7.23 CD O
% NN O
H5 IN O
3.18 CD O
% NN O
N. NNP O

Example NN O
2 CD O

Sodium NNP B-NP
hydride NN I-NP
suspended VBD O
in IN O
mineral JJ O
oil NN O
(60 IN O
% NN O
, , O
1.2 CD O
g NN O
, , O
30 CD O
mmol NN O
) -RRB- O
under IN O
argon NN B-NP
is VBZ O
washed VBN O
with IN O
anhydrous JJ O
hexane NN B-NP
( -LRB- O
3 CD O
x NN O
5 CD O
ml NN O
, , O
) -RRB- O
and CC O
then RB O
suspended VBD O
in IN O
anhydrous JJ O
tetrahydrofuran NN B-NP
( -LRB- O
10 CD O
ml NN O
) -RRB- O
. . O

A DT O
solution NN O
of IN O
benzyl-2-acetamido-2-deoxy-4,6-(9-isopropyliden-[alpha]-D- DT B-NP
glucopyranoside NN I-NP
III NNP O
( -LRB- O
3.5 CD O
g NN O
, , O
10 CD O
mmol NN O
) -RRB- O
in IN O
anhydrous JJ O
tetrahydrofuran NN B-NP
( -LRB- O
20 CD O
ml NN O
) -RRB- O
is VBZ O
added VBN O
to TO O
the DT O
mixed JJ O
suspension NN O
at IN O
room NN O
temperature NN O
and CC O
the DT O
mixture NN O
is VBZ O
heated VBN O
for IN O
2.5 CD O
h NN O
at IN O
50 CD O
[deg.]C NNS O

under IN O
stirring NN O
. . O

A DT O
solution NN O
of IN O
( -LRB- B-NP
S)-2-bromopropionic JJ I-NP
acid NN I-NP
( -LRB- O
1.1 CD O
ml NN O
, , O
12 CD O
mmol NN O
) -RRB- O
in IN O
anhydrous JJ O
tetrahydrofuran NN B-NP
( -LRB- O
10 CD O
ml NN O
) -RRB- O
is VBZ O
added VBN O
to TO O
the DT O
mixture NN O
during IN O
2 CD O
hours NNS O
and CC O
the DT O
mixture NN O
is VBZ O
heated VBN O
for IN O
the DT O
next JJ O
8 CD O
h NN O
at IN O
50 CD O
<0>C NNS O
under IN O
stirring VBG O
. . O

The DT O
mixture NN O
is VBZ O
cooled VBN O
down RB O
to TO O
room NN O
temperature NN O
, , O
methyl NN B-NP
iodide NN I-NP
( -LRB- O
1.0 CD O
ml NN O
, , O
16 CD O
mmol NN O
) -RRB- O
is VBZ O
added VBN O
under IN O
stirring VBG O
, , O
and CC O
the DT O
mixture NN O
is VBZ O
stirred VBN O
24 CD O
h NN O
at IN O
room NN O
temperature NN O
. . O

An DT O
excess JJ O
hydride NN O
is VBZ O
decomposed VBN O
with IN O
anhydrous JJ O
methanol NN B-NP
( -LRB- O
2.0 CD O
ml NN O
) -RRB- O
and CC O
solid JJ O
carbon NN B-NP
dioxide NN I-NP
and CC O
the DT O
resulted VBN O
mixture NN O
is VBZ O
evaporated VBN O
in IN O
vacuum NN O
. . O

Evaporated NNP O
residue NN O
is VBZ O
extracted VBN O
with IN O
ethyl NN B-NP
acetate NN I-NP
( -LRB- O
60 CD O
ml NN O
) -RRB- O
and CC O
water NN B-NP
( -LRB- O
20 CD O
ml NN O
) -RRB- O
, , O
organic JJ O
phase NN O
is VBZ O
separated VBN O
, , O
washed VBN O
with IN O
water NN B-NP
( -LRB- O
2 CD O
x NN O
20 CD O
ml NN O
) -RRB- O
, , O
dried VBD O
over IN O
anhydrous JJ O
magnesium NN B-NP
sulphate NN I-NP
, , O
and CC O
evaporated VBD O
in IN O
vacuum NN O
. . O

The DT O
evaporated JJ O
residue NN O
is VBZ O
filtered VBN O
through IN O
silica NN B-NP
gel NN I-NP
column NN O
in IN O
a DT O
mixture NN O
of IN O
ethyl NN B-NP
acetate-toluene NN I-NP
( -LRB- O
2:1 CD O
) -RRB- O
and CC O
filtrate NN O
is VBZ O
evaporated VBN O
in IN O
vacuum NN O
. . O

Crystallization NN O
of IN O
the DT O
product NN O
from IN O
toluene-diethyl NN B-NP
ether-petrolether JJ B-NP
mixture NN O
afforded VBN O
3.3 CD O
g NN O
( -LRB- O
75.4 CD O
% NN O
) -RRB- O
of IN O
benzyl-2-acetamido-2- CD B-NP
deoxy-4,6-+O-isopropyliden-3-O-[l-(R)-(methoxycarbonyl JJ I-NP
)ethyl]-[alpha]-D-glucopyranoside JJ I-NP
IV NNP O
, , O
identical JJ O
with IN O
compound NN O
IV NNP O
prepared VBD O
in IN O
Example NNP O
1 CD O
. . O

Example NN O
3 CD O

Ion NNP O
exchanger NN O
Dowex NNP O
50 CD O
in IN O
H NNP O
cycle NN O
( -LRB- O
35 CD O
g NN O
) -RRB- O
is VBZ O
added VBN O
to TO O
a DT O
solution NN O
of IN O
benzyl-2- DT B-NP
acetamido-2-deoxy-4,6-O-isopropyliden-3-O-[l-(R)-(methoxycarbonyl JJ I-NP
)ethyl]-[alpha]-D-glucopy- NNP I-NP
ranoside NN I-NP
IV NNP O
(87.5 CD O
g NN O
, , O
200 CD O
mmol NN O
) -RRB- O
in IN O
anhydrous JJ O
methanol NN B-NP
( -LRB- O
500 CD O
ml NN O
) -RRB- O
and CC O
this DT O
mixture NN O
is VBZ O
stirred VBN O
2 CD O
h NN O
at IN O
room NN O
temperature NN O
. . O

Reaction NN O
is VBZ O
monitored VBN O
by IN O
TLC NNP O
in IN O
chloroform-methanol NN B-NP
system NN O
( -LRB- O
10:1 CD O
) -RRB- O
. . O

Ion NNP O
exchanger NN O
is VBZ O
filtered VBN O
off RP O
, , O
washed VBN O
with IN O
methanol NN B-NP
( -LRB- O
2 CD O
x NN O
400 CD O
ml NN O
) -RRB- O
, , O
and CC O
the DT O
filtrate NN O
was VBD O
f NN O
evaporated VBN O
in IN O
vacuum NN O
. . O

Yield NN O
78.7 CD O
g NN O
(99 CD O
% NN O
) -RRB- O
of IN O
crystalline NN O
benzyl-2-acetamido-2-deoxy~3-<9 CD B-NP
- : I-NP
[l-(R)-(methoxycarbonyl JJ I-NP
)ethyl]-[alpha]-D-glucopyranoside JJ I-NP
V NNP O
that WDT O
was VBD O
without IN O
any DT O
purification NN O
treated VBN O
with IN O
benzoylimidazol JJ B-NP
as IN O
given VBN O
in IN O
Example NNP O
5 CD O
. . O
Crystallization NNP O
of IN O
the DT O
product NN O
from IN O
ethyl NN B-NP
acetate-diethyl NN I-NP
ether NN B-NP
afforded VBN O
an DT O
analytical JJ O
sample NN O
of IN O
compound NN O
V NNP O
; : O
m.p NN O
. . O
134 CD O
- : O
138 CD O
[deg.]C NN O
, , O

[[alpha] JJ O
][pi] NN O
+ NN O
152 CD O
( -LRB- O
c NN O
0.5 CD O
, , O
chloroform NN B-NP
) -RRB- O
; : O
lit VBD O
.<41> JJ O
m.p NN O
. . O
130 CD O
- : O
132 CD O
<0>C NN O
, , O
[[alpha]fo VB O
+ NN O
145 CD O
( -LRB- O
c NN O
1.0, JJ O
chloroform NN B-NP
) -RRB- O
; : O
lit VBD O
.<42> JJ O
m.p NN O
. . O
120 CD O
- : O
122 CD O
[deg.]C NN O
, , O

[[alpha]] NN O
D NNP O
+ . O
137 CD O
( -LRB- O
c NN O
0.9 CD O
, , O
chloroform NN B-NP
) -RRB- O
; : O
lit VBD O
.<43> JJ O
[[alpha]] NN O
D NNP O
+ . O
127 CD O
( -LRB- O
c NN O
1.0, JJ O
chloroform NN B-NP
) -RRB- O
. . O

For IN O
C19H27NO8 DT B-NP
calculated VBN O
: : O
relative JJ O
molecular JJ O
mass NN O
397.4 CD O
, , O

monoisotopic JJ O
mass NN O
397.2 CD O
. . O

ESI NNP O
MS NNP O
, , O
m/z NN O
: : O
420.3 CD O
[ NN O
M NNP O
+ NNP O
Na] NNP O
. . O

For IN O
C19H27NO8 DT B-NP
( -LRB- O
397.4 CD O
) -RRB- O
calculated VBN O
: : O
57.42 CD O
% NN O
C5 IN O
6.85 CD O
%H NNP O
, , O
3.52 CD O
% NN O
N NNP O
; : O
found VBD O
: : O
57.17 CD O
% NN O
C NNP O
, , O
6.88 CD O
% NN O
H NNP O
, , O
3.49 CD O
% NN O
N. NNP O

Example NNP O
4 CD O

Benzyl-2-acetamido-2-deoxy-4,6-(9-isopropyliden-3-0-[l-(R)-(methoxycarbonyl) JJ B-NP
- : I-NP
ethyl]-[alpha]-D-glucopyranoside NN I-NP
IV NNP O
( -LRB- O
8.8 CD O
g NN O
, , O
20 CD O
mmol NN O
) -RRB- O
is VBZ O
heated VBN O
under IN O
stirring VBG O
in IN O
a DT O
mixture NN O
acetic JJ B-NP
acid-water NN I-NP
( -LRB- O
1:1 CD O
, , O
80 CD O
ml JJ O
) -RRB- O
for IN O
30 CD O
min NN O
at IN O
90 CD O
[deg.]C. . O

The DT O
mixture NN O
was VBD O
evaporated VBN O
in IN O
vacuum NN O
. . O

Evaporated NNP O
residue NN O
was VBD O
crystallized VBN O
from IN O
ethyl NN B-NP
acetate-diethyl NN I-NP
ether JJ B-NP
mixture NN O
. . O

Yield NN O
6.2 CD O
g NN O
( -LRB- O
78.0 CD O
% NN O
) -RRB- O
of IN O
benzyl-2-acetamido-2-deoxy-3-O-[l-(R)-(methoxycarbonyl JJ B-NP
)ethyl]-[alpha]-D-glucopy- NNP I-NP
ranoside NN I-NP
V NNP O
, , O
identical JJ O
with IN O
compound NN O
V NNP O
prepared VBD O
according VBG O
to TO O
example NN O
3 CD O

Example NNP O
5 CD O

A DT O
solution NN O
of IN O
benzimidazol NN B-NP
( -LRB- O
37,9 CD O
g NN O
, , O
220 CD O
mmol NN O
) -RRB- O
in IN O
anhydrous JJ O
dichlormethane NN B-NP
( -LRB- O
150 CD O
ml NN O
) -RRB- O
was VBD O
added VBN O
to TO O
a DT O
mixed JJ O
suspension NN O
of IN O
benzyl-2-acetamido-2-deoxy-3-0-[l-(R)-(methoxy- DT B-NP
carbonyl NN I-NP
)ethyl]-[alpha]-D-glucopyranoside NN I-NP
V NNP O
(79.5 CD O
g NN O
, , O
200 CD O
mmol NN O
) -RRB- O
in IN O
anhydrous JJ O
dichlormethane NN B-NP
( -LRB- O
500 CD O
ml NN O
) -RRB- O
at IN O
0 CD O
<0>C. . O

A DT O
mixture NN O
is VBZ O
mixed JJ O
for IN O
30 CD O
min NN O
at IN O
0 CD O
[deg.]C . O

and CC O
then RB O
left VBD O
to TO O
stand VB O
for IN O
at IN O
least JJS O
24 CD O
h NN O
at IN O
room NN O
temperature NN O
. . O

The DT O
reaction NN O
process NN O
is VBZ O
monitored VBN O
with IN O
TLC NNP O
in IN O
chloroform-methanol NN B-NP
system NN O
( -LRB- O
10:1 CD O
) -RRB- O
and CC O
in IN O
toluene-ethyl NN B-NP
acetate NN B-NP
system NN O
( -LRB- O
1:1 CD O
) -RRB- O
. . O

The DT O
mixture NN O
is VBZ O
diluted VBN O
with IN O
chloroform NN B-NP
( -LRB- O
1000 CD O
ml NN O
) -RRB- O
and CC O
the DT O
obtained VBN O
solution NN O
is VBZ O
washed VBN O
with IN O
5 CD O
% NN O
sodium NN B-NP
hydrogen NN I-NP
sulphate NN I-NP
in IN O
water NN B-NP
( -LRB- O
700 CD O
ml NN O
) -RRB- O
, , O
water NN B-NP
( -LRB- O
1000 CD O
ml NN O
) -RRB- O
and CC O
saturated VBD O
sodium NN B-NP
chloride NN I-NP
solution NN O
in IN O
water NN B-NP
( -LRB- O
1000 CD O
ml NN O
) -RRB- O
, , O
dried VBD O
over IN O
anhydrous JJ O
magnesium NN B-NP
sulphate NN I-NP
and CC O
evaporated VBD O
in IN O
vacuum NN O
. . O

Yield NN O
99.3 CD O
g NN O
(99 CD O
% NN O
) -RRB- O
of IN O
crystalline NN O
benzyl-2-acetamido-6-0-benzoyl-2-deoxy-3-O-[l-(R)-(methoxycarbonyl JJ B-NP
)ethyl-[alpha]-D-glucopy- NNP I-NP
ranoside NN I-NP
II NNP O
which WDT O
is VBZ O
possible JJ O
to TO O
use VB O
without IN O
any DT O
purification NN O
as IN O
glycosyl NN O
acceptor NN O
for IN O
disacharide NN B-NP
synthesis NN O
( -LRB- O
see VB O
Example JJ O
6 CD O
) -RRB- O
. . O

Crystallization NN O
of IN O
the DT O
product NN O
from IN O
toluene-heptane JJ B-NP
mixture NN O
afforded VBN O
an DT O
analytical JJ O
sample NN O
of IN O
compound NN O
II NNP O
in IN O
the DT O
yield NN O
of IN O
90 CD O
% NN O
; : O
m.p NN O
. . O
133-135 CD O
<0>C NNP O
, , O
[[alpha]] NN O
D NNP O
+ NN O
85 CD O
( -LRB- O
c NN O
0,3 CD O
, , O
chloroform NN B-NP
) -RRB- O
. . O

Lit NNP O
.<44> NNP O
gives VBZ O
m.p NN O
. . O
98 CD O
- : O
100 CD O
<0>C NNP O
, , O
[[alpha]] NN O
D NN O
+ VBN O
81 CD O
( -LRB- O
c NN O
1.0, JJ O
chloroform NN B-NP
) -RRB- O
. . O

For IN O
C26H31NO9 DT B-NP
calculated VBN O
: : O
relative JJ O
molecular JJ O
mass NN O
501.5 CD O
, , O
monoisotopic JJ O
mass NN O
501.2 CD O
. . O

FAB NNP O
MS NNP O
, , O
m/z NN O
: : O
502.1 CD O
[ NN O
M NNP O
+ NNP O
H] NNP O
, , O
524.3 CD O
[ NN O
M NNP O
+ NNP O
Na] NNP O
. . O

For IN O
C26H31NO9 DT B-NP
( -LRB- O
501.5 CD O
) -RRB- O

calculated VBN O
: : O
62.27 CD O
% NN O
C NNP O
, , O
6.23 CD O
% NN O
H NNP O
, , O
2.79 CD O
% NN O
N NNP O
; : O
found VBD O
: : O
62.58 CD O
% NN O
C NNP O
, , O
6.45 CD O
% NN O
H NNP O
, , O
2.66 CD O
% NN O
N. NNP O

Example NNP O
6 CD O

A DT O
mixture NN O
of IN O
benzyl-2-acetamido-6-O-benzoyl-2-deoxy-3-O-[l-(R)-(methoxycarbo- DT B-NP
nyl NN I-NP
)ethyl]-[alpha]-D-glucopyranoside NN I-NP
II NNP O
( -LRB- O
50.2 CD O
g NN O
, , O
100 CD O
mmol NN O
) -RRB- O
and CC O
silver JJ B-NP
trifluoromethansulfonate JJ I-NP
( -LRB- O
46.3 CD O
g NN O
, , O
180 CD O
mmol NN O
) -RRB- O
is VBZ O
dried VBN O
for IN O
6 CD O
h NN O
at IN O
room NN O
temperature NN O
at IN O
1.32 CD O
Pa NNP O
. . O

Anhydrous JJ O
dichlorniethan FW B-NP
( -LRB- O
300 CD O
ml NN O
) -RRB- O
is VBZ O
added VBN O
to TO O
the DT O
mixture NN O
under IN O
argon NN B-NP
. . O

The DT O
mixture NN O
is VBZ O
cooled VBN O
down RB O
to TO O
-30 DT O
[deg.]C NNP O
and CC O
during IN O
1 CD O
h NN O
under IN O
stirring VBG O
a DT O
solution NN O
of IN O
3,4,6-tri-O-acetyl-2-deoxy-2-ftalimido-[beta]-D-glucopyi-a DT B-NP
- : I-NP
nosyl NN I-NP
bromide NN I-NP
(89.7 CD O
g NN O
, , O
180 CD O
mmol NN O
) -RRB- O
in IN O
anhydrous JJ O
dichlormethane NN B-NP
( -LRB- O
300 CD O
ml NN O
) -RRB- O
is VBZ O
added VBN O
. . O

The DT O
mixture NN O
is VBZ O
stirred VBN O
for IN O
1 CD O
h NN O
at IN O
-30 DT O
[deg.]C NNP O
and CC O
for IN O
2 CD O
h NN O
at IN O
-20 NNP O
<0>C. . O

Pyridine NNP B-NP
( -LRB- O
50 CD O
ml NN O
) -RRB- O
is VBZ O
then RB O
added VBN O
to TO O
the DT O
mixture NN O
under IN O
stirring VBG O
at IN O
-20 DT O
<0>C NNP O
and CC O
after IN O
rising VBG O
of IN O
temperature NN O
to TO O
room NN O
temperature NN O
the DT O
mixture NN O
is VBZ O
diluted VBN O
with IN O
chloroform NN B-NP
( -LRB- O
1000 CD O
ml NN O
) -RRB- O
and CC O
filtered VBD O
. . O

The DT O
filtrate NN O
is VBZ O
washed VBN O
with IN O
cool JJ O
( -LRB- O
+4 NN O
[deg.]C NN O
) -RRB- O

saturated VBD O
aqueous JJ O
sodium NN B-NP
hydrogen NN I-NP
carbonate NN I-NP
( -LRB- O
1000 CD O
ml NN O
) -RRB- O
, , O
water NN B-NP
( -LRB- O
1000 CD O
ml NN O
) -RRB- O
and CC O
saturated VBD O
aqueous JJ O
sodium NN B-NP
chloride NN I-NP
solution NN O
( -LRB- O
1000 CD O
ml NN O
) -RRB- O
, , O
dried VBD O
over IN O
anhydrous JJ O
magnesium NN B-NP
sulphate NN I-NP
, , O
evaporated VBD O
at IN O
vacuum NN O
a DT O
co-distilled JJ O
with IN O
toluene NN B-NP
( -LRB- O
2 CD O
x NN O
500 CD O
ml NN O
) -RRB- O
in IN O
vacuum NN O
. . O

Column NNP O
chromatography NN O
of IN O
the DT O
residue NN O
in IN O
ethyl NN B-NP
acetate-toluene NN I-NP
( -LRB- O
2:1 CD O
) -RRB- O
system NN O
afforded VBN O
78.1 CD O
g NN O
( -LRB- O
85.0 CD O
% NN O
) -RRB- O
of IN O
benzyl-3 NN B-NP
,4,6-tri-O-acetyl-2-deoxy-2-ftalimido-[beta]-D-glucopyranosyl-( . I-NP
1 CD I-NP
->4)-2-acetamido-6-0- : I-NP
benzoyl-2-deoxy-3-O-[l-(R)-(methoxycarbonyl JJ I-NP
)ethyl]-[alpha]-D-glucopyranoside JJ I-NP
VI NN O
as IN O
solid JJ O
foam NN O
; : O
[OC]D NN O
+37 CD O
( -LRB- O
c NN O
0.1 CD O
, , O
chloroform NN B-NP
) -RRB- O
. . O

For IN O
C46H50N2O18 DT B-NP
calculated VBN O
: : O
relative JJ O
molecular JJ O
mass NN O
918.9 CD O
, , O
monoisotopic JJ O
mass NN O
918.3 CD O
. . O

ESI NNP O
MS NNP O
, , O
m/z NN O
: : O
941.5 CD O
[ NN O
M NNP O
+ NNP O
Na] NNP O
. . O

For IN O
C46H50N2O18 JJ B-NP
(918.9 CD O
) -RRB- O

calculated VBN O
: : O
60.13 CD O
% NN O
C NNP O
, , O
5.48 CD O
% NN O
H NNP O
, , O
3.05 CD O
% NN O
N NNP O
; : O
found VBD O
: : O
60.33 CD O
% NN O
C NNP O
, , O
5.45 CD O
% NN O
H NNP O
, , O
2.86 CD O
% NN O
N. NNP O

Example NN O
7 CD O

A DT O
solution NN O
of IN O
ben2yl-3,4,6-tri-O-aceryl-2-deoxy-2-ftalimido-[beta]-D-glucopyranosyl-(l->4) JJ B-NP
- : I-NP
2-acetamido-6-O-benzoyl-2-deoxy-3-6>-[l-(R)-(methoxycarbonyl JJ I-NP
)ethyl-[alpha]-D-glucopyranoside JJ I-NP
VI NNS O
( -LRB- O
18.4 CD O
g NN O
, , O
20 CD O
mmol NN O
) -RRB- O
in IN O
0.01M CD O
sodium NN B-NP
methoxide NN I-NP
solution NN O
in IN O
anhydrous JJ O
methanol NN B-NP
( -LRB- O
500 CD O
ml NN O
) -RRB- O
is VBZ O
left VBN O
to TO O
stand VB O
for IN O
48 CD O
h NN O
at IN O
laboratory NN O
temperature NN O
and CC O
the DT O
mixture NN O
is VBZ O
neutralized VBN O
by IN O
adding VBG O
of IN O
ion NN O
exchanger NN O
Dowex NNP O
50 CD O
in IN O
pyridine JJ B-NP
cycle NN O
. . O

Ion NNP O
exchanger NN O
is VBZ O
filtered VBN O
off RP O
, , O
washed VBN O
with IN O
methanol NN B-NP
( -LRB- O
200 CD O
ml NN O
) -RRB- O
and CC O
filtrate NN O
was VBD O
evaporated VBN O
in IN O
vacuum NN O
. . O

Evaporated NNP O
residue NN O
is VBZ O
heated VBN O
under IN O
stirring VBG O
in IN O
0,25M DT O
aqueous JJ O
sodium NN B-NP
hydroxide NN I-NP
solution NN O
( -LRB- O
550 CD O
ml NN O
) -RRB- O
at IN O
60 CD O
<0>C CD O
for IN O
3.5 CD O
h NN O
. . O

After IN O
cooling VBG O
down RP O
to TO O
room NN O
temperature NN O
the DT O
mixture NN O
is VBZ O
neutralized VBN O
with IN O
ion NN O
exchanger NN O
Dowex NNP O
50 CD O
in IN O
pyridine JJ B-NP
cycle NN O
. . O

Ion NNP O
exchanger NN O
is VBZ O
filtered VBN O
off RP O
, , O
washed VBN O
with IN O
water NN B-NP
( -LRB- O
100 CD O
ml NN O
) -RRB- O
, , O
the DT O
eluate NN O
was VBD O
evaporated VBN O
in IN O
vacuum NN O
, , O
and CC O
the DT O
evaporated JJ O
residue NN O
is VBZ O
co-distilled JJ O
at IN O
vacuum NN O
with IN O
anhydrous JJ O
methanol NN B-NP
( -LRB- O
3 CD O
x NN O
80 CD O
ml NN O
) -RRB- O
. . O

The DT O
evaporated JJ O
residue NN O
is VBZ O
dissolved VBN O
in IN O
methanol NN B-NP
and CC O
n-butylamine JJ B-NP
mixture NN O
( -LRB- O
4 CD O
:1 NN O
, , O
300 CD O
ml NN O
) -RRB- O
and CC O
the DT O
solution NN O
is VBZ O
heated VBN O
in IN O
pressure NN O
tank NN O
for IN O
11 CD O
h NN O
at IN O
85-90 CD O
<0>C. . O

After IN O
cooling VBG O
down RP O
to TO O
room NN O
temperature NN O
, , O
the DT O
mixture NN O
is VBZ O
evaporated VBN O
in IN O
vacuum NN O
and CC O
the DT O
residue NN O
is VBZ O
extracted VBN O
with IN O
diethyl NN B-NP
ether NN I-NP
( -LRB- O
3 CD O
x NN O
150 CD O
ml NN O
) -RRB- O
. . O

Insoluble NNP O
residue NN O
is VBZ O
dissolved VBN O
in IN O
water NN B-NP
( -LRB- O
250 CD O
ml NN O
) -RRB- O
, , O
pH JJ O
solution NN O
is VBZ O
adjusted VBN O
with IN O
formic JJ O
acid NN O
to TO O
pH VB O
4 CD O
and CC O
the DT O
solution NN O
is VBZ O
applied VBN O
to TO O
ion NN O
exchanger NN O
Dowex NNP O
50 CD O
column NN O
in IN O
ammonium NN B-NP
cycle NN O
( -LRB- O
800 CD O
ml NN O
) -RRB- O
. . O

The DT O
column NN O
is VBZ O
washed VBN O
with IN O
water NN B-NP
( -LRB- O
1500 CD O
ml NN O
) -RRB- O
and CC O
product NN O
is VBZ O
liberated VBN O
from IN O
ion NN O
exchanger NN O
washing NN O
with IN O
5 CD O
% NN O
aqueous JJ O
ammonia NN B-NP
( -LRB- O
1000 CD O
ml NN O
) -RRB- O
. . O

The DT O
eluted VBD O
fraction NN O
was VBD O
evaporated VBN O
in IN O
vacuum NN O
. . O

The DT O
obtained VBD O
benzyl-2-amino-2-deoxy-[beta]-D-glucopyranosyl-(l->4)-2-acetamido-2-deoxy-3-O- DT B-NP
[l-(R)-carboxyethyl]-[alpha]-D-glucopyranoside JJ I-NP
VII NNP O
is VBZ O
N-acetylated JJ O
without IN O
any DT O
next JJ O
purification NN O
( -LRB- O
see VB O
Example JJ O
8 CD O
) -RRB- O
. . O

An DT O
analytical JJ O
sample NN O
of IN O
compound NN O
VII NNP O
is VBZ O
prepared VBN O
on IN O
crystallization NN O
from IN O
ethanol NN B-NP
; : O
m.p NN O
. . O
183-185 CD O
[deg.]C NNP O
; : O

[[alpha]] NN O
D NNP O
+109 CD O
( -LRB- O
c NN O
0.2 CD O
, , O
water NN B-NP
) -RRB- O
. . O

For IN O
C24H36N2O12 DT B-NP
calculated VBN O
: : O
relative JJ O
molecular JJ O
mass NN O
544.6 CD O
, , O
monoisotopic JJ O
mass NN O
544.2 CD O
. . O

ESI NNP O
MS NNP O
, , O
m/z NN O
: : O
545.0 CD O
[ NN O
M NNP O
+ NNP O
H] NNP O
, , O
567.3 CD O
[ NN O
M NNP O
+ NNP O
Na] NNP O
. . O

Example NNP O
8 CD O

Acetic JJ B-NP
acid NN I-NP
anhydride NN O
( -LRB- O
20 CD O
ml NN O
) -RRB- O
is VBZ O
stepwise RB O
added VBN O
to TO O
a DT O
stirred VBN O
benzyl-2-amino-2-deoxy-[beta] JJ B-NP
- : I-NP
D-glucopyranosyl-(l-->4)-2-acetamido-2-deoxy-3-O-[l-(R)-carboxyethyl-[alpha]-D-glucopyranosi- : I-NP
de FW I-NP
VII FW O
( -LRB- O
obtained VBN O
in IN O
Example JJ O
7 CD O
) -RRB- O
solution NN O
( -LRB- O
160 CD O
ml NN O
) -RRB- O
at IN O
room NN O
temperature NN O
during IN O
15 CD O
min NN O
. . O

After IN O
30 CD O
min NN O
the DT O
next JJ O
portion NN O
of IN O
acetic JJ B-NP
acid NN I-NP
anhydride NN O
is VBZ O
added VBN O
( -LRB- O
20 CD O
ml NN O
) -RRB- O
, , O
and CC O
the DT O
stirring NN O
continues VBZ O
for IN O
2 CD O
h NN O
. . O

The DT O
solution NN O
was VBD O
evaporated VBN O
in IN O
vacuum NN O
, , O
the DT O
evaporated JJ O
residue NN O
is VBZ O
dissolved VBN O
in IN O
water NN B-NP
and CC O
this DT O
solution NN O
is VBZ O
applied VBN O
to TO O
ion NN O
exchanger NN O
Dowex NNP O
50 CD O
column NN O
in IN O
pyridinium NN O
cycle NN O
( -LRB- O
300 CD O
ml NN O
) -RRB- O
. . O

The DT O
column NN O
is VBZ O
washed VBN O
with IN O
water NN B-NP
( -LRB- O
700 CD O
ml NN O
) -RRB- O
, , O
and CC O
eluted VBD O
portion NN O
was VBD O
evaporated VBN O
in IN O
vacuum NN O
. . O

The DT O
residue NN O
is VBZ O
lyofilized VBN O
from IN O
water NN B-NP
. . O

The DT O
yield NN O
is VBZ O
7.1 CD O
g VBG O
(60.5 CD O
% NN O
) -RRB- O
of IN O
benzyl-2-acetamido-2- CD B-NP
deoxy-[beta]-D-glucopyranosyl-(l-->4)-2-acetamido-2-deoxy-3-O-[l-(R)-carboxyethyl]-[alpha]-D- : I-NP
glucopyranoside NN I-NP
I PRP O
, , O
in IN O
relation NN O
to TO O
compound VB O
VI NNP O
; : O
[[alpha]]p JJ O
+ NN O
70 CD O
( -LRB- O
c NN O
0.2 CD O
, , O
water NN B-NP
) -RRB- O
. . O

For IN O
C26H38N2O13 DT B-NP
calculated VBN O
: : O
relative JJ O
molecular JJ O
mass NN O
586.6 CD O
, , O
monoisotopic JJ O
mass NN O
586.2 CD O
. . O

ESI NNP O
MS NNP O
, , O
m/z NN O
: : O
609.4 CD O
[ NN O
M NNP O
+ NNP O
Na] NNP O
. . O

For IN O
C26H38N2O13 DT B-NP
( -LRB- O
586.6 CD O
) -RRB- O

calculated VBN O
: : O
53.24 CD O
% NN O
C NNP O
, , O
6.53 CD O
%H NNP O
, , O
4.78 CD O
% NN O
N NNP O
; : O
found VBD O
: : O
53.05 CD O
% NN O
C5 IN O
6.82 CD O
% NN O
H5 IN O
4.55 CD O
% NN O
N. NNP O

Example NNP O
9 CD O

Bis(pentafluorophenyl)carbonate NNP B-NP
( -LRB- O
434 CD O
mg NN O
, , O
1.1 CD O
mmol NN O
) -RRB- O
and CC O
4-methylmorfoline JJ B-NP
( -LRB- O
0.11 CD O
ml NN O
, , O
1 CD O
mmol NN O
) -RRB- O
were VBD O
added VBN O
to TO O
a DT O
stirred VBD O
solution NN O
of IN O
benzyl-2-acetamido-2-deoxy-[beta]-D-gluco NN B-NP
- : I-NP
pyranosyl-( JJ I-NP
l JJ I-NP
->4)-2-acetamido-2-deoxy-3-0-[l JJ I-NP
-(R NN I-NP
)~carboxyethyl-[alpha]-D-glucopyranoside NN I-NP
I PRP O
( -LRB- O
587 CD O
mg NN O
, , O
1 CD O
mmol NN O
) -RRB- O
in IN O
iV NN B-NP
,iV-dimethylformamide NN I-NP
( -LRB- O
4 CD O
ml NN O
) -RRB- O
at IN O
room NN O
temperature NN O
, , O
and CC O
the DT O
mixture NN O
is VBZ O
stirred VBN O
for IN O
one CD O
hour NN O
. . O

Reaction NN O
process NN O
is VBZ O
monitored VBN O
by IN O
TLC NNP O
in IN O
ethanol NN B-NP
. . O

Dioxan JJ B-NP
( -LRB- O
20 CD O
ml NN O
) -RRB- O
is VBZ O
then RB O
added VBN O
and CC O
the DT O
mixture NN O
is VBZ O
lyofilized VBN O
. . O

A DT O
repeated VBN O
lyofilization NN O
of IN O
the DT O
product NN O
from IN O
dioxan NN B-NP
afforded VBN O
723 CD O
mg JJ O
(96 CD O
% NN O
) -RRB- O
benzyl-2-acetamido-2-deoxy-[beta]-D-glucopyranosyl-(l-->4)-2-acetami- . B-NP
do-2-deoxy-3-O-[l-(R)-(pentafluorophenoxycarbonyl JJ I-NP
)ethyl]-[alpha]-D-glucopyranoside JJ I-NP
X NNP O
that WDT O
is VBZ O
, , O
without IN O
any DT O
purification NN O
, , O
condensed VBN O
with IN O
a DT O
peptide NN B-NP
component NN O
( -LRB- O
see VB O
Example JJ O
10 CD O
) -RRB- O
. . O

For IN O
( -LRB- O
C32H37F5N2O1S NNS B-NP
) -RRB- O
calculated VBN O
: : O
relative JJ O
molecular JJ O
mass NN O
752.6 CD O
, , O
monoisotopic JJ O
mass NN O
752.2 CD O
. . O

ESI NNP O
MS NNP O
, , O
m/z NN O
: : O
775.6 CD O
[ NN O
M NNP O
+ NNP O
Na] NNP O
. . O

Example NNP O
10 CD O

A DT O
solution NN O
of IN O
L-Ala-D-iso-Gln-OBn NNP B-NP
( -LRB- O
615 CD O
mg NN O
, , O
2 CD O
mmol NN O
) -RRB- O
and CC O
iV-methylmorfoline JJ O
( -LRB- O
0.30 CD O
ml NN O
, , O
2.73 CD O
mmol NN O
) -RRB- O
in IN O
pyridine NN B-NP
( -LRB- O
6 CD O
ml NN O
) -RRB- O
at IN O
0 CD O
<0>C NNP O
is VBZ O
added VBN O
to TO O
a DT O
stirred VBD O
solution NN O
of IN O
ben2yl-2-acetamido NN B-NP
- : I-NP
2-deoxy-[beta]-D-glucopyranosyl-(l->-4)-2-acetamido-2-deoxy-3-O-[l-(R)-(pentafluorofenoxycar- : I-NP
bonyl NN I-NP
)ethyl]-[alpha]-D-glucopyranoside NN I-NP
X NNP O
( -LRB- O
753 CD O
mg NN O
, , O
1 CD O
mmol NN O
) -RRB- O
and CC O
the DT O
stirring NN O
continues VBZ O
for IN O
20 CD O
h NN O
at IN O
+5 CD O
<0>C. . O

The DT O
mixture NN O
was VBD O
evaporated VBN O
in IN O
vacuum NN O
, , O
the DT O
evaporated JJ O
residue NN O
is VBZ O
co-distilled JJ O
in IN O
vacuum NN O
with IN O
acetic JJ B-NP
acid NN I-NP
( -LRB- O
10 CD O
ml NN O
) -RRB- O
, , O
and CC O
the DT O
residue NN O
is VBZ O
chromatographed VBN O
on IN O
silica NN B-NP
gel NN I-NP
Cl NNP O
8 CD O
column NN O
in IN O
water-methanol NN B-NP
system NN O
( -LRB- O
linear JJ O
gradient NN O
: : O
0->30 CD O
% NN O
, , O
60 CD O
min NN O
) -RRB- O
. . O

Lyofilization NN O
of IN O
evaporated JJ O
residue NN O
of IN O
homogenous JJ O
fraction NN O
from IN O
water NN B-NP
afforded VBN O
744 CD O
mg NN O
( -LRB- O
85.0 CD O
% NN O
) -RRB- O
benzyl NN B-NP
ester NN I-NP
of IN O
N-{2-0-[benzyl-2-acetamido-2-deoxy-[beta]-D-glucopyranosyl-(l->4)-2-acetamido-2,3- DT B-NP
dideoxy-[alpha]-D-glucopyranosid-3-yl]-(R)-lactoyl}-L-alanyl-D-isoglutamine NN I-NP
of IN O
formulae JJ O
IX NNP O
( -LRB- O
wherein WRB O
X NNP O
is VBZ O
L-Ala-D-iso-Gln-OBn JJ B-NP
) -RRB- O
; : O
[[alpha]] NN O
D NN O
+50 . O
( -LRB- O
c NN O
0.4 CD O
, , O
50 CD O
% NN O
methanol NN B-NP
in IN O
water NN B-NP
) -RRB- O
. . O

For IN O
( -LRB- O
C41H57N5O16 NN B-NP
) -RRB- O
calculated VBN O
: : O
relative JJ O
molecular JJ O
mass NN O
875.9 CD O
, , O
monoisotopic JJ O
mass NN O
875.4 CD O
. . O

ESI NNP O
MS NNP O
, , O
m/z NN O
: : O
898.4 CD O
[ NN O
M NNP O
+ NNP O
Na] NNP O
. . O

For IN O
C4IH57N5O16 JJ B-NP
(875.9 CD O
) -RRB- O

calculated VBN O
: : O
56.22 CD O
% NN O
C5 IN O
6.56 CD O
% NN O
H NNP O
, , O
8.00 CD O
% NN O
N NNP O
; : O
found VBD O
: : O
55.81 CD O
% NN O
C5 IN O
6.60 CD O
% NN O
H5 IN O
7.90 CD O
% NN O
N. NNP O
Example NNP O
11 CD O

Benzyl NNP B-NP
ester NN I-NP
of IN O
N-{2-O-[benzyl-2-acetamido-2-deoxy-[beta]-D-gluco[rho]yranosyl-(l->4)-2- DT B-NP
acetamido-2,3-dideoxy-[alpha]-D-glucopyranosid-3-yl]-(R)-lactoyl}-L-alanyl-D-isoglutamine JJ I-NP
XI NNP O
(876 CD O
mg NN O
, , O
1 CD O
mmol NN O
) -RRB- O
is VBZ O
hydrogenolyzed JJ O
with IN O
hydrogen NN B-NP
on IN O
5 CD O
% NN O
palladium NN B-NP
catalyst NN O
on IN O
charcoal NN O
( -LRB- O
300 CD O
mg NN O
) -RRB- O
in IN O
acetic JJ B-NP
acid NN I-NP
( -LRB- O
14 CD O
ml NN O
) -RRB- O
at IN O
room NN O
temperature NN O
48 CD O
h NN O
. . O

After IN O
washing VBG O
out IN O
of IN O
apparatus NN O
with IN O
argon NN B-NP
, , O
the DT O
catalyst NN O
is VBZ O
filtered VBN O
off RP O
, , O
washed VBN O
with IN O
50 CD O
% NN O
acetic JJ B-NP
acid NN I-NP
( -LRB- O
30 CD O
) -RRB- O
, , O
and CC O
filtrate NN O
is VBZ O
evaporated VBN O
in IN O
vacuum NN O
. . O

The DT O
evaporated JJ O
residue NN O
is VBZ O
chromatographed VBN O
at IN O
silica NN B-NP
gel NN I-NP
Cl NNP O
8 CD O
column NN O
in IN O
water- DT B-NP
methanol NN B-NP
system NN O
( -LRB- O
linear JJ O
gradient NN O
: : O
0->20 CD O
% NN O
, , O
60 CD O
min NN O
) -RRB- O
. . O

Lyofilization NN O
of IN O
the DT O
residue NN O
of IN O
homogenous JJ O
fraction NN O
from IN O
water NN B-NP
afforded VBN O
612 IN O
mg JJ O
(88 CD O
% NN O
) -RRB- O
2-acetamido-2-deoxy-[beta]-D- CD B-NP
glucopyranosyl-(l-->4)-iV-acetylmuramyl-L-alanyl-D-isoglutamm JJ I-NP
( -LRB- O
GMDP NNP B-NP
) -RRB- O
IX NNP O
( -LRB- O
in IN O
which WDT O
X NNP O
is VBZ O
L-Ala-D-iso-Gln-OH) JJ B-NP
; : O
[[alpha]] NN O
D NN O
-3 NN O
( -LRB- O
c NN O
0.3 CD O
, , O
water NN B-NP
) -RRB- O
; : O
lit VBD O
.<27> JJ O
[[alpha]] NN O
D NN O
-2 NN O
( -LRB- O
c NN O
1.0, JJ O
water NN B-NP
) -RRB- O
. . O

For IN O
( -LRB- O
C27H45N5O16 NN B-NP
) -RRB- O
calculated VBN O
: : O
relative JJ O
molecular JJ O
mass NN O
695.7 CD O
, , O
monoisotopic JJ O
mass NN O
695.3 CD O
. . O

ESI NNP O
MS NNP O
, , O
m/z NN O
: : O
718.5 CD O
[ NN O
M NNP O
+ NNP O
Na] NNP O
. . O

For IN O
C27H45N5O16 DT B-NP
( -LRB- O
695.7 CD O
) -RRB- O

calculated VBN O
: : O
46.62 CD O
% NN O
C NNP O
, , O
6.52 CD O
% NN O
H NNP O
, , O
10.07 CD O
% NN O
N NNP O
; : O
found VBD O
: : O
46.21 CD O
% NN O
C NNP O
, , O
6.85 CD O
% NN O
H NNP O
, , O
9.96 CD O
% NN O
N. NNP O

Example NNP O
12 CD O

Ben2yl-2-acetamido-2-deoxy-[beta]-D-glucopyranosyl-(l- NNP B-NP
>4)-2-acetamido-2-deoxy-3-O- NNP I-NP
[l-(R)-carboxyethyl]-[alpha]-D-glucopyranoside NN I-NP
I PRP O
( -LRB- O
5.9 CD O
g NN O
, , O
10 CD O
mmol NN O
) -RRB- O
is VBZ O
hydrogenolyzed JJ O
with IN O
hydrogen NN B-NP
over IN O
5 CD O
% NN O
palladium NN B-NP
catalyst NN O
on IN O
charcoal NN O
( -LRB- O
3 CD O
g NN O
) -RRB- O
in IN O
acetic JJ B-NP
acid NN I-NP
( -LRB- O
140 CD O
ml NN O
) -RRB- O
at IN O
room NN O
temperature NN O
for IN O
48 CD O
h NN O
. . O

The DT O
apparatus NN O
was VBD O
washed VBN O
out RP O
with IN O
argon NN B-NP
, , O
the DT O
catalyst NN O
was VBD O
filtered VBN O
off RP O
, , O
washed VBN O
with IN O
50 CD O
% NN O
acetic JJ B-NP
acid NN I-NP
( -LRB- O
300 CD O
ml NN O
) -RRB- O
, , O
and CC O
filtrate NN O
was VBD O
evaporated VBN O
in IN O
vacuum NN O
. . O

The DT O
evaporated JJ O
residue NN O
is VBZ O
cliromatographed VBN O
on IN O
silica NN B-NP
gel NN I-NP
Cl NNP O
8 CD O
column NN O
in IN O
water-methanol NN B-NP
system NN O
( -LRB- O
linear JJ O
gradient NN O
: : O
0->20 CD O
% NN O
, , O
60 CD O
min NN O
) -RRB- O
. . O

Lyofilization NN O
of IN O
the DT O
evaporated JJ O
residue NN O
of IN O
homogenous JJ O
fraction NN O
afforded VBN O
4667 CD O
mg NN O
( -LRB- O
94 CD O
% NN O
) -RRB- O
of IN O
2-acetamido-2-deoxy-[beta]-D-glucopyranosyl-(l-->4)-iV JJ B-NP
- : I-NP
acetylmurarnic JJ I-NP
acid NN I-NP
VIII NNP O
; : O
[[alpha]] NN O
D NN O
+5 . O
( -LRB- O
c NN O
0.3 CD O
, , O
water NN B-NP
) -RRB- O
; : O
lit VBD O
.<29> JJ O
[[alpha]] NN O
D NN O
+4 . O
( -LRB- O
c NN O
1.0, JJ O
water NN B-NP
) -RRB- O
. . O

For IN O
( -LRB- O
C1PHs2N2O13 NN B-NP
) -RRB- O
calculated VBN O
: : O
relative JJ O
molecular JJ O
mass NN O
496.5 CD O
, , O
monoisotopic JJ O
mass NN O
496.2 CD O
. . O

ESI NNP O
MS NNP O
, , O
m/z NN O
: : O
519,4 CD O
[ NN O
M NNP O
+ NNP O
Na] NNP O
. . O

For IN O
C19H32N2O13 DT B-NP
( -LRB- O
496,5 CD O
) -RRB- O
calculated VBN O
: : O
45.97 CD O
% NN O
C5 IN O
6.50 CD O
% NN O
H NNP O
, , O
5.64 CD O
% NN O
N NNP O
; : O
found VBD O
: : O
45.57 CD O
% NN O
C NNP O
, , O
6.72 CD O
% NN O
H NNP O
, , O
5.43 CD O
% NN O
N. NNP O

The DT O
structures NNS O
of IN O
all DT O
above IN O
given VBN O
compounds NNS O
are VBP O
unambiguously RB O
proved VBN O
by IN O
their PRP$ O
<1>H NNS O
a DT O
<13>C JJ O
NMR NNP O
spectra NN O
. . O

Industrial NNP O
utility NN O

The DT O
compounds NNS O
of IN O
the DT O
present JJ O
invention NN O
can MD O
be VB O
used VBN O
in IN O
basic JJ O
research NN O
, , O
pharmaceutical JJ O
industry NN O
and CC O
both DT O
in IN O
human JJ O
and CC O
veterinary JJ O
medicine NN O
. . O

Formulae NNP O
: : O

[0073] . O

EMI18.1 . O

[0074] . O

EMI18.2 NN O

[0075 CD O
] NN O

EMI18.3 . O

[0076] . O

EMI18.4 . O

IV NNP O

EMI19.1 . O

V NNP O

[0079] . O

EMI19.2 NN O

[0080] . O

EMI19.3 . O

VII NNS O

[0081] . O

EMI19.4 . O

[0082 CD O
] NN O

EMI19.5 . O

EMI20.1 . O

[0083] . O

EMI20.2 NN O

Xl . O

REFERENCES NNS O

1 LS O
. . O
Adam NNP O
A.Adam NNP O
A. NN O
, , O
in IN O
: : O
Synthetic JJ O
Adjuvants NNS O
, , O
p NN O
. . O
1 LS O
. . O
John NNP O
Wiley NNP O
and CC O
Sons NNP O
, , O
New NNP O
York NNP O
2004 CD O
. . O

2. DT O
Andronova NNP O
T.M. NNP O
, , O
Ivanov NNP O
V.T. NNP O
: : O
Sov. NNP O

Nedical NNP O
. . O

Review NNP O
D. NNP O
Immunology NNP O
1991 CD O
, , O
4 CD O
, , O
1 CD O
. . O

3. DT O
Azuma NNP O
L: NNP O
Vaccine NNP O
1992 CD O
, , O
10 CD O
, , O
1000 CD O
. . O

4 CD O
. . O
Baschang NNP O
G. NNP O
: : O
Tetrahedron NNP O
1989 CD O
, , O
45 CD O
, , O
6331 CD O
. . O

5 CD O
. . O
Hiraoka NNP O
A. NN O
, , O
Masaoka NNP O
T. NNP O
, , O
Satoh NNP O
T. NNP O
, , O
Ota NNP O
K. NNP O
, , O
Oyama NNP O
A. NNP O
, , O
Horiuchi NNP O
A. NNP O
, , O
Hasegawa NNP O
H. NNP O
, , O
Nagai NNP O
K. NNP O
, , O
Kosaki NNP O
M. NNP O
, , O
Kanemaru NNP O
A. NN O
: : O
Arzneimittel-Forschung NNP O
1988 CD O
, , O
55,1499 CD O
. . O

6 CD O
. . O
Furuse VB O
K. NNP O
, , O
Sakuma NNP O
A. NN O
: : O
Arzneimittel-Forschung NNP O
1989 CD O
, , O
39,915 CD O
. . O

7. . O
Khaidukov NNP O
S. NNP O
, , O
V NNP O
, , O
Komaleva NNP O
R.L. NNP O
, , O
Nesmeyanov NNP O
V.A. NNP O
: : O
International NNP O
Journal NNP O
of IN O
Immunopharmacology NNP O
1995 CD O
, , O
77,903 CD O
. . O

8. DT O
Yoo NNP O
Y.C. NNP O
, , O
Yoshimatsu NNP O
K. NNP O
, , O
Koike NNP O
Y. NNP O
, , O
Hatsuse NNP O
R. NNP O
, , O
Yamanishi NNP O
K. NNP O
, , O
Tanishita NNP O
O. NNP O
, , O
Arikawa NNP O
J. NNP O
, , O
Azuma NNP O
L: NNP O
Vaccine NNP O
1998 CD O
, , O
16 CD O
, , O
216 CD O
. . O

9 CD O
. . O
Namba NNP O
K. NNP O
, , O
Nakajima NNP O
R. NNP O
, , O
Otani NNP O
T. NNP O
, , O
Azuma NNP O
I. NNP O
: : O
Vaccine NNP O
1996 CD O
, , O
7^,1149 CD O
. . O

10 CD O
. . O
Niki NNP O
Y. NNP O
, , O
Tatara NNP O
O. NNP O
: : O
Advances NNS O
in IN O
Experimental NNP O
Medicine NNP O
and CC O
Biology NNP O
1992 CD O
, , O
319,185 CD O
. . O

11 CD O
. . O
Yoo NNP O
Y.C. NNP O
, , O
Park NNP O
S. NNP O
Y. NNP O
, , O
Lee NNP O
K.B. NNP O
, , O
Azuma NNP O
L: NNP O
Journal NNP O
of IN O
Microbiology NNP O
and CC O
Biotechnology NNP O
2000 CD O
, , O
10 CD O
, , O
399 CD O
. . O

12 CD O
. . O
Aston NNP O
R. NNP O
( -LRB- O
( -LRB- O
Biokine NNP O
Technology NNP O
Ltd. NNP O
, , O
UK) NNP O
: : O
WO NN O
92-GB2137.9310148 CD O
; : O

13 CD O
. . O
Aston NNP O
R. NNP O
, , O
Maitchouk NNP O
L, NNP O
Andronova NNP O
T.M. NNP O
( -LRB- O
( -LRB- O
Peptech NNP O
( -LRB- O
Uk NNP O
) -RRB- O
Limited NNP O
, , O
UK) NNP O
: : O
WO NN O
95- CD O
GB2237.9609063 NNP O
; : O

14 CD O
. . O
Vosika NNP O
GJ. NNP O
, , O
Cornelius NNP O
D. NNP O
A. NN O
, , O
Bennek NNP O
J.A. NNP O
, , O
Sadlik NNP O
J.R. NNP O
, , O
Gilbert NNP O
CW. NNP O
: : O
MoI. . O

Biother NN O
. . O

1990 CD O
, , O
2 CD O
, , O
50 CD O
. . O

15 CD O
. . O
Vosika NNP O
G. NNP O
J. NNP O
, , O
Cornelius NNP O
D. NNP O
A. NNP O
, , O
Gilbert NNP O
C. NNP O
W. NNP O
, , O
Sadlik NNP O
J.R. NNP O
, , O
Bennek NNP O
J. NNP O
A. NN O
, , O
Doyle NNP O
A. NNP O
, , O
Hertsgaard NNP O
D. NNP O
: : O
J. NNP O
Immunother NNP O
. . O

1991 CD O
, , O
10 CD O
, , O
256 CD O
. . O

16 CD O
. . O
Fast NNP O
DJ. NNP O
, , O
Vosika NNP O
G.J. NNP O
: : O
Vaccine NNP O
1997 CD O
, , O
15 CD O
, , O
1748 CD O
. . O

W NNP O

17 CD O
. . O
Vosika NNP O
GJ. NNP O
( -LRB- O
( -LRB- O
Endorex NNP O
Corporation NNP O
, , O
USA NNP O
) -RRB- O
: : O
WO NN O
97-US8146.9743308 CD O
; : O

18 CD O
. . O
M.F.Powell NNP O
, , O
M. NNP O
J. NNP O
Newman NNP O
Eds NNP O
.Vaccine NNP O
design NN O
, , O
( -LRB- O
M.F.Powell NNP O
, , O
M. NNP O
J. NNP O
Newman NNP O
Eds NNP O
. . O
) -RRB- O
, , O
p NN O
. . O
141 CD O
. . O

Plenum NNP O
Press NNP O
, , O
New NNP O
York NNP O
1995 CD O
. . O

19 CD O
. . O
Banoub NNP O
J. NNP O
, , O
Boullanger NNP O
P. NNP O
, , O
Lafont NNP O
D. NNP O
: : O
Chemical NNP O
Reviews NNP O
1992 CD O
, , O
92 CD O
, , O
1167 CD O
. . O

20 CD O
. . O
Garegg NNP O
PJ. NNP O
: : O
Advances NNS O
in IN O
Carbohydrate NNP O
Chemistry NNP O
and CC O
Biochemistry NNP O
, , O
VoI NNP O
52 CD O
1997 CD O
, , O
52 CD O
, , O
179 CD O
. . O

21 CD O
. . O
Paulsen NNP O
H. NNP O
: : O
Angewandte NNP O
Chemie-International NNP O
Edition NNP O
in IN O
English NNP O
1982 CD O
, , O
21 CD O
, , O
155 CD O
. . O

22 CD O
. . O
Schmidt NNP O
R.R. NNP O
, , O
Kinzy NNP O
W. NNP O
: : O
Advances NNS O
in IN O
Carbohydrate NNP O
Chemistry NNP O
and CC O
Biochemistry NNP O
, , O
VoI NNP O
50 CD O
1994 CD O
, , O
50 CD O
, , O
21 CD O
. . O

23 CD O
. . O
Sinay NNP O
P. NNP O
: : O
Pure NNP O
and CC O
Applied NNP O
Chemistry NNP O
1991 CD O
, , O
63 CD O
, , O
519 CD O
. . O

24 CD O
. . O
Inage NNP O
M. NNP O
, , O
Imoto NNP O
M. NNP O
, , O
Kambayashi NNP O
Y. NNP O
, , O
Kusumoto NNP O
S. NNP O
, , O
Shiba NNP O
T. NNP O
: : O
Tetrahedron NNP O
Letters NNP O
1980 CD O
, , O
21 CD O
, , O
3767 CD O
. . O

25 CD O
. . O
Kusumoto NNP O
S. NNP O
, , O
Yamamoto NNP O
K. NNP O
, , O
Imoto NNP O
M. NNP O
, , O
Inage NNP O
M. NNP O
, , O
Tsujimoto NNP O
M. NNP O
, , O
Kotani NNP O
S. NNP O
, , O
Shiba NNP O
T. NNP O
: : O
Bulletin NNP O
of IN O
the DT O
Chemical NNP O
Society NNP O
of IN O
Japan NNP O
1986 CD O
, , O
59 CD O
, , O
1411 CD O
. . O

26 CD O
. . O
Durette NNP O
P.L. NNP O
, , O
Meitzner NNP O
E.P. NNP O
: : O
Carbohydr NNP O
. . O

Res NNP O
. . O

1981 CD O
, , O
89 CD O
, , O
279 CD O
. . O

27 CD O
. . O
Kiso NNP O
M. NNP O
, , O
Kaneda NNP O
Y. NNP O
, , O
Shimizu NNP O
R. NNP O
, , O
Hasegawa NNP O
A. NNP O
, , O
Azuma NNP O
L: NNP O
Carbohydr NNP O
. . O

Res NNP O
. . O

1982 CD O
, , O
104 CD O
, , O

253 CD O
. . O

28 CD O
. . O
Durette NNP O
PX NNP O
. . O
( -LRB- O
( -LRB- O
Merck NNP O
and CC O
Co. NNP O
, , O
Inc. NNP O

USA NNP O
) -RRB- O
: : O
EP JJ O
80-400566.18901 CD O

; : O

29 CD O
. . O
Kantoci NNP O
D. NNP O
, , O
Keglevic NNP O
D. NNP O
, , O
Derome NNP O
A.E. NNP O
: : O
Carbohydr NNP O
. . O

Res NNP O
. . O

1987 CD O
, , O
162 CD O
, , O
227 CD O
. . O

30 CD O
. . O

Kusumoto NNP O
S. NNP O
, , O
Imoto NNP O
M. NNP O
, , O
Ogiku NNP O
T. NNP O
, , O
Shiba NNP O
T. NNP O
: : O
Bulletin NNP O
of IN O
the DT O
Chemical NNP O
Society NNP O
of IN O
Japan NNP O
1986 CD O
, , O
59 CD O
, , O
1419 CD O
. . O

31 CD O
. . O

Termin NNP O
A. NN O
, , O
Schmidt NNP O
R.R. NNP O
: : O
Liebigs NNP O
Annalen NNP O
der FW O
Chemie NNP O
1989 CD O
,789 CD O
. . O

32 CD O
. . O
Termin NNP O
A. NNP O
, , O
Schmidt NNP O
R.R. NNP O
: : O
Liebigs NNP O
Annalen NNP O
der FW O
Chemie NNP O
1992 CD O
,527 NN O
. . O

33 CD O
. . O
Vosika NNP O
GJ. NNP O
( -LRB- O
( -LRB- O
Endorex NNP O
Corporation NNP O
, , O
USA NNP O
) -RRB- O
: : O
WO NN O
96-US CD O
15391.9712894 CD O
; : O

34. . O

Bezrukova NNP O
EJ. NNP O
( -LRB- O
( -LRB- O
Bezrukov NNP O
, , O
Mikhail NNP O
Vasilievich NNP O
Russia NNP O
and CC O
Bezrukova NNP O
, , O
Elena NNP O
Jurievna NNP O
) -RRB- O
: : O
WO NN O
96-RU254.9710259 CD O
; : O

35 CD O
. . O

Bistricenko NNP O
A. NN O
( -LRB- O
( -LRB- O
Bistricenko NNP O
, , O
Andrejs NNP O
Latvia NNP O
and CC O
Jerniolajevs NNP O
, , O
Jevgenijs NNP O
) -RRB- O
: : O
LV JJ O
94- CD O
940018.10963 CD O
; : O

36 CD O
. . O

Vosika NNP O
GJ. NNP O
( -LRB- O
( -LRB- O
ImmunoTherapeutics NNP O
, , O
Inc. NNP O

USA NNP O
) -RRB- O
: : O
WO NN O
89-US302.9000396 CD O
; : O

37 CD O
. . O
Farkas NNP O
J. NNP O
, , O
Ledvina NNP O
M. NNP O
, , O
Brokes NNP O
J. NNP O
, , O
Jezek NNP O
J. NNP O
, , O
Zajicek NNP O
J. NNP O
, , O
Zaoral NNP O
M. NNP O
: : O
Carbohydr NNP O
. . O

Res NNP O
. . O

1987 CD O
, , O
163 CD O
, , O
63 CD O
. . O

38 CD O
. . O
Vesely NNP O
J. NNP O
, , O
Ledvina NNP O
M. NNP O
, , O
Jindfich NNP O
J. NNP O
, , O
Saman NNP O
D. NNP O
, , O
Trnka NNP O
T. NNP O
: : O
Collect NNP O
. . O

Czech JJ O
. . O

Chem NNP O
. . O

Commun NNP O
. . O

2003 CD O
, , O
68 CD O
, , O
1264 CD O
. . O

39 CD O
. . O
Ledvina NNP O
M. NNP O
, , O
Farkas NNP O
J. NNP O
, , O
Zajicek NNP O
J. NNP O
, , O
Jezek NNP O
J. NNP O
, , O
Zaoral NNP O
M. NNP O
: : O
Collect NNP O
. . O

Czech JJ O
. . O

Chem NNP O
. . O

Commun NNP O
. . O

1989 CD O
, , O
54 CD O
, , O
2784 CD O
. . O

40 CD O
. . O

Zaoral NNP O
M. NNP O
, , O
Jezek NNP O
J. NNP O
, , O
Straka NNP O
R. NNP O
, , O
Masek NNP O
K. NNP O
: : O
Collect NNP O
. . O

Czech JJ O
. . O

Chem NNP O
. . O

Commun NNP O
. . O

1978 CD O
, , O
43 CD O
, , O
1977 CD O
. . O

41 CD O
. . O
Keglevic NNP O
D. NNP O
, , O
Pongracic NNP O
M. NNP O
: : O
Carbohydr NNP O
. . O

Res NNP O
. . O

1984 CD O
, , O
135 CD O
, , O
85 CD O
. . O

42 CD O
. . O
Flowers NNPS O
H.M. NNP O
, , O
Jeanloz NNP O
R. NNP O
: : O
Jouranal NNP O
of IN O
Organic NNP O
Chemistry NNP O
1963 CD O
, , O
28 CD O
, , O
2983 CD O
. . O

43 CD O
. . O
Arita NNP O
H. NNP O
, , O
Fukukawa NNP O
K. NNP O
, , O
Matsushima NNP O
Y NNP O
. . O
: : O
Bulletin NNP O
of IN O
the DT O
Chemical NNP O
Society NNP O
of IN O
Japan NNP O
1972 CD O
, , O
45 CD O
, , O
3611 CD O
. . O

44 CD O
. . O
Hasegawa NNP O
A. NN O
, , O
Kaneda NNP O
Y. NNP O
, , O
Amano NNP O
M. NNP O
, , O
Kiso NNP O
M. NNP O
, , O
Azuma NNP O
L: NNP O
Agricultural NNP O
and CC O
Biological NNP O
Chemistry NNP O
1978 CD O
, , O
42 CD O
, , O
2187 CD O
' '' O
. . O

Claims NNS O

1 LS O
. . O
Disaccharide VB B-NP
synthon NN O
I PRP O

EMI24.1 . O

2. DT O
Method NNP O
of IN O
synthesis NN O
of IN O
compound NN O
I PRP O
according VBG O
to TO O
the DT O
claim NN O
1 CD O
, , O
comprising VBG O
as IN O
glycosyl NN O
acceptor NN O
the DT O
derivative NN O
of IN O
muramic JJ B-NP
acid NN I-NP
of IN O
formula NN O
II NNP O

EMI24.2 NN O

which WDT O
is VBZ O
prepared VBN O
from IN O
compound NN O
III NNP O

EMI24.3 . O

which WDT O
is VBZ O
3-O-alkylated JJ O
on IN O
treatment NN O
with IN O
2-bromopropionic JJ B-NP
acid NN I-NP
and CC O
then RB O
transformed VBD O
on IN O
esterif[iota]cation NN O
to TO O
compound VB O
IV NNP O

EMI24.4 . O

IV NNP O

which WDT O
is VBZ O
then RB O
converted VBN O
by IN O
splitting NN O
off IN O
of IN O
the DT O
isopropylidene NN B-NP
group NN O
to TO O
compound VB O
V NNP O

EMI25.1 . O

which WDT O
is VBZ O
then RB O
transformed VBN O
on IN O
partial JJ O
benzoylation NN O
with IN O
benzoylimidazole NN B-NP
to TO O
glycosyl NN O
acceptor NN O
of IN O
formula NN O
II NNP O

EMI25.2 NN O

Il NNP O

which WDT O
on IN O
reaction NN O
with IN O
3,4,6-tri-(9-acetyl-2-deoxy-2-phthalimido-[beta]-D-glucopyranosyl- DT B-NP
bromide NN I-NP
, , O
as IN O
glycosyl NN O
donor NN O
, , O
affords NNS O
disaccharide VBP B-NP
VI VBG O

EMI25.3 . O

Vl NN O

which WDT O
is VBZ O
then RB O
transformed VBN O
by IN O
gradual JJ O
removing VBG O
of IN O
protecting VBG O
groups NNS O
, , O
sensitive JJ O
to TO O
alkali NNS O
, , O
e.g NN O
. . O

acetyl NN B-NP
, , O
benzoyl NN B-NP
, , O
methyl NN B-NP
ester NN I-NP
and CC O
phthalimide NN B-NP
groups NNS O
, , O
to TO O
compound VB O
VII NN O

EMI25.4 . O

VII NNS O

which WDT O
on IN O
N-acetylation NN O
affords NNS O
disaccharide VBP B-NP
synthon NN O
of IN O
formula NN O
I. NN O

3. DT O
Use NNP O
of IN O
disaccharide NN B-NP
synthon NN O
I PRP O
according VBG O
to TO O
the DT O
claims NNS O
1 CD O
and CC O
2 CD O
for IN O
the DT O
synthesis NN O
of IN O
2- CD B-NP
acetamido-2-deoxy-[beta]-D-glucopyranosyl-(l->4)--V-acetylniuramic JJ I-NP
acid NN I-NP
VIII NN O

EMI26.1 . O

which WDT O
is VBZ O
obtained VBN O
on IN O
hydrogenolytic JJ O
removing VBG O
of IN O
benzyl NN B-NP
protecting VBG O
group NN O
. . O

4 LS O
. . O
Use NNP O
of IN O
disaccharide NN B-NP
synthon NN O
I PRP O
according VBG O
to TO O
the DT O
claims NNS O
1 CD O
and CC O
2 CD O
for IN O
the DT O
synthesis NN O
of IN O
muramyl NN B-NP
glycopeptides NNS I-NP
based VBN O
on IN O
a DT O
GMDP NNP B-NP
molecule NN O
of IN O
general JJ O
formula NN O
IX . O

EMI26.2 NN O

in IN O
which WDT O
X NNP O
is VBZ O
a DT O
peptide NN B-NP
residue NN O
, , O
wherein WRB O
the DT O
disaccharide NN B-NP
synthon NN O
I PRP O
is VBZ O
transformed VBN O
on IN O
treatment NN O
with IN O
bis(pentafluoro- NNS B-NP
phenyl)carbonate JJ I-NP
to TO O
compound VB O
X NNP O

EMI26.3 . O

which WDT O
is VBZ O
then RB O
on IN O
treatment NN O
with IN O
peptide NN B-NP
component NN O
transformed VBN O
to TO O
compound NN O
of IN O
general JJ O
formula NN O
XI . O

EMI27.1 . O

Xl . O

in IN O
which WDT O
X NNP O
is VBZ O
a DT O
peptide NN B-NP
residue NN O
, , O
and CC O
this DT O
compound NN O
on IN O
removing VBG O
of IN O
protecting VBG O
groups NNS O
, , O
under IN O
conditions NNS O
given VBN O
by IN O
their PRP$ O
character NN O
, , O
affords NNS O
compound NN O
X NNP O

EMI27.2 NN O

in IN O
which WDT O
X NNP O
is VBZ O
a DT O
peptide NN B-NP
residue NN O
. . O

-DOCSTART- X X O

[0001] JJ O
PROCESS NNP O
FOR IN O
THE DT O
PREPARATION NN O
OF IN O
DULOXETINE NNP B-NP

Field NNP O
of IN O
the DT O
invention NN O

The DT O
present JJ O
invention NN O
relates NNS O
to TO O
a DT O
process NN O
for IN O
the DT O
preparation NN O
of IN O
1-naphthol JJ B-NP
mixed JJ O
ethers NNS B-NP
, , O
in IN O
particular JJ O
of IN O
duloxetine JJ B-NP
Ia NNP O
: : O

[0004 CD O
] NN O

EMI2.1 . O

1a . O

Background NN O
of IN O
the DT O
invention NN O

The DT O
preparation NN O
of IN O
1-naphthol JJ B-NP
mixed JJ O
ethers NNS O
raises VBZ O
remarkable JJ O
interest NN O
, , O
since IN O
it PRP O
regards VBZ O
, , O
for IN O
example NN O
, , O
the DT O
synthesis NN O
of IN O
duloxetine JJ B-NP
Ia NNP O
( -LRB- O
( -LRB- B-NP
+)-(S)-N- : I-NP
methyl-[gamma]-(l-naphthalenyloxy)-2-thiophenepropanamine NN I-NP
) -RRB- O
, , O
whose WP$ O
hydrochloride JJ B-NP
salt NN O
is VBZ O
used VBN O
as IN O
antidepressant JJ O
. . O

EP NNP O
273 CD O
658 CD O
discloses NNS O
two CD O
methods NNS O
for IN O
the DT O
preparation NN O
of IN O
duloxetine JJ B-NP
or CC O
of IN O
its PRP$ O
precursor NN O
Ib NN O
: : O

[0008 CD O
] NN O

EMI2.2 NN O

1b . O

A DT O
first JJ O
procedure NN O
comprises VBZ O
the DT O
use NN O
of IN O
1-naphthol JJ B-NP
3a CD O

[0011] . O

EMI2.3 . O

3a CD O
and CC O
of IN O
compounds NNS O
of IN O
formula NN O
2. . O

[0013] . O

EMI3.1 . O

2 CD O

in IN O
particular JJ O
compound NN O
2a . O
in IN O
which WDT O
X NNP O
= SYM O
N( NNP B-NP
CH3)2 NNP I-NP
. . O

The DT O
ether JJ B-NP
bond NN O
in IN O
compounds NNS O
Ia NNP O
and CC O
Ib NNP O
forms NNS O
through IN O
Mitsunobu NNP O
reaction NN O
, , O
which WDT O
consists VBZ O
in IN O
the DT O
treatment NN O
in IN O
a DT O
ether JJ B-NP
solvent NN O
, , O
for IN O
example NN O
tetrahydrofuran JJ B-NP
, , O
of IN O
compounds NNS O
3a . O
and CC O
2 CD O
with IN O
equimolecular JJ O
amounts NNS O
of IN O
triphenylphosphine NN B-NP
and CC O
of IN O
an DT O
azodicarboxylic JJ B-NP
acid NN I-NP
ester NN I-NP
(typically RB O
the DT O
diisopropyl JJ B-NP
ester NN I-NP
) -RRB- O
. . O

In IN O
this DT O
way NN O
the DT O
ether JJ B-NP
bond NN O
forms NNS O
with IN O
inversion NN O
of IN O
configuration NN O
, , O
obtaining VBG O
as IN O
by-products NNS O
equimolecular JJ O
amounts NNS O
of IN O
triphenylphosphine NN B-NP
oxide NN O
and CC O
diisopropyl NN B-NP
hydrazodicarboxylate NN I-NP
, , O
whose WP$ O
separation NN O
from IN O
the DT O
desired VBN O
ether NN B-NP
is VBZ O
troublesome JJ O
. . O

The DT O
X NNP O
substituent NN O
in IN O
compounds NNS O
2 CD O
can MD O
be VB O
, , O
further RB O
to TO O
-N( JJ B-NP
CH3)2 NNP I-NP
, , O
any DT O
good JJ O
leaving VBG O
group NN O
susceptible JJ O
of IN O
being VBG O
substituted VBN O
with IN O
a DT O
nitrogen NN B-NP
function NN O
which WDT O
allows VBZ O
to TO O
obtain VB O
( -LRB- B-NP
+) VB I-NP
- : I-NP
duloxetine JJ I-NP
Ia NNP O
. . O

The DT O
Mitsunobu NNP O
reaction NN O
with IN O
compound JJ O
2a JJ O
proceeds NNS O
in IN O
more JJR O
than IN O
24 CD O
h NN O
. . O

The DT O
equimolar JJ O
ratio NN O
of IN O
the DT O
two CD O
reagents NNS O
( -LRB- O
triphenylphosphine NN B-NP
and CC O
azodicarboxylate JJ B-NP
) -RRB- O
with IN O
respect NN O
to TO O
compounds NNS O
2 CD O
and CC O
3a CD O
and CC O
the DT O
prolonged JJ O
reaction NN O
times NNS O
make VBP O
this DT O
synthetic JJ O
procedure NN O
not RB O
very RB O
profitable JJ O
, , O
even RB O
if IN O
it PRP O
proceeds VBZ O
with IN O
inversion NN O
of IN O
configuration NN O
at IN O
the DT O
oxygen-bearing NN O
carbon NN O
in IN O
compounds NNS O
2. . O

A DT O
method NN O
for IN O
the DT O
synthesis NN O
of IN O
duloxetine JJ B-NP
Ia NNP O
that WDT O
is VBZ O
preferred VBN O
to TO O
the DT O
one CD O
reported VBN O
above IN O
envisages NNS O
the DT O
use NN O
of IN O
1-fluoronaphthalene JJ B-NP
3b NN O

[0017] . O

EMI3.2 NN O

3b JJ O
and CC O
2a JJ O
as IN O
substrates NNS O
. . O

Compound NNP O
2a NNP O
is VBZ O
converted VBN O
to TO O
the DT O
corresponding JJ O
alkoxide NN B-NP
by IN O
treatment NN O
with IN O
a DT O
strong JJ O
base NN O
, , O
for IN O
example NN O
NaH NNP B-NP
; : O
the DT O
alkoxide NN B-NP
replaces VBZ O
the DT O
fluorine NN B-NP
at IN O
position NN O
1 CD O
of IN O
3b CD O
, , O
leading VBG O
to TO O
Ib NNP O
. . O

The DT O
substitution NN O
reaction NN O
of IN O
the DT O
fluorine NN B-NP
on IN O
the DT O
aromatic JJ O
ring NN O
is VBZ O
a DT O
particular JJ O
reaction NN O
which WDT O
involves VBZ O
an DT O
ionic JJ O
intermediate JJ O
{ NNS O
Meisenheimer JJ O
intermediate JJ O
) -RRB- O
and CC O
which WDT O
occurs VBZ O
, , O
according VBG O
to TO O
the DT O
state NN O
of IN O
the DT O
art NN O
, , O
in IN O
N,N-dimethylacetamide NNP B-NP
and CC O
dimethylsulfoxide NN B-NP
. . O

When WRB O
NaH NNP B-NP
is VBZ O
used VBN O
as IN O
the DT O
base NN O
in IN O
DMSO NNP B-NP
, , O
a DT O
temperature NN O
of IN O
60-70<0>C JJ O
must MD O
not RB O
be VB O
exceeded VBN O
. . O

In IN O
particular JJ O
, , O
according VBG O
to TO O
EP NNP O
273 CD O
658 CD O
, , O
compound NN O
Ib NN O
is VBZ O
obtained VBN O
from IN O
3b JJ O
and CC O
2a JJ O
in IN O
N,N-dimethylacetamide NNP B-NP
, , O
by IN O
treatment NN O
of IN O
2 CD O
with IN O
sodium NN B-NP
hydride NN I-NP
, , O
at IN O
a DT O
temperature NN O
of IN O
70<0>C JJ O
, , O
to TO O
produce VB O
the DT O
alkoxide NN B-NP
, , O
followed VBN O
by IN O
addition NN O
of IN O

1-fluoronaphthalene JJ B-NP
3b NN O
in IN O
equimolecular JJ O
amount NN O
, , O
heating VBG O
at IN O
110<0>C CD O
for IN O
60 CD O
min NN O
. . O

The DT O
desired VBD O
product NN O
Ib NNP O
is VBZ O
recovered VBN O
as IN O
crystalline NN O
oxalate NN B-NP
in IN O
76 CD O
% NN O
yield NN O
. . O

Disclosure NN O
of IN O
the DT O
invention NN O
It PRP O
has VBZ O
now RB O
been VBN O
found VBN O
that IN O
the DT O
synthesis NN O
of IN O
duloxetine JJ B-NP
, , O
in IN O
particular JJ O
of IN O
its PRP$ O
precursor NN O
Ib NN O
, , O
can MD O
be VB O
carried VBN O
out RP O
more RBR O
conveniently RB O
from IN O
compounds NNS O
2 CD O
and CC O
3b CD O
, , O
if IN O
l,3-dimethyl-2-oxo-hexahydropyrimidine JJ B-NP
( -LRB- O
DMPU) NN B-NP
is VBZ O
used VBN O
as IN O
the DT O
solvent NN O
instead RB O
of IN O
dimethylacetamide NN B-NP
. . O

Accordingly RB O
, , O
the DT O
invention NN O
relates VBZ O
to TO O
a DT O
process NN O
for IN O
the DT O
preparation NN O
of IN O
duloxetine JJ B-NP
Ia NNP O
: : O

[0021] . O

EMI4.1 . O

1a DT O
which WDT O
comprises VBZ O
the DT O
reaction NN O
between IN O
1-fluoronaphthalene JJ B-NP
3b NN O

EMI5.1 . O

3b JJ O
and CC O
3-N,N-dimethylamino-l-(2-thienyl)-propan-l-ol JJ B-NP
2a . O

[0024] . O

EMI5.2 NN O

to TO O
give VB O
( -LRB- O
CK)-(S) NN B-NP
- : I-NP
N,N-dimethyl-[gamma]-(l-naphthalenyloxy)-2- : I-NP
thiophenepropanamine NN I-NP
) -RRB- O
Ib NN O
: : O

[0025 CD O
] NN O

EMI5.3 . O

1b JJ O
and CC O
the DT O
conversion NN O
of IN O
Ib NNP O
to TO O
duloxetine VB B-NP
Ia NNP O
, , O
characterized VBD O
in IN O
that IN O
the DT O
reaction NN O
between IN O
2a CD O
and CC O
3b NNP O
is VBZ O
carried VBN O
out RP O
in IN O
1,3- CD B-NP
dimethyl-2-oxo-hexahydropyrimidine JJ I-NP
( -LRB- O
DMPU) NN B-NP
as IN O
the DT O
solvent NN O
. . O

Typically RB O
, , O
the DT O
reaction NN O
takes VBZ O
place NN O
at IN O
a DT O
temperature NN O
ranging VBG O
from IN O
70 CD O
to TO O

120<0>C CD O
, , O
for IN O
a DT O
time NN O
ranging VBG O
from IN O
45 CD O
min NN O
. . O

to TO O
8 CD O
hours NNS O
. . O

Comparative JJ O
experiments NNS O
for IN O
the DT O
synthesis NN O
of IN O
Ib NNP O
from IN O
1-fluoronaphthalene JJ B-NP
3b JJ O
and CC O
3-N,N-dimethylamino-l-(2-thienyl)-propan-l-ol JJ B-NP

2a CD O
, , O
carried VBD O
out RP O
using VBG O
DMPU NNP B-NP
and CC O
dimethylacetamide JJ B-NP
as IN O
solvents NNS O
, , O
proved VBD O
that IN O

DMPU NNP B-NP
is VBZ O
economically RB O
more RBR O
advantageous JJ O
than IN O
dimethylacetamide JJ B-NP
, , O
as IN O
it PRP O
requires VBZ O
lower JJR O
reaction NN O
temperatures NNS O
, , O
shorter JJR O
reaction NN O
times NNS O
and CC O
provides VBZ O
higher JJR O
yields NNS O
. . O

Typically RB O
, , O
compound NN O
Ib NNP O
is VBZ O
recovered VBN O
as IN O
the DT O
oxalate NN B-NP
, , O
which WDT O
is VBZ O
subsequently RB O
hydrolysed JJ O
and CC O
subjected VBN O
to TO O
fractional JJ O
crystallization NN O
with IN O
tartaric JJ B-NP
acid NN I-NP
; : O
compound NN O
Ib NN O
is VBZ O
recovered VBN O
again RB O
by IN O
hydrolysis NN O
and CC O
each DT O
enantiomer NN O
is VBZ O
demethylated VBN O
to TO O
give VB O
duloxetine JJ B-NP
Ia NNP O
. . O

Duloxetine NNP B-NP
enantiomers NNS O
are VBP O
also RB O
separated VBN O
by IN O
fractional JJ O
crystallization NN O
of IN O
the DT O
respective JJ O
oxalates NNS B-NP
, , O
hydrolysis NN O
of IN O
the DT O
salts NNS O
, , O
conversion NN O
to TO O
hydrochloride NN B-NP
and CC O
recrystallization NN O
from IN O
ethanol NN B-NP
. . O

The DT O
invention NN O
is VBZ O
illustrated VBN O
in IN O
greater JJR O
detail NN O
in IN O
the DT O
following JJ O
experimental JJ O
section NN O
. . O

Experimental JJ O
section NN O

1 LS O
. . O
Comparative VB O
experiments NNS O
- : O
Synthesis NN O
of IN O
( -LRB- B-NP
+)-(S)-N,N-dimethyl- JJ I-NP
[gamma]-(l-naphthalenyloxy)-2-thiophenepropanamine NN I-NP
) -RRB- O
Ib NN O
either CC O
in IN O
dimethylacetamide NN B-NP
or CC O
DMPU NN B-NP

Sodium NNP B-NP
hydride NN I-NP
was VBD O
suspended VBN O
in IN O
either DT O
dimethylacetamide JJ B-NP
or CC O
DMPU NNP B-NP
in IN O
a DT O
slight JJ O
molar JJ O
excess NN O
with IN O
respect NN O
to TO O
alcohol NN O
2a CD O
, , O
which WDT O
was VBD O
added VBN O
under IN O
stirring JJ O
and CC O
nitrogen JJ B-NP
atmosphere NN O
. . O

The DT O
mixture NN O
was VBD O
heated VBN O
to TO O
70<0>C VB O
for IN O
30 CD O
min. NN O
, , O
thereafter RB O
1-fluoronaphthalene JJ B-NP
3b NN O
was VBD O
slowly RB O
added VBN O
, , O
keeping VBG O
again RB O
under IN O
stirring VBG O
and CC O
nitrogen NN B-NP
atmosphere NN O
, , O
then RB O
the DT O
temperature NN O
was VBD O
raised VBN O
and CC O
maintained VBN O
at IN O
80 CD O
or CC O
100<0>C CD O
for IN O
the DT O
required JJ O
time NN O
. . O

After IN O
that DT O
, , O
the DT O
mixture NN O
was VBD O
cooled VBN O
to TO O
room NN O
temperature NN O
, , O
added VBD O
with IN O
a DT O
few JJ O
ml NN O
of IN O
ethanol NN B-NP
to TO O
destroy VB O
any DT O
excess NN O
of IN O
NaH NNP B-NP
and CC O
poured VBD O
in IN O
2 CD O
volumes NNS O
of IN O
ice NN O
, , O
followed VBN O
by IN O
three CD O
extractions NNS O
with IN O
2 CD O
volumes NNS O
of IN O
ethyl NN B-NP
ether NN I-NP
. . O

The DT O
ether JJ B-NP
phase NN O
was VBD O
washed VBN O
three CD O
times NNS O
with IN O
1 CD O
volume NN O
of IN O
water NN O
and CC O
once RB O
with IN O
a DT O
saturated JJ O
NaCl NNP B-NP
solution NN O
. . O

After IN O
drying VBG O
over IN O
sodium NN B-NP
sulfate NN I-NP
, , O
the DT O
solvent NN O
was VBD O
evaporated VBN O
off RB O
and CC O
the DT O
oily JJ O
residue NN O
was VBD O
taken VBN O
up RP O
in IN O
three CD O
volumes NNS O
of IN O
methanol NN B-NP
and CC O
added VBD O
in IN O
the DT O
cold JJ O
with IN O
1.3 CD O
molar JJ O
equiv. NN O
of IN O
oxalic JJ B-NP
acid NN I-NP
in IN O
methanol NN B-NP
. . O

The DT O
resulting VBG O
mixture NN O
was VBD O
evaporated VBN O
to TO O
dryness NN O
and CC O
the DT O
solid JJ O
residue NN O
was VBD O
crystallized VBN O
from IN O
either DT O
hot JJ O
methanol NN B-NP
or CC O
ethyl NN B-NP
acetate/methanol NN I-NP
. . O

The DT O
crystalline NN O
oxalate NN B-NP
recovered VBN O
by IN O
filtration NN O
was VBD O
dried VBN O
and CC O
weighed VBN O
. . O

Ib NNP O
Oxalate NNP B-NP
: : O
<1>H CD O
NMR NN O
( -LRB- O
DMSO FW B-NP
- : O
d6 NNS O
) -RRB- O
[delta NN O
] NNS O
( -LRB- O
8.27 CD O
( -LRB- O
IH NNP O
, , O
m NN O
) -RRB- O
, , O
7.85 CD O
( -LRB- O
IH NNP O
, , O
m NN O
) -RRB- O
, , O
7.53 FW O
( -LRB- O
2H CD O
, , O
m NN O
) -RRB- O
, , O
7.44 FW O
( -LRB- O
2H NNP O
, , O
m NN O
) -RRB- O
, , O
7.33 CD O
( -LRB- O
IH NNP O
, , O
t NN O
, , O
J NNP O
= SYM O
7.9 CD O
Hz NN O
) -RRB- O
, , O
7.25 CD O
( -LRB- O
IH NNP O
, , O
d VBD O
, , O
J NNP O
= SYM O
3.4 CD O
Hz NN O
) -RRB- O
, , O
7.04 FW O
( -LRB- O
IH NNP O
, , O
d VBD O
, , O
J NNP O
= SYM O
7.7 CD O
Hz NN O
) -RRB- O
, , O
6.99 CD O
( -LRB- O
IH NNP O
, , O
dd JJ O
, , O
J NNP O
= SYM O
3.5 CD O
, , O
5.0 CD O
Hz NNP O
) -RRB- O
, , O
6.02 CD O
( -LRB- O
IH NNP O
, , O
dd JJ O
, , O
J NNP O
= SYM O
4.9 CD O
, , O
7.7 CD O
Hz NN O
) -RRB- O
, , O
3.25 CD O
( -LRB- O
IH NNP O
, , O
m NN O
) -RRB- O
, , O
3.15 FW O
( -LRB- O
IH NNP O
, , O
m NN O
) -RRB- O
, , O
2.70 CD O
( -LRB- O
6H NN O
, , O
s VBZ O
) -RRB- O
, , O
2.58 CD O
( -LRB- O
IH NNP O
, , O
m NN O
) -RRB- O
, , O
2.39 FW O
( -LRB- O
IH NNP O
, , O
m NN O
) -RRB- O
. . O

The DT O
experiments NNS O
were VBD O
followed VBN O
over IN O
time NN O
through IN O
GC/MS NNP O
analysis NN O
of IN O
sample NN O
aliquots NNS O
and CC O
the DT O
yield NN O
was VBD O
determined VBN O
on IN O
the DT O
weight NN O
of IN O
Ib NNP O
oxalate NNP B-NP
recovered VBD O
in IN O
crystalline NN O
pure JJ O
form NN O
after IN O
completion NN O
of IN O
the DT O
reaction NN O
. . O

In IN O
particular JJ O
, , O
we PRP O
calculated VBD O
the DT O
yields NNS O
in IN O
Ib NN O
resulting VBG O
from IN O
the DT O
addition NN O
of IN O
1.05 CD O
mol NN O
equiv. NN O
of IN O
1-fluoronaphthalene JJ B-NP
3b NN O
to TO O
2a CD O
sodium NN O
salt NN O
, , O
that WDT O
had VBD O
been VBN O
obtained VBN O
with IN O
1.1 CD O
mols NNS O
equiv. . O
of IN O
NaH NNP B-NP
(60 CD O
% NN O
suspension NN O
in IN O
oil NN O
) -RRB- O
in IN O
DMPU NNP B-NP
and CC O
dimethylacetamide JJ B-NP
respectively RB O
at IN O
70<0>C NNP O
for IN O
30 CD O
min NN O
. . O

The DT O
results NNS O
are VBP O
reported VBN O
hereinbelow RB O
. . O

1 CD O
) -RRB- O
At IN O
100<0>C CD O
and CC O
with IN O
2 CD O
% NN O
of IN O
2a CD O
in IN O
DMPU NNP B-NP
, , O
2a VBD O
completely RB O
disappeared VBN O
after IN O
50 CD O
min NN O
. . O

and CC O
Ib NNP O
as IN O
crystalline NN O
oxalate NN B-NP
was VBD O
obtained VBN O
in IN O
84 CD O
% NN O
yield NN O
, , O
whereas IN O
in IN O
dimethylacetamide NN B-NP
after IN O
the DT O
same JJ O
time NN O
13 CD O
% NN O
of IN O
2a CD O
remained VBD O
unreacted JJ O
and CC O
the DT O
reaction NN O
terminated VBN O
with IN O
complete JJ O
disappearance NN O
of IN O
2a DT O
( -LRB- O
which WDT O
is VBZ O
the DT O
limiting VBG O
substrate NN O
) -RRB- O
after IN O
180 CD O
min NN O
. . O

2 CD O
) -RRB- O
At IN O
100<0>C CD O
and CC O
with IN O
10 CD O
% NN O
of IN O
2a CD O
in IN O
DMPU NNP B-NP
, , O
3 CD O
% NN O
of IN O
2a CD O
remained VBD O
unreacted JJ O
after IN O
50 CD O
min. NN O
, , O

whereas IN O
in IN O
dimethylacetamide NN B-NP
the DT O
percentage NN O
of IN O
unreacted JJ O
2a CD O
was VBD O
14 CD O
% NN O
. . O

The DT O
reaction NN O
was VBD O
complete JJ O
in IN O
DMPU NNP B-NP
after IN O
90 CD O
min NN O
. . O

and CC O
in IN O
dimethylacetamide NN B-NP
after IN O
300 CD O
min NN O
. . O

( -LRB- O
2a CD O
concentration NN O
lower JJR O
than IN O
1 CD O
% NN O
) -RRB- O
. . O

3 CD O
) -RRB- O
At IN O
8O<0>C JJ O
and CC O
with IN O
2 CD O
% NN O
of IN O
2a CD O
in IN O
DMPU NNP B-NP
2a VBD O
completely RB O
disappeared VBN O
after IN O
50 CD O
min NN O
. . O

and CC O
oxalate JJ B-NP
Ib NN O
was VBD O
obtained VBN O
in IN O
85 CD O
% NN O
yield NN O
, , O
whereas IN O
in IN O
dimethylacetamide JJ B-NP
4 CD O
% NN O
of IN O
2a CD O
was VBD O
still RB O
unreacted JJ O
after IN O
300 CD O
min. NN O
. . O

If IN O
the DT O
reaction NN O
is VBZ O
interrupted VBN O
at IN O
this DT O
time NN O
, , O
the DT O
resulting VBG O
oxalate JJ B-NP
Ib NN O
is VBZ O
contaminated VBN O
by IN O
2a CD O
. . O

The DT O
separation NN O
of IN O
oxalates NNS B-NP
2a . O
and CC O
Ib PRP O
through IN O
fractional JJ O
crystallization NN O
is VBZ O
difficult JJ O
and CC O
involves VBZ O
remarkable JJ O
losses NNS O
. . O

In IN O
the DT O
present JJ O
case NN O
, , O
the DT O
reaction NN O
crude NN O
from IN O
this DT O
experiment NN O
led VBD O
to TO O
oxalate NNP B-NP
Ib NNP O
with IN O
a DT O
content NN O
in IN O
2a DT O
lower JJR O
than IN O
0.5 CD O
% NN O
after IN O
3 CD O
crystallizations NNS O
from IN O
ethyl NN B-NP
acetate/methanol NN I-NP
and CC O
with IN O
a DT O
final JJ O
yield NN O
of IN O
48 CD O
% NN O
. . O

It PRP O
is VBZ O
therefore RB O
of IN O
the DT O
utmost JJ O
importance NN O
that IN O
upon IN O
completion NN O
of IN O
the DT O
reaction NN O
Ib NN O
is VBZ O
free JJ O
from IN O
2a CD O
, , O
because IN O
the DT O
purification NN O
of IN O
the DT O
oxalates NNS B-NP
by IN O
fractional JJ O
crystallization NN O
involves VBZ O
a DT O
remarkable JJ O
decrease NN O
in IN O
yields NNS O
. . O

2. . O

Syhthesis NN O
of IN O
( -LRB- O
+ NN O
) -RRB- O
and CC O
(-)-duIoxetine JJ B-NP
Ia NNP O
( -LRB- O
+ NN O
) -RRB- O
And CC O
(-)-duloxetine JJ B-NP
Ia NNP O
were VBD O
obtained VBN O
from IN O
racemic JJ O
oxalate NN B-NP
Ib NNP O
according VBG O
to TO O
a DT O
known VBN O
method NN O
, , O
hydrolysing VBG O
Ib JJ O
base NN O
from IN O
the DT O
oxalate NN B-NP
by IN O
treatment NN O
with IN O
an DT O
excess NN O
of IN O
aqueous JJ O
NaOH NNP B-NP
and CC O
extraction NN O
of IN O
the DT O
free JJ O
base NN O
with IN O
ethyl NN B-NP
ether NN I-NP
. . O

The DT O
free JJ O
base NN O
was VBD O
combined VBN O
respectively RB O
with IN O
a DT O
non-natural JJ O
and CC O
natural JJ O
form NN O
of IN O
tartaric JJ B-NP
acid NN I-NP
to TO O
give VB O
, , O
after IN O
three CD O
crystallizations NNS O
of IN O
the DT O
crystalline NN O
salt NN O
from IN O
absolute JJ O
ethanol NN B-NP
, , O
the DT O
salts NNS O
of IN O
( -LRB- O
+ NN O
) -RRB- O
and CC O
(-) JJ O
Ia NNP O
. . O

The DT O
free JJ O
bases NNS O
were VBD O
recovered VBN O
by IN O
treatment NN O
with IN O
an DT O
excess NN O
of IN O
aqueous JJ O
base NN O
and CC O
extraction NN O
with IN O
an DT O
ether JJ B-NP
solvent NN O
. . O

N-demethylation NN O
of IN O
( -LRB- O
+ NN O
) -RRB- O
and CC O
(-) JJ O
Ib NNP O
was VBD O
carried VBN O
out RP O
by IN O
treatment NN O
with IN O
phenyl NN B-NP
chloroformate NN I-NP
in IN O
toluene NN B-NP
under IN O
reflux NN O
and CC O
subsequent JJ O
basic JJ O
hydrolysis NN O
in IN O
a DT O
high-boiling JJ O
solvent NN O
. . O

( -LRB- O
+ NN O
) -RRB- O
And CC O
(-)-duloxetine JJ B-NP
Ia NNP O
were VBD O
purified VBN O
by IN O
crystallization NN O
of IN O
the DT O
corresponding JJ O
oxalates NNS B-NP
and CC O
the DT O
free JJ O
bases NNS O
obtained VBD O
as IN O
described VBN O
above IN O
were VBD O
converted VBN O
to TO O
hydrochlorides NNS B-NP
by IN O
treatment NN O
with IN O
gaseous JJ O
HCl NNP B-NP
in IN O
ethanol NN B-NP
. . O

The DT O
solutions NNS O
were VBD O
evaporated VBN O
to TO O
dryness NN O
and CC O
the DT O
residue NN O
was VBD O
crystallized VBN O
from IN O
boiling VBG O
ethanol NN B-NP
. . O

The DT O
enantiomeric JJ O
excess NN O
of IN O
the DT O
products NNS O
, , O
determined VBN O
by IN O
HPLC NNP O
on IN O
a DT O
Chiracel NNP O
OD NN O
column NN O
( -LRB- O
hexane/isopropanol/triethylamine NN B-NP
) -RRB- O
was VBD O
higher JJR O
than IN O
99.9 CD O
% NN O
. . O

( -LRB- O
+)-la NNP O
hydrochloride NN B-NP
: : O
<1>H CD O
NMR NN O
( -LRB- O
DMSO FW B-NP
- : O
d6 NNS O
) -RRB- O
[delta NN O
] NN O
( -LRB- O
8.26 CD O
( -LRB- O
IH NNP O
, , O
m NN O
) -RRB- O
, , O
7.85 CD O
( -LRB- O
IH NNP O
, , O
m NN O
) -RRB- O
, , O
7.52 CD O
( -LRB- O
2H CD O
, , O
m NN O
) -RRB- O
, , O
7.45 CD O
( -LRB- O
2H NNP O
, , O
m NN O
) -RRB- O
, , O
7.34 CD O
( -LRB- O
IH NNP O
, , O
t NN O
, , O
J NNP O
= SYM O
8.0 CD O
Hz NNP O
) -RRB- O
, , O
7.26 FW O
( -LRB- O
IH NNP O
, , O
d VBD O
, , O
J NNP O
= SYM O
3.2 CD O
Hz RB O
) -RRB- O
, , O
7.06 CD O
( -LRB- O
IH NNP O
, , O
d VBD O
, , O
J NNP O
= SYM O
7.6 CD O
Hz NN O
) -RRB- O
, , O
6.98 FW O
( -LRB- O
IH NNP O
, , O
dd JJ O
, , O
J= JJ O
3.7 CD O
, , O
4.8 CD O
Hz NN O
) -RRB- O
, , O
6.14 FW O
( -LRB- O
IH NNP O
, , O
dd JJ O
, , O
J NNP O
= SYM O
5.6 CD O
, , O
7.3 CD O
Hz NN O
) -RRB- O
, , O
3.07 CD O
( -LRB- O
2H NNP O
, , O
m NN O
) -RRB- O
, , O
2.55 FW O
( -LRB- O
4H CD O
, , O
m NN O
+ NN O
s VBZ O
) -RRB- O
, , O
2.39 FW O
( -LRB- O
IH NNP O
, , O
m NN O
) -RRB- O
; : O
[[alpha]] JJ O
D<20> JJ O
= SYM O
+ NN O
121 CD O
( -LRB- O
c NN O
1,00 CD O
, , O
methanol NN B-NP
) -RRB- O
. . O

CLAIM NN O

A DT O
process NN O
for IN O
the DT O
preparation NN O
of IN O
duloxetine JJ B-NP
Ia NNP O
: : O

EMI9.1 . O

<1 CD O
a> NNS O
comprising VBG O
the DT O
reaction NN O
between IN O
1-fluoronaphthalene JJ B-NP
3b NN O

EMI9.2 NN O

3b JJ O
and CC O
3-N,N-dimethylamino-l-(2-thienyl)-propan-l-ol JJ B-NP
2a . O

EMI9.3 . O

2a RBR O
to TO O
give VB O
( -LRB- B-NP
( -LRB- I-NP
+)-(S)-N,N-dimethyl-[gamma]-(l-naphthalenyloxy)-2- : I-NP
thiophenepropanamine NN I-NP
) -RRB- I-NP
Ib NN O
: : O

EMI9.4 . O

1b JJ O
and CC O
the DT O
conversion NN O
of IN O
Ib NNP O
to TO O
duloxetine VB B-NP
Ia NNP O
, , O
characterized VBD O
in IN O
that IN O
the DT O
reaction NN O
between IN O
2a CD O
and CC O
3b NNP O
is VBZ O
carried VBN O
out RP O
in IN O
l,3-dimethyl-2-oxo-hexahydropyrimidine JJ B-NP
as IN O
the DT O
solvent NN O
. . O

-DOCSTART- X X O

[0001] JJ O
3-AMINOINDOLE JJ B-NP
COMPOUNDS NNS O
AS IN O
CRTH2 NNP O
RECEPTOR NNP O
LIGANDS NNPS O

Field NNP O
of IN O
the DT O
Invention NN O

This DT O
invention NN O
relates VBZ O
to TO O
a DT O
class NN O
of IN O
3-aminoindole JJ B-NP
compounds NNS O
which WDT O
are VBP O
ligands NNS O
of IN O
the DT O
CRTH2 NN O
receptor NN O
( -LRB- O
Chemoattractant NNP O
Receptor-homologous NNP O
molecule NN O
expressed VBD O
on IN O
T NNP O
Helper NNP O
cells NNS O
type NN O
2 CD O
) -RRB- O
, , O
and CC O
their PRP$ O
use NN O
in IN O
the DT O
treatment NN O
of IN O
diseases NNS O
responsive JJ O
to TO O
modulation NN O
of IN O
CRTH2 NNP O
receptor NN O
activity NN O
, , O
principally RB O
diseases NNS O
having VBG O
a DT O
significant JJ O
inflammatory NN O
component NN O
. . O

The DT O
invention NN O
also RB O
relates VBZ O
to TO O
novel JJ O
members NNS O
of IN O
that DT O
class NN O
of IN O
ligands NNS O
and CC O
pharmaceutical JJ O
compositions NNS O
containing VBG O
them PRP O
. . O

Background NN O
of IN O
the DT O
Invention NNP O
Mast NNP O
cells NNS O
are VBP O
known VBN O
to TO O
play VB O
an DT O
important JJ O
role NN O
in IN O
allergic JJ O
and CC O
immune JJ O
responses NNS O
through IN O
the DT O
release NN O
of IN O
a DT O
number NN O
of IN O
mediators NNS O
, , O
such JJ O
as IN O
histamine NN B-NP
, , O
leukotrienes NNS B-NP
, , O
cytokines NNS B-NP
, , O
prostaglandin NN B-NP
D2 NN I-NP
, , O
etc FW O
( -LRB- O
Boyce NNP O
; : O
Allergy NNP O
Asthma NNP O
Proc NNP O
, , O
2004 CD O
, , O
25 CD O
, , O
27-30 CD O
) -RRB- O
. . O

Prostaglandin NNP B-NP
D2 NNP I-NP
( -LRB- O
PGD2 NN B-NP
) -RRB- O
is VBZ O
the DT O
major JJ O
cyclooxygenase NN O
metabolite NN O
of IN O
arachadonic JJ B-NP
acid NN I-NP
produced VBN O
by IN O
mast NN O
cells NNS O
in IN O
response NN O
to TO O
allergen DT O
challenge NN O
( -LRB- O
Lewis NNP O
et NNP O
al NN O
; : O
J. NNP O
Immunol. NNP O
, , O
1982 CD O
, , O
129 CD O
, , O
1627-1631 CD O
) -RRB- O
. . O

It PRP O
has VBZ O
been VBN O
shown VBN O
that IN O
PGD2 DT B-NP
production NN O
is VBZ O
increased VBN O
in IN O
patients NNS O
with IN O
systemic JJ O
mastocytosis NN O
( -LRB- O
Roberts NNP O
; : O
N. NNP O
Engl NNP O
. . O

J. NNP O
Med NNP O
. . O
, , O
1980 CD O
, , O
303 CD O
, , O
1400-1404 CD O
) -RRB- O
, , O
allergic JJ O
rhinitis NN O
( -LRB- O
Naclerio NNP O
et NNP O
al NN O
; : O
Am NNP O
. . O

Rev. NNP O
Respir NNP O
. . O

Dis. NNP O
, , O
1983 CD O
, , O
128 CD O
, , O
597-602 CD O
; : O
Brown NNP O
et NNP O
al NN O
; : O
Arch NNP O
. . O

Otolarynol NNP O
. . O

Head NN O
Neck NNP O
Surg. NNP O
, , O
1987 CD O
, , O
113 CD O
, , O
179-183 CD O
; : O
Lebel NNP O
et NNP O
al NN O
; : O
J. NNP O
Allergy NNP O
Clin NNP O
. . O

Immunol. NNP O
, , O
1988 CD O
, , O
82 CD O
, , O
869-877 CD O
) -RRB- O
, , O
bronchial JJ O
asthma NN O
( -LRB- O
Murray NNP O
et NNP O
al NN O
; : O
N. NNP O
Engl NNP O
. . O

J. NNP O
Med NNP O
. . O
, , O
1986 CD O
, , O
315 CD O
, , O
800-804 CD O
; : O
Liu NNP O
et NNP O
al NN O
; : O
Am NNP O
. . O

Rev. NNP O
Respir NNP O
. . O

Dis. NNP O
, , O
1990 CD O
, , O
142 CD O
, , O
126-132 CD O
; : O
Wenzel NNP O
et NNP O
al NN O
; : O
J. NNP O
Allergy NNP O
Clin NNP O
. . O

Immunol. NNP O
, , O
1991 CD O
, , O
87 CD O
, , O
540-548 CD O
) -RRB- O
, , O
) -RRB- O
, , O
allergic JJ O
conjunctivitis NN O
( -LRB- O
Proud NNP O
et NNP O
al NN O
; : O
J NNP O
Allergy NNP O
Clin NNP O
Immunol NNP O
. . O

1990 CD O
May NNP O
;85(5 CD O
) -RRB- O
:896-905 CD O
) -RRB- O
and CC O
urticaria NNP O
( -LRB- O
Heavey NNP O
et NNP O
al NN O
; : O
J. NNP O
Allergy NNP O
Clin NNP O
. . O

Immunol. NNP O
, , O
1986 CD O
, , O
78 CD O
, , O
458-461 CD O
) -RRB- O
. . O

PGD2 PRP B-NP
mediates VBZ O
it PRP O
effects VBZ O
through IN O
two CD O
receptors NNS O
, , O
the DT O
PGD2 NNP B-NP
( -LRB- O
or CC O
DP NNP O
) -RRB- O
receptor NN O
( -LRB- O
Boie NNP O
et NNP O
al NN O
; : O
J. NNP O
Biol NNP O
. . O

Chem. NNP O
, , O
1995 CD O
, , O
270 CD O
, , O
18910-18916 CD O
) -RRB- O
and CC O
the DT O
chemoattractant NN O
receptor-homologous JJ O
molecule NN O
expressed VBD O
on IN O
Th2 DT O
( -LRB- O
or CC O
CRTH2 NN O
) -RRB- O
( -LRB- O
Nagata NNP O
et NNP O
al NN O
; : O
J. NNP O
Immunol. NNP O
, , O
1999 CD O
, , O
162 CD O
, , O
1278-1289 CD O
; : O
Powell NNP O
; : O
Prostaglandins NNP O
Luekot NNP O
. . O

Essent NNP O
. . O

Fatty NNP O
Acids NNP O
, , O
2003 CD O
, , O
69 CD O
, , O
179-185 CD O
) -RRB- O
. . O

Therefore RB O
, , O
it PRP O
has VBZ O
been VBN O
postulated VBN O
that IN O
agents NNS O
that IN O
antagonise IN O
the DT O
effects NNS O
of IN O
PGD2 NNP B-NP
at IN O
its PRP$ O
receptors NNS O
may MD O
have VB O
beneficial JJ O
effects NNS O
in IN O
a DT O
number NN O
of IN O
disease NN O
states NNS O
. . O

The DT O
CRTH2 NNP O
receptor NN O
has VBZ O
been VBN O
shown VBN O
to TO O
be VB O
expressed VBN O
on IN O
cell NN O
types NNS O
associated VBN O
with IN O
allergic DT O
inflammation NN O
, , O
such JJ O
as IN O
basophils NNS O
, , O
eosinophils NNS O
, , O
and CC O
Th2-type JJ O
immune JJ O
helper NN O
cells NNS O
( -LRB- O
Hirai NNP O
et NNP O
al NN O
; : O
J. NNP O
Exp NNP O
. . O

Med NNP O
. . O
, , O
2001 CD O
, , O
193 CD O
, , O
255-261 CD O
) -RRB- O
. . O

The DT O
CRTH2 NNP O
receptor NN O
has VBZ O
been VBN O
shown VBN O
to TO O
mediate VB O
PGD2-mediated JJ B-NP
cell NN O
migration NN O
in IN O
these DT O
cell NN O
types NNS O
( -LRB- O
Hirai NNP O
et NNP O
al NN O
; : O
J. NNP O
Exp NNP O
. . O

Med NNP O
. . O
, , O
2001 CD O
, , O
193 CD O
, , O
255-261 CD O
) -RRB- O
, , O
and CC O
also RB O
to TO O
play VB O
a DT O
major JJ O
role NN O
in IN O
neutrophil JJ O
and CC O
eosinophil JJ O
cell NN O
recruitment NN O
in IN O
a DT O
model NN O
of IN O
contact NN O
dermatitis NN O
( -LRB- O
Takeshita NNP O
et NNP O
al NN O
; : O
Int NNP O
. . O

Immunol. NNP O
, , O
2004 CD O
, , O
16 CD O
, , O
947-959 CD O
) -RRB- O
. . O

In IN O
addition NN O
, , O
PGD2 NNP B-NP
has VBZ O
been VBN O
shown VBN O
to TO O
activate VB O
human JJ O
eosinophils NNS O
and CC O
Th2 JJ O
cells NNS O
( -LRB- O
Gazi NNP O
et NNP O
al NN O
; : O
Prostaglandins NNP O
Other NNP O
Lipid NNP O
Mediat NNP O
. . O

2005 CD O
Jan;75(1-4) JJ O
:153-67 CD O
) -RRB- O
. . O
Ramatroban NNP B-NP
{(3R)-3-[(4-fluorophenyl NNP O
)sulfonyl- , B-NP
amino]-1 JJ I-NP
,2,3,4-tetrahydro-9H-carbazole-9-propanoic JJ I-NP
acid} NN I-NP
, , O
a DT O
dual JJ O
CRTH2 NNP O
and CC O
thromboxane DT O
A2 NN O
receptor NN O
antagonist NN O
, , O
has VBZ O
been VBN O
shown VBN O
to TO O
attenuate VB O
these DT O
responses NNS O
( -LRB- O
Sugimoto NNP O
et NNP O
al NN O
; : O
J. NNP O
Pharmacol NNP O
. . O

Exp NNP O
. . O

Ther. NNP O
, , O
2003 CD O
, , O
305 CD O
, , O
347-352 CD O
; : O
Takeshita NNP O
et NNP O
al NN O
; : O
op NN O
. . O
5 CD O
cit NN O
) -RRB- O
. . O

The DT O
potential NN O
of IN O
PGD2 NNP B-NP
both CC O
to TO O
enhance VB O
allergic DT O
inflammation NN O
and CC O
induce VB O
an DT O
inflammatory NN O
response NN O
has VBZ O
been VBN O
demonstrated VBN O
in IN O
mice NNS O
and CC O
rats NNS O
. . O

Transgenic NNP O
mice NNS O
over IN O
expressing VBG O
PGD2 DT B-NP
synthase NN O
exhibit VBP O
an DT O
enhanced JJ O
pulmonary NN O
eosinophilia NNS O
and CC O
increased VBD O
levels NNS O
of IN O
Th2 DT O
cytokines NNS B-NP
in IN O
response NN O
to TO O
allergen DT O
challenge NN O
( -LRB- O
Fujitani NNP O
et NNP O
al NN O
, , O
J. NNP O
Immunol. NNP O
, , O
2002 CD O
, , O
168 CD O
, , O
443-449 CD O
) -RRB- O
. . O

In IN O
addition NN O
, , O
exogenously RB O
administered VBN O
CRTH2 CC O

10 CD O
agonists NNS O
enhance VB O
the DT O
allergic JJ O
response NN O
in IN O
sensitised JJ O
mice NNS O
( -LRB- O
Spik NNP O
et NNP O
al NN O
; : O
J. NNP O
Immunol. NNP O
, , O
2005 CD O
, , O
174 CD O
, , O
3703-3708 CD O
) -RRB- O
. . O

In IN O
rats NNS O
exogenously RB O
applied VBD O
CRTH2 NNP O
agonists NNS O
cause VBP O
a DT O
pulmonary NN O
eosinophilia NNS O
but CC O
a DT O
DP NNP O
agonist NN O
( -LRB- O
BW JJ O
245C CD O
) -RRB- O
or CC O
a DT O
TP NNP O
agonist NN O
(l-BOP) NN O
showed VBD O
no DT O
effect NN O
( -LRB- O
Shirashi NNP O
et NNP O
al NN O
; : O
J. NNP O
Pharmacol NNP O
. . O

Exp NNP O
. . O

Ther. NNP O
, , O
2005 CD O
, , O
312 CD O
, , O
954-960 CD O
) -RRB- O
. . O

These DT O
observations NNS O
suggest VBP O
that IN O
CRTH2 NNP O
antagonists NNS O
may MD O
have VB O
valuable JJ O
properties NNS O
for IN O
the DT O

15 CD O
treatment NN O
of IN O
diseases NNS O
mediated VBN O
by IN O
PGD2 NNP B-NP
. . O

As IN O
there EX O
is VBZ O
significant JJ O
evidence NN O
to TO O
support VB O
a DT O
role NN O
for IN O
PGD2 NNP B-NP
in IN O
eosinophil NN O
, , O
basophil NN O
and CC O
lymphocyte NN O
recruitment NN O
it PRP O
is VBZ O
anticipated VBN O
that IN O
CRTH2 DT O
antagonists NNS O
can MD O
also RB O
be VB O
used VBN O
in IN O
the DT O
treatment NN O
of IN O
eosinophilic JJ O
disorders NNS O
such JJ O
as IN O
Churg-Strauss NNP O
syndrome NN O
and CC O
sinusitis NN O
; : O
basophil NN O
associated VBN O
diseases NNS O
such JJ O
as IN O
chronic JJ O
urticaria NN O
; : O
inflammatory JJ O
diseases NNS O
associated VBN O
with IN O
T NNP O
lymphocytes NNS O
including VBG O

20 CD O
psoriasis NN O
, , O
eczema NN O
, , O
inflammatory NN O
bowel NN O
disease NN O
, , O
Crohn NNP O
's POS O
Disease NN O
, , O
Chronic NNP O
Obstructive NNP O
Pulmonary NNP O
Disease NNP O
and CC O
arthritis NN O
. . O

In IN O
addition NN O
to TO O
Ramatroban NNP B-NP
a DT O
number NN O
of IN O
other JJ O
CRTH2 NNP O
antagonists NNS O
have VBP O
been VBN O
described VBN O
. . O

Examples NNS O
include VBP O
: : O
indole-acetic JJ B-NP
acids NNS B-NP
( -LRB- O
WO2003/022813 NN O
; : O
WO2003/066046 CD O
; : O
WO2003/066047 CD O
; : O
WO2003/097042 NN O
; : O
WO2003/097598 CD O
; : O

25 CD O
WO2003/101961 CD O
; : O
WO2003/101981 CD O
; : O
WO2004/007451 CD O
; : O
WO2004/078719 CD O
; : O
WO2004/106302 NN O
; : O
WO2005/019171 NNP O
; : O
GB2407318 : O
; : O
WO2005/040112 NN O
; : O

WO2005/040114 NN O
; : O
WO2005/044260 CD O
) -RRB- O
; : O
tetrahydroquinolines NNS B-NP
( -LRB- O
EP1413306 NNP O
; : O
EP1435356 NNP O
; : O
WO2004/032848 CD O
; : O
WO2004/035543 CD O
; : O
WO2005/007094 NN O
) -RRB- O
, , O
and CC O
phenylacetic JJ B-NP
acids NNS I-NP
( -LRB- O
WO2004/058164 NN O
; : O
WO2004/089884 CD O
; : O
WO2004/089885 CD O
; : O
WO2005/018529 CD O
) -RRB- O
. . O

30 CD O
Recently RB O
, , O
International NNP O
Patent NNP O
Application NNP O
No. NN O
WO NN O
2006/060535 CD O
relating VBG O
to TO O
modulators NNS O
of IN O
PPARs NNP O
has VBZ O
been VBN O
published VBN O
. . O

The DT O
general JJ O
structural JJ O
formula NN O
defined VBN O
therein RB O
encompasses VBZ O
CRTH2 NNP O
receptor NN O
antagonist NN O
aminoindoles NNS B-NP
of IN O
the DT O
kind NN O
with IN O
which WDT O
this DT O
invention NN O
is VBZ O
concerned VBN O
, , O
but CC O
neither RB O
their PRP$ O
utility NN O
nor CC O
any DT O
specific JJ O
examples NNS O
of IN O
any DT O
such JJ O
compound NN O
are VBP O
disclosed VBN O
. . O

35 CD O
. . O

Detailed VBN O
Description NN O
of IN O
the DT O
invention NN O

One CD O
aspect NN O
of IN O
the DT O
invention NN O
provides VBZ O
a DT O
compound NN O
of IN O
general JJ O
formula NN O
[ IN O
I] NN O
or CC O
a DT O
pharmaceutically RB O
acceptable JJ O
salt NN O
, , O
N-oxide NN B-NP
, , O
hydrate JJ B-NP
, , O
or CC O
solvate JJ O
thereof . O
: : O

EMI5.1 . O

[ NN O
I] NNP O
in IN O
which WDT O
: : O

R<1> NNP O
, , O
R<2> NNP O
, , O
R<3> NNP O
and CC O
R<4> NNP O
are VBP O
independently RB O
hydrogen NN B-NP
, , O
( -LRB- B-NP
CrC6 NNP I-NP
) -RRB- I-NP
alkyl NN I-NP
, , O
( -LRB- B-NP
C1-C6 NNP I-NP
) -RRB- I-NP
haloalkyl NN I-NP
, , O
halo NN B-NP
, , O
-S( JJ O
O)nR<10> NNP O
, , O
-NR<11>SO2R<10> JJ O
, , O
-SO2N( JJ O
R<11>)2 NNP O
, , O
-N( JJ O
R<11>)2 NNP O
, , O
-NR<11>C( JJ O
O)R<10> NNP B-NP
, , O
-C( JJ O
O)N( NNP O
R<11>)2 NNP O
, , O
- : O
CO2R<11> PRP B-NP
, , O
-C( NNP O
O)R<10> NNP B-NP
, , O
CN NNP B-NP
or CC O
a DT O
group NN O
OR<12> NN O
; : O
wherein WRB O
each DT O
R<10> NN O
is VBZ O
independently RB O
( -LRB- B-NP
CrC6)alkyl NN I-NP
, , O
( -LRB- B-NP
C1-C6 NNP I-NP
) -RRB- I-NP
haloalkyl NN I-NP
, , O
cycloalkyl NN B-NP
, , O
aryl NN B-NP
, , O
or CC O
heteroaryl NN B-NP
; : O

R<11> NNP O
is VBZ O
independently RB O
hydrogen NN B-NP
, , O
( -LRB- B-NP
C1-C6 NNP I-NP
) -RRB- I-NP
alkyl NN I-NP
, , O
( -LRB- B-NP
C1-C6 NNP I-NP
) -RRB- I-NP
haloalkyl NN I-NP
, , O
cycloalkyl NN B-NP
, , O
aryl NN B-NP
, , O
or CC O
heteroaryl NN B-NP
; : O

R<12> NN O
is VBZ O
hydrogen NN B-NP
, , O
( -LRB- B-NP
C1-C6 NNP I-NP
) -RRB- I-NP
alkyl NN I-NP
, , O
( -LRB- B-NP
C1-C6 NNP I-NP
) -RRB- I-NP
haloalkyl NN I-NP
, , O
cycloalkyl NN B-NP
, , O
or CC O
a DT O
group NN O
- : O
SO2R<10> JJ B-NP
, , O
wherein WRB O
n NN O
is VBZ O
O NNP O
1 CD O
or CC O
2 CD O
; : O

R<5> NNP O
and CC O
R<6> NNP O
are VBP O
independently RB O
hydrogen NN B-NP
, , O
( -LRB- B-NP
CrC6 NNP I-NP
) -RRB- I-NP
alkyl NN I-NP
or CC O
( -LRB- B-NP
CrC6 NN I-NP
) -RRB- I-NP
haloalkyl NN I-NP
, , O
or CC O
R<5> NNP O
and CC O
R<6> NNP O
together RB O
with IN O
the DT O
atom NN O
to TO O
which WDT O
they PRP O
are VBP O
attached VBN O
form NN O
a DT O
cycloalkyl NN B-NP
group NN O
; : O
R<7> NNP O
is VBZ O
hydrogen NN B-NP
, , O
( -LRB- B-NP
C1-C6 NN I-NP
) -RRB- I-NP
alkyl NN I-NP
, , O
or CC O
( -LRB- B-NP
C1-C6 NN I-NP
) -RRB- I-NP
haloalkyl NN I-NP
; : O

R<8> NNP O
is VBZ O
aryl RB B-NP
, , O
heteroaryl NN B-NP
, , O
aryl-fused-heterocycloalkyl NN B-NP
, , O
heteroaryl-fused-cycloalkyl NN B-NP
, , O
heteroaryl-fused-heterocycloalkyl NN B-NP
or CC O
aryl-fused-cycloalkyl NN B-NP
; : O
and CC O

R<9> NN O
is VBZ O
hydrogen NN B-NP
, , O
( -LRB- B-NP
C1-C6 NNP I-NP
) -RRB- I-NP
alkyl NN I-NP
, , O
( -LRB- B-NP
C1-C6 NNP I-NP
) -RRB- I-NP
haloalkyl NN I-NP
, , O
or CC O
cycloalkyl NN B-NP
. . O

Compounds NNS O
with IN O
which WDT O
the DT O
invention NN O
is VBZ O
concerned VBN O
are VBP O
CRTH2 IN O
receptor NN O
antagonists NNS O
, , O
and CC O
are VBP O
selective JJ O
over IN O
the DT O
DP NNP O
receptor NN O
. . O

A DT O
second JJ O
aspect NN O
of IN O
the DT O
invention NN O
is VBZ O
a DT O
pharmaceutical JJ O
composition NN O
comprising VBG O
a DT O
compound NN O
( -LRB- O
I PRP O
) -RRB- O
as IN O
defined VBN O
above IN O
together RB O
with IN O
one CD O
or CC O
more JJR O
pharmaceutically RB O
acceptable JJ O
carriers NNS O
. . O

A DT O
third JJ O
aspect NN O
of IN O
the DT O
invention NN O
is VBZ O
the DT O
use NN O
of IN O
a DT O
compound NN O
( -LRB- O
I PRP O
) -RRB- O
as IN O
defined VBN O
above IN O
, , O
or CC O
a DT O
pharmaceutically RB O
acceptable JJ O
salt NN O
, , O
N-oxide NN B-NP
, , O
hydrate JJ B-NP
or CC O
solvate JJ O
thereof RB O
, , O
in IN O
the DT O
manufacture NN O
of IN O
a DT O
composition NN O
for IN O
treatment NN O
of IN O
conditions NNS O
responsive JJ O
to TO O
modulation NN O
of IN O
CRTH2 NNP O
receptor NN O
activity NN O
. . O

A DT O
fourth JJ O
aspect NN O
of IN O
the DT O
invention NN O
is VBZ O
a DT O
method NN O
of IN O
treatment NN O
of IN O
conditions NNS O
responsive JJ O
to TO O
modulation NN O
of IN O
CRTH2 NNP O
receptor NN O
activity NN O
, , O
comprising NN O
administering NN O
to TO O
a DT O
patient JJ O
suffering NN O
such JJ O
disease NN O
an DT O
effective JJ O
amount NN O
of IN O
a DT O
compound NN O
( -LRB- O
I PRP O
) -RRB- O
as IN O
defined VBN O
above IN O
, , O
or CC O
a DT O
pharmaceutically RB O
acceptable JJ O
salt NN O
, , O
N-oxide NN B-NP
, , O
hydrate JJ B-NP
or CC O
solvate JJ O
thereof '' O
. . O

Important JJ O
conditions NNS O
responsive JJ O
to TO O
modulation NN O
of IN O
CRTH2 NNP O
receptor NN O
activity NN O
include VBP O
asthma NN O
, , O
chronic JJ O
obstructive JJ O
pulmonary NN O
disease NN O
, , O
allergic JJ O
airway NN O
syndrome NN O
, , O
bronchitis NN O
, , O
cystic JJ O
fibrosis NN O
, , O
emphysema NN O
and CC O
rhinitis NN O
, , O

Other JJ O
conditions NNS O
responsive JJ O
to TO O
modulation NN O
of IN O
CRTH2 NNP O
receptor NN O
activity NN O
include VBP O
psoriasis NN O
, , O
dermatitis NN O
(atopic NN O
and CC O
non-atopic JJ O
) -RRB- O
, , O
Crohn NNP O
's POS O
disease NN O
, , O
ulcerative JJ O
colitis NN O
, , O
and CC O
irritable JJ O
bowel NN O
disease NN O
. . O

Terminology NN O

As IN O
used VBN O
herein RB O
, , O
the DT O
term NN O
"( JJ O
Ca-Cb JJ B-NP
) -RRB- I-NP
alkyl NN I-NP
" `` O
wherein WRB O
a DT O
and CC O
b NN O
are VBP O
integers NNS O
refers VBZ O
to TO O
a DT O
straight JJ O
or CC O
branched JJ B-NP
chain NN I-NP
alkyl RB I-NP
radical JJ O
having VBG O
from IN O
a DT O
to TO O
b NN O
carbon NN O
atoms NNS O
. . O

Thus RB O
when WRB O
a DT O
is VBZ O
1 CD O
and CC O
b NN O
is VBZ O
6 CD O
, , O
for IN O
example NN O
, , O
the DT O
term NN O
includes VBZ O
methyl NN B-NP
, , O
ethyl NN B-NP
, , O
n-propyl JJ B-NP
, , O
isopropyl JJ B-NP
, , O
n-butyl JJ B-NP
, , O
isobutyl JJ B-NP
, , O
sec-butyl JJ B-NP
, , O
t-butyl JJ B-NP
, , O
n-pentyl JJ B-NP
and CC O
n-hexyl JJ B-NP
. . O

As IN O
used VBN O
herein RB O
, , O
the DT O
term NN O
"( JJ O
Ca-Cb JJ B-NP
) -RRB- I-NP
fluoroalkyl NN I-NP
" `` O
wherein WRB O
a DT O
and CC O
b NN O
are VBP O
integers NNS O
refers VBZ O
to TO O
a DT O
straight JJ O
or CC O
branched JJ B-NP
chain NN I-NP
alkyl RB I-NP
radical JJ O
having VBG O
from IN O
a DT O
to TO O
b NN O
carbon NN O
atoms NNS O
in IN O
which WDT O
the DT O
hydrogen NN B-NP
atoms NNS O
all DT O
replaced VBN O
by IN O
fluorine NN B-NP
( -LRB- O
fully RB O
fluorinated VBN O
) -RRB- O
or CC O
in IN O
which WDT O
some DT O
of IN O
the DT O
hydrogen NN B-NP
atoms NNS O
are VBP O
replaced VBN O
by IN O
fluorine NN B-NP
( -LRB- O
partially RB O
fluorinated VBN O
) -RRB- O
. . O

The DT O
term NN O
includes VBZ O
, , O
for IN O
example NN O
-CF3 JJ O
, , O
-CHF2 JJ O
, , O
-CFH2 JJ O
, , O
and CC O
CF3CH2-. NNP B-NP

As IN O
used VBN O
herein PDT O
the DT O
term NN O
" `` O
carbocyclic NN O
" '' O
refers VBZ O
to TO O
an DT O
optionally RB O
substituted VBN O
mono-, JJ O
bi- NNS O
or CC O
tricyclic JJ O
, , O
radical JJ O
having VBG O
up RP O
to TO O
16 CD O
ring NN O
atoms NNS O
, , O
all DT O
of IN O
which WDT O
are VBP O
carbon NN O
, , O
and CC O
includes VBZ O
aryl NN B-NP
and CC O
cycloalkyl NN B-NP
. . O

As IN O
used VBN O
herein PDT O
the DT O
term NN O
" `` O
cycloalkyl NN B-NP
" '' O
refers VBZ O
to TO O
an DT O
optionally RB O
substituted VBN O
monocyclic JJ O
saturated VBD O
carbocyclic NN O
radical JJ O
having VBG O
from IN O
3-8 CD O
carbon NN O
atoms NNS O
and CC O
includes VBZ O
, , O
for IN O
example NN O
, , O
cyclopropyl NN B-NP
, , O
cyclobutyl NN B-NP
, , O
cyclopentyl NN B-NP
, , O
cyclohexyl NN B-NP
, , O
cycloheptyl NN B-NP
and CC O
cyclooctyl NN B-NP
. . O

As IN O
used VBN O
herein IN O
the DT O
unqualified JJ O
term NN O
"aryl NN O
" `` O
refers VBZ O
to TO O
an DT O
optionally RB O
substituted VBN O
mono-, JJ O
bi- NNS O
or CC O
tri-cyclic JJ O
carbocyclic NN O
aromatic IN O
radical JJ O
, , O
and CC O
includes VBZ O
radicals NNS O
having VBG O
two CD O
monocyclic JJ O
carbocyclic JJ O
aromatic JJ O
rings NNS O
which WDT O
are VBP O
directly RB O
linked VBN O
by IN O
a DT O
covalent JJ O
bond NN O
. . O

Aryl NNP B-NP
radicals NNS O
may MD O
have VB O
, , O
for IN O
example NN O
, , O
from IN O
6 CD O
to TO O
14 CD O
ring NN O
carbon NN O
atoms NNS O
, , O
preferably RB O
from IN O

6 CD O
to TO O
10 CD O
carbon NN O
atoms NNS O
. . O

Illustrative NNP O
of IN O
aryl NN B-NP
radicals NNS O
are VBP O
phenyl NN B-NP
, , O
biphenyl NN B-NP
and CC O
napthyl NN B-NP
. . O

As IN O
used VBN O
herein RB O
, , O
the DT O
term NN O
"aryl-fused-cycloalkyl NN O
" `` O
refers VBZ O
to TO O
a DT O
carbocyclic NN O
radical JJ O
consisting VBG O
of IN O
a DT O
monocyclic NN O
aryl NN B-NP
ring NN O
, , O
such JJ O
as IN O
phenyl NN B-NP
, , O
fused VBN O
to TO O
a DT O
cycloalkyl NN B-NP
group NN O
, , O
in IN O
which WDT O
the DT O
aryl NN B-NP
and CC O
cycloalkyl NN B-NP
parts NNS O
are VBP O
as IN O
defined VBN O
herein RB O
. . O

Exemplary NNP O
aryl-fused JJ B-NP
- : I-NP
cycloalkyl NN I-NP
groups NNS O
include VBP O
tetrahydronaphthyl NN B-NP
and CC O
indanyl NN B-NP
. . O

The DT O
aryl-fused-cycloalkyl NN B-NP
radical JJ O
may MD O
be VB O
attached VBN O
to TO O
the DT O
remainder NN O
of IN O
the DT O
molecule NN O
by IN O
any DT O
available JJ O
carbon NN O
atom NN O
. . O

As IN O
used VBN O
herein IN O
the DT O
unqualified JJ O
term NN O
"heteroaryl NN O
" `` O
refers VBZ O
to TO O
an DT O
optionally RB O
substituted VBN O
mono-, JJ O
bi- NNS O
or CC O
tri-cyclic JJ O
aromatic IN O
radical JJ O
containing VBG O
one CD O
or CC O
more JJR O
heteroatoms NNS O
selected VBN O
from IN O
S NNP O
, , O
N NNP O
and CC O
O NNP O
, , O
and CC O
includes VBZ O
radicals NNS O
having VBG O
two CD O
such JJ O
monocyclic NN O
rings NNS O
, , O
or CC O
one CD O
such JJ O
monocyclic JJ O
ring NN O
and CC O
one CD O
monocyclic NN O
aryl NN B-NP
ring NN O
, , O
which WDT O
are VBP O
directly RB O
linked VBN O
by IN O
a DT O
covalent JJ O
bond NN O
. . O

Illustrative NNP O
of IN O
such JJ O
radicals NNS O
are VBP O
thienyl NN B-NP
, , O
benzthienyl NN B-NP
, , O
furyl NN B-NP
, , O
benzfuryl NN B-NP
, , O
pyrrolyl NN B-NP
, , O
imidazolyl NN B-NP
, , O
benzimidazolyl NN B-NP
, , O
thiazolyl NN B-NP
, , O
benzthiazolyl NN B-NP
, , O
isothiazolyl NN B-NP
, , O
benzisothiazolyl NN B-NP
, , O
pyrazolyl NN B-NP
, , O
oxazolyl NN B-NP
, , O
benzoxazolyl NN B-NP
, , O
isoxazolyl NN B-NP
, , O
benzisoxazolyl NN B-NP
, , O
isothiazolyl NN B-NP
, , O
triazolyl NN B-NP
, , O
benztriazolyl NN B-NP
, , O
thiadiazolyl NN B-NP
, , O
oxadiazolyl NN B-NP
, , O
pyridinyl NN B-NP
, , O
pyridazinyl NN B-NP
, , O
pyrimidinyl NN B-NP
, , O
pyridazinyl NN B-NP
, , O
triazinyl NN B-NP
, , O
indolyl NN B-NP
and CC O
indazolyl NN B-NP
. . O

As IN O
used VBN O
herein IN O
the DT O
unqualified JJ O
term NN O
"heterocycloalkyl NN O
" '' O
or CC O
"heterocyclyl JJ O
" '' O
or CC O
"heterocyclic JJ O
" `` O
includes VBZ O
"heteroaryl JJ O
" '' O
as IN O
defined VBN O
above IN O
, , O
and CC O
in IN O
addition NN O
means VBZ O
an DT O
optionally RB O
substituted VBN O
mono-, JJ O
bi- NNS O
or CC O
tri-cyclic JJ O
non-aromatic JJ O
radical JJ O
containing VBG O
one CD O
or CC O
more JJR O
heteroatoms NNS O
selected VBN O
from IN O
S NNP O
, , O
N NNP O
and CC O
O NNP O
, , O
and CC O
to TO O
groups NNS O
consisting VBG O
of IN O
a DT O
monocyclic JJ O
non-aromatic JJ O
radical JJ O
containing VBG O
one CD O
or CC O
more JJR O
such JJ O
heteroatoms NNS O
which WDT O
is VBZ O
covalently RB O
linked VBN O
to TO O
another DT O
such JJ O
radical JJ O
or CC O
to TO O
a DT O
monocyclic NN B-NP
carbocyclic NN I-NP
radical JJ I-NP
. . O

Illustrative NNP O
of IN O
such JJ O
radicals NNS O
are VBP O
pyrrolyl NN B-NP
, , O
furanyl NN B-NP
, , O
thienyl NN B-NP
, , O
piperidinyl NN B-NP
, , O
imidazolyl NN B-NP
, , O
oxazolyl NN B-NP
, , O
isoxazolyl NN B-NP
, , O
thiazolyl NN B-NP
, , O
thiadiazolyl NN B-NP
, , O
pyrazolyl NN B-NP
, , O
pyridinyl NN B-NP
, , O
pyrrolidinyl NN B-NP
, , O
pyrimidinyl NN B-NP
, , O
morpholinyl NN B-NP
, , O
piperazinyl NN B-NP
, , O
indolyl NN B-NP
, , O
quinolyl NN B-NP
, , O
morpholinyl NN B-NP
, , O
benzfuranyl NN B-NP
, , O
pyranyl NN B-NP
, , O
isoxazolyl NN B-NP
, , O
benzimidazolyl NN B-NP
, , O
methylenedioxyphenyl NN B-NP
, , O
ethylenedioxyphenyl NN B-NP
, , O
maleimido NN B-NP
and CC O
succinimido NN B-NP
groups NNS O
. . O

As IN O
used VBN O
herein RB O
, , O
the DT O
term NN O
"heteroaryl-fused-cycloalkyl NN O
" '' O
means VBZ O
a DT O
heterocyclic NN B-NP
radical JJ I-NP
consisting VBG O
of IN O
monocyclic JJ O
heteroaryl NN B-NP
group NN O
, , O
such JJ O
as IN O
pyridyl NN B-NP
or CC O
furanyl NN B-NP
, , O
fused VBN O
to TO O
a DT O
cycloalkyl NN B-NP
group NN O
, , O
in IN O
which WDT O
the DT O
heteroaryl NN B-NP
and CC O
cycloalkyl NN B-NP
parts NNS O
are VBP O
as RB O
defined VBN O
herein RB O
. . O

Exemplary NNP O
heteroaryl-fused-cycloalkyl NN B-NP
groups NNS O
include VBP O
tetrahydroquinolinyl NN B-NP
and CC O
tetrahydrobenzofuranyl NN B-NP
. . O

The DT O
heteroaryl-fused-cycloalkyl JJ B-NP
group NN O
may MD O
be VB O
attached VBN O
to TO O
the DT O
remainder NN O
of IN O
the DT O
molecule NN O
by IN O
any DT O
available JJ O
carbon NN O
or CC O
nitrogen NN O
atom NN O
. . O

As IN O
used VBN O
herein RB O
, , O
the DT O
term NN O
"aryl-fused-heterocycloalkyl NN O
" `` O
refers VBZ O
to TO O
a DT O
heterocyclic NN B-NP
radical JJ I-NP
consisting VBG O
of IN O
a DT O
monocyclic NN O
aryl NN B-NP
ring NN O
, , O
such JJ O
as IN O
phenyl NN B-NP
, , O
fused VBN O
to TO O
a DT O
heterocycloalkyl NN B-NP
group NN O
, , O
in IN O
which WDT O
the DT O
aryl NN B-NP
and CC O
heterocycloalkyl NN B-NP
parts NNS O
are VBP O
as IN O
defined VBN O
above IN O
. . O

Exemplary NNP O
aryl-fused-heterocycloalkyl NN B-NP
groups NNS O
include VBP O
tetrahydroquinolinyl NN B-NP
, , O
indolinyl NN B-NP
, , O
benzodioxinyl NN B-NP
, , O
benxodioxolyl NN B-NP
, , O
dihydrobenzofuranyl NN B-NP
and CC O
isoindolonyl NN B-NP
. . O

The DT O
aryl-fused-heterocycloalkyl NN B-NP
radical JJ O
may MD O
be VB O
attached VBN O
to TO O
the DT O
remainder NN O
of IN O
molecule NN O
by IN O
any DT O
available JJ O
carbon NN O
or CC O
nitrogen NN O
atom NN O
. . O

As IN O
used VBN O
herein RB O
, , O
the DT O
term NN O
"heteroaryl-fused-heterocycloalkyl NN O
" `` O
refers VBZ O
to TO O
a DT O
heterocyclic NN B-NP
radical JJ I-NP
consisting VBG O
of IN O
a DT O
monocyclic JJ O
heteroaryl NN B-NP
group NN O
, , O
such JJ O
as IN O
pyridyl NN B-NP
or CC O
furanyl NN B-NP
, , O
fused VBN O
to TO O
a DT O
heterocycloalkyl NN B-NP
group NN O
, , O
in IN O
which WDT O
the DT O
heteroaryl NN B-NP
and CC O
heterocycloalkyl NN B-NP
parts NNS O
are VBP O
as IN O
defined VBN O
herein RB O
. . O

Exemplary NNP O
heteroaryl-fused JJ B-NP
- : I-NP
heterocycloalkyl NN I-NP
groups NNS O
include VBP O
dihydrodioxinopyridinyl NN B-NP
, , O
dihydropyrrolopyridinyl NN B-NP
, , O
dihydrofuranopyridinyl NN B-NP
and CC O
dioxolopyridinyl NN B-NP
. . O

The DT O
heteroaryl-fused-heterocycloalkyl JJ B-NP
group NN O
may MD O
be VB O
attached VBN O
to TO O
the DT O
remainder NN O
of IN O
the DT O
molecule NN O
by IN O
any DT O
available JJ O
carbon NN O
or CC O
nitrogen NN O
atom NN O
. . O

Unless IN O
otherwise RB O
specified VBN O
in IN O
the DT O
context NN O
in IN O
which WDT O
it PRP O
occurs VBZ O
, , O
the DT O
term NN O
" `` O
substituted VBN O
" '' O
as IN O
applied VBN O
to TO O
any DT O
moiety NN O
herein PRP O
means VBZ O
substituted VBN O
with IN O
up RB O
to TO O
four CD O
compatible JJ O
substituents NNS O
, , O
each DT O
of IN O
which WDT O
independently RB O
may MD O
be VB O
, , O
for IN O
example NN O
, , O
( -LRB- B-NP
Ci-C6 NNP I-NP
) -RRB- I-NP
alkyl NN I-NP
, , O
cycloalkyl NN B-NP
, , O
( -LRB- B-NP
C1-C6 NNP I-NP
) -RRB- I-NP
alkoxy RB I-NP
, , O
hydroxy JJ B-NP
, , O
hydroxy( JJ B-NP
CrC6 NNP I-NP
) -RRB- I-NP
alkyl NN I-NP
, , O
mercapto NN B-NP
, , O
mercapto( NN B-NP
Ci-C6 NNS I-NP
) -RRB- I-NP
alkyl NN I-NP
, , O
( -LRB- B-NP
C1-C6 NNP I-NP
) -RRB- I-NP
alkylthio RB I-NP
, , O
phenyl NN B-NP
, , O
monocyclic NN O
heteroaryl NN B-NP
having VBG O
5 CD O
or CC O
6 CD O
ring NN O
atoms NNS O
, , O
halo FW B-NP
( -LRB- O
including VBG O
fluoro NN B-NP
, , O
bromo NN B-NP
and CC O
chloro NN B-NP
) -RRB- O
, , O
trifluoromethyl NN B-NP
, , O
trifluoromethoxy JJ B-NP
, , O
nitro NN B-NP
, , O
nitrile JJ B-NP
(-CN) JJ O
, , O
oxo RB B-NP
, , O
-COOH NNP O
, , O
-COOR JJ O
, , O
-COR JJ O
, , O
-SO2R JJ O
, , O
-CONH2 JJ O
, , O
-SO2NH2 JJ O
, , O
-CONHR JJ O
, , O
-SO2NHR JJ O
, , O

-CONRR JJ O
, , O
-SO2NRR JJ O
, , O
-NH2 JJ O
, , O
-NHR JJ O
, , O
-NRR JJ O
, , O
- : O
OCONH2 PRP B-NP
, , O
-OCONHR NNP O
, , O
-OCONRR NNP O
, , O
-NHC0R JJ O
, , O
-NHCOOR JJ O
, , O
-NRCOOR JJ O
, , O
- : O
NHSO2OR NN B-NP
, , O
-NR<6>SO2OH NNP O
, , O
-NRSO2OR,-NHCONH2 JJ O
, , O
-NRCONH2 JJ O
, , O
-NHCONHR<6> JJ O
- : O
NRCONHR NN B-NP
, , O
-NHC0NRR JJ O
or CC O
-NRC0NRR<6> JJ O
wherein IN O
R NN O
and CC O
R NN O
are VBP O
independently RB O
a DT O
( -LRB- O
CrC6 NN O
) -RRB- O
alkyl NN O
, , O
( -LRB- O
C3-C6 NNP O
) -RRB- O
cycloalkyl NN B-NP
, , O
phenyl NN B-NP
, , O
or CC O
monocyclic JJ B-NP
heterocyclic JJ I-NP
group NN I-NP
having VBG O
5 CD O
or CC O
6 CD O
ring NN O
atoms NNS O
, , O
or CC O
R NN O
and CC O
R NN O
when WRB O
attached VBN O
to TO O
the DT O
same JJ O
nitrogen NN O
atom NN O
may MD O
form VB O
a DT O
ring NN O
with IN O
that DT O
nitrogen NN O
of IN O
5 CD O
or CC O
6 CD O
ring NN O
atoms NNS O
, , O
optionally RB O
containing VBG O
further JJ O
heteroatoms NNS O
selected VBN O
from IN O
N NNP O
, , O
O UH O
or CC O
S NNP O
( -LRB- O
examples NNS O
being VBG O
morpholinyl JJ B-NP
, , O
piperidinyl NN B-NP
, , O
piperazinyl NN B-NP
, , O
4-methylpiperazinyl JJ B-NP
, , O
and CC O
tetrahydropyrrole NN B-NP
) -RRB- O
. . O

An DT O
"optional JJ O
substituent JJ O
" `` O
may MD O
be VB O
one CD O
of IN O
the DT O
foregoing JJ O
substituent JJ O
groups NNS O
. . O

As IN O
used VBN O
herein PDT O
the DT O
term NN O
" `` O
salt NN O
" '' O
includes VBZ O
base NN O
addition NN O
, , O
acid NN O
addition NN O
and CC O
quaternary JJ O
salts NNS O
. . O

Compounds NNS O
of IN O
the DT O
invention NN O
which WDT O
are VBP O
acidic NN O
can MD O
form VB O
salts NNS O
, , O
including VBG O
pharmaceutically NN O
acceptable JJ O
salts NNS O
, , O
with IN O
bases NNS O
such JJ O
as IN O
alkali JJ B-NP
metal NN I-NP
hydroxides NNS I-NP
, , O
e.g NN O
. . O

sodium NN B-NP
and CC O
potassium NN B-NP
hydroxides NNS I-NP
; : O
alkaline NN B-NP
earth NN I-NP
metal NN I-NP
hydroxides NNS I-NP
e.g NN O
. . O

calcium NN B-NP
, , O
barium NN B-NP
and CC O
magnesium NN B-NP
hydroxides NNS I-NP
; : O
with IN O
organic JJ O
bases NNS O
e.g NN O
. . O

N-methyl- NNP B-NP
D-glucamine NNP I-NP
, , O
choline NN B-NP
tris( NN I-NP
hydroxymethyl NN I-NP
)amino-methane NN I-NP
, , O
L-arginine NNP B-NP
, , O
L-lysine NNP B-NP
, , B-NP
N-ethyl NNP I-NP
piperidine NN I-NP
, , O
dibenzylamine NN B-NP
and CC O
the DT O
like JJ O
. . O

Specific JJ O
salts NNS O
with IN O
bases NNS O
include VBP O
the DT O
benzathine NN B-NP
, , O
calcium NN B-NP
, , O
diolamine NN B-NP
, , O
meglumine NN B-NP
, , O
olamine NN B-NP
, , O
potassium NN B-NP
, , O
procaine NN B-NP
, , O
sodium NN B-NP
, , O
tromethamine NN B-NP
and CC O
zinc NN B-NP
salts NNS O
. . O

Those DT O
compounds NNS O
( -LRB- O
I PRP O
) -RRB- O
which WDT O
are VBP O
basic JJ O
can MD O
form VB O
salts NNS O
, , O
including VBG O
pharmaceutically NN O
acceptable JJ O
salts NNS O
with IN O
inorganic JJ O
acids NNS O
, , O
e.g NN O
. . O
with IN O
hydrohalic JJ B-NP
acids NNS I-NP
such JJ O
as IN O
hydrochloric JJ B-NP
or CC O
hydrobromic JJ B-NP
acids NNS I-NP
, , O
sulphuric JJ B-NP
acid NN I-NP
, , O
nitric JJ B-NP
acid NN I-NP
or CC O
phosphoric JJ B-NP
acid NN I-NP
and CC O
the DT O
like JJ O
, , O
and CC O
with IN O
organic JJ O
acids NNS O
e.g NN O
. . O
with IN O
acetic JJ B-NP
, , O
tartaric JJ B-NP
, , O
succinic JJ B-NP
, , O
fumaric JJ B-NP
, , O
maleic JJ B-NP
, , O
malic JJ B-NP
, , O
salicylic JJ B-NP
, , O
citric JJ B-NP
, , O
methanesulphonic JJ B-NP
, , O
p-toluenesulphonic JJ B-NP
, , O
benzoic JJ B-NP
, , O
benzenesunfonic JJ B-NP
, , O
glutamic JJ B-NP
, , O
lactic JJ B-NP
, , O
and CC O
mandelic JJ O
acids NNS O
and CC O
the DT O
like JJ O
. . O

Additional JJ O
salt NN O
forms NNS O
are VBP O
detailed VBN O
in IN O
the DT O
" `` O
Handbook JJS O
of IN O
Pharmaceutical NNP O
Salts NNP O
. . O

Properties NNP O
, , O
selection NN O
and CC O
use" VB O
, , O
P. NNP O
Heinrich NNP O
Stahl NNP O
& CC O
Camille NNP O
G. NNP O
Wermuth NNP O
, , O
Wiley-VCH NNP O
, , O
2002 CD O
. . O

Compounds NNS O
with IN O
which WDT O
the DT O
invention NN O
is VBZ O
concerned VBN O
which WDT O
may MD O
exist VB O
in IN O
one CD O
or CC O
more JJR O
stereoisomer NN O
^ IN O
form NN O
, , O
because IN O
of IN O
the DT O
presence NN O
of IN O
asymmetric JJ O
atoms NNS O
or CC O
rotational JJ O
restrictions NNS O
, , O
and CC O
in IN O
such JJ O
cases NNS O
can MD O
exist VB O
as IN O
a DT O
number NN O
of IN O
stereoisomers NNS O
with IN O
R NN O
or CC O
S NNP O
stereochemistry NN O
at IN O
each DT O
chiral JJ O
centre NN O
or CC O
as IN O
atropisomeres NNS O
with IN O
R NN O
or CC O
S NNP O
stereochemistry NN O
at IN O
each DT O
chiral JJ O
axis NN O
. . O

The DT O
invention NN O
includes VBZ O
all DT O
such JJ O
enantiomers NNS O
and CC O
diastereoisomers NNS O
and CC O
mixtures NNS O
thereof RB O
. . O

Use NN O
of IN O
prodrugs NNS O
, , O
such JJ O
as IN O
esters NNS B-NP
, , O
of IN O
compounds NNS O
with IN O
which WDT O
the DT O
invention NN O
is VBZ O
concerned VBN O
is VBZ O
also RB O
part NN O
of IN O
the DT O
invention NN O
. . O

" `` O
Prodrug" VB O
means VBZ O
a DT O
compound NN O
which WDT O
is VBZ O
convertible JJ O
in IN O
vivo NN O
by IN O
metabolic JJ O
means NNS O
( -LRB- O
e NN O
.g NN O
. . O
by IN O
hydrolysis NN O
, , O
reduction NN O
or CC O
oxidation NN O
) -RRB- O
to TO O
a DT O
compound NN O
of IN O
formula NN O
( -LRB- O
I PRP O
) -RRB- O
. . O

For IN O
example NN O
an DT O
ester NN O
prodrug NN O
of IN O
a DT O
compound NN O
of IN O
formula NN O
( -LRB- O
I PRP O
) -RRB- O
may MD O
be VB O
convertible JJ O
by IN O
hydrolysis NN O
in IN O
vivo NN O
to TO O
the DT O
parent NN O
molecule NN O
. . O

Suitable JJ O
esters NNS B-NP
of IN O
compounds NNS O
of IN O
formula NN O
( -LRB- O
I PRP O
) -RRB- O
are VBP O
for IN O
example NN O
acetates NNS B-NP
, , O
citrates NNS B-NP
, , O
lactates VBZ B-NP
, , O
tartrates NNS B-NP
, , O
malonates NNS B-NP
, , O
oxalates NNS B-NP
, , O
salicylates NNS B-NP
, , O
propionates NNS B-NP
, , O
succinates VBZ B-NP
, , O
fumarates NNS B-NP
, , O
maleates NNS B-NP
, , O
methylene-bis-[beta]-hydroxynaphthoates NNS B-NP
, , O
gentisates NNS B-NP
, , O
isethionates VBZ B-NP
, , O
di-p-toluoyltartrates NNS B-NP
, , O
methanesulphonates NNS O
, , O
ethanesulphonates NNS B-NP
, , O
benzenesulphonates NNS B-NP
, , O
jOtoluene NNP B-NP
- : I-NP
sulphonates NNS I-NP
, , O
cyclohexylsulphamates NNS B-NP
and CC O
quinates NNS B-NP
. . O

Examples NNS O
of IN O
ester NN O
prodrugs NNS O
are VBP O
those DT O
described VBN O
by IN O
F. NNP O
J. NNP O
Leinweber NNP O
, , O
Drug NNP O
Metab NNP O
. . O

Res NNP O
. . O
, , O
1987 CD O
, , O
18 CD O
, , O
379 CD O
. . O

As IN O
used VBN O
in IN O
herein RB O
, , O
references NNS O
to TO O
the DT O
compounds NNS O
of IN O
formula NN O
( -LRB- O
I PRP O
) -RRB- O
are VBP O
meant VBN O
to TO O
also RB O
include VB O
the DT O
prodrug NN O
forms NNS O
. . O

The DT O
variables NNS O
Ff NNP O
'-R<9> . O

In IN O
compounds NNS O
with IN O
which WDT O
the DT O
invention NN O
is VBZ O
concerned VBN O
, , O
the DT O
following VBG O
structural JJ O
characteristics NNS O
are VBP O
currently RB O
preferred VBN O
, , O
in IN O
any DT O
compatible JJ O
combination NN O
: : O

R<1> NNP O
, , O
R<2> NNP O
, , O
R<3> NNP O
and CC O
R<4> NNP O
are VBP O
independently RB O
hydrogen NN B-NP
, , O
( -LRB- B-NP
C1-C6 NN I-NP
) -RRB- I-NP
alkyl NN I-NP
, , O
for IN O
example NN O
methyl NN B-NP
, , O
ethyl NN B-NP
, , O
or CC O
n- NNS O
or CC O
iso-propyl NN B-NP
; : O
( -LRB- B-NP
C1-C6 NN I-NP
) -RRB- I-NP
fluoroalkyl NN I-NP
, , O
for IN O
example NN O
trifluoromethyl NN B-NP
or CC O
difluoromethyl NN B-NP
; : O
cycloalkyl NN B-NP
, , O
for IN O
example NN O
cyclopropyl NN B-NP
or CC O
cyclobutyl NN B-NP
; : O
halo NN B-NP
, , O
for IN O
example NN O
fluoro NN B-NP
, , O
chloro NN B-NP
or CC O
bromo NN B-NP
; : O
-S( JJ O
O)nR<10> JJ O
, , O
-SO2N( JJ O
R<11>)2 NNP O
, , O
-N( JJ O
R<11>)2 NNP O
, , O
-NR<11>C( JJ O
O)R<10> NNP B-NP
, , O
-CO2R<11> JJ O
, , O
- : O
C( PRP B-NP
O)R<10> JJ I-NP
, , O
CN NNP B-NP
or CC O
a DT O
group NN O
OR<12> NNP O
; : O
wherein WRB O
each DT O
R<10> NN O
is VBZ O
independently RB O
d-C-6 JJ O
alkyl NN O
, , O
for IN O
example NN O
methyl NN B-NP
, , O
ethyl NN B-NP
, , O
or CC O
n- NNS O
or CC O
iso-propyl NN B-NP
; : O
fully RB O
or CC O
partially RB O
fluorinated VBN O
C1-C6 DT B-NP
alkyl NN I-NP
, , O
for IN O
example NN O
trifluoromethyl NN B-NP
or CC O
difluoromethyl NN B-NP
; : O
cycloalkyl NN B-NP
for IN O
example NN O
cyclopropyl NN B-NP
, , O
cyclobutyl NN B-NP
, , O
cyclopentyl NN B-NP
or CC O
cyclohexyl NN B-NP
; : O
aryl NN B-NP
, , O
for IN O
example NN O
phenyl NN B-NP
; : O
or CC O
heteroaryl NN B-NP
, , O
for IN O
example NN O
pyridyl NN B-NP
, , O
thienyl NN B-NP
or CC O
furanyl NN B-NP
; : O
each DT O
R11 NN O
is VBZ O
independently RB O
C1-C6 DT B-NP
alkyl NN I-NP
, , O
for IN O
example NN O
methyl NN B-NP
, , O
ethyl NN B-NP
, , O
or CC O
n- NNS O
or CC O
iso NN B-NP
- : I-NP
propyl NN I-NP
; : O
fully RB O
or CC O
partially RB O
fluorinated VBN O
C1-C6 DT B-NP
alkyl NN I-NP
, , O
for IN O
example NN O
trifluoromethyl NN B-NP
or CC O
difluoromethyl NN B-NP
; : O
cycloalkyl NN B-NP
for IN O
example NN O
cyclopropyl NN B-NP
, , O
cyclobutyl NN B-NP
, , O
cyclopentyl NN B-NP
or CC O
cyclohexyl NN B-NP
; : O
cycloalkyl-( JJ B-NP
CrC6 NNP O
alkyl)-, NN O
for IN O
example NN O
cyclopropylmethyl NN B-NP
, , O
cyclopentylmethyl NN B-NP
, , O
cyclohexylmethyl NN B-NP
, , O
cyclopropylethyl NN B-NP
, , O
cyclopentylethyl NN B-NP
, , O
cyclohexylethyl NN B-NP
; : O
aryl NN B-NP
, , O
for IN O
example NN O
phenyl NN B-NP
; : O
or CC O
heteroaryl NN B-NP
, , O
for IN O
example NN O
pyridyl NN B-NP
, , O
thienyl NN B-NP
or CC O
furanyl NN B-NP
; : O
or CC O
hydrogen NN B-NP
; : O

Currently RB O
preferred JJ O
instances NNS O
of IN O
R<1>-R<4> NNP O
are VBP O
: : O

R<1> NN O
is VBZ O
hydrogen NN B-NP
; : O
5 CD O
R<2> NN O
is VBZ O
chloro NN B-NP
; : O

R<3> NN O
is VBZ O
hydrogen NN B-NP
; : O

R<4> NN O
is VBZ O
hydrogen NN B-NP
. . O

R<5> NNP O
and CC O
R<6> NNP O
are VBP O
independently RB O
hydrogen NN B-NP
, , O
( -LRB- B-NP
C1-C6 NN I-NP
) -RRB- I-NP
alkyl NN I-NP
, , O
for IN O
example NN O
methyl NN B-NP
, , O
ethyl NN B-NP
, , O
or CC O
n- NNS O
or CC O
iso-propyl NN B-NP
; : O
( -LRB- B-NP
CrC6 NNP I-NP
) -RRB- I-NP
fluoroalkyl NN I-NP
, , O
for IN O
example NN O
trifluoromethyl NN B-NP
or CC O

10 CD O
difluoromethyl NN B-NP
; : O
cycloalkyl NN B-NP
, , O
for IN O
example NN O
cyclopropyl NN B-NP
or CC O
cyclobutyl NN B-NP
, , O
or CC O
R<5> NNP O
and CC O
R<6> NNP O
together RB O
with IN O
the DT O
atom NN O
to TO O
which WDT O
they PRP O
are VBP O
attached VBN O
form NN O
a DT O
cycloalkyl JJ B-NP
ring NN O
such JJ O
as IN O
a DT O
cyclopropyl NN B-NP
ring NN O
. . O

Presently RB O
it PRP O
is VBZ O
preferred VBN O
that IN O
both DT O
of IN O
R<5> NNP O
and CC O
R<6> NNP O
are VBP O
hydrogen NN B-NP
. . O

R<7> NN O
is VBZ O
hydrogen NN B-NP
, , O
( -LRB- B-NP
C1-C6 NNP I-NP
) -RRB- I-NP
alkyl NN I-NP
, , O
for IN O
example NN O
methyl NN B-NP
, , O
ethyl NN B-NP
, , O
or CC O
n- NNS O
or CC O
iso-propyl NN B-NP
; : O
( -LRB- B-NP
CrC6 NNP I-NP
) -RRB- I-NP
fluoroalkyl NN I-NP
, , O
for IN O
example NN O
trifluoromethyl NN B-NP
or CC O
difluoromethyl NN B-NP
. . O

Presently RB O
it PRP O
is VBZ O
15 CD O
preferred VBN O
that IN O
R<7> NNP O
be VB O
methyl NN B-NP
. . O

R<8> NNP O
is VBZ O
optionally RB O
substituted VBN O
aryl NN B-NP
such JJ O
as IN O
phenyl NN B-NP
or CC O
naphthy NN B-NP
) -RRB- O
; : O
heteroaryl NN B-NP
for IN O
example NN O
quinolinyl RB B-NP
, , O
pyridyl NN B-NP
, , O
thienyl NN B-NP
, , O
furanyl NN B-NP
, , O
azolyl NN B-NP
, , O
thiazolyl NN B-NP
, , O
diazolyl NN B-NP
, , O
or CC O
imidazolyl NN B-NP
, , O
aryl-fused-heterocycloalkyl NN B-NP
, , O
for IN O
example NN O
tetrahydroquinolinyl NN B-NP
, , O
indolinyl NN B-NP
, , O
benzodioxinyl NN B-NP
, , O
benxodioxolyl NN B-NP
, , O
dihydrobenzofuranyl NN B-NP
and CC O
isoindolonyl NN B-NP
; : O
heteroaryl-fused-cycloalkyl NN B-NP
, , O
for IN O
20 CD O
example NN O
tetrahydroquinolyl NN B-NP
; : O
heteroaryl-fused-heterocycloalkyl NN B-NP
, , O
for IN O
example NN O
indolinyl NN B-NP
, , O
benzodioxinyl NN B-NP
, , O
benzodioxolyl NN B-NP
, , O
dihydrobenzofuranyl NN B-NP
or CC O
isoindolonyl NN B-NP
; : O
or CC O
aryl-fused JJ B-NP
- : I-NP
cycloalkyl NN I-NP
group NN O
such JJ O
as IN O
tetrahydronaphthyl NN B-NP
and CC O
indanyl NN B-NP
. . O

One CD O
currently RB O
preferred VBN O
R<8> NNP O
is VBZ O
optionally RB O
substituted VBN O
phenyl NN B-NP
. . O

Optional JJ O
substituents NNS O
in IN O
R<8> NNP O
include VBP O
: : O
fluoro NN B-NP
, , O
chloro NN B-NP
, , O
phenyl NN B-NP
, , O
methanesulfonyl NN B-NP
, , O
4-ethanesulfonylphenyl JJ B-NP
, , O
25 CD O
trifluoromethyl NN B-NP
, , O
morpholine-4-sulfonyl JJ B-NP
, , O
pyrrolidine JJ B-NP
- : I-NP
1-carbonyl JJ I-NP
, , O
and CC O
cyclobutylcarbamoyl NN B-NP
. . O

Currently RB O
preferred VBN O
R<8> RP O
radicals NNS O
include VBP O
4-chlorophenyl JJ B-NP
, , O
2- CD B-NP
chlorophenyl NN I-NP
, , O
4-(trifluoromethyl)phenyl JJ B-NP
, , O
4-(methylsulfonyl)phenyl JJ B-NP
, , O
4-fluorophenyl JJ B-NP
, , O
2- CD B-NP
naphthyl NN I-NP
, , O
1-naphthyl JJ B-NP
, , O
2,3-dichlorophenyl JJ B-NP
, , O
8-quinolinyl JJ B-NP
, , O
3,5-dichlorophenyl JJ B-NP
, , O
3,4- CD B-NP
dichlorophenyl NN I-NP
. . O

30 CD O
R<9> NN O
is VBZ O
hydrogen NN B-NP
, , O
( -LRB- B-NP
C1-C6 NN I-NP
) -RRB- I-NP
alkyl NN I-NP
, , O
for IN O
example NN O
methyl NN B-NP
, , O
ethyl NN B-NP
, , O
or CC O
n- NNS O
or CC O
iso-propyl NN B-NP
; : O

( -LRB- B-NP
C1-C6 NN I-NP
) -RRB- I-NP
fluoroalkyl NN I-NP
, , O
for IN O
example NN O
trifluoromethyl NN B-NP
or CC O
difluoromethyl NN B-NP
; : O
cycloalkyl NN B-NP
, , O
for IN O
example NN O
cyclopropyl NN B-NP
or CC O
cyclobutyl NN B-NP
. . O

Currently RB O
it PRP O
is VBZ O
preferred VBN O
that IN O
R<9> NNP O
be VB O
hydrogen NN B-NP
. . O

Specific JJ O
compounds NNS O
with IN O
which WDT O
the DT O
invention NN O
is VBZ O
concerned VBN O
include VBP O
those DT O
of IN O
the DT O
Examples NNS O
herein RB O
, , O
and CC O
pharmaceutically RB O
acceptable JJ O
salts NNS O
, , O
N-oxides NNS B-NP
, , O
hydrates NNS B-NP
or CC O
35 CD O
. . O

solvates NNS O
thereof RB O
. . O

Compositions NNS O

As IN O
mentioned VBN O
above IN O
, , O
the DT O
compounds NNS O
with IN O
which WDT O
the DT O
invention NN O
, , O
is VBZ O
concerned VBN O
are VBP O
CRTH2 IN O
receptor NN O
antagonists NNS O
, , O
and CC O
are VBP O
useful JJ O
in IN O
the DT O
treatment NN O
of IN O
diseases NNS O
which WDT O
benefit VBP O
from IN O
such JJ O
modulation NN O
. . O

Examples NNS O
of IN O
such JJ O
diseases NNS O
are VBP O
referred VBN O
to TO O
above IN O
, , O
and CC O
include VBP O
asthma NN O
, , O
rhinitis NN O
, , O
allergic JJ O
airway NN O
syndrome NN O
, , O
and CC O
bronchitis NN O
. . O

It PRP O
will MD O
be VB O
understood VBN O
that IN O
the DT O
specific JJ O
dose NN O
level NN O
for IN O
any DT O
particular JJ O
patient NN O
will MD O
depend VB O
upon IN O
a DT O
variety NN O
of IN O
factors NNS O
including VBG O
the DT O
activity NN O
of IN O
the DT O
specific JJ O
compound NN O
employed VBN O
, , O
the DT O
age NN O
, , O
body NN O
weight NN O
, , O
general JJ O
health NN O
, , O
sex NN O
, , O
diet NN O
, , O
time NN O
of IN O
administration NN O
, , O
route NN O
of IN O
administration NN O
, , O
rate NN O
of IN O
excretion NN O
, , O
drug NN O
combination NN O
and CC O
the DT O
severity NN O
of IN O
the DT O
particular JJ O
disease NN O
undergoing VBG O
treatment NN O
. . O

Optimum NNP O
dose NN O
levels NNS O
and CC O
frequency NN O
of IN O
dosing NN O
will MD O
be VB O
determined VBN O
by IN O
clinical JJ O
trial NN O
, , O
as IN O
is VBZ O
required VBN O
in IN O
the DT O
pharmaceutical JJ O
art NN O
. . O

In IN O
general JJ O
, , O
the DT O
daily JJ O
dose NN O
range NN O
will MD O
lie VB O
within IN O
the DT O
range NN O
of IN O
from IN O
about IN O
0.001 CD O
mg NN O
to TO O
about IN O
100 CD O
mg NN O
per IN O
kg JJ O
body NN O
weight NN O
of IN O
a DT O
mammal NN O
, , O
often RB O
0.01 CD O
mg NN O
to TO O
about IN O
50 CD O
mg NN O
per IN O
kg NN O
, , O
for IN O
example NN O
0.1 CD O
to TO O
10 CD O
mg NN O
per IN O
kg NN O
, , O
in IN O
single JJ O
or CC O
divided VBN O
doses NNS O
. . O

On IN O
the DT O
other JJ O
hand NN O
, , O
it PRP O
may MD O
be VB O
necessary JJ O
to TO O
use VB O
dosages NNS O
outside IN O
these DT O
limits NNS O
in IN O
some DT O
cases NNS O
. . O

The DT O
compounds NNS O
with IN O
which WDT O
the DT O
invention NN O
is VBZ O
concerned VBN O
may MD O
be VB O
prepared VBN O
for IN O
administration NN O
by IN O
any DT O
route NN O
consistent JJ O
with IN O
their PRP$ O
pharmacokinetic JJ O
properties NNS O
. . O

Orally RB O
administrable JJ O
compositions NNS O
may MD O
be VB O
in IN O
the DT O
form NN O
of IN O
tablets NNS O
, , O
capsules NNS O
, , O
powders NNS O
, , O
granules NNS O
, , O
lozenges NNS O
, , O
liquid JJ O
or CC O
gel JJ O
preparations NNS O
, , O
such JJ O
as IN O
oral JJ O
, , O
topical JJ O
, , O
or CC O
sterile JJ O
parenteral JJ O
solutions NNS O
or CC O
suspensions NNS O
. . O

Tablets NNS O
and CC O
capsules NNS O
for IN O
oral JJ O
administration NN O
may MD O
be VB O
in IN O
unit NN O
dose NN O
presentation NN O
form NN O
, , O
and CC O
may MD O
contain VB O
conventional JJ O
excipients NNS O
such JJ O
as IN O
binding JJ O
agents NNS O
, , O
for IN O
example NN O
syrup NN O
, , O
acacia NN O
, , O
gelatin NN O
, , O
sorbitol NN B-NP
, , O
tragacanth NN O
, , O
or CC O
polyvinyl-pyrrolidone NN B-NP
; : O
fillers NNS O
for IN O
example NN O
lactose NN B-NP
, , O
sugar NN B-NP
, , O
maize-starch NN O
, , O
calcium NN B-NP
phosphate NN I-NP
, , O
sorbitol NN B-NP
or CC O
glycine NN B-NP
; : O
tabletting NN O
lubricant NN O
, , O
for IN O
example NN O
magnesium NN B-NP
stearate NN I-NP
, , O
talc NN B-NP
, , O
polyethylene NN B-NP
glycol NN I-NP
or CC O
silica NN B-NP
; : O
disintegrants NNS O
for IN O
example NN O
potato NN O
starch NN B-NP
, , O
or CC O
acceptable JJ O
wetting VBG B-NP
agents NNS I-NP
such JJ O
as IN O
sodium NN B-NP
lauryl NN I-NP
sulfate NN I-NP
. . O

The DT O
tablets NNS O
may MD O
be VB O
coated JJ O
according VBG O
to TO O
methods NNS O
well RB O
known VBN O
in IN O
normal JJ O
pharmaceutical JJ O
practice NN O
. . O

Oral NNP O
liquid NN O
preparations NNS O
may MD O
be VB O
in IN O
the DT O
form NN O
of IN O
, , O
for IN O
example NN O
, , O
aqueous JJ O
or CC O
oily JJ O
suspensions NNS O
, , O
solutions NNS O
, , O
emulsions NNS O
, , O
syrups NNS O
or CC O
elixirs NNS O
, , O
or CC O
may MD O
be VB O
presented VBN O
as IN O
a DT O
dry JJ O
product NN O
for IN O
reconstitution NN O
with IN O
water NN B-NP
or CC O
other JJ O
suitable JJ O
vehicle NN O
before IN O
use NN O
. . O

Such JJ O
liquid NN O
preparations NNS O
may MD O
contain VB O
conventional JJ O
additives NNS O
such JJ O
as IN O
suspending VBG O
agents NNS O
, , O
for IN O
example NN O
sorbitol NN B-NP
, , O
syrup NN O
, , O
methyl NN B-NP
cellulose NN I-NP
, , O
glucose NN O
syrup NN O
, , O
gelatin VBG O
hydrogenated JJ O
edible JJ O
fats NNS O
; : O
emulsifying VBG O
agents NNS O
, , O
for IN O
example NN O
lecithin JJ B-NP
, , O
sorbitan JJ B-NP
monooleate NN I-NP
, , O
or CC O
acacia NN O
; : O
nonaqueous JJ O
vehicles NNS O
( -LRB- O
which WDT O
may MD O
include VB O
edible JJ O
oils NNS O
) -RRB- O
, , O
for IN O
example NN O
almond CC O
oil NN O
, , O
fractionated VBD O
coconut JJ O
oil NN O
, , O
oily JJ O
esters NNS B-NP
such JJ O
as IN O
glycerine NN B-NP
, , O
propylene NN B-NP
glycol NN I-NP
, , O
or CC O
ethyl NN B-NP
alcohol NN I-NP
; : O
preservatives NNS O
, , O
for IN O
example NN O
methyl NN B-NP
or CC O
propyl NN B-NP
p-hydroxybenzoate NN I-NP
or CC O
sorbic JJ B-NP
acid NN I-NP
, , O
and CC O
if IN O
desired VBN O
conventional JJ O
flavouring NN O
or CC O
colouring VBG O
agents NNS O
. . O

For IN O
topical JJ O
application NN O
to TO O
the DT O
skin NN O
, , O
the DT O
drug NN O
may MD O
be VB O
made VBN O
up RP O
into IN O
a DT O
cream NN O
, , O
lotion NN O
or CC O
ointment NN O
. . O

Cream NN O
or CC O
ointment NN O
formulations NNS O
which WDT O
may MD O
be VB O
used VBN O
for IN O
the DT O
drug NN O
are VBP O
conventional JJ O
formulations NNS O
well RB O
known VBN O
in IN O
the DT O
art NN O
, , O
for IN O
example NN O
as IN O
described VBN O
in IN O
standard JJ O
textbooks NNS O
of IN O
pharmaceutics NNS O
such JJ O
as IN O
the DT O
British JJ O
Pharmacopoeia NNP O
. . O

The DT O
drug NN O
may MD O
also RB O
be VB O
formulated VBN O
for IN O
inhalation NN O
, , O
for IN O
example NN O
as IN O
a DT O
nasal NN O
spray NN O
, , O
or CC O
dry JJ O
powder NN O
or CC O
aerosol NN O
inhalers NNS O
. . O

For IN O
delivery NN O
by IN O
inhalation NN O
, , O
the DT O
active JJ O
compound NN O
is VBZ O
preferably RB O
in IN O
the DT O
form NN O
of IN O
microparticles NNS O
. . O

They PRP O
may MD O
be VB O
prepared VBN O
by IN O
a DT O
variety NN O
of IN O
techniques NNS O
, , O
including VBG O
spray-drying NN O
, , O
freeze-drying JJ O
and CC O
micronisation NN O
. . O

Aerosol NNP O
generation NN O
can MD O
be VB O
carried VBN O
out RP O
using VBG O
, , O
for IN O
example NN O
, , O
pressure-driven JJ O
jet NN O
atomizers NNS O
or CC O
ultrasonic JJ O
atomizers NNS O
, , O
preferably RB O
using VBG O
propellant-driven JJ O
metered JJ O
aerosols NNS O
or CC O
propellant-free JJ O
administration NN O
of IN O
micronized JJ O
active JJ O
compounds NNS O
from IN O
, , O
for IN O
example NN O
, , O
inhalation IN O
capsules NNS O
or CC O
other JJ O
"dry JJ O
powder NN O
" '' O
delivery NN O
systems NNS O
. . O

The DT O
active JJ O
ingredient NN O
may MD O
also RB O
be VB O
administered VBN O
parenterally RB O
in IN O
a DT O
sterile JJ O
medium NN O
. . O

Depending VBG O
on IN O
the DT O
vehicle NN O
and CC O
concentration NN O
used VBN O
, , O
the DT O
drug NN O
can MD O
either RB O
be VB O
suspended VBN O
or CC O
dissolved VBN O
in IN O
the DT O
vehicle NN O
. . O

Advantageously RB O
, , O
adjuvants NNS O
such JJ O
as IN O
a DT O
local JJ O
anaesthetic JJ O
, , O
preservative JJ O
and CC O
buffering VBG O
agents NNS O
can MD O
be VB O
dissolved VBN O
in IN O
the DT O
vehicle NN O
. . O

Other JJ O
compounds NNS O
may MD O
be VB O
combined VBN O
with IN O
compounds NNS O
of IN O
this DT O
invention NN O
of IN O
formula NN O
[ NN O
I] NN O
for IN O
the DT O
prevention NN O
and CC O
treatment NN O
of IN O
prostaglandin-mediated JJ O
diseases NNS O
. . O

Thus RB O
the DT O
present JJ O
invention NN O
is VBZ O
also RB O
concerned VBN O
with IN O
pharmaceutical JJ O
compositions NNS O
for IN O
preventing VBG O
and CC O
treating VBG O
PGD2-mediated JJ B-NP
diseases NNS O
comprising VBG O
a DT O
therapeutically RB O
effective JJ O
amount NN O
of IN O
a DT O
compound NN O
of IN O
the DT O
invention NN O
of IN O
formula NN O
[ VBN O
I] NNP O
and CC O
one CD O
or CC O
more JJR O
other JJ O
therapeutic JJ O
agents NNS O
. . O

Suitable JJ O
therapeutic JJ O
agents NNS O
for IN O
a DT O
combination NN O
therapy NN O
with IN O
compounds NNS O
of IN O
formula NN O
[ VBN O
I] NNP O
include VBP O
, , O
but CC O
are VBP O
not RB O
limited VBN O
to TO O
: : O
( -LRB- O
1 CD O
) -RRB- O
corticosteroids NNS O
, , O
such JJ O
as IN O
fluticasone NN B-NP
, , O
ciclesonide NN B-NP
or CC O
budesonide NN B-NP
; : O
( -LRB- O
2 CD O
) -RRB- O
[beta]2-adrenoreceptor NN O
agonists NNS O
, , O
such JJ O
as IN O
salmeterol NN B-NP
, , O
indacaterol NN B-NP
or CC O
formoterol NN B-NP
; : O
( -LRB- O
3 CD O
) -RRB- O
leukotriene NN O
modulators NNS O
, , O
for IN O
example NN O
leukotriene NN O
antagonists NNS O
such JJ O
as IN O
montelukast NN B-NP
, , O
zafirulast NN B-NP
or CC O
pranlukast NN B-NP
or CC O
leukotriene NN O
biosynthesis NN O
inhibitors NNS O
such JJ O
as IN O
Zileuton NNP B-NP
or CC O
BAY-1005 CD O
; : O
( -LRB- O
4 CD O
) -RRB- O
anticholinergic JJ O
agents NNS O
, , O
for IN O
example NN O
muscarinic-3 JJ O
( -LRB- O
M3 IN O
) -RRB- O
receptor NN O
antagonists NNS O
such JJ O
as IN O
tiotropium NN B-NP
bromide NN B-NP
; : O
( -LRB- O
5 CD O
) -RRB- O
phosphodiesterase-IV NN O
( -LRB- O
PDE-IV NNP O
) -RRB- O
inhibitors NNS O
, , O
such JJ O
as IN O
roflumilast JJ B-NP
or CC O
cilomilast JJ B-NP
; : O
( -LRB- O
6 CD O
) -RRB- O
antihistamines NNS O
, , O
for IN O
example NN O
selective JJ O
histamine-1 NN O
( -LRB- O
H1 NNP O
) -RRB- O
receptor NN O
antagonists NNS O
, , O
such JJ O
as IN O
fexofenadine NN B-NP
, , O
citirizine NN B-NP
, , O
loratidine JJ B-NP
or CC O
astemizole JJ B-NP
; : O
( -LRB- O
7 CD O
) -RRB- O
antitussive JJ O
agents NNS O
, , O
such JJ O
as IN O
codeine NN B-NP
or CC O
dextramorphan JJ B-NP
; : O
( -LRB- O
8 CD O
) -RRB- O
non-selective JJ O
COX-1 JJ O
/ NN O
COX-2 NN O
inhibitors NNS O
, , O
such JJ O
as IN O
ibuprofen NN B-NP
or CC O
ketoprofen NN B-NP
; : O
( -LRB- O
9 CD O
) -RRB- O
COX-2 NN O
inhibitors NNS O
, , O
such JJ O
as IN O
celecoxib NN B-NP
and CC O
rofecoxib NN B-NP
; : O
( -LRB- O
10 CD O
) -RRB- O
VLA-4 NN O
antagonists NNS O
, , O
such JJ O
as IN O
those DT O
described VBN O
in IN O
WO97/03094 NNP O
and CC O
WO97/02289 CD O
; : O
( -LRB- O
11 CD O
) -RRB- O
TACE NNP O
inhibitors NNS O
and CC O
TNF-[alpha] JJ O
inhibitors NNS O
, , O
for IN O
example NN O
anti-TNF JJ O
monoclonal JJ O
antibodies NNS O
, , O
such JJ O
as IN O
Remicade NNP B-NP
and CC O
CDP-870 NNP O
and CC O
TNF NNP O
receptor NN O
immunoglobulin NN O
molecules NNS O
, , O
such JJ O
as IN O
Enbrel NNP O
; : O
( -LRB- O
12 CD O
) -RRB- O
inhibitors NNS O
of IN O
matrix NN O
metalloprotease NN O
, , O
for IN O
example NN O
MMP12 CD O
; : O
( -LRB- O
13 CD O
) -RRB- O
human NN O
neutrophil NN O
elastase NN O
inhibitors NNS O
, , O
such JJ O
as IN O
those DT O
described VBN O
in IN O
WO2005/026124 CD O
, , O
WO2003/053930 CD O
and CC O
WO06/082412 CD O
; : O
( -LRB- O
14 CD O
) -RRB- O
A2a . O
agonists NNS O
such JJ O
as IN O
those DT O
described VBN O
in IN O
EP1052264 NNP O
and CC O
EP1241176 NNP O
( -LRB- O
15 CD O
) -RRB- O
A2b IN O
antagonists NNS O
such JJ O
as IN O
those DT O
described VBN O
in IN O
WO2002/42298 CD O
; : O
( -LRB- O
16 CD O
) -RRB- O
modulators NNS O
of IN O
chemokine NN O
receptor NN O
function NN O
, , O
for IN O
example NN O
antagonists NNS O
of IN O
CCR3 NNP O
and CC O
CCR8 PRP O
; : O
( -LRB- O
17 CD O
) -RRB- O
compounds NNS O
which WDT O
modulate VBP O
the DT O
action NN O
of IN O
other JJ O
prostanoid JJ O
receptors NNS O
, , O
for IN O
example NN O
a DT O
DP NNP O
receptor NN O
antagonist NN O
or CC O
a DT O
thromboxane NN B-NP
A2 IN O
antagonist NN O
; : O
and CC O
( -LRB- O
18 CD O
) -RRB- O
agents NNS O
that WDT O
modulate VBP O
Th2 DT O
function NN O
, , O
such JJ O
as IN O
PPAR NNP O
agonists NNS O

The DT O
weight NN O
ratio NN O
of IN O
the DT O
compound NN O
of IN O
the DT O
invention NN O
to TO O
the DT O
second JJ O
active JJ O
ingredient NN O
may MD O
be VB O
varied VBN O
and CC O
will MD O
depend VB O
upon IN O
the DT O
effective JJ O
dose NN O
of IN O
each DT O
ingredient NN O
. . O

Generally RB O
, , O
an DT O
effective JJ O
dose NN O
of IN O
each DT O
will MD O
be VB O
used VBN O
. . O

Methods NNS O
of IN O
Synthesis NN O

The DT O
present JJ O
invention NN O
is VBZ O
also RB O
concerned JJ O
with IN O
processes NNS O
for IN O
preparing VBG O
the DT O
compounds NNS O
of IN O
this DT O
invention NN O
. . O

The DT O
compounds NNS O
can MD O
be VB O
prepared VBN O
according VBG O
to TO O
the DT O
procedures NNS O
of IN O
the DT O
following VBG O
schemes NNS O
and CC O
examples NNS O
, , O
using VBG O
appropriate JJ O
materials NNS O
, , O
and CC O
are VBP O
further JJ O
exemplified VBN O
by IN O
the DT O
following VBG O
specific JJ O
examples NNS O
. . O

Moreover RB O
, , O
by IN O
utilizing VBG O
the DT O
procedures NNS O
described VBN O
with IN O
the DT O
disclosure NN O
contained VBD O
herein RB O
, , O
one CD O
of IN O
ordinary JJ O
skill NN O
in IN O
the DT O
art NN O
can MD O
readily RB O
prepare VB O
additional JJ O
compounds NNS O
of IN O
the DT O
present JJ O
invention NN O
claimed VBD O
herein RB O
. . O

The DT O
compounds NNS O
illustrated VBD O
in IN O
the DT O
examples NNS O
are VBP O
not RB O
, , O
however RB O
, , O
to TO O
be VB O
construed VBN O
as IN O
forming VBG O
the DT O
only JJ O
genus NN O
that WDT O
is VBZ O
considered VBN O
as IN O
the DT O
invention NN O
. . O

The DT O
examples NNS O
further RB O
illustrate VBP O
details NNS O
for IN O
the DT O
preparation NN O
of IN O
the DT O
compounds NNS O
of IN O
the DT O
present JJ O
invention NN O
. . O

Those DT O
skilled JJ O
in IN O
the DT O
art NN O
will MD O
readily RB O
understand VB O
that DT O
known JJ O
variations NNS O
of IN O
the DT O
conditions NNS O
and CC O
processes NNS O
of IN O
the DT O
following VBG O
preparative JJ O
procedures NNS O
can MD O
be VB O
used VBN O
to TO O
prepare VB O
these DT O
compounds NNS O
. . O

Compounds NNS O
of IN O
formula NN O
[l-a] NN O
, , O
wherein WRB O
R<1> NNP O
, , O
R<2> NNP O
, , O
R<3> NNP O
, , O
R<4> NNP O
, , O
R<5> NNP O
, , O
R<6> NNP O
, , O
R<7> NNP O
, , O
R<8> NNP O
and CC O
R<9> NNP O
are VBP O
as IN O
defined VBN O
for IN O
formula NN O
[ IN O
I] NN O
above IN O
, , O
may MD O
be VB O
prepared VBN O
from IN O
compounds NNS O
of IN O
formula NN O
[ll-a] , O
wherein WRB O
X NNP O
represents VBZ O
an DT O
appropriate JJ O
ester NN O
protecting VBG O
group NN O
. . O

Suitable JJ O
ester NN O
protecting VBG O
groups NNS O
include VBP O
, , O
for IN O
example NN O
, , O
methyl NN B-NP
or CC O
ethyl NN B-NP
, , O
which WDT O
may MD O
be VB O
removed VBN O
by IN O
acid NN O
- : O
or CC O
base-catalysed JJ O
aqueous JJ O
hydrolysis NN O
or CC O
by IN O
treatment NN O
with IN O
potassium NN B-NP
trimethylsilanoate NN I-NP
in IN O
a DT O
solvent NN O
such JJ O
as IN O
THF NNP B-NP
; : O
benzyl NN B-NP
, , O
which WDT O
may MD O
be VB O
removed VBN O
by IN O
catalytic JJ O
hydrogenation NN O
, , O
or CC O
te/f-butyl NN B-NP
, , O
which WDT O
may MD O
be VB O
removed VBN O
by IN O
treatment NN O
with IN O
a DT O
strong JJ O
acid NN O
such JJ O
as IN O
trifluoroacetic JJ B-NP
acid/dichloromethane NN I-NP
mixtures NNS O
, , O
or CC O
a DT O
solution NN O
of IN O
hydrogen NN B-NP
chloride NN I-NP
in IN O
dioxane NN B-NP
. . O

[0056] . O

EMI14.1 . O

Compounds NNS O
of IN O
formula NN O
[ll-a] NN O
may MD O
be VB O
prepared VBN O
from IN O
compounds NNS O
of IN O
formula NN O
[III NNS O
- : O
a] SYM O
, , O
wherein WRB O
R<1> NNP O
, , O
R<2> NNP O
, , O
R<3> NNP O
, , O
R<4> NNP O
, , O
R<5> NNP O
, , O
R<6> NNP O
, , O
R<7> NNP O
, , O
R<9> NNP O
and CC O
X NNP O
are VBP O
as IN O
defined VBN O
above IN O
, , O
by IN O
reaction NN O
with IN O
a DT O
compound NN O
of IN O
formula NN O
[VIII IN O
] NN O
wherein WRB O
R<8> NNP O
is VBZ O
as IN O
defined VBN O
above IN O
for IN O
general JJ O
formula NN O
[ IN O
I] NN O
. . O

[0058] . O

EMI14.2 NN O

[VIII NNP O
] NN O

The DT O
reaction NN O
solvent NN O
may MD O
be VB O
a DT O
polar JJ O
organic JJ O
solvent NN O
such JJ O
as IN O
pyridine NN B-NP
or CC O
tetrahydrofuran NN B-NP
. . O

Compounds NNS O
of IN O
formula NN O
[VIlI NNS O
] SYM O
are VBP O
well RB O
known VBN O
and CC O
are VBP O
either RB O
readily RB O
available JJ O
or CC O
can MD O
be VB O
prepared VBN O
by IN O
methods NNS O
well RB O
known VBN O
to TO O
those DT O
skilled JJ O
in IN O
the DT O
art NN O
. . O

Compounds NNS O
of IN O
formula NN O
[lll-a] NN O
may MD O
be VB O
prepared VBN O
by IN O
the DT O
reaction NN O
between IN O
a DT O
compound NN O
of IN O
formula NN O
[IV-a] NN O
, , O
wherein WRB O
R<1> NNP O
, , O
R<2> NNP O
, , O
R<3> NNP O
, , O
R<4> NNP O
R<5> NNP O
, , O
R<6> NNP O
, , O
R<7> NNP O
and CC O
X NNP O
are VBP O
as IN O
defined VBN O
above IN O
, , O
and CC O
an DT O
appropriate JJ O
compound NN O
of IN O
formula NN O
[IX] NN O
, , O
wherein WRB O
R<9> NNP O
is VBZ O
as IN O
defined VBN O
above IN O
, , O
and CC O
LG NNP O
represents VBZ O
a DT O
suitable JJ O
leaving NN O
group NN O
( -LRB- O
for IN O
example NN O
, , O
chloro NN B-NP
, , O
bromo NN B-NP
, , O
or CC O
methanesulfonyloxy NN B-NP
) -RRB- O
. . O

R-LG . O

[IX NNP O
] NN O

The DT O
transformation NN O
of IN O
compounds NNS O
of IN O
formula NN O
[V-a] NN O
, , O
wherein WRB O
R<1> NNP O
, , O
R<2> NNP O
, , O
R<3> NNP O
, , O
R<4> NNP O
R<5> NNP O
, , O

R<6> NNP O
, , O
R<7> NNP O
and CC O
X NNP O
are VBP O
as IN O
defined VBN O
above IN O
, , O
into IN O
those DT O
of IN O
formula NN O
[IV-a] NN O
may MD O
conveniently RB O
be VB O
achieved VBN O
by IN O
reduction NN O
with IN O
zinc/acetic JJ B-NP
acid NN O
or CC O
with IN O
hydrogen NN B-NP
in IN O
the DT O
presence NN O
of IN O
a DT O
suitable JJ O
catalyst NN O
, , O
such JJ O
as IN O
palladium NN B-NP
supported VBD O
on IN O
carbon NN O
. . O

Compounds NNS O
of IN O
formula NN O
[V-a] NN O
may MD O
be VB O
prepared VBN O
from IN O
compounds NNS O
of IN O
formula NN O
[Vl-a] NN O
, , O
wherein WRB O
R<1> NNP O
, , O
R<2> NNP O
, , O
R<3> NNP O
, , O
R<4> NNP O
R<5> NNP O
, , O
R<6> NNP O
R<7> NNP O
and CC O
X NNP O
are VBP O
as IN O
defined VBN O
above IN O
, , O
by IN O
nitration NN O
with IN O
nitric JJ B-NP
acid NN I-NP
and CC O
acetic JJ B-NP
anhydride NN I-NP
, , O
at IN O
a DT O
temperature NN O
between IN O
-8O<0>C JJ O
and CC O
room NN O
temperature NN O
. . O

Compounds NNS O
of IN O
formula NN O
[Vl-a] NN O
may MD O
be VB O
prepared VBN O
from IN O
compounds NNS O
of IN O
formula NN O
[Vll-a] NN O
, , O
wherein WRB O
R<1> NNP O
, , O
R<2> NNP O
, , O
R<3> NNP O
, , O
R<4> NNP O
and CC O
R<7> NNP O
are VBP O
as IN O
defined VBN O
above IN O
, , O
by IN O
reaction NN O
with IN O
a DT O
compound NN O
of IN O
general JJ O
formula NN O
[X] NN O
, , O
wherein WRB O
R<5> NNP O
and CC O
R<6> NNP O
are VBP O
as IN O
defined VBN O
in IN O
formula NN O
[ IN O
I] NNP O
, , O
X NNP O
is VBZ O
as IN O
defined VBN O
above IN O
and CC O
LG NNP O
is VBZ O
a DT O
leaving VBG O
group NN O
, , O
such JJ O
as IN O
a DT O
halogen NN B-NP
, , O
particularly RB O
chlorine NN B-NP
, , O
bromine NN B-NP
or CC O
an DT O
iodine JJ B-NP
atom NN O
. . O

Typically RB O
, , O
the DT O
alkylation NN O
reaction NN O
is VBZ O
carried VBN O
out RP O
in IN O
the DT O
presence NN O
of IN O
a DT O
base NN O
( -LRB- O
for IN O
example NN O
, , O
potassium NN B-NP
carbonate NN I-NP
) -RRB- O
in IN O
an DT O
inert JJ O
solvent NN O
( -LRB- O
for IN O
example NN O
, , B-NP
[ NNP I-NP
Lambda]/ NNP I-NP
,[Lambda]/-dimethylformamide NNP I-NP
) -RRB- O
. . O

[0068 CD O
] NN O

EMI15.1 . O

M NNP O

Compounds NNS O
of IN O
general JJ O
formula NN O
[Vll-a] NN O
are VBP O
well RB O
known VBN O
and CC O
are VBP O
either RB O
readily RB O
available JJ O
or CC O
can MD O
be VB O
prepared VBN O
by IN O
methods NNS O
well RB O
known VBN O
to TO O
those DT O
skilled JJ O
in IN O
the DT O
art NN O
. . O

Examples NNS O
The DT O
invention NN O
will MD O
now RB O
be VB O
described VBN O
in IN O
detail NN O
with IN O
reference NN O
to TO O
the DT O
following VBG O
examples NNS O
. . O

It PRP O
will MD O
be VB O
appreciated VBN O
that IN O
the DT O
invention NN O
is VBZ O
described VBN O
by IN O
way NN O
of IN O
example NN O
only RB O
and CC O
modification NN O
of IN O
detail NN O
may MD O
be VB O
made VBN O
without IN O
departing VBG O
from IN O
the DT O
scope NN O
of IN O
the DT O
invention NN O
. . O

<1>H NNP B-NP
NMR NNP O
spectra NN O
were VBD O
recorded VBN O
at IN O
ambient JJ O
temperature NN O
using VBG O
a DT O
Varian JJ O
Unity NN O

Inova NNP O
( -LRB- O
400MHz CD O
) -RRB- O
spectrometer NN O
with IN O
a DT O
triple JJ O
resonance NN O
5 CD O
mm CD O
probe NN O
spectrometer NN O
. . O

Chemical NNP O
shifts NNS O
are VBP O
expressed VBN O
in IN O
ppm NN O
relative JJ O
to TO O
tetramethylsilane NN B-NP
. . O

The DT O
following VBG O
abbreviations NNS O
have VBP O
been VBN O
used VBN O
: : O
br NN O
s VBZ O
= SYM O
broad JJ O
singlet NN O
, , O
s VBZ O
= SYM O
singlet NN O
, , O
d VBD O
= SYM O
doublet VB O
, , O
dd VB O
= SYM O
double JJ O
doublet NN O
, , O
t NN O
= SYM O
triplet NN O
, , O
q NNP O
= SYM O
quartet NN O
, , O
m NN O
= SYM O
multiplet VB O
. . O

Mass NNP O
Spectrometry NNP O
(LCMS NNP O
) -RRB- O
experiments NNS O
to TO O
determine VB O
retention NN O
times NNS O
and CC O
associated VBN O
mass NN O
ions NNS O
were VBD O
performed VBN O
using VBG O
the DT O
following JJ O
methods NNS O
: : O
Method NNP O
A: NNPS O
experiments NNS O
were VBD O
performed VBN O
on IN O
a DT O
Micromass NNP O
Platform NNP O
LCT NNP O
spectrometer NN O
with IN O
positive JJ O
ion NN O
electrospray NN O
and CC O
single JJ O
wavelength NN O
UV NN O
254 CD O
nm NN O
detection NN O
using VBG O
a DT O
Higgins NNP O
Clipeus NNP O
C18 IN O
5 CD O
[mu]m IN O
100 CD O
x NN O
3.0 CD O
mm CD O
column NN O
and CC O
a DT O
2 CD O
mL/minute NN O
flow NN O
rate NN O
. . O

The DT O
initial JJ O
solvent NN O
system NN O
was VBD O
95 CD O
% NN O
water NN B-NP
containing VBG O
0.1 CD O
% NN O
formic JJ B-NP
acid NN I-NP
( -LRB- O
solvent NN O
A) NN O
and CC O
5 CD O
% NN O
acetonithle NN B-NP
containing VBG O
0.1 CD O
% NN O
formic JJ B-NP
acid NN I-NP
( -LRB- O
solvent NN O
B) NN O
for IN O
the DT O
first JJ O
minute NN O
followed VBN O
by IN O
a DT O
gradient NN O
up IN O
to TO O
5 CD O
% NN O
solvent NN O
A NNP O
and CC O
95 CD O
% NN O
solvent NN O
B NNP O
over IN O
the DT O
next JJ O
14 CD O
minutes NNS O
. . O

The DT O
final JJ O
solvent NN O
system NN O
was VBD O
held VBN O
constant JJ O
for IN O
a DT O
further RBR O
2 CD O
minutes NNS O
. . O

Method NNP O
B NNP O
: : O
experiments NNS O
were VBD O
performed VBN O
on IN O
a DT O
Micromass NNP O
Platform NNP O
LC NNP O
spectrometer NN O
with IN O
positive JJ O
and CC O
negative JJ O
ion NN O
electrospray NN O
and CC O
ELS/Diode NNP O
array NN O
detection NN O
using VBG O
a DT O
Phenomenex NNP O
Luna NNP O
C18( JJ O
2 CD O
) -RRB- O
30 CD O
x NN O
4.6 CD O
mm CD O
column NN O
and CC O
a DT O
2 CD O
mL/minute NN O
flow NN O
rate NN O
. . O

The DT O
solvent JJ O
system NN O
was VBD O
95 CD O
% NN O
solvent NN O
A DT O
and CC O
5 CD O
% NN O
solvent NN O
B NNP O
for IN O
the DT O
first JJ O
0.50 CD O
minutes NNS O
followed VBN O
by IN O
a DT O
gradient NN O
up IN O
to TO O
5 CD O
% NN O
solvent NN O
A NNP O
and CC O
95 CD O
% NN O
solvent NN O
B NNP O
over IN O
the DT O
next JJ O
4 CD O
minutes NNS O
. . O

The DT O
final JJ O
solvent NN O
system NN O
was VBD O
held VBN O
constant JJ O
for IN O
a DT O
further JJ O
0.50 CD O
minutes NNS O

Microwave NNP O
experiments NNS O
were VBD O
carried VBN O
out RP O
using VBG O
a DT O
Personal NNP O
Chemistry NNP O
Smith NNP O
Synthesizer( NNP O
TM) NNP O
, , O
which WDT O
uses VBZ O
a DT O
single-mode NN O
resonator NN O
and CC O
dynamic JJ O
field NN O
tuning NN O
, , O
both DT O
of IN O
which WDT O
give VBP O
reproducibility NN O
and CC O
control NN O
. . O

Temperatures NNS O
from IN O
40-250<0>C DT O
can MD O
be VB O
achieved VBN O
, , O
and CC O
pressures NNS O
of IN O
up RB O
to TO O
20 CD O
bar NN O
can MD O
be VB O
reached VBN O
. . O

Two CD O
types NNS O
of IN O
vial JJ O
are VBP O
available JJ O
for IN O
this DT O
processor NN O
, , O
0.5-2.0 CD O

mL NN O
and CC O
2.0-5.0 CD O
mL NNS O

Reverse-phase NN O
preparative JJ O
HPLC NNP O
purifications NNS O
were VBD O
carried VBN O
out RP O
using VBG O
Genesis NNP O
7 CD O
micron NN O
C-18 NN O
bonded VBD O
silica JJ B-NP
stationary JJ O
phase NN O
in IN O
columns NNS O
10 CD O
cm NN O
in IN O
le[eta]gth NN O
and CC O
2 CD O
cm JJ O
internal JJ O
diameter NN O
. . O

The DT O
mobile JJ O
phase NN O
used VBN O
was VBD O
mixtures NNS O
of IN O
acetonitrile NN B-NP
and CC O
water NN B-NP
( -LRB- O
both DT O
buffered VBN O
with IN O
01 CD O
% NN O
v/v NN O
trifluoroacetic JJ B-NP
acid NN I-NP
) -RRB- O
with IN O
a DT O
flow NN O
rate NN O
of IN O
10 CD O
mL NNS O
per IN O
minute NN O
and CC O
typical JJ O
gradients NNS O
of IN O
40 CD O
to TO O
90 CD O
% NN O
organic JJ O
modifier NN O
ramped VBD O
up RP O
over IN O
30 CD O
to TO O
40 CD O
minutes NNS O
. . O

Fractions NNS O
containing VBG O
the DT O
required JJ O
product NN O
( -LRB- O
identified VBN O
by IN O
LC-MS JJ O
analysis NN O
) -RRB- O
were VBD O
pooled VBN O
, , O
the DT O
organic JJ O
fraction NN O
removed VBN O
by IN O
evaporation NN O
, , O
and CC O
the DT O
remaining VBG O
aqueous JJ O
fraction NN O
lyophilised VBD O
, , O
to TO O
give VB O
the DT O
final JJ O
product NN O
. . O

Example NNP O
1 CD O
: : O
[5-chloro-3-(4-chlorobenzenesulf JJ B-NP
onylamino)-2-methylindol-1 JJ I-NP
- : I-NP
yl]acetic JJ I-NP
acid NN I-NP
(l-a NN O
: : O
R<1> NNP O
, , O
R<3> NNP O
, , O
R<4> NNP O
, , O
R<5> NNP O
, , O
R<6> NNP O
, , O
R<9> NNP O
= SYM O
H NNP O
, , O
R<2> NNP O
= SYM O
Cl NNP B-NP
, , O
R<7> DT O
= SYM O
CH3 JJ B-NP
, , O
R<8> JJ O
= SYM O
4-CIPh JJ B-NP
) -RRB- O

[0076] . O

EMI17.1 . O

Preparation NN O
1a VBD O
( -LRB- B-NP
[delta]-chloro^-methylindol-i-yljacetic JJ I-NP
acid NN I-NP
methyl NN I-NP
ester NN I-NP

A DT O
mixture NN O
of IN O
5-chloro-2-methyl-1 JJ B-NP
H-indole JJ I-NP
( -LRB- O
1.0 CD O
g NN O
) -RRB- O
, , O
bromoacetic JJ B-NP
acid NN I-NP
methyl NN I-NP
ester NN I-NP
( -LRB- O
0.83 CD O
mL NN O
) -RRB- O
, , O
potassium NN B-NP
carbonate NN I-NP
( -LRB- O
2.5 CD O
g NN O
) -RRB- O
and CC O
[ NNP B-NP
Lambda]/ NNP I-NP
,/V-dimethylformamide NNP I-NP
( -LRB- O
7.0 CD O
ml_ NN O
) -RRB- O
was VBD O
stirred VBN O
at IN O
45<0>C JJ O
overnight JJ O
. . O

The DT O
reaction NN O
mixture NN O
was VBD O
diluted VBN O
with IN O
1.0 CD O
M NNP O
aqueous JJ O
hydrochloric JJ B-NP
acid NN I-NP
and CC O
the DT O
resulting VBG O
precipitate NN O
collected VBN O
by IN O
filtration NN O
and CC O
dried VBD O
to TO O
afford VB O
(5-chloro-2-methyl-indol-1-yl JJ B-NP
)acetic JJ I-NP
acid NN I-NP
methyl NN I-NP
ester NN I-NP
, , O
1.3 CD O
g NN O
. . O

<1>H JJ B-NP
NMR NNP O
( -LRB- O
DMSO-d6 NN B-NP
) -RRB- O
: : O
[delta JJ O
] SYM O
2.30 FW O
( -LRB- O
d NN O
, , O
J NNP O
= SYM O
0.9 CD O
Hz NNP O
, , O
3H) NNP O
, , O
3.70 CD O
( -LRB- O
s VBZ O
, , O
3H) CC O
, , O
5.10 CD O
( -LRB- O
s VBZ O
, , O
2H) CC O
, , O
6.25 CD O
( -LRB- O
t NN O
, , O
J NNP O
= SYM O
0.9 CD O
Hz NNP O
, , O
1H) JJ O
, , O
7.05 CD O
( -LRB- O
dd NN O
, , O
J NNP O
= SYM O
1.9 CD O
, , O
8.7 CD O
Hz NNP O
, , O
1H) CD O
, , O
7.40 CD O
( -LRB- O
d NN O
, , O
J NNP O
= SYM O
8.7 CD O
Hz NNP O
, , O
1H) JJ O
, , O
7.45 CD O
( -LRB- O
d NN O
, , O
J NNP O
= SYM O
1.9 CD O
Hz NNP O
, , O
1H) CD O
. . O

Preparation NNP O
1 CD O
b NN O
(5-chloro-2-methyl-3-nitroindol-1-yl JJ B-NP
)acetic JJ I-NP
acid NN I-NP
methyl NN I-NP
ester NN I-NP

Nitric JJ B-NP
acid NN I-NP
(90 VBD O
% NN O
, , O
0.74 CD O
mL NN O
) -RRB- O
was VBD O
added VBN O
to TO O
stirred VBN O
acetic JJ B-NP
anhydride NN I-NP
( -LRB- O
11 CD O
mL NN O
) -RRB- O
at IN O
O<0>C NNP O
and CC O
the DT O
resulting VBG O
solution NN O
was VBD O
left VBN O
to TO O
stand VB O
at IN O
room NN O
temperature NN O
for IN O
ten CD O
minutes NNS O
. . O

This DT O
solution NN O
was VBD O
added VBN O
slowly RB O
to TO O
a DT O
solution NN O
of IN O
(5-chloro-2-methyl-indol-1-yl JJ B-NP
)acetic JJ I-NP
acid NN I-NP
methyl NN I-NP
ester NN I-NP
( -LRB- O
1.3 CD O
g NN O
) -RRB- O
in IN O
acetic JJ B-NP
anhydride NN I-NP
( -LRB- O
27 CD O
mL NN O
) -RRB- O
at IN O
-7O<0>C NNP O
and CC O
the DT O
resulting VBG O
mixture NN O
was VBD O
allowed VBN O
to TO O
warm VB O
to TO O
room NN O
temperature NN O
over IN O
three CD O
hours NNS O
. . O

The DT O
reaction NN O
mixture NN O
was VBD O
poured VBN O
onto IN O
a DT O
mixture NN O
of IN O
ice NN O
and CC O
water NN B-NP
and CC O
stirred VBD O
for IN O
one CD O
hour NN O
. . O

The DT O
resulting VBG O
precipitate NN O
was VBD O
collected VBN O
by IN O
filtration NN O
and CC O
dried VBD O
to TO O
afford VB O
(5-chloro-2-methyl- DT B-NP
3-nitroindol-1-yl JJ I-NP
)acetic JJ I-NP
acid NN I-NP
methyl NN I-NP
ester NN I-NP
( -LRB- O
1.4 CD O
g NN O
) -RRB- O
. . O

<1>H JJ B-NP
NMR NNP O
( -LRB- O
DMSO-d6 NN B-NP
) -RRB- O
: : O
[delta JJ O
] SYM O
2.75 CD O
( -LRB- O
s VBZ O
, , O
3H) CC O
, , O
3.75 CD O
( -LRB- O
s VBZ O
, , O
3H) CC O
, , O
5.40 CD O
( -LRB- O
s VBZ O
, , O
2H) CC O
, , O
7.40 CD O
( -LRB- O
dd NN O
, , O
J NNP O
= SYM O
2.2 CD O
, , O
8.8 CD O
Hz NNP O
, , O
1H) JJ O
, , O
7.75 CD O
( -LRB- O
dd NN O
, , O
J NNP O
= SYM O
0.4 CD O
, , O
8.8 CD O
Hz NNP O
, , O
1H) IN O
, , O
8.10 CD O
( -LRB- O
dd NN O
, , O
J NNP O
= SYM O
0.4 CD O
, , O
2.2 CD O
Hz NNP O
, , O
1H) CD O
. . O

MS NNP O
: : O
ESI NNP O
( -LRB- O
+ve NN O
) -RRB- O
( -LRB- O
Method NNP O
B) NNP O
: : O
283 CD O
( -LRB- O
M+H) NNP O
, , O
Retention NNP O
time NN O
3.6 CD O
min NN O
. . O

Preparation NNP O
1c VBD O
(3-amino-5-chloro-2-methylindol-1-yl JJ B-NP
)acetic JJ I-NP
acid NN I-NP
methyl NN I-NP
ester NN I-NP
hydrochloride NN I-NP

Zinc NNP B-NP
dust NN O
( -LRB- O
3.0 CD O
g NN O
) -RRB- O
was VBD O
added VBN O
to TO O
a DT O
solution NN O
of IN O
(5-chloro-2-methyl-3-nitroindol-1- DT B-NP
yl NN I-NP
)acetic JJ I-NP
acid NN I-NP
methyl NN I-NP
ester NN I-NP
( -LRB- O
2.7 CD O
g NN O
) -RRB- O
in IN O
glacial JJ B-NP
acetic JJ I-NP
acid NN I-NP
( -LRB- O
150 CD O
mL NN O
) -RRB- O
and CC O
the DT O
resulting VBG O
mixture NN O
was VBD O
stirred VBN O
at IN O
room NN O
temperature NN O
for IN O
three CD O
hours NNS O
. . O

The DT O
reaction NN O
mixture NN O
was VBD O
filtered VBN O
and CC O
the DT O
filtrate NN O
concentrated VBD O
under IN O
reduced JJ O
pressure NN O
. . O

The DT O
residue NN O
was VBD O
dissolved VBN O
in IN O
methanol NN B-NP
and CC O
treated VBD O
with IN O
1.25 CD O
M NNP O
hydrochloric JJ B-NP
acid NN I-NP
in IN O
methanol NN B-NP
and CC O
the DT O
resulting VBG O
precipitate NN O
was VBD O
collected VBN O
by IN O
filtration NN O
and CC O
triturated VBD O
with IN O
diethyl NN B-NP
ether NN I-NP
to TO O
afford VB O
(S-amino-[delta]-chloro-a-methylindol-i-yOacetic JJ B-NP
acid NN I-NP
methyl NN I-NP
ester NN I-NP
hydrochloride NN I-NP
as IN O
a DT O
brown JJ O
solid JJ O
, , O
2.7 CD O
g NN O
. . O
MS NNP O
: : O
ESI NNP O
( -LRB- O
+ve NN O
) -RRB- O
( -LRB- O
Method NNP O
B) NNP O
: : O
253 CD O
( -LRB- O
M+H) NNP O
, , O
Retention NNP O
time NN O
1.9 CD O
min NN O
. . O

Preparation NNP O
1d VBD O
[5-chloro-3-(4-chlorobenzenesulfonylamino)-2-methylindol-1- DT B-NP
yl]acetic JJ I-NP
acid NN I-NP
methyl NN I-NP
ester NN I-NP

A DT O
mixture NN O
of IN O
4-chlorobenzenesulfonyl JJ B-NP
chloride NN I-NP
( -LRB- O
0.26 CD O
g NN O
) -RRB- O
, , O
(3-amino-5-chloro-2- CC B-NP
methylindol-1-yl JJ I-NP
)acetic JJ I-NP
acid NN I-NP
methyl NN I-NP
ester NN I-NP
hydrochloride NN I-NP
( -LRB- O
0.28 CD O
g NN O
) -RRB- O
, , O
triethylamine NN B-NP
( -LRB- O
0.47 CD O
imL NN O
) -RRB- O
and CC O
dichloromethane NN B-NP
( -LRB- O
10 CD O
ml_ NN O
) -RRB- O
was VBD O
stirred VBN O
at IN O
O<0>C NNP O
for IN O
seventy CD O
five CD O
minutes NNS O
. . O

The DT O
solvent NN O
was VBD O
removed VBN O
under IN O
reduced JJ O
pressure NN O
and CC O
purification NN O
of IN O
the DT O
residue NN O
by IN O
column NN O
chromatography NN O
on IN O
silica NN B-NP
gel NN O
, , O
eluting VBG O
with IN O
a DT O
mixture NN O
of IN O
diethyl NN B-NP
ether NN I-NP
and CC O
cyclohexane NN B-NP
( -LRB- O
2:3 CD O
by IN O
volume NN O
) -RRB- O
gave VBD O
[5-chloro-3-(4-chlorobenzenesulfonylamino)-2- DT B-NP
methylindol-1-yl]acetic JJ I-NP
acid NN I-NP
methyl NN I-NP
ester NN I-NP
, , O
0.17 CD O
g NN O
. . O

MS NNP O
: : O
ESI NNP O
( -LRB- O
+ve NN O
) -RRB- O
( -LRB- O
Method NNP O
B) NNP O
: : O
425 CD O
(M-H) NN O
, , O
Retention NNP O
time NN O
3.6 CD O
min NN O
. . O

Preparation NNP O
1 CD O
e NN O
[5-chloro-3-(4-ch JJ B-NP
!orobenzenesulf NN I-NP
onyIamino)-2-methylindol-1 JJ I-NP
- : I-NP
yl]acetic JJ I-NP
acid NN I-NP

A DT O
solution NN O
of IN O
[5-chloro-3-(4-chlorobenzenesulfonylamino)-2-methylindol-1- DT B-NP
yljacetic JJ I-NP
acid NN I-NP
methyl NN I-NP
ester NN I-NP
( -LRB- O
0.43 CD O
g NN O
) -RRB- O
, , O
ethanol FW B-NP
( -LRB- O
2.0 CD O
mL NN O
) -RRB- O
and CC O
4.0 CD O
M NNP O
aqueous JJ O
sodium NN B-NP
hydroxide NN I-NP
solution NN O
( -LRB- O
2.0 CD O
mL NN O
) -RRB- O
was VBD O
stirred VBN O
at IN O
room NN O
temperature NN O
for IN O
one CD O
hour NN O
. . O

The DT O
ethanol NN B-NP
was VBD O
removed VBN O
under IN O
reduced JJ O
pressure NN O
and CC O
the DT O
pH NN O
of IN O
the DT O
residue NN O
adjusted VBN O
to TO O
pH1 VB O
by IN O
the DT O
addition NN O
of IN O
1.0 CD O
M NNP O
aqueous JJ O
hydrochloric JJ B-NP
acid NN I-NP
. . O

The DT O
resulting VBG O
precipitate NN O
was VBD O
collected VBN O
by IN O
filtration NN O
and CC O
washed VBD O
with IN O
water NN B-NP
to TO O
afford VB O
after IN O
drying VBG O
, , O
[5-chloro-3-(4 CD B-NP
- : I-NP
chlorobenzenesulf NN I-NP
onylamino)-2-methylindol-1 JJ I-NP
-yl]acetic JJ I-NP
acid NN I-NP
, , O
0.34 CD O
g NN O
<1>H CD B-NP
NMR NNP O
( -LRB- O
DMSO-d6 NN B-NP
) -RRB- O
: : O
[delta JJ O
] SYM O
1.95 FW O
( -LRB- O
s PRP O
, , O
3H) CC O
, , O
4.95 CD O
( -LRB- O
s VBZ O
, , O
2H) CC O
, , O
6.80 CD O
( -LRB- O
m NN O
, , O
1 CD O
H) NNP O
, , O
7.00 CD O
( -LRB- O
m NN O
, , O
1 CD O
H) NNP O
, , O

7.35 CD O
( -LRB- O
d NN O
, , O
J NNP O
= SYM O
8.8 CD O
Hz NNP O
, , O
1 CD O
H) NNP O
, , O
7.55 CD O
( -LRB- O
m NN O
, , O
4H) JJ O
, , O
9.50 CD O
( -LRB- O
s VBZ O
, , O
1 CD O
H) NN O
, , O
13.1 CD O
( -LRB- O
br NN O
s VBZ O
, , O
1 CD O
H) NN O
. . O

MS NNP O
: : O
ESI NNP O
( -LRB- O
+ve NN O
) -RRB- O
( -LRB- O
Method NNP O
A) NNP O
: : O
413 CD O
( -LRB- O
M+H) NNP O
, , O
Retention NNP O
time NN O
10.3 CD O
min NN O
. . O

Example NNP O
2 CD O
: : O
[5-chloro-3-(2-chlorobenzenesulf NN B-NP
onylamino)-2-methylindol-1 JJ I-NP
- : I-NP
yl]acetic JJ I-NP
acid NN I-NP
(l-a NN O
: : O
R<1> NNP O
, , O
R<3> NNP O
, , O
R<4> NNP O
, , O
R<5> NNP O
, , O
R<6> NNP O
, , O
R<9> NNP O
= SYM O
H NNP O
, , O
R<2> NNP O
= SYM O
Cl NNP B-NP
, , O
R<7> NNP O
= SYM O
CH3 NNP B-NP
, , O
R<8> NNP O
= SYM O
2-CIPh JJ B-NP
) -RRB- O

[0090 CD O
] NN O

EMI18.1 . O

Preparation NNP O
2a CD O
[5-chloro-3-(2-chlorobenzenesulfonylamino)-2-methylindol-1 NN B-NP
- : I-NP
yl]acetic JJ I-NP
acid NN I-NP
methyl NN I-NP
ester NN I-NP

2-Chlorobenzenesulfonyl JJ B-NP
chloride NN I-NP
( -LRB- O
0.05 CD O
g NN O
) -RRB- O
was VBD O
added VBN O
to TO O
a DT O
stirred VBD O
solution NN O
of IN O
(3-amino-5-chloro-2-methylindol-1-yl JJ B-NP
)acetic JJ I-NP
acid NN I-NP
methyl NN I-NP
ester NN I-NP
hydrochloride NN I-NP
( -LRB- O
compound NN O
of IN O
Preparation NNP O
1c CD O
, , O
0.05 CD O
g NN O
) -RRB- O
in IN O
pyridine NN B-NP
( -LRB- O
5.0 CD O
ml_ NN O
) -RRB- O
at IN O
room NN O
temperature NN O
. . O

After IN O
one CD O
hour NN O
and CC O
thirty CD O
minutes NNS O
the DT O
pyridine NN B-NP
was VBD O
removed VBN O
under IN O
reduced JJ O
pressure NN O
. . O

The DT O
residue NN O
was VBD O
washed VBN O
with IN O
1.0 CD O
M NNP O
aqueous JJ O
hydrochloric JJ B-NP
acid NN I-NP
and CC O
then RB O
water NN B-NP
and CC O
dried VBD O
to TO O
afford VB O
[5-chloro-3-(2-chlorobenzenesulfonylamino)-2-methylindol-1-yl]acetic JJ B-NP
acid NN I-NP
methyl NN I-NP
ester NN I-NP
, , O
0.06 CD O
g NN O
. . O

MS NNP O
: : O
ESI NNP O
( -LRB- O
+ve NN O
) -RRB- O
( -LRB- O
Method NNP O
B) NNP O
: : O
425 CD O
(M-H) NN O
, , O
Retention NNP O
time NN O
3.7 CD O
min NN O
. . O

Preparation NNP O
2b VBD O
[5-chloro-3-(2-chlorobenzenesulfonylamino)-2-methylindol-1- DT B-NP
yl]acetic JJ I-NP
acid NN I-NP

A DT O
mixture NN O
of IN O
[5-chloro-3-(2-chlorobenzenesulfonylamino)-2-methylindol-1- CD B-NP
yl]acetic JJ I-NP
acid NN I-NP
methyl NN I-NP
ester NN I-NP
( -LRB- O
0.06 CD O
g NN O
) -RRB- O
, , O
potassium NN B-NP
trimethylsilanoate NN I-NP
( -LRB- O
0.05 CD O
g NN O
) -RRB- O
and CC O
tetrahydrofuran JJ B-NP
( -LRB- O
2.0 CD O
ml_ NN O
) -RRB- O
was VBD O
heated VBN O
by IN O
microwave NN O
irradiation NN O
at IN O
100<0>C CD O
for IN O
five CD O
minutes NNS O
. . O

The DT O
solvent NN O
was VBD O
removed VBN O
under IN O
reduced JJ O
pressure NN O
and CC O
the DT O
pH NN O
of IN O
the DT O
residue NN O
adjusted VBN O
to TO O
1 CD O
by IN O
the DT O
addition NN O
of IN O
concentrated JJ O
hydrochloric JJ B-NP
acid NN I-NP
. . O

The DT O
resulting VBG O
precipitate NN O
was VBD O
collected VBN O
by IN O
filtration NN O
, , O
washed VBN O
with IN O
water NN B-NP
and CC O
dried VBD O
to TO O
afford VB O
[5-chloro- DT B-NP
3-(2-chlorobenzenesulfonylamino)-2-methylindol-1-yl]acetic JJ I-NP
acid NN I-NP
, , O
0.035 CD O
g NN O
. . O
<1>H '' B-NP
NMR NNP O
( -LRB- O
DMSO-d6 NN B-NP
) -RRB- O
: : O
[delta JJ O
] SYM O
2.05 FW O
( -LRB- O
s PRP O
, , O
3H) CC O
, , O
4.90 CD O
( -LRB- O
s VBZ O
, , O
2H) CC O
, , O
7.00 CD O
( -LRB- O
m NN O
, , O
2H) JJ O
, , O
7.30-7.40 CD O

( -LRB- O
m NN O
, , O

2H) JJ O
, , O
7.60-7.70 CD O

( -LRB- O
m NN O
, , O
3H) NNP O
, , O
9.70 CD O
( -LRB- O
s VBZ O
, , O
1 CD O
H) NNP O
, , O
13.00 CD O
( -LRB- O
br NN O
s VBZ O
, , O
1H) UH O
. . O

MS NNP O
: : O
ESI NNP O
( -LRB- O
+ve NN O
) -RRB- O
( -LRB- O
Method NNP O
A) NNP O
: : O
413 CD O
( -LRB- O
M+H) NNP O
, , O
Retention NNP O
time NN O
9.8 CD O
min NN O
. . O

Example NNP O
3 CD O
: : B-NP
[5-chloro-2-methyl-3-(4-trifluoromethylbenzenesulfonylamino NN I-NP
)indol- NNS I-NP
1-yl]acetic JJ I-NP
acid NN I-NP
( -LRB- O
R<1> NNP O
, , O
R<3> NNP O
, , O
R<4> NNP O
, , O
R<5> NNP O
, , O
R<6> NNP O
, , O
R<9> NNP O
= SYM O
H NNP B-NP
, , O
R<2> NNP O
= SYM O
Cl NNP B-NP
, , O
R<7> NNP O
= SYM O
CH3 NNP B-NP
, , O
R<8> NNP O
= SYM O
4-CF3Ph JJ B-NP
) -RRB- O

[0096] . O

EMI19.1 . O

Preparation NNP O
3a CD O
[5-chloro-2-methyl-3-(4 CD B-NP
- : I-NP
trifluoromethylbenzenesulfonylamino NN I-NP
)indol-1-yl]acetic JJ I-NP
acid NN I-NP
methyl NN I-NP
ester NN I-NP
To TO O
a DT O
mixture NN O
of IN O
3-amino-5-chloro-2-methylindol-1-yl JJ B-NP
)acetic JJ I-NP
acid NN I-NP
methyl NN I-NP
ester NN I-NP
hydrochloride NN I-NP
( -LRB- O
compound NN O
of IN O
Preparation NNP O
1c CD O
, , O
0.15 CD O
g NN O
) -RRB- O
, , O
triethylamine NN B-NP
( -LRB- O
0.21 CD O
ml_ NN O
) -RRB- O
and CC O
tetrahydrofuran JJ B-NP
( -LRB- O
2.0 CD O
ml_ NN O
) -RRB- O
at IN O
-55<0>C NNP O
was VBD O
added VBN O
4-trifluoromethylbenzenesulf[omicron]nyl JJ B-NP
chloride NN I-NP
( -LRB- O
0.13 CD O
g NN O
) -RRB- O
and CC O
the DT O
resulting VBG O
mixture NN O
was VBD O
stirred VBN O
at IN O
-5O<0>C JJ O
for IN O
thirty CD O
minutes NNS O
. . O

The DT O
reaction NN O
mixture NN O
was VBD O
filtered VBN O
and CC O
the DT O
filtrate NN O
concentrated VBD O
under IN O
reduced JJ O
pressure NN O
. . O

Purification NN O
of IN O
the DT O
residue NN O
by IN O
column NN O
chromatography NN O
on IN O
silica NN B-NP
gel NN O
gave VBD O
[5-chloro-2- DT B-NP
methyl-3-(4-trifluoromethylbenzenesulfonylamino NN I-NP
)indol-1-yl]acetic JJ I-NP
acid NN I-NP
methyl NN I-NP
ester NN I-NP
, , O
0.13 CD O
g NN O
. . O

<1>H JJ B-NP
NMR NNP O
( -LRB- O
CD3OD NN O
) -RRB- O
: : O
[delta JJ O
] SYM O
2.10 CD O
( -LRB- O
s VBZ O
, , O
3H) CC O
, , O
3.75 CD O
( -LRB- O
s VBZ O
, , O
3H) CC O
, , O
4.95 CD O
( -LRB- O
s VBZ O
, , O
2H) CC O
, , O
6.70 CD O
( -LRB- O
d NN O
, , O
J NNP O
= SYM O
2.0 CD O
Hz NNP O
, , O
1 CD O
H) NNP O
, , O
6.95 CD O
( -LRB- O
dd NN O
, , O
J NNP O
= SYM O
2.0, CD O
8.7 CD O
Hz NNP O
, , O
1 CD O
H) NNP O
, , O
7.20 CD O
( -LRB- O
d NN O
, , O
J NNP O
= SYM O
8.7 CD O
Hz NNP O
, , O
1 CD O
H) NNP O
, , O
7.70-7.80 CD O

( -LRB- O
m NN O
, , O
4H) JJ O
. . O

MS NNP O
: : O
ESI NNP O
( -LRB- O
+ve NN O
) -RRB- O
( -LRB- O
Method NNP O
B) NNP O
: : O
459 CD O
(M-H)-, JJ O
Retention NNP O
time NN O
3.7 CD O
min NN O
. . O

Preparation NNP O
3b CD B-NP
[5-chloro-2-methyl-3-(4 CD I-NP
- : I-NP
trifluoromethylbenzenesulfonylamino NN I-NP
)indol-1-yl]acetic JJ I-NP
acid NN I-NP

A DT O
solution NN O
of IN O
[5-chloro-2-methyl-3-(4-trifluoromethylbenzenesulfonylamino) JJ B-NP
- : I-NP
indol-1-yl]acetic JJ I-NP
acid NN I-NP
methyl NN I-NP
ester NN I-NP
( -LRB- O
0.12 CD O
g NN O
) -RRB- O
, , O
tetrahydrofuran JJ B-NP
( -LRB- O
5.0 CD O
mL NN O
) -RRB- O
and CC O
4.0 CD O
M NNP O
aqueous JJ O
sodium NN B-NP
hydroxide NN I-NP
solution NN O
( -LRB- O
2.0 CD O
mL NN O
) -RRB- O
was VBD O
stirred VBN O
at IN O
room NN O
temperature NN O
for IN O
one CD O
hour NN O
. . O

The DT O
tetrahydrofuran NN B-NP
was VBD O
removed VBN O
under IN O
reduced JJ O
pressure NN O
and CC O
pH NN O
of IN O
the DT O
residue NN O
adjusted VBN O
to TO O
-3-4 VB O
by IN O
the DT O
addition NN O
of IN O
concentrated JJ O
hydrochloric JJ B-NP
acid NN I-NP
. . O

The DT O
resulting VBG O
precipitate NN O
was VBD O
collected VBN O
by IN O
filtration NN O
and CC O
dried VBD O
to TO O
afford VB O
[5-chloro-2-methyl- DT B-NP
3-(4-trifluoromethylbenzenesulfonylamino JJ I-NP
)indol-1-yl]acetic JJ I-NP
acid NN I-NP
, , O
0.05 CD O
g NN O
. . O

<1>H JJ B-NP
NMR NNP O
( -LRB- O
DMSO-d6 NN B-NP
) -RRB- O
: : O
[delta JJ O
] SYM O
2.00 CD O
( -LRB- O
s VBZ O
, , O
3H) CC O
, , O
4.65 CD O
( -LRB- O
s VBZ O
, , O
2H) CC O
, , O
6.60 CD O
( -LRB- O
d NN O
, , O
J NNP O
= SYM O
2.0 CD O
Hz NNP O
, , O
1 CD O
H) NN O
, , O
6.90 CD O
( -LRB- O
dd NN O
, , O
J NNP O
= SYM O
2.0, CD O
8.8 CD O
Hz NNP O
, , O
1 CD O
H) NNP O
, , O
7.30 CD O
( -LRB- O
d NN O
, , O
J NNP O
= SYM O
8.8 CD O
Hz NNP O
, , O
1 CD O
H) NNP O
, , O
7.75-7.85 CD O

( -LRB- O
m NN O
, , O
4H) JJ O
, , O
9.65 CD O
( -LRB- O
s VBZ O
, , O
1 CD O
H) NN O
. . O

MS NNP O
: : O
ESI NNP O
( -LRB- O
+ve NN O
) -RRB- O
( -LRB- O
Method NNP O
A) NNP O
: : O
447 CD O
( -LRB- O
M+H) NNP O
, , O
Retention NNP O
time NN O
10.6 CD O
min NN O
. . O

Example NNP O
4 CD O
: : O
[5-chloro-3-(4-methanesulfonylbenzenesulfonylamino)-2- DT B-NP
methylindol-1-yl]acetic JJ I-NP
acid NN I-NP
( -LRB- O
R<1> NNP O
, , O
R<3> NNP O
, , O
R<4> NNP O
, , O
R<5> NNP O
, , O
R<6> NNP O
, , O
R<9> NNP O
= SYM O
H NNP O
, , O
R<2> NNP O
= SYM O
Cl NNP B-NP
, , O
R<7> NNP O
= SYM O
CH3 NNP B-NP
, , O
R<8> NNP O
= SYM O
4- JJ B-NP
CH3SO2Ph NNP I-NP
) -RRB- O

[0103] . O

EMI20.1 . O

Preparation NNP O
4a VBD O
[5-chloro-3-(4-methanesulfonylbenzenesulfonyIamino)-2- DT B-NP
methylindol-1-yl]acetic JJ I-NP
acid NN I-NP
methyl NN I-NP
ester NN I-NP
To TO O
a DT O
mixture NN O
of IN O
3-amino-5-chloro-2-methylindol-1-yl JJ B-NP
)acetic JJ I-NP
acid NN I-NP
methyl NN I-NP
ester NN I-NP
hydrochloride NN I-NP
( -LRB- O
compound NN O
of IN O
Preparation NNP O
1c CD O
, , O
0.15 CD O
g NN O
) -RRB- O
, , O
triethylamine NN B-NP
( -LRB- O
0.21 CD O
mL NN O
) -RRB- O
and CC O
tetrahydrofuran JJ B-NP
( -LRB- O
2.0 CD O
mL NN O
) -RRB- O
at IN O
-55<0>C NNP O
was VBD O
added VBN O
4-methanesulfonylbenzenesulfonyl JJ B-NP
chloride NN I-NP
( -LRB- O
0.13 CD O
g NN O
) -RRB- O
and CC O
the DT O
resulting VBG O
mixture NN O
was VBD O
stirred VBN O
at IN O
-50<0>C JJ O
for IN O
thirty CD O
minutes NNS O
. . O

The DT O
reaction NN O
mixture NN O
was VBD O
filtered VBN O
and CC O
the DT O
filtrate NN O
concentrated VBD O
under IN O
reduced JJ O
pressure NN O
. . O

Purification NN O
of IN O
the DT O
residue NN O
by IN O
column NN O
chromatography NN O
on IN O
silica NN B-NP
gel NN O
gave VBD O
5-chloro-3- DT B-NP
( -LRB- I-NP
4-methanesulfonylbenzenesulfonylamino)-2-methylindol-1 JJ I-NP
-yl]acetic JJ I-NP
acid NN I-NP
methyl NN I-NP
ester NN I-NP
, , O
0.13 CD O
g NN O
. . O

MS NNP O
: : O
ESI NNP O
( -LRB- O
+ve NN O
) -RRB- O
( -LRB- O
Method NNP O
B) NNP O
: : O
469 CD O
(M-H) NN O
, , O
Retention NNP O
time NN O
3.1 CD O
min NN O
. . O

Preparation NNP O
4b VBD O
[5-chloro-3-(4-methanesulfonylbenzenesulfonylamino)-2- DT B-NP
methylindol-1-yl]acetic JJ I-NP
acid NN I-NP

A DT O
solution NN O
of IN O
[5-chloro-3-(4-methanesulfonylbenzenesulfonylamino)-2- DT B-NP
methylindol-1-yl]acetic JJ I-NP
acid NN I-NP
methyl NN I-NP
ester NN I-NP
( -LRB- O
0.13 CD O
g NN O
) -RRB- O
, , O
tetrahydrofuran JJ B-NP
( -LRB- O
5.0 CD O
ml_ NN O
) -RRB- O
and CC O
4.0 CD O
M NNP O
aqueous JJ O
sodium NN B-NP
hydroxide NN I-NP
solution NN O
( -LRB- O
2.0 CD O
ml_ NN O
) -RRB- O
was VBD O
stirred VBN O
at IN O
room NN O
temperature NN O
for IN O
one CD O
hour NN O
. . O

The DT O
tetrahydrofuran NN B-NP
was VBD O
removed VBN O
under IN O
reduced JJ O
pressure NN O
and CC O
pH NN O
of IN O
the DT O
residue NN O
adjusted VBN O
to TO O
-3-4 VB O
by IN O
the DT O
addition NN O
of IN O
concentrated JJ O
hydrochloric JJ B-NP
acid NN I-NP
. . O

The DT O
resulting VBG O
precipitate NN O
was VBD O
collected VBN O
by IN O
filtration NN O
and CC O
dried VBD O
to TO O
afford VB O
[5-chloro-3-(4 DT B-NP
- : I-NP
methanesulfonylbenzenesulfonylamino)-2-methylindol-1-yl]acetic JJ I-NP
acid NN I-NP
, , O
0.20 CD O
g NN O
. . O

<1>H JJ B-NP
NMR NNP O
( -LRB- O
DMSO-d6 NN B-NP
) -RRB- O
: : O
[delta JJ O
] SYM O
1.90 CD O
( -LRB- O
s VBZ O
, , O
3H) CC O
, , O
3.25 CD O
( -LRB- O
s VBZ O
, , O
3H) CC O
, , O
4.95 CD O
( -LRB- O
s VBZ O
, , O
2H) CC O
, , O
6.80 CD O
( -LRB- O
d NN O
, , O
J NNP O
= SYM O
2.2 CD O
Hz NNP O
, , O
1 CD O
H) NNP O
, , O
7.00 CD O
( -LRB- O
dd NN O
, , O
J NNP O
= SYM O
2.2 CD O
, , O
8.8 CD O
Hz NNP O
, , O
1 CD O
H) NNP O
, , O
7.40 CD O
( -LRB- O
d NN O
, , O
J NNP O
= SYM O
8.8 CD O
Hz NNP O
, , O
1 CD O
H) NNP O
, , O
7.8 CD O
( -LRB- O
m NN O
, , O
2H) JJ O
, , O
8.05 CD O
( -LRB- O
m NN O
, , O
2H) JJ O
, , O
9.95 CD O
( -LRB- O
s VBZ O
, , O
1 CD O
H) NNP O
, , O
13.10 CD O
( -LRB- O
br NN O
s VBZ O
, , O
1 CD O
H) NN O
. . O

MS NNP O
: : O
ESI NNP O
( -LRB- O
+V[ NN O
Theta] DT O
) -RRB- O
( -LRB- O
Method NNP O
A) NNP O
: : O
457 CD O
( -LRB- O
M+H) NNP O
, , O
Retention NNP O
time NN O
8.8 CD O
min NN O
. . O

Example NNP O
5 CD O
: : O
[5-chloro-3-(4-fluorobenzenesulfonyIamino)-2-methylindol-1- DT B-NP
yl]acetic JJ I-NP
acid NN I-NP
( -LRB- O
R<1> NNP O
, , O
R<3> NNP O
, , O
R<4> NNP O
, , O
R<5> NNP O
, , O
R<6> NNP O
, , O
R<9> NNP O
= SYM O
H NNP O
, , O
R<2> NNP O
= SYM O
Cl NNP B-NP
, , O
R<7> DT O
= SYM O
CH3 JJ B-NP
, , O
R<8> JJ O
= SYM O
4-FPh JJ B-NP
) -RRB- O

[0109 CD O
] NN O

EMI21.1 . O

Preparation NNP O
5a VBD O
[5-chloro-3-(4-fluorobenzenesulfonylamino)-2-methylindol-1- DT B-NP
yl]acetic JJ I-NP
acid NN I-NP
methyl NN I-NP
ester NN I-NP

To TO O
a DT O
mixture NN O
of IN O
3-amino-5-chloro-2-methylindol-1-yl JJ B-NP
)acetic JJ I-NP
acid NN I-NP
methyl NN I-NP
ester NN I-NP
hydrochloride NN I-NP
( -LRB- O
compound NN O
of IN O
Preparation NNP O
1c CD O
, , O
0.15 CD O
g NN O
) -RRB- O
, , O
triethylamine NN B-NP
( -LRB- O
0.21 CD O
ml_ NN O
) -RRB- O
and CC O
tetrahydrofuran JJ B-NP
( -LRB- O
2.0 CD O
ml_ NN O
) -RRB- O
at IN O
-55<0>C NNP O
was VBD O
added VBN O
4-fluorobenzenesulfonyl JJ B-NP
chloride NN I-NP
( -LRB- O
0.10 CD O
g NN O
) -RRB- O
and CC O
the DT O
resulting VBG O
mixture NN O
was VBD O
stirred VBN O
at IN O
-50<0>C JJ O
for IN O
thirty CD O
minutes NNS O
. . O

The DT O
reaction NN O
mixture NN O
was VBD O
filtered VBN O
and CC O
the DT O
filtrate NN O
concentrated VBD O
under IN O
reduced JJ O
pressure NN O
. . O

Purification NN O
of IN O
the DT O
residue NN O
by IN O
column NN O
chromatography NN O
on IN O
silica NN B-NP
gel NN O
gave VBD O
[5-chloro-3- . B-NP

( -LRB- O
4-fluorobenzenesulfonylamino)-2-methylindol-1-yl]acetic JJ O
acid NN O
methyl NN O
ester NN O
, , O
0.1O CD O
g NN O
. . O

<1>H JJ B-NP
NMR NNP O
( -LRB- O
CD3OD NN O
) -RRB- O
: : O
[delta JJ O
] SYM O
2.10 CD O
( -LRB- O
s VBZ O
, , O
3H) CC O
, , O
3.75 CD O
( -LRB- O
s VBZ O
, , O
3H) CC O
, , O
4.95 CD O
( -LRB- O
s VBZ O
, , O
2H) CC O
, , O
6.80 CD O
( -LRB- O
d NN O
, , O
J NNP O
= SYM O
1.9 CD O

Hz NNP O
, , O
1 CD O
H) NNP O
, , O
7.00 CD O
( -LRB- O
dd NN O
, , O
J NNP O
= SYM O
1.9 CD O
, , O
8.7 CD O
Hz NNP O
, , O
1H) JJ O
, , O
7.10-7.20 CD O
( -LRB- O
m NN O
, , O
3H) NNP O
, , O
7.65 CD O
( -LRB- O
m NN O
, , O
2H) JJ O
. . O

MS NNP O
: : O
ESI NNP O
( -LRB- O
+ve NN O
) -RRB- O
( -LRB- O
Method NNP O
B) NNP O
: : O
409 CD O
(M-H) NN O
, , O
Retention NNP O
time NN O
3.4 CD O
min NN O
. . O

Preparation NNP O
5b CD O
: : O
[5-chloro-3-(4-fluorobenzenesulfonylamino)-2-methylindol-1- CD B-NP
yl]acetic JJ I-NP
acid NN I-NP

A DT O
solution NN O
of IN O
[5-chloro-3-(4-fluorobenzenesulfonylamino)-2-methylindol-1- DT B-NP
yl]acetic JJ I-NP
acid NN I-NP
methyl NN I-NP
ester NN I-NP
( -LRB- O
0.09 CD O
g NN O
) -RRB- O
, , O
tetrahydrofuran JJ B-NP
( -LRB- O
5.0 CD O
ml_ NN O
) -RRB- O
and CC O
4.0 CD O
M NNP O
aqueous JJ O
sodium NN B-NP
hydroxide NN I-NP
solution NN O
( -LRB- O
2.0 CD O
ml_ NN O
) -RRB- O
was VBD O
stirred VBN O
at IN O
room NN O
temperature NN O
for IN O
one CD O
hour NN O
. . O

The DT O
tetrahydrofuran NN B-NP
was VBD O
removed VBN O
under IN O
reduced JJ O
pressure NN O
and CC O
pH NN O
of IN O
the DT O
residue NN O
adjusted VBN O
to TO O
-3-4 VB O
by IN O
the DT O
addition NN O
of IN O
concentrated JJ O
hydrochloric JJ B-NP
acid NN I-NP
. . O

The DT O
resulting VBG O
precipitate NN O
was VBD O
collected VBN O
by IN O
filtration NN O
and CC O
dried VBD O
to TO O
afford VB O
[5-chloro-3-(4 DT B-NP
- : I-NP
fluorobenzenesulfonylamino)-2-methylindol-1-yl]acetic JJ I-NP
acid NN I-NP
, , O
0.07 CD O
g NN O
. . O
<1>H '' B-NP
NMR NNP O
( -LRB- O
DMSO-d6 NN B-NP
) -RRB- O
: : O
[delta JJ O
] SYM O
1.95 FW O
( -LRB- O
s PRP O
, , O
3H) CC O
, , O
4.95 CD O
( -LRB- O
s VBZ O
, , O
2H) CC O
, , O
6.80 CD O
( -LRB- O
d NN O
, , O
J NNP O
= SYM O
2.1 CD O
Hz NNP O
, , O
1 CD O
H) NNP O
, , O

7.00 CD O
( -LRB- O
dd NN O
, , O
J NNP O
= SYM O
2.1 CD O
, , O
8.6 CD O
Hz1 NNP O
1 CD O
H) NNP O
, , O
7.30 CD O
( -LRB- O
m NN O
, , O
2H) JJ O
, , O
7.35 CD O
( -LRB- O
d NN O
, , O
J NNP O
= SYM O
8.6 CD O
Hz NNP O
, , O
1 CD O
H) NNP O
, , O
9.45 CD O
( -LRB- O
s VBZ O
, , O
1 CD O
H) NNP O
, , O

13.05 CD O
( -LRB- O
br NN O
s VBZ O
, , O
1 CD O
H) NN O
. . O

MS NNP O
: : O
ESI NNP O
( -LRB- O
+ve NN O
) -RRB- O
( -LRB- O
Method NNP O
A) NNP O
: : O
397 CD O
( -LRB- O
M+H) NNP O
, , O
Retention NNP O
time NN O
9.7 CD O
min NN O
. . O

Example NNP O
6 CD O
: : O
[S^BiphenyM-sulfonylaminoJ-S-chloro^-methylindol-i-ylfocetic JJ B-NP
acid NN I-NP
( -LRB- O
R<1> NNP O
, , O
R<3> NNP O
, , O
R<4> NNP O
, , O
R<5> NNP O
, , O
R<6> NNP O
, , O
R<9> NNP O
= SYM O
H5 CD O
R<2> CD O
= SYM O
Cl5 : O
R<7> JJ O
= SYM O
CH3 JJ B-NP
, , O
R<8> JJ O
= SYM O
4-Biphenyl JJ B-NP
) -RRB- O

[0122] . O

EMI22.1 . O

Preparation NNP O
6a VBD O
[3-( JJ B-NP
Biphenyl-4-sulf JJ I-NP
onylamino)-5-chloro-2-methylindol-1 JJ I-NP
-yl]acetic JJ I-NP
acid NN I-NP
methyl NN I-NP
ester NN I-NP

Biphenyl-4-sulfonyl JJ B-NP
chloride NN I-NP
( -LRB- O
0.12 CD O
g NN O
) -RRB- O
was VBD O
added VBN O
to TO O
a DT O
stirred VBD O
solution NN O
of IN O
(3 CD B-NP
- : I-NP
amino-5-chloro~2-methylindol-1-yl JJ I-NP
)acetic JJ I-NP
acid NN I-NP
methyl NN I-NP
ester NN I-NP
hydrochloride NN I-NP
( -LRB- O
compound NN O
of IN O
Preparation NNP O
1c CD O
, , O
0.10 CD O
g NN O
) -RRB- O
in IN O
pyridine NN B-NP
( -LRB- O
5.0 CD O
ml_ NN O
) -RRB- O
at IN O
room NN O
temperature NN O
. . O

After IN O
thirty CD O
minutes NNS O
the DT O
pyridine NN B-NP
was VBD O
removed VBN O
under IN O
reduced JJ O
pressure NN O
and CC O
the DT O
residue JJ O
washed VBN O
with IN O
1.0 CD O
M NNP O
aqueous JJ O
hydrochloric JJ B-NP
acid NN I-NP
to TO O
afford VB O
[3-(biphenyl-4-sulfonylamino)-5- DT B-NP
chloro-2-methylindol-1-yl]acetic JJ I-NP
acid NN I-NP
methyl NN I-NP
ester NN I-NP
, , O
0.17 CD O
g NN O
. . O

MS NNP O
: : O
ESI NNP O
( -LRB- O
+ve NN O
) -RRB- O
( -LRB- O
Method NNP O
B) NNP O
: : O
467 CD O
(M-H) NN O
, , O
Retention NNP O
time NN O
3.8 CD O
min NN O
. . O

Preparation NNP O
6b VBD O
[3-(biphenyl-4-sulfonylamino)-5-chloro-2-methylindol-1 JJ B-NP
-yl]acetic JJ I-NP
acid NN I-NP

A DT O
mixture NN O
of IN O
[3-(biphenyl-4-sulfonylamino)-5-chloro-2-methylindol-1-yl]acetic JJ B-NP
acid NN I-NP
methyl NN I-NP
ester NN I-NP
( -LRB- O
0.17 CD O
g NN O
) -RRB- O
, , O
potassium NN B-NP
trimethylsilanoate NN I-NP
( -LRB- O
0.14 CD O
g NN O
) -RRB- O
and CC O
tetrahydrofuran JJ B-NP
( -LRB- O
2.0 CD O
mL NN O
) -RRB- O
was VBD O
heated VBN O
by IN O
microwave NN O
irradiation NN O
at IN O
100<0>C CD O
for IN O
five CD O
minutes NNS O
. . O

The DT O
solvent NN O
was VBD O
removed VBN O
under IN O
reduced JJ O
pressure NN O
and CC O
the DT O
pH NN O
of IN O
the DT O
residue NN O
adjusted VBN O
to TO O
1 CD O
by IN O
the DT O
addition NN O
of IN O
concentrated JJ O
hydrochloric JJ B-NP
acid NN I-NP
. . O

The DT O
resulting VBG O
precipitate NN O
was VBD O
collected VBN O
by IN O
filtration NN O
, , O
washed VBN O
with IN O
water NN B-NP
and CC O
dried VBD O
to TO O
afford VB O
[3-(biphenyl-4-sulfonylamino)-5- DT B-NP
chloro-2-methylindol-1-yl]acetic JJ I-NP
acid NN I-NP
, , O
0.070 CD O
g NN O
. . O
<1>H '' B-NP
NMR NNP O
( -LRB- O
DMSO-d6 NN B-NP
) -RRB- O
: : O
[delta JJ O
] SYM O
1.95 FW O
( -LRB- O
s PRP O
, , O
3H) CC O
, , O
4.95 CD O
( -LRB- O
s VBZ O
, , O
2H) CC O
, , O
6.80 CD O
( -LRB- O
d NN O
, , O
J NNP O
= SYM O
2.2 CD O
Hz NNP O
, , O
1 CD O
H) NNP O
, , O

6.95 CD O
( -LRB- O
dd NN O
, , O
J NNP O
= SYM O
2.2 CD O
, , O
8.8 CD O
Hz NNP O
, , O
1H) CD O
, , O
7.35 CD O
( -LRB- O
d NN O
, , O
J NNP O
= SYM O
8.8 CD O
Hz NNP O
, , O
1H) CD O
, , O
7.40-7.50 CD O

( -LRB- O
m NN O
, , O
3H) NNP O
, , O
7.60-7.70 CD O

( -LRB- O
m NN O
, , O
4H) JJ O
, , O
7.75 CD O
( -LRB- O
m NN O
, , O
2H) JJ O
, , O
9.45 CD O
( -LRB- O
s VBZ O
, , O
1 CD O
H) NNP O
, , O
13.05 CD O
( -LRB- O
br NN O
s VBZ O
, , O
1H) UH O
. . O

MS NNP O
: : O
ESI NNP O
( -LRB- O
+ve NN O
) -RRB- O
( -LRB- O
Method NNP O
A) NNP O
: : O
455 CD O
( -LRB- O
M+H) NNP O
, , O
Retention NNP O
time NN O
11.0 CD O
min NN O
. . O

Example NN O
7 CD O
: : O
[5-chloro-2-methyl-3-(naphthalene-2-sulfonylamino NN B-NP
)indol-1-yl]acetic JJ I-NP
acid NN I-NP
( -LRB- O
R<1> NNP O
, , O
R<3> NNP O
, , O
R<4> NNP O
, , O
R<5> NNP O
, , O
R<6> NNP O
, , O
R<9> NNP O
= SYM O
H NNP O
, , O
R<2> NNP O
= SYM O
Cl5 . O
R<7> . O
= SYM O
CH3 JJ B-NP
, , O
R<8> JJ O
= SYM O
2-naphthyl JJ B-NP
) -RRB- O

[0129 CD O
] NN O

EMI23.1 . O

Preparation NNP O
7a VBD O
[5-chloro-2-methyl-3-(naphthalene-2-sulfonylamino DT B-NP
)indol-1 JJ I-NP
- : I-NP
yl]acetic JJ I-NP
acid NN I-NP
methyl NN I-NP
ester NN I-NP

Naphthalene-2-sulfonyl JJ B-NP
chloride NN I-NP
( -LRB- O
0.11 CD O
g NN O
) -RRB- O
was VBD O
added VBN O
to TO O
a DT O
stirred VBD O
solution NN O
of IN O
(3 CD B-NP
- : I-NP
amino-5-chloro-2-methylindol-1-yl JJ I-NP
)acetic JJ I-NP
acid NN I-NP
methyl NN I-NP
ester NN I-NP
hydrochloride NN I-NP
( -LRB- O
compound NN O
of IN O
Preparation NNP O
1c CD O
, , O
0.10 CD O
g NN O
) -RRB- O
in IN O
pyridine NN B-NP
( -LRB- O
5.0 CD O
mL NN O
) -RRB- O
at IN O
room NN O
temperature NN O
. . O

After IN O
thirty CD O
minutes NNS O
the DT O
pyridine NN B-NP
was VBD O
removed VBN O
under IN O
reduced JJ O
pressure NN O
and CC O
the DT O
residue JJ O
washed VBN O
with IN O
1.0 CD O
M NNP O
aqueous JJ O
hydrochloric JJ B-NP
acid NN I-NP
to TO O
afford VB O
[5-chloro-2-methyl-3-(naphthalene-2- DT B-NP
sulfonylamino NN I-NP
)indol-1-yl]acetic JJ I-NP
acid NN I-NP
methyl NN I-NP
ester NN I-NP
, , O
0.18 CD O
g NN O
. . O

MS NNP O
: : O
ESI NNP O
( -LRB- O
+ve NN O
) -RRB- O
( -LRB- O
Method NNP O
B) NNP O
: : O
441 CD O
(M-H)-, JJ O
Retention NNP O
time NN O
3.6 CD O
min NN O
. . O

Preparation NNP O
7b VBD O
[5-chloro-2-methyl-3-(naphthalene-2-sulfonylamino DT B-NP
)indol-1 JJ I-NP
- : I-NP
yl]acetic JJ I-NP
acid NN I-NP
A DT O
mixture NN O
of IN O
[5-chloro-2-methyl-3-(naphthalene-2-sulfonylamino JJ B-NP
)indol-1- CC I-NP
yl]acetic JJ I-NP
acid NN I-NP
methyl NN I-NP
ester NN I-NP
( -LRB- O
0.18 CD O
g NN O
) -RRB- O
, , O
potassium NN B-NP
trimethylsilanoate NN I-NP
( -LRB- O
0.16 CD O
g NN O
) -RRB- O
and CC O
tetrahydrofuran JJ B-NP
( -LRB- O
2.0 CD O
mL NN O
) -RRB- O
was VBD O
heated VBN O
by IN O
microwave NN O
irradiation NN O
at IN O
100<0>C CD O
for IN O
five CD O
minutes NNS O
. . O

The DT O
solvent NN O
was VBD O
removed VBN O
under IN O
reduced JJ O
pressure NN O
and CC O
the DT O
pH NN O
of IN O
the DT O
residue NN O
adjusted VBN O
to TO O
1 CD O
by IN O
the DT O
addition NN O
of IN O
concentrated JJ O
hydrochloric JJ B-NP
acid NN I-NP
. . O

The DT O
resulting VBG O
precipitate NN O
was VBD O
collected VBN O
by IN O
filtration NN O
, , O
washed VBN O
with IN O
water NN B-NP
and CC O
dried VBD O
to TO O
afford VB O
[5-chloro- DT B-NP
2-methyl-3-(naphthalene-2-sulfonylamino JJ I-NP
)indol-1-yl]acetic JJ I-NP
acid NN I-NP
, , O
0.080 CD O
g NN O
. . O
<1>H '' B-NP
NMR NNP O
( -LRB- O
DMSO-d[theta] NN B-NP
) -RRB- O
: : O
[delta JJ O
] SYM O
1.90 CD O
( -LRB- O
s VBZ O
, , O
3H) CC O
, , O
4.90 CD O
( -LRB- O
s VBZ O
, , O
2H) CC O
, , O
6.80 CD O
( -LRB- O
d NN O
, , O
J NNP O
= SYM O
2.1 CD O
Hz NNP O
, , O
1 CD O
H) NNP O
, , O

6.90 CD O
( -LRB- O
dd NN O
. . O

J NNP O
= SYM O
2.1 CD O
, , O
8.7 CD O
Hz NNP O
, , O
1 CD O
H) NNP O
, , O
7.35 CD O
( -LRB- O
d NN O
, , O
J NNP O
= SYM O
8.7 CD O
Hz NNP O
, , O
1 CD O
H) NN O
, , O
7.60 CD O
( -LRB- O
m NN O
, , O
1 CD O
H) NNP O
, , O
7.65 CD O
( -LRB- O
m NN O
, , O
1 CD O
H) NN O
, , O
7.75 CD O
( -LRB- O
dd NN O
, , O
J NNP O
= SYM O
1.9 CD O
, , O
8.7 CD O
Hz NNP O
, , O
1H)1 CD O
8.00 CD O
( -LRB- O
m NN O
, , O
2H) JJ O
, , O
8.05 CD O
( -LRB- O
d NN O
, , O
J NNP O
= SYM O
8.7 CD O
Hz NNP O
, , O
1H) JJ O
, , O
8.20 CD O
( -LRB- O
d NN O
, , O
J NNP O
= SYM O
1.5 CD O
Hz NNP O
, , O
1 CD O
H) NNP O
, , O
9.50 CD O
( -LRB- O
s VBZ O
, , O
1 CD O
H) NNP O
, , O
13.05 CD O
( -LRB- O
br NN O
s VBZ O
, , O
1 CD O
H) NN O
. . O

MS NNP O
: : O
ESI NNP O
( -LRB- O
+ve NN O
) -RRB- O
( -LRB- O
Method NNP O
A) NNP O
: : O
429 CD O
( -LRB- O
M+H) NNP O
, , O
Retention NNP O
time NN O
10.5 CD O
min NN O
. . O

Example NNP O
8 CD O
: : O
[5-chloro-3-(2,3-dichlorobenzenesulfonylamino)-2-methylindol-1- CD B-NP
yl]acetic JJ I-NP
acid NN I-NP
( -LRB- O
R<1> NNP O
, , O
R<3> NNP O
, , O
R<4> NNP O
, , O
R<5> NNP O
, , O
R<6> NNP O
, , O
R<9> NNP O
= SYM O
H NNP O
, , O
R<2> NNP O
= SYM O
Cl NNP B-NP
, , O
R<7> DT O
= SYM O
CH3 JJ B-NP
, , O
R<8> JJ O
= SYM O
2,3-CI2Ph JJ B-NP
) -RRB- O

[0135] . O

EMI24.1 . O

Preparation NNP O
8a VBD O
[5-chloro-3-(2,3-dichlorobenzenesulfonylamino)-2-methylindol- DT B-NP
1-yl]acetic JJ I-NP
acid NN I-NP
methyl NN I-NP
ester NN I-NP

2,3-Dichlorobenzenesulfonyl JJ B-NP
chloride NN I-NP
( -LRB- O
0.12 CD O
g NN O
) -RRB- O
was VBD O
added VBN O
to TO O
a DT O
stirred VBD O
solution NN O
of IN O
(3-amino-5-chloro-2-methylindol-1-yl JJ B-NP
)acetic JJ I-NP
acid NN I-NP
methyl NN I-NP
ester NN I-NP
hydrochloride NN I-NP
( -LRB- O
compound NN O
of IN O
Preparation NNP O
1c CD O
, , O
0.10 CD O
g NN O
) -RRB- O
in IN O
pyridine NN B-NP
( -LRB- O
5.0 CD O
mL NN O
) -RRB- O
at IN O
room NN O
temperature NN O
. . O

After IN O
thirty CD O
minutes NNS O
the DT O
pyridine NN B-NP
was VBD O
removed VBN O
under IN O
reduced JJ O
pressure NN O
and CC O
the DT O
residue JJ O
washed VBN O
with IN O
1.0 CD O
M NNP O
aqueous JJ O
hydrochloric JJ B-NP
acid NN I-NP
to TO O
afford VB O
[5-chloro-3-(2,3-dichloro- DT B-NP
benzenesulfonylamino)-2-methylindol-1-yl]acetic JJ I-NP
acid NN I-NP
methyl NN I-NP
ester NN I-NP
, , O
0.18 CD O
g NN O
. . O

MS NNP O
: : O
ESI NNP O
( -LRB- O
+ve NN O
) -RRB- O
( -LRB- O
Method NNP O
B) NNP O
: : O
459 CD O
(M-H) NN O
, , O
Retention NNP O
time NN O
3.7 CD O
min NN O
. . O

Preparation NNP O
8b VBD O
[5-chloro-3-(2,3-dichlorobenzenesulfonylamino)-2-methylindol- DT B-NP
1-yl]acetic JJ I-NP
acid NN I-NP
A DT O
mixture NN O
of IN O
[5-chloro-3-(2,3-dichlorobenzenesulfonylamino)-2-methylindol-1- CD B-NP
yl]acetic JJ I-NP
acid NN I-NP
methyl NN I-NP
ester NN I-NP
( -LRB- O
0.18 CD O
g NN O
) -RRB- O
, , O
potassium NN B-NP
trimethylsilanoate NN I-NP
( -LRB- O
0.15 CD O
g NN O
) -RRB- O
and CC O
tetrahydrofuran JJ B-NP
( -LRB- O
2.0 CD O
mL NN O
) -RRB- O
was VBD O
heated VBN O
by IN O
microwave NN O
irradiation NN O
at IN O
100<0>C CD O
for IN O
five CD O
minutes NNS O
. . O

The DT O
solvent NN O
was VBD O
removed VBN O
under IN O
reduced JJ O
pressure NN O
and CC O
the DT O
pH NN O
of IN O
the DT O
residue NN O
adjusted VBN O
to TO O
1 CD O
by IN O
the DT O
addition NN O
of IN O
concentrated JJ O
hydrochloric JJ B-NP
acid NN I-NP
. . O

The DT O
resulting VBG O
precipitate NN O
was VBD O
collected VBN O
by IN O
filtration NN O
, , O
washed VBN O
with IN O
water NN B-NP
and CC O
dried VBD O
to TO O
afford VB O
[5-chloro- DT B-NP
3-(2,3-dichlorobenzenesulfonylamino)-2-methylindol-1-yl]acetic JJ I-NP
acid NN I-NP
, , O
0.096 CD O
g NN O
. . O
<1>H '' B-NP
NMR NNP O
( -LRB- O
DMSO-d6 NN B-NP
) -RRB- O
: : O
[delta JJ O
] SYM O
2.05 FW O
( -LRB- O
s PRP O
, , O
3H)1 CC O
4.95 CD O
( -LRB- O
s VBZ O
, , O
2H) CC O
, , O
6.90 CD O
( -LRB- O
d NN O
, , O
J NNP O
= SYM O
2.1 CD O
Hz NNP O
, , O
1H) JJ O
, , O
7.00 CD O
( -LRB- O
dd NN O
, , O
J NNP O
= SYM O
2.1 CD O
, , O
8.7 CD O
Hz NNP O
, , O
1H) CD O
, , O
7.35 CD O
( -LRB- O
m NN O
, , O
2H) JJ O
, , O
7.65 CD O
( -LRB- O
dd NN O
, , O
J NNP O
= SYM O
1.5 CD O
, , O
7.9 CD O
Hz NNP O
, , O
1 CD O
H) NN O
, , O
7.90 CD O
( -LRB- O
dd NN O
, , O
J NNP O
= SYM O
1.5 CD O
, , O
7.9 CD O
Hz NNP O
, , O
1H) JJ O
, , O
9.90 CD O
( -LRB- O
s VBZ O
, , O
1H) CC O
, , O
13.05 CD O
( -LRB- O
br NN O
s PRP O
, , O
1H) UH O
. . O

MS NNP O
: : O
ESI NNP O
( -LRB- O
+ve NN O
) -RRB- O
( -LRB- O
Method NNP O
A) NNP O
: : O
447 CD O
( -LRB- O
M+H) NNP O
, , O
Retention NNP O
time NN O
10.6 CD O
min NN O
. . O

Example NNP O
9 CD O
: : O
[5-Chloro-2-methyl-3-(naphthalene-1 NN B-NP
-sulf NN I-NP
onylamino IN I-NP
)indol-1 JJ I-NP
- : I-NP
yl]acetic JJ I-NP
acid NN I-NP
( -LRB- O
R<1> NNP O
, , O
R<3> NNP O
, , O
R<4> NNP O
, , O
R<5> NNP O
, , O
R<6> NNP O
, , O
R<9> NNP O
= SYM O
H5 CD O
R<2> CD O
= SYM O
Cl NNP B-NP
, , O
R<7> NNP O
= SYM O
CH3 NNP B-NP
, , O
R<8> NNP O
= SYM O
1-naphthyl JJ B-NP
) -RRB- O

[0140] . O

EMI25.1 . O

Preparation NNP O
9a CD O
[5-chloro-2-methyl-3-(naphthalene-1-sulfonylamino . B-NP
)indol-1- -RRB- I-NP
yl]acetic JJ I-NP
acid NN I-NP
methyl NN I-NP
ester NN I-NP

Naphthalene NNP B-NP
- : I-NP
1 CD I-NP
-sulf NN I-NP
onyl NN I-NP
chloride NN I-NP
( -LRB- O
0.11 CD O
g NN O
) -RRB- O
was VBD O
added VBN O
to TO O
a DT O
stirred VBD O
solution NN O
of IN O
(3 CD B-NP
- : I-NP
amino-5-chloro-2-methylindol-1-yl JJ I-NP
)acetic JJ I-NP
acid NN I-NP
methyl NN I-NP
ester NN I-NP
hydrochloride NN I-NP
( -LRB- O
compound NN O
of IN O
Preparation NNP O
1c CD O
, , O
0.10 CD O
g NN O
) -RRB- O
in IN O
pyridine NN B-NP
( -LRB- O
5.0 CD O
ml_ NN O
) -RRB- O
at IN O
room NN O
temperature NN O
. . O

After IN O
thirty CD O
minutes NNS O
the DT O
pyridine NN B-NP
was VBD O
removed VBN O
under IN O
reduced JJ O
pressure NN O
and CC O
the DT O
residue JJ O
washed VBN O
with IN O
1.0 CD O
M NNP O
aqueous JJ O
hydrochloric JJ B-NP
acid NN I-NP
to TO O
afford VB O
[5-chloro-2-methyl-3-(naphthalene-1- DT B-NP
sulfonylamino NN I-NP
)indol-1-yl]acetic JJ I-NP
acid NN I-NP
methyl NN I-NP
ester NN I-NP
, , O
0.15 CD O
g NN O
. . O

MS NNP O
: : O
ESI NNP O
( -LRB- O
+ve NN O
) -RRB- O
( -LRB- O
Method NNP O
B) NNP O
: : O
441 CD O
(M-H) NN O
, , O
Retention NNP O
time NN O
3.6 CD O
min NN O
. . O

Preparation NNP O
9b VBD O
[5-chloro-2-methyl-3-(naphthalene-1 JJ B-NP
-sulfonylamino NN I-NP
)indol-1- : I-NP
yl]acetic JJ I-NP
acid NN I-NP

A DT O
mixture NN O
of IN O
[5-chloro-2-methyl-3-(naphthalene-1-sulfonylamino JJ B-NP
)indol-1- CC I-NP
yl]acetic JJ I-NP
acid NN I-NP
methyl NN I-NP
ester NN I-NP
( -LRB- O
0.15 CD O
g NN O
) -RRB- O
, , O
potassium NN B-NP
trimethylsilanoate NN I-NP
( -LRB- O
0.13 CD O
g NN O
) -RRB- O
and CC O
tetrahydrofuran JJ B-NP
( -LRB- O
2.0 CD O
mL NN O
) -RRB- O
was VBD O
heated VBN O
by IN O
microwave NN O
irradiation NN O
at IN O
100<0>C CD O
for IN O
five CD O
minutes NNS O
. . O

The DT O
solvent NN O
was VBD O
removed VBN O
under IN O
reduced JJ O
pressure NN O
and CC O
the DT O
pH NN O
of IN O
the DT O
residue NN O
adjusted VBN O
to TO O
1 CD O
by IN O
the DT O
addition NN O
of IN O
concentrated JJ O
hydrochloric JJ B-NP
acid NN I-NP
. . O

The DT O
resulting VBG O
precipitate NN O
was VBD O
collected VBN O
by IN O
filtration NN O
, , O
washed VBN O
with IN O
water NN B-NP
and CC O
dried VBD O
to TO O
afford VB O
[5-chloro- DT B-NP
2-methyl-3-(naphthalene-1-sulfonylamino JJ I-NP
)indol-1-yl]acetic JJ I-NP
acid NN I-NP
, , O
0.083 CD O
g NN O
. . O

<1>H JJ B-NP
NMR NNP O
( -LRB- O
DMSO-d6 NN B-NP
) -RRB- O
: : O
[delta NN O
] NN O
1.80 CD O
( -LRB- O
s VBZ O
, , O
3H) CC O
, , O
4.85 CD O
( -LRB- O
s VBZ O
, , O
2H) CC O
, , O
6.40 CD O
( -LRB- O
d NN O
, , O
J NNP O
= SYM O
2.0 CD O
Hz NNP O
, , O
1H) CD O
, , O
6.90 CD O
( -LRB- O
dd NN O
, , O
J NNP O
= SYM O
2.0, CD O
8.6 CD O
Hz NNP O
, , O
1 CD O
H) NNP O
, , O
7.30 CD O
( -LRB- O
d NN O
, , O
J NNP O
= SYM O
8.6 CD O
Hz NNP O
, , O
1 CD O
H) NN O
, , O
7.45 CD O
( -LRB- O
dd NN O
, , O
J NNP O
= SYM O
7.4 CD O
, , O
8.1 CD O
Hz NNP O
, , O
1H) CD O
, , O
7.65-7.75 CD O

( -LRB- O
m NN O
, , O
2H) JJ O
, , O
7.85 CD O
( -LRB- O
dd NN O
, , O
J NNP O
= SYM O
1.2 CD O
, , O
7.4 CD O
Hz NNP O
, , O
1H) JJ O
, , O
8.10 CD O
( -LRB- O
dd NN O
, , O
J NNP O
= SYM O
2.0, CD O
7.9 CD O
Hz NNP O
, , O
1H) JJ O
, , O
8.15 CD O
( -LRB- O
d NN O
, , O
J NNP O
= SYM O
8.1 CD O
Hz NNP O
, , O
1H) JJ O
, , O
8.80 CD O
( -LRB- O
dd NN O
, , O
J NNP O
= SYM O
1.2 CD O
, , O
8.1 CD O
Hz NNP O
, , O
1 CD O
H) NNP O
, , O
9.65 CD O
( -LRB- O
s VBZ O
, , O
1 CD O
H) NNP O
, , O
13.00 CD O
( -LRB- O
br NN O
s PRP O
, , O
1H) UH O
. . O

MS NNP O
: : O
ESl NNP O
( -LRB- O
+ve NN O
) -RRB- O
( -LRB- O
Method NNP O
A) NNP O
: : O
429 CD O
( -LRB- O
M+H) NNP O
, , O
Retention NNP O
time NN O
10.4 CD O
min NN O
. . O

Example NNP O
10 CD O
: : O
[S-Chloro^-methyl-S-tquinoline-[delta]-sulfonylaminoJindoH-y[pi]acetic JJ B-NP
acid NN I-NP
( -LRB- O
R<1> NNP O
, , O
R<3> NNP O
, , O
R<4> NNP O
, , O
R<5> NNP O
, , O
R<6> NNP O
, , O
R<9> NNP O
= SYM O
H NNP O
, , O
R<2> NNP O
= SYM O
. . O

Ci NNP O
, , O
R<7> DT O
= SYM O
CH3 JJ B-NP
, , O
R<8> JJ O
= SYM O
8-quinolinyl CD B-NP
) -RRB- O

[0146] . O

EMI26.1 . O

Preparation NNP O
10a CD O
[5-chloro-2-methyl-3-(quinoline-8-sulfonylamino . B-NP
)indol-1- -RRB- I-NP
yljacetic JJ I-NP
acid NN I-NP
methyl NN I-NP
ester NN I-NP

Quinoline-8-sulfonyl JJ B-NP
chloride NN I-NP
( -LRB- O
0.11 CD O
g NN O
) -RRB- O
was VBD O
added VBN O
to TO O
a DT O
stirred VBD O
solution NN O
of IN O
(3 CD B-NP
- : I-NP
amino-5-chloro-2-methy\indo\-<'>i-[gamma]i)acet\c JJ I-NP
acid NN I-NP
methyl NN I-NP
ester NN I-NP
hydrochloride NN I-NP
( -LRB- O
compound NN O
of IN O
Preparation NNP O
1c CD O
, , O
0.10 CD O
g NN O
) -RRB- O
in IN O
pyridine NN B-NP
( -LRB- O
5.0 CD O
mL NN O
) -RRB- O
at IN O
room NN O
temperature NN O
. . O

After IN O
thirty CD O
minutes NNS O
the DT O
pyridine NN B-NP
was VBD O
removed VBN O
under IN O
reduced JJ O
pressure NN O
and CC O
the DT O
residue JJ O
washed VBN O
with IN O
1.0 CD O
M NNP O
aqueous JJ O
hydrochloric JJ B-NP
acid NN I-NP
to TO O
afford VB B-NP
[5-chloro-2-methyl-3-(quinoline-8- DT I-NP
sulfonylamino NN I-NP
)indol-1-yl]acetic JJ I-NP
acid NN I-NP
methyl NN I-NP
ester NN I-NP
, , O
0.09 CD O
g NN O
. . O

MS NNP O
: : O
ESI NNP O
( -LRB- O
+ve NN O
) -RRB- O
( -LRB- O
Method NNP O
B) NNP O
: : O
442 CD O
(M-H) NN O
, , O
Retention NNP O
time NN O
3.4 CD O
min NN O
. . O

Preparation NNP O
10b CD O
(5-cWoro-2-rnethyl-3-(quinoline-8-sulf JJ B-NP
onylamino NN I-NP
)indol-1 NN I-NP
- : I-NP
yl]acetic JJ I-NP
acid NN I-NP

A DT O
mixture NN O
of IN O
[5-chloro-2-methyl-3-(quinoline-8-sulfonylamino JJ B-NP
)indol-1-yl]acetic JJ I-NP
acid NN I-NP
methyl NN I-NP
ester NN I-NP
( -LRB- O
0.09 CD O
g NN O
) -RRB- O
, , O
potassium NN B-NP
trimethylsilanoate NN I-NP
( -LRB- O
0.08 CD O
g NN O
) -RRB- O
and CC O
tetrahydrofuran JJ B-NP
( -LRB- O
2.0 CD O
mL NN O
) -RRB- O
was VBD O
heated VBN O
by IN O
microwave NN O
irradiation NN O
at IN O
100<0>C CD O
for IN O
five CD O
minutes NNS O
. . O

The DT O
solvent NN O
was VBD O
removed VBN O
under IN O
reduced JJ O
pressure NN O
and CC O
the DT O
pH NN O
of IN O
the DT O
residue NN O
adjusted VBN O
to TO O
1 CD O
by IN O
the DT O
addition NN O
of IN O
concentrated JJ O
hydrochloric JJ B-NP
acid NN I-NP
. . O

The DT O
resulting VBG O
precipitate NN O
was VBD O
collected VBN O
by IN O
filtration NN O
, , O
washed VBN O
with IN O
water NN B-NP
and CC O
purified VBN O
by IN O
preparative JJ O
reverse-phase NN O
HPLC NNP O
using VBG O
a DT O
gradient NN O
over IN O
30 CD O
minutes NNS O
of IN O
acetonitrile JJ B-NP
in IN O
water NN B-NP
( -LRB- O
40 CD O
to TO O
90 CD O
% NN O
of IN O
organic JJ O
modifier NN O
) -RRB- O
to TO O
afford VB O
[5-chloro-2-methyl-3-(quinoline-8-sulfonylamino JJ B-NP
)indol-1-yl]acetic JJ I-NP
acid NN I-NP
, , O
0.020 CD O
g NN O
. . O

<1>H JJ B-NP
NMR NNP O
( -LRB- O
DMSO-d6 NN B-NP
) -RRB- O
: : O
S NNP O
1.95 CD O
( -LRB- O
s VBZ O
, , O
3H) CC O
, , O
4.85 CD O
( -LRB- O
s VBZ O
, , O
2H) CC O
, , O
6.20 CD O
( -LRB- O
d NN O
, , O
J NNP O
= SYM O
2.1 CD O
Hz NNP O
, , O
1H) CD O
, , O

6.85 CD O
( -LRB- O
dd NN O
, , O
J NNP O
= SYM O
2.1 CD O
, , O
8.7 CD O
Hz NNP O
, , O
1H) NNP O
, , O
7.25 CD O
( -LRB- O
d NN O
, , O
J NNP O
= SYM O
8.7 CD O
Hz NNP O
, , O
1H) CD O
, , O
7.55 CD O
( -LRB- O
dd NN O
, , O
J NNP O
= SYM O
7.4 CD O
, , O
8.2 CD O
Hz NNP O
, , O
1H) . O

7.80 CD O
( -LRB- O
dd NN O
, , O
J NNP O
= SYM O
4.2 CD O
, , O
8.2 CD O
Hz NNP O
, , O
1H) NNP O
, , O
8.05 CD O
( -LRB- O
dd NN O
, , O
J NNP O
= SYM O
1.4 CD O
, , O

7.4 CD O
Hz NNP O
, , O
1 CD O
H) NNP O
, , O
8.25 CD O
( -LRB- O
dd NN O
, , O
J NNP O
= SYM O
1.4 CD O
, , O

8.3 CD O

Hz NNP O
, , O
1H) JJ O
, , O
8.60 CD O
( -LRB- O
dd NN O
, , O
J NNP O
= SYM O
1.8 CD O
, , O
8.3 CD O
Hz NNP O
, , O
1H)1 CD O
9.25 CD O
( -LRB- O
dd NN O
, , O
J NNP O
= SYM O
1.8 CD O
, , O
4.2 CD O
Hz NNP O
, , O
1H) JJ O
, , O
9.30 CD O
( -LRB- O
s VBZ O
, , O
1H) CC O
, , O
13.0 CD O
br NN O
s VBZ O
, , O
1 CD O
H) NN O
. . O

MS NNP O
: : O
ESI NNP O
( -LRB- O
+VB NN O
) -RRB- O
( -LRB- O
Method NNP O
A) NNP O
: : O
430 CD O
( -LRB- O
M+H) NNP O
, , O
Retention NNP O
time NN O
9.5 CD O
min NN O
. . O

Example NNP O
11 CD O
: : O
[delta]-Chloro-S-[beta]jS-dichloro-benzenesulfonylamino^-methyl-indol-i- DT B-NP
yl]-acetic JJ I-NP
acid NN I-NP
( -LRB- O
R<1> NNP O
, , O
R<3> NNP O
, , O
R<4> NNP O
, , O
R<5> NNP O
, , O
R<6> NNP O
, , O
R<9> NNP O
= SYM O
H NNP O
, , O
R<2> NNP O
= SYM O
Cl NNP B-NP
, , O
R<7> NNP O
= SYM O
CH3 NNP B-NP
, , O
R<8> NNP O
= SYM O
3,5-CI2Ph JJ B-NP
) -RRB- O
. . O

[0156] . O

EMI27.1 . O

Preparation NNP O
11a CD O
[5-Chloro-3-(3,5-dichloro-benzenesulfonylamino)-2-methyl- : B-NP
indol-1-yl]-acetic JJ I-NP
acid NN I-NP
methyl NN I-NP
ester NN I-NP
. . O

To TO O
a DT O
mixture NN O
of IN O
3-amino-5-chloro-2-methylindol-1-yl JJ B-NP
)acetic JJ I-NP
acid NN I-NP
methyl NN I-NP
ester NN I-NP
hydrochloride NN I-NP
( -LRB- O
compound NN O
of IN O
Preparation NNP O
1c CD O
, , O
0.15 CD O
g NN O
) -RRB- O
, , O
triethylamine NN B-NP
( -LRB- O
0.20 CD O
mL NN O
) -RRB- O
and CC O
tetrahydrofuran JJ B-NP
( -LRB- O
2.0 CD O
mL NN O
) -RRB- O
at IN O
-55<0>C NNP O
was VBD O
added VBN O
3,5-dichloro-benzenesulfonyl NN B-NP
chloride NN I-NP

( -LRB- O
0.13 CD O
g NN O
) -RRB- O
and CC O
the DT O
resulting VBG O
mixture NN O
was VBD O
stirred VBN O
at IN O
-5O<0>C JJ O
for IN O
thirty CD O
minutes NNS O
. . O

The DT O
reaction NN O
mixture NN O
was VBD O
filtered VBN O
and CC O
the DT O
filtrate NN O
concentrated VBD O
under IN O
reduced JJ O
pressure NN O
. . O

Purification NN O
of IN O
the DT O
residue NN O
by IN O
column NN O
chromatography NN O
on IN O
silica NN B-NP
gel NN O
gave VBD O
[5-chloro-3- . B-NP

( -LRB- O
S.[delta]-dichloro-benzenesulfonylamino^-methylindol-i-yOacetic JJ O
acid NN O
methyl NN O
ester NN O
, , O
0.08 CD O
g NN O
. . O

MS NNP O
: : O
ESI NNP O
( -LRB- O
+ve NN O
) -RRB- O
( -LRB- O
Method NNP O
B) NNP O
: : O
459 CD O
(M-H) NN O
, , O
Retention NNP O
time NN O
3.8 CD O
min NN O
. . O

Preparation NNP O
11b CD O
: : O
[5-chloro-3-(3,5-dichlorobenzenesulfonylamino)-2- CD B-NP
methylindol-1-yl]acetic JJ I-NP
acid NN I-NP
. . O

A DT O
solution NN O
of IN O
[5-chloro-3-(3,5-dichlorobenzenesulfonylamino)-2-methylindol-1- DT B-NP
yl]acetic JJ I-NP
acid NN I-NP
methyl NN I-NP
ester NN I-NP
( -LRB- O
0.08 CD O
g NN O
) -RRB- O
, , O
tetrahydrofuran JJ B-NP
( -LRB- O
2.0 CD O
mL NN O
) -RRB- O
and CC O
4.0 CD O
M NNP O
aqueous JJ O
sodium NN B-NP
hydroxide NN I-NP
solution NN O
( -LRB- O
2.0 CD O
mL NN O
) -RRB- O
was VBD O
stirred VBN O
at IN O
room NN O
temperature NN O
for IN O
one CD O
hour NN O
. . O

The DT O
tetrahydrofuran NN B-NP
was VBD O
removed VBN O
under IN O
reduced JJ O
pressure NN O
and CC O
pH NN O
of IN O
the DT O
residue NN O
adjusted VBN O
to TO O
-3-4 VB O
by IN O
the DT O
addition NN O
of IN O
concentrated JJ O
hydrochloric JJ B-NP
acid NN I-NP
. . O

The DT O
resulting VBG O
precipitate NN O
was VBD O
collected VBN O
by IN O
filtration NN O
and CC O
dried VBD O
to TO O
afford VB O
[5-chloro-3-(3,4- DT B-NP
dichlorobenzenesulfonylamino)-2-methylindol-1-yl]acetic JJ I-NP
acid NN I-NP
, , O
0.06 CD O
g NN O
. . O

<1>H JJ B-NP
NMR NNP O
( -LRB- O
DMSO-d6 NN B-NP
) -RRB- O
: : O
[delta JJ O
] SYM O
2.07 CD O
( -LRB- O
s VBZ O
, , O
3H) CC O
, , O
4.96 CD O
( -LRB- O
s VBZ O
, , O
2H)1 CC O
6.75 CD O
( -LRB- O
d NN O
, , O
J NNP O
= SYM O
2.1 CD O
Hz NNP O
, , O
1 CD O
H) NNP O
, , O
7.01 CD O
( -LRB- O
dd NN O
, , O
J NNP O
= SYM O
2.1 CD O
, , O
8.7 CD O
Hz NNP O
, , O
1H) CD O
, , O
7.40 CD O
( -LRB- O
d NN O
, , O
J NNP O
= SYM O
8.7 CD O
Hz NNP O
, , O
1 CD O
H) NNP O
, , O
7.54 CD O
( -LRB- O
d NN O
, , O
J NNP O
= SYM O
1.9 CD O
Hz NNP O
, , O
1 CD O
H) NNP O
, , O
7.94 CD O
( -LRB- O
t NN O
, , O
J NNP O
= SYM O
1.9 CD O
Hz NNP O
, , O
1 CD O
H) NNP O
, , O
9.73 CD O
( -LRB- O
s VBZ O
, , O
1H) CC O
, , O
13.10 CD O
(v.br NN O
s VBZ O
, , O
1 CD O
H) NN O
. . O

. . O
MS NNP O
: : O
ESI NNP O
( -LRB- O
+ve NN O
) -RRB- O
( -LRB- O
Method NNP O
A) NNP O
: : O
448 CD O
( -LRB- O
M+H) NNP O
\ , O
Retention NNP O
time NN O
11.12 CD O
min NN O
. . O

Example NNP O
12 CD O
: : O
S-Chloro-S-[beta]^-dichloro-benzenesulfonylamino^-methyl-indol-i- NNP B-NP
yl]-acetic JJ I-NP
acid NN I-NP
( -LRB- O
R<1> NNP O
, , O
R<3> NNP O
, , O
R<4> NNP O
, , O
R<5> NNP O
, , O
R<6> NNP O
, , O
R<9> NNP O
= SYM O
H5 CD O
R<2> CD O
= SYM O
Cl5 : O
R<7> JJ O
= SYM O
CH3 JJ B-NP
, , O
R<8> JJ O
= SYM O
3,4-CI2Ph JJ B-NP
) -RRB- O
. . O

[0167 CD O
] NN O

EMI28.1 . O

Preparation NNP O
12a CD O
[5-Chloro"3-(3,4-dichloro-benzenesulfonylamino)-2-methyl- : B-NP
indol-1-yl]-acetic JJ I-NP
acid NN I-NP
methyl NN I-NP
ester NN I-NP
. . O

To TO O
a DT O
mixture NN O
of IN O
3-amino-5-chloro-2-methylinclol-1-yl JJ B-NP
)acetic JJ I-NP
acid NN I-NP
methyl NN I-NP
ester NN I-NP
hydrochloride NN I-NP
( -LRB- O
compound NN O
of IN O
Preparation NNP O
1c CD O
, , O
0.15 CD O
g NN O
) -RRB- O
, , O
triethylamine NN B-NP
( -LRB- O
0.20 CD O
mL NN O
) -RRB- O
and CC O
tetrahydrofuran JJ B-NP
( -LRB- O
2.0 CD O
mL NN O
) -RRB- O
at IN O
-55<0>C NNP O
was VBD O
added VBN O
3,4-dichlorobenzenesulfonyl NN B-NP
chloride NN I-NP

( -LRB- O
0.13 CD O
g NN O
) -RRB- O
and CC O
the DT O
resulting VBG O
mixture NN O
was VBD O
stirred VBN O
at IN O
-5O<0>C JJ O
for IN O
thirty CD O
minutes NNS O
. . O

The DT O
reaction NN O
mixture NN O
was VBD O
filtered VBN O
and CC O
the DT O
filtrate NN O
concentrated VBD O
under IN O
reduced JJ O
pressure NN O
. . O

Purification NN O
of IN O
the DT O
residue NN O
by IN O
column NN O
chromatography NN O
on IN O
silica NN B-NP
gel NN O
gave VBD O
[5-chloro-3- . B-NP

( -LRB- O
3,4-dichloro-benzenesulfonylamino)-2-methylindol-1-yl]acetic JJ O
acid NN O
methyl NN O
ester NN O
, , O
0.08 CD O
g NN O
. . O

MS NNP O
: : O
ESI NNP O
( -LRB- O
+ve NN O
) -RRB- O
( -LRB- O
Method NNP O
B) NNP O
: : O
459 CD O
(M-H) NN O
, , O
Retention NNP O
time NN O
3.8 CD O
min NN O
. . O

Preparation NNP O
12b CD O
: : O
[5-chloro-3-(3,4-dichlorobenzenesulf JJ B-NP
onylamino)-2- CC I-NP
methylindol-1-yl]acetic JJ I-NP
acid NN I-NP
. . O

A DT O
solution NN O
of IN O
[5-chloro-3-(3,4-dichlorobenzenesulfonylamino)-2-methylindol-1- DT B-NP
yl]acetic JJ I-NP
acid NN I-NP
methyl NN I-NP
ester NN I-NP
( -LRB- O
0.08 CD O
g NN O
) -RRB- O
, , O
tetrahydrofuran JJ B-NP
( -LRB- O
2.0 CD O
mL NN O
) -RRB- O
and CC O
4.0 CD O
M NNP O
aqueous JJ O
sodium NN B-NP
hydroxide NN I-NP
solution NN O
( -LRB- O
2.0 CD O
mL NN O
) -RRB- O
was VBD O
stirred VBN O
at IN O
room NN O
temperature NN O
for IN O
one CD O
hour NN O
. . O

The DT O
tetrahydrofuran NN B-NP
was VBD O
removed VBN O
under IN O
reduced JJ O
pressure NN O
and CC O
pH NN O
of IN O
the DT O
residue NN O
adjusted VBN O
to TO O
-3-4 VB O
by IN O
the DT O
addition NN O
of IN O
concentrated JJ O
hydrochloric JJ B-NP
acid NN I-NP
. . O

The DT O
resulting VBG O
precipitate NN O
was VBD O
collected VBN O
by IN O
filtration NN O
and CC O
dried VBD O
to TO O
afford VB O
[5-chloro-3-(3,4-dichloro- DT B-NP
benzenesulfonylamino)-2-methylindol-1-yl]acetic JJ I-NP
acid NN I-NP
, , O
0.06 CD O
g NN O
. . O

<1>H JJ B-NP
NMR NNP O
( -LRB- O
DMSO-d6 NN B-NP
) -RRB- O
: : O
[delta JJ O
] SYM O
2.05 FW O
( -LRB- O
s PRP O
, , O
3H) CC O
, , O
4.96 CD O
( -LRB- O
s VBZ O
, , O
2H) CC O
, , O
6.70 CD O
( -LRB- O
d NN O
, , O
J NNP O
= SYM O
2.1 CD O
Hz NNP O
, , O
1 CD O
H) NNP O
, , O
7.00 CD O
( -LRB- O
dd NN O
, , O
J NNP O
= SYM O
2.1 CD O
, , O
8.7 CD O
Hz NNP O
, , O
1 CD O
H) NNP O
, , O
7.39 CD O
( -LRB- O
d NN O
, , O
J NNP O
= SYM O
8.8 CD O
Hz NNP O
, , O
1 CD O
H) NN O
, , O
7.51 CD O
( -LRB- O
dd NN O
, , O
J NNP O
= SYM O
2.1 CD O
, , O
8.4 CD O
Hz NNP O
, , O
1 CD O
H) NNP O
, , O
7.71 CD O
( -LRB- O
d NN O
, , O
J NNP O
= SYM O
2.1 CD O
Hz NNP O
, , O
1 CD O
H) NNP O
, , O
7.76 CD O
( -LRB- O
t NN O
, , O
J NNP O
= SYM O
8.4 CD O
Hz NNP O
, , O
1 CD O
H) NNP O
, , O
9.65 CD O
( -LRB- O
s VBZ O
, , O
1H) CC O
, , O
13.10 CD O
(v.br NN O
s VBZ O
, , O
1H) UH O
. . O

MS NNP O
: : O
ESI NNP O
( -LRB- O
+ve NN O
) -RRB- O
( -LRB- O
Method NNP O
A) NNP O
: : O
448 CD O
( -LRB- O
M+H) NNP O
, , O
Retention NNP O
time NN O
10.94 CD O
min NN O
. . O

Biological NNP O
Methods NNPS O

Compounds NNS O
of IN O
the DT O
invention NN O
were VBD O
tested VBN O
using VBG O
the DT O
following VBG O
biological JJ O
test NN O
methods NNS O
to TO O
determine VB O
their PRP$ O
ability NN O
to TO O
displace VB O
PGD2 NNP B-NP
from IN O
the DT O
CRTH2 NN O
receptor NN O
and CC O
for IN O
their PRP$ O
ability NN O
to TO O
antagonise VB O
the DT O
functional JJ O
effects NNS O
of IN O
PGD2 NN B-NP
at IN O
the DT O
CRTH2 NNP O
receptor NN O
. . O

Radioligand NNP O
Binding NNP O
Assay NNP O

The DT O
receptor NN O
binding NN O
assay NN O
is VBZ O
performed VBN O
in IN O
a DT O
final JJ O
volume NN O
of IN O
200 CD O
[mu]l JJ O
_ NN O
binding NN O
buffer NN O
[10 IN O
mM NN O
BES NNS B-NP
( -LRB- O
pH NN O
7.4) CD O
, , O
1 CD O
mM JJ O
EDTA NNP B-NP
, , O
10 CD O
mM NNS O
manganese JJ B-NP
chloride NN I-NP
, , O
0.01 CD O
% NN O
BSA NNP B-NP
] NNP O
and CC O
1 CD O
nM JJ O
[<3>H]-PGD2 JJ O
( -LRB- O
Amersham NNP O
Biosciences NNP O
UK NNP O
Ltd) NNP O
. . O

Ligands NNS O
are VBP O
added VBN O
in IN O
assay NN O
buffer NN O
containing VBG O
a DT O
constant JJ O
amount NN O
of IN O
DMSO NNP B-NP
( -LRB- O
1 CD O
% NN O
by IN O
volume NN O
) -RRB- O
. . O

Total JJ O
binding NN O
is VBZ O
determined VBN O
using VBG O
1 CD O
% NN O
by IN O
volume NN O
of IN O
DMSO NNP B-NP
in IN O
assay NN O
buffer NN O
and CC O
non-specific JJ O
binding NN O
is VBZ O
determined VBN O
using VBG O
10 CD O
[mu]M NNS O
of IN O
unlabeled JJ O
PGD2 NNS B-NP
( -LRB- O
Sigma NNP O
) -RRB- O
. . O

Human JJ O
embryonic JJ O
kidney NN O
( -LRB- O
HEK NN O
) -RRB- O
cell NN O
membranes NNS O
( -LRB- O
3.5 CD O
[mu]g NN O
) -RRB- O
expressing VBG O
the DT O
CRTH2 NN O
receptor NN O
are VBP O
incubated VBN O
with IN O
1.5 CD O
mg JJ O
wheatgerm NN O
agglutinin IN O
SPA NNP O
beads NNS O
and CC O
1 CD O
nM JJ O
[<3>H]-PGD2 JJ O
( -LRB- O
Amersham NNP O
Biosciences NNP O
UK NNP O
Ltd) NNP O
and CC O
the DT O
mixture NN O
incubated VBN O
for IN O
3 CD O
hours NNS O
at IN O
room NN O
temperature NN O
. . O

Bound NNP O
[<3>H]-PGD2 NNP O
is VBZ O
detected VBN O
using VBG O
a DT O
Microbeta NNP O
TRILUX NNP O
liquid JJ O
scintillation NN O
counter NN O
( -LRB- O
Perkin JJ O
Elmer NNP O
) -RRB- O
. . O

Compound NN O
IC50 IN O
value NN O
is VBZ O
determined VBN O
using VBG O
a DT O
6-point JJ O
dose NN O
response NN O
curve NN O
in IN O
duplicate NN O
with IN O
a DT O
semi-log JJ O
compound NN O
dilution NN O
series NN O
. . O

IC50 DT O
calculations NNS O
are VBP O
performed VBN O
using VBG O
Excel NNP O
and CC O
XLfit NNP O
( -LRB- O
Microsoft NNP O
) -RRB- O
, , O
and CC O
this DT O
value NN O
is VBZ O
used VBN O
to TO O
determine VB O
a DT O
Ki NNP O
value NN O
for IN O
the DT O
test NN O
compound NN O
using VBG O
the DT O
Cheng-Prusoff JJ O
equation NN O
. . O

Compounds NNS O
of IN O
the DT O
invention NN O
that WDT O
have VBP O
been VBN O
tested VBN O
in IN O
the DT O
binding NN O
assay NN O
are VBP O
illustrated VBN O
below IN O
in IN O
the DT O
following VBG O
Table NN O
. . O

[0180] . O

EMI29.1 . O

Key NN O
: : O
" `` O
++ NNS O
+ VBP O
" `` O
CRTH2 VB O
Ki NNP O
< NNP O
10OnM CC O
; : O
" `` O
++ VB O
" `` O
Ki NNP O
< NNP O
1[mu]M NNP O
; : O
V NNP O
Ki NNP O
< NNP O
10[mu]M . O
Functional NNP O
Assay NNP O
: : O
GTP[gamma]S NNP B-NP
Assay NNP O

The DT O
GTP[gamma]S NNP B-NP
Assay NNP O
is VBZ O
performed VBN O
in IN O
a DT O
final JJ O
volume NN O
of IN O
200 CD O
ml_ CD O
assay NN O
buffer NN O
( -LRB- O
2OmM IN O
HEPES NNP B-NP
pH IN O
7.4 CD O
, , O
1OmM NNP O
MgCI2 NNP B-NP
, , O
10OmM DT O
NaCI NNP B-NP
, , O
10[mu]g/ml_ JJ O
saponin NN O
) -RRB- O
. . O

DMSO NNP B-NP
concentrations NNS O
are VBP O
kept VBN O
constant JJ O
at IN O
1 CD O
% NN O
by IN O
volume NN O
. . O

Human JJ O
embryonic JJ O
kidney NN O
( -LRB- O
HEK NN O
) -RRB- O
cell NN O
membranes NNS O
( -LRB- O
3.5 CD O
[mu]g NN O
) -RRB- O
expressing VBG O
the DT O
CRTH2 NN O
receptor NN O
are VBP O
incubated VBN O
with IN O
the DT O
compounds NNS O
for IN O
15 CD O
min NN O
at IN O
3O<0>C JJ O
prior JJ O
to TO O
addition NN O
of IN O
PGD2 NNP B-NP
( -LRB- O
3OnM VBP O
final JJ O
concentration NN O
) -RRB- O
and CC O
GTP NNP B-NP
( -LRB- O
10[mu]M VBP O
final JJ O
concentration NN O
) -RRB- O
. . O

The DT O
assay NN O
solutions NNS O
are VBP O
then RB O
incubated VBN O
for IN O
30 CD O
minutes NNS O
at IN O
3O<0>C CD O
, , O
followed VBN O
by IN O
addition NN O
of IN O
[<35>S]-GTPyS NNS O
( -LRB- O
0.1 CD O
nM RB O
final JJ O
concentration NN O
) -RRB- O
. . O

The DT O
assay NN O
plate NN O
is VBZ O
than IN O
shaken VBN O
and CC O
incubated VBN O
for IN O
5 CD O
minutes NNS O
at IN O
3O<0>C. VBG O

Finally RB O
, , O
SPA JJ O
beads NNS O
( -LRB- O
Amersham NNP O
Biosciences NNP O
, , O
UK) NNP O
are VBP O
added VBN O
to TO O
a DT O
final JJ O
concentration NN O
of IN O
1.5mg/well CD O
and CC O
the DT O
plate NN O
shaken VBN O
and CC O
incubated VBN O
for IN O
30 CD O
minute NN O
at IN O
3O<0>C. VBG O

The DT O
sealed JJ O
plate NN O
is VBZ O
centrifuged VBN O
at IN O
1000g CD O
for IN O
10 CD O
mins NNS O
at IN O
30<0>C NNP O
and CC O
the DT O
bound JJ O
[<35>S]-GTPyS NNS O
is VBZ O
detected VBN O
on IN O
Microbeta NNP O
scintillation NN O
counter NN O
( -LRB- O
Perkin JJ O
Elmer NNP O
) -RRB- O
. . O

Compound NN O
IC50 IN O
value NN O
is VBZ O
determined VBN O
using VBG O
a DT O
6-point JJ O
dose NN O
response NN O
curve NN O
in IN O
duplicate NN O
with IN O
a DT O
semi-log JJ O
compound NN O
dilution NN O
series NN O
. . O

IC5O IN O
calculations NNS O
are VBP O
performed VBN O
using VBG O
Excel NNP O
and CC O
XLfit NNP O
( -LRB- O
Microsoft NNP O
) -RRB- O
, , O
and CC O
this DT O
value NN O
is VBZ O
used VBN O
to TO O
determine VB O
a DT O
Ki NNP O
value NN O
for IN O
the DT O
test NN O
compound NN O
using VBG O
the DT O
Cheng-Prusoff JJ O
equation NN O
. . O

As IN O
an DT O
illustration NN O
, , O
Examples NNP O
1 CD O
and CC O
9 CD O
had VBD O
a DT O
Ki NNP O
of IN O
<1 CD O
[mu]M NNS O
in IN O
this DT O
assay NN O
, , O
and CC O
Example NNP O
8 CD O
was VBD O
shown VBN O
to TO O
have VB O
a DT O
Ki NNP O
< NNP O
10OnM CD O
in IN O
this DT O
assay NN O
. . O

CLAIMS NNS O

1 CD O
. . O

A DT O
compound NN O
of IN O
general JJ O
formula NN O
[ IN O
I] NN O
or CC O
a DT O
pharmaceutically RB O
acceptable JJ O
salt NN O
, , O
N- NNP B-NP
oxide NN I-NP
, , O
hydrate JJ B-NP
, , O
or CC O
solvate JJ O
thereof . O
: : O

EMI31.1 . O

[ NN O
I] NNP O
in IN O
which WDT O
: : O

R<1> NNP O
, , O
R<2> NNP O
, , O
R<3> NNP O
and CC O
R<4> NNP O
are VBP O
independently RB O
hydrogen NN B-NP
, , O
( -LRB- B-NP
C1-C6 NNP I-NP
) -RRB- I-NP
alkyl NN I-NP
, , O
( -LRB- B-NP
C1-C6 NNP I-NP
) -RRB- I-NP
haloalkyl NN I-NP
, , O
halo NN B-NP
, , O
-S( JJ O
O)nR<10> NNP O
, , O
-NR<11>SO2R<10> JJ O
, , O
-SO2N( JJ O
R<11>)2 NNP O
, , O
-N( JJ O
R<11>)2 NNP O
, , O
-NR<11>C( JJ O
O)R<10> NNP B-NP
, , O
-C( JJ O
O)N( NNP O
R<11>)2 NNP O
, , O
CO2R<11> NNP B-NP
, , O
-C( JJ O
O)R<10> NNP B-NP
, , O
CN NNP B-NP
or CC O
a DT O
group NN O
OR<12> NNP O
; : O
wherein WRB O
each DT O
R<10> NN O
is VBZ O
independently RB O
( -LRB- B-NP
C1-C6 NNS I-NP
) -RRB- I-NP
alkyl NN I-NP
, , O
( -LRB- B-NP
C1-C6 NNP I-NP
) -RRB- I-NP
haloalkyl NN I-NP
, , O
cycloalkyl NN B-NP
, , O
aryl NN B-NP
, , O
or CC O
heteroaryl NN B-NP
; : O

R<11> NNP O
is VBZ O
independently RB O
hydrogen NN B-NP
, , O
( -LRB- B-NP
C1-C6 NNP I-NP
) -RRB- I-NP
alkyl NN I-NP
, , O
( -LRB- B-NP
Ci-C6 NNP I-NP
) -RRB- I-NP
haloalkyl NN I-NP
, , O
cycloalkyl NN B-NP
, , O
aryl NN B-NP
, , O
or CC O
heteroaryl NN B-NP
; : O

R<12> NN O
is VBZ O
hydrogen NN B-NP
, , O
( -LRB- B-NP
C1-C6 NNP I-NP
) -RRB- I-NP
alkyl NN I-NP
, , O
( -LRB- B-NP
C1-C6 NNP I-NP
) -RRB- I-NP
haloalkyl NN I-NP
, , O
cycloalkyl NN B-NP
, , O
or CC O
a DT O
group NN O
SO2R<10> NNP B-NP
, , O
wherein WRB O
n NN O
is VBZ O
O NNP O
1 CD O
or CC O
2 CD O
; : O

R<5> NNP O
and CC O
R<6> NNP O
are VBP O
independently RB O
hydrogen NN B-NP
, , O
( -LRB- B-NP
C1-C6 NNP I-NP
) -RRB- I-NP
alkyl NN I-NP
or CC O
( -LRB- B-NP
CrC6 NN I-NP
) -RRB- I-NP
haloalkyl NN I-NP
, , O
or CC O
R<5> NNP O
and CC O
R<6> NNP O
together RB O
with IN O
the DT O
atom NN O
to TO O
which WDT O
they PRP O
are VBP O
attached VBN O
form NN O
a DT O
cycloalkyl NN B-NP
group NN O
; : O
R<7> NNP O
is VBZ O
hydrogen NN B-NP
, , O
( -LRB- B-NP
C1-C6 NNP I-NP
) -RRB- I-NP
alkyl NN I-NP
, , O
or CC O
( -LRB- B-NP
C1-C6 NN I-NP
) -RRB- I-NP
haloalkyl NN I-NP
; : O

R<8> NNP O
is VBZ O
aryl RB B-NP
, , O
heteroaryl NN B-NP
, , O
aryl-fused-heterocycloalkyl NN B-NP
, , O
heteroaryl-fused-cycloalkyl NN B-NP
, , O
heteroaryl-fused-heterocycloalkyl NN B-NP
or CC O
aryl-fused-cycloalkyl NN B-NP
; : O
and CC O

R<9> NN O
is VBZ O
hydrogen NN B-NP
, , O
( -LRB- B-NP
C1-C6 NNP I-NP
) -RRB- I-NP
alkyl NN I-NP
, , O
( -LRB- B-NP
C1-C6 NNP I-NP
) -RRB- I-NP
haloalkyl NN I-NP
, , O
or CC O
cycloalkyl NN B-NP
. . O

2. CD O
A DT O
compound NN O
as RB O
claimed VBD O
in IN O
claim NN O
1 CD O
wherein WRB O
R<1> NNP O
, , O
R<2> NNP O
, , O
R<3> NNP O
and CC O
R<4> NNP O
are VBP O
independently RB O
selected VBN O
from IN O
hydrogen NN B-NP
, , O
methyl NN B-NP
, , O
ethyl NN B-NP
, , O
n- NNS O
and CC O
iso-propyl NN B-NP
, , O
trifluoromethyl NN B-NP
, , O
difluoromethyl NN B-NP
, , O
cyclopropyl NN B-NP
, , O
cyclobutyl NN B-NP
, , O
fluoro NN B-NP
, , O
chloro NN B-NP
, , O
bromo NN B-NP
, , O
nitrile NN B-NP

( -LRB- O
CN) NNP B-NP
, , O
-S( NNP O
O)nR<10> NNP O
, , O
-SO2N( JJ O
R<11>)2 NNP O
, , O
-N( JJ O
R<11>)2 NNP O
, , O
-NR<11>C( JJ O
O)R<10> NNP B-NP
, , O
-CO2R<11> JJ O
, , O
-C( JJ O
O)R<10> NNP B-NP
, , O
and CC O
-OR<12> JJ O
wherein IN O
each DT O
R<10> NN O
is VBZ O
independently RB O
selected VBN O
from IN O
methyl NN B-NP
, , O
ethyl NN B-NP
, , O
n- NNS O
and CC O
iso-propyl NN B-NP
; : O
trifluoromethyl NN B-NP
difluoromethyl NN B-NP
, , O
cyclopropyl NN B-NP
, , O
cyclobutyl NN B-NP
, , O
cyclopentyl NN B-NP
, , O
cyclohexyl NN B-NP
, , O
phenyl NN B-NP
, , O
pyridyl NN B-NP
, , O
thienyl NN B-NP
and CC O
furanyl NN B-NP
, , O
and CC O
each DT O
R<11> NN O
is VBZ O
independently RB O
selected VBN O
from IN O
hydrogen NN B-NP
, , O
methyl NN B-NP
, , O
ethyl NN B-NP
, , O
n- NNS O
and CC O
iso-propyl NN B-NP
, , O
trifluoromethyl NN B-NP
, , O
difluoromethyl NN B-NP
, , O
cyclopropyl NN B-NP
, , O
cyclobutyl NN B-NP
, , O
cyclopentyl NN B-NP
, , O
cyclohexyl NN B-NP
, , O
cyclopropylmethyl NN B-NP
, , O
cyclopentylmethyl NN B-NP
, , O
cyclohexylmethyl NN B-NP
, , O
cyclopropylethyl NN B-NP
, , O
cyclopentylethyl NN B-NP
, , O
cyclohexylethyl NN B-NP
, , O
phenyl NN B-NP
, , O
pyridyl NN B-NP
, , O
thienyl NN B-NP
and CC O
furanyl NN B-NP
. . O

3. CD O
A DT O
compound NN O
as RB O
claimed VBD O
in IN O
claim NN O
1 CD O
wherein WRB O
R<1> NNP O
, , O
R<2> NNP O
, , O
R<3> NNP O
and CC O
R<4> NNP O
are VBP O
independently RB O
selected VBN O
from IN O
hydrogen NN B-NP
and CC O
chloro NN B-NP
. . O

4 LS O
. . O
A DT O
compound NN O
as RB O
claimed VBD O
in IN O
claim NN O
1 CD O
wherein WRB O
R<1> NNP O
, , O
R<3> NNP O
and CC O
R<4> NNP O
are VBP O
each DT O
hydrogen NN B-NP
and CC O
R<2> NNP O
is VBZ O
chloro NN B-NP
. . O

5 CD O
. . O
A DT O
compound NN O
as IN O
claimed VBN O
in IN O
any DT O
of IN O
the DT O
preceding VBG O
claims NNS O
wherein IN O
R<5> NNP O
and CC O
R<6> NNP O
are VBP O
independently RB O
selected VBN O
from IN O
hydrogen NN B-NP
, , O
methyl NN B-NP
, , O
ethyl NN B-NP
, , O
n- NNS O
and CC O
iso-propyl NN B-NP
, , O
trifluoromethyl NN B-NP
, , O
difluoromethyl NN B-NP
, , O
cyclopropyl NN B-NP
, , O
and CC O
cyclobutyl NN B-NP
. . O

6 CD O
. . O

A DT O
compound NN O
as IN O
claimed VBN O
in IN O
any DT O
of IN O
claims NNS O
1 CD O
to TO O
4 CD O
wherein WRB O
R<5> NNP O
and CC O
R<6> NNP O
together RB O
with IN O
the DT O
atom NN O
to TO O
which WDT O
they PRP O
are VBP O
attached VBN O
form NN O
a DT O
cyclopropyl NN B-NP
, , O
cyclopentyl NN B-NP
or CC O
cyclohexyl NN B-NP
ring NN O
. . O

7. CD O
A DT O
compound NN O
as IN O
claimed VBN O
in IN O
any DT O
of IN O
claims NNS O
1 CD O
to TO O
4 CD O
wherein CD O
both DT O
of IN O
R<5> NNP O
and CC O
R<6> NNP O
are VBP O
hydrogen NN B-NP
. . O

8. CD O
A DT O
compound NN O
as IN O
claimed VBN O
in IN O
any DT O
of IN O
the DT O
preceding VBG O
claims NNS O
wherein WRB O
R<7> NNP O
is VBZ O
selected VBN O
from IN O
hydrogen NN B-NP
, , O
methyl NN B-NP
, , O
ethyl NN B-NP
, , O
n- NNS O
and CC O
iso-propyl NN B-NP
, , O
trifluoromethyl NN B-NP
and CC O
difluoromethyl NN B-NP
. . O

9 CD O
. . O
A DT O
compound NN O
as IN O
claimed VBN O
in IN O
any DT O
of IN O
claims NNS O
1 CD O
to TO O
7 CD O
wherein WRB O
R<7> NNP O
is VBZ O
methyl NN B-NP
. . O

10 CD O
. . O

A DT O
compound NN O
as IN O
claimed VBN O
in IN O
any DT O
of IN O
the DT O
preceding VBG O
claims NNS O
wherein WRB O
R<8> NNP O
is VBZ O
optionally RB O
substituted VBN O
phenyl NN B-NP
, , O
naphthyl NN B-NP
, , O
quinolinyl NN B-NP
, , O
pyridyl NN B-NP
, , O
thienyl NN B-NP
, , O
furanyl NN B-NP
, , O
azolyl NN B-NP
, , O
thiazolyl NN B-NP
, , O
diazolyl NN B-NP
, , O
imidazolyl NN B-NP
, , O
tetrahydroquinolinyl NN B-NP
, , O
indolinyl NN B-NP
, , O
benzodioxinyl NN B-NP
, , O
benxodioxolyl NN B-NP
, , O
dihydrobenzofuranyl NN B-NP
, , O
isoindolonyl NN B-NP
, , O
indolinyl NN B-NP
, , O
benzodioxinyl NN B-NP
, , O
benzodioxolyl NN B-NP
, , O
dihydrobenzofuranyl NN B-NP
, , O
isoindolonyl NN B-NP
, , O
tetrahydronaphthyl NN B-NP
and CC O
indanyl NN B-NP
. . O

11 CD O
. . O

A DT O
compound NN O
as IN O
claimed VBN O
in IN O
any DT O
of IN O
claims NNS O
1 CD O
to TO O
9 CD O
wherein WRB O
R<8> NNP O
is VBZ O
optionally RB O
substituted VBN O
phenyl NN B-NP
. . O

12 CD O
. . O
A DT O
compound NN O
as RB O
claimed VBD O
in IN O
claim NN O
10 CD O
or CC O
claim NN O
11 CD O
wherein WRB O
any DT O
optional JJ O
substitutents NNS O
present JJ O
in IN O
R<8> NNP O
are VBP O
selected VBN O
from IN O
fluoro NN B-NP
, , O
chloro NN B-NP
, , O
phenyl NN B-NP
, , O
methanesulfonyl NN B-NP
, , O
4-ethanesulfonylphenyl JJ B-NP
, , O
trifluoromethyl JJ B-NP
, , O
morpholine-4-sulfonyl JJ B-NP
, , O
pyrrolidine-1-carbonyl JJ B-NP
, , O
and CC O
cyclobutylcarbamoyl NN B-NP
. . O
13 CD O
. . O

A DT O
compound NN O
as IN O
claimed VBN O
in IN O
any DT O
of IN O
claims NNS O
1 CD O
to TO O
9 CD O
wherein WRB O
R<8> PRP O
is VBZ O
selected VBN O
from IN O
A- NNP B-NP
chlorophenyl NN I-NP
, , O
2-chlorophenyl JJ B-NP
, , O
4-(trifluoromethyl)phenyl JJ B-NP
, , O
4-(methylsulfonyl)phenyl JJ B-NP
, , O
A- NNP B-NP
fluorophenyl NN I-NP
, , O
2-naphthyl JJ B-NP
, , O
1 CD B-NP
-naphthyl NN I-NP
, , O
2,3-dichlorophenyl JJ B-NP
, , O
8-quinolinyl JJ B-NP
, , O
3,5- CD B-NP
dichlorophenyl NN I-NP
, , O
3,4-dichlorophenyl JJ B-NP
. . O

14 CD O
. . O

A DT O
compound NN O
as IN O
claimed VBN O
in IN O
any DT O
of IN O
the DT O
preceding VBG O
claims NNS O
wherein WRB O
R<9> NNP O
is VBZ O
selected VBN O
from IN O
hydrogen NN B-NP
, , O
methyl NN B-NP
, , O
ethyl NN B-NP
, , O
n- NNS O
or CC O
iso-propyl NN B-NP
, , O
trifluoromethyl NN B-NP
, , O
difluoromethyl NN B-NP
, , O
cyclopropyl NN B-NP
and CC O
cyclobutyl NN B-NP
. . O

15 CD O
. . O

A DT O
compound NN O
as IN O
claimed VBN O
in IN O
any DT O
of IN O
claims NNS O
1 CD O
to TO O
13 CD O
wherein WRB O
R<9> NNP O
is VBZ O
hydrogen NN B-NP
. . O

16 CD O
. . O

A DT O
compound NN O
as RB O
claimed VBD O
in IN O
claim NN O
1 CD O
wherein WRB O
R<1> NNP O
, , O
R<3> NNP O
, , O
R<4> NNP O
, , O
R<5> NNP O
, , O
R<6> NNP O
and CC O
R<9> NNP O
are VBP O
each DT O
hydrogen NN B-NP
, , O
R<2> NNP O
is VBZ O
chloro NN B-NP
, , O
R<7> NNP O
is VBZ O
methyl NN B-NP
, , O
and CC O
R<8> NNP O
is VBZ O
selected VBN O
from IN O
4-chlorophenyl JJ B-NP
, , O
2- CD B-NP
chlorophenyl NN I-NP
, , O
4-(trifluoromethyl)phenyl JJ B-NP
, , O
4-(methylsulfonyl)phenyl JJ B-NP
, , O
4-fluorophenyl JJ B-NP
, , O
Z NNP B-NP
- : I-NP
naphthyl NN I-NP
, , O
1-naphthyl JJ B-NP
, , O
2,3-dichlorophenyl JJ B-NP
, , O
8-quinolinyl JJ B-NP
, , O
3,5-dichlorophenyl JJ B-NP
, , O
and CC O
3,4- CD B-NP
dichlorophenyl NN I-NP
. . O

17 CD O
. . O

A DT O
pharmaceutical JJ O
composition NN O
comprising VBG O
a DT O
compound NN O
as IN O
claimed VBN O
in IN O
any DT O
of IN O
the DT O
preceding VBG O
claims NNS O
together RB O
with IN O
one CD O
or CC O
more JJR O
pharmaceutically RB O
acceptable JJ O
carriers NNS O
. . O

18 CD O
. . O

The DT O
use NN O
of IN O
a DT O
compound NN O
as IN O
claimed VBN O
in IN O
any DT O
of IN O
claims NNS O
1 CD O
to TO O
16 CD O
in IN O
the DT O
manufacture NN O
of IN O
a DT O
composition NN O
for IN O
treatment NN O
of IN O
a DT O
condition NN O
responsive JJ O
to TO O
modulation NN O
of IN O
CRTH2 NNP O
receptor NN O
activity NN O
. . O

19 CD O
. . O

A DT O
method NN O
of IN O
treatment NN O
of IN O
a DT O
condition NN O
responsive JJ O
to TO O
modulation NN O
of IN O
CRTH2 NNP O
receptor NN O
activity NN O
, , O
comprising NN O
administering NN O
to TO O
a DT O
patient JJ O
suffering NN O
such JJ O
condition NN O
an DT O
effective JJ O
amount NN O
of IN O
a DT O
compound NN O
as IN O
claimed VBN O
in IN O
any DT O
of IN O
claims NNS O
1 CD O
to TO O
16 CD O
. . O
20 CD O
. . O

The DT O
use NN O
as IN O
claimed VBN O
in IN O
claim NN O
18 CD O
or CC O
a DT O
method NN O
as IN O
claimed VBN O
in IN O
claim NN O
19 CD O
wherein WRB O
the DT O
condition NN O
is VBZ O
selected VBN O
from IN O
asthma NN O
, , O
chronic JJ O
obstructive JJ O
pulmonary NN O
disease NN O
, , O
allergic JJ O
airway NN O
syndrome NN O
, , O
bronchitis NN O
, , O
cystic JJ O
fibrosis NN O
, , O
emphysema NN O
and CC O
rhinitis NN O
. . O

21 CD O
. . O

The DT O
use NN O
as IN O
claimed VBN O
in IN O
claim NN O
18 CD O
or CC O
a DT O
method NN O
as IN O
claimed VBN O
in IN O
claim NN O
19 CD O
wherein WRB O
the DT O
condition NN O
is VBZ O
selected VBN O
from IN O
psoriasis NN O
, , O
atopic NN O
and CC O
non-atopic JJ O
dermatitis NN O
Crohn NNP O
's POS O
disease NN O
, , O
ulcerative JJ O
colitis NN O
, , O
and CC O
irritable JJ O
bowel NN O
disease NN O
. . O

-DOCSTART- X X O

[0001] JJ O
INHIBITION NN O
OF IN O
POLYMERISATION NNP O
Field NNP O
of IN O
the DT O
Invention NN O

This DT O
invention NN O
relates VBZ O
to TO O
the DT O
inhibition NN O
of IN O
premature JJ O
polymerisation NN O
of IN O
monomers NNS O
, , O
in IN O
particular JJ O
ethylenically NN O
unsaturated JJ O
monomers NNS O
. . O

Background NN O
to TO O
the DT O
Invention NN O

Many JJ O
of IN O
the DT O
industrially NN O
important JJ O
ethylenically RB O
unsaturated JJ O
monomers NNS O
are VBP O
highly RB O
susceptible JJ O
to TO O
unwanted JJ O
radical JJ O
polymerisation NN O
. . O

Examples NNS O
of IN O
these DT O
monomers NNS O
include VBP O
styrene NN B-NP
, , O
[alpha]-methylstyrene JJ B-NP
, , O
styrene JJ B-NP
sulphonic JJ I-NP
acid NN I-NP
, , O
vinyltoluene NN B-NP
, , O
divinylbenzenes NNS B-NP
and CC O
dienes NNS B-NP
such JJ O
as IN O
butadiene NN B-NP
or CC O
isoprene NN B-NP
. . O

Premature NNP O
polymerisation NN O
may MD O
occur VB O
during IN O
manufacture NN O
, , O
purification NN O
or CC O
storage NN O
of IN O
the DT O
monomer NN O
. . O

Many JJ O
of IN O
these DT O
monomers NNS O
are VBP O
purified VBN O
by IN O
distillation NN O
. . O

It PRP O
is VBZ O
in IN O
this DT O
operation NN O
where WRB O
premature JJ O
polymerisation NN O
is VBZ O
most RBS O
likely JJ O
to TO O
occur VB O
and CC O
is VBZ O
the DT O
most RBS O
troublesome JJ O
. . O

Methods NNS O
to TO O
prevent VB O
or CC O
reduce VB O
the DT O
amount NN O
of IN O
such JJ O
polymerisations NNS O
are VBP O
essential JJ O
to TO O
prevent VB O
a DT O
dangerous JJ O
runaway JJ O
reaction NN O
, , O
which WDT O
can MD O
decrease VB O
cost-effectiveness NN O
of IN O
the DT O
process NN O
and CC O
be VB O
potentially RB O
explosive JJ O
in IN O
nature NN O
. . O

Stable JJ O
nitroxides NNS B-NP
are VBP O
known VBN O
to TO O
inhibit VB O
the DT O
premature JJ O
polymerization NN O
of IN O
ethylenically RB O
unsaturated JJ O
monomers NNS O
. . O

Many JJ O
of IN O
these DT O
nitroxides NNS B-NP
are VBP O
based VBN O
on IN O
2,2,6,6- CD B-NP
tetramethylpiperidine-1 NN I-NP
-oxide NN I-NP
( -LRB- O
"TEMPO" NN O
) -RRB- O
, , O
a DT O
particular JJ O
example NN O
being VBG O
4-hydroxy-2 JJ B-NP
, , I-NP
2,6,6- CD I-NP
tetramethylpiperidine-1 NN I-NP
-oxide NN I-NP
( -LRB- O
"4-hydroxy-TEMPO" JJ O
) -RRB- O
, , O
i FW O
.e FW O
. . O

[0006 CD O
] NN O

EMI2.1 . O

US PRP O
5932735 CD O
and CC O
US PRP O
6080864 CD O
describe VBP O
various JJ O
TEMPO NNP B-NP
derivatives NNS O
which WDT O
are VBP O
stated VBN O
to TO O
be VB O
useful JJ O
in IN O
inhibiting VBG O
the DT O
premature JJ O
polymerisation NN O
of IN O
unsaturated JJ O
acids NNS B-NP
, , O
esters NNS B-NP
, , O
amides NNS B-NP
, , O
nitriles NNS O
and CC O
ethers NNS B-NP
; : O
vinyl NN B-NP
pyridine NN I-NP
, , O
diethyl NN B-NP
vinylphosphonate NN I-NP
and CC O
sodium NN B-NP
styrenesulfonate NN I-NP
. . O

Examples NNS O
of IN O
the DT O
nitroxide NN O
compounds VBZ O
taught VBN O
in IN O
this DT O
publication NN O
include VBP O
4-allyloxy- DT B-NP
TEMPO NNP I-NP
and CC O
4-(2-methoxyethoxy)-TEMPO JJ B-NP
. . O
US PRP O
6403850 CD O
discloses NNS O
nitroxide JJ B-NP
derivatives NNS I-NP
, , O
including VBG O
4-carbomethoxy-TEMPO JJ B-NP
, , O
A- NNP B-NP
carboethoxy-TEMPO NN I-NP
and CC O
4-ethanoyloxy-TEMPO JJ B-NP
, , O
as IN O
being VBG O
useful JJ O
as IN O
inhibitors NNS O
of IN O
premature JJ O
polymerisation NN O
of IN O
ethylenically RB O
unsaturated JJ O
monomers NNS O
. . O

EP-A-0574666 CD O
describes VBZ O
the DT O
synthesis NN O
of IN O
various JJ O
4-alkoxy-TEMPO JJ B-NP
compounds NNS O
. . O

In IN O
particular JJ O
, , O
this DT O
publication NN O
teaches VBZ O
the DT O
compounds NNS O
4-methoxy-TEMPO JJ B-NP
, , O
4-ethoxy-TEMPO JJ B-NP
and CC O
4-n-butoxy-TEMPO JJ B-NP
. . O

US PRP O
5631366 CD O
teaches VBZ O
that IN O
4-alkoxy-TEMPO JJ B-NP
derivatives NNS O
can MD O
be VB O
used VBN O
as IN O
catalysts NNS O
in IN O
the DT O
synthesis NN O
of IN O
3-formylcephem JJ B-NP
derivatives NNS O
. . O

Specifically RB O
disclosed VBN O
are VBP O
4-methoxy-TEMPO JJ B-NP
, , O
4-butoxy-TEMPO JJ B-NP
and CC O
4-hexoxy-TEMPO JJ B-NP
. . O

JP-A-5320217 DT O
teaches VBZ O
that IN O
4-alkoxy-TEMPO JJ B-NP
compounds NNS O
are VBP O
useful JJ O
in IN O
preventing VBG O
polymerisation NN O
of IN O
methacrylic JJ B-NP
acid NN I-NP
monomers NNS O
when WRB O
used VBN O
in IN O
combination NN O
with IN O
phenothiazines NNS B-NP
, , O
aromatic JJ O
amines NNS B-NP
of IN O
phenolic JJ B-NP
compounds NNS I-NP
. . O

Specifically RB O
disclosed VBN O
are VBP O
A- NNP B-NP
methoxy-TEMPO NN I-NP
and CC O
4-ethoxy-TEMPO JJ B-NP
. . O

WO-A-98/56746 CD O
describes VBZ O
a DT O
composition NN O
for IN O
inhibiting VBG O
the DT O
premature JJ O
polymerisation NN O
of IN O
certain JJ O
ethylenically RB O
unsaturated JJ O
acrylate NN O
monomers NNS O
. . O

The DT O
composition NN O
comprises VBZ O
an DT O
ethylenically RB O
unsaturated JJ O
acrylate NN O
monomer NN O
and CC O
a DT O
synergistic JJ O
mixture NN O
of IN O
two CD O
nitroxide JJ O
compounds NNS O
. . O

This DT O
publication NN O
describes VBZ O
a DT O
range NN O
of IN O
nitroxide NN O
compounds NNS O
, , O
including VBG O
A- NNP B-NP
hydroxy-TEMPO NN I-NP
, , O
4-propoxy-TEMPO JJ B-NP
, , O
4-(2-methoxyethoxyacetoxy)-TEMPO JJ B-NP
. . O

The DT O
purification NN O
of IN O
ethylenically RB O
unsaturated JJ O
monomers NNS O
usually RB O
involves VBZ O
the DT O
partition NN O
of IN O
the DT O
monomers NNS O
into IN O
organic JJ O
and CC O
aqueous JJ O
phases NNS O
. . O

Often RB O
, , O
when WRB O
a DT O
stable JJ O
nitroxide NN B-NP
inhibitor NN O
is VBZ O
used VBN O
, , O
the DT O
inhibitor NN O
only RB O
partitions NNS O
sufficiently RB O
well RB O
into IN O
only RB O
one CD O
of IN O
the DT O
phases NNS O
. . O

Compounds NNS O
such JJ O
as IN O
4-hydroxy-TEMPO NNS B-NP
have VBP O
good JJ O
water NN B-NP
solubility NN O
but CC O
are VBP O
generally RB O
poorly RB O
soluble JJ O
in IN O
non-polar JJ O
organic JJ O
solvents NNS O
. . O

As IN O
a DT O
result NN O
, , O
premature JJ O
polymerisation NN O
is VBZ O
only RB O
effectively RB O
inhibited VBN O
in IN O
the DT O
aqueous JJ O
phase NN O
, , O
not RB O
the DT O
organic JJ O
phase NN O
. . O

There EX O
remains VBZ O
a DT O
need NN O
for IN O
compounds NNS O
and CC O
compositions NNS O
which WDT O
allow VBP O
for IN O
effective JJ O
inhibition NN O
of IN O
polymerisation NN O
in IN O
both DT O
the DT O
aqueous JJ O
and CC O
organic JJ O
phases NNS O
. . O

Summary NNP O
of IN O
the DT O
Invention NN O

The DT O
present JJ O
invention NN O
is VBZ O
based VBN O
in IN O
part NN O
on IN O
the DT O
discovery NN O
that IN O
, , O
by IN O
using VBG O
hydrocarbyloxy JJ B-NP
substituents NNS O
at IN O
the DT O
4-position JJ O
, , O
the DT O
miscibility NN O
of IN O
TEMPO NNP B-NP
in IN O
organic JJ O
solvents NNS O
may MD O
be VB O
significantly RB O
increased VBN O
. . O

Such JJ O
derivatives NNS O
may MD O
be VB O
effective JJ O
at IN O
inhibiting VBG O
the DT O
premature JJ O
polymerisation NN O
of IN O
ethylenically RB O
unsaturated JJ O
monomers NNS O
, , O
especially RB O
when WRB O
used VBN O
in IN O
combination NN O
with IN O
a DT O
more JJR O
hydrophilic JJ O
nitroxide NN B-NP
compound NN I-NP
such JJ O
as IN O
4-hydroxy-TEMPO JJ B-NP
. . O

According VBG O
to TO O
a DT O
first JJ O
aspect NN O
of IN O
the DT O
invention NN O
, , O
a DT O
method NN O
of IN O
inhibiting VBG O
polymerisation NN O
of IN O
an DT O
ethylenically NN O
unsaturated JJ O
monomer NN O
comprises VBZ O
contacting VBG O
the DT O
monomer NN O
with IN O
a DT O
compound NN O
of IN O
formula NN O
( -LRB- O
I PRP O
) -RRB- O
: : O

[0017] . O

EMI4.1 . O

( -LRB- O
I PRP O
) -RRB- O
wherein WRB O

R<1> PRP O
is VBZ O
C4-20 JJ B-NP
hydrocarbyl NN I-NP
; : O
and CC O

R NN O
[iota]2 NN O
, , O
R NN O
r>3 VBZ O
, , O
O UH O
R4 . O
and CC O
R NN O
are VBP O
independently RB O
each DT O
Ci-6 NN B-NP
alkyl NN I-NP
. . O

A DT O
second JJ O
aspect NN O
of IN O
the DT O
invention NN O
is VBZ O
a DT O
composition NN O
for IN O
inhibiting VBG O
polymerisation NN O
of IN O
an DT O
ethylenically NN O
unsaturated JJ O
monomer NN O
, , O
which WDT O
comprises VBZ O
first JJ O
and CC O
second JJ O
inhibitors NNS O
of IN O
said VBD O
polymerisation NN O
, , O
wherein WRB O
the DT O
first JJ O
inhibitor NN O
is VBZ O
a DT O
first JJ O
nitroxide JJ B-NP
compound NN I-NP
and CC O
is VBZ O
of IN O
the DT O
formula NN O
( -LRB- O
I PRP O
) -RRB- O
, , O
and CC O
the DT O
second JJ O
inhibitor NN O
is VBZ O
, , O
for IN O
example NN O
but CC O
not RB O
limited JJ O
thereto NN O
, , O
a DT O
second JJ O
nitroxide NN B-NP
compound NN I-NP
. . O

Another DT O
aspect NN O
of IN O
the DT O
invention NN O
is VBZ O
the DT O
use NN O
of IN O
a DT O
compound NN O
of IN O
formula NN O
( -LRB- O
I PRP O
) -RRB- O
as IN O
an DT O
inhibitor NN O
of IN O
polymerisation NN O
of IN O
an DT O
ethylenically NN O
unsaturated JJ O
monomer NN O
. . O

Another DT O
aspect NN O
of IN O
the DT O
invention NN O
is VBZ O
the DT O
use NN O
of IN O
a DT O
composition NN O
of IN O
the DT O
invention NN O
, , O
as IN O
an DT O
inhibitor NN O
of IN O
polymerisation NN O
of IN O
an DT O
ethylenically NN O
unsaturated JJ O
monomer NN O
. . O

The DT O
present JJ O
invention NN O
is VBZ O
particularly RB O
useful JJ O
in IN O
inhibiting VBG O
the DT O
polymerisation NN O
of IN O
monomers NNS O
such JJ O
as IN O
styrenes NNS B-NP
, , O
vinyltoluenes NNS B-NP
, , O
divinylbenzenes NNS B-NP
, , O
dienes NNS B-NP
( -LRB- O
e NN O
.g NN O
. . O

butadiene NN B-NP
or CC O
isoprene NN B-NP
) -RRB- O
, , O
acrylonitrile VBP B-NP
and CC O
esters NNS B-NP
( -LRB- O
e NN O
.g NN O
. . O

butyl NN B-NP
acrylate NN I-NP
, , O
2-ethylhexyl JJ B-NP
acrylate NN I-NP
or CC O
vinyl NN B-NP
acetate NN I-NP
) -RRB- O
. . O

Of IN O
particular JJ O
mention NN O
are VBP O
hydrocarbon NN B-NP
monomers NNS O
. . O

Compounds NNS O
of IN O
the DT O
present JJ O
invention NN O
, , O
particularly RB O
those DT O
wherein IN O
R<1> NNP O
is VBZ O
C4-6 DT B-NP
hydrocarbyl NN I-NP
, , O
may MD O
be VB O
prepared VBN O
in IN O
liquid JJ O
form NN O
and CC O
thus RB O
may MD O
be VB O
easier JJR O
and CC O
more JJR O
environmentally RB O
acceptable JJ O
compared VBN O
with IN O
conventional JJ O
solid JJ O
inhibitors NNS O
. . O

Furthermore RB O
, , O
the DT O
compounds NNS O
may MD O
improve VB O
the DT O
solubility NN O
of IN O
monomers NNS O
and/or CC O
other JJ O
inhibitors NNS O
in IN O
organic JJ O
solvents NNS O
. . O

Description NN O
of IN O
Various JJ O
Embodiments NNS O

The DT O
term NN O
" `` O
TEMPO VB B-NP
" '' O
as IN O
used VBN O
herein RB O
refers VBZ O
to TO O
2,2,6,6-tetramethy JJ B-NP
!piperidine~1-oxide NN I-NP
. . O

The DT O
term NN O
"ethylenically RB O
unsaturated JJ O
monomer NN O
" '' O
as IN O
used VBN O
herein RB O
refers VBZ O
to TO O
a DT O
monomer NN O
comprising VBG O
at IN O
least JJS O
one CD O
carbon-carbon NN O
double JJ O
bond NN O
. . O

Such JJ O
a DT O
monomer NN O
may MD O
comprise VB O
an DT O
aliphatic JJ O
and/or CC O
an DT O
aromatic JJ O
moiety NN O
. . O

Examples NNS O
of IN O
such JJ O
monomers NNS O
include VBP O
styrenes NNS B-NP
( -LRB- O
e NN O
.g NN O
. . O

styrene NN B-NP
, , O
styrene NN B-NP
sulphonic JJ I-NP
acid NN I-NP
and CC O
[alpha]-methylstyrene NN B-NP
) -RRB- O
, , O
vinyltoluene NN B-NP
, , O
divinylbenzenes NNS B-NP
and CC O
dienes NNS B-NP
( -LRB- O
e NN O
.g NN O
. . O

butadiene NN B-NP
and CC O
isoprene NN B-NP
) -RRB- O
, , O
esters NNS B-NP
( -LRB- O
including VBG O
acetates NNS B-NP
, , O
e.g NN O
. . O

vinyl NN B-NP
acetate NN I-NP
, , O
and CC O
acrylates NNS B-NP
, , O
e.g NN O
. . O

2-ethylhexyl JJ B-NP
acrylate NN I-NP
and CC O
butyl NN B-NP
acrylate NN I-NP
) -RRB- O
, , O
acids NNS B-NP
( -LRB- O
e NN O
.g NN O
. . O

methacrylic JJ B-NP
acid NN I-NP
) -RRB- O
, , O
and CC O
the DT O
like JJ O
. . O

The DT O
term NN O
"ethylenically RB O
unsaturated JJ B-NP
hydrocarbon NN I-NP
monomer NN I-NP
" '' O
as IN O
used VBN O
herein RB O
refers VBZ O
to TO O
a DT O
monomer NN O
comprising VBG O
at IN O
least JJS O
one CD O
carbon-carbon NN O
double JJ O
bond NN O
and CC O
consisting VBG O
exclusively RB O
of IN O
hydrogen NN O
and CC O
carbon NN O
atoms NNS O
. . O

Such JJ O
a DT O
monomer NN O
may MD O
comprise VB O
an DT O
aliphatic JJ O
and/or CC O
an DT O
aromatic JJ O
moiety NN O
. . O

Examples NNS O
of IN O
such JJ O
monomers NNS O
include VBP O
styrenes NNS B-NP
( -LRB- O
e NN O
.g NN O
. . O

styrene NN B-NP
and CC O
[alpha] SYM B-NP
- : I-NP
methylstyrene NN I-NP
) -RRB- O
, , O
vinyltoluene NN B-NP
, , O
divinylbenzenes NNS B-NP
and CC O
dienes NNS B-NP
( -LRB- O
e NN O
.g NN O
. . O

butadiene NN B-NP
and CC O
isoprene NN B-NP
) -RRB- O
and CC O
the DT O
like JJ O
. . O

The DT O
term NN O
" `` O
C4-2O FW B-NP
hydrocarbyl JJ I-NP
" `` O
refers VBZ O
to TO O
a DT O
group NN O
consisting VBG O
exclusively RB O
of IN O
hydrogen NN O
and CC O
carbon NN O
atoms NNS O
, , O
and CC O
which WDT O
has VBZ O
4 CD O
, , O
5 CD O
, , O
6 CD O
, , O
7 CD O
, , O
8 CD O
, , O
9 CD O
, , O
10 CD O
, , O
11 CD O
, , O
12 CD O
, , O
13 CD O
, , O
14 CD O
, , O
15 CD O
, , O
16 CD O
, , O
17 CD O
, , O
18 CD O
, , O
19 CD O
or CC O
20 CD O
carbon NN O
atoms NNS O
. . O

Examples NNS O
of IN O
such JJ O
groups NNS O
include VBP O
C4-I0 JJ B-NP
alkyl NN I-NP
, , O
C4-I0 DT B-NP
alkenyl NN I-NP
, , O
C4-10 JJ B-NP
alkynyl NN I-NP
, , O
C4-I0 DT B-NP
cycloalkyl NN I-NP
, , O
aryl NN B-NP
, , O
-C%i0 DT O
alkyl-aryl NN O
and CC O
-C1-I0 DT O
alkyl-C^o JJ B-NP
cycloalkyl NN B-NP
. . O

The DT O
term NN O
" '' O
Ci-6 CC B-NP
alkyl RB I-NP
" '' O
as IN O
used VBN O
refers VBZ O
to TO O
a DT O
straight JJ O
or CC O
branched JJ O
chain NN O
alkyl NN O
moiety NN O
having VBG O
from IN O
1 CD O
, , O
2 CD O
, , O
3 CD O
, , O
4 CD O
, , O
5 CD O
or CC O
6 CD O
carbon NN O
atoms NNS O
. . O

This DT O
term NN O
refers VBZ O
to TO O
groups NNS O
such JJ O
as IN O
methyl NN B-NP
, , O
ethyl NN B-NP
, , O
propyl NN B-NP
(n-propyl NN O
or CC O
isopropyl NN B-NP
) -RRB- O
, , O
butyl NN B-NP
(n-butyl NN O
, , O
sec-butyl JJ B-NP
or CC O
tert-butyl JJ B-NP
) -RRB- O
, , O
pentyl JJ B-NP
, , O
hexyl NN B-NP
and CC O
the DT O
like JJ O
. . O

The DT O
term NN O
" `` O
C4-I0 JJ B-NP
alkyl NN I-NP
" '' O
as IN O
used VBN O
herein RB O
refers VBZ O
to TO O
a DT O
straight JJ O
or CC O
branched JJ O
chain NN O
alkyl NN O
moiety NN O
having VBG O
4 CD O
, , O
5 CD O
, , O
6 CD O
, , O
7 CD O
, , O
8 CD O
, , O
9 CD O
or CC O
10 CD O
carbon NN O
atoms NNS O
. . O

This DT O
term NN O
refers VBZ O
to TO O
groups NNS O
such JJ O
as IN O
butyl NN B-NP
(n- , O
butyl NN B-NP
, , O
sec-butyl JJ B-NP
or CC O
tert-butyl JJ B-NP
) -RRB- O
, , O
pentyl NN B-NP
, , O
hexyl NN B-NP
, , O
heptyl NN B-NP
, , O
octyl NN B-NP
, , O
nonyl NN B-NP
, , O
decyl NN B-NP
and CC O
the DT O
like JJ O
. . O

The DT O
term NN O
" `` O
C4-I0 JJ B-NP
alkenyl NN I-NP
" '' O
as IN O
used VBN O
herein RB O
refers VBZ O
to TO O
a DT O
straight JJ O
or CC O
branched JJ O
chain NN O
alkenyl NN B-NP
moiety NN O
having VBG O
4 CD O
, , O
5 CD O
, , O
6 CD O
, , O
7 CD O
, , O
8 CD O
, , O
9 CD O
or CC O
10 CD O
carbon NN O
atoms NNS O
. . O

This DT O
term NN O
refers VBZ O
to TO O
groups NNS O
such JJ O
as IN O
1- NNP B-NP
methylprop-1en-1-yl NN I-NP
, , O
2-methylprop-1-en-1-yl JJ B-NP
, , O
1-methylprop-2-en-1-yl JJ B-NP
, , O
2-methylprop-2-en- CD B-NP
1-yl JJ I-NP
, , O
penten-1-yl JJ B-NP
, , I-NP
penten-2-yl JJ I-NP
, , O
penten-3-yl JJ B-NP
, , O
penten-4-yl JJ B-NP
, , O
1-methylbut-1-en-1-yl JJ B-NP
, , O
2- CD B-NP
methylbut-1-en-1-yl NN I-NP
and CC O
the DT O
like JJ O
. . O

The DT O
term NN O
" `` O
C4-I0 JJ B-NP
cycloalkyl NN I-NP
" '' O
as IN O
used VBN O
herein RB O
refers VBZ O
to TO O
an DT O
alicyclic JJ O
moiety NN O
having VBG O
4 CD O
, , O
5 CD O
, , O
6 CD O
, , O
7 CD O
, , O
8 CD O
, , O
9 CD O
or CC O
10 CD O
carbon NN O
atoms NNS O
. . O

The DT O
group NN O
may MD O
be VB O
a DT O
monocyclic NN O
, , O
polycyclic NN O
, , O
fused VBN O
or CC O
bridged VBN O
ring NN O
system NN O
. . O

This DT O
term NN O
includes VBZ O
reference NN O
to TO O
groups NNS O
such JJ O
as IN O
cyclobutyl NN B-NP
, , O
cyclopentyl NN B-NP
, , O
cyclohexyl NN B-NP
, , O
cycloheptyl NN B-NP
, , O
cyclooctyl NN B-NP
, , O
cyclononyl NN B-NP
, , O
cyclodecyl NN B-NP
and CC O
the DT O
like JJ O
. . O

The DT O
term NN O
"aryl NN O
" '' O
as IN O
used VBN O
herein RB O
refers VBZ O
to TO O
an DT O
aromatic JJ O
ring NN O
system NN O
comprising NN O
6 CD O
, , O
7 CD O
, , O
8 CD O
, , O
9 CD O
, , O
10 CD O
, , O
11 CD O
, , O
12 CD O
, , O
13 CD O
, , O
14 CD O
, , O
15 CD O
or CC O
16 CD O
ring NN O
carbon NN O
atoms NNS O
. . O

The DT O
group NN O
is VBZ O
often RB O
phenyl JJ B-NP
but CC O
may MD O
be VB O
a DT O
polycyclic JJ O
ring NN O
system NN O
, , O
having VBG O
two CD O
or CC O
more JJR O
rings NNS O
, , O
at IN O
least JJS O
one CD O
of IN O
which WDT O
is VBZ O
aromatic JJ O
. . O

This DT O
term NN O
includes VBZ O
reference NN O
to TO O
groups NNS O
such JJ O
as IN O
phenyl NN B-NP
, , O
naphthyl NN B-NP
, , O
fluorenyl NN B-NP
and CC O
the DT O
like JJ O
. . O

The DT O
term NN O
" `` O
substituted VBN O
" '' O
as IN O
used VBN O
herein RB O
in IN O
reference NN O
to TO O
a DT O
moiety NN O
or CC O
group NN O
means VBZ O
that IN O
one CD O
or CC O
more JJR O
hydrogen NN O
atoms NNS O
in IN O
the DT O
respective JJ O
moiety NN O
, , O
especially RB O
up RB O
to TO O
5 CD O
, , O
more RBR O
especially RB O
1 CD O
, , O
2 CD O
or CC O
3 CD O
of IN O
the DT O
hydrogen NN O
atoms NNS O
are VBP O
replaced VBN O
independently RB O
of IN O
each DT O
other JJ O
by IN O
the DT O
corresponding JJ O
number NN O
of IN O
the DT O
described VBN O
substituents NNS O
. . O

It PRP O
will MD O
, , O
of IN O
course NN O
, , O
be VB O
understood VBN O
that IN O
substituents NNS O
are VBP O
only RB O
at IN O
positions NNS O
where WRB O
they PRP O
are VBP O
chemically RB O
possible JJ O
, , O
the DT O
person NN O
skilled JJ O
in IN O
the DT O
art NN O
being VBG O
able JJ O
to TO O
decide VB O
(either JJ O
experimentally RB O
or CC O
theoretically RB O
) -RRB- O
without IN O
inappropriate JJ O
effort NN O
whether IN O
a DT O
particular JJ O
substitution NN O
is VBZ O
possible JJ O
. . O

Additionally RB O
, , O
it PRP O
will MD O
of IN O
course NN O
be VB O
understood VBN O
that IN O
the DT O
substituents NNS O
described VBN O
herein RB O
may MD O
themselves PRP O
be VB O
substituted VBN O
by IN O
any DT O
substituent JJ O
, , O
subject JJ O
to TO O
the DT O
aforementioned JJ O
restriction NN O
to TO O
appropriate JJ O
substitutions NNS O
as IN O
recognised VBN O
by IN O
the DT O
skilled JJ O
man NN O
. . O

Embodiments NNS O
of IN O
the DT O
invention NN O
are VBP O
described VBN O
below IN O
. . O

It PRP O
will MD O
be VB O
appreciated VBN O
that IN O
the DT O
features NNS O
specified VBN O
in IN O
each DT O
embodiment NN O
may MD O
be VB O
combined VBN O
with IN O
other JJ O
specified VBN O
features NNS O
, , O
to TO O
provide VB O
further JJ O
embodiments NNS O
. . O

The DT O
present JJ O
invention NN O
involves VBZ O
the DT O
use NN O
of IN O
a DT O
compound NN O
of IN O
formula NN O
( -LRB- O
I PRP O
) -RRB- O
: : O

EMI7.1 . O

( -LRB- O
I PRP O
) -RRB- O
wherein WRB O

R<1> PRP O
is VBZ O
C4-10 JJ B-NP
hydrocarbyl NN I-NP
; : O
and CC O

R<2> NNP O
, , O
R<3> NNP O
, , O
R<4> NNP O
and CC O
R<5> NNP O
are VBP O
independently RB O
each DT O
C1-6 NN B-NP
alkyl NN I-NP
. . O

R<2> NNP O
, , O
R<3> NNP O
, , O
R<4> NNP O
and CC O
R<5> NNP O
may MD O
be VB O
independently RB O
selected VBN O
from IN O
methyl NN B-NP
, , O
ethyl NN B-NP
, , O
propyl NN B-NP
(n-propyl NN O
or CC O
isopropyl NN B-NP
) -RRB- O
, , O
butyl NN B-NP
(n-butyl NN O
, , O
sec-butyl JJ B-NP
or CC O
tert-butyl JJ B-NP
) -RRB- O
, , O
pentyl JJ B-NP
and CC O
hexyl NN B-NP
. . O

In IN O
one CD O
embodiment NN O
, , O
R<2> NNP O
, , O
R<3> NNP O
, , O
R<4> NNP O
and CC O
R<5> NNP O
are VBP O
each DT O
methyl NN B-NP
, , O
i IN O
.e NN O
. . O
the DT O
compound NN O
is VBZ O
of IN O
the DT O
formula NN O
( -LRB- O
II NNP O
) -RRB- O
: : O

[0042] . O

EMI7.2 NN O

( -LRB- O
H) NN O

In IN O
one CD O
embodiment NN O
of IN O
the DT O
invention NN O
, , O
R<1> NNP O
is VBZ O
a DT O
C4-10 JJ B-NP
hydrocarbyl NN I-NP
group NN O
comprising VBG O
an DT O
aliphatic JJ B-NP
hydrocarbon NN I-NP
group NN I-NP
( -LRB- O
e NN O
.g NN O
. . O

Ci-6 DT B-NP
alkyl NN I-NP
or CC O
C4-10 JJ B-NP
alkyl NN I-NP
) -RRB- O
optionally RB O
substituted VBN O
with IN O
a DT O
cyclic JJ B-NP
hydrocarbon NN I-NP
group NN I-NP
( -LRB- O
e NN O
.g NN O
. . O

cycloalkyl NN B-NP
or CC O
aryl NN B-NP
) -RRB- O
. . O

In IN O
another DT O
embodiment NN O
, , O
R<1> NNP O
is VBZ O
C4-I0 JJ B-NP
alkyl NN I-NP
, , O
C4-10 JJ B-NP
alkenyl NN I-NP
, , O
aryl NN B-NP
or CC O
-C1-6 NN O
alkyl-aryl NN B-NP
, , O
wherein WRB O
aryl NN B-NP
and CC O
-Ci-6 NN O
alkyl-aryl NN B-NP
are VBP O
optionally RB O
substituted VBN O
with IN O
Ci-6 DT B-NP
alkyl NN I-NP
or CC O
C2-6 NN B-NP
alkenyl NN I-NP
. . O

In IN O
a DT O
further JJ O
embodiment NN O
, , O
R<1> NNP O
is VBZ O
C4--I0 JJ B-NP
alkyl NN I-NP
, , O
for IN O
example NN O
butyl NN B-NP
(n-butyl NN O
, , O
sec-butyl JJ B-NP
or CC O
tert- JJ B-NP
butyl NN I-NP
) -RRB- O
, , O
pentyl NN B-NP
, , O
hexyl NN B-NP
, , O
heptyl NN B-NP
, , O
octyl NN B-NP
, , O
nonyl NN B-NP
or CC O
decyl NN B-NP
. . O

More RBR O
preferably RB O
, , O
R<1> NNP O
is VBZ O
n-butyl JJ B-NP
, , O
sec-butyl JJ B-NP
or CC O
tert-butyl JJ B-NP
, , O
pentyl JJ B-NP
, , O
hexyl NN B-NP
, , O
heptyl NN B-NP
or CC O
octyl NN B-NP
, , O
in IN O
particular JJ O
n-butyl NN B-NP
, , O
sec-butyl NN B-NP
or CC O
tert- DT B-NP
butyl NN I-NP
. . O

In IN O
a DT O
further JJ O
embodiment NN O
, , O
R<1> NNP O
is VBZ O
C4-10 JJ B-NP
alkenyl NN I-NP
, , O
for IN O
example NN O
C4 NNP O
, , O
C5 NNP O
, , O
C6 NNP O
, , O
C7 NNP O
or CC O
C8 DT O
alkenyl NN B-NP
. . O

In IN O
particular JJ O
, , O
R<1> NNP O
may MD O
be VB O
1-methy JJ B-NP
!prop-1-en-1-yl NN I-NP
, , O

2-methylprop-1~en-1-yl JJ B-NP
, , O
1-methylprop-2- CC B-NP
en-1-yl JJ I-NP
, , O
2-methyIprop-2-en-1-yl JJ O
, , O
penten-1-yl JJ B-NP
, , I-NP
penten-2-yl JJ I-NP
, , O
penten-3-yl JJ B-NP
, , O
penten-4-yl JJ B-NP
, , O
1- JJ B-NP
methylbut-1-en-1-yl NN I-NP
or CC O
2-methylbut-1-en-1-yl JJ B-NP
. . O

In IN O
a DT O
further JJ O
embodiment NN O
, , O
R<1> NNP O
is VBZ O
aryl RB B-NP
, , O
for IN O
example NN O
phenyl NN B-NP
or CC O
naphthyl NN B-NP
, , O
either DT O
of IN O
which WDT O
may MD O
be VB O
substituted VBN O
with IN O
one CD O
or CC O
more JJR O
substituents NNS O
selected VBN O
from IN O
Ci-6 DT O
alky JJ O
! . O
( -LRB- O
e NN O
.g NN O
. . O

methyl NN B-NP
or CC O
ethyl NN B-NP
) -RRB- O
, , O
C2-6 DT B-NP
alkenyl NN I-NP
and CC O
C2-6 NN B-NP
alkynyl NN I-NP
. . O

In IN O
a DT O
further JJ O
embodiment NN O
, , O
R<1> NNP O
is VBZ O
-Ci-6 DT O
alkyl-aryl NN B-NP
optionally RB O
substituted VBN O
with IN O
C1-6 DT B-NP
alkyl NN I-NP
, , O
C2-6 DT B-NP
alkenyl NN I-NP
or CC O
C2-6 NN B-NP
alkynyl NN I-NP
. . O

A DT O
particular JJ O
nitroxide NN B-NP
compound NN I-NP
is VBZ O
4-butoxy-2,2,6,6-tetramethylpiperidine-1 JJ B-NP
-oxide NN I-NP
( -LRB- O
"4- : O
butoxy-TEMPO" NN B-NP
) -RRB- O
. . O

The DT O
nitroxide JJ B-NP
compound NN I-NP
may MD O
be VB O
used VBN O
in IN O
combination NN O
with IN O
a DT O
second JJ O
inhibitor NN O
of IN O
polymerisation NN O
. . O

The DT O
invention NN O
therefore RB O
provides VBZ O
methods NNS O
and CC O
compositions NNS O
in IN O
which WDT O
the DT O
nitroxide JJ B-NP
compound NN I-NP
is VBZ O
used VBN O
in IN O
combination NN O
with IN O
a DT O
second JJ O
inhibitor NN O
of IN O
polymerisation NN O
. . O

The DT O
second JJ O
inhibitor NN O
is VBZ O
preferably RB O
more RBR O
hydrophilic JJ O
than IN O
the DT O
nitroxide JJ B-NP
compound NN I-NP
. . O

In IN O
a DT O
particular JJ O
embodiment NN O
, , O
the DT O
nitroxide JJ B-NP
compound NN I-NP
is VBZ O
used VBN O
in IN O
combination NN O
with IN O
a DT O
second JJ O
nitroxide NN B-NP
compound NN I-NP
which WDT O
is VBZ O
an DT O
inhibitor NN O
of IN O
premature JJ O
monomer NN O
polymerisation NN O
. . O

The DT O
second JJ O
nitroxide NN B-NP
compound NN I-NP
may MD O
be VB O
present JJ O
in IN O
a DT O
composition NN O
comprising VBG O
the DT O
first JJ O
nitroxide JJ B-NP
compound NN I-NP
. . O

The DT O
second JJ O
nitroxide NN B-NP
compound NN I-NP
is VBZ O
preferably RB O
more RBR O
hydrophilic JJ O
( -LRB- O
i FW O
.e FW O
. . O
more RBR O
oleophobic JJ O
, , O
having VBG O
a DT O
greater JJR O
solubility NN O
in IN O
aqueous JJ O
media NNS O
such JJ O
as IN O
water NN B-NP
) -RRB- O
than IN O
the DT O
first JJ O
nitroxide JJ B-NP
compound NN I-NP
. . O

In IN O
one CD O
embodiment NN O
, , O
the DT O
second JJ O
nitroxide NN B-NP
compound NN I-NP
is VBZ O
a DT O
compound NN O
of IN O
formula NN O
( -LRB- O
III NNP O
) -RRB- O
: : O

EMI9.1 . O

( -LRB- O
III NNP O
) -RRB- O
wherein WRB O

1 CD O
. . O

R NN O
is VBZ O
an DT O
atom NN O
or CC O
group NN O
which WDT O
is VBZ O
more RBR O
hydrophilic JJ O
than IN O
-OR JJ O
; : O
and CC O

R NN O
J' NNP O
, , O
R->8 NN O
, , O
R NN O
i->9 . O
and CC O
R<1U> PRP O
are VBP O
each DT O
C1-6 JJ B-NP
alkyl NN I-NP
. . O

In IN O
one CD O
embodiment NN O
, , O
R<7> NNP O
, , O
R<8> NNP O
, , O
R<9> NNP O
and CC O
R<10> NNP O
are VBP O
each DT O
independently RB O
selected VBN O
from IN O
methyl NN B-NP
, , O
ethyl NN B-NP
, , O
propyl NN B-NP
(n-propyl NN O
or CC O
isopropyl NN B-NP
) -RRB- O
, , O
butyl NN B-NP
(n-butyl NN O
, , O
sec-butyl JJ B-NP
or CC O
tert-butyl JJ B-NP
) -RRB- O
, , O
pentyl JJ B-NP
and CC O
hexyl NN B-NP
. . O

In IN O
another DT O
embodiment NN O
, , O
R<7> NNP O
, , O
R<8> NNP O
, , O
R<9> NNP O
and CC O
R<10> NNP O
are VBP O
each DT O
methyl NN B-NP
, , O
i IN O
.e NN O
. . O
the DT O
second JJ O
nitroxide NN B-NP
compound NN I-NP
is VBZ O
of IN O
the DT O
formula NN O
( -LRB- O
IV NNP O
) -RRB- O
: : O

[0061] . O

EMI9.2 NN O

( -LRB- O
IV NNP O
) -RRB- O

In IN O
a DT O
particular JJ O
embodiment NN O
, , O
R NN O
is VBZ O
hydroxyl JJ B-NP
or CC O
oxo. POS B-NP

The DT O
second JJ O
nitroxide NN B-NP
compound NN I-NP
may MD O
be VB O
4-hydroxy-2,2,6,6-tetramethylpiperidine-1 JJ B-NP
-oxide NN I-NP
( -LRB- O
"4-hydroxy-TEMPO" JJ O
) -RRB- O
. . O

Alternatively RB O
, , O
the DT O
second JJ O
nitroxide NN B-NP
compound NN I-NP
may MD O
be VB O
4-oxo-2,2,6,6- DT B-NP
tetramethylpiperidine-1 JJ I-NP
-oxide NN I-NP
( -LRB- O
"4-oxo-TEMPO" JJ O
) -RRB- O
. . O

In IN O
a DT O
preferred JJ O
embodiment NN O
, , O
the DT O
first JJ O
nitroxide JJ B-NP
compound NN I-NP
is VBZ O
4-butoxy-TEMPO JJ B-NP
, , O
and CC O
the DT O
second JJ O
nitroxide NN B-NP
compound NN I-NP
is VBZ O
4-hydroxy-TEMPO JJ B-NP
. . O

Alternatively RB O
or CC O
additionally RB O
, , O
the DT O
invention NN O
may MD O
involve VB O
the DT O
use NN O
of IN O
one CD O
or CC O
more JJR O
inhibitors NNS O
selected VBN O
from IN O
phenols NNS B-NP
, , O
alkylated VBN B-NP
phenols NNS I-NP
, , O
nitrophenols NNS B-NP
, , O
nitrosophenols NNS B-NP
, , O
quinones NNS B-NP
, , O
hydroquinones NNS B-NP
, , O
quinone NN B-NP
ethers NNS I-NP
, , O
amines NNS B-NP
, , O
phenothiazines NNS B-NP
, , O
hydroxylamines NNS B-NP
and CC O
quinone NN B-NP
methides NNS I-NP
. . O

These DT O
compounds NNS O
may MD O
be VB O
used VBN O
in IN O
combination NN O
with IN O
the DT O
first JJ O
nitroxide JJ B-NP
compound NN I-NP
and CC O
, , O
in IN O
place NN O
of IN O
or CC O
in IN O
addition NN O
to TO O
, , O
the DT O
optional JJ O
second JJ O
nitroxide JJ B-NP
compound NN I-NP
. . O

Of IN O
particular JJ O
mention NN O
are VBP O
phenothiazine NN B-NP
and CC O
alkoxylated VBD O
phenol NN O
compounds NNS O
( -LRB- O
e NN O
.g NN O
. . O

4- JJ B-NP
methoxyphenol NN I-NP
) -RRB- O
. . O

The DT O
ethylenically NN O
unsaturated JJ O
monomer NN O
may MD O
be VB O
, , O
for IN O
example NN O
, , O
a DT O
hydrocarbon NN B-NP
monomer NN O
such JJ O
as IN O
a DT O
styrene NN B-NP
( -LRB- O
e NN O
.g NN O
. . O

styrene NN B-NP
or CC O
[alpha]-methylstyrene JJ B-NP
) -RRB- O
, , O
acrylonitrile VBP B-NP
, , O
vinyltoluene NN B-NP
, , O
a DT O
divinylbenzene NN B-NP
or CC O
a DT O
diene NN B-NP
( -LRB- O
e NN O
.g NN O
. . O

butadiene NN B-NP
or CC O
isoprene NN B-NP
) -RRB- O
. . O

Other JJ O
monomers NNS O
include VBP O
esters NNS B-NP
( -LRB- O
e NN O
.g NN O
. . O

vinyl NN B-NP
acetate NN I-NP
, , O
butyl NN B-NP
acrylate NN I-NP
or CC O
2-ethylhexyl JJ B-NP
acrylate NN I-NP
) -RRB- O
. . O

In IN O
a DT O
particular JJ O
embodiment NN O
, , O
the DT O
monomer NN O
is VBZ O
a DT O
styrene NN B-NP
( -LRB- O
e NN O
.g NN O
. . O

styrene NN B-NP
) -RRB- O
or CC O
acrylonitrile VBP B-NP
. . O

The DT O
monomer NN O
may MD O
be VB O
present JJ O
in IN O
a DT O
mixture NN O
with IN O
one CD O
or CC O
more JJR O
comonomers NNS O
. . O

A DT O
composition NN O
of IN O
the DT O
invention NN O
may MD O
comprise VB O
an DT O
ethylenically RB O
unsaturated JJ O
monomer NN O
, , O
in IN O
particular JJ O
a DT O
hydrocarbon NN B-NP
monomer NN O
. . O

Again RB O
, , O
the DT O
ethylenically NN O
unsaturated JJ O
monomer NN O
may MD O
be VB O
a DT O
styrene NN B-NP
( -LRB- O
e NN O
.g NN O
. . O

styrene NN B-NP
, , O
styrene NN B-NP
sulphonic JJ O
acid NN O
or CC O
[alpha]-methylstyrene NN B-NP
) -RRB- O
, , O
acrylonitrile VBP B-NP
, , O
vinyltoluene NN B-NP
, , O
a DT O
divinylbenzene NN B-NP
, , O
a DT O
diene NN B-NP
( -LRB- O
e NN O
.g NN O
. . O

butadiene NN B-NP
or CC O
isoprene NN B-NP
) -RRB- O
, , O
or CC O
an DT O
ester NN B-NP
( -LRB- O
e NN O
.g NN O
. . O

vinyl NN B-NP
acetate NN I-NP
, , O
butyl NN B-NP
acrylate NN I-NP
or CC O
2-ethylhexyl JJ B-NP
acrylate NN I-NP
) -RRB- O
. . O

In IN O
a DT O
particular JJ O
embodiment NN O
, , O
the DT O
composition NN O
comprises VBZ O
a DT O
styrene NN B-NP
( -LRB- O
e NN O
.g NN O
. . O

styrene NN B-NP
) -RRB- O
or CC O
acrylonitrile VBP B-NP
. . O

The DT O
composition NN O
may MD O
optionally RB O
comprise VB O
one CD O
or CC O
more JJR O
comonomers NNS O
. . O

A DT O
composition NN O
of IN O
the DT O
invention NN O
may MD O
comprise VB O
a DT O
solvent NN O
, , O
e.g NN O
. . O
an DT O
organic JJ O
solvent NN O
. . O

Of IN O
particular JJ O
mention NN O
are VBP O
non-polar JJ O
organic JJ O
solvents NNS O
, , O
e.g NN O
. . O

ethylbenzene NN B-NP
. . O

The DT O
amount NN O
of IN O
the DT O
or CC O
each DT O
nitroxide JJ B-NP
compound NN I-NP
present NN O
may MD O
be VB O
varied VBN O
according VBG O
to TO O
the DT O
conditions NNS O
and CC O
the DT O
type NN O
of IN O
monomer NN O
present NN O
. . O

For IN O
the DT O
purposes NNS O
of IN O
illustration NN O
, , O
the DT O
or CC O
each DT O
compound NN O
may MD O
be VB O
present JJ O
in IN O
amount NN O
of IN O
from IN O
about IN O
1 CD O
to TO O
about IN O
1000 CD O
ppm NN O
( -LRB- O
relative JJ O
to TO O
the DT O
amount NN O
of IN O
monomer NN O
) -RRB- O
, , O
more JJR O
preferably RB O
from IN O
about IN O
5 CD O
to TO O
about IN O
500 CD O
ppm NN O
, , O
more JJR O
preferably RB O
still RB O
from IN O
about IN O
10 CD O
to TO O
about IN O
100 CD O
ppm NN O
. . O

In IN O
one CD O
embodiment NN O
of IN O
the DT O
invention NN O
, , O
the DT O
first JJ O
nitroxide JJ B-NP
compound NN I-NP
is VBZ O
present JJ O
in IN O
an DT O
amount NN O
of IN O
from IN O
about IN O
60 CD O
to TO O
about IN O
80 CD O
ppm JJ O
, , O
and CC O
the DT O
second JJ O
nitroxide NN B-NP
compound NN I-NP
is VBZ O
present JJ O
in IN O
an DT O
amount NN O
of IN O
from IN O
about IN O
5 CD O
to TO O
about IN O
15 CD O
ppm NN O
. . O

The DT O
inhibitor NN O
or CC O
inhibitor NN O
composition NN O
may MD O
be VB O
brought VBN O
into IN O
contact NN O
with IN O
monomer NN O
by IN O
any DT O
conventional JJ O
method NN O
. . O

It PRP O
may MD O
be VB O
added VBN O
as IN O
a DT O
concentrate NN O
solution NN O
in IN O
suitable JJ O
solvents NNS O
just RB O
upstream RB O
of IN O
the DT O
point NN O
of IN O
desired VBN O
application NN O
by IN O
any DT O
suitable JJ O
means NNS O
. . O

In IN O
addition NN O
, , O
these DT O
compounds NNS O
may MD O
be VB O
injected VBN O
separately RB O
into IN O
the DT O
extraction NN O
or CC O
distillation NN O
train NN O
along IN O
with IN O
the DT O
incoming NN O
feed NN O
, , O
or CC O
through IN O
separate JJ O
entry NN O
points NNS O
providing VBG O
efficient JJ O
distribution NN O
of IN O
the DT O
inhibitor NN O
composition NN O
. . O

Since IN O
the DT O
inhibitor NN O
is VBZ O
gradually RB O
depleted VBN O
during IN O
operation NN O
, , O
it PRP O
is VBZ O
generally RB O
necessary JJ O
to TO O
maintain VB O
the DT O
appropriate JJ O
amount NN O
of IN O
the DT O
inhibitor NN O
in IN O
the DT O
extraction NN O
or CC O
distillation NN O
apparatus NN O
by IN O
adding VBG O
inhibitor NN O
during IN O
the DT O
course NN O
of IN O
the DT O
extraction NN O
or CC O
distillation NN O
process NN O
. . O

Such JJ O
addition NN O
may MD O
be VB O
carried VBN O
out RP O
either RB O
on IN O
a DT O
generally RB O
continuous JJ O
basis NN O
or CC O
it PRP O
may MD O
consist VB O
of IN O
intermittently RB O
charging VBG O
inhibitor NN O
into IN O
the DT O
extraction NN O
or CC O
distillation NN O
system NN O
if IN O
the DT O
concentration NN O
of IN O
inhibitor NN O
is VBZ O
to TO O
be VB O
maintained VBN O
above IN O
the DT O
minimum NN O
required VBD O
level NN O
. . O

Processes NNS O
for IN O
obtaining VBG O
the DT O
nitroxide NN O
compounds NNS O
of IN O
the DT O
invention NN O
are VBP O
well RB O
known VBN O
in IN O
the DT O
art NN O
and CC O
will MD O
be VB O
apparent JJ O
to TO O
the DT O
skilled JJ O
person NN O
; : O
see VB O
, , O
for IN O
example NN O
, , O
the DT O
teachings NNS O
of IN O
EP-A- NNP O
0574666 CD O
, , O
US NNP O
5631366 CD O
, , O
JP-A-5320217 CD O
and CC O
WO-A-98/56746 CD O
. . O

By IN O
way NN O
of IN O
example NN O
, , O
the DT O
compounds NNS O
may MD O
be VB O
obtained VBN O
by IN O
reacting VBG O
R<1>Br JJ O
with IN O
4-hydroxy-TEMPO JJ B-NP
in IN O
a DT O
nucleophilic JJ O
substitution NN O
reaction NN O
, , O
conducted VBN O
in IN O
the DT O
presence NN O
of IN O
, , O
for IN O
example NN O
, , O
aqueous JJ O
sodium NN B-NP
hydroxide NN I-NP
, , O
toluene NN B-NP
and CC O
Bu4NBr NNP B-NP
. . O

The DT O
following VBG O
Examples NNS O
illustrate VBP O
the DT O
invention NN O
. . O

Example NNP O
1 CD O

The DT O
solubilities NNS O
of IN O
4-oxo-TEMPO JJ B-NP
, , O
4-hydroxy-TEMPO JJ B-NP
and CC O
4-butoxy-TEMPO JJ B-NP
in IN O
water NN B-NP
and CC O
toluene NN B-NP
were VBD O
tested VBN O
by IN O
preparing VBG O
saturated JJ O
solutions NNS O
and CC O
measuring VBG O
the DT O
amounts NNS O
dissolved VBN O
. . O

The DT O
solubilities NNS O
of IN O
the DT O
compounds NNS O
are VBP O
given VBN O
in IN O
Table NN O
1 CD O
. . O

4-butoxy-TEMPO . B-NP
was VBD O
found VBN O
to TO O
have VB O
a DT O
greater JJR O
solubility NN O
in IN O
toluene NN B-NP
than IN O
the DT O
4-oxo- NNS O
and CC O
4-hydroxy-TEMPO JJ B-NP
compounds NNS O
. . O

[0076] . O

EMI12.1 . O

Table NN O
1 CD O

Example NN O
2 CD O

The DT O
evaluation NN O
of IN O
the DT O
efficacy NN O
of IN O
a DT O
selection NN O
of IN O
nitroxide JJ O
compounds NNS O
of IN O
the DT O
invention NN O
was VBD O
carried VBN O
out RP O
using VBG O
a DT O
continuous JJ O
stirred VBN O
tank NN O
reactor NN O
( -LRB- O
CSTR NN O
) -RRB- O
which WDT O
mimicked VBP O
the DT O
re-boiler NN O
of IN O
a DT O
styrene NN B-NP
distillation NN O
column NN O
. . O

The DT O
styrene NN B-NP
had VBD O
a DT O
residence NN O
time NN O
of IN O
approximately RB O
2 CD O
hours NNS O
inside IN O
the DT O
reactor NN O
and CC O
, , O
at IN O
110<0>C CD O
, , O
the DT O
CSTR NNP O
dead JJ O
volume NN O
was VBD O
180 CD O
ml NN O
. . O

A DT O
steady JJ O
state NN O
was VBD O
reached VBN O
in IN O
four CD O
hours NNS O
using VBG O
a DT O
styrene NN B-NP
flow NN O
rate NN O
of IN O
90 CD O
ml/hr NN O
. . O

Data NNP O
gathered VBD O
after IN O
this DT O
point NN O
was VBD O
averaged VBN O
to TO O
give VB O
the DT O
steady JJ O
state NN O
polymer NN O
level NN O
. . O

Nitrogen NN B-NP
sparging VBG O
to TO O
remove VB O
oxygen NN B-NP
gas NN O
was VBD O
carried VBN O
out RP O
at IN O
a DT O
measured JJ O
rate NN O
of IN O
200 CD O
ml/minute NN O
. . O

Apart RB O
from IN O
the DT O
inhibitors NNS O
, , O
the DT O
only JJ O
variable NN O
was VBD O
the DT O
inherent JJ O
variation NN O
in IN O
the DT O
rate NN O
of IN O
thermal JJ O
initiation NN O
of IN O
styrene NN B-NP
polymerisation NN O
. . O

The DT O
nitroxides NNS B-NP
tested VBN O
were VBD O
4-methoxy-TEMPO JJ B-NP
, , O
4-hydroxy- CC B-NP
TEMPO NNP I-NP
, , O
TEMPO NNP B-NP
, , O
4-butoxy-TEMPO JJ B-NP
and CC O
4-allyloxy-TEMPO JJ B-NP
. . O

The DT O
steady JJ O
state NN O
polymer NN O
levels NNS O
for IN O
each DT O
compound NN O
are VBP O
given VBN O
in IN O
Table NN O
2. . O
Taking VBG O
into IN O
account NN O
differences NNS O
in IN O
molecular JJ O
weight NN O
( -LRB- O
for IN O
example NN O
, , O
the DT O
molecular JJ O
weights NNS O
of IN O
4- JJ B-NP
hydroxy-TEMPO NN I-NP
and CC O
4-butoxy-TEMPO JJ B-NP
are VBP O
172 CD O
and CC O
228 CD O
respectively RB O
, , O
giving VBG O
about RB O
25 CD O
% NN O
less JJR O
4-butoxy-TEMPO JJ B-NP
than IN O
4-hydroxy-TEMPO CD B-NP
at IN O
a DT O
fixed VBN O
ppm NN O
level NN O
) -RRB- O
, , O
the DT O
inhibitory JJ O
activity NN O
of IN O
4-butoxy-TEMPO JJ B-NP
is VBZ O
comparable JJ O
to TO O
the DT O
inhibitory JJ O
activities NNS O
of IN O
4-methoxy-TEMPO JJ B-NP
and CC O
4-hydroxy-TEMPO JJ B-NP
. . O

[0081] . O

EMI13.1 . O

Table NN O
2 CD O

Example NN O
3 CD O

The DT O
experiment NN O
of IN O
Example NNP O
2 CD O
was VBD O
repeated VBN O
using VBG O
combinations NNS O
of IN O
4-hydroxy-TEMPO JJ B-NP
and CC O
the DT O
other JJ O
compounds NNS O
. . O

The DT O
steady JJ O
state NN O
polymer NN O
levels NNS O
for IN O
each DT O
combination NN O
are VBP O
given VBN O
in IN O
Table NN O
3. . O

It PRP O
is VBZ O
evident JJ O
that IN O
the DT O
combination NN O
of IN O
4-butoxy-TEMPO JJ B-NP
and CC O
4-hydroxy-TEMPO JJ B-NP
was VBD O
a DT O
more RBR O
effective JJ O
inhibitor NN O
than IN O
any DT O
of IN O
the DT O
other JJ O
combinations NNS O
. . O

In IN O
addition NN O
, , O
this DT O
combination NN O
was VBD O
considerably RB O
more RBR O
effective JJ O
than IN O
the DT O
individual JJ O
compounds NNS O
as IN O
tested VBN O
in IN O
Example NNP O
2. . O

[0086 CD O
] NN O

EMI13.2 NN O

Table NN O
3 CD O
Example NNP O
4 CD O

The DT O
efficacy NN O
of IN O
various JJ O
inhibitors NNS O
was VBD O
evaluated VBN O
with IN O
respect NN O
to TO O
the DT O
monomers NNS O
vinyl NN B-NP
acetate NN I-NP
, , O
acrylonitrile VBP B-NP
, , O
2-ethylhexyl JJ B-NP
acrylate NN I-NP
and CC O
isoprene NN B-NP
. . O

The DT O
efficacy NN O
of IN O
each DT O
inhibitor NN O
was VBD O
determined VBN O
by IN O
heating NN O
in IN O
pure JJ O
monomer NN O
or CC O
a DT O
solution NN O
of IN O
monomer NN O
in IN O
a DT O
suitable JJ O
solvent( NN O
s VBZ O
) -RRB- O
for IN O
a DT O
set VBN O
time NN O
and CC O
at IN O
a DT O
known VBN O
temperature NN O
. . O

The DT O
storage NN O
inhibitor NN O
was VBD O
removed VBN O
from IN O
each DT O
monomer NN O
by IN O
distillation NN O
or CC O
treatment NN O
with IN O
neutral JJ O
silica NN O
. . O

In IN O
each DT O
of IN O
the DT O
tables NNS O
below IN O
, , O
the DT O
amount NN O
of IN O
polymer NN O
generated VBN O
is VBZ O
expressed VBN O
as IN O
% NN O
w/w NN O
of IN O
the DT O
monomer NN O
. . O

Vinyl NNP B-NP
acetate NN I-NP
monomer NN O

In IN O
this DT O
case NN O
, , O
the DT O
tubes NNS O
and CC O
solution NN O
were VBD O
degassed VBN O
with IN O
nitrogen NN B-NP
prior RB O
to TO O
sealing NN O
and CC O
heating NN O
at IN O
16O<0>C CD O
for IN O
48 CD O
hours NNS O
. . O

As IN O
the DT O
table NN O
below IN O
illustrates VBZ O
, , O
4-butoxy-TEMPO UH B-NP
was VBD O
found VBN O
to TO O
be VB O
a DT O
more RBR O
effective JJ O
inhibitor NN O
than IN O
phenothiazine NN B-NP
. . O

Synergy NNP O
was VBD O
observed VBN O
with IN O
a DT O
combination NN O
of IN O
4- JJ B-NP
butoxytempo NN I-NP
and CC O
phenothiazine NN B-NP
. . O

[0092 CD O
] NN O

EMI14.1 . O

Acrylonitrile NNP B-NP
monomer NN O

Similarly RB O
, , O
tubes NNS O
containing VBG O
acrylonitrile JJ B-NP
and CC O
various JJ O
inhibitors NNS O
were VBD O
heated VBN O
at IN O
120<0>C CD O
for IN O
7 CD O
days NNS O
. . O

The DT O
air NN O
was VBD O
not RB O
removed VBN O
from IN O
these DT O
solutions NNS O
prior RB O
to TO O
heating NN O
. . O

As IN O
the DT O
table NN O
below IN O
illustrates VBZ O
, , O
4-butoxy-TEMPO UH B-NP
was VBD O
found VBN O
to TO O
be VB O
a DT O
more RBR O
effective JJ O
inhibitor NN O
than IN O
4-hydroxy-TEMPO JJ B-NP
. . O

EMI15.1 . O

2-Ethylhexyl JJ B-NP
acrylate NN I-NP
monomer NN O

Similarly RB O
, , O
tubes NNS O
containing VBG O
5 CD O
ppm JJ O
inhibitor NN O
in IN O
2-ethylhexyl JJ B-NP
acrylate NN I-NP
were VBD O
heated VBN O
at IN O
145<0>C CD O
and CC O
the DT O
results NNS O
expressed VBD O
as IN O
inhibition NN O
time NN O
( -LRB- O
i FW O
.e NN O
. . O
the DT O
time NN O
to TO O
appearance NN O
of IN O
insoluble JJ O
polymer NN O
) -RRB- O
. . O

Data NNP O
were VBD O
generated VBN O
in IN O
nitrogen NN B-NP
and CC O
in IN O
the DT O
presence NN O
of IN O
air NN O
. . O

As IN O
the DT O
table NN O
below IN O
illustrates VBZ O
, , O
4-butoxy-TEMPO UH B-NP
was VBD O
found VBN O
to TO O
be VB O
an DT O
effective JJ O
inhibitor NN O
of IN O
polymerisation NN O
. . O

[0098] . O

EMI15.2 NN O

lsoprene NN B-NP
monomer NN O

Similarly RB O
tubes NNS O
containing VBG O
100 CD O
ppm JJ O
inhibitor NN O
in IN O
a DT O
solution NN O
of IN O
lsoprene NN B-NP
in IN O
dimethylformamide NN O
containing VBG O
1 CD O
or CC O
3 CD O
% NN O
furfural JJ O
were VBD O
heated VBN O
at IN O
160 CD O
<0>C CD O
for IN O
1hr JJ O
. . O

As IN O
the DT O
table NN O
below IN O
illustrates VBZ O
, , O
4-butoxy-TEMPO UH B-NP
was VBD O
found VBN O
to TO O
be VB O
an DT O
effective JJ O
inhibitor NN O
of IN O
polymerisation NN O
. . O

The DT O
results NNS O
are VBP O
expressed VBN O
as IN O
ppm NN O
insoluble JJ O
polymer NN O
. . O

[0101] . O

EMI15.3 . O

Example NNP O
5 CD O

Saturated NNP O
solutions NNS O
of IN O
the DT O
inhibitors/retarders NNS O
phenothiazine NN B-NP
and CC O
4-methoxyphenol JJ B-NP
were VBD O
prepared VBN O
in IN O
4-butoxy-TEMPO JJ B-NP
. . O

These DT O
saturated JJ O
solutions NNS O
were VBD O
then RB O
added VBN O
to TO O
styrene VB B-NP
so RB O
that IN O
the DT O
concentration NN O
of IN O
each DT O
inhibitor/retarder NN O
was VBD O
above IN O
the DT O
solubility NN O
limit NN O
for IN O
that DT O
material NN O
in IN O
styrene NN B-NP
alone RB O
. . O

The DT O
solutions NNS O
were VBD O
observed VBN O
for IN O
physical JJ O
stability NN O
at IN O
20<0>C. VBG O

The DT O
table NN O
below IN O
shows NNS O
the DT O
soluble JJ O
amount NN O
of IN O
each DT O
inhibitor/retarder NN O
in IN O
4-butoxy-TEMPO JJ B-NP
plus CC O
styrene NN B-NP
: : O

[0104 CD O
] NN O

EMI16.1 . O

The DT O
same JJ O
inhibitors NNS O
were VBD O
then RB O
added VBN O
to TO O
styrene VB B-NP
monomer NN O
at IN O
various JJ O
concentrations NNS O
in IN O
the DT O
absence NN O
of IN O
4-butoxy-TEMPO JJ B-NP
, , O
to TO O
determine VB O
if IN O
solubility NN O
was VBD O
enhanced VBN O
by IN O
including VBG O
4- JJ B-NP
butoxyTEMPO NN I-NP
in IN O
the DT O
formulation NN O
. . O

The DT O
table NN O
below IN O
shows NNS O
the DT O
solubility NN O
of IN O
the DT O
inhibitors/retarders NNS O
in IN O
styrene NN B-NP
in IN O
the DT O
absence NN O
of IN O
4-butoxy-TEMPO JJ B-NP
: : O

[0106 CD O
] NN O

EMI16.2 NN O

Comparing VBG O
the DT O
two CD O
sets NNS O
of IN O
experiments NNS O
, , O
it PRP O
was VBD O
apparent JJ O
that IN O
the DT O
presence NN O
of IN O
4-butoxy- DT B-NP
TEMPO NNP I-NP
enhanced VBD O
the DT O
solubility NN O
of IN O
the DT O
other JJ O
inhibitors NNS O
. . O

Example NNP O
6 CD O

The DT O
solubility NN O
of IN O
4-hydroxytempo JJ O
in IN O
ethylbenzene NN B-NP
is VBZ O
only RB O
8.1 CD O
% NN O
wt/wt NN O
at IN O
20<0>C. VBG O

A DT O
solution NN O
of IN O
4-hydroxy-TEMPO JJ B-NP
and CC O
4-butoxy-TEMPO JJ B-NP
in IN O
ethylbenzene NN B-NP
was VBD O
prepared VBN O
with IN O
a DT O
4- JJ B-NP
hydroxy-TEMPO JJ I-NP
concentration NN O
of IN O
14.9 CD O
% NN O
with IN O
respect NN O
to TO O
ethylbenzene NN B-NP
. . O

This DT O
gave VBD O
a DT O
clear JJ O
red JJ O
solution NN O
, , O
indicating VBG O
that IN O
the DT O
presence NN O
of IN O
4-butoxy-TEMPO JJ B-NP
enhanced VBN O
the DT O
solubility NN O
of IN O
4-hydroxy-TEMPO JJ B-NP
in IN O
ethylbenzene NN B-NP
. . O

CLAIMS NNS O

1 CD O
. . O

A DT O
method NN O
of IN O
inhibiting VBG O
polymerisation NN O
of IN O
an DT O
ethylenically NN O
unsaturated JJ O
monomer NN O
, , O
which WDT O
comprises VBZ O
contacting VBG O
the DT O
monomer NN O
with IN O
a DT O
nitroxide JJ B-NP
compound NN I-NP
of IN O
formula NN O
( -LRB- O
I PRP O
) -RRB- O
: : O

EMI17.1 . O

( -LRB- O
I PRP O
) -RRB- O
wherein WRB O

R<1> PRP O
is VBZ O
C4-20 JJ B-NP
hydrocarbyl NN I-NP
; : O
and CC O

R NN O
[upsilon]2 NN O
, , O
R NN O
D3 NN O
, , O
R NN O
and CC O
R NN O
are VBP O
independently RB O
each DT O
Ci-6 NN B-NP
alkyl NN I-NP
. . O

2. DT O
A DT O
method NN O
according VBG O
to TO O
claim NN O
1 CD O
, , O
wherein WRB O
the DT O
compound NN O
is VBZ O
of IN O
formula NN O
( -LRB- O
N) NN O
: : O

EMI17.2 NN O

( -LRB- O
II NNP O
) -RRB- O

3. CD O
A DT O
method NN O
according VBG O
to TO O
claim NN O
1 CD O
or CC O
claim NN O
2 CD O
, , O
wherein WRB O
R<1> NNP O
comprises VBZ O
an DT O
aliphatic JJ B-NP
hydrocarbon NN I-NP
group NN I-NP
optionally RB O
substituted VBN O
with IN O
a DT O
cyclic JJ B-NP
hydrocarbon NN I-NP
group NN I-NP
. . O

4 LS O
. . O
A DT O
method NN O
according VBG O
to TO O
claim NN O
3 CD O
, , O
wherein WRB O
R<1> NNP O
is VBZ O
C4-I0 JJ B-NP
alkyl NN I-NP
, , O
C4--I0 DT B-NP
alkenyl NN I-NP
, , O
aryl NN B-NP
or CC O
-C1-6 NN O
alkyl-aryl NN B-NP
, , O
wherein WRB O
aryl NN B-NP
and CC O
-C1-6 NN O
alkyl-aryl NN B-NP
are VBP O
optionally RB O
substituted VBN O
with IN O
C1-6 DT B-NP
alkyl NN I-NP
or CC O
C2-6 NN B-NP
alkenyl NN I-NP
. . O

5 CD O
. . O
A DT O
method NN O
according VBG O
to TO O
claim VB O
4 CD O
, , O
wherein WRB O
R<1> NNP O
is VBZ O
C4--I0 JJ B-NP
alkyl NN I-NP
, , O
in IN O
particular JJ O
butyl NN B-NP
, , O
pentyl NN B-NP
or CC O
heptyl NN B-NP
. . O

6 CD O
. . O

A DT O
method NN O
according VBG O
to TO O
claim NN O
5 CD O
, , O
wherein WRB O
R<1> NNP O
is VBZ O
n-butyl JJ B-NP
, , O
sec-butyl JJ B-NP
or CC O
tert-butyl JJ B-NP
. . O

7. CD O
A DT O
method NN O
according VBG O
to TO O
claim NN O
1 CD O
, , O
wherein WRB O
the DT O
compound NN O
is VBZ O
4-butoxy-2,2,6,6- JJ B-NP
tetramethylpiperidine-1 NN I-NP
-oxide NN I-NP
( -LRB- O
"4-butoxy-TEMPO" JJ O
) -RRB- O
. . O

8. CD O
A DT O
method NN O
according VBG O
to TO O
any DT O
preceding VBG O
claim NN O
, , O
which WDT O
further RB O
comprises VBZ O
contacting VBG O
the DT O
monomer NN O
with IN O
a DT O
second JJ O
inhibitor NN O
of IN O
said VBD O
polymerisation NN O
. . O

9 CD O
. . O
A DT O
method NN O
according VBG O
to TO O
claim VB O
8 CD O
, , O
wherein WRB O
the DT O
second JJ O
inhibitor NN O
is VBZ O
a DT O
second JJ O
nitroxide NN B-NP
compound NN I-NP
. . O

10 CD O
. . O

A DT O
method NN O
according VBG O
to TO O
claim NN O
9 CD O
, , O
wherein WRB O
the DT O
second JJ O
nitroxide NN B-NP
compound NN I-NP
is VBZ O
more RBR O
hydrophilic JJ O
than IN O
the DT O
first JJ O
nitroxide JJ B-NP
compound NN I-NP
. . O

11 CD O
. . O

A DT O
method NN O
according VBG O
to TO O
claim NN O
10 CD O
, , O
wherein WRB O
the DT O
second JJ O
nitroxide NN B-NP
compound NN I-NP
is VBZ O
a DT O
compound NN O
of IN O
formula NN O
( -LRB- O
III NNP O
) -RRB- O
: : O

EMI18.1 . O

( -LRB- O
III NNP O
) -RRB- O
wherein WRB O

R<6> NNP O
is VBZ O
an DT O
atom NN O
or CC O
group NN O
which WDT O
is VBZ O
more RBR O
hydrophilic JJ O
than IN O
-OR<1> JJ O
; : O
and CC O

R<7> NNP O
, , O
R<8> NNP O
, , O
R<9> NNP O
and CC O
R<10> NNP O
are VBP O
each DT O
C1-6 JJ B-NP
alkyl NN I-NP
. . O

12 CD O
. . O
A DT O
method NN O
according VBG O
to TO O
claim NN O
11 CD O
, , O
which WDT O
is VBZ O
of IN O
formula NN O
( -LRB- O
IV NNP O
) -RRB- O
: : O

EMI19.1 . O

( -LRB- O
IV NNP O
) -RRB- O

13 CD O
. . O

A DT O
method NN O
according VBG O
to TO O
claim NN O
11 CD O
or CC O
claim NN O
12 CD O
, , O
wherein WRB O
R<6> NNP O
is VBZ O
hydroxy JJ B-NP
or CC O
oxo. POS B-NP

14 CD O
. . O

A DT O
method NN O
according VBG O
to TO O
claim NN O
9 CD O
, , O
wherein WRB O
the DT O
second JJ O
nitroxide NN B-NP
compound NN I-NP
is VBZ O
4- JJ B-NP
hydroxy-2,2,6,6-tetramethylpiperidine-1-oxide JJ I-NP
( -LRB- O
"4-hydroxy-TEMPO" JJ O
) -RRB- O
. . O

15 CD O
. . O

A DT O
method NN O
according VBG O
to TO O
claim NN O
9 CD O
, , O
wherein WRB O
the DT O
second JJ O
nitroxide NN B-NP
compound NN I-NP
is VBZ O
4-oxo- CD B-NP
2,2,6,6-tetramethylpiperidine-i-oxide JJ I-NP
( -LRB- O
"4-oxo-TEMPO" JJ O
) -RRB- O
. . O

16 CD O
. . O

A DT O
method NN O
according VBG O
to TO O
claim NN O
9 CD O
, , O
wherein WRB O
the DT O
first JJ O
nitroxide JJ B-NP
compound NN I-NP
is VBZ O
4-butoxy- DT B-NP
2,2,6,6-tetramethylpiperidine-1 JJ I-NP
-oxide NN I-NP
, , O
and CC O
the DT O
second JJ O
nitroxide NN B-NP
compound NN I-NP
is VBZ O
4-hydroxy- JJ B-NP
2,2,6,6-tetramethylpiperidine-1-oxide JJ I-NP
. . O

17 CD O
. . O

A DT O
method NN O
according VBG O
to TO O
any DT O
of IN O
claims NNS O
9 CD O
to TO O
16 CD O
, , O
which WDT O
further RB O
comprises VBZ O
contacting VBG O
the DT O
monomer NN O
with IN O
one CD O
or CC O
more JJR O
compounds NNS O
selected VBN O
from IN O
phenols NNS B-NP
, , O
alkylated VBN B-NP
phenols NNS I-NP
, , O
nitrophenols NNS B-NP
, , O
nitrosophenols NNS B-NP
, , O
quinones NNS B-NP
, , O
hydroquinones NNS B-NP
, , O
quinone NN B-NP
ethers NNS I-NP
, , O
amines NNS B-NP
, , O
hydroxylamines NNS B-NP
and CC O
quinone NN B-NP
methides NNS I-NP
. . O

18 CD O
. . O

A DT O
method NN O
according VBG O
to TO O
any DT O
of IN O
claims NNS O
9 CD O
to TO O
17 CD O
, , O
which WDT O
further RB O
comprises VBZ O
contacting VBG O
the DT O
monomer NN O
with IN O
a DT O
phenothiazine NN B-NP
, , O
for IN O
example NN O
phenothiazine NN B-NP
. . O

19 CD O
. . O

A DT O
method NN O
according VBG O
to TO O
claim VB O
8 CD O
, , O
wherein WRB O
the DT O
second JJ O
inhibitor NN O
is VBZ O
selected VBN O
from IN O
phenols NNS B-NP
, , O
alkylated VBN B-NP
phenols NNS I-NP
, , O
nitrophenols NNS B-NP
, , O
nitrosophenols NNS B-NP
, , O
quinones NNS B-NP
, , O
hydroquinones NNS B-NP
, , O
quinone NN B-NP
ethers NNS I-NP
, , O
amines NNS B-NP
, , O
phenothiazines NNS B-NP
, , O
hydroxylamines NNS B-NP
and CC O
quinone NN B-NP
methides NNS I-NP
. . O

20 CD O
. . O

A DT O
method NN O
according VBG O
to TO O
any DT O
of IN O
claims NNS O
8 CD O
to TO O
19 CD O
, , O
wherein WRB O
the DT O
second JJ O
inhibitor NN O
is VBZ O
more RBR O
hydrophilic JJ O
than IN O
the DT O
nitroxide JJ B-NP
compound NN I-NP
. . O

21 CD O
. . O

A DT O
method NN O
according VBG O
to TO O
any DT O
preceding VBG O
claim NN O
, , O
wherein WRB O
the DT O
monomer NN O
is VBZ O
a DT O
hydrocarbon NN B-NP
monomer NN O
, , O
for IN O
example NN O
styrene NN B-NP
, , O
[alpha]-methylstyrene JJ B-NP
, , O
acrylonitrile JJ B-NP
, , O
vinyltoluene NN B-NP
, , O
a DT O
divinylbenzene NN B-NP
or CC O
a DT O
diene NN B-NP
. . O

22 CD O
. . O
A DT O
method NN O
according VBG O
to TO O
claim NN O
21 CD O
, , O
wherein WRB O
the DT O
monomer NN O
is VBZ O
styrene NN B-NP
. . O

23 CD O
. . O

A DT O
method NN O
according VBG O
to TO O
claim NN O
21 CD O
, , O
wherein WRB O
the DT O
monomer NN O
is VBZ O
acrylonitrile JJ B-NP
. . O

24 CD O
. . O

A DT O
method NN O
according VBG O
to TO O
any DT O
of IN O
claims NNS O
1 CD O
to TO O
20 CD O
, , O
wherein WRB O
the DT O
monomer NN O
is VBZ O
an DT O
ester NN B-NP
. . O

25 CD O
. . O

A DT O
method NN O
according VBG O
to TO O
claim VB O
24 CD O
, , O
wherein WRB O
the DT O
monomer NN O
is VBZ O
butyl NN B-NP
acrylate NN I-NP
, , O
vinyl NN B-NP
acetate NN I-NP
or CC O
2-ethylhexyl JJ B-NP
acrylate NN I-NP
. . O

26 CD O
. . O

A DT O
composition NN O
for IN O
inhibiting VBG O
polymerisation NN O
of IN O
an DT O
ethylenically NN O
unsaturated JJ O
monomer NN O
, , O
which WDT O
comprises VBZ O
first JJ O
and CC O
second JJ O
inhibitors NNS O
of IN O
said VBD O
polymerisation NN O
, , O
wherein WRB O
the DT O
first JJ O
inhibitor NN O
is VBZ O
a DT O
nitroxide JJ B-NP
compound NN I-NP
and CC O
is VBZ O
of IN O
the DT O
formula NN O
( -LRB- O
I PRP O
) -RRB- O
: : O

EMI20.1 . O

( -LRB- O
I PRP O
) -RRB- O
wherein WRB O

R<1> PRP O
is VBZ O
C4-20 JJ B-NP
hydrocarbyl NN I-NP
; : O
and CC O

R<2> NNP O
, , O
R<3> NNP O
, , O
R<4> NNP O
and CC O
R<5> NNP O
are VBP O
independently RB O
each DT O
C1-6 NN B-NP
alkyl NN I-NP
. . O

27 CD O
. . O

A DT O
composition NN O
according VBG O
to TO O
claim NN O
26 CD O
, , O
wherein WRB O
the DT O
nitroxide JJ B-NP
compound NN I-NP
is VBZ O
a DT O
compound NN O
of IN O
formula NN O
( -LRB- O
II NNP O
) -RRB- O
: : O

EMI21.1 . O

OD . O

28 CD O
. . O

A DT O
composition NN O
according VBG O
to TO O
claim NN O
26 CD O
or CC O
claim NN O
27 CD O
, , O
wherein WRB O
R<1> NNP O
comprises VBZ O
an DT O
aliphatic JJ B-NP
hydrocarbon NN I-NP
group NN I-NP
optionally RB O
substituted VBN O
with IN O
a DT O
cyclic JJ B-NP
hydrocarbon NN I-NP
group NN I-NP
. . O

29 CD O
. . O
. . O

A DT O
composition NN O
according VBG O
to TO O
claim NN O
28 CD O
, , O
wherein WRB O
R<1> NNP O
is VBZ O
C4-10 JJ B-NP
alky JJ I-NP
! . I-NP
, , O
C4-I0 DT B-NP
alkenyl NN I-NP
, , O
aryl NN B-NP
or CC O
-Ci-6 NN O
alkyl-aryl NN B-NP
, , O
wherein WRB O
aryl NN B-NP
and CC O
-C1-6 NN O
alkyl-aryl NN B-NP
are VBP O
optionally RB O
substituted VBN O
with IN O
Ci-6 DT B-NP
alkyl NN I-NP
or CC O
C2-6 NN B-NP
alkenyl NN I-NP
. . O

30 CD O
. . O

A DT O
composition NN O
according VBG O
to TO O
claim VB O
29 CD O
, , O
wherein WRB O
R<1> NNP O
is VBZ O
C4-I0 JJ B-NP
alkyl NN I-NP
, , O
in IN O
particular JJ O
butyl NN B-NP
, , O
pentyl NN B-NP
or CC O
hexyl NN B-NP
. . O

31 CD O
. . O

A DT O
composition NN O
according VBG O
to TO O
claim NN O
30 CD O
, , O
wherein WRB O
R<1> NNP O
is VBZ O
n-butyl JJ B-NP
, , O
sec-butyl JJ B-NP
or CC O
tert-butyl JJ B-NP
. . O

32 CD O
. . O

A DT O
composition NN O
according VBG O
to TO O
claim NN O
26 CD O
, , O
wherein WRB O
the DT O
nitroxide JJ B-NP
compound NN I-NP
is VBZ O
4- JJ B-NP
butoxy-2,2,6,6-tetramethylpiperidine-1-oxide NN I-NP
( -LRB- O
"4-butoxy-TEMPO" JJ O
) -RRB- O
. . O

33 CD O
. . O

A DT O
composition NN O
according VBG O
to TO O
any DT O
of IN O
claims NNS O
26 CD O
to TO O
32 CD O
, , O
wherein WRB O
the DT O
second JJ O
inhibitor NN O
is VBZ O
a DT O
second JJ O
nitroxide NN B-NP
compound NN I-NP
. . O

34. . O

A DT O
composition NN O
according VBG O
to TO O
claim NN O
33 CD O
, , O
wherein WRB O
the DT O
second JJ O
nitroxide NN B-NP
compound NN I-NP
is VBZ O
more RBR O
hydrophilic JJ O
than IN O
the DT O
first JJ O
nitroxide JJ B-NP
compound NN I-NP
. . O

35 CD O
. . O

A DT O
composition NN O
according VBG O
to TO O
claim NN O
34 CD O
, , O
wherein WRB O
the DT O
second JJ O
nitroxide NN B-NP
compound NN I-NP
is VBZ O
a DT O
compound NN O
of IN O
formula NN O
( -LRB- O
III NNP O
) -RRB- O
: : O

EMI21.2 NN O

( -LRB- O
III NNP O
) -RRB- O
wherein WRB O

R<6> NNP O
is VBZ O
an DT O
atom NN O
or CC O
group NN O
which WDT O
is VBZ O
more RBR O
hydrophilic JJ O
than IN O
-OR<1> JJ O
; : O
and CC O

R<7> NNP O
, , O
R<8> NNP O
, , O
R<9> NNP O
and CC O
R<10> NNP O
are VBP O
each DT O
C1-6 JJ B-NP
alkyl NN I-NP
. . O

36 CD O
. . O

A DT O
composition NN O
according VBG O
to TO O
claim NN O
35 CD O
, , O
wherein WRB O
the DT O
second JJ O
nitroxide NN B-NP
compound NN I-NP
is VBZ O
of IN O
formula NN O
( -LRB- O
IV NNP O
) -RRB- O
: : O

EMI22.1 . O

( -LRB- O
IV NNP O
) -RRB- O

37 CD O
. . O
A DT O
composition NN O
according VBG O
to TO O
claim NN O
35 CD O
or CC O
claim NN O
36 CD O
, , O
wherein WRB O
R<5> NNP O
is VBZ O
hydroxy JJ B-NP
or CC O
oxo. POS B-NP

38 CD O
. . O

A DT O
composition NN O
according VBG O
to TO O
claim NN O
33 CD O
, , O
wherein WRB O
the DT O
second JJ O
nitroxide NN B-NP
compound NN I-NP
is VBZ O
4-hydroxy-2,2,6,6-tetramethylpiperidine-1~oxide JJ B-NP
( -LRB- O
"4-hydroxy-TEMPO" JJ O
) -RRB- O
. . O

39 CD O
. . O

A DT O
composition NN O
according VBG O
to TO O
claim NN O
33 CD O
, , O
wherein WRB O
the DT O
second JJ O
nitroxide NN B-NP
compound NN I-NP
is VBZ O
4-oxo-2,2,6,6-tetramethylpiperidine-1-oxide JJ B-NP
( -LRB- O
"4-oxo-TEMPO" JJ O
) -RRB- O
. . O

40 CD O
. . O

A DT O
composition NN O
according VBG O
to TO O
claim NN O
33 CD O
, , O
wherein WRB O
the DT O
first JJ O
nitroxide JJ B-NP
compound NN I-NP
is VBZ O
4- JJ B-NP
butoxy-2,2,6,6-tetramethylpiperidine-1-oxide NN I-NP
, , O
and CC O
the DT O
second JJ O
nitroxide NN B-NP
compound NN I-NP
is VBZ O
4- JJ B-NP
hydroxy-2,2,6,6-tetramethylpiperidine-1 JJ I-NP
-oxide NN I-NP
. . O

41 CD O
. . O

A DT O
composition NN O
according VBG O
to TO O
any DT O
of IN O
claims NNS O
33 CD O
to TO O
40 CD O
, , O
which WDT O
further RB O
comprises VBZ O
one CD O
or CC O
more JJR O
compounds NNS O
selected VBN O
from IN O
phenols NNS B-NP
, , O
alkylated VBN B-NP
phenols NNS I-NP
, , O
nitrophenols NNS B-NP
, , O
nitrosophenols NNS B-NP
, , O
quinones NNS B-NP
, , O
hydroquinones NNS B-NP
, , O
quinone NN B-NP
ethers NNS I-NP
, , O
amines NNS B-NP
, , O
hydroxylamines NNS B-NP
and CC O
quinone NN B-NP
methides NNS I-NP
. . O

42 CD O
. . O

A DT O
composition NN O
according VBG O
to TO O
any DT O
of IN O
claims NNS O
33 CD O
to TO O
41 CD O
, , O
which WDT O
further RB O
comprises VBZ O
a DT O
phenothiazine NN B-NP
, , O
for IN O
example NN O
phenothiazine NN B-NP
. . O

43 CD O
. . O

A DT O
composition NN O
according VBG O
to TO O
any DT O
of IN O
claims NNS O
26 CD O
to TO O
32 CD O
, , O
wherein WRB O
the DT O
second JJ O
inhibitor NN O
is VBZ O
selected VBN O
from IN O
phenols NNS B-NP
, , O
alkylated VBN B-NP
phenols NNS I-NP
, , O
nitrophenols NNS B-NP
, , O
nitrosophenols NNS B-NP
, , O
quinones NNS B-NP
, , O
hydroquinones NNS B-NP
, , O
quinone NN B-NP
ethers NNS I-NP
, , O
amines NNS B-NP
, , O
phenothiazines NNS B-NP
, , O
hydroxylamines NNS B-NP
and CC O
quinone NN B-NP
methides NNS I-NP
. . O

44 CD O
. . O

A DT O
composition NN O
according VBG O
to TO O
any DT O
of IN O
claims NNS O
26 CD O
to TO O
43 CD O
, , O
wherein WRB O
the DT O
second JJ O
inhibitor NN O
is VBZ O
more RBR O
hydrophilic JJ O
than IN O
the DT O
first JJ O
inhibitor NN O
. . O

45 CD O
. . O

A DT O
composition NN O
according VBG O
to TO O
any DT O
of IN O
claims NNS O
26 CD O
to TO O
44 CD O
, , O
which WDT O
further RB O
comprises VBZ O
an DT O
ethylenically RB O
unsaturated JJ O
monomer NN O
, , O
for IN O
example NN O
a DT O
hydrocarbon NN B-NP
monomer NN O
. . O

46 CD O
. . O

A DT O
composition NN O
according VBG O
to TO O
claim NN O
45 CD O
, , O
wherein WRB O
the DT O
monomer NN O
is VBZ O
styrene JJ B-NP
, , O
[alpha] SYM B-NP
- : I-NP
methylstyrene NN I-NP
, , O
styrene NN B-NP
sulphonic JJ I-NP
acid NN I-NP
, , O
acrylonitrile VBP B-NP
, , O
vinyltoluene NN B-NP
, , O
a DT O
divinylbenzene NN B-NP
or CC O
a DT O
diene NN B-NP
. . O

47 CD O
. . O

A DT O
composition NN O
according VBG O
to TO O
claim NN O
46 CD O
, , O
wherein WRB O
the DT O
monomer NN O
is VBZ O
styrene NN B-NP
. . O

48 CD O
. . O

A DT O
composition NN O
according VBG O
to TO O
claim NN O
46 CD O
, , O
wherein WRB O
the DT O
monomer NN O
is VBZ O
acrylonitrile JJ B-NP
. . O

49 CD O
. . O

A DT O
composition NN O
according VBG O
to TO O
claim NN O
45 CD O
, , O
wherein WRB O
the DT O
monomer NN O
is VBZ O
an DT O
ester NN B-NP
. . O

50 CD O
. . O

A DT O
composition NN O
according VBG O
to TO O
claim VB O
49 CD O
, , O
wherein WRB O
the DT O
monomer NN O
is VBZ O
butyl NN B-NP
acrylate NN I-NP
, , O
vinyl NN B-NP
acetate NN I-NP
or CC O
2-ethylhexyl JJ B-NP
acrylate NN I-NP
. . O

51 CD O
. . O
Use NN O
of IN O
a DT O
compound NN O
of IN O
formula NN O
( -LRB- O
I PRP O
) -RRB- O
as IN O
defined VBN O
in IN O
claim NN O
1 CD O
, , O
as IN O
an DT O
inhibitor NN O
of IN O
polymerisation NN O
of IN O
an DT O
ethylenically NN O
unsaturated JJ O
monomer NN O
, , O
for IN O
example NN O
a DT O
hydrocarbon NN B-NP
monomer NN O
. . O

52 CD O
. . O
Use NNP O
according VBG O
to TO O
claim NN O
51 CD O
, , O
wherein WRB O
the DT O
compound NN O
is VBZ O
as IN O
defined VBN O
in IN O
any DT O
of IN O
claims NNS O
2 CD O
to TO O
8. CD O

53 CD O
. . O
Use NNP O
of IN O
a DT O
composition NN O
as IN O
defined VBN O
in IN O
any DT O
of IN O
claims NNS O
26 CD O
to TO O
50 CD O
, , O
as IN O
an DT O
inhibitor NN O
of IN O
polymerisation NN O
of IN O
an DT O
ethylenically NN O
unsaturated JJ O
monomer NN O
, , O
for IN O
example NN O
a DT O
hydrocarbon NN B-NP
monomer NN O
. . O

